<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006654.pub2" GROUP_ID="SCHIZ" ID="758106090713152935" MERGED_FROM="" MODIFIED="2013-05-01 15:55:23 +0100" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;/p&gt;" NOTES_MODIFIED="2010-02-17 14:49:29 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.23" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2013-05-01 15:55:23 +0100" MODIFIED_BY="Claire Irving">
<TITLE>Olanzapine versus other atypical antipsychotics for schizophrenia</TITLE>
<CONTACT MODIFIED="2013-05-01 15:55:23 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="87F1AFC682E26AA20078D4E6A8FF088C" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Katja</FIRST_NAME><LAST_NAME>Komossa</LAST_NAME><POSITION>4th Year Resident (Dr. Med)</POSITION><EMAIL_1>k.komossa@lrz.tu-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychosomatische und Medizin und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München, Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Moehlstrasse 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049 (0) 89 4141/4247</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-05-01 15:55:23 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="87F1AFC682E26AA20078D4E6A8FF088C" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Katja</FIRST_NAME><LAST_NAME>Komossa</LAST_NAME><POSITION>4th Year Resident (Dr. Med)</POSITION><EMAIL_1>k.komossa@lrz.tu-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychosomatische und Medizin und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München, Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Moehlstrasse 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049 (0) 89 4141/4247</PHONE_1></ADDRESS></PERSON><PERSON ID="11852B3682E26AA201DC7B3E1C938991" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Christine</FIRST_NAME><LAST_NAME>Rummel-Kluge</LAST_NAME><POSITION>Fachärztin für Psychiatrie und Psychotherapie</POSITION><EMAIL_1>Christine.rummel-kluge@medizin.uni-leipzig.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie der Universität Leipzig</DEPARTMENT><ORGANISATION/><ADDRESS_1>Semmelweisstr. 10</ADDRESS_1><CITY>04103 Leipzig</CITY><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-34-1972-4493</PHONE_1><FAX_1>+49-34-1972-4599</FAX_1></ADDRESS></PERSON><PERSON ID="2E84257C82E26AA201BA4B54250245B7" ROLE="AUTHOR"><FIRST_NAME>Heike</FIRST_NAME><LAST_NAME>Hunger</LAST_NAME><EMAIL_1>mailtoHeike@gmx.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+498 941 404247</PHONE_1></ADDRESS></PERSON><PERSON ID="D99E43AC82E26AA201BA4B549DE5F4E8" ROLE="AUTHOR"><FIRST_NAME>Franziska</FIRST_NAME><LAST_NAME>Schmid</LAST_NAME><EMAIL_1>supra.renin@web.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049/89/4140/4247</PHONE_1></ADDRESS></PERSON><PERSON ID="90591E5482E26AA201AA8B42BEBB7D04" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sandra</FIRST_NAME><LAST_NAME>Schwarz</LAST_NAME><EMAIL_1>sandra.schwarz@khsweb.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049/89/4140/4247</PHONE_1></ADDRESS></PERSON><PERSON ID="7396" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lorna</FIRST_NAME><LAST_NAME>Duggan</LAST_NAME><POSITION>Medical Director</POSITION><EMAIL_1>lornaduggan@yahoo.co.uk</EMAIL_1><EMAIL_2>lorna.duggan@partnershipsincare.co.uk</EMAIL_2><MOBILE_PHONE>07843527047</MOBILE_PHONE><ADDRESS><ORGANISATION>Kneeswork House Hosptial</ORGANISATION><ADDRESS_1>Partnership in Care</ADDRESS_1><ADDRESS_2>Bassingbourn</ADDRESS_2><CITY>Herts</CITY><ZIP>SG8 5JP</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 176 325 5724</PHONE_1><PHONE_2>+44 754 092 0903</PHONE_2><FAX_1>+44 176 325 5718</FAX_1></ADDRESS></PERSON><PERSON ID="11850D1F82E26AA201DC7B3E2041CA58" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Werner</FIRST_NAME><LAST_NAME>Kissling</LAST_NAME><POSITION>Leitender Oberarzt</POSITION><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>49-89-4140-4207</PHONE_1><FAX_1>49-89-4140-4894</FAX_1></ADDRESS></PERSON><PERSON ID="D3501EE082E26AA20080535F42019853" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Stefan</FIRST_NAME><LAST_NAME>Leucht</LAST_NAME><POSITION>Oberarzt</POSITION><EMAIL_1>Stefan.Leucht@lrz.tu-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Ismaningerstrasse 22</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140 ext: 4249</PHONE_1><FAX_1>+49-89-4140-4888</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-11-10 15:30:47 +0100" MODIFIED_BY="Claire Irving">
<UP_TO_DATE>
<DATE DAY="21" MONTH="5" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="21" MONTH="5" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="19" MONTH="5" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2013-05-01 15:55:23 +0100" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-05-01 15:55:23 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="1" MONTH="5" YEAR="2013"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY></WHATS_NEW>
<HISTORY MODIFIED="2013-05-01 15:55:23 +0100" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-05-01 15:55:23 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="10" MONTH="11" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY></HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Psychiatrische Klinik, Klinikum rechts der Isar, TU München, Freistaat Bayern</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Bundesministerium für Bildung und Forschung, Nr FKZ: 01 KG 0606, GZ:GF-GFKG01100506</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-02-17 14:37:37 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2010-02-17 14:37:37 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-12-08 12:04:24 +0000" MODIFIED_BY="[Empty name]">Olanzapine versus other atypical antipsychotics for schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2010-02-17 14:37:37 +0000" MODIFIED_BY="[Empty name]">
<P>This review examined the effects of olanzapine compared to other second generation antipsychotic drugs for schizophrenia. We identified 50 relevant studies with 9476 participants, comparing olanzapine with amisulpride, aripiprazole, clozapine, quetiapine, risperidone and ziprasidone. Comparisons of olanzapine with the second generation antipsychotic drugs sertindole or zotepine are currently not available. Olanzapine was somewhat more efficacious than aripiprazole, quetiapine, risperidone and ziprasidone, whereas there was no efficacy difference compared to amisulpride and clozapine. The main disadvantage of olanzapine was its higher weight gain and associated metabolic problems compared to all other second generation antipsychotic drugs, except for clozapine.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-02-17 14:36:52 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2008-12-26 13:03:34 +0000" MODIFIED_BY="[Empty name]">
<P>In many countries of the industrialised world second generation ("atypical") antipsychotics have become the first line drug treatment for people with schizophrenia. The question as to whether, and if so how much, the effects of the various second generation antipsychotics differ is a matter of debate. In this review we examined how the efficacy and tolerability of olanzapine differs from that of other second generation antipsychotics.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the effects of olanzapine compared to other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychosis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>1. Electronic searching<BR/>We searched the Cochrane Schizophrenia Group Trials Register (April 2007) which is based on regular searches of BIOSIS, CENTRAL, CINAHL, EMBASE, MEDLINE and PsycINFO. </P>
<P>2. Reference searching<BR/>We inspected the reference of all identified studies for more trials.</P>
<P>3. Personal contact<BR/>We contacted the first author of each included study for missing information.</P>
<P>4. Drug companies<BR/>We contacted the manufacturers of all atypical antipsychotics included for additional data.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-09-30 11:40:42 +0100" MODIFIED_BY="[Empty name]">
<P>We included all randomised trials that used at least single-blind (rater-blind) design, comparing oral olanzapine with oral forms of amisulpride, aripiprazole, clozapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia-like psychosis.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-09-30 14:04:09 +0100" MODIFIED_BY="[Empty name]">
<P>We extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random effects model. We calculated numbers needed to treat/harm (NNT/NNH) where appropriate. For continuous data, we calculated weighted mean differences (WMD) again based on a random effects model.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-02-17 14:36:22 +0000" MODIFIED_BY="[Empty name]">
<P>The review currently includes 50 studies and 9476 participants which provided data for six comparisons (olanzapine compared to amisulpride, aripiprazole, clozapine, quetiapine, risperidone or ziprasidone). The overall attrition from the included studies was considerable (49.2%) leaving the interpretation of results problematic.</P>
<P>Olanzapine improved the general mental state (PANSS total score) more than aripiprazole (2 RCTs, n=794, WMD -4.96 CI -8.06 to -1.85), quetiapine (10 RCTs, n=1449, WMD -3.66 CI -5.39 to -1.93), risperidone (15 RCTs, n=2390, WMD -1.94 CI -3.31 to -0.58) and ziprasidone (4 RCTs, n=1291, WMD -8.32 CI -10.99 to -5.64), but not more than amisulpride or clozapine. This somewhat better efficacy was confirmed by fewer participants in the olanzapine groups leaving the studies early due to inefficacy of treatment compared to quetiapine (8 RCTs, n=1563, RR 0.56 CI 0.44 to 0.70, NNT 11 CI 6 to 50), risperidone (14 RCTs, n=2744, RR 0.78 CI 0.62 to 0.98, NNT 50 CI 17 to 100) and ziprasidone (5 RCTs, n=1937, RR 0.64 CI 0.51 to 0.79, NNT 17, CI 11 to 33).</P>
<P>Fewer participants in the olanzapine group than in the quetiapine (2 RCTs, n=876, RR 0.56 CI 0.41 to 0.77, NNT 11 CI 7 to 25) and ziprasidone (2 RCTs, n=766, RR 0.65 CI 0.45 to 0.93, NNT 17 CI 9 to 100) treatment groups, but not in the clozapine group (1 RCT, n=980, RR 1.28 CI 1.02 to 1.61, NNH not estimable), had to be re-hospitalised in the trials.</P>
<P>Except for clozapine, all comparators induced less weight gain than olanzapine (olanzapine compared to amisulpride: 3 RCTs, n=671, WMD 2.11kg CI 1.29kg to 2.94kg; aripiprazole: 1 RCT, n=90, WMD 5.60kg CI 2.15kg to 9.05kg; quetiapine: 7 RCTs, n=1173, WMD 2.68kg CI 1.10kg to 4.26kg; risperidone: 13 RCTs, n=2116, WMD 2.61kg CI 1.48kg to 3.74kg; ziprasidone: 5 RCTs, n=1659, WMD 3.82kg CI 2.96kg to 4.69kg). Associated problems such as glucose and cholesterol increase were usually also more frequent in the olanzapine group.</P>
<P>Other differences in adverse effects were less well documented. Nevertheless, olanzapine may be associated with slightly more extrapyramidal side effects than quetiapine (use of antiparkinson medication (6 RCTs, n=1090, RR 2.05 CI 1.26 to 3.32, NNH 25 CI 14 to 100), but less than risperidone (use of antiparkinson medication 13 RCTs, n=2599, RR 0.78 CI 0.65 to 0.95, NNH 17 CI 9 to 100) and ziprasidone (use of antiparkinson medication 4 RCTs, n=1732, RR 0.70 CI 0.50 to 0.97, NNH not estimable). It may also increase prolactin somewhat more than aripiprazole, clozapine and quetiapine, but clearly less so than risperidone (6 RCTs, n=1291, WMD -22.84 CI -27.98 to -17.69).
<BR/>

</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-02-17 14:36:52 +0000" MODIFIED_BY="[Empty name]">
<P>Olanzapine may be a somewhat more efficacious drug than some other second generation antipsychotic drugs. This small superiority in efficacy needs to be weighed against a larger weight gain and associated metabolic problems than most other second generation antipsychotic drugs, except clozapine. These conclusions are tentative due to the large number of people leaving the studies early which possibly limits the validity of the findings. Further large, well-designed trials are necessary to establish the relative effects of different second generation antipsychotic drugs.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-02-17 12:33:04 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2010-02-16 20:39:41 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2009-09-30 11:48:42 +0100" MODIFIED_BY="[Empty name]">
<P>Schizophrenia is usually a chronic and disabling psychiatric disorder which afflicts approximately one per cent of the population world-wide with little gender differences. The annual incidence of schizophrenia averages 15 per 100,000, the point prevalence averages approximately 4.5 per population of 1000, and the risk of developing the illness over one's lifetime averages 0.7%. (<LINK REF="REF-Tandon-2008" TYPE="REFERENCE">Tandon 2008</LINK>). Its typical manifestations are positive symptoms such as fixed, false beliefs (delusions) and perceptions without cause (hallucinations) plus negative symptoms such as apathy and lack of drive, disorganisation of behaviour and thought, and catatonic symptoms such as mannerisms and bizarre posturing (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>). The degree of suffering and disability is considerable with 80% - 90% not working (<LINK REF="REF-Marvaha-2004" TYPE="REFERENCE">Marvaha 2004</LINK>) and up to 10% dying (<LINK REF="REF-Tsuang-1978" TYPE="REFERENCE">Tsuang 1978</LINK>). In the age group of 15-44 years, schizophrenia is among the top ten leading causes of disease-related disability in the world (<LINK REF="REF-WHO-2001" TYPE="REFERENCE">WHO 2001</LINK>). </P>
</CONDITION>
<INTERVENTION MODIFIED="2009-09-30 11:49:41 +0100" MODIFIED_BY="[Empty name]">
<P>Conventional antipsychotic drugs such as chlorpromazine and haloperidol have traditionally been used as first line antipsychotics for people with schizophrenia (<LINK REF="REF-Kane-1993" TYPE="REFERENCE">Kane 1993</LINK>). The introduction of clozapine in the United States of America in 1990 and a finding that clozapine was more efficacious and associated with fewer movement disorders than chlorpromazine (<LINK REF="REF-Kane-1988" TYPE="REFERENCE">Kane 1988</LINK>) has boosted the development of so-called "atypical " or second generation antipsychotics (SGA). There is no good definition of what an "atypical" or second generation antipsychotic is, but they were initially said to differ from typical antipsychotics in that they do not cause movement disorders (catalepsy) in rats at clinically effective doses (<LINK REF="REF-Arnt-1998" TYPE="REFERENCE">Arnt 1998</LINK>). The terms "new" or "second generation" antipsychotics are not much better, because clozapine is a very old drug. According to treatment guidelines (<LINK REF="REF-APA-2004" TYPE="REFERENCE">APA 2004</LINK>, <LINK REF="REF-Gaebel-2006" TYPE="REFERENCE">Gaebel 2006</LINK>) second generation antipsychotics include drugs such as amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone and zotepine, although it is unclear whether some old and cheap compounds such as sulpiride or perazine have similar properties (<LINK REF="REF-M_x00f6_ller-2000" TYPE="REFERENCE">Möller 2000</LINK>). The second generation antipsychotics raised major hopes of superior effects in a number of areas such as compliance, cognitive functioning, negative symptoms, movement disorders, quality of life and the treatment of people with treatment resistant schizophrenia.</P>
</INTERVENTION>
<THEORY MODIFIED="2008-12-26 13:39:08 +0000" MODIFIED_BY="[Empty name]">
<P>Technical background<BR/>Olanzapine, a thienobenzodiazepine derivative, is an 'atypical' antipsychotic showing affinity at D1-D5, serotinergic (5HT2, 3, 6), muscarinic (subtypes 1-5), adrenergic (alpha 1-2) and histaminergic (H1) binding sites (<LINK REF="REF-Conley-1998" TYPE="REFERENCE">Conley 1998</LINK>, <LINK REF="REF-Tollefson-1997" TYPE="REFERENCE">Tollefson 1997</LINK>, <LINK REF="REF-Reus-1997" TYPE="REFERENCE">Reus 1997</LINK>, <LINK REF="REF-Anonymous-1997" TYPE="REFERENCE">Anonymous 1997</LINK>). It is structurally similar to clozapine but has a slightly different binding site affinity. It is weaker than clozapine as an alpha-1 and alpha-2 adrenergic agonist relative to D2, D4 or 5HT2a antagonism.</P>
</THEORY>
<IMPORTANCE MODIFIED="2010-02-16 20:39:41 +0000" MODIFIED_BY="[Empty name]">
<P>The debate as to how far the SGA improve these outcomes compared to conventional antipsychotics continues (<LINK REF="REF-Duggan-2005" TYPE="REFERENCE">Duggan 2005</LINK>, <LINK REF="REF-El_x002d_Sayeh-2006" TYPE="REFERENCE">El-Sayeh 2006</LINK>) and the results from recent studies were sobering (<LINK REF="REF-Liebermann-2005" TYPE="REFERENCE">Liebermann 2005</LINK>, <LINK REF="REF-Jones-2006" TYPE="REFERENCE">Jones 2006</LINK>). Nevertheless, in some parts of the world, especially in the highly industrialised countries, second generation antipsychotics have become the mainstay of treatment. The second generation antipsychotics also differ in terms of their costs; while amisulpride and risperidone are already generic in many countries and olanzapine is generic in India other antipsychotics such as aripiprazole and ziprasidone are still not. Therefore the question as to whether they differ from each other in their clinical effects becomes increasingly important. In this review we aim to summarise evidence from randomised controlled trials that compared olanzapine with other second generation antipsychotics.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To review the effects of olanzapine compared to other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychosis.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-02-16 20:41:42 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-02-16 20:41:42 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-02-16 20:40:44 +0000" MODIFIED_BY="[Empty name]">
<P>We included randomised controlled trials which were at least single-blind (blind raters). Where a trial was described as 'double-blind', but it was only implied that the study was randomised, we included these trials in a sensitivity analysis. If there was no substantive difference within primary outcomes (see <LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>) when these 'implied randomisation' studies were added, then we included these in the final analysis. If there was a substantive difference, we only used clearly randomised trials and described the results of the sensitivity analysis in the text. We excluded quasi-randomised studies, such as those allocating by using alternate days of the week.</P>
<P>We included randomised cross-over studies, but only data up to the point of first cross-over because of the instability of the problem behaviours and the likely carry-over effects of all treatments.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-09-30 11:54:32 +0100" MODIFIED_BY="[Empty name]">
<P>We included people with schizophrenia and other types of schizophrenia-like psychosis (e.g. schizophreniform and schizoaffective disorders), irrespective of the diagnostic criteria used. There is no clear evidence that the schizophrenia-like psychoses are caused by fundamentally different disease processes or require different treatment approaches (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-02-16 20:41:42 +0000" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: any oral form of application, any dose<BR/>2. Other atypical antipsychotic drugs: amisulpride, aripiprazole, clozapine, quetiapine, risperidone, sertindole, ziprasidone, zotepine: any oral form of application, any dose.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-09-30 16:16:55 +0100" MODIFIED_BY="[Empty name]">
<P>We grouped outcomes into the short term (up to 12 weeks), medium term (13-26 weeks) and long term (over 26 weeks).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-07-28 10:37:54 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: no clinically important response as defined by the individual studies (e.g. global impression less than much improved or less than 50% reduction on a rating scale).</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-09-30 14:03:53 +0100" MODIFIED_BY="[Empty name]">
<P>1. Leaving the studies early (any reason, adverse events, inefficacy of treatment)</P>
<P>2. Global state<BR/>2.1 No clinically important change in global state (as defined by individual studies)<BR/>2.2 Relapse (as defined by the individual studies)</P>
<P>3. Mental state (with particular reference to the 'positive' and 'negative' symptoms of schizophrenia)<BR/>3.1 No clinically important change in general mental state score<BR/>3.2 Average endpoint general mental state score<BR/>3.3 Average change in general mental state score<BR/>3.4 No clinically important change in specific symptoms (positive symptoms of schizophrenia, negative symptoms of schizophrenia)<BR/>3.5 Average endpoint specific symptom score<BR/>3.6 Average change in specific symptom score</P>
<P>4. General functioning<BR/>4.1 No clinically important change in general functioning<BR/>4.2 Average endpoint general functioning score<BR/>4.3 Average change in general functioning score</P>
<P>5. Quality of life/satisfaction with treatment<BR/>5.1 No clinically important change in general quality of life<BR/>5.2 Average endpoint general quality of life score<BR/>5.3 Average change in general quality of life score</P>
<P>6. Cognitive functioning<BR/>6.1 No clinically important change in overall cognitive functioning<BR/>6.2 Average endpoint of overall cognitive functioning score<BR/>6.3 Average change of overall cognitive functioning score</P>
<P>7. Service use<BR/>7.1 Numbers hospitalised</P>
<P>8. Adverse effects<BR/>8.1 Number of participants with at least one adverse effect<BR/>8.2 Clinically important specific adverse effects (cardiac effects, death, movement disorders, prolactin increase and associated effects, sedation, seizures, weight gain, effects on white blood cell count)<BR/>8.3 Average endpoint in specific adverse effects<BR/>8.4 Average change in specific adverse effects</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-07-28 10:41:25 +0100" MODIFIED_BY="[Empty name]">
<P>No language restriction was applied within the limitations of the search tools.</P>
<ELECTRONIC_SEARCHES MODIFIED="2009-07-28 10:41:04 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Schizophrenia Group's Specialised Register (April 2007) using the phrase:</P>
<P>[((ziprasidon* AND (amisulprid* OR aripiprazol* OR clozapin* OR olanzapin* OR quetiapin* OR sertindol* OR risperidon* OR zotepin*)) in title, abstract or index terms of REFERENCE) or ((ziprasidon* AND (amisulprid* OR aripiprazol* OR clozapin* OR olanzapin* OR quetiapin* OR sertindol* OR risperidon * OR zotepin*)) in interventions of STUDY)]</P>
<P>This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/SCHIZ/frame.html">Group Module</A>). The Cochrane Schizophrenia Group Trials Register is maintained on Meerkat 1.5. This version of Meerkat stores references as studies. When an individual reference is selected through a search, all references which have been identified as the same study are also selected.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-07-28 10:41:13 +0100" MODIFIED_BY="[Empty name]">
<P>1. Reference searching<BR/>We inspected the reference lists of all studies identified in the search for more trials.</P>
<P>2. Personal contact<BR/>We contacted the first author of each included study for missing information.</P>
<P>3. Drug companies<BR/>We contacted the manufacturers of all atypical antipsychotics included for additional data.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-02-13 10:46:02 +0000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<STUDY_SELECTION MODIFIED="2008-12-08 16:09:32 +0000" MODIFIED_BY="[Empty name]">
<P>We independently extracted data from selected trials. When disputes arose we attempted to resolve these by discussion. When this was not possible and further information was necessary to resolve the dilemma, we did not enter data and added the trial to the list of those awaiting assessment.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-09-30 16:04:02 +0100" MODIFIED_BY="[Empty name]">
<P>1. Data extraction<BR/>We independently extracted data from selected trials. When disputes arose we attempted to resolve these by discussion. When this was not possible and further information was necessary to resolve the dilemma, we did not enter data and added the trial to the list of those awaiting assessment.</P>
<P>2. Management<BR/>We extracted the data onto standard simple forms. Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for olanzapine.</P>
<P>3. Rating scales<BR/>A wide range of instruments are available to measure outcomes in mental health studies. These instruments vary in quality and many are not validated, or are even ad hoc. It is accepted generally that measuring instruments should have the properties of reliability (the extent to which a test effectively measures anything at all) and validity (the extent to which a test measures that which it is supposed to measure) (<LINK REF="REF-Rust-1989" TYPE="REFERENCE">Rust 1989</LINK>). Unpublished scales are known to be subject to bias in trials of treatments for schizophrenia (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>). Therefore continuous data from rating scales were included only if the measuring instrument had been described in a peer-reviewed journal.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-09-30 13:27:08 +0100" MODIFIED_BY="[Empty name]">
<P>Again working independently, KK and SL assessed risk of bias using the tool described in the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). This tool encourages consideration of how the sequence was generated, how allocation was concealed, the integrity of blinding at outcome, the completeness of outcome data, selective reporting and other biases.</P>
<P>The risk of bias in each domain and overall were assessed and categorised into:</P>
<P>A. Low risk of bias: plausible bias unlikely to seriously alter the results (categorised as 'Yes' in Risk of Bias table)<BR/>B. High risk of bias: plausible bias that seriously weakens confidence in the results (categorised as 'No' in Risk of Bias table)<BR/>C. Unclear risk of bias: plausible bias that raises some doubt about the results (categorised as 'Unclear' in Risk of Bias table)</P>
<P>We categorised trials with high risk of bias (defined as at least four out of seven domains) as 'No'. Where allocation was clearly not concealed we did not include these trials in the review. If the initial raters disagreed, the final rating was made by consensus with the involvement of another member of the review group. Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors the studies in order to obtain further information. Non-concurrence in quality assessment was reported.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-09-30 14:06:06 +0100" MODIFIED_BY="[Empty name]">
<P>1. Data types<BR/>We assessed outcomes using continuous (for example changes on a behaviour scale), categorical (for example, one of three categories on a behaviour scale, such as "little change", "moderate change" or "much change") or dichotomous (for example, either "no important changes or "important change" in a person's behaviour) measures. Currently RevMan does not support categorical data so we were unable to analyse this.</P>
<P>2. Dichotomous- yes/no- data<BR/>We carried out an intention to treat analysis. Everyone allocated to the intervention were counted, whether they completed the follow up or not. It was assumed that those who dropped out had no change in their outcome. This rule is conservative concerning response to treatment, because it assumes that those discontinuing the studies would not have responded. It is not conservative concerning adverse effects, but we felt that assuming that all those leaving early would have developed side effects would overestimate risk. Where possible, efforts were made to convert outcome measures to dichotomous data. This can be done by identifying cut off points on rating scales and dividing participants accordingly into "clinically improved" or "not clinically improved". It was generally assumed that if there had been a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or the Positive and Negative Syndrome Scale (PANSS, <LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), this could be considered as a clinically significant response (<LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>, <LINK REF="REF-Leucht-2005b" TYPE="REFERENCE">Leucht 2005b</LINK>). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.</P>
<P>We calculated the relative risk (RR) and its 95% confidence interval (CI) based on the random effects model, as this takes into account any differences between studies even if there is no statistically significant heterogeneity. It has been shown that RR is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). This misinterpretation then leads to an overestimate of the impression of the effect. When the overall results were significant we calculated the number needed to treat (NNT) and the number- needed- to- harm (NNH) as the inverse of the risk difference.</P>
<P>3 Continuous data<BR/>3.1 Normal distribution of the data<BR/>The meta-analytic formulas applied by RevMan Analyses (the statistical programme included in RevMan) require a normal distribution of data. The software is robust towards some skew, but to which degree of skewness meta-analytic calculations can still be reliably carried out is unclear. On the other hand, excluding all studies on the basis of estimates of the normal distribution of the data also leads to a bias, because a considerable amount of data may be lost leading to a selection bias. Therefore, we included all studies in the primary analysis. In a sensitivity analysis we excluded potentially skewed data applying the following rules:<BR/>a) When a scale started from the finite number zero the standard deviation, when multiplied by two, was more than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution <LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>).<BR/>b) If a scale started from a positive value (such as PANSS which can have values from 30 to 210) the calculation described above was modified to take the scale starting point into account. In these cases skew is present if 2SD&gt;(S-Smin), where S is the mean score and Smin is the minimum score.<BR/>c) In large studies (as a cut-off we used 200 participants) skewed data pose less of a problem. In these cases we entered the data in a synthesis.<BR/>d) The rules explained in a) and b) do not apply to change data. The reasons is that when continuous data are presented on a scale which includes a possibility of negative values, it is difficult to tell whether data are non-normally distributed (skewed) or not. This is also the case for change data (endpoint minus baseline). In the absence of individual patient data it is impossible to know if data are skewed, though this is likely. After consulting the ALLSTAT electronic statistics mailing list, we presented change data in RevMan Analyses in order to summarise available information. In doing this, it was assumed either that data were not skewed or that the analysis could cope with the unknown degree of skew. Without individual patient data it is impossible to test this assumption. We therefore included change data and did not apply a sensitivity analysis.</P>
<P>3.2 Data synthesis<BR/>For continuous outcomes we estimated a weighted mean difference (WMD) between groups. WMDs were again based on the random effects model, as this takes into account any differences between studies even if there is no statistically significant heterogeneity. We combined both endpoint data and change data in the analysis, because there is no principal statistical reason why endpoint and change data should measure different effects (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). When standard errors instead of standard deviations (SD) were presented, we converted the former to standard deviations. If both were missing we estimated SDs from p-values or used the average SD of the other studies (<LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>)</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2010-02-13 10:46:02 +0000" MODIFIED_BY="[Empty name]">
<P>1. Cluster trials<BR/>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intraclass correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type 1 errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>, <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Where clustering was not accounted for in primary studies, we would have presented the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we would have seeked to contact first authors of studies to obtain intraclass correlation coefficients of their clustered data and to adjust for this using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering had been incorporated into the analysis of primary studies, we would also have presented these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intraclass correlation coefficient (ICC) [Design effect=1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>If cluster studies had been appropriately analysed taking into account intraclass correlation coefficients and relevant data documented in the report, we would have synthesised these with other studies using the generic inverse variance technique.</P>
<P>2. Cross-over trials<BR/>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are very likely in schizophrenia, we will only use data of the first phase of cross-over studies.</P>
<P>3. Studies with multiple treatment groups<BR/>Where a study involved more than two treatment groups, if relevant, the additional treatment groups were presented in additional relevant comparisons. Data were not double counted. Where the additional treatment groups were not relevant, these data were not reproduced.<BR/>
</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2009-07-28 11:30:15 +0100" MODIFIED_BY="[Empty name]">
<P>At some degree of loss of follow-up data must lose credibility (<LINK REF="REF-Xia-2007" TYPE="REFERENCE">Xia 2007</LINK>). Although high rates of premature discontinuation are a major problem in this field, we felt that it is unclear which degree of attrition leads to a high degree of bias. We therefore did not exclude trials on the basis of the percentage of participants completing them. However we addressed the drop-out problem in all parts of the review, including the abstract. For this purpose we calculated, presented and commented on frequency statistics (overall rates of leaving the studies early in all studies and comparators pooled).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-07-28 11:32:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical heterogeneity<BR/>We considered all the included studies within any comparison to judge for clinical heterogeneity.</P>
<P>2. Statistical<BR/>2.1 Visual inspection<BR/>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</P>
<P>2.2 Employing the I<SUP>2</SUP> statistic<BR/>Visual inspection was supplemented using, primarily, the I<SUP>2</SUP>statistic. This provides an estimate of the percentage of variability due to heterogeneity rather than chance alone. Where the I<SUP>2</SUP> estimate was greater than or equal to 50% we interpreted this as indicating the presence of considerable levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2009-07-28 11:37:00 +0100" MODIFIED_BY="[Empty name]">
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). These are described in section 10.1 of the Cochrane Handbook (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). We are aware that funnel plots may be useful in investigating small-study effects but are of limited power to detect such effects when there are few studies. We entered data from all identified and selected trials into a funnel graph (trial effect versus trial size) in an attempt to investigate the likelihood of overt publication bias. We did not undertake a formal test for funnel-plot asymmetry.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-07-28 11:38:32 +0100" MODIFIED_BY="[Empty name]">
<P>Where possible for both dichotomous and continuous data we used the random-effects model for data synthesis as this takes into account any differences between studies even if there is no statistically significant heterogeneity. We understand that there is no closed argument for preference for use of fixed or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This does seem true to us, however, random-effects does put added weight onto the smaller of the studies - those trials that are most vulnerable to bias.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2009-07-28 11:38:24 +0100" MODIFIED_BY="[Empty name]">
<P>If data are clearly heterogeneous we checked that data are correctly extracted and entered and that we had made no unit of analysis errors. If inconsistency was high and clear reasons explaining the heterogeneity were found, we presented the data separately. If not, we commented on the heterogeneity of the data.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-12-10 09:31:42 +0000" MODIFIED_BY="[Empty name]">
<P>In sensitivity analyses we excluded studies with potentially skewed data. A recent report showed that some of the comparisons of atypical antipsychotics may have been biased by using inappropriate comparator doses (<LINK REF="REF-Heres-2006" TYPE="REFERENCE">Heres 2006</LINK>). We, therefore, also analysed whether the exclusion of studies with inappropriate comparator doses changed the results of the primary outcome and the general mental state.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-02-17 11:46:36 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-02-16 20:54:14 +0000" MODIFIED_BY="[Empty name]">
<P>For substantive description of studies please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> tables.</P>
<SEARCH_RESULTS MODIFIED="2010-01-12 09:50:12 +0000" MODIFIED_BY="[Empty name]">
<P>The search strategy yielded 3620 reports. 193 reports were closely inspected. 110 of them had to be excluded, 50 were included and nine studies are ongoing (<LINK REF="STD-Eli-Lilly-2003a" TYPE="STUDY">Eli Lilly 2003a</LINK>, <LINK REF="STD-Eli-Lilly-2003b" TYPE="STUDY">Eli Lilly 2003b</LINK>, <LINK REF="STD-Eli-Lilly-2004a" TYPE="STUDY">Eli Lilly 2004a</LINK>, <LINK REF="STD-Eli-Lilly-2004b" TYPE="STUDY">Eli Lilly 2004b</LINK>, <LINK REF="STD-Eli-Lilly-2006" TYPE="STUDY">Eli Lilly 2006</LINK>, <LINK REF="STD-NCT00001656" TYPE="STUDY">NCT00001656</LINK>, <LINK REF="STD-Mortimer-2001" TYPE="STUDY">Mortimer 2001</LINK>, <LINK REF="STD-N0081052094" TYPE="STUDY">N0081052094</LINK>, <LINK REF="STD-N0081121981" TYPE="STUDY">N0081121981</LINK>). No studies are awaiting assessment. For further descriptions please see below and the included, excluded and ongoing studies tables.</P>
<P>The fifty included studies provided data on six comparisons: olanzapine versus amisulpride, olanzapine versus aripiprazole, olanzapine versus clozapine, olanzapine versus quetiapine, olanzapine versus risperidone and olanzapine versus ziprasidone. For the following comparisons no relevant RCTs were identified: olanzapine versus sertindole and olanzapine versus zotepine.<BR/>
</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-02-16 20:54:13 +0000" MODIFIED_BY="[Empty name]">
<P>The 50 included studies randomised approximately 9100 people. All but eight included studies were double blind. Seventeen studies were sponsored by pharmaceutical companies producing olanzapine and 14 studies were sponsored by pharmaceutical companies marketing the comparing substances,15 studies had a neutral sponsor. Four studies did not provide data on sponsoring.
<BR/>

</P>
<P>1 Length of studies<BR/>Twenty-eight studies fell in the short-term category (up to twelve weeks). <LINK REF="STD-Mori-2004" TYPE="STUDY">Mori 2004</LINK> was the shortest trial with a duration of 4 weeks. Eight studies lasted 6 weeks (<LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK>, <LINK REF="STD-CN138003" TYPE="STUDY">CN138003</LINK>, <LINK REF="STD-Ozguven-2004" TYPE="STUDY">Ozguven 2004</LINK>, <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>, <LINK REF="STD-Svestka-2003a" TYPE="STUDY">Svestka 2003a</LINK>, <LINK REF="STD-Svestka-2003b" TYPE="STUDY">Svestka 2003b</LINK>, <LINK REF="STD-Svestka-2005" TYPE="STUDY">Svestka 2005</LINK>, <LINK REF="STD-Van-Nimwegen-2006" TYPE="STUDY">Van Nimwegen 2006</LINK>). Fifteen trials lasted 8 weeks (<LINK REF="STD-Canive-2000" TYPE="STUDY">Canive 2000</LINK>, <LINK REF="STD-Conley-2001" TYPE="STUDY">Conley 2001</LINK>, <LINK REF="STD-Conley-2003" TYPE="STUDY">Conley 2003</LINK>, <LINK REF="STD-Dollfus-2005" TYPE="STUDY">Dollfus 2005</LINK>, <LINK REF="STD-Dolnak-2001" TYPE="STUDY">Dolnak 2001</LINK>, <LINK REF="STD-Jeste-2003" TYPE="STUDY">Jeste 2003</LINK>, <LINK REF="STD-Moresco-2004" TYPE="STUDY">Moresco 2004</LINK>, <LINK REF="STD-Riedel-2007" TYPE="STUDY">Riedel 2007</LINK>, <LINK REF="STD-Sacchetti-2004" TYPE="STUDY">Sacchetti 2004</LINK>, <LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK>, <LINK REF="STD-Sikich-2004" TYPE="STUDY">Sikich 2004</LINK>, <LINK REF="STD-Vanelle-2006" TYPE="STUDY">Vanelle 2006</LINK>, <LINK REF="STD-Wagner-2005" TYPE="STUDY">Wagner 2005</LINK>, <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK>, and <LINK REF="STD-Wynn-2007" TYPE="STUDY">Wynn 2007</LINK>) and four studies lasted 12 weeks (<LINK REF="STD-Krakowski-2006" TYPE="STUDY">Krakowski 2006</LINK>, <LINK REF="STD-Kumra-2007" TYPE="STUDY">Kumra 2007</LINK>, <LINK REF="STD-Sirota-2006" TYPE="STUDY">Sirota 2006</LINK>, <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>).</P>
<P>Thirteen studies fell into the medium-term category (13-26 weeks) (<LINK REF="STD-Bai-2005" TYPE="STUDY">Bai 2005</LINK>, <LINK REF="STD-Bitter-2004" TYPE="STUDY">Bitter 2004</LINK>, <LINK REF="STD-Kinon-2006a" TYPE="STUDY">Kinon 2006a</LINK>, <LINK REF="STD-Kinon-2006b" TYPE="STUDY">Kinon 2006b</LINK>, <LINK REF="STD-Lecrubier-2006" TYPE="STUDY">Lecrubier 2006</LINK>, <LINK REF="STD-McEvoy-2006" TYPE="STUDY">McEvoy 2006</LINK>, <LINK REF="STD-McQuade-2004" TYPE="STUDY">McQuade 2004</LINK>, <LINK REF="STD-Mortimer-2004" TYPE="STUDY">Mortimer 2004</LINK>, <LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK>, <LINK REF="STD-Robinson-2006" TYPE="STUDY">Robinson 2006</LINK>, <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK>, <LINK REF="STD-Tollefson-2001" TYPE="STUDY">Tollefson 2001</LINK>, <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>).</P>
<P>Nine trials (<LINK REF="STD-Breier-2005" TYPE="STUDY">Breier 2005</LINK>, <LINK REF="STD-Gureje-2003" TYPE="STUDY">Gureje 2003</LINK>, <LINK REF="STD-Keefe-2006" TYPE="STUDY">Keefe 2006</LINK>, <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>, <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK>, <LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK>, <LINK REF="STD-Purdon-2000" TYPE="STUDY">Purdon 2000</LINK>, <LINK REF="STD-Tran-1997" TYPE="STUDY">Tran 1997</LINK>, and <LINK REF="STD-Voruganti-2007" TYPE="STUDY">Voruganti 2007</LINK>) were long-term (more than 26 weeks).<BR/>
<BR/>2. Setting<BR/>In 22 trials in- and outpatients could be included, sixteen used an inpatient setting and three studies an outpatient setting. Nine study reports did not provide information on the setting.
<BR/>

<BR/>3. Participants</P>
<P>Most studies used operationalised diagnostic criteria, most frequently on the basis of the Diagnostic and Statistical Manual (DSM-IV, <LINK REF="REF-APA-2004" TYPE="REFERENCE">APA 2004</LINK>, or older). Other diagnostic systems were the International Classification of Diseases (ICD 10 or older). <LINK REF="STD-Sikich-2004" TYPE="STUDY">Sikich 2004</LINK> used the DSM-IV as well as the Schedule for Affective Disorders and Schizophrenia. Chinese trialists applied the Chinese Classification of Mental Disorders (CCDM, Version 3 or older).</P>
<P>All studies included people with schizophrenia, twenty-one studies additionally included those with schizoaffective disorder (<LINK REF="STD-Conley-2001" TYPE="STUDY">Conley 2001</LINK>, <LINK REF="STD-Gureje-2003" TYPE="STUDY">Gureje 2003</LINK>, <LINK REF="STD-Jeste-2003" TYPE="STUDY">Jeste 2003</LINK>, <LINK REF="STD-Keefe-2006" TYPE="STUDY">Keefe 2006</LINK>, <LINK REF="STD-Kinon-2006a" TYPE="STUDY">Kinon 2006a</LINK>, <LINK REF="STD-Kinon-2006b" TYPE="STUDY">Kinon 2006b</LINK>, <LINK REF="STD-Krakowski-2006" TYPE="STUDY">Krakowski 2006</LINK>, <LINK REF="STD-Kumra-2007" TYPE="STUDY">Kumra 2007</LINK>, <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK>, <LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK>, <LINK REF="STD-Robinson-2006" TYPE="STUDY">Robinson 2006</LINK>, <LINK REF="STD-Sikich-2004" TYPE="STUDY">Sikich 2004</LINK>, <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>, <LINK REF="STD-Svestka-2003a" TYPE="STUDY">Svestka 2003a</LINK>, <LINK REF="STD-Svestka-2003b" TYPE="STUDY">Svestka 2003b</LINK>, <LINK REF="STD-Svestka-2005" TYPE="STUDY">Svestka 2005</LINK>, <LINK REF="STD-Tran-1997" TYPE="STUDY">Tran 1997</LINK>, <LINK REF="STD-Van-Nimwegen-2006" TYPE="STUDY">Van Nimwegen 2006</LINK>, <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>, <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>, <LINK REF="STD-Wynn-2007" TYPE="STUDY">Wynn 2007</LINK>) and seven studies also included people with schizophreniform disorder (<LINK REF="STD-Gureje-2003" TYPE="STUDY">Gureje 2003</LINK>, <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK>, <LINK REF="STD-Mortimer-2004" TYPE="STUDY">Mortimer 2004</LINK>, <LINK REF="STD-Robinson-2006" TYPE="STUDY">Robinson 2006</LINK>, <LINK REF="STD-Sikich-2004" TYPE="STUDY">Sikich 2004</LINK>, <LINK REF="STD-Tran-1997" TYPE="STUDY">Tran 1997</LINK>, <LINK REF="STD-Van-Nimwegen-2006" TYPE="STUDY">Van Nimwegen 2006</LINK>).</P>
<P>In most studies there was a preponderance of men but <LINK REF="STD-Svestka-2003b" TYPE="STUDY">Svestka 2003b</LINK> included only women.</P>
<P>In most studies the participants were relatively chronic with a median mean age of 37.6 years. However, eight studies included only children and adolescents, participants with a first episode or people in the early stages of the illness (<LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK>, <LINK REF="STD-Purdon-2000" TYPE="STUDY">Purdon 2000</LINK>, <LINK REF="STD-Robinson-2006" TYPE="STUDY">Robinson 2006</LINK>, <LINK REF="STD-Sikich-2004" TYPE="STUDY">Sikich 2004</LINK>, <LINK REF="STD-Kumra-2007" TYPE="STUDY">Kumra 2007</LINK>, <LINK REF="STD-Svestka-2003a" TYPE="STUDY">Svestka 2003a</LINK>, <LINK REF="STD-Svestka-2003b" TYPE="STUDY">Svestka 2003b</LINK>, <LINK REF="STD-Svestka-2005" TYPE="STUDY">Svestka 2005</LINK>). In contrast, <LINK REF="STD-Jeste-2003" TYPE="STUDY">Jeste 2003</LINK> randomised only elderly people with schizophrenia aged 60 or older.</P>
<P>Nine studies required suboptimal response to, or intolerance of, at least one previous standard antipsychotic therapy (<LINK REF="STD-Bitter-2004" TYPE="STUDY">Bitter 2004</LINK>, <LINK REF="STD-Conley-2003" TYPE="STUDY">Conley 2003</LINK>, <LINK REF="STD-Kumra-2007" TYPE="STUDY">Kumra 2007</LINK>, <LINK REF="STD-McEvoy-2006" TYPE="STUDY">McEvoy 2006</LINK>, <LINK REF="STD-Moresco-2004" TYPE="STUDY">Moresco 2004</LINK>, <LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK>, <LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK>, <LINK REF="STD-Tollefson-2001" TYPE="STUDY">Tollefson 2001</LINK>, and <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>). The definitions for non-response and treatment resistance, however, differed.</P>
<P>While most studies required a minimum of positive symptoms for inclusion, <LINK REF="STD-Lecrubier-2006" TYPE="STUDY">Lecrubier 2006</LINK>, <LINK REF="STD-Kinon-2006b" TYPE="STUDY">Kinon 2006b</LINK> focused on people with predominant negative symptoms. <LINK REF="STD-Dollfus-2005" TYPE="STUDY">Dollfus 2005</LINK> addressed people with postpsychotic depression, and <LINK REF="STD-Kinon-2006a" TYPE="STUDY">Kinon 2006a</LINK> examined participants with predominant depressive symptoms.</P>
<P>
<BR/>4. Study size<BR/>
<LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK> was the largest study (1460 participants) whilst <LINK REF="STD-Conley-2003" TYPE="STUDY">Conley 2003</LINK> was the smallest study, randomising only 13 people. Eleven studies had fewer than fifty participants, fifteen had 50-100 participants, sixteen studies had 100 to 400 participants and six randomised more than four hundred people. Two studies did not indicate the total number of randomised participants.</P>
<P>5. Interventions<BR/>5.1 Olanzapine<BR/>The trialists gave olanzapine in a wide range of flexible doses from 2.5 mg/day to 50 mg/day. Only five studies were fixed dose trials (<LINK REF="STD-Conley-2003" TYPE="STUDY">Conley 2003</LINK>: 50mg/day; <LINK REF="STD-Kinon-2006a" TYPE="STUDY">Kinon 2006a</LINK> three doses: 10, 15, 20 mg/day, <LINK REF="STD-Lecrubier-2006" TYPE="STUDY">Lecrubier 2006</LINK>: 5 and 20mg/day, <LINK REF="STD-Wynn-2007" TYPE="STUDY">Wynn 2007</LINK>: 15mg/day). In seven reports a dose range was not indicated.</P>
<P>5.2 Comparators<BR/>Six other second generation antipsychotic drugs were used as comparators with the following dose ranges: amisulpride (150 mg/day to 800 mg/day), aripiprazole (15 mg/day to 30 mg/day), clozapine (25 mg/day to 900 mg/day), quetiapine (50 mg/day to 826.67 mg/day), risperidone (0.5 mg/day to 16 mg/day) and zisprasidone (40 mg/day to 160 mg/day). Some studies also included additional arms with the typical antipsychotic drugs haloperidol, perospirone, perphenazine as comparators. These results were not considered in the current review.</P>
<P>6 Outcomes<BR/>6.1 Leaving the study early<BR/>We evaluated numbers leaving early for any reason, for adverse events or for lack of efficacy.</P>
<P>6.2 Response to treatment<BR/>The studies rarely reported the response cut off of at least 50% reduction of a scale's baseline value that we considered clinically meaningful. The criteria of at least 50% PANSS total score reduction was used by <LINK REF="STD-Bitter-2004" TYPE="STUDY">Bitter 2004</LINK>, <LINK REF="STD-Dollfus-2005" TYPE="STUDY">Dollfus 2005</LINK>, <LINK REF="STD-Gureje-2003" TYPE="STUDY">Gureje 2003</LINK>, <LINK REF="STD-Svestka-2003b" TYPE="STUDY">Svestka 2003b</LINK>, <LINK REF="STD-Tollefson-2001" TYPE="STUDY">Tollefson 2001</LINK>, <LINK REF="STD-Tran-1997" TYPE="STUDY">Tran 1997</LINK> and <LINK REF="STD-Wagner-2005" TYPE="STUDY">Wagner 2005</LINK>. <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK> used 50% BPRS total score reduction. In contrast, <LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK> described at least 50% SANS reduction from baseline, <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK> at least 40% BPRS total score reduction from baseline, <LINK REF="STD-Breier-2005" TYPE="STUDY">Breier 2005</LINK> and <LINK REF="STD-Zhong-2006" TYPE="STUDY">Zhong 2006</LINK> at least 30% PANSS total score reduction from baseline, <LINK REF="STD-Conley-2001" TYPE="STUDY">Conley 2001</LINK> at least 20% PANSS total score reduction from baseline, <LINK REF="STD-Lecrubier-2006" TYPE="STUDY">Lecrubier 2006</LINK> at least 20% SANS total reduction from baseline in addition to 10% PANSS total score reduction, <LINK REF="STD-Ozguven-2004" TYPE="STUDY">Ozguven 2004</LINK> at least 20% SANS total score reduction from baseline, <LINK REF="STD-McQuade-2004" TYPE="STUDY">McQuade 2004</LINK>, <LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK> and <LINK REF="STD-Vanelle-2006" TYPE="STUDY">Vanelle 2006</LINK> at least much improved on CGI, <LINK REF="STD-CN138003" TYPE="STUDY">CN138003</LINK> a CGI of 3 or less or at least 20% PANSS total reduction, <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK> all PANSS items of 3 or less plus a CGI-S item of 3 or less, <LINK REF="STD-Sikich-2004" TYPE="STUDY">Sikich 2004</LINK> a CGI at least much improved in addition to at least 20% BPRS reduction and <LINK REF="STD-Robinson-2006" TYPE="STUDY">Robinson 2006</LINK> applied a criterion mild or less on certain SADS-C+PD items plus at least much improved on CGI.<BR/>

<BR/>
6.3 Relapse<BR/>Only three studies (<LINK REF="STD-Dollfus-2005" TYPE="STUDY">Dollfus 2005</LINK>, <LINK REF="STD-Keefe-2006" TYPE="STUDY">Keefe 2006</LINK>, <LINK REF="STD-Lecrubier-2006" TYPE="STUDY">Lecrubier 2006</LINK>) provided data for relapse and used different definitions.</P>
<P>6.4 Service use<BR/>Some studies indicated the number of participants re-hospitalised during the trial.
<BR/>

<BR/>6.5 Outcome scales<BR/>Details of scales that provided usable data are shown below. Reasons for exclusion of data from other instruments are given under 'Outcomes' in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<P>6.5.1 Global state scales<BR/>6.5.1.1 Clinical Global Impression Scale - CGI (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>This is used to assess both severity of illness and clinical improvement, by comparing the conditions of the person standardised against other people with the same diagnosis. A seven-point scoring system is usually used with low scores showing decreased severity and/or overall improvement.</P>
<P>6.5.2 Mental state scales<BR/>6.5.2.1 Brief Psychiatric Rating Scale - BPRS (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>)<BR/>This is used to assess the severity of abnormal mental state. The original scale has 16 items, but a revised 18-item scale is commonly used. Each item is defined on a seven-point scale varying from 'not present' to 'extremely severe', scoring from 0-6 or 1-7. Scores can range from 0-126, with high scores indicating more severe symptoms.</P>
<P>6.5.2.2 Positive and Negative Syndrome Scale - PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>)<BR/>This schizophrenia scale has 30 items, each of which can be defined on a seven-point scoring system varying from 1 - absent to 7 - extreme. It can be divided into three sub-scales for measuring the severity of general psychopathology, positive symptoms (PANSS-P), and negative symptoms (PANSS-N). A low score indicates lesser severity.</P>
<P>6.5.2.3 Scale for the Assessment of Negative Symptoms - SANS (<LINK REF="REF-Andreasen-1984" TYPE="REFERENCE">Andreasen 1984</LINK>)<BR/>This six-point scale gives a global rating of the following negative symptoms: alogia, affective blunting, avolition-apathy, anhedonia-asociality and attention impairment. Higher scores indicate more symptoms.</P>
<P>6.5.2.4 Scale for the Assessment of Positive Symptoms - SAPS (<LINK REF="REF-Andreasen-1983" TYPE="REFERENCE">Andreasen 1983</LINK>)<BR/>This four-point scale gives a global rating of the following positive symptoms: hallucinations, paranoia, disorganised behaviour and disorganised thinking. Higher scores indicate more symptoms.</P>
<P>6.5.3 General functioning scales<BR/>6.5.3.1 Social and Occupational Functioning Assessment Scale - SOFAS (<LINK REF="REF-Goldman-1992" TYPE="REFERENCE">Goldman 1992</LINK>)<BR/>The SOFAS scale focuses on the different levels of social and occupational functioning. Higher scores indicate a higher level of functioning.</P>
<P>1.6.5.3.2 Global Assessment of Functioning - GAF (<LINK REF="REF-APA-2004" TYPE="REFERENCE">APA 2004</LINK>)<BR/>This is a rating scale for a participant's overall capacity of psychosocial functioning scoring from 1-100. Higher scores indicate a higher level of functioning.</P>
<P>6.5.4 Quality of life scales<BR/>6.5.4.1 Quality of Life Scale - QLS (<LINK REF="REF-Carpenter-1984" TYPE="REFERENCE">Carpenter 1984</LINK>)<BR/>This semi-structured interview is administered and rated by trained clinicians. It contains 21 items rated on a seven-point scale based on the interviewers judgement of patient functioning. A total QLS and four sub-scale scores are calculated, with higher scores indicating less impairment.</P>
<P>6.5.4.2 Subjective Well-being under Neuroleptics Scale - SWN (<LINK REF="STD-De-Haan-2002" TYPE="STUDY">De Haan 2002</LINK>)<BR/>The SWN is an instrument to measure the subtle subjective changes, such as restrictions in emotionality, the clarity of thinking and spontaneity, that are frequently referred as 'pharmacogenic depression' or the 'neuroleptic induced deficit syndrome'.</P>
<P>6.5.5 Cognitive functioning scales<BR/>6.5.5.1 Global Cognitive Index (<LINK REF="STD-Wagner-2005" TYPE="STUDY">Wagner 2005</LINK>)<BR/>For cognitive assessment <LINK REF="STD-Wagner-2005" TYPE="STUDY">Wagner 2005</LINK> used a global cognitive index that was constructed by summing and averaging the z-scores of various cognitive tests. The tests were grouped into four cognitive domains: attention, executive functions, working memory, and verbal learning and memory.<BR/>
<BR/>6.5.5.2 Global Neurocognitive Score (<LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>)<BR/>This score consists of 15 tests that assess the domains general ability, learning and memory, attention, executive functions, and motor skills. 16 variables were selected from 12 tests. For each test variable, z-scores were computed. This global score was then computed by averaging the z-scores of contributing variables. All z-scores were computed in a way that positive scores indicate better performance.</P>
<P>6.5.5.3 Neurocognitive Composite Score (<LINK REF="STD-Keefe-2006" TYPE="STUDY">Keefe 2006</LINK>)<BR/>The Neurocognitive Composite score comprises individual cognitive domains (executive function, learning and memory, processing speed, attention/vigilance, verbal working memory, verbal fluency, motor function, and visuospatial ability) measured by various tests that were transformed into a composite score.</P>
<P>6.5.5.4 PANSS cognitive subscore<BR/>This score has been derived from the Positive and Negative Syndrome Scale - PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>).</P>
<P>6.5.6 Adverse effects scales<BR/>6.5.6.1 Abnormal Involuntary Movement Scale - AIMS (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>This has been used to assess tardive dyskinesia, a long-term, drug-induced movement disorder and short-term movement disorders such as tremor.</P>
<P>6.5.6.2 Barnes Akathisia Scale - BAS (<LINK REF="REF-Barnes-1989" TYPE="REFERENCE">Barnes 1989</LINK>)<BR/>The scale comprises items rating the observable, restless movements that characterise akathisia, a subjective awareness of restlessness, and any distress associated with the condition. These items are rated from 0 - normal to 3 - severe. In addition, there is an item for rating global severity (from 0 - absent to 5 - severe). A low score indicates low levels of akathisia.</P>
<P>6.5.6.3 Extrapyramidal Symptom Rating Scale - ESRS (<LINK REF="REF-Chouinard-1980" TYPE="REFERENCE">Chouinard 1980</LINK>)<BR/>This consists of a questionnaire relating to parkinsonian symptoms (nine items), a physician's examination for parkinsonism and dyskinetic movements (eight items), and a clinical global impression of tardive dyskinesia. High scores indicate severe levels of movement disorder.</P>
<P>6.5.6.4 Hillside Akathisia Scale - HAS (<LINK REF="REF-Fleischhacker-1989" TYPE="REFERENCE">Fleischhacker 1989</LINK>)<BR/>The Hillside Akathisia Scale has two subjective and three objective items for which anchored rating points are provided.</P>
<P>6.5.6.5 Simpson Angus Scale - SAS (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>)<BR/>This ten-item scale, with a scoring system of 0-4 for each item, measures drug-induced parkinsonism, a short-term drug-induced movement disorder. A low score indicates low levels of parkinsonism.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-02-13 10:50:30 +0000" MODIFIED_BY="[Empty name]">
<P>We excluded a total of 110 studies. Of these, 54 were excluded because of open-label treatment, 29 were excluded because of lack of randomisation, and twelve due to pooled-analyses. Nine were excluded because of inappropriate intervention, three because of no usable data and two were excluded because of other aims. One study was excluded because of inadequate diagnosis.</P>
<SUBSECTION>
<HEADING LEVEL="5">Awaiting assessment</HEADING>
<P>No studies are waiting assessment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Ongoing studies</HEADING>
<P>Nine RCTs comparing olanzapine with other atypical antipsychotics are considered as ongoing (<LINK REF="STD-Eli-Lilly-2003a" TYPE="STUDY">Eli Lilly 2003a</LINK>, <LINK REF="STD-Eli-Lilly-2003b" TYPE="STUDY">Eli Lilly 2003b</LINK>, <LINK REF="STD-Eli-Lilly-2004a" TYPE="STUDY">Eli Lilly 2004a</LINK>, <LINK REF="STD-Eli-Lilly-2004b" TYPE="STUDY">Eli Lilly 2004b</LINK>, <LINK REF="STD-Eli-Lilly-2006" TYPE="STUDY">Eli Lilly 2006</LINK>, <LINK REF="STD-NCT00001656" TYPE="STUDY">NCT00001656</LINK>, <LINK REF="STD-Mortimer-2001" TYPE="STUDY">Mortimer 2001</LINK>, <LINK REF="STD-N0081052094" TYPE="STUDY">N0081052094</LINK>, <LINK REF="STD-N0081121981" TYPE="STUDY">N0081121981</LINK>).<BR/>
<BR/>
</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-02-16 20:57:40 +0000" MODIFIED_BY="[Empty name]">
<P>For details of risk of bias please refer to risk of bias table (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>, <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<ALLOCATION MODIFIED="2010-02-16 20:55:36 +0000" MODIFIED_BY="[Empty name]">
<P>All of the included studies were randomised, but only thirteen provided some details about the allocation process: <LINK REF="STD-Gureje-2003" TYPE="STUDY">Gureje 2003</LINK>, <LINK REF="STD-Kinon-2006b" TYPE="STUDY">Kinon 2006b</LINK>, <LINK REF="STD-Kumra-2007" TYPE="STUDY">Kumra 2007</LINK>, <LINK REF="STD-Mortimer-2004" TYPE="STUDY">Mortimer 2004</LINK>, <LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK>, <LINK REF="STD-Purdon-2000" TYPE="STUDY">Purdon 2000</LINK> and <LINK REF="STD-Sikich-2004" TYPE="STUDY">Sikich 2004</LINK> used a computer-generated randomisation, <LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK> used a random-numbers chart (blocks of four) and <LINK REF="STD-Wagner-2005" TYPE="STUDY">Wagner 2005</LINK> used medication containers according to a pseudo-random computer algorithm. These studies had a relatively low risk of bias. For all the others information was so little, that it remained unclear, whether there was a risk of bias. <LINK REF="STD-Conley-2001" TYPE="STUDY">Conley 2001</LINK> mentioned that randomisation was stratified by site and <LINK REF="STD-Krakowski-2006" TYPE="STUDY">Krakowski 2006</LINK> used block randomisation (block size of three). <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK> described two steps of randomisation: in phase two the participants were re-randomised to a different medication than in phase one. <LINK REF="STD-Wynn-2007" TYPE="STUDY">Wynn 2007</LINK> randomly assigned most participants to three different treatment arms (olanzapine, risperidone or haloperidol; blocks of 15) while those participants with a history of haloperidol induced adverse events were randomly assigned to either olanzapine or risperidone. Only two studies (<LINK REF="STD-Mortimer-2004" TYPE="STUDY">Mortimer 2004</LINK>, <LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK>) provided some information on allocation concealment, whereas the other studies did not report on this.</P>
</ALLOCATION>
<BLINDING MODIFIED="2009-09-30 13:50:24 +0100" MODIFIED_BY="[Empty name]">
<P>Forty-two of the included studies were described as double-blind and eight as single-blind (<LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK>, <LINK REF="STD-Robinson-2006" TYPE="STUDY">Robinson 2006</LINK>, <LINK REF="STD-Bai-2005" TYPE="STUDY">Bai 2005</LINK>, <LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK>, <LINK REF="STD-Voruganti-2007" TYPE="STUDY">Voruganti 2007</LINK>, <LINK REF="STD-Ozguven-2004" TYPE="STUDY">Ozguven 2004</LINK>, <LINK REF="STD-Sacchetti-2004" TYPE="STUDY">Sacchetti 2004</LINK> and <LINK REF="STD-Sirota-2006" TYPE="STUDY">Sirota 2006</LINK>). Nine studies (<LINK REF="STD-Kinon-2006b" TYPE="STUDY">Kinon 2006b</LINK>, <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>, <LINK REF="STD-McEvoy-2006" TYPE="STUDY">McEvoy 2006</LINK>, <LINK REF="STD-Mortimer-2004" TYPE="STUDY">Mortimer 2004</LINK>, <LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK>, <LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK>, <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK>, <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>, <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>) described using identical capsules for blinding. No study examined whether blinding was effective. We found that the side-effect profiles of the examined compounds are quite different which may have made blinding difficult. We therefore conclude that the risk of bias for objective outcomes (e.g. death or laboratory values) was low, but there was a risk of bias for subjective outcomes.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2010-02-13 11:10:56 +0000" MODIFIED_BY="[Empty name]">
<P>The overall number of participants leaving the study early was high 49.2%. Ten studies did not provide data on leaving the study early (<LINK REF="STD-Canive-2000" TYPE="STUDY">Canive 2000</LINK>, <LINK REF="STD-Dolnak-2001" TYPE="STUDY">Dolnak 2001</LINK>, <LINK REF="STD-Mori-2004" TYPE="STUDY">Mori 2004</LINK>, <LINK REF="STD-Svestka-2003a" TYPE="STUDY">Svestka 2003a</LINK>, <LINK REF="STD-Svestka-2003b" TYPE="STUDY">Svestka 2003b</LINK>, <LINK REF="STD-Svestka-2005" TYPE="STUDY">Svestka 2005</LINK>, <LINK REF="STD-Van-Nimwegen-2006" TYPE="STUDY">Van Nimwegen 2006</LINK>, <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK>, <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>, <LINK REF="STD-Wynn-2007" TYPE="STUDY">Wynn 2007</LINK>). The majority of trials that had been published in peer reviewed journals described the participant disposition well. Most studies applied the last-observation-carried-forward method to account for participants leaving the study early which is an imperfect method. It assumes that a participant who left the study prematurely would not have had a change of his condition if he had stayed in the study. This assumption can be wrong. This may be less of a problem in the studies with low attrition or people leaving close to the end of the trial, but clearly problematic in studies with high attrition.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2010-02-13 11:18:56 +0000" MODIFIED_BY="[Empty name]">
<P>In nine studies the reporting on secondary or even primary outcomes was incomplete ( <LINK REF="STD-Dollfus-2005" TYPE="STUDY">Dollfus 2005</LINK>, <LINK REF="STD-Mori-2004" TYPE="STUDY">Mori 2004</LINK>, <LINK REF="STD-Purdon-2000" TYPE="STUDY">Purdon 2000</LINK>, <LINK REF="STD-Sacchetti-2004" TYPE="STUDY">Sacchetti 2004</LINK>, <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK>, <LINK REF="STD-Van-Nimwegen-2006" TYPE="STUDY">Van Nimwegen 2006</LINK>, <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>, <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>, <LINK REF="STD-Wynn-2007" TYPE="STUDY">Wynn 2007</LINK>). Some authors only described those treatment emergent adverse events with an incidence of at least 5% or 10%, or only in case of moderate or worse severity, or only if there was a significant difference between groups ( <LINK REF="STD-Conley-2001" TYPE="STUDY">Conley 2001</LINK>, <LINK REF="STD-Gureje-2003" TYPE="STUDY">Gureje 2003</LINK>, <LINK REF="STD-Jeste-2003" TYPE="STUDY">Jeste 2003</LINK>, <LINK REF="STD-Keefe-2006" TYPE="STUDY">Keefe 2006</LINK>, <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK>, <LINK REF="STD-Tran-1997" TYPE="STUDY">Tran 1997</LINK> <LINK REF="STD-Zhong-2006" TYPE="STUDY">Zhong 2006</LINK>). This procedure is problematic, because rare, but potentially serious side-effects may be missed. Only five studies appeared to have a low risk of bias (<LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK>, <LINK REF="STD-Purdon-2000" TYPE="STUDY">Purdon 2000</LINK>, <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>, <LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK>, <LINK REF="STD-Sikich-2004" TYPE="STUDY">Sikich 2004</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2010-02-16 20:57:40 +0000" MODIFIED_BY="[Empty name]">
<P>None of the studies was clearly free of other bias. 29 studies were industry sponsored which poses a problem due to an inevitable conflict of interest (<LINK REF="STD-Bitter-2004" TYPE="STUDY">Bitter 2004</LINK>, <LINK REF="STD-Breier-2005" TYPE="STUDY">Breier 2005</LINK>, <LINK REF="STD-Conley-2001" TYPE="STUDY">Conley 2001</LINK>, <LINK REF="STD-Canive-2000" TYPE="STUDY">Canive 2000</LINK>, <LINK REF="STD-Conley-2003" TYPE="STUDY">Conley 2003</LINK>, <LINK REF="STD-Dollfus-2005" TYPE="STUDY">Dollfus 2005</LINK>, <LINK REF="STD-Gureje-2003" TYPE="STUDY">Gureje 2003</LINK>, <LINK REF="STD-Jeste-2003" TYPE="STUDY">Jeste 2003</LINK>, <LINK REF="STD-Keefe-2006" TYPE="STUDY">Keefe 2006</LINK>, <LINK REF="STD-Kinon-2006a" TYPE="STUDY">Kinon 2006a</LINK>, <LINK REF="STD-Kinon-2006b" TYPE="STUDY">Kinon 2006b</LINK>, <LINK REF="STD-Lecrubier-2006" TYPE="STUDY">Lecrubier 2006</LINK>, <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK>, <LINK REF="STD-McQuade-2004" TYPE="STUDY">McQuade 2004</LINK>, <LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK>, <LINK REF="STD-Mortimer-2004" TYPE="STUDY">Mortimer 2004</LINK>, <LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK>, <LINK REF="STD-Purdon-2000" TYPE="STUDY">Purdon 2000</LINK>, <LINK REF="STD-Riedel-2007" TYPE="STUDY">Riedel 2007</LINK>, <LINK REF="STD-Sacchetti-2004" TYPE="STUDY">Sacchetti 2004</LINK>, <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>, <LINK REF="STD-Sirota-2006" TYPE="STUDY">Sirota 2006</LINK>, <LINK REF="STD-Tollefson-2001" TYPE="STUDY">Tollefson 2001</LINK>, <LINK REF="STD-Tran-1997" TYPE="STUDY">Tran 1997</LINK>, <LINK REF="STD-Vanelle-2006" TYPE="STUDY">Vanelle 2006</LINK>, <LINK REF="STD-Voruganti-2007" TYPE="STUDY">Voruganti 2007</LINK>, <LINK REF="STD-Wagner-2005" TYPE="STUDY">Wagner 2005</LINK>, <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>, <LINK REF="STD-Wynn-2007" TYPE="STUDY">Wynn 2007</LINK>). Sponsoring of nine studies remained unclear. There is evidence that pharmaceutical companies sometimes highlight the benefits of their compounds and tend to suppress their disadvantages (<LINK REF="REF-Heres-2006" TYPE="REFERENCE">Heres 2006</LINK>).<BR/>Other methodological shortcomings of recent antipsychotic drug trials such as short wash-out phases, selected and usually chronic participants, and lack of standardised response criteria also applied here (<LINK REF="REF-Leucht-2008" TYPE="REFERENCE">Leucht 2008</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-02-17 11:46:36 +0000" MODIFIED_BY="[Empty name]">
<P>1. Comparison 1. OLANZAPINE versus AMISULPRIDE<BR/>Five included studies (<LINK REF="STD-Bai-2005" TYPE="STUDY">Bai 2005</LINK>, <LINK REF="STD-Lecrubier-2006" TYPE="STUDY">Lecrubier 2006</LINK>, <LINK REF="STD-Mortimer-2004" TYPE="STUDY">Mortimer 2004</LINK>, <LINK REF="STD-Vanelle-2006" TYPE="STUDY">Vanelle 2006</LINK>, <LINK REF="STD-Wagner-2005" TYPE="STUDY">Wagner 2005</LINK>) compared olanzapine with amisulpride.</P>
<P>1.1 Global state<BR/>1.1.1 Global state - no clinically significant response to treatment - as defined by the original studies<BR/>There was no significant difference between olanzapine and amisulpride (4 RCTs, n=724, RR 0.97 CI 0.82 to 1.14).</P>
<P>1.1.2 Global state - no clinically important change<BR/>There was no significant difference (3 RCTs, n=514, RR 1.10 CI 0.84 to 1.43).
<BR/>

<BR/>1.1.3 Global state - relapse - as defined by the original studies<BR/>There was no significant difference (1 RCT, n=210, RR 1.07 CI 0.46 to 2.51).</P>
<P>1.2 Leaving the study early<BR/>There was no significant difference between groups. More than one third, 38% of the participants in the treatment group and 37% of those in the control group, left the studies early due to any reason (5 RCTs, n=804, RR 0.94 CI 0.79 to 1.11). Due to adverse events 9% of the participants of each groups left the studies early (4 RCTs, n=724, RR 0.84 CI 0.52 to 1.36) and 15% of the participants of each group left the studies early due to inefficacy of treatment (4 RCTs, n=724, RR 0.84 CI 0.50 to 1.40).</P>
<P>1.3 Mental state<BR/>1.3.1 General - no clinically important change - less than 50% PANSS total score reduction<BR/>There was no significant difference (1 RCT, n=52, RR 1.45 CI 0.85 to 2.50).</P>
<P>1.3.2 General - average score at endpoint - PANSS total<BR/>There was no significant difference in the overall analysis (4 RCTs, n=701, WMD -1.57 CI -6.09 to 2.94),<BR/>short term (2 RCTs, n=119, WMD 2.86 CI -11.36 to 17.08), medium term (2 RCTs, n=582, WMD -2.53 CI -7.45 to 2.48)</P>
<P>1.3.3 General - no clinically important change - less than 50% BPRS total score reduction
<BR/>
There was no significant difference (1 RCT, n=377, RR 0.92 CI 0.73 to 1.14).</P>
<P>1.3.4 General - average score at endpoint - BPRS total<BR/>There was no significant difference analysis (3 RCTs, n=665, WMD -1.26 CI -3.34 to 0.82), as well as in short term data (1 RCT, n=83, WMD -1.40 CI -4.98 to 2.18) and medium term data (2 RCTs, n=582, WMD -1.39 CI -4.83 to 2.04).</P>
<P>1.3.5 Positive symptoms - no clinically important change (less than 50% PANSS positive sub-score reduction)
<BR/>
There was no significant difference (1 RCT, n=52, RR 1.44 CI 0.75 to 2.78).</P>
<P>1.3.6 Positive symptom - average score at endpoint - PANSS positive<BR/>There was no significant difference (4 RCTs, n=701, WMD -0.66 CI -1.88 to 0.56), as well as in short term data (2 RCTs, n=119, WMD -0.15 CI -2.57 to 2.27) and medium term data (2 RCTs, n=582, WMD -0.98 CI -3.12 to 1.16).
<BR/>

</P>
<P>1.3.7 Negative symptoms - average score at endpoint - PANSS negative<BR/>There was no significant difference in the overall analysis (4 RCTs, n=701, WMD -0.21 CI -1.10 to 0.69), as well as in short term (2 RCTs, n=119, WMD 0.49 CI -2.05 to 3.02) and medium term data (2 RCTs, n=582, WMD -0.38 CI -1.56 to 0.80).</P>
<P>1.3.8 Negative symptoms - no clinically important change - less than 20% SANS total score reduction<BR/>There was no significant difference (1 RCT, n=210, RR 0.88 CI 0.63 to 1.25).</P>
<P>1.3.9 Negative symptoms - average score at endpoint - SANS total<BR/>There was no significant difference in the overall analysis (2 RCTs, n=243, WMD 0.00 CI -1.43 to 1.43), as well as in short term (1 RCT, n=33, WMD 8.62 CI -10.45 to 27.69) and medium term data (1 RCT, n=210, WMD -0.05 CI -1.49 to 1.39).</P>
<P>1.4 General functioning - average score at endpoint - SOFAS total - percent change<BR/>There was no significant difference (1 RCT, n=359, WMD -0.20 CI -10.94 to 10.54).</P>
<P>1.5 Quality of Life - average score at endpoint - QLS total score<BR/>There was no significant difference (2 RCTs, n=510, WMD 0.00 CI -0.22 to 0.22).</P>
<P>1.6 Cognitive functioning<BR/>1.6.1 Cognitive functioning: no clinically important change- less than 50% Global Cognitive Index reduction<BR/>There was no significant difference (1 RCT, n=52, RR 1.00 CI 0.74 to 1.35).</P>
<P>1.6.2 Global cognitive index - average score at endpoint<BR/>There was no significant difference (1 RCT, n=36, WMD 0.13 CI -0.09 to 0.35).</P>
<P>1.7 Adverse effects<BR/>1.7.1 Numbers of participants with at least one adverse effect<BR/>There was no significant difference (2 RCTs, n=462, RR 0.97 CI 0.82 to 1.15).</P>
<P>1.7.2 Death<BR/>There was no significant difference in the number of participants dying due to 'natural causes' (1 RCT, n=377, RR 0.34 CI 0.01 to 8.17) or due to suicide (1 RCT, n=377, RR 3.02 CI 0.12 to 73.56). There was also no significant difference in the number of suicide attempts (1 RCT, n=210, RR 1.50 CI 0.16 to 14.16).</P>
<P>1.7.3 Cardiac effects - number of participants with a QTc interval &gt; 500 ms<BR/>There was no significant difference (1 RCT, n=377, RR not estimable).</P>
<P>1.7.4 Cardiac effects - mean change of QTc interval from baseline in ms<BR/>There was no significant difference (2 RCTs, n=303, WMD -5.25 CI -11.07 to 0.57).</P>
<P>1.7.5 Central nervous system - sedation<BR/>There was no significant difference (2 RCTs, n=587, RR 0.82 CI 0.43 to 1.57).</P>
<P>1.7.6 Central nervous system - seizures<BR/>There was no significant difference (1 RCT, n=210, RR 1.51 CI 0.06 to 36.61).</P>
<P>1.7.7 Extrapyramidal effects<BR/>There was no significant difference in the number of participants with extrapyramidal side effects reported as akathisia (2 RCTs, n=587, RR 1.52 CI 0.82 to 2.81), dyskinesia (1 RCT, n=210, RR 1.51 CI 0.06 to 36.61), dystonia (1 RCT, n=377, RR 0.20 CI 0.01 to 4.16), 'extrapyramidal symptoms' (1 RCT, n=210, RR 0.83 CI 0.50 to 1.39), parkinsonism (data are of two studies are presented separately due to heterogeneity, I² = 61%, <LINK REF="STD-Mortimer-2004" TYPE="STUDY">Mortimer 2004</LINK>: n=377, RR 0.09 CI 0.01 to 0.70 and <LINK REF="STD-Lecrubier-2006" TYPE="STUDY">Lecrubier 2006</LINK>: n=210, RR 0.75 CI 0.13 to 4.39), tremor (1 RCT, n=210, RR 1.75 CI 0.37 to 8.20), and use of antiparkinson medication (1 RCT, n=377, RR 0.66 CI 0.37 to 1.17).</P>
<P>1.7.8 Extrapyramidal symptoms - scale measured<BR/>There was no significant difference between amisulpride and olanzapine in dyskinesia (AIMS: 1 RCT, n=356, WMD 0.40 CI -0.33 to 1.13) and general extrapyramidal side-effects (SAS: 2 RCTs, n=406, WMD 0.00 CI -0.08 to 0.08).</P>
<P>1.7.9 Haematological - white blood cell count - leukopenia<BR/>There was no significant difference in numbers of people with leukopenia (1 RCT, n=210, RR 2.52 CI 0.12 to 51.74).</P>
<P>1.7.10 Prolactin associated side effects<BR/>There were no significant differences between olanzapine and amisulpride in the number of participants with amenorrhoea (1 RCT, n=66, RR 0.65 CI 0.12 to 3.61), galactorrhoea (1 RCT, n=66, RR 0.15 CI 0.01 to 3.51) and sexual dysfunction (2 RCTs, n=521, RR 0.74 CI 0.08 to 7.02).</P>
<P>1.7.11 Metabolic - cholesterol - change from baseline in mg/dl<BR/>There was no significant difference (1 RCT, n=85, WMD 3.42 CI -5.48 to 12.32).</P>
<P>1.7.12 Metabolic - glucose - number of participants with diabetes mellitus<BR/>There was no significant difference between olanzapine and amisulpride (1 RCT, n=377, RR 3.02 CI 0.12 to 73.56).</P>
<P>1.7.13 Metabolic - glucose - mean change from baseline in mg/dl<BR/>Amisulpride was associated with significantly less glucose increase than olanzapine (2 RCTs, n=406, WMD 7.30 CI 6.99 to 7.62).</P>
<P>1.7.14 Metabolic - weight gain - number of participants with weight gain<BR/>More participants in the olanzapine group than in the amisulpride group gained weight (3 RCTs, n=672, RR 1.83 CI 1.34 to 2.50, NNH 9 CI 6 to 20).</P>
<P>1.7.15 Metabolic - weight gain - change from baseline in kg<BR/>On the average olanzapine was associated with more weight gain than amisulpride (3 RCTs, n=671, WMD 2.11 CI 1.29 to 2.94).</P>
<P>1.9 Publication bias:<BR/>Due to small number of included studies a funnel plot analysis was not performed.</P>
<P>1.10 Investigation for heterogeneity and sensitivity analysis:<BR/>The reasons for the preplanned sensitivity analysis did not apply and were therefore not performed.<BR/>
</P>
<P>2. Comparison 2. OLANZAPINE versus ARIPIPRAZOLE<BR/>Two included studies (<LINK REF="STD-CN138003" TYPE="STUDY">CN138003</LINK>, <LINK REF="STD-McQuade-2004" TYPE="STUDY">McQuade 2004</LINK>) compared olanzapine with aripiprazole.</P>
<P>2.1 Global state<BR/>2.1.1 Global state - no clinically significant response - as defined by the original studies<BR/>There was no significant difference (2 RCTs, n=1020, RR 0.95 CI 0.85 to 1.05).</P>
<P>2.1.2 Global state - no clinically important change 
<BR/>
There was no significant difference in the overall analysis (2 RCTs, n=1020, RR 0.95 CI 0.85 to 1.05), as well as in the short term (1 RCT, n=703, RR 1.00 CI 0.82 to 1.23) and medium term (1 RCT, n=317, RR 0.93 CI 0.82 to 1.05).</P>
<P>2.2 Leaving the study early<BR/>37% of the participants in the olanzapine group and 43% of the participants in the aripiprazole group left the studies early, a non-significant difference (2 RCTs, n=1020, RR 0.87 CI 0.69 to 1.09). The results were somewhat heterogeneous, I² = 62%, but the direction of the effect was the same in both studies (<LINK REF="STD-McQuade-2004" TYPE="STUDY">McQuade 2004</LINK>: n=317, RR 0.94 CI 0.82 to 1.08; <LINK REF="STD-CN138003" TYPE="STUDY">CN138003</LINK>: n=703, RR 0.87 CI 0.69 to 1.09). Only <LINK REF="STD-McQuade-2004" TYPE="STUDY">McQuade 2004</LINK> provided data on leaving early due to adverse events or inefficacy of treatment, but again there was no significant difference. 19% of the participants in the olanzapine group and 24% of the participants of the aripiprazole group left the study early because of adverse events (n=317, RR 0.79 CI 0.51 to 1.21). 9% of the participants treated with olanzapine and 15% of the participants treated with aripiprazole left the study early due to lack of efficacy of treatment (n=317, RR 0.59 CI 0.32 to 1.10).</P>
<P>2.3 Mental state<BR/>2.3.1 General - average score at endpoint - PANSS total<BR/>Olanzapine was significantly more efficacious than aripiprazole in the overall analysis (2 RCTs, n=794, WMD -4.96 CI -8.06 to -1.85), which was mainly seen in the short term data analysis (1 RCT, n=703, WMD -5.21 CI -8.51 to -1.91) but not in the medium term data analysis (1 RCT, n=91, WMD 3.00 CI -12.21 to 6.21) .</P>
<P>2.4 Adverse effects<BR/>2.4.1 Cardiac effects - number of participants with QTc prolongation<BR/>There was no significant difference (1 RCT, n=317, RR 2.91 CI 0.60 to 14.18).</P>
<P>2.4.2 Cardiac effects - mean change of QTc interval from baseline in ms<BR/>There was no significant difference (1 RCT, n=317, WMD 3.70 CI -2.11 to 9.51).</P>
<P>2.4.3 Central nervous system - sedation<BR/>Sedation was significantly less frequent in the aripiprazole group than in the olanzapine group (1 RCT, n=317, RR 2.99 CI 1.62 to 5.51, NNH 7 CI 4 to 13).</P>
<P>2.4.4 Extrapyramidal effects<BR/>There was no significant difference in akathisia (1 RCT, n=317, RR 0.54 CI 0.18 to 1.57), 'extrapyramidal symptoms' (1 RCT, n=317, RR 0.93 CI 0.56 to 1.54) and parkinsonism (1 RCT, n=317, RR 1.08 CI 0.58 to 2.01).</P>
<P>2.4.5 Prolactin - numbers of participants with prolactin level increase<BR/>Abnormally high prolactin levels were reported by one study indicating a significant difference favouring aripiprazole (1 RCT, n=317, RR 3.74 CI 1.68 to 8.33, NNH 8 CI 5 to 17).</P>
<P>2.4.6 Metabolic - cholesterol - number of participants with cholesterol increase<BR/>More participants in the olanzapine group than in the aripiprazole group had a cholesterol increase (1 RCT, n=223, RR 3.15 CI 1.84 to 5.39, NNH 4 CI 3 to 6).</P>
<P>2.4.7 Metabolic - cholesterol - mean change from baseline in mg/dl<BR/>Olanzapine was associated with a significantly higher increase of cholesterol levels than aripiprazole (1 RCT, n=223, WMD 17.43 CI 7.65 to 27.21).</P>
<P>2.4.8 Metabolic - glucose - mean change from baseline in mg/dl<BR/>There was no significant difference (1 RCT, n=317, WMD 2.00 CI -6.48 to 10.48).</P>
<P>2.4.9 Metabolic - weight gain - number of participants with 7% or more increase of total body weight<BR/>More participants in the olanzapine group gained more than 7% of their initial weight (1 RCT, n=317, RR 2.68 CI 1.71 to 4.19, NNH 4 CI 3 to 8).</P>
<P>2.4.10 Metabolic - weight gain - mean change from baseline in kg<BR/>Weight gain reported as mean change from baseline indicated a significant difference favouring aripiprazole (1 RCT, n=90, WMD 5.60 CI 2.15 to 9.05).</P>
<P>2.5 Publication bias:<BR/>Due to small number of included studies a funnel plot analysis was not performed.</P>
<P>2.6 Investigation for heterogeneity and sensitivity analysis:<BR/>The reasons for the preplanned sensitivity analysis did not apply and were therefore not performed.<BR/>
</P>
<P>3.Comparison 3. OLANZAPINE versus CLOZAPINE<BR/>Twelve included studies (<LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK>, <LINK REF="STD-Bitter-2004" TYPE="STUDY">Bitter 2004</LINK>, <LINK REF="STD-Conley-2003" TYPE="STUDY">Conley 2003</LINK>, <LINK REF="STD-Krakowski-2006" TYPE="STUDY">Krakowski 2006</LINK>, <LINK REF="STD-Kumra-2007" TYPE="STUDY">Kumra 2007</LINK>, <LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK>, <LINK REF="STD-Moresco-2004" TYPE="STUDY">Moresco 2004</LINK>, <LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK>, <LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK>, <LINK REF="STD-Tollefson-2001" TYPE="STUDY">Tollefson 2001</LINK>, <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>, <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK>) compared olanzapine with clozapine.</P>
<P>3.1 Global state<BR/>3.1.1 Global state - no clinically significant response - as defined by the original studies<BR/>There was no statistically significant difference (6 RCTs, n=518, RR 0.99 CI 0.91 to 1.09).</P>
<P>3.1.2 Global state - no clinically important change<BR/>There was no significant difference in the overall analysis (5 RCTs, n=505, RR 0.97 CI 0.81 to 1.16), as well as in short term data analysis (2 RCTs, n=44, RR 1.32 CI 0.39 to 4.44) but not in the medium term data analysis (2 RCTs, n=441, WMD 0.92 CI 0.77 to 1.10) .</P>
<P>3.2 Leaving the study early<BR/>A similar amount of participants in the olanzapine group (38%) and in the clozapine group (40%) left the studies early due to any reason (11 RCTs, n=1702, RR 0.96 CI 0.86 to 1.08 ). However, significantly fewer participants in the olanzapine group (7%) than in the clozapine group (11%) left the studies early due to adverse events (10 RCTs, n=1674, RR 0.62 CI 0.43 to 0.92, NNT 20 CI 13 to 100). There was no significant difference in the number of participants leaving early due to lack of efficacy (15% versus 9%, 10 RCTs, n=1674, RR 1.38 CI 0.77 to 2.47).</P>
<P>3.3 Mental state<BR/>3.3.1 General - no clinically important change (less than 50% PANSS total score reduction)<BR/>There was no significant difference (2 RCTs, n=327, RR 1.00 CI 0.91 to 1.09).</P>
<P>3.3.2 General - no clinically important change (less than 50% BPRS total score reduction)<BR/>There was no significant difference (1 RCT, n=61, RR 0.89 CI 0.49 to 1.59).</P>
<P>3.3.3 General - no clinically important change (less than 20% BPRS total score reduction)<BR/>There was no significant difference (1 RCT, n=25, RR 1.27 CI 0.80 to 2.02).</P>
<P>3.3.4 General - average score at endpoint - PANSS total<BR/>There was no significant difference in the overall analysis (7 RCTs, n=618, WMD -1.97 CI -4.66 to 0.71), as well as in short term data (3 RCTs, n=117, WMD -1.97 CI -5.42 to 1.48) or medium term data (4 RCTs, n=503, WMD -1.99 CI -6.27 to 2.29).</P>
<P>3.3.5 General - average score at endpoint - BPRS total<BR/>There was a statistically significant difference favouring the olanzapine (6 RCTs, n=412, WMD -1.47 CI -2.68 to -0.25). Nevertheless, the data of two studies <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK>, <LINK REF="STD-Kumra-2007" TYPE="STUDY">Kumra 2007</LINK> were possibly skewed. Excluding these two studies the difference was no longer significant (4 RCTs, n=312, WMD -1.56 CI -4.53 to 1.40),</P>
<P>3.3.6 Positive symptoms - average score at endpoint - PANSS positive<BR/>There was no significant difference in the overall analysis (6 RCTs, n=592, WMD -0.08 CI -1.11 to 0.96),<BR/>as well as in the short term data analysis (2 RCTs, n=89, WMD 0.63 CI -1.00 to 2.27) and in the medium term data analysis (4 RCTs, n=503, WMD -0.54 CI -1.87 to 0.78).</P>
<P>3.3.7 Positive symptoms - average score at endpoint - BPRS positive<BR/>There was no significant difference in the overall analysis (3 RCTs, n=297, WMD -0.13 CI -1.25 to 1.00)<BR/>as well as in short term data analysis (1 RCT, n=13, WMD 1.11 CI -2.10 to 4.32) and medium term data analyis (2 RCTs, n=284, WMD -0.30 CI -1.51 to 0.91).</P>
<P>3.3.8 Positive symptoms - average score at endpoint - SAPS total<BR/>There was no significant difference (1 RCT, n=25, WMD 9.00 CI -4.06 to 22.06).</P>
<P>3.3.9 Negative symptoms - average score at endpoint - PANSS negative<BR/>There was no significant difference (6 RCTs, n=592, WMD -0.78 CI -1.77 to 0.21), as well as in the short term data analysis (2 RCTs, n=89, WMD -1.32 CI -3.05 to 0.42) and in the medium term data analysis (4 RCTs, n=503, WMD -0.52 CI -1.72 to 0.68).</P>
<P>3.3.10 Negative symptoms - average score at endpoint - BPRS negative<BR/>There was no significant difference (3 RCTs, n=297, WMD 0.18 CI -0.44 to 0.80), as well as in short term data analysis (1 RCT, n=13, WMD 0.78 CI -0.23 to 1.79) and medium term data analyis (2 RCTs, n=284, WMD -0.15 CI -0.89 to 0.60).</P>
<P>3.3.11 Negative symptoms - average score at endpoint - SANS total<BR/>Overall there was no significant difference (2 RCTs, n=64, WMD 4.81 CI -4.71 to 14.33), but the results were heterogeneous I² =73%. <LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK> found a significant superiority of clozapine (n=25, WMD 11.00 CI 1.10 to 20.90) while in <LINK REF="STD-Kumra-2007" TYPE="STUDY">Kumra 2007</LINK> there was only a small trend in the same direction (n=39, WMD 1.00 CI -1.60 to 3.60).</P>
<P>3.4 Quality of Life - average score at endpoint - SWN total score<BR/>There was no significant difference (1 RCT, n=99, WMD -8.20 CI -21.67 to 5.27).</P>
<P>3.5 Cognitive functioning<BR/>3.5.1 Cognitive functioning - no clinically important change - less than half a standard deviation improvement in the global neurocognitive score<BR/>Only one study reported data on this outcome and showed a statistically significant superiority of olanzapine (n=79, RR 0.61 CI 0.43 to 0.87, NNT 3 CI 2 to 9).</P>
<P>3.5.2 Global neurocognitive score - average score at endpoint<BR/>There was no significant difference (1 RCT, n=50, WMD 0.29 CI -0.08 to 0.66).</P>
<P>3.6 Service use - number of participants rehospitalised<BR/>In a single large study (<LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK>) more participants in the olanzapine group had to be rehospitalized than in the clozapine group (1 RCT, n=980, RR 1.28 CI 1.02 to 1.61, NNH not estimable).</P>
<P>3.7 Adverse effects<BR/>3.7.1 Number of participants with at least one adverse effect<BR/>Data on 'at least one adverse effect' showed a statistically significant difference favouring olanzapine (7 RCTs, n=422, RR 0.65 CI 0.45 to 0.94, NNT 5 CI 3 to 33). Although the results were heterogeneous, I² = 81%, the trend in all single studies was in favour of olanzapine (<LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK>: n=61, RR 0.30 CI 0.16 to 0.54, NNH 2 CI 1 to 2; <LINK REF="STD-Conley-2003" TYPE="STUDY">Conley 2003</LINK>: n=13, RR not estimable; <LINK REF="STD-Bitter-2004" TYPE="STUDY">Bitter 2004</LINK>: n=147, RR 0.61 CI 0.25 to 1.49; <LINK REF="STD-Moresco-2004" TYPE="STUDY">Moresco 2004</LINK>: n=23, RR 0.73 CI 0.28 to 1.91; <LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK>: n=114, RR 0.85 CI 0.72 to 1.00; <LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK>: n=25, RR 0.46 CI 0.19 to 1.14; <LINK REF="STD-Kumra-2007" TYPE="STUDY">Kumra 2007</LINK>: n=39, RR 0.91 CI 0.77 to 1.08).<BR/>

<BR/>
3.7.2 Death<BR/>There was no significant difference on death due to 'any reason' (1 RCT, n=980, RR 0.67 CI 0.27 to 1.62) and due to 'natural causes (2 RCTs, n=193, RR not estimable). Suicide attempts were reported by one study revealing a statistically significant difference favouring the clozapine (<LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK>) (1 RCT, n=980, RR 1.78 CI 1.22 to 2.62, NNH 17 CI 10 to 50) Analysis of data on death due to suicide did not show a statistically significant difference between groups (2 RCTs, n=993, RR 0.60 CI 0.14 to 2.50).</P>
<P>3.7.3 Cardiac effects
<BR/>
There was no significant difference in 'ECG abnormalities' (1 RCT, n=25, RR 0.46 CI 0.05 to 4.46) and 'QTc prolongation' (2 RCTs, n=127, RR 0.33 CI 0.01 to 8.01).</P>
<P>3.7.4 Central nervous system - sedation<BR/>Olanzapine was less sedating than clozapine (7 RCTs, n=1445, RR 0.54 CI 0.32 to 0.89, NNT 7 CI 5 to 13). Although the direction of the effect was the same in all studies, there was a high degree of heterogeneity, I² = 88%, caused by <LINK REF="STD-Kumra-2007" TYPE="STUDY">Kumra 2007</LINK>. Excluding this single first episode study resolved the heterogeneity and olanzapine was still less sedating than clozapine (6 RCTS, n=1406, RR 0.52 CI 0.43 to 0.62, NNT 5 CI 4 to 12).</P>
<P>3.7.5 Central nervous system - seizures<BR/>Fewer participants in the olanzapine groups than in the clozapine groups had seizures (4 RCTs, n=1097, RR 0.15 CI 0.04 to 0.58, NNT 50 CI 25 to 100)</P>
<P>3.7.6 Extrapyramidal effects<BR/>There was no significant difference in the number of participants with akathisia (4 RCTs, n=1320, RR 1.37 CI 0.71 to 2.63), dyskinesia (2 RCTs, n=327, RR 2.29 CI 0.81 to 6.45), 'extrapyramidal symptoms' (2 RCTs, n=84, RR not estimable), parkinsonism (2 RCTs, n=327, RR 0.78 CI 0.30 to 2.00), rigor (1 RCT, n=980, RR 6.00 CI 0.73 to 49.65) or use of antiparkinson medication (6 RCTs, n=561, RR 1.14 CI 0.60 to 2.19).</P>
<P>3.7.7 Extrapyramidal effects - scale measured<BR/>There was no significant difference in akathisia (BAS: 1 RCT, n=175, WMD 0.10 CI -0.18 to 0.38; Hillside Akathisia Scale: 1 RCT, n=137, WMD 0.40 CI -2.30 to 3.10), dyskinesia (AIMS: 3 RCTs, n=352, WMD -0.13 CI -0.51 to 0.25) or overall extrapyramidal side-effects (ESRS: 1 RCT, n=79, WMD -1.30 CI -2.83 to 0.23; SAS: 6 RCTs, n=481, WMD -0.43 CI -1.30 to 0.45).</P>
<P>3.7.8 Haematological - white blood cells - low white blood cell count<BR/>Significantly fewer participants in the olanzapine groups had a low white blood cell count (4 RCTs, n=1264, RR 0.18 CI 0.08 to 0.41, NNT 20 CI 14 to 33).</P>
<P>3.7.9 Prolactin - change from baseline in ng/ml<BR/>In three studies olanzapine was associated with more prolactin increase than clozapine, although the amount of the difference varied. One study reported prolactin increase for men and women combined (n=120, WMD 0.57 CI 0.09 to 1.05), two studies for men only (2 RCTs, n=47, WMD 8.65 CI -3.26 to 20.55, I² = 63%), and one study for women only (n=18, WMD 54.40 CI 22.06 to 86.74).</P>
<P>3.7.10 Metabolic - cholesterol - number of participants with a cholesterol increase<BR/>There was no significant difference (1 RCT, n=25, RR 0.31 CI 0.01 to 6.94).</P>
<P>3.7.11 Metabolic - cholesterol - mean change from baseline in mg/dl<BR/>There was no significant difference (3 RCTs, n=89, WMD 1.16 CI -17.52 to 19.85).</P>
<P>3.7.12 Metabolic - glucose - number of participants with diabetes mellitus<BR/>There was no significant difference (1 RCT, n=980, RR 1.31 CI 0.69 to 2.48).</P>
<P>3.7.13 Metabolic - glucose - change from baseline in mg/dl<BR/>There was no significant difference (3 RCTs, n=89, WMD -2.62 CI -16.34 to 11.09). The results were heterogeneous, because two studies found no difference (<LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>: n=39, WMD 9.90 CI -3.50 to 23.30; <LINK REF="STD-Conley-2003" TYPE="STUDY">Conley 2003</LINK>: n=12, WMD -7.40 CI -28.15 to 13.35), while a single first episode study found a superiority of olanzapine (<LINK REF="STD-Kumra-2007" TYPE="STUDY">Kumra 2007</LINK>: n=38, WMD -10.10 CI -18.74 to -1.46).</P>
<P>3.7.14 Metabolic - weight gain - number of participants with weight gain<BR/>Weight gain was either reported as 'the number of participants with significant weight gain' or as 'weight gain reported as an adverse event'. Overall, there was no significant difference (7 RCTs, n=1600, RR 1.13 CI 0.70 to 1.81), but the data were heterogeneous I² = 73%. When both categories were analysed separately there was no significant difference in 'the number of participants with significant weight gain' (3 RCTs, n=232, RR 0.92 CI 0.40 to 2.13), whereas 'weight gain reported as an adverse event' indicated a significant difference in favour of clozapine (4 RCTs, n=1368, RR 1.67 CI 1.39 to 2.01, NNH not estimable).</P>
<P>3.7.15 Metabolic - weight gain - mean change from baseline in kg<BR/>There was no significant difference (7 RCTs, n=581, WMD 0.04 CI -0.97 to 1.06).</P>
<P>3.8 Publication bias<BR/>Due to small number of included studies a funnel plot analysis was not performed.</P>
<P>3.9 Investigation for heterogeneity and sensitivity analyses:<BR/>After excluding two studies due to possibly skewed data from the analysis of the BPRS total score (<LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK>, <LINK REF="STD-Kumra-2007" TYPE="STUDY">Kumra 2007</LINK>) the significant superiority of clozapine disappeared. When <LINK REF="STD-Kumra-2007" TYPE="STUDY">Kumra 2007</LINK> (possibly skewed data) was excluded from the analysis of the SANS total score clozapine was significantly more efficacious than olanzapine.<BR/>
</P>
<P>4. Comparison 4. OLANZAPINE versus QUETIAPINE<BR/>Thirteen included studies (<LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK>, <LINK REF="STD-Kinon-2006b" TYPE="STUDY">Kinon 2006b</LINK>, <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>, <LINK REF="STD-McEvoy-2006" TYPE="STUDY">McEvoy 2006</LINK>, <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK>, <LINK REF="STD-Mori-2004" TYPE="STUDY">Mori 2004</LINK>, <LINK REF="STD-Ozguven-2004" TYPE="STUDY">Ozguven 2004</LINK>, <LINK REF="STD-Riedel-2007" TYPE="STUDY">Riedel 2007</LINK>, <LINK REF="STD-Sacchetti-2004" TYPE="STUDY">Sacchetti 2004</LINK>, <LINK REF="STD-Sirota-2006" TYPE="STUDY">Sirota 2006</LINK>, <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK>, <LINK REF="STD-Svestka-2003b" TYPE="STUDY">Svestka 2003b</LINK>, <LINK REF="STD-Voruganti-2007" TYPE="STUDY">Voruganti 2007</LINK>) compared olanzapine with quetiapine.</P>
<P>4.1 Global state<BR/>4.1.1 Global state - no clinically significant response - as defined by the original studies<BR/>There was no significant difference (3 RCTs, n=339, RR 0.90 CI 0.70 to 1.16).</P>
<P>4.1.2 Global state - no clinically important change<BR/>There was no significant difference in the overall analysis (2 RCTs, n=309, RR 0.85 CI 0.64 to 1.13),<BR/>as well as in the short term data analysis (1 RCT, n=42, RR 0.73 CI 0.32 to 1.69) and in the medium term data analysis (1 RCT, n=267, RR 0.86 CI 0.64 to 1.17).</P>
<P>4.2 Leaving the study early<BR/>Significantly fewer participants in the olanzapine group (57%) than in the quetiapine group (70%) left the studies early due to any reason (10 RCTs, RR 0.82 CI 0.76 to 0.88, NNT 10 CI 6 to 33), as well as due to lack of efficacy (14% versus 25%, 8 RCTs, n=1563, RR 0.56 CI 0.44 to 0.70, NNT 11 CI 6 to 50). There was no significant difference in the number of participants leaving the studies early due to adverse events (8 RCTs, n=1573, RR 1.11 CI 0.85 to 1.46).</P>
<P>4.3 Mental state<BR/>4.3.1 General - no clinically important change - less than 50% PANSS total score reduction<BR/>There was no significant difference (1 RCT, n=42, RR 1.10 CI 0.65 to 1.86).</P>
<P>4.3.2 General - average endpoint score - PANSS total<BR/>Olanzapine improved the general mental state as measured by the PANSS total score more than quetiapine (10 RCTs, n=1449, WMD -3.66 CI -5.39 to -1.93), which was not significant in short term data (4 RCTs, n=142, WMD -2.17 CI -5.85 to -1.51) but in medium (3 RCTs, n=482, WMD -5.57 CI -9.17 to -1.97) and long term data (3 RCTs, n=825, WMD -3.40 CI -5.88 to -0.91) there was a benefit for olanzapine.</P>
<P>4.3.3 Positive symptoms - no clinically important change - less than 20% SAPS total score reduction<BR/>Only one study used the SAPS to examine positive symptoms and found only a trend in favour of olanzapine (1 RCT, n=30, RR 0.07 CI 0.00 to 1.07).<BR/>
</P>
<P>4.3.4 Positive symptoms - average score at endpoint - PANSS positive subscore<BR/>Olanzapine improved positive symptoms as measured by the PANSS positive subscore significantly better than quetiapine (7 RCTs, n=679, WMD -1.80 CI -2.59 to -1.02), which was not significant in short term data (3 RCTs, n=115, WMD -1.05 CI -2.85 to 0.75) but in medium (3 RCTs, n=483, WMD -2.21 CI -3.52 to -0.90) and long term data (1 RCT, n=81, WMD -1.80 CI -3.21 to -0.39)</P>
<P>4.3.5 Positive symptoms - average score at endpoint - SAPS total score - percent change<BR/>There was a significant difference favouring olanzapine (1 RCT, n=30, WMD -40.84 CI -57.71 to -23.97).</P>
<P>4.3.6 Negative symptoms - no clinically important change - less than 20% SANS total score reduction<BR/>There was no significant difference (1 RCT, n=30, RR 0.67 CI 0.23 to 1.89).</P>
<P>4.3.7 Negative symptoms - average score at endpoint - PANSS negative<BR/>There was no significant difference in the overall analysis (7 RCTs, n=679, WMD -0.41 CI -1.18 to 0.36), as well as in the short term data (3 RCTs, n=115, WMD -0.01 CI -1.73 to 1.72) medium term data<BR/>(3 RCTs, n=484, WMD -0.40 CI -1.47 to 0.67) and long term data analysis (1 RCT, n=81, WMD -0.70 CI -2.13 to 0.73)</P>
<P>4.3.8 Negative symptoms - average score at endpoint - SANS total<BR/>There was no significant difference (1 RCT, n=335, WMD -3.70 CI -7.88 to 0.48).</P>
<P>4.3.9 Negative symptoms - average score at endpoint - SANS total score - percent change<BR/>There was no significant difference (1 RCT, n=30, WMD -2.46 CI -36.82 to 31.90).</P>
<P>4.4 General functioning - average score at endpoint - GAF total score<BR/>There was a statistically significant difference favouring olanzapine (1 RCT, n=278, WMD -3.80 CI -6.83 to -0.77).</P>
<P>4.5 Quality of life - average score at endpoint - QLS total<BR/>There was no significant difference (1 RCT, n=286, WMD -1.80 CI -6.02 to 2.42).</P>
<P>4.6 Service use - number of participants rehospitalised<BR/>There was a statistically significant difference favouring olanzapine (2 RCTs, n=876, RR 0.56 CI 0.41 to 0.77, NNT 11 CI 7 to 25), this tendency was seen in both medium term (1 RCT, n=203, RR 0.56 CI 0.28 to 1.08) and long term data but the difference was significant in the long term data analysis ((1 RCT, n=673, RR 0.56 CI 0.39 to 0.81, NNT 11 CI 7 to 25).</P>
<P>4.7 Adverse effects<BR/>4.7.1 Number of participants with at least one adverse effect<BR/>There was no significant difference (6 RCTs, n=1269, RR 1.04 CI 0.95 to 1.13).</P>
<P>4.7.2 Death<BR/>There was no significant difference in the number of suicides (2 RCT, n=470, RR 0.20 CI 0.01 to 4.16) and suicide attempts (2 RCTs, n=940, RR 2.86 CI 0.44 to 18.71).</P>
<P>4.7.3 Cardiac effects - number of participants with QTc prolongation<BR/>There was no significant difference (1 RCT, n=673, RR 0.08 CI 0.00 to 1.36).</P>
<P>4.7.4 Cardiac effects - change of QTc interval from baseline in ms<BR/>Quetiapine was associated with a significantly longer mean increase of the QTc interval than olanzapine (3 RCTs, n=643, WMD -4.81 CI -9.28 to -0.34).</P>
<P>4.7.5 Central nervous system - sedation<BR/>There was no significant difference (7 RCTs, n=1615, RR 1.01 CI 0.88 to 1.15).</P>
<P>4.7.6 Central nervous system - seizures<BR/>There was no significant difference (1 RCT, n=40, RR 0.30 CI 0.01 to 7.02).</P>
<P>4.7.7 Extrapyramidal effects<BR/>There was no significant difference in the following extrapyramidal side effects: akathisia (6 RCTs, n=1277, RR 1.03 CI 0.72 to 1.47), akinesia (1 RCT, n=267, RR 0.98 CI 0.64 to 1.49), dystonia (1 RCT, n=42, RR 0.22 CI 0.01 to 4.30), 'extrapyramidal symptoms' (2 RCTs, n=245, RR 0.62 CI 0.27 to 1.39), parkinsonism (1 RCT, n=40, RR 1.51 CI 0.42 to 5.48), and tremor (1 RCT, n=42, RR 2.57 CI 0.77 to 8.60). Nevertheless, significantly fewer participants in the quetiapine group received at least one dose of antiparkinson medication (6 RCTs, n=1090, RR 2.05 CI 1.26 to 3.32, NNH 25 CI 14 to 100).</P>
<P>4.7.8 Extrapyramidal effects - scale measured<BR/>There was no significant difference of data in akathisia (BAS: 1 RCT, n=50, WMD 0.10 CI -0.38 to 0.58) or general extrapyramidal side effects (ESRS total score: 1 RCT, n=33, WMD 0.00 CI -2.68 to 2.68; SAS: 1 RCT, n=50, WMD -0.60 CI -2.58 to 1.38).</P>
<P>4.7.9 Prolactin associated side effects<BR/>There was no significant difference in the number of participants with an abnormally high prolactin value (1 RCT, n=42, RR 9.86 CI 0.56 to 172.33), amenorrhoea (3 RCTs, n=252, RR 1.51 CI 0.83 to 2.76), galactorrhoea (4 RCTs, n=1015, RR 1.52 CI 0.58 to 3.98) and gynaecomastia (1 RCT, n=267, RR 3.02 CI 0.84 to 10.92). Significantly fewer people in the quetiapine group reported sexual dysfunctions (4 RCTs, n=1177, RR 1.25 CI 1.01 to 1.55, NNH 20 CI 10 to 100).</P>
<P>4.7.10 Prolactin - change from baseline in ng/ml<BR/>Olanzapine was associated with significantly more prolactin increase than quetiapine (5 RCTs, n=1021, WMD 5.89 CI 0.16 to 11.62). The results were heterogeneous, but the direction of the effect was the same in all single studies. The small first episode study by <LINK REF="STD-Svestka-2003b" TYPE="STUDY">Svestka 2003b</LINK> found an especially pronounced difference (n=35, WMD 40.07 CI 16.04 to 64.10).<BR/>
</P>
<P>4.7.11 Metabolic - cholesterol - number of participants with cholesterol increase<BR/>There was no significant difference (1 RCT, n=267, RR 1.01 CI 0.60 to 1.70).</P>
<P>4.7.12 Metabolic - cholesterol - mean change from baseline in mg/dl<BR/>Overall, there was no significant difference between groups (4 RCTs, n=986, WMD 4.69 CI -4.45 to 13.84).<BR/>The results were heterogeneous, because the first episode study by <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK> showed a trend in favour of olanzapine, while in all other studies olanzapine was associated with more cholesterol increase than quetiapine. Indeed, excluding <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK> there was a significant superiority of quetiapine (3 RCTs, n=905, WMD 7.84 CI 1.57 to 14.12).</P>
<P>4.7.13 Metabolic - glucose - number of participants with abnormally high fasting glucose value<BR/>There was no significant difference (1 RCT, n=267, RR 1.41 CI 0.65 to 3.06).</P>
<P>4.7.14 Metabolic - glucose - change from baseline in mg/dl<BR/>There was a statistical significant difference favouring quetiapine (4 RCTs, n=986, WMD 9.32 CI 0.82 to 17.82). The data were heterogeneous, because again the first episode study by <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK> showed a different direction of the effect than the other three studies. Excluding <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK>, statistical significance prevailed (3 RCTs, n=905, WMD 14.04 CI 2.44 to 25.65).</P>
<P>4.7.15 Metabolic - weight gain - number of participants with weight gain<BR/>Weight gain was reported either as 'significant weight gain' (as defined by the original studies)' or as 'weight gain reported as an adverse event'. Overall fewer participants in the quetiapine group gained weight (8 RCTs, n=1667, RR 1.47 CI 1.09 to 1.98, NNH not estimable).</P>
<P>4.7.16 Metabolic - weight gain - change from baseline in kg<BR/>There was a statistically significant difference favouring quetiapine (7 RCTs, n=1173, WMD 2.68 CI 1.10 to 4.26). The results were heterogeneous, but all studies consistently favoured quetiapine concerning this outcome.</P>
<P>4.8 Publication bias<BR/>The funnel plot for the outcome PANSS total score (10 included studies) did not suggest a publication bias.</P>
<P>4.9 Investigation for heterogeneity and sensitivity analyses:<BR/>Excluding <LINK REF="STD-Mori-2004" TYPE="STUDY">Mori 2004</LINK> from the outcome 'PANSS positive subscore' due to potentially skewed data the results remained significant<BR/>
</P>
<P>5. Comparison 5. OLANZAPINE versus RISPERIDONE<BR/>Twenty-three included studies (<LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK>, <LINK REF="STD-Canive-2000" TYPE="STUDY">Canive 2000</LINK>, <LINK REF="STD-Conley-2001" TYPE="STUDY">Conley 2001</LINK>, <LINK REF="STD-Dollfus-2005" TYPE="STUDY">Dollfus 2005</LINK>, <LINK REF="STD-Dolnak-2001" TYPE="STUDY">Dolnak 2001</LINK>, <LINK REF="STD-Gureje-2003" TYPE="STUDY">Gureje 2003</LINK>, <LINK REF="STD-Jeste-2003" TYPE="STUDY">Jeste 2003</LINK>, <LINK REF="STD-Keefe-2006" TYPE="STUDY">Keefe 2006</LINK>, <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>, <LINK REF="STD-McEvoy-2006" TYPE="STUDY">McEvoy 2006</LINK>, <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK>, <LINK REF="STD-Mori-2004" TYPE="STUDY">Mori 2004</LINK>, <LINK REF="STD-Purdon-2000" TYPE="STUDY">Purdon 2000</LINK>, <LINK REF="STD-Robinson-2006" TYPE="STUDY">Robinson 2006</LINK>, <LINK REF="STD-Sacchetti-2004" TYPE="STUDY">Sacchetti 2004</LINK>, <LINK REF="STD-Sikich-2004" TYPE="STUDY">Sikich 2004</LINK>, <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK>, <LINK REF="STD-Svestka-2003a" TYPE="STUDY">Svestka 2003a</LINK>, <LINK REF="STD-Tran-1997" TYPE="STUDY">Tran 1997</LINK>, <LINK REF="STD-Van-Nimwegen-2006" TYPE="STUDY">Van Nimwegen 2006</LINK>, <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>, <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>, <LINK REF="STD-Wynn-2007" TYPE="STUDY">Wynn 2007</LINK>) compared olanzapine with risperidone.</P>
<P>5.1 Global state<BR/>5.1.1 Global state - no clinically significant response (as defined by the original studies)<BR/>There was no statistically significant difference (7 RCTs, n=1376, RR 0.94 CI 0.88 to 1.01)</P>
<P>5.1.2 Global state - no clinically important change<BR/>Overall, there was no significant difference (5 RCTs, n=975, RR 1.03 CI 0.92 to 1.14), which was similar for all the time periods (short term data (3 RCTs, n=589, RR 1.00 CI 0.86 to 1.15), medium term data (1 RCT, n=120, RR 1.20 CI 0.87 to 1.66) and long term data (1 RCT, n=266, RR 1.02 CI 0.74 to 1.41)) .</P>
<P>5.1.3 Global state - relapse<BR/>There was no significant difference (2 RCTs, n=211, RR 0.80 CI 0.37 to 1.75), neither in short term (1 RCT, n=76, RR 1.33 CI 0.44 to 4.00) nor long term data (1 RCT, n=135, RR 0.59 CI 0.27 to 1.27) .</P>
<P>5.2 Leaving the study early<BR/>Significantly fewer participants in the olanzapine group (48%) than in the risperidone group (56%) left the studies early due to any reason (16 RCTs, n=2738, RR 0.88 CI 0.82 to 0.94, NNT 13 CI 9 to 25).<BR/>Leaving the studies early due to adverse events did not differ between groups (12% versus 11%, 13 RCTs, n=2595, RR 1.04 CI 0.77 to 1.42). Fewer participants in the olanzapine group (11%) than in the risperidone group (15%) left the studies early due to inefficacy of treatment (14 RCTs, n=2744, RR 0.78 CI 0.62 to 0.98, NNT 50 CI 17 to 100).</P>
<P>5.3 Mental State<BR/>5.3.1 General - no clinically important change - less than 50% PANSS total score reduction<BR/>There was a tendency that more participants in the olanzapine group than in the risperidone group responded to treatment (3 RCTs, n=472, RR 0.92 CI 0.85 to 1.00, NNT not estimable), this was rather due to longterm data (2 RCTs, n=401, RR 0.92 CI 0.85 to 1.00, NNT not estimable) than short term data (1 RCT, n=71, RR 2.30 CI 0.22 to 24.26).</P>
<P>5.3.2 General - no clinically important change - less than 20% PANSS total score reduction<BR/>There was no significant difference (2 RCTs, n=553, RR 0.98 CI 0.84 to 1.14).</P>
<P>5.3.3 General - average score at endpoint - PANSS total<BR/>Olanzapine improved the general mental state as measured by the PANSS total score more than risperidone (15 RCTs, n=2390, WMD -1.94 CI -3.31 to -0.58), which was significantly different in long term data (5 RCTs, n=1431, WMD -2.59 CI -4.98 to - 0.20), whereas short term (7 RCTs, n=728, WMD -0.97 CI -3.05 to 1.10) and medium term data (3 RCTs, n=231, WMD -4.11 CI -8.93 to 0.71) indicated the same direction, but did not show a significant difference</P>
<P>5.3.4 General - average score ate endpoint - BPRS total<BR/>Again, olanzapine improved the general mental state more than risperidone in the overall analysis (3 RCTs, n=428, WMD -4.16 CI -8.29 to -0.03).</P>
<P>5.3.5 Positive symptoms - no clinically important change (less than 50% PANSS positive subscore reduction)<BR/>There was no significant difference (1 RCT, n=377, RR 1.02 CI 0.96 to 1.07).</P>
<P>5.3.6 Positive symptoms - average score at endpoint - PANSS positive<BR/>There was no significant difference in the overall analysis (13 RCTs, n=1702, WMD -0.46 CI -1.02 to 0.09), short term data (5 RCT, n=661, WMD 0.48 CI -0.57 to 1.53), medium term data (3 RCT, n=231, WMD -1.58 CI -3.20 to 0.03) and long term data (5 RCT, n=810, WMD -0.68 CI -1.40 to 0.04).</P>
<P>5.3.7 Negative symptoms - average score at endpoint - PANSS negative<BR/>There was no significant difference (13 RCTs, n=1702, WMD -0.44 CI -0.96 to 0.08), short term data (5 RCT, n=661, WMD -0.19 CI -1.22 to 0.85), medium term data (3 RCT, n=231, WMD -0.00 CI -1.59 to 1.58) and long term data (5 RCT, n=810, WMD -0.81 CI -1.54 to -0.07).</P>
<P>5.3.8 Negative symptoms - average score at endpoint - SANS total<BR/>There was a significant difference favouring olanzapine (1 RCT, n=308, WMD -1.40 CI -2.43 to -0.37).</P>
<P>5.4 Quality of life - average score at endpoint - QLS total score<BR/>There was a significant difference in favour of olanzapine (2 RCTs, n=296, WMD -5.10 CI -9.10 to -1.09).</P>
<P>5.5 Cognitive functioning<BR/>5.5.1 Cognitive functioning - no clinically important change (less than half a standard deviation improvement of the Global Neurocognitive Score)<BR/>There was no significant difference (1 RCT, n=80, RR 0.77 CI 0.52 to 1.14).</P>
<P>5.5.2 Global neurocognitive score - average score at endpoint<BR/>There was no significant difference (1 RCT, n=52, WMD -0.04 CI -0.39 to 0.31).</P>
<P>5.5.3 Neurocognitive composite score - average score at endpoint<BR/>There was no significant difference (1 RCT, n=263, WMD -0.01 CI -0.13 to 0.11).</P>
<P>5.6 Service use - number of participants re-hospitalised<BR/>There was no significant difference (3 RCTs, n=965, RR 0.75 CI 0.54 to 1.04).</P>
<P>5.7 Adverse effects<BR/>5.7.1 Number of participants with at least one adverse effect<BR/>There was no significant difference (11 RCTs, n=2576, RR 1.05 CI 0.97 to 1.13).</P>
<P>5.7.2 Death<BR/>There was no significant difference in the number of participants dying due to any reason (1 RCT, n=339, RR 0.32 CI 0.01 to 7.89), due to natural causes (2 RCTs, n=252, RR 2.93 CI 0.12 to 71.04) or suicide (4 RCTs, n=730, RR 0.32 CI 0.01 to 7.79). There was also no clear difference in the number of suicide attempts (5 RCTs, n=1724, RR 0.87 CI 0.28 to 2.67).</P>
<P>5.7.3 Cardiac effects<BR/>Cardiac effects were reported as 'ECG abnormalities' (2 RCTs, n=415, RR 2.39 CI 0.43 to 13.14) and 'QTc prolongation'. There were no significant differences. As the results of the latter outcome were heterogeneous I² = 74%, we present the results of the two single studies separately (<LINK REF="STD-Jeste-2003" TYPE="STUDY">Jeste 2003</LINK>: n=176, RR 1.30 CI 0.30 to 5.65; <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>: n=677, RR 0.07 CI 0.00 to 1.18).</P>
<P>5.7.4 Cardiac effects - mean change of QTc interval from baseline in ms<BR/>There was no significant difference (6 RCTs, n=1518, WMD -0.96 CI -4.67 to 2.74).</P>
<P>5.7.5 Central nervous system - sedation<BR/>There was no significant difference (11 RCTs, n=2576, RR 1.07 CI 0.96 to 1.19).</P>
<P>5.7.6 Central nervous system - seizures<BR/>There was no significant difference (4 RCTs, n=671, RR 3.82 CI 0.43 to 34.35).</P>
<P>5.7.7 Extrapyramidal effects<BR/>Significantly fewer participants in the olanzapine group than in the risperidone group suffered from akathisia (8 RCTs, n=1988, RR 0.77 CI 0.60 to 0.98, NNH not estimable) and parkinsonism (4 RCTs, n=776, RR 0.61 CI 0.40 to 0.92, NNH not estimable) or needed antiparkinson medication (13 RCTs, n=2599, RR 0.78 CI 0.65 to 0.95, NNH 17 CI 9 to 100). There was no significant difference in other extrapyramidal side effects such as akinesia (3 RCTs, n=681, RR 0.83 CI 0.56 to 1.23), dyskinesia (3 RCTs, n=580, RR 0.98 CI 0.34 to 2.80), dystonia (3 RCTs, n=591, RR 0.56 CI 0.11 to 2.73), rigor (2 RCTs, n=141, RR 2.44 CI 0.37 to 16.14), and tremor (5 RCTs, n=973, RR 1.15 CI 0.64 to 2.08) or 'extrapyramidal symptoms' (4 RCTs, n=1104, RR 0.75 CI 0.47 to 1.21). The results of the latter outcome were heterogeneous I² = 62%, we therefore also present the results of the single studies separately, (<LINK REF="STD-Tran-1997" TYPE="STUDY">Tran 1997</LINK>: n=339, RR 0.59 CI 0.40 to 0.87, <LINK REF="STD-Conley-2001" TYPE="STUDY">Conley 2001</LINK>: n=377, RR 0.84 CI 0.57 to 1.23, <LINK REF="STD-Jeste-2003" TYPE="STUDY">Jeste 2003</LINK>: n=176, RR 1.71 CI 0.76 to 3.87 and <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK>: n=212, RR 0.32 CI 0.11 to 0.96).</P>
<P>5.7.8 Extrapyramidal effects - scale measured<BR/>There was no significant difference in akathisia (BAS: 2 RCTs, n=353, WMD -0.72 CI -1.81 to 0.36; but the data were extremely heterogeneous , I² = 94%; ESRS akathisia subscore: 1 RCT, n=359, WMD 0.00 CI -0.27 to 0.27), dyskinesia (AIMS: 1 RCT, n=302, WMD -0.03 CI -0.78 to 0.72; ESRS dyskinesia subscore: 3 RCTs, n=572, WMD 0.08 CI -0.60 to 0.76), dystonia (ESRS dystonia subscore: 1 RCT, n=42, WMD 0.09 CI -0.73 to 0.91), overall extrapyramidal symptoms (ESRS total score: 4 RCTs, n=682, WMD -0.30 CI -0.94 to 0.35; SAS: 5 RCTs, n=522, WMD -0.62 CI -1.33 to 0.08; I² = 60%) or parkinsonism (ESRS parkinsonism subscore: 3 RCTs, n=572, WMD -0.24 CI -1.57 to 1.09; I² = 58%). It should be noted that several of these results were heterogeneous, but no clear reason for the heterogeneity could be identified.</P>
<P>5.7.9 Haematological - white blood cells - number of participants with low white blood cell count<BR/>Overall there was no significant difference (3 RCTs, n=484, RR 1.00 CI 0.09 to 10.59). The results of the three studies were heterogeneous I² = 56%, but the single trials did not show significant differences between olanzapine and risperidone either (<LINK REF="STD-Tran-1997" TYPE="STUDY">Tran 1997</LINK>: n=339, RR 6.80 CI 0.85 to 54.64; <LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>: n=80, RR 0.21 CI 0.01 to 4.24; <LINK REF="STD-Gureje-2003" TYPE="STUDY">Gureje 2003</LINK>: n=65, RR 0.34 CI 0.01 to 8.13).</P>
<P>5.7.10 Prolactin associated side effects<BR/>Significantly fewer participants in the olanzapine group suffered from amenorrhoea (7 RCTs, n=565, RR 0.67 CI 0.45 to 0.98, NNH not estimable) and 'abnormal ejaculation' (3 RCTs, n=531, RR 0.23 CI 0.08 to 0.67, NNH not estimable). Fewer participants in the olanzapine group had abnormally high prolactin levels, but this result did not reach conventional levels of statistical signifcance (3 RCTs, n=477, RR 0.33 CI 0.11 to 1.01).There were no significant differences in decreased libido (3 RCTs, n=781, RR 0.40 CI 0.12 to 1.30), galactorrhea (7 RCTs, n=547, RR 0.61 CI 0.30 to 1.26), gynaecomastia (5 RCTs, n=1083, RR 0.72 CI 0.36 to 1.42), impotence (3 RCTs, n=531, RR 0.50 CI 0.17 to 1.47), orgastic dysfunction (1 RCT, n=377, RR 0.20 CI 0.01 to 4.12) and sexual dysfunction (7 RCTs, n=1715, RR 0.93 CI 0.78 to 1.11).</P>
<P>5.7.11 Prolactin - mean change from baseline in ng/ml<BR/>Olanzapine was associated with significantly less prolactin increase than risperidone (men and women combined: 6 RCTs, n=1291, WMD -22.84 CI -27.98 to -17.69; men only: 2 RCTs, n=70, WMD -19.91 CI -26.18 to -13.64; women only: 1 RCT, n=71, WMD -41.40 CI -53.16 to -29.64). There was some heterogeneity in the degree of the difference, but all studies consistently favoured olanzapine.</P>
<P>5.7.12 Metabolic - cholesterol - number of participants with cholesterol increase<BR/>There was no significant difference (1 RCT, n=266, RR 1.28 CI 0.72 to 2.26).</P>
<P>5.7.13 Metabolic - cholesterol - change from baseline in mg/dl<BR/>There was a significant difference in favour of risperidone (7 RCTs, n=1391, WMD 10.36 CI 6.28 to 14.43).</P>
<P>5.7.14 Metabolic - glucose - number of participants with abnormally high glucose value<BR/>There was no significant difference (3 RCTs, n=670, RR 1.99 CI 0.87 to 4.60).</P>
<P>5.7.15 Metabolic - glucose - mean change from baseline in mg/dl<BR/>Risperidone produced significantly less glucose increase than olanzapine (7 RCTs, n=1201, WMD 7.58 CI 3.93 to 11.23).</P>
<P>5.7.16 Metabolic - weight gain - number of participants with weight gain<BR/>Significantly fewer participants in the risperidone group than in the olanzapine group suffered from weight gain (11 RCTs, n=2594, RR 1.81 CI 1.39 to 2.35, NNH 9 CI 7 to 14). Again, there was some heterogeneity I² = 52% due to the first episode study <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK>, but overall the trend was very consistent in favour of risperidone.</P>
<P>5.7.17 Metabolic - weight gain - mean change from baseline in kg<BR/>Risperidone was associated with significantly less weight gain than olanzapine (13 RCTs, n=2116, WMD 2.61 CI 1.48 to 3.74). The results were heterogeneous I² = 83%, because <LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK> showed an extreme superiority of risperidone. Excluding this study resolved the heterogeneity and risperidone's superiority remained (12 RCTs, n=2116, WMD 2.06 CI 1.37, 2.74).</P>
<P>5.8 Publication bias<BR/>The funnel plot of the PANSS total score (&gt;10 included studies) did not suggest a publication bias.</P>
<P>5.9 Investigation for heterogeneity and sensitivity analyses:<BR/>We identified some heterogeneity, but clear reasons explaining this could not be found. Excluding (<LINK REF="STD-Mori-2004" TYPE="STUDY">Mori 2004</LINK>) from the outcome 'PANSS positive score' (skewed data) did not change the result. The exclusion of <LINK REF="STD-Sikich-2004" TYPE="STUDY">Sikich 2004</LINK> (skewed data) from the analysis of the BPRS total score did not have an important impact on the result.<BR/>
</P>
<P>6. Comparison 6. OLANZAPINE versus ZIPRASIDONE<BR/>Six included studies (<LINK REF="STD-Breier-2005" TYPE="STUDY">Breier 2005</LINK>, <LINK REF="STD-Kinon-2006a" TYPE="STUDY">Kinon 2006a</LINK>, <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>, <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>, <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK>, <LINK REF="STD-Svestka-2005" TYPE="STUDY">Svestka 2005</LINK>) compared olanzapine with ziprasidone.</P>
<P>6.1 Global state<BR/>6.1.1 Global state - no clinically significant response - as defined by the original studies<BR/>There was no significant difference (2 RCTs, n=817, RR 0.83 CI 0.64 to 1.09), but the studies were heterogeneous, I² = 84%. In <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK> (maximum olanzapine dose 15mg/day) there was no significant difference (n=269, RR 0.94 CI 0.83 to 1.06), whereas in <LINK REF="STD-Breier-2005" TYPE="STUDY">Breier 2005</LINK> (maximum olanzapine dose 20mg/day) olanzapine was superior (n=548, RR 0.73 CI 0.62 to 0.87).</P>
<P>6.1.2 Global state - no clinically important change<BR/>There was no significant difference (1 RCT, n=269, RR 0.84 CI 0.65 to 1.09).</P>
<P>6.2 Leaving the study early<BR/>Fewer participants in the olanzapine group (53%) than in the ziprasidone group (66%) left the studies early due to any reason (5 RCTs, n=1937, RR 0.79 CI 0.74 to 0.85, NNT 7 CI 5 to 10). Olanzapine was also superior in the number of participants leaving the studies early due to lack of efficacy (12% versus 19%; 5 RCTs, n=1937, RR 0.64 CI 0.51 to 0.79, NNH 17 CI 11 to 33). A similar number of participants left the studies early due to adverse events (12% versus 13%, 5 RCTs, n=1937, RR 0.90 CI 0.62 to 1.29).</P>
<P>6.3 Mental State<BR/>6.3.1 General - no clinically important change - less than 30% PANSS total score reduction<BR/>There was a significant difference favouring olanzapine (1 RCT, n=548, RR 0.73 CI 0.62 to 0.87, NNH 6 CI 4 to 14).</P>
<P>6.3.2 General - no clinically important change - less than 40% BPRS total score reduction<BR/>There was no significant difference (1 RCT, n=269, RR 0.94 CI 0.83 to 1.06)</P>
<P>6.3.3 General - average score at endpoint - PANSS total<BR/>Olanzapine improved the general mental state significantly more than ziprasidone in the overall analysis (PANSS total score: 4 RCTs, n=1291, WMD -8.32 CI -10.99 to -5.64). Short term (1 RCT, n=48, WMD -8.37 CI -18.74 to 2.00) medium term (1 RCT, n=201, WMD -6.50 CI -13.07 to 0.07) and long term data (2 RCTs, n=1042, WMD -6.50 CI -13.07 to 0.07) indicated the same direction.</P>
<P>6.3.4 General - average score at endpoint - BPRS total<BR/>There was no significant difference (1 RCT, n=251, WMD -0.50 CI -3.85 to 2.85).</P>
<P>6.3.5 Positive symptoms - average score at endpoint - PANSS positive<BR/>Olanzapine improved positive symptoms as measured by the PANSS positive subscore significantly better than ziprasidone in the overall analysis (2 RCTs, n=730, WMD -3.11 CI -4.30 to -1.93) as well as in medium term (1 RCT, n=201, WMD -3.60 CI -5.75 to -1.45), and long term data (1 RCT, n=529, WMD -2.90 CI -4.33 to -1.47).</P>
<P>6.3.6 Negative symptoms - average score at endpoint - PANSS negative<BR/>There was no significant difference (2 RCTs, n=730, WMD -0.68 CI -3.81 to 2.45), but the results were heterogeneous, I² = 87%. <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK> found no difference between groups (n=201, WMD 1.00 CI -0.91 to 2.91), whereas <LINK REF="STD-Breier-2005" TYPE="STUDY">Breier 2005</LINK> significantly favoured olanzapine (1 RCT, n=529, WMD -2.20 CI -3.48 to -0.92).</P>
<P>6.4 General functioning<BR/>6.4.1 General functioning - no clinically important change (less than 5 points improvement on GAF total score)<BR/>More participants in the olanzapine had an improvement of general functioning (1 RCT, n=394, RR 0.83 CI 0.71 to 0.98, NNT 9 CI 5 to 50).</P>
<P>6.4.2 General functioning - average score at endpoint - GAF total<BR/>Data on this outcome showed a significant difference in favour of olanzapine (1 RCT, n=326, WMD -3.49 CI -6.34 to -0.64).</P>
<P>6.5 Quality of life - average endpoint score - QLS total (Heinrichs-Carpenter Scale)<BR/>There was no significant difference (1 RCT, n=393, WMD -3.70 CI -8.61 to 1.21).</P>
<P>6.6 Cognitive functioning - average endpoint score - PANSS cognitive subscore<BR/>Olanzapine improved cognitive function more than ziprasidone (1 RCT, n=529, WMD -2.40 CI -3.63 to -1.17).</P>
<P>6.7 Service use - number of participants rehospitalised<BR/>There was a significant difference in favour of olanzapine in the overall analysis (2 RCTs, n=766, RR 0.65 CI 0.45 to 0.93, NNT 17 CI 9 to 100), medium term (1 RCT, n=245, RR 0.69 CI 0.36 to 1.33) an and long term data (1 RCT, n=521, RR 0.63 CI 0.41 to 0.98, NNT not estimable).</P>
<P>6.8 Adverse effects<BR/>6.8.1 Numbers of participants with at least one adverse effect<BR/>Overall there was no significant difference (4 RCTs, n=1583, RR 0.95 CI 0.85 to 1.07). There was some heterogeneity I² = 62%, but we did not find obvious reasons for the heterogeneity. In <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK> olanzapine was superior (n=269, RR 0.84 CI 0.74 to 0.96), whereas <LINK REF="STD-Breier-2005" TYPE="STUDY">Breier 2005</LINK> (n=548, RR 0.93 CI 0.85 to 1.02), <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK> (n=521, RR 1.09 CI 0.96 to 1.24) and <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK> (1 RCT, n=245, RR 0.97 CI 0.64 to 1.46) reported no significant differences.</P>
<P>6.8.2 Death<BR/>There was no significant difference in the number of suicides (1 RCT, n=245, RR 0.25 CI 0.01 to 5.22) and suicide attempts (1 RCT, n=521, RR 1.10 CI 0.10 to 12.06).</P>
<P>6.8.3 Cardiac effects - number of participants with QTc prolongation<BR/>Overall there was no significant difference between olanzapine and ziprasidone (3 RCT, n=521, RR 0.63 CI 0.04 to 9.93). There was some heterogeneity I² = 65%, but the single studies did not find a significant difference either (<LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>: n=269, RR not estimable; <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK> n=521, RR 0.11 CI 0.01 to 2.29; <LINK REF="STD-Kinon-2006a" TYPE="STUDY">Kinon 2006a</LINK> (1 RCT, n=394, RR 1.90 CI 0.48 to 7.49).</P>
<P>6.8.4 Cardiac effects - mean change of QTc interval from baseline in ms<BR/>There was no significant difference (4 RCTs, n=1372, WMD -2.19 CI -4.96 to 0.58).</P>
<P>6.8.5 Central nervous system - sedation<BR/>There was no significant difference (2 RCTs, n=766, RR 1.56 CI 0.96 to 2.55). The results of the two studies were heterogeneous, I² = 63%. <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK> found a significant superiority of ziprasidone (n=245, RR 2.11 CI 1.25 to 3.58), whereas in <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK> the superiority was less pronounced (n=521, RR 1.27 CI 0.94 to 1.72).<BR/>
</P>
<P>6.8.6 Extrapyramidal effects<BR/>There was no significant difference in the number of participants suffering from akathisia (2 RCTs, n=766, RR 0.71 CI 0.40 to 1.28), dystonia (1 RCT, n=548, RR 0.08 CI 0.00 to 1.33) or extrapyramidal symptoms (2 RCTs, n=793, RR 0.53 CI 0.21 to 1.31). Nevertheless, fewer participants in the olanzapine groups needed at least one dose of antiparkinson medication (4 RCTs, n=1732, RR 0.70 CI 0.50 to 0.97, NNH not estimable).</P>
<P>6.8.7 Extrapyramidal effects - scale measured<BR/>There was no significant difference in dyskinesia (AIMS: 2 RCTs, n=925, WMD -0.16 CI -0.46 to 0.15), akathisia (BAS: 2 RCTs, n=924, WMD -0.07 CI -0.17 to 0.04) or general EPS (ESRS total score: 1 RCT, n=269, WMD -0.40 CI -1.53 to 0.73; SAS: 2 RCTs, n=922, WMD -0.34 CI -0.81 to 0.13).</P>
<P>6.8.8 Prolactin associated side effects<BR/>There was no significant difference in the number of participants with an abnormally high prolactin value (1 RCT, n=394, RR 1.12 CI 0.74 to 1.71), amenorrhoea (1 RCT, n=148, RR 0.84 CI 0.36 to 1.95), galactorrhoea (2 RCTs, n=597, RR 0.64 CI 0.22 to 1.88) or sexual dysfunction (2 RCTs, n=766, RR 1.33 CI 0.99 to 1.79).</P>
<P>6.8.9 Prolactin - change from baseline in ng/ml<BR/>There was no significant difference (3 RCTs, n=1079, WMD -0.20 CI -3.72 to 3.33).</P>
<P>6.8.10 Metabolic - cholesterol - number of participants with cholesterol increase<BR/>There was no significant difference (1 RCT, n=394, RR 1.43 CI 0.24 to 8.44).</P>
<P>6.8.11 Metabolic - cholesterol - mean change from baseline in mg/dl<BR/>Olanzapine was associated with significantly more cholesterol increase than ziprasidone (4 RCTs, n=1502, WMD 15.83 CI 5.95 to 25.72). There was some heterogeneity, I² = 87%, in the degree of the difference, but the direction of the effect consistently favoured ziprasidone (<LINK REF="STD-Breier-2005" TYPE="STUDY">Breier 2005</LINK>: n=418, WMD 7.39 CI 4.35 to 10.43; <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>: n=521, WMD 18.90 CI 7.91 to 29.89; <LINK REF="STD-Kinon-2006a" TYPE="STUDY">Kinon 2006a</LINK>: n=318, WMD 9.43 CI 2.04 to 16.82; <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK>: n=245, WMD 30.40 CI 20.97 to 39.83).</P>
<P>6.8.12 Metabolic - glucose - number of participants with abnormally high fasting glucose<BR/>There was no significant difference (1 RCT, n=394, RR 0.95 CI 0.14 to 6.68).</P>
<P>6.8.13 Metabolic - glucose - change from baseline in mg/dl<BR/>Olanzapine was associated with significantly more glucose increase than ziprasidone (4 RCTs, n=1420, WMD 8.25 CI 2.77 to 13.72).</P>
<P>6.8.14 Metabolic - weight gain - number of participants with weight gain<BR/>More participants in the olanzapine group than in the ziprasidone group had weight gain (4 RCTs, n=1708, RR 4.90 CI 3.38 to 7.12, NNH 6 CI 5 to 10).</P>
<P>6.8.15 Metabolic - weight gain - mean change from baseline in kg<BR/>Olanzapine produced significantly more weight gain than ziprasidone (5 RCTs, n=1659, WMD 3.82 CI 2.96 to 4.69). There was some heterogeneity, I² = 59%, in the degree of weight gain, but the direction of the effect was the same in all single studies (<LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>: n=238, WMD 2.62 CI 1.32 to 3.92; <LINK REF="STD-Breier-2005" TYPE="STUDY">Breier 2005</LINK>: n=529, WMD 4.18 CI 3.18 to 5.18; <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>: n=468, WMD 5.00 CI 3.75 to 6.25; <LINK REF="STD-Svestka-2005" TYPE="STUDY">Svestka 2005</LINK>: n=48, WMD 2.12 CI -0.12 to 4.36; <LINK REF="STD-Kinon-2006a" TYPE="STUDY">Kinon 2006a</LINK>: n=376, WMD 4.18 CI 3.26 to 5.10).</P>
<P>6.9 Publication bias<BR/>Due to small number of included studies a funnel plot analysis was not performed.</P>
<P>6.10 Investigation for heterogeneity and sensitivity analyses<BR/>The reasons for the preplanned sensitivity analyses did not apply and were therefore not performed.<BR/>
</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-02-17 12:31:23 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2010-02-17 12:26:16 +0000" MODIFIED_BY="[Empty name]">
<P>1. General<BR/>In the last years the number of randomised olanzapine trials has dramatically increased. A previous Cochrane review comparing olanzapine with any other treatment included 55 studies (<LINK REF="REF-Duggan-2005" TYPE="REFERENCE">Duggan 2005</LINK>). The current review includes 50 RCTs, although we included only comparisons of olanzapine with other second generation antipsychotic drugs and we excluded open RCTs. Nevertheless, the many problems that were identified by the previous review have not been solved.</P>
<P>The number of participants leaving schizophrenia trials prematurely remain high (<LINK REF="REF-Wahlbeck-2001" TYPE="REFERENCE">Wahlbeck 2001</LINK>). The overall attrition of 49% in the included studies is a threat to the validity of the findings.</P>
<P>Often adverse events were only reported if they had a frequency of 10% or greater. This procedure results in underreporting of rare but important adverse effects. We suggest to abandon the &gt;10% frequency rule for reporting of adverse effects and suggest that all adverse events should be reported instead, for example as online supplements, that are nowadays made available by most journals.</P>
<P>Most trials provide data on leaving the studies early and overall efficacy. Outcomes that are possibly more important for daily life such as general functioning or satisfaction with treatment are rarely presented. Authors keep using different criteria for 'response to treatment' making comparisons difficult, although validated suggestions for the presentation of response to treatment are available (<LINK REF="REF-Van-Os-2006" TYPE="REFERENCE">Van Os 2006</LINK>, <LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>, <LINK REF="REF-Leucht-2005b" TYPE="REFERENCE">Leucht 2005b</LINK>).</P>
<P>Half of the fifty included trials were categorised as 'short term' studies and only nine were 'long term' studies with a length of more than 26 weeks. Schizophrenia is a chronic, often life-long disorder making more long term studies necessary.</P>
<P>Thirty-one studies were sponsored by pharmaceutical companies producing either olanzapine or its comparator drugs, whereas only fifteen studies had a neutral sponsor. Due to the inevitable conflict of interest, industry sponsorship is a concern (<LINK REF="REF-Heres-2006" TYPE="REFERENCE">Heres 2006</LINK>).</P>
<P>Finally, most studies compared olanzapine with risperidone, quetiapine and clozapine. Fewer RCTs comparing olanzapine with amisulpride, aripiprazole and ziprasidone are available, and comparisons with sertindole and zotepine are missing.<BR/>
</P>
<P>2. Comparison 1. OLANZAPINE versus AMISULPRIDE</P>
<P>2.1 Efficacy outcomes (global state, overall and specific mental state)<BR/>Efficacy related outcomes that were measured with the Clinical Global Impression Scale, the PANSS total score and its positive and negative symptoms subscores, the BPRS total score and the SANS total score showed no significant difference between groups. Olanzapine and amisulpride may thus be similarly efficacious. Nevertheless, this finding should be cautiously interpreted, because all studies were sponsored by the manufacturers of either olanzapine or amisulpride.<BR/>
</P>
<P>2.2 Leaving the studies early<BR/>There was no significant difference between olanzapine and amisulpride in the number of participants leaving the studies early, neither due to any reason, nor due to adverse events or inefficacy of treatment. This suggests that both compounds may be similarly acceptable for people with schizophrenia, at least within the confines of a trial. Nevertheless, the high discontinuation rate in the five trials of overall 37.2% calls the validity of other findings into question, because the results must be estimated by statistical modelling.<BR/>

<BR/>
2.3 General functioning and quality of life<BR/>Only two studies reported on general functioning and on overall quality of life and found no significant difference between groups. It is disappointing that no more data on these important outcomes are available.</P>
<P>2.4 Cognitive functioning<BR/>Only <LINK REF="STD-Wagner-2005" TYPE="STUDY">Wagner 2005</LINK> examined cognitive function and found no difference between olanzapine and amisulpride. Further studies are needed. Such studies should also try to find out whether differences in cognitive effects are associated with better general functioning, such as an improved ability to work.</P>
<P>2.5 Adverse effects<BR/>The reporting of adverse effects was incomplete and usually based on only one or two studies. Some data on extrapyramidal symptoms, cardiac effects, cholesterol, death, glucose, prolactin associated side effects, weight gain, white blood cell count, sedation and seizures are available. Among these olanzapine was associated with significantly more weight gain and increase of glucose levels than amisulpride. Amisulpride may therefore be a preferable drug for people at risk to develop diabetes or metabolic syndrome. It was surprising that prolactin increase has not been reported in the publications, although this is a well known side effect of amisulpride. Nevertheless, the few available data did not show a significant difference in prolactin associated adverse events.<BR/>
</P>
<P>3. Comparison 2. OLANZAPINE versus ARIPIPRAZOLE<BR/>
<BR/>Only two studies that presented very limited data could be in included in this comparison. One of the studies had only been presented on the internet (<LINK REF="STD-CN138003" TYPE="STUDY">CN138003</LINK>). It only provided data for the outcomes leaving the study early due to any reason and general mental state.</P>
<P>3.1 Efficacy outcomes (global state, overall and specific mental state)<BR/>Olanzapine improved the general mental state (PANSS total score) more than aripiprazole. This finding was not confirmed by dichotomous data on response to treatment. Results on specific symptoms of schizophrenia, namely positive and negative symptoms, have not been reported.</P>
<P>3.2 Leaving the studies early<BR/>There was no significant difference between groups but the overall rate of participants leaving the two studies early of 40.1% was considerable. It should be noted that one of the two studies (<LINK REF="STD-CN138003" TYPE="STUDY">CN138003</LINK>) did not present data on the specific reasons for leaving the study early. This limited the statistical power to detect significant differences.</P>
<P>3.3 Adverse effects<BR/>One study provided some data on extrapyramidal symptoms, cardiac effects, cholesterol, prolactin levels and associated side effects, weight gain and sedation. Among these aripiprazole produced less prolactin increase, weight gain, cholesterol increase and sedation than olanzapine. Therefore, the overall tolerability profile of aripiprazole seems to be better than that of olanzapine, but it must be kept in mind that this result is based on only one study. Replications are needed.</P>
<P>4. Comparison 3. OLANZAPINE versus CLOZAPINE</P>
<P>4.1 Efficacy outcomes (global state, overall and specific mental state)<BR/>Although a number of different efficacy domains were addressed there was no clear difference in efficacy between olanzapine and clozapine. This finding was surprising, because clozapine is generally considered to be the most efficacious antipsychotic drug available. This superiority has recently been confirmed by the industry independent studies CATIE II (<LINK REF="STD-McEvoy-2006" TYPE="STUDY">McEvoy 2006</LINK>) and CUtLASS (<LINK REF="REF-Lewis-2006" TYPE="REFERENCE">Lewis 2006</LINK>), which could not be included here. The clozapine group of CATIE II was a non-blinded study arm and CUtLASS compared clozapine with a number of second generation antipsychotics as a group. Almost all studies described including treatment resistant participants, but the criteria of refractoriness varied. Hardly any studies had a run-in phase to confirm refractoriness. A possible explanation for the failure to find clozapine superiorioty may be relatively low clozapine doses. The mean doses in two pivotal studies demonstrating clozapine&#8217;s superiority to first generation antipsychotic drugs were 600mg/day (<LINK REF="REF-Kane-1988" TYPE="REFERENCE">Kane 1988</LINK>) and 523mg/day (<LINK REF="REF-Rosenheck-1997" TYPE="REFERENCE">Rosenheck 1997</LINK>). A randomised, blinded dose finding study found that a clozapine dose of 600mg/day was more efficacious than lower doses (<LINK REF="REF-Simpson-1999" TYPE="REFERENCE">Simpson 1999</LINK>). In contrast, of the 12 trials included in this review only two studies had mean clozapine doses higher than 500mg/day (<LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>: 526mg/day; <LINK REF="STD-Krakowski-2006" TYPE="STUDY">Krakowski 2006</LINK>: 565mg/day) and several trials limited the upper clozapine dose range to 400mg/day.</P>
<P>4.2 Leaving the studies early<BR/>A similar number of participants in the olanzapine and the clozapine group left the studies early due to any reason, suggesting a similar overall acceptability of treatment of both compounds. The fact that clozapine was associated with somewhat more premature discontinuations due to adverse events was not surprising. Clozapine induces many side-effects such as agranulocytosis, seizures, sedation and weight gain (see below).</P>
<P>4.3 Quality of life<BR/>Only a single study (<LINK REF="STD-Naber-2005" TYPE="STUDY">Naber 2005</LINK>) reported on quality of life and found no difference between olanzapine and clozapine. This finding is certainly not conclusive. It is disappointing that so few data on this important outcome are available.</P>
<P>4.4 Cognitive functioning<BR/>Again only one out of twelve included studies reported on cognitive function and used a global cognitive score for this outcome (<LINK REF="STD-Volavka-2002" TYPE="STUDY">Volavka 2002</LINK>). The results are equivocal, because dichotomous data (number of participants with improvement of at least half a standard deviation of the baseline score) suggested a superiority of olanzapine, while the mean change from baseline of the same cognitive score yielded no difference.</P>
<P>4.5 Service use<BR/>In a single large study (<LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK>) more participants in the olanzapine group than in the clozapine group had to be re-hospitalised. The difference was small and the NNH could not be calculated, because the risk difference was not significant. No firm conclusion can be drawn.<BR/>

<BR/>
4.6 Adverse effects<BR/>There were no differences in cardiac effects, cholesterol, death, diabetes mellitus, glucose, extrapyramidal side effects and weight gain, but the often small number of trials contributing data to these outcomes must be kept in mind.</P>
<P>Nevertheless, significantly fewer participants in the olanzapine group had 'at least one adverse effect', suffered from sedation, had seizures, and had a low white blood cell count. These are well known side effects of clozapine. It is reassuring that the review was able to document these expected differences in tolerability between olanzapine and clozapine.</P>
<P>On the other hand clozapine was associated with less prolactin increase. Clozapine's very low propensity to increase prolactin levels can be important in specific patients, e.g. women with a history of breast cancer.</P>
<P>There is a theory that clozapine reduces suicide attempts in schizophrenia. This hypothesis has to date been confirmed by only one large RCT (<LINK REF="STD-Meltzer-2003" TYPE="STUDY">Meltzer 2003</LINK>), which formed the basis of our review and recorded fewer suicide attempts in the clozapine group.<BR/>
</P>
<P>5. Comparison 4. OLANZAPINE versus QUETIAPINE<BR/>
<BR/>5.1 Efficacy outcomes (global state, overall and specific mental state)<BR/>Olanzapine was more efficacious than quetiapine in a number of measures of the general mental state and positive symptoms. There was no difference in global state, but the interpretation is limited, because only three studies contributed to this outcome. More robust data of seven RCTs suggest that there may be no difference in efficacy for negative symptoms between olanzapine and quetiapine.</P>
<P>5.2 Leaving the study early<BR/>Fewer participants in the olanzapine group than in the quetiapine group left the studies early due to any reason. This better acceptability of treatment of olanzapine may be mainly explained by a better efficacy, because olanzapine was also significantly superior in the number of people leaving early due to inefficacy of treatment, whereas there was no difference in the outcome leaving early due to adverse events. This somewhat better efficacy of olanzapine is also supported by other efficacy parameters such as the general mental state (PANSS total score, see below). Nevertheless, the high overall discontinuation rate of 63.2% needs to be highlighted. It is an important threat to the validity of the findings, because a large amount of data must be estimated by statistical modelling.</P>
<P>5.3 General functioning / Quality of life<BR/>Only one study (<LINK REF="STD-Kinon-2006b" TYPE="STUDY">Kinon 2006b</LINK>) reported on general functioning (GAF total score) and showed a superiority of olanzapine. The same trial examined quality of life and found no difference between groups. It is disappointing that so few data on these important outcomes are available.</P>
<P>5.4 Service use<BR/>Fewer participants in the olanzapine group than in the quetiapine group had to be re-hospitalised. Although based on only two studies, this is an important finding for policy makers, because in many industrialised countries hospital costs are the main cost factor in the treatment of schizophrenia.</P>
<P>5.5 Adverse effects<BR/>Limited data on cardiac effects, cholesterol, death, extrapyramidal side effects, glucose, prolactin increase and associated side effects (amenorrhoea, galactorrhoea, gynaecomastia, sexual dysfunction), sedation and seizures were available.<BR/>
<BR/>Among these, quetiapine was associated with fewer EPS (use of antiparkinson medication), prolactin increase, sexual adverse events, weight gain and glucose increase. These results suggest that the overall tolerability profile of quetiapine may be better than that of olanzapine. Especially the marked weight gain and glucose increase associated with olanzapine is a major concern, because it may lead to diabetes, metabolic syndrome and cardiac problems in the long run. Only QTc prolongation was less pronounced in the olanzapine group than in the quetiapine group. This side effect may make olanzapine a preferable antipsychotic drug in people with cardiac arrhythmias.</P>
<P>6. Comparison 5. OLANZAPINE versus RISPERIDONE</P>
<P>6.1 Efficacy outcomes (global state, overall and specific mental state)<BR/>Most data were available for the general mental state (PANSS total score, 15 RCTs) and positive and negative symptoms of schizophrenia (PANSS positive and negative subscore, 13 RCTs). Olanzapine was superior in the improvement of the general mental state, but not of specific symptoms of schizophrenia. Most other efficacy related outcomes were equivocal.</P>
<P>6.2 Leaving the study early<BR/>The high overall rate of participants leaving the studies early (52%) is a source of concern. The field must urgently find ways to decrease the amount of attrition in schizophrenia trials, because the typically high discontinuation rates make the validity of the results questionable. Olanzapine may be a somewhat more acceptable treatment than risperidone for people with schizophrenia, because fewer participants in the olanzapine group left the studies early due to any reason. In addition, fewer olanzapine treated participants left the studies early due to inefficacy of treatment. This may reflect a somewhat better efficacy of olanzapine which is also supported by a stronger improvement of the participants' general mental state (see below). Leaving the studies early due to adverse events showed no difference between groups suggesting a similar overall tolerability of olanzapine and risperidone.<BR/>
</P>
<P>6.3 Quality of life<BR/>The results suggested a better quality of life of participants treated with olanzapine compared to risperidone. Since only two studies provided data on this outcome, any recommendation would be premature.</P>
<P>6.4 Cognitive functioning<BR/>Only two studies compared the cognitive effects of olanzapine and risperidone and found no significant difference between groups.<BR/>
</P>
<P>6.5 Service use<BR/>In three trials a similar number of participants in the olanzapine and risperidone groups had to be re-hospitalised. This lack of a difference suggest a similar efficacy of both compounds. Or possible efficacy differences are so small that they do not translate to more global outcomes such as re-hospitalisation.<BR/>
</P>
<P>6.6 Adverse effects<BR/>The adverse effects that occurred in a statistically significantly different frequency can be grouped into three categories.</P>
<P>Olanzapine was associated with more weight gain and associated metabolic problems such as cholesterol and glucose increase. Therefore, olanzapine might not be an appropriate treatment for people at risk to develop a metabolic syndrome, overweight people, individuals suffering from diabetes or those with high cholesterol levels.</P>
<P>Risperidone produced some extrapyramidal side effects more frequently than olanzapine. Namely, the participants in the risperidone group used more antiparkinson medication and suffered more frequently from akathisia and parkinsonism. Although the number needed to treat for use of antiparkinson medication was relatively high (NNT 17), movement disorders are very unpleasant side effects and should be avoided.</P>
<P>Risperidone was also associated with clearly more prolactin increase and related sexual dysfunctions such as abnormal ejaculation in men and amenorrhoea in women. Clinicians and people with schizophrenia may consider these different tolerability profiles of both compounds in their drug choice.</P>
<P>7. Comparison 6. OLANZAPINE versus ZIPRASIDONE<BR/>
</P>
<P>7.1 Efficacy outcomes (global state, overall and specific mental state)<BR/>Most data were available for the general mental state (PANSS total score, 4 RCT), which showed a superiority of olanzapine. All other efficacy outcomes were reported less consistently, but there was also some superiority of olanzapine in positive symptoms and negative symptoms. A single study applied the BPRS instead of the PANSS and found no significant difference between groups (<LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>). It is a limitation of this study that it restricted the upper olanzapine dose range to 15mg/day, although the registered maximum olanzapine dose is 20mg/day.</P>
<P>7.2 Leaving the studies early<BR/>As in most other comparisons the overall number of participants leaving the studies early was very high (59.1%). Such high attrition rates call into question the validity of all other outcomes beyond leaving the study early.</P>
<P>Fewer participants in the olanzapine group than in the ziprasidone group left the studies early due to any reason. This better acceptability of treatment of olanzapine was mainly due to better efficacy, because olanzapine was also significantly superior in the number of people leaving early due to inefficacy of treatment, whereas there was no difference in the outcome leaving early due to adverse events. Other efficacy parameters such as the general mental state or positive symptoms suggested a somewhat better efficacy of olanzapine, as well (see below).</P>
<P>7.3 General functioning<BR/>In one study the participants' general functioning (GAF score) improved more than in the ziprasidone group (<LINK REF="STD-Kinon-2006a" TYPE="STUDY">Kinon 2006a</LINK>). The small evidence base is not sufficient for this important outcome.</P>
<P>7.4 Cognitive functioning<BR/>Only one study reported on cognitive function and found a superiority of olanzapine (<LINK REF="STD-Breier-2005" TYPE="STUDY">Breier 2005</LINK>). Nevertheless, this result was based on the PANSS cognition score which is not really a cognitive test. More data on this outcome would be desirable because cognitive function could be an important component of a person's daily functioning, including the ability to work.</P>
<P>7.5 Service use<BR/>Fewer people in the olanzapine had to be re-hospitalised during the studies. This result may again reflect a better efficacy of olanzapine. Furthermore, the result may be important for policy makers, because in many industrialised countries hospitalisation is the main cost factor in the treatment of schizophrenia.</P>
<P>7.6 Adverse effects<BR/>The studies reported some data on the following adverse effects: cardiac effects, cholesterol, death, extrapyramidal side effects, prolactin increase, sedation and weight gain. Olanzapine was associated with somewhat fewer extrapyramidal side effects than ziprasidone in terms of antiparkinson medication. On the other hand olanzapine clearly induced more weight gain, plus glucose and cholesterol increase than ziprasidone. This high propensity of olanzapine to induce these potentially dangerous metabolic side effects limits its use in daily practice.</P>
<P>8. Summary<BR/>The review currently includes 50 studies and 9476 participants, which provided data for six comparisons (olanzapine compared to amisulpride, aripiprazole, clozapine, quetiapine, risperidone or ziprasidone). For two comparisons - olanzapine versus sertindole and olanzapine versus zotepine - RCTs are not available. The overall attrition from the included studies was considerable (49.2%). This high attrition makes the interpretation of the results problematic, because half of the results must be estimated by statistical modelling.</P>
<P>Olanzapine improved the general mental state somewhat more than some other second generation antipsychotic drugs, namely aripiprazole, quetiapine, risperidone, and ziprasidone. A difference in efficacy compared to amisulpride and clozapine has not been documented. This somewhat better efficacy was confirmed by fewer participants in the olanzapine groups leaving the studies early due to inefficacy of treatment compared to quetiapine, risperidone and ziprasidone. Furthermore, fewer participants in the olanzapine group than in the quetiapine and ziprasidone treatment groups, but not in the clozapine group, had to be re-hospitalised in the trials.</P>
<P>It is a major concern that olanzapine induced more weight gain than all other second generation antipsychotic drugs, except clozapine. This more pronounced weight gain of olanzapine was usually accompanied by more glucose and cholesterol increase compared to the other second generation antipsychotic drugs.</P>
<P>Other differences in adverse effects were less well documented. Nevertheless, olanzapine may be associated with slightly more extrapyramidal side effects than quetiapine, but less than risperidone and ziprasidone. It may also increase prolactin somewhat more than aripiprazole, clozapine and quetiapine, but clearly less so than risperidone. 
<BR/>

</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2010-02-17 12:28:10 +0000" MODIFIED_BY="[Empty name]">
<P>The amount of RCTs comparing olanzapine with the other second generation antipsychotic drugs varied substantially. A high number of studies compared olanzapine with risperidone (N=23). A reasonable amount of trials comparing olanzapine with clozapine (N=12) and quetiapine (N=13) were available. In contrast, relatively few trials compared olanzapine with ziprasidone (N=6), amisulpride (N=5) and aripiprazole (N=2). We did not identify any randomised controlled trial comparing olanzapine with sertindole or zotepine. Therefore the evidence is incomplete. Furthermore, it is also obvious that most of the studies reported on leaving the studies early due to any reason and overall symptoms of schizophrenia. All other outcomes were usually based on much smaller numbers. Very little information is available on general functioning, satisfaction with care or cognition. These outcomes may be more important for people suffering from schizophrenia than the improvement of symptoms. Only three included studies reported on service use, although such data would be very important for policy makers. Most of the included studies had tight inclusion criteria, thus limiting external validity. Further effectiveness studies are needed. The high attrition in the studies also limits the applicability of the evidence to daily practice.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2010-02-17 12:28:46 +0000" MODIFIED_BY="[Empty name]">
<P>A major threat for the quality of the evidence is the high overall attrition of 49.2% in the studies. It is questionable whether even a sophisticated statistical method can account for such a high percentage of participants leaving the studies before their end. All included studies were stated to be randomised and all but eight studies were double-blind. The remaining eight trials used blinded raters. Nevertheless, the randomisation and blinding methods were rarely described. The study authors did also not make attempts to verify whether blinding was successful. The majority of the trials fell in the short term category which is problematic in a chronic disease such as schizophrenia. All these factors limit the overall quality of the evidence.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2010-02-17 12:28:57 +0000" MODIFIED_BY="[Empty name]">
<P>We are not aware of obvious flaws in our review process. Nevertheless, we admit that we present only a selection of outcomes. Although these outcomes were defined a priori in the protocols, and although we think that we made a meaningful selection, other people may have different opinions.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2010-02-17 12:31:23 +0000" MODIFIED_BY="[Empty name]">
<P>A previous Cochrane review examined the effects of olanzapine compared to placebo, first generation antipsychotic drugs and second generation antipsychotic drugs for schizophrenia (<LINK REF="REF-Duggan-2005" TYPE="REFERENCE">Duggan 2005</LINK>). The results can not be directly compared with our findings, because the previous review pooled all other second generation antipsychotic drugs together and compared them as a group with olanzapine. Nevertheless, <LINK REF="REF-Duggan-2005" TYPE="REFERENCE">Duggan 2005</LINK> also found that olanzapine produces more weight gain than other second generation antipsychotic drugs.</P>
<P>Another Cochrane review compared olanzapine with risperidone (<LINK REF="REF-Jayaram-2006" TYPE="REFERENCE">Jayaram 2006</LINK>) The authors describe a high attrition rate in the trials and little differences between both comparators, except for side effects where olanzapine was associated with more weight gain. They also found more people in the risperidone group required more medication to alleviate extrapyramidal symptoms.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-02-17 12:33:04 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-02-17 12:33:04 +0000" MODIFIED_BY="[Empty name]">
<P>1. For people with schizophrenia<BR/>Olanzapine may be a slightly more efficacious antipsychotic drug than aripiprazole, quetiapine, risperidone and ziprasidone. On the other hand, olanzapine is associated with more weight gain than any other second generation antipsychotic drug included in this review, except for clozapine. This weight gain is a source of major concern, because in the long run it can lead to diabetes and cardiovascular problems. Differences in other adverse effects are less clear, but olanzapine may be associated with slightly more movement disorders than quetiapine, but less than risperidone and ziprasidone. It may also increase prolactin somewhat more than aripiprazole, clozapine and quetiapine, but clearly less so than risperidone.</P>
<P>2. For clinicians<BR/>The great attrition makes recommendations difficult. 49.2% of the participants discontinued the trials prematurely meaning that almost half of the results had to be estimated by statistical modelling. Olanzapine was more efficacious than some other second generation antipsychotic drugs in terms of the general mental state and in terms of the number of participants leaving the studies early due to inefficacy. The major disadvantage of olanzapine is its weight gain and the associated metabolic problems. There is no clear evidence on the question as to whether people treated with olanzapine will have a better quality of life or will be more satisfied by olanzapine than by other second generation antipsychotic drugs.</P>
<P>3. For managers/policy makers<BR/>Unfortunately, there is very little information to guide the decisions of managers and policy makers. Service use was reported by only three of the fifty included studies. Fewer people in the olanzapine groups had to be hospitalised than those treated with quetiapine, risperidone or ziprasidone, but more than those treated with clozapine. The evidence base is too limited for making any recommendation.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-09-30 14:00:18 +0100" MODIFIED_BY="[Empty name]">
<P>1. General<BR/>There is room for improvement in the conduct and reporting of randomised controlled schizophrenia trials. Rating scale derived efficacy outcomes dominate the trials and even in this regard authors keep using different definitions for response to treatment making a comparison of the results difficult. Potentially important outcomes such as satisfaction with care, functioning in the community or service use are rarely examined. Simple descriptions of the randomisation or blinding methods are usually not presented. Strict adherence to the CONSORT statement (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>) would improve the reporting and conduct of future trials.</P>
<P>2. Specific<BR/>Comparisons of olanzapine with some second generation antipsychotic drugs are completely lacking, and the number of available trials for some other ones is small. These gaps need to be filled by future trials (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-02-11 10:59:06 +0000" MODIFIED_BY="[Empty name]">
<P>We would like to thank all members of the Cochrane Schizophrenia Group for their editorial assistance. We also would like to thank the following authors and pharmaceutical companies for providing additional information on their studies: I. Bitter, R.Conley, S.Dollfus, R.Keefe, M.Krakowski, Y.Liu, K.Mori, A.Mortimer, D.Naber, H.Ozguven, J Svestka, J.Volavka, M.Wagner, Astra Zeneca, Eli Lilly, Pfizer and Sanofi Aventis.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-02-15 15:59:03 +0000" MODIFIED_BY="[Empty name]">
<P>Katja Komossa: none.<BR/>Stefan Leucht received speaker/consultancy honoria from Sanofi-Aventis, BMS, Eli Lilly, Janssen, Lundbeck and Pfizer. He received research support from Sanofi-Aventis and Eli Lilly.<BR/>Christine Rummel received lecture honoraria and travel grants to attend scientific meetings from AstraZeneca, Janssen-Cilag, Eli Lilly and Pfizer. <BR/>Werner Kissling: received speaker or consultancy honoraria from SanofiAventis, BMS, Lilly, Janssen, Lundbeck, Bayer and Pfizer.<BR/>Heike Hunger: none.<BR/>Franziska Schmidt: none<BR/>Sandra Schwarz: none.<BR/>Lorna Duggan: has attended functions sponsored by Lundbeck, Janssen, Pfizer, Bristol Myers Squibb and Zeneca and has accepted sponsorship from Eli Lilly for internal flights in the United States.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-09-08 11:09:23 +0100" MODIFIED_BY="[Empty name]">
<P>Katja Komossa: protocol development, searching, study selection, data extraction, report writing.<BR/>Christine Rummel: protocol development, searching, study selection, data extraction.<BR/>Stefan Leucht: protocol development, searching, study selection, data extraction, report writing.<BR/>Werner Kissling: protocol development.<BR/>Heike Hunger: helped with data extraction and writing.<BR/>Franziska Schmid: helped with data extraction and writing.<BR/>Sandra Schwarz: helped with data extraction and writing.<BR/>Lorna Duggan: protocol development.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-12-29 15:35:24 +0000" MODIFIED_BY="[Empty name]">
<P>The review was slightly adapted to new functions available in Review Manager 5, namely the risk of bias table.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-01-12 10:37:23 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-01-12 09:50:12 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-01-12 09:09:45 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Atmaca-2003" MODIFIED="2008-12-17 23:02:25 +0000" MODIFIED_BY="[Empty name]" NAME="Atmaca 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-12-17 23:02:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Atmaca M, Kuloglu M, Tezcan E, Ustundag B</AU>
<TI>Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64</VL>
<NO>5</NO>
<PG>598-604</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:02:25 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bai-2005" MODIFIED="2010-01-12 08:28:10 +0000" MODIFIED_BY="[Empty name]" NAME="Bai 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-12 08:28:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bai YM, Ping LY, Lin CC, Wang YC, Liou YJ, Wu BJ, Chen TT, Chen JY, Lin CY, Chou P</AU>
<TI>Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24-week randomized, single-blind, controlled study</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>Suppl 3</NO>
<PG>S473</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:02:34 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bitter-2004" MODIFIED="2010-01-12 08:28:21 +0000" MODIFIED_BY="[Empty name]" NAME="Bitter 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-12 08:28:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bitter I, Dossenbach MRK, Brook S, Feldman PD, Metcalfe S, Gagiano CA, Furedi J, Bartko G, Janka Z, Banki CM, Kovacs G, Breier A</AU>
<TI>Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia</TI>
<SO>Progress in Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>2004</YR>
<VL>28</VL>
<PG>173-80</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:02:44 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breier-2005" MODIFIED="2010-01-12 08:33:18 +0000" MODIFIED_BY="[Empty name]" NAME="Breier 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-12 08:33:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, Walker DJ, Roychowdhury SM, Kane JM</AU>
<TI>Olanzapine versus ziprasidone: Results of a 28-week double-blind study in patients with schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>162</VL>
<PG>1879-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 23:03:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Phillips GA, Van Brunt DL, Roychowdhury SM, Xu W, Naber D</AU>
<TI>The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2006</YR>
<VL>67</VL>
<NO>9</NO>
<PG>1397-403</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:03:00 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Canive-2000" MODIFIED="2010-01-12 08:34:09 +0000" MODIFIED_BY="[Empty name]" NAME="Canive 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-12 08:33:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Canive JM, Edgar JC, LaNoue MD, Miller GA, Weisend MP, Tuason VB</AU>
<TI>A magnetoencephalographic examination on the effects of olanzapine and risperidone in patients with schizophrenia</TI>
<SO>Proceedings of the 40th Annual Meeting of the New Clinical Drug Evaluation Unit; 2000 May 30 - Jun 2; Boca Raton, Florida, USA</SO>
<YR>2000</YR>
<CY>USA</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:03:12 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 08:34:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Canive JM, Miller GA, Irwin JG, Moses SN, Thoma RJ, Edgar JC, Sherwood A, Torres F, LaNoue M, Lewis S, Hanlos F, Weisend MP, Mead V, Tuason VB</AU>
<TI>Efficacy of olanzapine and risperidone in schizophrenia: A randomized double-blind crossover design</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>2000</YR>
<VL>39</VL>
<NO>1</NO>
<PG>105-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CN138003" MODIFIED="2010-01-12 08:35:23 +0000" MODIFIED_BY="[Empty name]" NAME="CN138003" YEAR="2005">
<REFERENCE MODIFIED="2010-01-12 08:35:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>CN138003</AU>
<TI>A multicenter, double-blind, randomized, comparative study of aripiprazole and olanzapine in the treatment of patients with acute schizophrenia</TI>
<SO>Clinical Study Report</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Conley-2001" MODIFIED="2010-01-12 08:38:50 +0000" MODIFIED_BY="[Empty name]" NAME="Conley 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-12 08:35:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Conley RR, Mahmoud R, =Risperidone Study Group</AU>
<TI>Risperidone versus olanzapine in patients with schizophrenia and schizoaffective disorder</TI>
<SO>Proceedings of the 10th Biennial Winter Workshop on Schizophrenia; 2000 Feb 5-11; Davos, Switzerland</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:03:22 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 08:35:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Conley RR, Mahmoud R, Risperidone Study Group</AU>
<TI>Risperidone versus olanzapine in patients with schizophrenia and schizoaffective psychosis</TI>
<TO>Risperidon versus olanzapin bei patienten mit schizophrenie und schizoaffektiven psychosen</TO>
<SO>Nervenheilkunde</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>5</NO>
<PG>110-2</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:03:28 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 23:03:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Conley RR, Mahmoud R</AU>
<TI>A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>158</VL>
<NO>5</NO>
<PG>765-74</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:03:33 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 08:38:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Conley RR, Mahmoud R</AU>
<TI>Risperidone and olanzapine in people with schizophrenia or schizoaffective disorder: a randomised double-blind study (as supplied 2001)</TI>
<SO>Data on file</SO>
<PB>Maryland Psychiatric Research Center</PB>
<CY>Baltimore, USA</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:03:40 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 23:03:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Green MF, McGurk SR, Meltzer HY</AU>
<TI>Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study</TI>
<SO>Psychopharmacology</SO>
<YR>2003</YR>
<VL>169</VL>
<NO>3-4</NO>
<PG>404-11</PG>
<CY>Germany</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:03:46 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Conley-2003" MODIFIED="2010-01-12 08:40:09 +0000" MODIFIED_BY="[Empty name]" NAME="Conley 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-12 08:40:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kelly DL, Conley RR, Richardson CM, Tamminga CA, Carpenter Jr WT</AU>
<TI>Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia</TI>
<SO>Annals of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>3-4</NO>
<PG>181-6</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:03:55 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dollfus-2005" MODIFIED="2010-01-12 08:41:00 +0000" MODIFIED_BY="[Empty name]" NAME="Dollfus 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-12-17 23:04:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dollfus S, Olivier V, Chabot B, Deal C, Perrin E</AU>
<TI>Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>78</VL>
<NO>2-3</NO>
<PG>157-9</PG>
<CY>Netherlands</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:04:05 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 08:41:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dollfus S</AU>
<TI>The treatment of post-psychotic depression</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S165</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:04:11 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dolnak-2001" MODIFIED="2010-01-12 08:41:07 +0000" MODIFIED_BY="[Empty name]" NAME="Dolnak 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-12 08:41:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dolnak R, Rapaport MH</AU>
<TI>A prospective, randomized, doubleblind study examining functioning in schizophrenic patients treated with olanzapine and risperidone</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>1, 2</NO>
<PG>225-6</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:04:23 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gureje-2003" MODIFIED="2008-12-17 23:04:51 +0000" MODIFIED_BY="[Empty name]" NAME="Gureje 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-12-17 23:04:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gureje O, Miles W, Keks N, Grainger D, Lambert T, McGrath J, Tran P, Catts S, Fraser A, Hustig H, Andersen S, Crawford AM</AU>
<TI>Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand</TI>
<SO>Schizophrenia Research</SO>
<YR>2003</YR>
<VL>61</VL>
<NO>2-3</NO>
<PG>303-14</PG>
<CY>Netherlands</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:04:51 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jeste-2003" MODIFIED="2010-01-12 08:42:19 +0000" MODIFIED_BY="[Empty name]" NAME="Jeste 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-12-17 23:04:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Napolitano JA, Mao L, Gharabawi G</AU>
<TI>Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>9</NO>
<PG>820-8</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:04:58 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 23:05:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jeste DV, Barak Y, Madhusoodanan S, Grossman F, Gharabawi G</AU>
<TI>International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>2003</YR>
<VL>11</VL>
<NO>6</NO>
<PG>638-47</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:05:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 08:42:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tune L, Mulsant B, Gharabawi G</AU>
<TI>Anticholinergic effect of atypical antipsychotics in elderly patients</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>Suppl 3</NO>
<PG>S314</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:05:09 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keefe-2006" MODIFIED="2009-01-05 15:32:40 +0000" MODIFIED_BY="[Empty name]" NAME="Keefe 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-12-17 23:07:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Keefe RSE, Young CA, Rock SL, Purdon SE, Gold JM, Breier A</AU>
<TI>One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2006</YR>
<VL>81</VL>
<NO>1</NO>
<PG>1-15</PG>
<CY>Netherlands</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:07:09 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-05 15:32:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lysaker PH</AU>
<TI>Olanzapine and risperidone may improve neurocognition more than haloperidol in people with schizophrenia who continue treatment for 52 weeks</TI>
<SO>Evidence-Based Mental Health</SO>
<YR>2006</YR>
<VL>9</VL>
<NO>3</NO>
<PG>71</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:32:40 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinon-2006a" MODIFIED="2008-12-17 23:07:19 +0000" MODIFIED_BY="[Empty name]" NAME="Kinon 2006a" YEAR="2006">
<REFERENCE MODIFIED="2008-12-17 23:07:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kinon BJ, Lipkovich I, Edwards SB, Adams DH, Ascher-Svanum H, Siris SG</AU>
<TI>A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>2</NO>
<PG>157-62</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:07:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinon-2006b" MODIFIED="2008-12-17 23:07:45 +0000" MODIFIED_BY="[Empty name]" NAME="Kinon 2006b" YEAR="2006">
<REFERENCE MODIFIED="2008-12-17 23:07:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kinon BJ, Noordsy DL, Liu-Seifert H, Gulliver AH, Ascher-Svanum H, Kollack-Walker S</AU>
<TI>Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>5</NO>
<PG>453-61</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:07:45 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krakowski-2006" MODIFIED="2010-01-12 08:43:52 +0000" MODIFIED_BY="[Empty name]" NAME="Krakowski 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-12-17 23:07:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB</AU>
<TI>Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2006</YR>
<VL>63</VL>
<NO>6</NO>
<PG>622-9</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:07:56 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 08:43:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Krakowski MI</AU>
<TI>Clozapine and olanzapine in violent schizophrenics</TI>
<SO>CRISP database (https://www-commons.cit.nih.gov/crisp/index.html</SO>
<YR>(accessed 19th February 2001)</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:08:02 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kumra-2007" MODIFIED="2010-01-12 08:44:37 +0000" MODIFIED_BY="[Empty name]" NAME="Kumra 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-01-12 08:44:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, DeThomas C, Kafantaris V, Correll CU, Kane JM</AU>
<TI>Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: A 12-week randomized and double-blind comparison</TI>
<SO>Biological Psychiatry</SO>
<YR>2007</YR>
<VL>4</VL>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lecrubier-2006" MODIFIED="2010-01-12 08:44:59 +0000" MODIFIED_BY="[Empty name]" NAME="Lecrubier 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-12 08:44:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lecrubier Y, Quintin P, Bouhassira M, Perrin E, Lancrenon S</AU>
<TI>The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>2006</YR>
<VL>114</VL>
<PG>319-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lieberman-2005" MODIFIED="2008-12-17 23:08:20 +0000" MODIFIED_BY="[Empty name]" NAME="Lieberman 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-12-17 23:08:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK</AU>
<TI>Effectiveness of antipsychotic drugs in patients with chronic schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<NO>12</NO>
<PG>1209-23</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:08:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McEvoy-2006" MODIFIED="2008-12-17 23:08:31 +0000" MODIFIED_BY="[Empty name]" NAME="McEvoy 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-12-17 23:08:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK</AU>
<TI>Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<NO>4</NO>
<PG>600-10</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:08:31 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McEvoy-2007" MODIFIED="2010-01-12 08:52:30 +0000" MODIFIED_BY="[Empty name]" NAME="McEvoy 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-01-12 08:45:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Keefe RSE, Gu H, Sweeney JA, Perkins DO, McEvoy JP, Hamer RM, Lieberman JA</AU>
<TI>The effects of olanzapine, quetiapine and risperidone on neurocognitive function in first-episode psychosis: a double-blind 52-week comparison</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:09:17 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 08:52:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman J, McEvoy JP, Perkins D, Hamer RH</AU>
<TI>Comparison of atypicals in first-episode psychosis: a randomized, 52-week comparison of olanzapine, quetiapine, and risperidone</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>Suppl 3</NO>
<PG>S525</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 08:51:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD</AU>
<TI>Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: A randomized, double-blind 52-week comparison</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2007</YR>
<VL>164</VL>
<PG>1050-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McEvoy JP, Perkins DO, Gu H, Hamer RM, Lieberman JA</AU>
<TI>Clinical effectiveness and predictors of treatment non-adherence: comparison of olanzapine, quetiapine, and risperidone in first-episode psychosis</TI>
<SO>Schizophrenia Research</SO>
<YR>2006</YR>
<VL>86</VL>
<NO>Suppl 1</NO>
<PG>S130</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 08:51:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McEvoy JP, Perkins DO, Gu H, Hamer RM, Lieberman JA</AU>
<TI>Olanzapine, quetiapine, and risperidone in the treatment of first-episode psychosis: effectiveness and factors influencing adherence to treatment</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S425</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:09:35 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McQuade-2004" MODIFIED="2010-01-12 08:53:09 +0000" MODIFIED_BY="[Empty name]" NAME="McQuade 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-12-17 23:09:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jody D, Mcquade Rd, Kujawa M, Carson W, Iwamoto T, Archibald D, Stock E</AU>
<TI>Long-term weight effects of aripiprazole versus olanzapine</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>67</VL>
<NO>1</NO>
<PG>187</PG>
<CY>Po Box 211, 1000 Ae Amsterdam, Netherlands</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:09:46 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 08:52:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Kujawa MJ, McQuade RD, Jody DN, Carson WH, Abou-Gharbia N, Iwamoto T, Archibald DG, Stock EG</AU>
<TI>Long-term weight effects of aripiprazole vs olanzapine in a 26-week, double-blind study</TI>
<SO>Proceedings of the XXIVth Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 June 20&#8211;24, Paris, France</SO>
<YR>2004</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:09:51 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 08:53:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Carson WH</AU>
<TI>A comparison of weight change during treatment with olanzapine or aripiprazole: Results from a randomized, double-blind study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>Suppl 18</NO>
<PG>47-56</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:10:01 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meltzer-2003" MODIFIED="2010-01-12 08:54:29 +0000" MODIFIED_BY="[Empty name]" NAME="Meltzer 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-12-17 23:10:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alphs L, Anand R, Islam MZ, Meltzer HY, Kane JM, Krishnan R, Green AI, Potkin S, Chouinard G, Lindenmayer JP, Kerwin R</AU>
<TI>The International Suicide Prevention Trial (InterSePT): Rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>3</NO>
<PG>577-86</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:10:30 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 08:53:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bourgeois M, Swendsen J, Young F, Amador X, Pini S, Cassano GB, Lindenmayer JP, Hsu C, Alphs L, Meltzer HY, InterSePT Study Group</AU>
<TI>Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2004</YR>
<VL>161</VL>
<NO>8</NO>
<PG>1494-6</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:10:37 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 23:10:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glick ID, Zaninelli R, Hsu C, Young FK, Weiss L, Gunay I, Kumar V</AU>
<TI>Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>5</NO>
<PG>679-85</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:10:43 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 08:53:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer HY, Alphs L, Greem AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer J-P, Potkin S, InterSePT Study Group</AU>
<TI>Clozapine treatment for suicidality in schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2003</YR>
<VL>60</VL>
<PG>82-91</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:10:49 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 08:54:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Potkin SG, Alphs L, Hsu C, Krishn NK, Ranga R, Anand R, Young FK, Meltzer H, Green A</AU>
<TI>Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial</TI>
<SO>Biological Psychiatry</SO>
<YR>2003</YR>
<VL>54</VL>
<NO>4</NO>
<PG>444-52</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:10:53 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moresco-2004" MODIFIED="2008-12-17 23:12:01 +0000" MODIFIED_BY="[Empty name]" NAME="Moresco 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-12-17 23:12:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Moresco RM, Cavallaro R, Messa C, Bravi D, Gobbo C, Galli LLG, Colombo C, Rizzo G, Velona I, Smeraldi E, Fazio F</AU>
<TI>Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>3</NO>
<PG>355-65</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:12:01 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mori-2004" MODIFIED="2008-12-17 23:12:42 +0000" MODIFIED_BY="[Empty name]" NAME="Mori 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-12-17 23:12:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mori K, Nagao M, Yamashita H, Morinobu S, Yamawaki S</AU>
<TI>Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia</TI>
<SO>Progress in Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>2004</YR>
<VL>28</VL>
<NO>4</NO>
<PG>659-65</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:12:42 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mortimer-2004" MODIFIED="2008-12-17 23:12:57 +0000" MODIFIED_BY="[Empty name]" NAME="Mortimer 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-12-17 23:12:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mortimer A, Martin S, Loo H, Peuskens J, SOLIANOL Sudy Group</AU>
<TI>A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>2</NO>
<PG>63-9</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:12:52 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 23:12:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Mortimer A</AU>
<TI>The European First Episode Schizophrenia Trial: comparison of outcome in first episode schizophrenia with different low dose antipsychotic regimens (EUFEST)</TI>
<SO>National Research Register</SO>
<YR>2003</YR>
<VL>1</VL>
<IDENTIFIERS MODIFIED="2008-12-17 23:12:57 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naber-2005" MODIFIED="2008-12-17 23:13:13 +0000" MODIFIED_BY="[Empty name]" NAME="Naber 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-12-17 23:13:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bender S, Dittmann-Balcar A, Schall U, Wolstein J, Klimke A, Riedel M, Vorbach E-U, Kuhn K-U, Lambert M, Dittmann RW, Naber D</AU>
<TI>Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs clozapine</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>9</VL>
<NO>2</NO>
<PG>135-45</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:13:06 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 23:13:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Naber D, Riedel M, Klimke A, Vorbach E-U, Lambert M, Kühn K-U, Bender S, Bandelow B, Lemmer W, Moritz S, Dittmann RW</AU>
<TI>Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>2005</YR>
<VL>111</VL>
<NO>2</NO>
<PG>106-15</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:13:13 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ozguven-2004" MODIFIED="2010-01-12 08:55:32 +0000" MODIFIED_BY="[Empty name]" NAME="Ozguven 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-12 08:55:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ozguven HD, Oner O, Baskak B, Oner P, Atbasoglu EC</AU>
<TI>The metabolic and clinical effects of olanzapine and quetiapine: preliminary findings from a randomized single-blind trial in patients with schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>67</VL>
<NO>1</NO>
<PG>190-1</PG>
<CY>Po Box 211, 1000 Ae Amsterdam, Netherlands</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:13:21 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Purdon-2000" MODIFIED="2008-12-17 23:13:34 +0000" MODIFIED_BY="[Empty name]" NAME="Purdon 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-12-17 23:13:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, Breier A, Tollefson GD</AU>
<TI>Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2000</YR>
<VL>57</VL>
<NO>3</NO>
<PG>249-58</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:13:29 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 23:13:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Purdon SE, Woodward N, Lindborg SR, Stip E</AU>
<TI>Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol</TI>
<SO>Psychopharmacology</SO>
<YR>2003</YR>
<VL>169</VL>
<NO>3-4</NO>
<PG>390-7</PG>
<CY>Germany</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:13:34 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riedel-2007" MODIFIED="2009-07-28 19:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Riedel 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-28 19:16:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Riedel M, Müller N, Spellmann I, Engel RR, Musil R, Valdevit R, Dehning S, Douhet A, Cerovecki A, Strassnig M, Möller H-J</AU>
<TI>Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia</TI>
<SO>European Archieves of Psychiatry and Clinical Neuroscience</SO>
<YR>2007</YR>
<VL>748</VL>
<PG>360-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robinson-2006" MODIFIED="2010-01-12 08:56:55 +0000" MODIFIED_BY="[Empty name]" NAME="Robinson 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-12 08:56:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Robinson DG, Woerner MG, Napolitano B, Patel RC, Sevy SM, Gunduz-Bruce H, Soto-Perello JM, Mendelowitz A, Khadivi A, Miller R, McCormack J, Lorell BS, Lesser ML, Schooler NR, Kane JM</AU>
<TI>Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcome</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<PG>2096-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sacchetti-2004" MODIFIED="2010-01-12 08:57:28 +0000" MODIFIED_BY="[Empty name]" NAME="Sacchetti 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-12 08:57:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sacchetti E, Valsecchi P, Regini C, Galluzzo A, Cacciani P, Agrimi E, Mencacci C</AU>
<TI>Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater-blinded study</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>4</NO>
<PG>S350</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:13:51 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 08:57:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sacchetti E, Valsecchi P, Regini C, Galluzzo A, Cacciani P, Agrimi E, Mencacci C</AU>
<TI>Comparison of quetiapine, olanzapine, and risperidone in schizophrenia</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>Suppl 3</NO>
<PG>S286</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:13:56 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 08:57:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sacchetti E, Valsecchi P, Regini C, Galluzzo A, Cacciani P</AU>
<TI>Comparison of quetiapine, olanzapine and risperidone in a randomized study in patients with schizophrenia</TI>
<SO>Proceedings of the Thematic Conference of the World Psychiatric Association on "Treatments in Psychiatry: An Update"; 2004 Nov 10-13; Florence, Italy</SO>
<YR>2004</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:14:02 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shaw-2006" MODIFIED="2008-12-17 23:14:10 +0000" MODIFIED_BY="[Empty name]" NAME="Shaw 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-12-17 23:14:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P, Tossell JW, Lenane M, Rapoport JL</AU>
<TI>Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2006</YR>
<VL>63</VL>
<NO>7</NO>
<PG>721-30</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:14:10 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sikich-2004" MODIFIED="2010-01-12 08:58:21 +0000" MODIFIED_BY="[Empty name]" NAME="Sikich 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-01-06 14:43:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA</AU>
<TI>A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial</TI>
<SO>Neuropyschopharmacology</SO>
<YR>2004</YR>
<VL>29</VL>
<NO>1</NO>
<PG>133-45</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2009-01-06 14:43:48 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 08:57:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sikich L, Williamson K, Malekpour A, Bashford RA, Hooper S, Sheitman B, Lieberman JA</AU>
<TI>Interim results of a randomized controlled trial of haloperidol, risperidone, and olanzapine in psychotic youth</TI>
<SO>Proceedings of the 38th Annual Meeting of the American College of Neuropsychopharmacology; 1999 Dec 12-16; Acapulco, Mexico</SO>
<YR>1999</YR>
<CY>USA</CY>
<IDENTIFIERS MODIFIED="2009-01-06 14:43:56 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-06 14:44:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sikich L</AU>
<TI>Critical decisions in the treatment of adolescent and pediatric psychosis</TI>
<SO>155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2009-01-06 14:44:13 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 08:58:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sikich L</AU>
<TI>Critical decisions in the treatment of adolescent and pediatric psychosis</TI>
<SO>Proceeding of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA</SO>
<YR>2001</YR>
<PB>Marathon Multimedia</PB>
<IDENTIFIERS MODIFIED="2009-01-06 14:44:06 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simpson-2004" MODIFIED="2010-01-12 08:59:45 +0000" MODIFIED_BY="[Empty name]" NAME="Simpson 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-12 08:58:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD, Bowie C, Loebel AD</AU>
<TI>Long-term cognitive improvement: ziprasidone versus olanzapine</TI>
<SO>Proceedings of the 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, New York, USA</SO>
<YR>2004</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:15:26 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 08:58:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Bowie CR, Loebel A, Warrington L</AU>
<TI>Cognitive improvement and neuropsychological normalization with ziprasidone or olanzapine: Results of a 6-month study</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>Suppl 3</NO>
<PG>S294</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:16:27 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 23:16:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Siu CO, Romano S</AU>
<TI>Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder</TI>
<SO>Psychopharmacology</SO>
<YR>2004</YR>
<VL>172</VL>
<NO>3</NO>
<PG>324-32</PG>
<CY>Germany</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:16:35 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 08:59:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Masand PS, Loebel AD</AU>
<TI>Analysis of remission in a six-month double-blind continuation study of ziprasidone versus olanzapine</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:16:41 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 08:59:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Meyer J, Nasrallah H, Loebel A, Parsons B</AU>
<TI>Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a 6-week randomized study in patients with acute schizophrenia</TI>
<SO>Proceedings of the Collegium Internationale Neuro-Psychopharmacologium 25th Biennial Congress; 2006 July 9-13, Chicago, Illinois</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:16:46 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 08:59:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Meyer JM, Loebel AD</AU>
<TI>Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a six-week randomized study in patients with acute schizophrenia</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:16:51 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 23:16:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO, Simpson</AU>
<TI>Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2004</YR>
<VL>161</VL>
<NO>10</NO>
<PG>1837-47</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:16:56 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 23:17:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Weiden P, Pigott T, Murray S, Siu CO, Romano SJ</AU>
<TI>Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>162</VL>
<NO>8</NO>
<PG>1535-8</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:17:01 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sirota-2006" MODIFIED="2010-01-12 09:00:23 +0000" MODIFIED_BY="[Empty name]" NAME="Sirota 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-12-17 23:17:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sirota P, Pannet I, Koren A, Tchernichovsky E</AU>
<TI>Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia</TI>
<SO>Human Psychopharmacology</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>4</NO>
<PG>227-34</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:17:14 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 09:00:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sirota P, Tchernichowsky E, Panet I, Koren A</AU>
<TI>The effectiveness of quetiapine versus olanzapine in improving negative symptoms of patients with schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>67</VL>
<NO>1</NO>
<PG>170</PG>
<CY>Po Box 211, 1000 Ae Amsterdam, Netherlands</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:17:28 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 09:00:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sirota P</AU>
<TI>Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:17:23 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stroup-2006" MODIFIED="2008-12-17 23:17:37 +0000" MODIFIED_BY="[Empty name]" NAME="Stroup 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-12-17 23:17:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK</AU>
<TI>Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<NO>4</NO>
<PG>611-22</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:17:37 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-2003a" MODIFIED="2010-01-12 09:00:52 +0000" MODIFIED_BY="[Empty name]" NAME="Svestka 2003a" YEAR="2003">
<REFERENCE MODIFIED="2010-01-12 09:00:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J, Synek O, Zourkova A</AU>
<TI>Olanzapine versus risperidone in first-episode schizophrenic and schizoform disorders: a double-blind comparison</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>4</NO>
<PG>S291</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:17:44 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-2003b" MODIFIED="2010-01-12 09:01:10 +0000" MODIFIED_BY="[Empty name]" NAME="Svestka 2003b" YEAR="2003">
<REFERENCE MODIFIED="2010-01-12 09:01:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J, Synek O, Zourkova A</AU>
<TI>A double-blind comparison of olanzapine and quetiapine in treatment of acute exacerbations of schizophrenic or schizoaffective disorders</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>4</NO>
<PG>S291</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:17:51 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-2005" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Svestka 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J</AU>
<TI>Comparison of olanzapine versus ziprasidone in acute schizophrenia</TI>
<SO>Psychiatrie Prague</SO>
<YR>2005</YR>
<VL>9</VL>
<PG>4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tollefson-2001" MODIFIED="2010-01-12 09:02:09 +0000" MODIFIED_BY="[Empty name]" NAME="Tollefson 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-12 09:02:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Beuzen JN, Birkett M, Kiesler G, Wood A</AU>
<TI>Olanzapine vs. clozapine in resistant schizophrenic patients - results of an international double- blind randomised clinical trial</TI>
<SO>Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK</SO>
<YR>1998</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:18:00 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 23:18:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson GD, Birkett MA, Kiesler GM, Wood AJ, Lilly Resistant Schizophrenia Study Group</AU>
<TI>Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine</TI>
<SO>Biological Psychiatry</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>1</NO>
<PG>52-63</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:18:05 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tran-1997" MODIFIED="2010-01-12 09:03:28 +0000" MODIFIED_BY="[Empty name]" NAME="Tran 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-01-12 09:03:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ahmed S, Zhang F, Walker D, Beglinger L, Earley WR, Tran PV</AU>
<TI>Olanzapine versus risperidone for treatment of negative symptoms in schizophrenia</TI>
<SO>Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA</SO>
<YR>2003</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:18:14 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edgell ET, Andersen SW, Johnstone BM, Dulisse B, Revicki D, Breier A</AU>
<TI>Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>S92</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 23:18:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feldman PD, Kaiser CJ, Kennedy JS, Sutton VK, Tran PV, Tollefson GD, Zhang F, Breier A</AU>
<TI>Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64</VL>
<NO>9</NO>
<PG>998-1004</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:18:28 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 23:18:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glick ID, Berg PH</AU>
<TI>Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>2</NO>
<PG>65-8</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:18:34 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 23:18:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson GD, Tran PV, Hamilton S, Kuntz A</AU>
<TI>Olanzapine versus risperidone in the treatment of psychosis. Preliminary report</TI>
<SO>Biological Psychiatry</SO>
<YR>1997</YR>
<VL>41</VL>
<PG>20S</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:18:39 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 23:18:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, Tollefson GD</AU>
<TI>Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>5</NO>
<PG>407-18</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:18:45 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Nimwegen-2006" MODIFIED="2010-01-12 09:05:23 +0000" MODIFIED_BY="[Empty name]" NAME="Van Nimwegen 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-12 09:04:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Van Nimwegen L, De Haan L, Van Beveren N, Laan W, Van De Brink W, Linszen D</AU>
<TI>Obsessive compulsive symptoms in a randomized double blind</TI>
<SO>Proceedings of the 13th Biennial Winter Workshop on Schizophrenia; 2006 Feb 6-10; Davos, Switzerland</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:18:52 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 09:05:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Van Nimwegen L, De Haan L, Van Beveren N, Laan W, Van De Brink W, Linszen D</AU>
<TI>Subjective well-being and craving for cannabis in first psychosis, a randomized double blind comparison of olanzapine versus risperidone</TI>
<SO>Proceedings of the 13th Biennial Winter Workshop on Schizophrenia; 2006 Feb 6-10; Davos, Switzerland</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:18:57 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 09:05:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Nimwegen L, De Haan L</AU>
<TI>Early withdrawal in a double-blind randomized clinical trial with olanzapine and risperidone performed in adolescents with first psychosis</TI>
<SO>Psychopathology</SO>
<YR>2006</YR>
<VL>39</VL>
<NO>3</NO>
<PG>158</PG>
<CY>Switzerland</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:19:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vanelle-2006" MODIFIED="2010-01-12 09:05:52 +0000" MODIFIED_BY="[Empty name]" NAME="Vanelle 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-12 09:05:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vanelle JM, Douki S</AU>
<TI>A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression</TI>
<SO>European Psychiatry</SO>
<YR>2006</YR>
<VL>21</VL>
<PG>523-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 09:05:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vanelle JM, Douki S</AU>
<TI>Metabolic control in patients with comorbid schizophrenia and depression treated with amisulpride or olanzapine</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>Suppl 3</NO>
<PG>S284</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:19:13 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Volavka-2002" MODIFIED="2010-01-12 09:07:57 +0000" MODIFIED_BY="[Empty name]" NAME="Volavka 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-12-17 23:19:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA</AU>
<TI>Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>159</VL>
<NO>6</NO>
<PG>1018-28</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:19:22 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 23:19:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Citrome L, Volavka J, Czobor P, Sheitman B, Lindenmayer J-P, McEvoy J, Cooper TB, Chakos M, Lieberman JA</AU>
<TI>Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia</TI>
<SO>Psychiatric Services</SO>
<YR>2001</YR>
<VL>52</VL>
<NO>11</NO>
<PG>1510-4</PG>
<PB>American Psychiatric Association, US</PB>
<CY>USA</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:19:26 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 09:07:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czobor P, Volavka J, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA</AU>
<TI>Antipsychotic-induced weight gain and therapeutic response: A differential association</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>3</NO>
<PG>244-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-12 09:07:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA</AU>
<TI>Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2003</YR>
<VL>160</VL>
<NO>2</NO>
<PG>290-6</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:19:34 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 23:19:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M</AU>
<TI>Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>4</NO>
<PG>551-6</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:19:39 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 23:19:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nolan KA, Volavka J, Czobor P, Sheitman B, Lindenmayer J-P, Citrome LL, McEvoy J, Lieberman JA</AU>
<TI>Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>2005</YR>
<VL>39</VL>
<NO>1</NO>
<PG>109-15</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:19:47 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 23:19:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Lieberman JA</AU>
<TI>Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>1</NO>
<PG>57-61</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:19:53 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 23:19:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volavka J, Czobor P, Nolan K, Sheitman B, Lindenmayer JP, Citrome LMJP, Cooper TB, Lieberman JA</AU>
<TI>Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>2</NO>
<PG>225-8</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:19:59 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 23:20:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA</AU>
<TI>Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>159</VL>
<NO>2</NO>
<PG>255-62</PG>
<EN>2</EN>
<CY>USA</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:20:05 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Voruganti-2007" MODIFIED="2010-01-12 09:09:45 +0000" MODIFIED_BY="[Empty name]" NAME="Voruganti 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-01-12 09:09:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Voruganti LP, Awad AG, Parker G, Forrest C, Usmani Y, Fernando MLD, Senthilal S</AU>
<TI>Cognition, functioning and quality of life in schizophrenia treatment: Results of a one-year randomized controlled trial of olanzapine and quetiapine</TI>
<SO>Schizophrenia Research</SO>
<YR>2007</YR>
<VL>96</VL>
<NO>1-3</NO>
<PG>146-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wagner-2005" MODIFIED="2008-12-17 23:20:23 +0000" MODIFIED_BY="[Empty name]" NAME="Wagner 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-12-17 23:20:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quednow BB, Wagner M, Westheide J, Beckmann K, Bliesener N, Maier W, Kuhn KU</AU>
<TI>Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine</TI>
<SO>Biological Psychiatry</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>6</NO>
<PG>536-45</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:20:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-17 23:20:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wagner M, Quednow BB, Westheide J, Schlaepfer TE, Maier W, Kuhn K-U</AU>
<TI>Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>2</NO>
<PG>381-90</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:20:23 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2002" MODIFIED="2008-12-17 23:20:30 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-12-17 23:20:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wang C, Feng Y, Wang L</AU>
<TI>A double-blind randomized controlled study of olanzapine and clozapine on treatment of schizophrenia</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>3</NO>
<PG>143-5</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:20:30 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2006" MODIFIED="2008-12-17 23:20:50 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-12-17 23:20:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wang X, Savage R, Borisov A, Rosenberg J, Woolwine B, Tucker M, May R, Feldman J, Nemeroff CB, Miller AH</AU>
<TI>Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>2006</YR>
<VL>40</VL>
<NO>7</NO>
<PG>669-76</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:20:50 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wynn-2007" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Wynn 2007" YEAR="2007">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wynn JK, Green MF, Sprock J, Light GA, Widmark C, Reist C, Erhart S, Marder SR, Mintz J, Braff DL</AU>
<TI>Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: A double-blind, randomized controlled trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2007</YR>
<VL>5</VL>
<PG>1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-01-12 09:44:55 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Almond-1999" MODIFIED="2010-01-12 09:12:02 +0000" MODIFIED_BY="[Empty name]" NAME="Almond 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-01-12 09:12:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Almond S, O'Donnell O, McKendrick J</AU>
<TI>The cost-analysis of olanzapine compared with haloperidol and risperidone in the treatment of schizophrenia in the UK</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>9</VL>
<PG>S289</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:21:15 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alvarez-2006" MODIFIED="2008-12-17 23:21:23 +0000" MODIFIED_BY="[Empty name]" NAME="Alvarez 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-12-17 23:21:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alvarez E, Ciudad A, Olivares JM, Bousono M, Gomez JC</AU>
<TI>A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>3</NO>
<PG>238-49</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:21:23 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alvarez_x002d_Jimenez-2006" MODIFIED="2008-12-17 23:21:32 +0000" MODIFIED_BY="[Empty name]" NAME="Alvarez-Jimenez 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-12-17 23:21:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alvarez-Jimenez M, Gonzalez-Blanch C, Vazquez-Barquero JL, Perez-Iglesias R, Martinez-Garcia O, Perez-Pardal T, Ramirez-Bonilla ML, Crespo-Facorro B</AU>
<TI>Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2006</YR>
<VL>67</VL>
<NO>8</NO>
<PG>1253-60</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:21:32 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Antonova-2005" MODIFIED="2008-12-17 23:21:49 +0000" MODIFIED_BY="[Empty name]" NAME="Antonova 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-12-17 23:21:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Antonova E, Kumari V, Halari R, Zachariah E, Mehrotra R, Kumar A, Sharma T</AU>
<TI>Superior cognitive efficacy of atypical antipsychotics olanzapine, risperidone, and quetiapine, as a group, relative to low doses of conventional antipsychotics</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>474</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:21:49 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Apiquian-2003" MODIFIED="2008-12-17 23:21:55 +0000" MODIFIED_BY="[Empty name]" NAME="Apiquian 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-12-17 23:21:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Apiquian R, Fresan A, Herrera K, Ulloa RE, Loyzaga C, De LaFuente-Sandoval C, Gutierrez D, Nicolini H</AU>
<TI>Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>6</VL>
<NO>4</NO>
<PG>403-8</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:21:55 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aquila-2000" MODIFIED="2010-01-12 09:13:32 +0000" MODIFIED_BY="[Empty name]" NAME="Aquila 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-12 09:13:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Aquila R, Weiden PJ, Kinon BJ, Milton DR, Zygmunt A, Swindle RW, Stauffer VL</AU>
<TI>Effectiveness of olanzapine upon psychiatric and vocational rehabilitation outcomes</TI>
<SO>Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:22:02 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ascher_x002d_Svanum-2006" MODIFIED="2009-07-28 19:17:55 +0100" MODIFIED_BY="[Empty name]" NAME="Ascher-Svanum 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-28 19:17:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J</AU>
<TI>Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia</TI>
<SO>BMC Psychiatry</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>8</NO>
<PG>1-16</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:22:08 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baloescu-2006" MODIFIED="2010-01-12 09:13:52 +0000" MODIFIED_BY="[Empty name]" NAME="Baloescu 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-12 09:13:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baloescu A, Vasile D, Gheorghe MD, Grigorescu G</AU>
<TI>Side effects of atypical antipsychotics - prediction factor for compliance</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S403</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:22:15 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Basson-2001" MODIFIED="2008-12-17 23:22:21 +0000" MODIFIED_BY="[Empty name]" NAME="Basson 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-12-17 23:22:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD</AU>
<TI>Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2001</YR>
<VL>62</VL>
<NO>4</NO>
<PG>231-8</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:22:21 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beasley-2001" MODIFIED="2008-12-17 23:22:28 +0000" MODIFIED_BY="[Empty name]" NAME="Beasley 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-12-17 23:22:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beasley CM, Berg PH, Dananberg J, Kwong KC, Taylor CCM, Breier A</AU>
<TI>Treatment-emergent potential impaired glucose tolerance and potential diabetes with olanzapine compared to other antipsychotic agents and placebo</TI>
<SO>Biological Psychiatry</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>8</NO>
<PG>121S</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:22:28 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beasley-2003a" MODIFIED="2010-01-12 09:14:19 +0000" MODIFIED_BY="[Empty name]" NAME="Beasley 2003a" YEAR="2003">
<REFERENCE MODIFIED="2010-01-12 09:14:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beasley CM, Sowell MO, Carlson C, Mukhopadhyay N, Dananberg J, Henry R, Breier A, Cavazzoni P</AU>
<TI>Prospective evaluation of insulin sensitivity by the hyperinsulinemic, euglycemic clamp in healthy volunteers treated with olanzapine, risperidone or placebo</TI>
<SO>Schizophrenia Research</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>1</NO>
<PG>309</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:22:34 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beasley-2003b" MODIFIED="2008-12-17 23:22:49 +0000" MODIFIED_BY="[Empty name]" NAME="Beasley 2003b" YEAR="2003">
<REFERENCE MODIFIED="2008-12-17 23:22:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beasley CM, Sutton VK, Hamilton SH, Walker DJ, Dossenbach M, Taylor CC, Alaka KJ, Bykowski D, Tollefson GD</AU>
<TI>A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>6</NO>
<PG>582-94</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:22:49 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bera-2001" MODIFIED="2010-01-12 09:14:36 +0000" MODIFIED_BY="[Empty name]" NAME="Bera 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-12 09:14:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bera RB</AU>
<TI>A comparison of patient satisfaction between seroquel, olanzapine and risperidal</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>1, 2</NO>
<PG>220</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:22:56 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beuzen-2005" MODIFIED="2010-01-12 09:14:48 +0000" MODIFIED_BY="[Empty name]" NAME="Beuzen 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-12 09:14:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Beuzen J-N, Pans M, Modell S, Hagens P, McQuade R, Iwamoto T, Carson W</AU>
<TI>Naturalistic study of aripiprazole treatment</TI>
<SO>Proceedings of the XIII World Congress of Psychiatry; 2005 10-15th Sept; Cairo, Egypt</SO>
<YR>2005</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:23:05 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bitter-2005" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Bitter 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bitter I, Basson BR, Dossenbach M</AU>
<TI>Antipsychotic treatment and sexual functioning in first-time neuroleptic-treated schizophrenic patients</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2005</YR>
<VL>20</VL>
<PG>19-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blonde-2004" MODIFIED="2010-01-12 09:15:20 +0000" MODIFIED_BY="[Empty name]" NAME="Blonde 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-12 09:15:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blonde L, Ray S, Corey-Lisle PK, Cislo PR, L'Italien G</AU>
<TI>The risk of new-onset type 2 diabetes and coronary heart disease in chronic schizophrenic patients treated with aripiprazole and olanzapine</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>Suppl 3</NO>
<PG>S275</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:24:42 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boylan-2004" MODIFIED="2008-12-17 23:24:48 +0000" MODIFIED_BY="[Empty name]" NAME="Boylan 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-12-17 23:24:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boylan LS, Labovitz DL</AU>
<TI>Unbalanced statistical analysis of combined divalproex and antipsychotic therapy for schizophrenia</TI>
<SO>Neuropyschopharmacology</SO>
<YR>2004</YR>
<VL>29</VL>
<NO>3</NO>
<PG>636</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:24:48 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Briken-2002" MODIFIED="2010-01-12 09:15:34 +0000" MODIFIED_BY="[Empty name]" NAME="Briken 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-12 09:15:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Briken P, Nika E, Moritz S, Haasen C, Perro C, Yagdiran O, Naber D, Krausz M</AU>
<TI>Effect of zotepine, olanzapine and risperidone on hostility in schizophrenic patients</TI>
<SO>Schizophrenia Research</SO>
<YR>2002</YR>
<VL>57</VL>
<PG>311-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cao-2005" MODIFIED="2008-12-17 23:25:03 +0000" MODIFIED_BY="[Empty name]" NAME="Cao 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-12-17 23:25:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cao D, Xie S-P, Chen Q-B, Yuan Y-G, Fang Q</AU>
<TI>Characteristics of the sexual disturbance caused by chlorpromazine, risperidone, quetiapine and olanzapine and their associations with the changes of blood glucose and blood lipids in male patients with schizophrenia</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2005</YR>
<VL>9</VL>
<NO>36</NO>
<PG>63-8</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:25:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casey-2003" MODIFIED="2010-01-12 09:16:10 +0000" MODIFIED_BY="[Empty name]" NAME="Casey 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-12 09:16:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Casey D, L'Italien G, Waldeck R, Cislo P, Carson W</AU>
<TI>Metabolic syndrome comparison between olanzapine, aripiprazole, and placebo</TI>
<SO>Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17&#8211;22; San Francisco, California, USA</SO>
<YR>2003</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:25:22 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chaudhry-2006" MODIFIED="2010-01-12 09:16:23 +0000" MODIFIED_BY="[Empty name]" NAME="Chaudhry 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-12 09:16:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chaudhry HR, Niaz S, Arshad N, Peracha F, Ayub A, Mufti KA</AU>
<TI>Comparison of risperidone, olanzapine and quetiapine in relation to body weight, serum blood glucose and prolactin levels</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S241</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:25:28 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2003" MODIFIED="2010-01-12 09:18:01 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-12 09:18:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen F, Liang L, Zhu XH</AU>
<TI>A control study of elderly patients with schizophrenia treated with olanzapine or clozapine</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>5</NO>
<PG>298-9</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:25:46 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2005" MODIFIED="2008-12-17 23:26:08 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-12-17 23:26:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen J, Li Z</AU>
<TI>A controlled study of olanzapine versus clozapine in schizophrenia</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>3</NO>
<PG>217-8</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:26:08 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chrzanowski-2006" MODIFIED="2010-01-12 09:19:25 +0000" MODIFIED_BY="[Empty name]" NAME="Chrzanowski 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-12 09:19:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD</AU>
<TI>Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine</TI>
<SO>Psychopharmacology</SO>
<YR>2006</YR>
<VL>189</VL>
<NO>2</NO>
<PG>259-66</PG>
<CY>Germany</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:26:15 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Citrome-2004" MODIFIED="2008-12-17 23:26:37 +0000" MODIFIED_BY="[Empty name]" NAME="Citrome 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-12-17 23:26:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Citrome L, Casey DE, Daniel DG, Wozniak P, Kochan LD, Tracy KA</AU>
<TI>Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone</TI>
<SO>Psychiatric Services</SO>
<YR>2004</YR>
<VL>55</VL>
<NO>3</NO>
<PG>290-4</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:26:37 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ciudad-2004" MODIFIED="2010-01-12 09:23:26 +0000" MODIFIED_BY="[Empty name]" NAME="Ciudad 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-12 09:23:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ciudad A, Álvarez E, Bousoño M, Cuesta M, Gómez JC, Olivares JM</AU>
<TI>Olanzapine versus risperidone: Results of a one-year randomized trial in outpatients with schizophrenia with prominent negative symptoms</TI>
<SO>Proceedings of the 11th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-14; Davos, Switzerland</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Conley-1999" MODIFIED="2008-12-17 23:26:48 +0000" MODIFIED_BY="[Empty name]" NAME="Conley 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-12-17 23:26:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Conley J, Goldman RS, Bilder RM, Bates J, Reiter G, Pappadopulos E, Robinson D, Alvir JMA, Liebrman J, Schooler N</AU>
<TI>A comparison of the neurocognitive effects of treatment with typical and atypical neuroleptics in first-episode schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1999</YR>
<VL>36</VL>
<NO>1-3</NO>
<PG>128</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:26:48 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cornblatt-2002" MODIFIED="2008-12-17 23:26:55 +0000" MODIFIED_BY="[Empty name]" NAME="Cornblatt 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-12-17 23:26:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cornblatt B, Kern RS, Carson WH, Ali MW, Luo X, Green M</AU>
<TI>Neurocognitive effects of aripiprazole versus olanzapine in stable psychosis</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>S185</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:26:55 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crespo_x002d_Facorro-2006" MODIFIED="2008-12-17 23:27:05 +0000" MODIFIED_BY="[Empty name]" NAME="Crespo-Facorro 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-12-17 23:27:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crespo-Facorro B, Perez-Iglesias R, Ramirez-Bonilla M, Martinez-Garcia O, Llorca J, Vazquez-Barquero JL</AU>
<TI>A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2006</YR>
<VL>67</VL>
<NO>10</NO>
<PG>1511-21</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:27:05 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Czekalla-2001" MODIFIED="2008-12-17 23:27:11 +0000" MODIFIED_BY="[Empty name]" NAME="Czekalla 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-12-17 23:27:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czekalla J, Beasley CM Jr, Dellva MA, Berg PH, Grundy S</AU>
<TI>Analysis of the qtc interval during olanzapine treatment of patients with schizophrenia and related psychosis</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2001</YR>
<VL>62</VL>
<NO>3</NO>
<PG>191-8</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:27:11 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dai-2004a" MODIFIED="2010-01-12 09:21:25 +0000" MODIFIED_BY="[Empty name]" NAME="Dai 2004a" YEAR="2004">
<REFERENCE MODIFIED="2010-01-12 09:21:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dai J-P, Zhao Z-H, Mai G-Y</AU>
<TI>Comparative study on the effect of olanzapine and seroquel of schizophrenia</TI>
<SO>Chinese Journal of Behavioral Medical Science</SO>
<YR>2004</YR>
<VL>13</VL>
<NO>3</NO>
<PG>291-93</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:27:18 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dai-2004b" MODIFIED="2010-01-12 09:21:35 +0000" MODIFIED_BY="[Empty name]" NAME="Dai 2004b" YEAR="2004">
<REFERENCE MODIFIED="2010-01-12 09:21:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dai J-P, Zhao Z-H, Mai G-Y</AU>
<TI>Comparative study on the influence of olanzapine and clozapine on efficacy and quality of life in schizophrenia</TI>
<SO>Chinese Journal of Behavioral Medical Science</SO>
<YR>2004</YR>
<VL>13</VL>
<NO>4</NO>
<PG>396-98</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:27:23 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dakhale-2005" MODIFIED="2008-12-17 23:27:31 +0000" MODIFIED_BY="[Empty name]" NAME="Dakhale 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-12-17 23:27:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dakhale GN, Khanzode SD, Khanzode SS, Saoji A</AU>
<TI>Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia</TI>
<SO>Psychopharmacology</SO>
<YR>2005</YR>
<VL>182</VL>
<NO>4</NO>
<PG>494-8</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:27:31 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-David-2000a" MODIFIED="2008-12-17 23:27:36 +0000" MODIFIED_BY="[Empty name]" NAME="David 2000a" YEAR="2000">
<REFERENCE MODIFIED="2008-12-17 23:27:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>David SR, Taylor CC, Kinon BJ, Breier A</AU>
<TI>The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia</TI>
<SO>Clinical Therapeutics</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>9</NO>
<PG>1085-96</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:27:36 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-David-2000b" MODIFIED="2008-12-17 23:27:49 +0000" MODIFIED_BY="[Empty name]" NAME="David 2000b" YEAR="2000">
<REFERENCE MODIFIED="2008-12-17 23:27:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>David SR, Meehan KM, Sutton VK, Taylor CC</AU>
<TI>Treatment of negative symptoms with olanzapine in comparison with other novel antipsychotic agents</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>s140</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:27:49 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Haan-2002" MODIFIED="2010-01-12 09:22:22 +0000" MODIFIED_BY="[Empty name]" NAME="De Haan 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-12 09:22:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Haan L, Beuk N, Hoogenboom B, Dingemans P, Linszen D</AU>
<TI>Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>2</NO>
<PG>104-7</PG>
<CY>USA</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:27:56 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deng-2000" MODIFIED="2010-01-12 09:24:25 +0000" MODIFIED_BY="[Empty name]" NAME="Deng 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-12 09:24:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deng H, Zheng H, He Z</AU>
<TI>A comparative trial of olanzapine versus clozapine in the treatment of schizophrenia</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2000</YR>
<VL>12</VL>
<NO>3</NO>
<PG>143-45</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:28:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dossenbach-2005" MODIFIED="2010-01-12 09:25:18 +0000" MODIFIED_BY="[Empty name]" NAME="Dossenbach 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-12 09:25:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dossenbach M, Arango-Dávila C, Ibarra HS, Landa E, Aguilar J, Caro O, Leadbetter J, Assuncao S</AU>
<TI>Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2005</YR>
<VL>66</VL>
<PG>1021-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ertugrul-2006" MODIFIED="2010-01-12 09:25:35 +0000" MODIFIED_BY="[Empty name]" NAME="Ertugrul 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-12 09:25:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ertugrul A, Anil Yagcioglu AE, Woodward ND, Jayathilake K, Meltzer HY</AU>
<TI>Genetic predictors of cognitive function and response to treatment in schizophrenia</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S406</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:28:21 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fleischhacker-2005" MODIFIED="2008-12-17 23:28:27 +0000" MODIFIED_BY="[Empty name]" NAME="Fleischhacker 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-12-17 23:28:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fleischhacker WW, Keet IPM, Kahn RS</AU>
<TI>The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>78</VL>
<NO>2-3</NO>
<PG>147-56</PG>
<CY>Netherlands</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:28:27 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garc_x00ed_a-2006" MODIFIED="2010-01-12 09:25:53 +0000" MODIFIED_BY="[Empty name]" NAME="García 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-12 09:25:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>García MC, Vidal M, Ramos R</AU>
<TI>Sexual side effects of antipsychoticcs and treatment adherence</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S378</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:28:33 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldberg-2000" MODIFIED="2008-12-17 23:28:40 +0000" MODIFIED_BY="[Empty name]" NAME="Goldberg 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-12-17 23:28:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg TE, Dodge M, Aloia M, Egan MF, Weinberger DR</AU>
<TI>Effects of neuroleptic medications on speech disorganization in schizophrenia: biasing associative networks towards meaning</TI>
<SO>Psychological Medicine</SO>
<YR>2000</YR>
<VL>30</VL>
<NO>5</NO>
<PG>1123-30</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:28:40 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harrigan-2004" MODIFIED="2008-12-17 23:28:45 +0000" MODIFIED_BY="[Empty name]" NAME="Harrigan 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-12-17 23:28:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, Sramek J, Shiovitz T, Middle M</AU>
<TI>A randomized evaluation of the effects of six antipsychotic agents on QTC, in the absence and presence of metabolic inhibition</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>1</NO>
<PG>62-9</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:28:45 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harrison-2004" MODIFIED="2010-01-12 09:26:49 +0000" MODIFIED_BY="[Empty name]" NAME="Harrison 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-12 09:26:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harrison D, Leaderer M, Loebel A, Murray S</AU>
<TI>Ziprasidone vs. olanzapine: change in coronary heart disease risk during a 6-week trial</TI>
<SO>Proceedings of the thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: An Update"; 2004 Nov 10-13; Florence, Italy</SO>
<YR>2004</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:28:51 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heresco_x002d_Levy-2005" MODIFIED="2008-12-17 23:28:56 +0000" MODIFIED_BY="[Empty name]" NAME="Heresco-Levy 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-12-17 23:28:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar GCS, Ermilov M</AU>
<TI>D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>2005</YR>
<VL>57</VL>
<NO>6</NO>
<PG>577-85</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:28:56 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hrdlicka-2001" MODIFIED="2008-12-17 23:29:02 +0000" MODIFIED_BY="[Empty name]" NAME="Hrdlicka 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-12-17 23:29:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hrdlicka M, Rosillon D, Duchesne I</AU>
<TI>Czech results of the RODOS study: comparison of risperidone and olanzapine from the point of view of efficacy, tolerability and treatment costs</TI>
<TO>Ceske vysledky studie RODOS: Porovnani risperidonu a olanzapinu z hlediska ucinnosti, snasenlivosti a nakladu lecby</TO>
<SO>Ceska A Slovenská Psychiatrie</SO>
<YR>2001</YR>
<VL>97</VL>
<NO>7</NO>
<PG>343-9</PG>
<PB>Czech Medical Society JEv Purkyne, Czech Republic</PB>
<CY>Czech Republic</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:29:02 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huber-2004" MODIFIED="2008-12-17 23:29:07 +0000" MODIFIED_BY="[Empty name]" NAME="Huber 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-12-17 23:29:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huber TJ, Borsutzky M, Schneider U, Emrich HM</AU>
<TI>Psychotic disorders and gonadal function: Evidence supporting the oestrogen hypothesis</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>2004</YR>
<VL>109</VL>
<NO>4</NO>
<PG>269-74</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:29:07 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karow-2002" MODIFIED="2008-12-17 23:29:14 +0000" MODIFIED_BY="[Empty name]" NAME="Karow 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-12-17 23:29:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karow A, Naber D</AU>
<TI>Subjective well-being and quality of life under atypical antipsychotic treatment</TI>
<SO>Psychopharmacology</SO>
<YR>2002</YR>
<VL>162</VL>
<PG>3-10</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:29:14 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keks-2006" MODIFIED="2009-07-28 19:18:14 +0100" MODIFIED_BY="[Empty name]" NAME="Keks 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-28 19:18:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keks NA, Tonso M, Tabone K, Mchugh M, Thomas R, Tune P, Gelman M</AU>
<TI>Clinical experience with atypical antipsychotics in an acute inpatient unit: Focus on quetiapine</TI>
<SO>International Journal of Psychiatry in Clinical Practice</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>2</NO>
<PG>1-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kelemen-2006" MODIFIED="2010-01-12 09:27:39 +0000" MODIFIED_BY="[Empty name]" NAME="Kelemen 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-12 09:27:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelemen O, Nagy O, Máttyássy A, Kiss I, Janka Z, Kéri S</AU>
<TI>Do second-generation antipsychotics disrupt decision-making abilities in schizophrenia?</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S430</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:29:24 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kern-2006" MODIFIED="2010-01-12 09:27:48 +0000" MODIFIED_BY="[Empty name]" NAME="Kern 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-12 09:27:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kern RS, Green MF, Cornblatt B, Owen JR, McQuade RD, Carson WH, Ali M, Marcus R</AU>
<TI>The neurocognitive effects of aripriprazole: an open-label comparison with olanzapine</TI>
<SO>Psychopharmacology</SO>
<YR>2006</YR>
<VL>187</VL>
<PG>312-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2004" MODIFIED="2010-01-12 09:28:00 +0000" MODIFIED_BY="[Empty name]" NAME="Kim 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-12 09:28:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim JG, Cho DH, Choi HK, Kim HJ, Cho JH, Kang SH, Lee SJ, Lee JG, Kim HT</AU>
<TI>The comparison of risperidone, olanzapine and quetiapine in the treatment of chronic schizophrenia and schizoaffective disorder</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>Suppl 3</NO>
<PG>S245</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:29:38 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinon-2001" MODIFIED="2008-12-17 23:29:43 +0000" MODIFIED_BY="[Empty name]" NAME="Kinon 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-12-17 23:29:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinon BJ, Roychowdhury SM, Milton DR, Hill AL</AU>
<TI>Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2001</YR>
<VL>62</VL>
<NO>Suppl 2</NO>
<PG>17-21</PG>
<PB>Physicians Postgraduate Press Inc.</PB>
<CY>USA</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:29:43 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kolff-2000" MODIFIED="2010-01-12 09:28:36 +0000" MODIFIED_BY="[Empty name]" NAME="Kolff 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-12 09:28:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kolff M, Coenen A, Van Dis H, Duigemans P</AU>
<TI>Differential effects of antipsychotic drugs on clinical symptoms and cognitive functions in the treatment of schizophrenia</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>10</VL>
<NO>Suppl 2</NO>
<PG>S59</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:29:49 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kores-2003" MODIFIED="2008-12-17 23:29:55 +0000" MODIFIED_BY="[Empty name]" NAME="Kores 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-12-17 23:29:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kores Plesnicar B, Zalar B, Tomori M, Krajnc I</AU>
<TI>Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia</TI>
<SO>Wiener Klinische Wochenschrift</SO>
<YR>2003</YR>
<VL>115</VL>
<NO>1-2</NO>
<PG>58-62</PG>
<CY>Austria</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:29:55 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kropp-2004" MODIFIED="2010-01-12 09:29:33 +0000" MODIFIED_BY="[Empty name]" NAME="Kropp 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-12 09:29:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Kropp S, Grohmann R, Hauser U, Rüther E, Degner D</AU>
<TI>Hyperglycemia associated with antipsychotic treatment in a multicenter drug safety project</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2004</YR>
<VL>37</VL>
<NO>79-83</NO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2006" MODIFIED="2008-12-17 23:30:05 +0000" MODIFIED_BY="[Empty name]" NAME="Lee 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-12-17 23:30:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee C, Wu K-H, Habil H, Dyachkova Y, Lee P</AU>
<TI>Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>40</VL>
<NO>5</NO>
<PG>437-45</PG>
<CY>Australia</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:30:05 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2005" MODIFIED="2008-12-17 23:30:11 +0000" MODIFIED_BY="[Empty name]" NAME="Lin 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-12-17 23:30:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin Z-Y, Li F-Q, Yu Y-Y, Zhong T-P</AU>
<TI>A controlled study of olanzapine and risperidol in the treatment of elderly patients with schizophrenia</TI>
<SO>Hainan Medical Journal</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>8</NO>
<PG>37-8</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:30:11 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lipkovich-2005" MODIFIED="2008-12-17 23:30:16 +0000" MODIFIED_BY="[Empty name]" NAME="Lipkovich 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-12-17 23:30:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lipkovich I, Baron D, Houston J, Ahl J, Rotelli M</AU>
<TI>Flexible-dose clinical trials: predictors and outcomes of antipsychotic dose adjustments</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>4</NO>
<PG>381-6</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:30:16 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Littrell-1999" MODIFIED="2010-01-12 09:31:08 +0000" MODIFIED_BY="[Empty name]" NAME="Littrell 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-01-12 09:31:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Littrell KH</AU>
<TI>Patients switched from depot antipsychotics to oral risperidone or olanzapine: an open-label randomized trial</TI>
<SO>Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington DC, USA</SO>
<YR>1999</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:30:22 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2004" MODIFIED="2010-01-12 09:31:22 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-12 09:31:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu W, Li H, Zheng L</AU>
<TI>A controlled study on olanzapine and clozapine in the treatment of the acute phase of schizophrenia</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>5</NO>
<PG>282-84</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:30:29 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loza-2005" MODIFIED="2010-01-12 09:31:38 +0000" MODIFIED_BY="[Empty name]" NAME="Loza 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-12 09:31:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loza B, Bartyzel M, Matysiewicz W, Mazurek I, Mosiolek A, Opielak G, Varghese S</AU>
<TI>Hyperprolactinemia during schizophrenia treatment with atypical antipsychotics: oral risperidone, depot risperidone, and oral olanzapine</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>Suppl 3</NO>
<PG>S522</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:30:37 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malla-2004" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Malla 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malla A, Norman R, Scholten D, Townsend L, Manchanda R, Takhar J, Haricharan R</AU>
<TI>A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition</TI>
<SO>Psychiatry Research</SO>
<YR>2004</YR>
<VL>129</VL>
<PG>159-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malyarov-1999" MODIFIED="2010-01-12 09:32:01 +0000" MODIFIED_BY="[Empty name]" NAME="Malyarov 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-01-12 09:32:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malyarov S, Dzub G</AU>
<TI>Comparative assessment of the positive and negative symptom dynamics in schizophrenic patients treated with atypical antipsychotics or haloperidol</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>9</VL>
<PG>S296</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:30:51 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mazurek-2003" MODIFIED="2010-01-12 09:32:14 +0000" MODIFIED_BY="[Empty name]" NAME="Mazurek 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-12 09:32:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mazurek I, Loza B, Lecyk A</AU>
<TI>Atypical versus typical antipsychotic treatment prognosis based on veps and wcst scores in paranoid schizophrenia</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>4</NO>
<PG>S347</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:30:56 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meltzer-2002" MODIFIED="2010-01-12 09:32:35 +0000" MODIFIED_BY="[Empty name]" NAME="Meltzer 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-12 09:32:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Meltzer HY, Gilliam JH, Nasdahl C</AU>
<TI>Olanzapine causes greater increases in serum lipids than risperidone</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:31:02 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moritz-2002" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Moritz 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moritz S, Woodward TS, PERSIST Study Group, Krausz M, Naber D</AU>
<TI>Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2002</YR>
<VL>17</VL>
<PG>41-44</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mortimer-2002" MODIFIED="2008-12-17 23:31:14 +0000" MODIFIED_BY="[Empty name]" NAME="Mortimer 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-12-17 23:31:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Mortimer A</AU>
<TI>Randomised prospective parallel group comparison of clozapine vs olanzapine in the reduction of suicidality in patients with schizophrenia/schizoaffective disorder</TI>
<SO>National Research Register</SO>
<YR>2002</YR>
<VL>1</VL>
<IDENTIFIERS MODIFIED="2008-12-17 23:31:14 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Musil-2006" MODIFIED="2010-01-12 09:33:02 +0000" MODIFIED_BY="[Empty name]" NAME="Musil 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-12 09:33:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Musil RL, Spellmann I, Riedel M, Douhet A, Dehning S, Maino K, Zill P, Müller N, Möller HJ, Bondy B</AU>
<TI>SNAP-25 gene polymorphisms and weight gain in schizophrenic patients treated with atypical antipsychotics</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S415</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:31:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naber-2001" MODIFIED="2008-12-17 23:31:27 +0000" MODIFIED_BY="[Empty name]" NAME="Naber 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-12-17 23:31:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naber D, Moritz S, Lambert M, Pajonk F, Holzbach R, Mass R, Andresen B</AU>
<TI>Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>50</VL>
<PG>79-88</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:31:27 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naber-2002" MODIFIED="2008-12-17 23:31:37 +0000" MODIFIED_BY="[Empty name]" NAME="Naber 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-12-17 23:31:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naber D, Karow A, Lambert M</AU>
<TI>Psychosocial outcomes in patients with schizophrenia: quality of life and reintegration</TI>
<SO>Current Opinion in Psychiatry</SO>
<YR>2002</YR>
<VL>15</VL>
<PG>31-6</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:31:37 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newcomer-2006" MODIFIED="2010-01-12 09:33:43 +0000" MODIFIED_BY="[Empty name]" NAME="Newcomer 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-12 09:33:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Newcomer JW, L'Italien G, Vester-Blockland, McQuade RD, Carson WH, Marcus RN</AU>
<TI>Improvement of non-hdl cholesterol levels among patients randomized to aripiprazole versus olanzapine</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:31:45 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oliemeulen-2000" MODIFIED="2010-01-12 09:34:17 +0000" MODIFIED_BY="[Empty name]" NAME="Oliemeulen 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-12 09:34:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oliemeulen EAP, Van Hoof JJM, Jogem-Kosterman BJM, Hulsttijn W, Tuynman-Qua HG</AU>
<TI>Is olanzapine a substitute for clozapine? The effects on psychomotor performance</TI>
<SO>Schizophrenia Research</SO>
<YR>2000</YR>
<VL>41</VL>
<NO>1</NO>
<PG>187</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:33:31 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Opjordsmoen-2000" MODIFIED="2010-01-12 09:34:35 +0000" MODIFIED_BY="[Empty name]" NAME="Opjordsmoen 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-12 09:34:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Opjordsmoen S, Brunsvik S, Melle I, Dahl A, Friis S, Haahr U, Hustoft K, Johannessen JO, Larsen TK, McGlashan TH, Simonsen E, Vaglum P</AU>
<TI>A comparison between novel and traditional antipsychotics as first-line medication in early psychosis</TI>
<SO>Proceedings of the 2nd International Conference on Early Psychosis; 2000 Mar 31 - Apr 2; New York, New York, USA</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:33:37 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ortega_x002d_Soto-1997" MODIFIED="2010-01-12 09:34:50 +0000" MODIFIED_BY="[Empty name]" NAME="Ortega-Soto 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-01-12 09:34:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ortega-Soto H, Apiquian R, Ulloa RE, Salas M, Loyzaga C, Mendizabal A, Brunner E</AU>
<TI>Olanzapine vs risperidone. A double blind trial in Mexican patients</TI>
<SO>Proceedings of the Collegium Internationale Neuro-Psychopharmacologicum Regional Meeting; 1997 Aug 21-23; Acapulco, Mexico</SO>
<YR>1997</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:33:43 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pan-2006" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Pan 2006" YEAR="">
<REFERENCE MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pan SM, Zhao LJ</AU>
<TI>A study of olanzapine and clozapine in treatment of schizophrenia</TI>
<SO>Zhejiang Journal of Integrated Traditional Chinese and Western Medicine</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>1</NO>
<PG>32-3</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perro-1999" MODIFIED="2010-01-12 09:35:23 +0000" MODIFIED_BY="[Empty name]" NAME="Perro 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-01-12 09:35:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Perro C, Naber D, Lambert M, Moritz S, Krause M</AU>
<TI>A prospective clinical comparative-study of four atypical antipsychotic agents in the treatment of schizophrenia</TI>
<SO>Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany</SO>
<YR>1999</YR>
<VL>2</VL>
<PG>13</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:33:56 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peuskens-2004" MODIFIED="2010-01-12 09:35:43 +0000" MODIFIED_BY="[Empty name]" NAME="Peuskens 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-12 09:35:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peuskens J, Deberdt W, Van Brunt D, Hill A, Liu-Seifert H, Csernansky J, Buckley P</AU>
<TI>Medication-specific correlates of relapse risk in schizophrenia</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>Suppl 3</NO>
<PG>S238</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:34:01 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rabinowitz-2005" MODIFIED="2010-01-12 09:36:34 +0000" MODIFIED_BY="[Empty name]" NAME="Rabinowitz 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-12 09:36:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rabinowitz J</AU>
<TI>Pattern mixture approach to comparing outcomes - of benefit in guideline development</TI>
<SO>Proceedings of the 18th European College of Neuropsychopharmacology Congress; 2005 October 22-26, Amsterdam, Netherlands</SO>
<YR>2005</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:34:07 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ray-2004" MODIFIED="2010-01-12 09:36:51 +0000" MODIFIED_BY="[Empty name]" NAME="Ray 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-12 09:36:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ray S, Corey-Lisle PK, Cislo PR, L'Italien G, Weiden P</AU>
<TI>An economic evaluation of aripiprazole compared to olanzapine based on metabolic side-effect profile</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>Suppl 3</NO>
<PG>S279</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:34:13 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reznik-2004" MODIFIED="2010-01-12 09:37:08 +0000" MODIFIED_BY="[Empty name]" NAME="Reznik 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-12 09:37:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Reznik I, Slavkin L, Shabash E, Shaked G, Kertzman S, Spivak B, Weizman A, Kotler M</AU>
<TI>Quetiapine ('Seroquel') and olanzapine for acute treatment of patients with schizophrenia: an open-label, comparative study</TI>
<SO>Proceedings of the XXIVth Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 June 20&#8211;24, Paris, France</SO>
<YR>2004</YR>
<PG>1-4</PG>
<CY>France</CY>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roerig-2004" MODIFIED="2010-01-12 09:37:47 +0000" MODIFIED_BY="[Empty name]" NAME="Roerig 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-12 09:37:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Roerig JL, Mitchell JE, de Zwaan M, Crosby RD, Gosnell BA, Pederson K</AU>
<TI>A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors and ghrelin plasma levels in normal human subjects</TI>
<SO>Proceedings of the thematic conference of the World Psychiatric Association on "Treatments in Psychiatry: An Update"; 2004 Nov 10-13; Florence, Italy</SO>
<YR>2004</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:34:23 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ryu-2006" MODIFIED="2010-01-12 09:38:08 +0000" MODIFIED_BY="[Empty name]" NAME="Ryu 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-12 09:38:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ryu SH, Jang WS, Cho EY, Kim SK, Lee DS, Hong KS</AU>
<TI>Association of leptin gene polymorphism with antipsychotic drug-induced weight gain</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S419</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:34:31 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanchez-2006" MODIFIED="2010-01-12 09:38:24 +0000" MODIFIED_BY="[Empty name]" NAME="Sanchez 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-12 09:38:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sanchez R, Kostic D, Stock E, Torbeyns AF, Kerselaers W, Nyilas M, McQuade R, Carson WH, Marcus RN</AU>
<TI>Aripiprazole vs olanzapine in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week open-label extension study</TI>
<SO>Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 February 4-10, Davos, Switzerland</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:34:51 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-2003" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Sharma 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma T, Hughes C, Soni W, Kumari V</AU>
<TI>Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia</TI>
<SO>Psychopharmacology</SO>
<YR>2003</YR>
<VL>169</VL>
<PG>398-403</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sowell-2002" MODIFIED="2008-12-17 23:35:01 +0000" MODIFIED_BY="[Empty name]" NAME="Sowell 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-12-17 23:35:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sowell M, Cavazzoni P, Roychowdhury SM, Breier A</AU>
<TI>Antipsychotics and diabetes: lack of evidence for a causal relationship</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>S170</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:35:01 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Su-2005" MODIFIED="2008-12-17 23:35:07 +0000" MODIFIED_BY="[Empty name]" NAME="Su 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-12-17 23:35:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Su K-P, Wu P-L, Pariante CM</AU>
<TI>A crossover study on lipid and weight changes associated with olanzapine and risperidone</TI>
<SO>Psychopharmacology</SO>
<YR>2005</YR>
<VL>183</VL>
<NO>3</NO>
<PG>383-6</PG>
<CY>Germany</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:35:07 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swanson-2006" MODIFIED="2010-01-12 09:39:02 +0000" MODIFIED_BY="[Empty name]" NAME="Swanson 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-12 09:39:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Swanson JW, Swartz MS, Van Dorn RA</AU>
<TI>Effectiveness of atypical antipsychotics for substance abuse in schizophrenia patients</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:35:13 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tudor-2006" MODIFIED="2010-01-12 09:39:14 +0000" MODIFIED_BY="[Empty name]" NAME="Tudor 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-12 09:39:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tudor C, Ungureanu D, Gheorghe MD</AU>
<TI>Olanzapine versus ziprasidone in parenteral administration in psychotic relapse of schizophrenia</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S397</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:35:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tunis-2006" MODIFIED="2008-12-17 23:35:25 +0000" MODIFIED_BY="[Empty name]" NAME="Tunis 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-12-17 23:35:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R</AU>
<TI>Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial</TI>
<SO>Value in Health</SO>
<YR>2006</YR>
<VL>9</VL>
<NO>2</NO>
<PG>77-89</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:35:25 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Bruggen-2003" MODIFIED="2010-01-12 09:39:38 +0000" MODIFIED_BY="[Empty name]" NAME="Van Bruggen 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-12 09:39:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Bruggen J, Tijssen J, Dingemans P, Gersons B, Linszen D</AU>
<TI>Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>6</NO>
<PG>341-6</PG>
<CY>Netherlands</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:35:32 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaughan-2000" MODIFIED="2010-01-12 09:40:19 +0000" MODIFIED_BY="[Empty name]" NAME="Vaughan 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-12 09:40:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaughan K, McConaghy N, Wolf C, Myhr C, Black T</AU>
<TI>Community treatment orders: Relationship to clinical care, medication compliance, behavioural disturbance and readmission</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>34</VL>
<NO>5</NO>
<PG>801-8</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:35:37 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2003" MODIFIED="2008-12-17 23:35:43 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-12-17 23:35:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang K, Zhang K</AU>
<TI>A study of olanzapine and clozapine in the treatment of schizophrenia.</TI>
<SO>Shandong Archires of Psychiatry</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>03</NO>
<PG>141-3</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:35:43 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2004a" MODIFIED="2008-12-17 23:35:50 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2004a" YEAR="2004">
<REFERENCE MODIFIED="2008-12-17 23:35:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang X, Wen Q, Jiang F</AU>
<TI>Comparison of efficacy safety of olanzapine and risperidone in the treatment of first episode schizophrenia</TI>
<SO>International Medicine and Health Guidance News</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>8</NO>
<PG>9-11</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:35:50 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2004b" MODIFIED="2010-01-12 09:40:51 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2004b" YEAR="2004">
<REFERENCE MODIFIED="2010-01-12 09:40:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang H</AU>
<TI>Controlled study of the effect of olanzapine and clozapine on electroencephalogram of schizophrenic patients</TI>
<SO>Journal of North China Coal Medical College</SO>
<YR>2004</YR>
<VL>6</VL>
<NO>3</NO>
<PG>289-90</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:35:57 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005" MODIFIED="2009-01-05 15:36:30 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-05 15:36:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Y-B, Xu H-C, Sun Y, Yang M-S, Wang X-H, Li Y-C</AU>
<TI>Effectiveness of olanzapine in treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>4</NO>
<PG>224-5</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:36:08 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weickert-2003" MODIFIED="2008-12-17 23:36:14 +0000" MODIFIED_BY="[Empty name]" NAME="Weickert 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-12-17 23:36:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weickert TW, Goldberg TE, Marenco S, Bigelow LB, Egan MF, Weinberger DR</AU>
<TI>Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds</TI>
<SO>Neuropyschopharmacology</SO>
<YR>2003</YR>
<VL>28</VL>
<NO>8</NO>
<PG>1491-500</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:36:14 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolf-2002" MODIFIED="2010-01-12 09:41:32 +0000" MODIFIED_BY="[Empty name]" NAME="Wolf 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-12 09:41:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wolf K, Wolf K, Mass R, Kiefer F, Wiedemann K, Naber D</AU>
<TI>Improvement of facial expression of emotions (fee) of schizophrenic patients under olanzapine versus risperidone. A prospective facial-emg study</TI>
<SO>Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:36:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolf-2005" MODIFIED="2008-12-17 23:36:25 +0000" MODIFIED_BY="[Empty name]" NAME="Wolf 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-12-17 23:36:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolf K, Mass R, Kiefer F, Eckert K, Stritzky AV, Haasen C, Wiedemann K, Naber D</AU>
<TI>The influence of olanzapine versus risperidone on facial expression of emotions in schizophrenia-preliminary results of a facial electromyogram study</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>3</NO>
<PG>278-81</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:36:25 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2006" MODIFIED="2008-12-17 23:36:30 +0000" MODIFIED_BY="[Empty name]" NAME="Wu 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-12-17 23:36:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu R-R, Zhao J-P, Liu Z-N, Zhai J-G, Guo X-F, Guo W-B, Tang J-S</AU>
<TI>Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia</TI>
<SO>Psychopharmacology</SO>
<YR>2006</YR>
<VL>186</VL>
<NO>4</NO>
<PG>572-8</PG>
<CY>Germany</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:36:30 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wyszogrodzka_x002d_Kuchars-2006" MODIFIED="2010-01-12 09:42:05 +0000" MODIFIED_BY="[Empty name]" NAME="Wyszogrodzka-Kuchars 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-12 09:42:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wyszogrodzka-Kucharska A, Rabe-Jablonska J</AU>
<TI>Vitamin D deficiency and impaired parathormone metabolism as a risk factor of low bone mineral density in patients with diagnosis of schizophrenia treated with second generation antipsychotics</TI>
<SO>European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S373</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:36:36 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yagdiran-2000" MODIFIED="2010-01-12 09:44:09 +0000" MODIFIED_BY="[Empty name]" NAME="Yagdiran 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-12 09:44:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yagdiran O, Krausz M, =PERSIST</AU>
<TI>Depressive symptoms under atypical neuroleptic treatment in schizophrenia</TI>
<SO>Nervenarzt</SO>
<YR>2000</YR>
<VL>71</VL>
<NO>Suppl 1</NO>
<PG>S135-36</PG>
<CY>Germany</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:36:55 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamashita-2005" MODIFIED="2008-12-17 23:37:01 +0000" MODIFIED_BY="[Empty name]" NAME="Yamashita 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-12-17 23:37:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamashita H, Mori K, Nagao M, Okamoto Y, Morinobu S, Yamawaki S</AU>
<TI>Influence of aging on the improvement of subjective sleep quality by atypical antipsychotic drugs in patients with schizophrenia: comparison of middle-aged and older adults</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>5</NO>
<PG>377-84</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:37:01 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2003" MODIFIED="2010-01-12 09:44:29 +0000" MODIFIED_BY="[Empty name]" NAME="Yang 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-12 09:44:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang X, Mei Q</AU>
<TI>A comparison of olanzapine and risperidone in the treatment of first-episode schizophrenia</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>6</NO>
<PG>338-48</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:37:07 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-2002" MODIFIED="2008-12-17 23:37:19 +0000" MODIFIED_BY="[Empty name]" NAME="Yu 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-12-17 23:37:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu G, Ding G, Li X</AU>
<TI>An economic burden comparison of typical and atypical antipsychotic therapies for schizophrenia</TI>
<SO>Chinese Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>35</VL>
<NO>3</NO>
<PG>177-9</PG>
<IDENTIFIERS MODIFIED="2008-12-17 23:37:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zelaschi-2006" MODIFIED="2010-01-12 09:44:55 +0000" MODIFIED_BY="[Empty name]" NAME="Zelaschi 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-12 09:44:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Zelaschi Sr NM, Rodriguez Sr JL, Gaitan Sr S, Palacios Vallejos Sr ME, Zieher Sr LM</AU>
<TI>The effects of the switch of conventional neuroleptics to atypical antipsychotics: a follow-up study of patients with chronic schizophrenia</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2008-12-17 23:37:32 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2004" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang HY, Lin QC, Lin JC, Guo YB</AU>
<TI>A study of olanzapine and clozapine in EEG</TI>
<SO>International Medicine and Health Guidance News</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>14</NO>
<PG>113-4</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zheng-2001" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Zheng 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zheng H, Xu CT</AU>
<TI>A clinical study of clozapine and olanzapine in treatment of resistant schizophrenia</TI>
<SO>Journal of Qiqihar Medical College</SO>
<YR>2001</YR>
<VL>22</VL>
<PG>865</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhong-2006" MODIFIED="2008-12-17 23:37:48 +0000" MODIFIED_BY="[Empty name]" NAME="Zhong 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-12-17 23:37:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhong Z-Y, Tao J, Wang X-L, Wu X-L, Zhang J-B</AU>
<TI>Effect of antipsychotic plus buflomedil hydrochlorde in ameliorating the negative symptoms of patients with schizophrenia</TI>
<SO>Zhongguo Linchuang Kangfu</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>2</NO>
<PG>30-2</PG>
<CY>China</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:37:48 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zoccali-2003" MODIFIED="2008-12-17 23:38:04 +0000" MODIFIED_BY="[Empty name]" NAME="Zoccali 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-12-17 23:38:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zoccali R, Muscatello MR, Torre DL, Malara G, Canale A, Crucitti DDC, Spina E</AU>
<TI>Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia</TI>
<SO>Pharmacological Research</SO>
<YR>2003</YR>
<VL>48</VL>
<NO>4</NO>
<PG>411-4</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2008-12-17 23:38:04 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2010-01-12 09:50:12 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Eli-Lilly-2003a" MODIFIED="2010-01-12 09:45:52 +0000" MODIFIED_BY="[Empty name]" NAME="Eli Lilly 2003a" YEAR="2003">
<REFERENCE MODIFIED="2010-01-12 09:45:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Eli Lilly and Company</AU>
<TI>Study of olanzapine vs aripiprazole in the treatment of schizophrenia</TI>
<SO>Eli Lilly and Company Clinical Trial Registry</SO>
<YR>2003</YR>
<IDENTIFIERS MODIFIED="2010-01-12 09:45:52 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eli-Lilly-2003b" MODIFIED="2010-01-12 09:46:08 +0000" MODIFIED_BY="[Empty name]" NAME="Eli Lilly 2003b" YEAR="2003">
<REFERENCE MODIFIED="2010-01-12 09:46:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Eli Lilly and Company</AU>
<TI>Safety study of olanzapine and a comparator in patients with schizophrenia and schizoaffective disorder</TI>
<SO>Eli Lilly and Company Clinical Trial Registry</SO>
<YR>2003</YR>
<IDENTIFIERS MODIFIED="2010-01-12 09:46:08 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eli-Lilly-2004a" MODIFIED="2010-01-12 09:46:13 +0000" MODIFIED_BY="[Empty name]" NAME="Eli Lilly 2004a" YEAR="2004">
<REFERENCE MODIFIED="2010-01-12 09:46:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Eli Lilly and Company</AU>
<TI>Olanzapine versus aripiprazole in the treatment of acutely ill patients with schizophrenia</TI>
<SO>Eli Lilly and Company Clinical Trial Registry</SO>
<YR>2004</YR>
<IDENTIFIERS MODIFIED="2010-01-12 09:46:13 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eli-Lilly-2004b" MODIFIED="2010-01-12 09:46:51 +0000" MODIFIED_BY="[Empty name]" NAME="Eli Lilly 2004b" YEAR="2004">
<REFERENCE MODIFIED="2010-01-12 09:46:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Eli Lilly and Company</AU>
<TI>Comparison of continuing olanzapine to switching to quetiapine in overweight or obese patients with schizophrenia and schizoaffective disorder</TI>
<SO>Eli Lilly and Company Clinical Trial Registry</SO>
<YR>2004</YR>
<IDENTIFIERS MODIFIED="2010-01-12 09:46:51 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eli-Lilly-2006" MODIFIED="2010-01-12 09:46:57 +0000" MODIFIED_BY="[Empty name]" NAME="Eli Lilly 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-12 09:46:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Eli Lilly and Company</AU>
<TI>Efficacy study of early onset of antipsychotic drug action in schizophrenia</TI>
<SO>Eli Lilly and Company Clinical Trial Registry</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2010-01-12 09:46:57 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mortimer-2001" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Mortimer 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Mortimer A</AU>
<TI>A1281014 a phase IIIb, 12 week, multi-centre, double-blind, double-dummy, randomised, parallel group study comparing the effects of ziprasidone versus olanzapine on quality of life in the treatment of schizophrenia and schizoaffective disorder</TI>
<SO>National Research Register</SO>
<YR>2001</YR>
<VL>3</VL>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="N0084096621"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-N0081052094" MODIFIED="2010-01-12 09:49:41 +0000" MODIFIED_BY="[Empty name]" NAME="N0081052094" YEAR="2000">
<REFERENCE MODIFIED="2010-01-12 09:49:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Reveley M</AU>
<TI>Ris-int-45 an international, multicentre, randomised double-blind parallel-group trial comparing the safety and efficacy of risperidone and olanzapine in the treatment of patients with schizophrenia</TI>
<SO>National Research Register</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2010-01-12 09:49:37 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-12 09:49:37 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="National Research Register "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-N0081121981" MODIFIED="2010-01-12 09:50:12 +0000" MODIFIED_BY="[Empty name]" NAME="N0081121981" YEAR="2003">
<REFERENCE MODIFIED="2010-01-12 09:49:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Reveley M</AU>
<TI>MREC/00/1/47 a phase IIIb multicentre randomised double-blind trial of ziprasidone vs olanzapine in schizophrenia</TI>
<SO>National Research Register</SO>
<YR>2003</YR>
<VL>2</VL>
<IDENTIFIERS MODIFIED="2010-01-12 09:49:56 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-12 09:49:56 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="N0081121981"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00001656" MODIFIED="2010-01-12 09:48:56 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00001656" YEAR="2001">
<REFERENCE MODIFIED="2010-01-12 09:48:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Magnuson WG</AU>
<TI>Childhood onset psychotic disorders:characterization and treatment with atypical neuroleptics / Treatment of childhood onset psychotic disorders with olanzapine or clozapine</TI>
<SO>National Institutes of Health</SO>
<YR>2001</YR>
<IDENTIFIERS MODIFIED="2010-01-12 09:48:56 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-01-12 10:37:23 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-01-12 10:37:23 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" MODIFIED="2008-12-27 19:41:31 +0000" MODIFIED_BY="[Empty name]" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecing skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS MODIFIED="2008-12-27 19:41:31 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1983" MODIFIED="2010-01-12 10:31:37 +0000" MODIFIED_BY="[Empty name]" NAME="Andreasen 1983" TYPE="BOOK">
<AU>Andeasen NC</AU>
<SO>Scale for the assessment of negative symptoms (SANS)</SO>
<YR>1983</YR>
<PB>University of Iowa</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1984" MODIFIED="2010-01-12 10:32:39 +0000" MODIFIED_BY="[Empty name]" NAME="Andreasen 1984" TYPE="BOOK">
<AU>Andreasen NC</AU>
<SO>Scale for the assessment of positive symptoms (SAPS)</SO>
<YR>1984</YR>
<PB>University of Iowa</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anonymous-1997" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Anonymous 1997" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Olanzapine, sertindole and schizophrenia</TI>
<SO>Drugs and Therapeutics Bulletin</SO>
<YR>1997</YR>
<VL>35</VL>
<PG>11</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-APA-2004" MODIFIED="2010-01-12 10:23:42 +0000" MODIFIED_BY="[Empty name]" NAME="APA 2004" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Practice guidelines for the treatment of patients with schizophrenia</SO>
<YR>2004</YR>
<PG>1-114</PG>
<EN>2nd</EN>
<PB>American Psychiatric Association</PB>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Arnt-1998" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Arnt 1998" TYPE="JOURNAL_ARTICLE">
<AU>Arnt J, Skarsfeldt T</AU>
<TI>Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1998</YR>
<VL>18</VL>
<PG>63-101</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1989" MODIFIED="2008-12-12 10:13:48 +0000" MODIFIED_BY="[Empty name]" NAME="Barnes 1989" TYPE="JOURNAL_ARTICLE">
<AU>Barnes TR</AU>
<TI>A rating scale for drug-induced akathisia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>154</VL>
<PG>672-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM, Kerry SM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1984" MODIFIED="2008-12-12 10:59:33 +0000" MODIFIED_BY="[Empty name]" NAME="Carpenter 1984" TYPE="JOURNAL_ARTICLE">
<AU>Heinrichs DW, Hanlon ET, Carpenter WTJr</AU>
<TI>The quality of life scale: an instrument for rating the schizophrenic deficit syndrom</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1984</YR>
<VL>10</VL>
<PG>388-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1994" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Carpenter 1994" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT Jr, Buchanan RW</AU>
<TI>Schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>681-90</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Chouinard-1980" MODIFIED="2010-01-12 09:53:58 +0000" MODIFIED_BY="[Empty name]" NAME="Chouinard 1980" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Ross-Chouinard A, Annable L, Jones BD</AU>
<TI>The extrapyramidal symptom rating scale</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1980</YR>
<VL>7</VL>
<PG>233</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Conley-1998" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Conley 1998" TYPE="JOURNAL_ARTICLE">
<AU>Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J, Hegerty J, Love R, Gounaris C, Zaremba S</AU>
<TI>Olanzapine compared with chlorpromazine in treatment-resistent schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1998</YR>
<VL>155</VL>
<PG>914-20</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" MODIFIED="2010-01-12 09:55:19 +0000" MODIFIED_BY="[Empty name]" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazer LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>623-9</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Duggan-2005" MODIFIED="2009-07-28 18:50:49 +0100" MODIFIED_BY="[Empty name]" NAME="Duggan 2005" TYPE="COCHRANE_REVIEW">
<AU>Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S</AU>
<TI>Olanzapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<PB>Wiley and Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2009-07-28 18:50:49 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-28 18:50:49 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001359.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2009-07-28 11:34:49 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey-Smith G, Schneider M, Minder CSO</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>13</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-El_x002d_Sayeh-2006" MODIFIED="2009-07-28 18:51:28 +0100" MODIFIED_BY="[Empty name]" NAME="El-Sayeh 2006" TYPE="COCHRANE_REVIEW">
<AU>El-Sayeh HG, Morganti C</AU>
<TI>Aripiprazole for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<PB>Wiley and Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2009-07-28 18:51:28 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-28 18:51:28 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858. CD004578.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2010-01-12 09:57:14 +0000" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS MODIFIED="2010-01-12 09:57:14 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-12 09:57:14 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11914310"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fleischhacker-1989" MODIFIED="2010-01-12 09:58:19 +0000" MODIFIED_BY="[Empty name]" NAME="Fleischhacker 1989" TYPE="JOURNAL_ARTICLE">
<AU>Fleischhacker WW, Bergmann KJ, Perovich R, Pestreich LK, Borenstein M, Lieberman JA, Kane JM</AU>
<TI>The Hillside Akathisia Skale: a new rating instrument for neuroleptic-induced akathisia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1989</YR>
<VL>25</VL>
<PG>222-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2006" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Furukawa 2006" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N</AU>
<TI>Imputing missing standard deviations in meta-analyses can provide accurate results</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<PG>7-10</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Gaebel-2006" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Gaebel 2006" TYPE="OTHER">
<AU>Gaebel W, Falkai P, Weinmann S, Wobrock T</AU>
<TI>Treatment guidelines for schizophrenia</TI>
<TO>Behandlungsleitlinie Schizophrenie</TO>
<SO>Steinkopf</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Goldman-1992" MODIFIED="2010-01-12 09:59:57 +0000" MODIFIED_BY="[Empty name]" NAME="Goldman 1992" TYPE="JOURNAL_ARTICLE">
<AU>Goldman HH, Skodol AE, Lave TR</AU>
<TI>Revising axis V for DSM-IV: a review of measures of social functioning</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1992</YR>
<VL>149</VL>
<PG>1148-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC, Ukoumunne OC, Chinn S</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2010-01-12 10:00:14 +0000" MODIFIED_BY="[Empty name]" NAME="Guy 1976" TYPE="OTHER">
<AU>Guy U</AU>
<TI>ECDEU assessment manual for psychopharmacology. Revised.</TI>
<SO>National Institute of MentalHealth</SO>
<YR>1976</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heres-2006" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Heres 2006" TYPE="JOURNAL_ARTICLE">
<AU>Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S</AU>
<TI>Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<PG>185-94</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2010-01-12 10:03:18 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Jayaram-2006" MODIFIED="2010-01-12 10:24:39 +0000" MODIFIED_BY="[Empty name]" NAME="Jayaram 2006" TYPE="COCHRANE_REVIEW">
<AU>Jayaram MB, Hosalli P, Stroup S</AU>
<TI>Risperidone versus olanzapine for schizophrenia.</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2009-01-13 16:32:49 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-13 16:32:49 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005237.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jones-2006" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Jones 2006" TYPE="JOURNAL_ARTICLE">
<AU>Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW</AU>
<TI>Randomized controlled trial of the effect on quality of life</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2006</YR>
<VL>63</VL>
<PG>1079-6</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kane-1988" MODIFIED="2010-01-12 10:09:50 +0000" MODIFIED_BY="[Empty name]" NAME="Kane 1988" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group</AU>
<TI>Clozapine for the treatment of treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1988</YR>
<VL>45</VL>
<PG>789-96</PG>
<IDENTIFIERS MODIFIED="2010-01-12 10:09:50 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kane-1993" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Kane 1993" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM</AU>
<TI>Treatment programme and long term outcome in chronic schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1993</YR>
<VL>46</VL>
<PG>585-93</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<SO>Positive and negative syndrome scale (PANSS) manual</SO>
<YR>1986</YR>
<PB>Multi-Health Systems</PB>
<CY>North Tonawanda (NY)</CY>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<PG>231-8</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005b" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of Brief Psychiatric Rating Scale Scores</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Lewis-2006" MODIFIED="2010-01-12 10:25:16 +0000" MODIFIED_BY="[Empty name]" NAME="Lewis 2006" TYPE="JOURNAL_ARTICLE">
<AU>Lewis SW, Davies L, Jones P, Barnes TRE, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Marwick A, Lloyd H, Dunn G</AU>
<TI>Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment</TI>
<SO>Health Technology Assessment</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>17</NO>
<PG>iii-iv, ix-xi, 1-165</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liebermann-2005" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Liebermann 2005" TYPE="JOURNAL_ARTICLE">
<AU>Liebermann JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM</AU>
<TI>Effectiveness of antipsychotic drugs in patients with chronic schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<PG>1209-23</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Marvaha-2004" MODIFIED="2009-07-15 12:25:08 +0100" MODIFIED_BY="[Empty name]" NAME="Marvaha 2004" TYPE="JOURNAL_ARTICLE">
<AU>Marvaha S, Johnson S</AU>
<TI>Schizophrenia and employment - a review</TI>
<SO>Social Psychiatry and Psychiatric Epidemiology</SO>
<YR>2004</YR>
<VL>39</VL>
<PG>337-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" MODIFIED="2010-01-12 10:12:48 +0000" MODIFIED_BY="[Empty name]" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman D</AU>
<TI>The CONSORT Statement: Revised recommendations for improving the quality of reports of parrallel-group randomized trials</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<PG>1987-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-M_x00f6_ller-2000" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Möller 2000" TYPE="JOURNAL_ARTICLE">
<AU>Möller HJ</AU>
<TI>New assessment of atypical antipsychotics</TI>
<TO>Aktuelle Bewertung neuer/atypischer Neuroleptika</TO>
<SO>Nervenarzt</SO>
<YR>2000</YR>
<VL>71</VL>
<PG>329-44</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Reus-1997" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Reus 1997" TYPE="JOURNAL_ARTICLE">
<AU>Reus VI</AU>
<TI>Olanzapine: a novel atypical neuroleptic agent</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<PG>1264-5</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Rosenheck-1997" MODIFIED="2008-12-28 09:25:42 +0000" MODIFIED_BY="[Empty name]" NAME="Rosenheck 1997" TYPE="JOURNAL_ARTICLE">
<AU>Rosenheck R, Cramer J, Xu WC, Thomas J, Henderson W, Frisman L, Fye C, Charney D</AU>
<TI>A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>337</VL>
<PG>809-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rust-1989" MODIFIED="2009-07-28 11:29:56 +0100" MODIFIED_BY="[Empty name]" NAME="Rust 1989" TYPE="BOOK">
<AU>Rust J, Golombok S</AU>
<SO>Modern Psychometrics</SO>
<YR>1989</YR>
<PB>Routledge</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" MODIFIED="2010-01-12 10:13:36 +0000" MODIFIED_BY="[Empty name]" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson EN, Angus JWF</AU>
<TI>A rating scale for extrapyramidal side-effects</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1970</YR>
<VL>212</VL>
<PG>11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1999" MODIFIED="2008-12-28 09:26:55 +0000" MODIFIED_BY="[Empty name]" NAME="Simpson 1999" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Josiassen RC, Stanilla JK, De Leon J, Nair C, Abraham G, Odom WA, Turner RM</AU>
<TI>Double-blind study of clozapine dose response in chronic schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>156</VL>
<PG>1744-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tandon-2008" MODIFIED="2009-07-15 12:25:08 +0100" MODIFIED_BY="[Empty name]" NAME="Tandon 2008" TYPE="JOURNAL_ARTICLE">
<AU>Tandon R, Keshavan MS, Nasralllah HA</AU>
<TI>Schizophrenia, "Just the Facts" What we know in 2008. 2. Epidemiology and etiology</TI>
<SO>Schizophrenia research</SO>
<YR>2008</YR>
<VL>102</VL>
<PG>1-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tollefson-1997" MODIFIED="2010-01-12 10:34:39 +0000" MODIFIED_BY="[Empty name]" NAME="Tollefson 1997" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME</AU>
<TI>Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorder: results of an international collaborative trial</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>154</VL>
<NO>4</NO>
<PG>457-65</PG>
<IDENTIFIERS MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Tsuang-1978" MODIFIED="2009-07-15 12:25:08 +0100" MODIFIED_BY="[Empty name]" NAME="Tsuang 1978" TYPE="JOURNAL_ARTICLE">
<AU>Tsuang MT</AU>
<TI>Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1978</YR>
<VL>35</VL>
<PG>153-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" MODIFIED="2010-01-12 10:15:48 +0000" MODIFIED_BY="[Empty name]" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>3-92</PG>
<IDENTIFIERS MODIFIED="2010-01-12 10:15:48 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-12 10:15:48 +0000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10982317"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Van-Os-2006" MODIFIED="2010-01-12 10:15:56 +0000" MODIFIED_BY="[Empty name]" NAME="Van Os 2006" TYPE="JOURNAL_ARTICLE">
<AU>Van Os J, Burns T, Cavallaro R, Leucht S, Peuskens J, Helldin L, Bernardo M,Arango C, Fleischhacker W, Lachaux B, Kane JM</AU>
<TI>Standardized remission criteria in schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>2006</YR>
<VL>113</VL>
<PG>91-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wahlbeck-2001" MODIFIED="2008-12-27 19:44:07 +0000" MODIFIED_BY="[Empty name]" NAME="Wahlbeck 2001" TYPE="JOURNAL_ARTICLE">
<AU>Wahlbeck K, Tuunainen A, Ahokas A, Leucht S</AU>
<TI>Drop-out rates in randomised antipsychotic drug trials</TI>
<SO>Psychopharmacology</SO>
<YR>2001</YR>
<VL>155</VL>
<PG>230-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2001" MODIFIED="2010-01-12 10:26:56 +0000" MODIFIED_BY="[Empty name]" NAME="WHO 2001" TYPE="BOOK">
<AU>WHO</AU>
<SO>The World Health report 2001-Mental Health: New understanding, new hope</SO>
<YR>2001</YR>
<PB>World Health Organisation</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xia-2007" MODIFIED="2010-01-12 10:16:57 +0000" MODIFIED_BY="[Empty name]" NAME="Xia 2007" TYPE="CONFERENCE_PROC">
<AU>Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al</AU>
<TI>The Leeds Outcomes Stakeholders Survey (LOSS) Study</TI>
<SO>Proceedings of the 15th Cochrane Colloquium; 2007 Oct 23-27; Sao Paulo</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-07-28 18:52:59 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Leucht-2008" MODIFIED="2009-07-28 18:52:59 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2008" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo-Lobos C, Schwarz S, Davis JM</AU>
<TI>A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2009</YR>
<VL>166</VL>
<PG>152-63</PG>
<IDENTIFIERS MODIFIED="2009-07-28 18:52:38 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-28 18:52:38 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1176/appi.ajp.2008.08030368"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-02-17 14:30:19 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-02-17 14:30:19 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-02-17 12:49:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Atmaca-2003">
<CHAR_METHODS MODIFIED="2010-02-14 17:29:21 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 6 weeks.<BR/>Design: parallel.<BR/>Location: single centre. <BR/>Country: Turkey.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 12:40:30 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia.<BR/>N=56.<BR/>Age: 19-46 years (mean clozapine=31.3 years, mean olanzapine=29.6 years, mean quetiapine=30.1 years, mean risperidone=27.9 years, mean control group=32.1 years).<BR/>Sex: 24 M, 29 F (3 not reported).<BR/>History: duration ill mean clozapine=6.6 years, mean olanzapine=6.3 years, mean quetiapine=5.9 years, mean risperidone=5.6, age at onset: not reported.<BR/>Setting: not described, probably inpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 12:47:08 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: not reported. Mean dose: 207.1 mg/day. N=14.<BR/>2. Olanzapine: flexible dose. Allowed dose range: not reported. Mean dose: 15.7 mg/day. N=14.<BR/>3. Quetiapine: flexible dose. Allowed dose range: not reported. Mean dose: 535.7 mg/day. N=14.<BR/>4. Risperidone: flexible dose. Allowed dose range: not reported. Mean dose: 6.7 mg/day. N=14.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 12:49:54 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason.<BR/>Mental state: PANSS total score.<BR/>Adverse effects: EPS (use of antiparkinson medication), weight gain (BMI), laboratory (serum leptin, triglyceride levels).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-28 12:47:03 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 12:50:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bai-2005">
<CHAR_METHODS MODIFIED="2010-02-14 17:53:14 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: single, no further details.<BR/>Duration: 24 weeks.<BR/>Design: parallel.<BR/>Location: not described. <BR/>Country: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 12:50:46 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: chronic schizophrenia.<BR/>N=80.<BR/>Age: mean ~ 50.2 years, range not described.<BR/>Sex: 39M, 41F.<BR/>History: duration illness not described, age of onset not described.<BR/>Setting: not described.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 14:34:15 +0100" MODIFIED_BY="[Empty name]">
<P>1. Amisulpride: dose range not described, mean dose not described, fixed/flexible dose not described. N=40.<BR/>2. Olanzapine: dose range not described, mean dose not described, fixed/flexible dose not described. N=40.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-28 12:48:32 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason.<BR/>Cognitive functioning: Wisconsin card sorting test.<BR/>
</P>
<P>Unable to use -<BR/>Mental state: BPRS change (no data).<BR/>Adverse effects: BAS, SAS, UKU (no data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-02-14 17:35:49 +0000" MODIFIED_BY="[Empty name]">
<P>There are control groups without further details provided.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 12:53:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bitter-2004">
<CHAR_METHODS MODIFIED="2010-02-14 17:38:55 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 18 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Countries: Hungary, South Africa.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 12:53:09 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, non-response to, or intolerance of, standard antipsychotic therapy, BPRS of 42 or more.<BR/>N=147.<BR/>Age: 18-65 years (mean=37.6).<BR/>Sex: 88 M, 59 F.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 12:51:50 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 100-500 mg/day. Mean dose: 216.2 mg/day. N=72.<BR/>2. Olanzapine: flexible dose. Allowed dose range: 5-25 mg/day. Mean dose: 17.2 mg/day. N=75.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 12:53:54 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global state: CGI.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Adverse effects: open interviews, cardiac effects (ECG), EPS (akathisia, dyskinesia, parkinsonism, use of antiparkinson medication, AIMS, Hillside Akathisia Scale, SAS), sedation, headache, back pain, asthenia, flu syndrome, dizziness, hypersalivation, postural hypertension, weight, laboratory (liver enzymes, hematology, urine analysis).<BR/>
</P>
<P>Unable to use -<BR/>Leukopenia (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:00:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Breier-2005">
<CHAR_METHODS MODIFIED="2010-02-17 12:54:40 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 28 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Countries: not reported. (Continents: Europe, North - South America).<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 12:55:04 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, BPRS of 42 or more, CGI-S of 4 or more.<BR/>N=548.<BR/>Age: 18-75 years (mean olanzapine=40.1 years, mean ziprasidone=38.2 years).<BR/>Sex: 352 M, 196 F.<BR/>History: duration ill not reported, age at onset mean olanzapine=23.9 years, mean ziprasidone=22.8 years.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 12:59:19 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose, allowed dose range: 10-20 mg/day, mean dose=15.27 mg/day. N=277.<BR/>2. Ziprasidone: flexible dose, allowed dose range: 80-160 mg/day, mean dose=115.96 mg/day. N=271.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:00:08 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore, PANSS cognition subscore, depression MADRS, HAMD.<BR/>Quality of life: Heinrichs - Carpenter Scale.<BR/>Adverse effects: open interviews, EPS (use of antiparkinson medication, dystonia, extrapyramidal symptoms, AIMS, BAS, SAS), cardiac effects (ECG), weight gain, laboratory (prolactin, glucose, lipids).<BR/>
<BR/>Unable to use -<BR/>Prolactin (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-28 12:58:46 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 12:58:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Canive-2000">
<CHAR_METHODS MODIFIED="2010-02-14 17:52:00 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 16 weeks (first 8 weeks observed).<BR/>Design: cross-over.<BR/>Location: not reported.<BR/>Country: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 12:56:40 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N=8.<BR/>Age: not reported.<BR/>Sex: not reported.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 13:00:07 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported. Mean dose: not reported. N=not reported.</P>
<P>2. Risperidone: fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported. Mean dose: not reported. N=not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 12:58:43 +0000" MODIFIED_BY="[Empty name]">
<P>Global State: CGI.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore depression Calgary depression scale.</P>
<P>Unable to use -<BR/>Global state: CGI (no usable data).<BR/>Mental State: (no usable data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 12:58:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CN138003">
<CHAR_METHODS MODIFIED="2010-02-14 17:45:21 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 52 weeks (first 6 weeks observed).<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Countries: Argentina, Brazil, Canada, Mexico, USA.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-30 16:10:45 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) acute schizophrenia, PANSS of 60 or more.<BR/>N=703.<BR/>Age: not reported.<BR/>Sex: not reported.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 12:57:13 +0100" MODIFIED_BY="[Empty name]">
<P>1. Aripiprazole: flexible dose. Allowed dose range: 15-30 mg/day. Mean dose: not reported. N=355.<BR/>2. Olanzapine: flexible dose. Allowed dose range: 10-20mg/day. Mean dose: not reported. N=348</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 12:58:14 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason.<BR/>Global state: CGI.<BR/>Mental state: PANSS total score, depression MADRS.<BR/>Quality of life/satisfaction with treatment: Quality of Life Enjoyment and Satisfaction Questionnaire, Medication adherence scale.<BR/>Adverse effects: open interviews, EPS (SAS, AIMS, BAS), cardiac effects (ECG), weight gain (BMI).</P>
<P>Unable to use -<BR/>Adverse effects: (no data, interim report).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-28 12:57:09 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:01:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Conley-2001">
<CHAR_METHODS MODIFIED="2010-02-14 17:48:19 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, stratified by site.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Country: USA.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-14 20:03:25 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia (n=325) paranoid (n=213) or schizoaffective disorder (n=52), PANSS between 60 and 120.<BR/>N=377.<BR/>Age: 18-64 years (mean=40.0 years).<BR/>Sex: 274 M, 103 F.<BR/>History: duration ill mean olanzapine=15.4 years, mean risperidone=16.5 years, age at onset mean olanzapine=23.6 years, mean risperidone=24.5 years.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 13:04:34 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 5-20 mg/day. Mean dose: 13.1 mg/day. N=189.<BR/>2. Risperidone: flexible dose. Allowed dose range: 2-6 mg/day. Mean dose: 4.7 mg/day. N=188.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:01:37 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Adverse effects: open interviews, cardiac effects (ECG), death (suicide attempt), EPS (use of antiparkinson medication, ESRS), prolactin associated side effects (abnormal ejaculation, amenorrhoea, decreased libido, galactorrhoea, gynaecomastia, impotence, orgastic dysfunction, sexual dysfunction) depression, insomnia, dry mouth, agitation, rhinitis, dizziness, anxiety, vision abnormalities, sedation, weight gain, laboratory (liver enzymes, lipids).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 14:25:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Conley-2003">
<CHAR_METHODS MODIFIED="2010-02-14 17:51:23 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 16 weeks (first 8 weeks observed).<BR/>Design: cross-over.<BR/>Location: not reported.<BR/>Country: not reported. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 13:02:01 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, resistance to previous treatment, BPRS of 45 or more, CGI of 4 or more.<BR/>N=13.<BR/>Age: mean=37.58 years.<BR/>Sex: 8 M, 5 F.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 13:09:23 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: fixed dose: 450 mg/day. N=5.<BR/>2. Olanzapine: fixed dose: 50 mg/day. N=8.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 14:25:25 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: BPRS total score, BPRS positive subscore, BPRS negative subscore.<BR/>Adverse effects: open interviews, cardiac effects (ECG), death (natural causes, suicide), EPS (akathisia, use of antiparkinson medication, SAS), sedation, dry mouth, blurry vision, urinary hesitancy, constipation, tachycardia, diarrhoea, dyspepsia, headache, lethargy, myoclonus, stuttering, sialorrhoea, sweating, urinary frequency, dysphagia, orthostasis, dizziness increased appetite.<BR/>Seizures, Weight change, laboratory (cholesterol, glucose, liver enzymes).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:07:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dollfus-2005">
<CHAR_METHODS MODIFIED="2010-02-14 18:01:12 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Country: France.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-14 20:02:49 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia with post-psychotic depression, PANSS positive subscore of 28 or less and MADRS score of 16 or more.<BR/>N=76.<BR/>Age: 18-65 years (mean olanzapine=39 years, mean risperidone=39.6 years).<BR/>Sex: 53 M, 23 F.<BR/>History: duration ill mean olanzapine=13.7 years, mean risperidone=13.1 years, age at onset not reported.<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 13:13:50 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 5-15 mg/day. Mean dose: not reported. N=36.<BR/>2. Risperidone: flexible dose. Allowed dose range: 4-8 mg/day. Mean dose: not reported. N=40.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:07:18 +0000" MODIFIED_BY="[Empty name]">
<P>Global state: relapse.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore, depression MADRS.<BR/>Service use: number of participants re-hospitalised.<BR/>Adverse effects: open interviews, cardiac effects (ECG), death (natural causes, suicide), EPS (akathisia, akinesia, dystonia, parkinsonism, rigor, tremor, use of antiparkinson medication, continuous: ESRS total score), prolactin associated side effects (abnormally high prolactin value, amenorrhoea, sexual dysfunction), sedation, seizures, weight gain.<BR/>Weight: (change from baseline in kg).<BR/>
</P>
<P>Unable to use-<BR/>White blood cell count (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:08:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dolnak-2001">
<CHAR_METHODS MODIFIED="2010-02-14 18:00:09 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>Country: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 13:07:44 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia.<BR/>N=40.<BR/>Age: 18-65 years.<BR/>Sex: not reported.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-17 13:08:08 +0000" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported. Mean dose: not reported. N=20.<BR/>2. Risperidone:<BR/>Fixed/flexible dose: not reported. Allowed dose range: not reported. Mean dose: not reported. N=20.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-28 13:19:26 +0100" MODIFIED_BY="[Empty name]">
<P>General functioning: Scale of functioning.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:10:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gureje-2003">
<CHAR_METHODS MODIFIED="2010-02-14 18:03:33 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, computer-generated randomisation.<BR/>Blindness: double, double-dummy design.<BR/>Duration: 30 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Countries: Australia, New Zealand.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 13:08:43 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, schizoaffective disorder or schizophreniform disorder, BPRS total score of 36 or more.<BR/>N=65.<BR/>Age: 18 years or more (mean olanzapine=35.6 years, mean risperidone=34.8 years).<BR/>Sex: 38 M, 27 F.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 13:21:08 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 10-20 mg/day. Mean dose: 17.2 mg/day. N=32.<BR/>2. Risperidone: flexible dose. Allowed dose range: 4-8 mg/day. Mean dose: 6.6 mg/day. N=33.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:10:16 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, inefficacy.<BR/>Global state: CGI-S.<BR/>Mental State: PANSS total score, BPRS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Quality of life: QLS, SF-36.<BR/>Adverse effects: open interviews, death (suicide attempt), cardiac effects (ECG), EPS (akathisia, dyskinesia, parkinsonism, rigor, tremor, use of antiparkinson medication), prolactin associated side effects (abnormal ejaculation, decreased libido, gynaecomastia, impotence), sedation, Weight change,<BR/>laboratory (glucose, leukopenia).<BR/>
</P>
<P>Unable to use:<BR/>Cardiac effects (no data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:11:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jeste-2003">
<CHAR_METHODS MODIFIED="2010-02-14 18:06:03 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Countries: USA, Israel, Poland, Norway, Netherlands, Austria.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-14 20:01:44 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia (n=149) or schizoaffective disorder (n=26), PANSS between 50 and 120.<BR/>N=176.<BR/>Age: 60 years or more (mean olanzapine=71.4 years, mean risperidone=70.9 years) (of intent-to-treat population).<BR/>Sex: 62 M, 113 F (of intent-to-treat population).<BR/>History: duration ill mean=36.5 years, age at onset mean olanzapine=33.4 years, mean risperidone=36.0 years (of intent-to-treat population).<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 13:25:37 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 5-20 mg/day. Mean dose: 11.1 mg/day. N=89.<BR/>2. Risperidone: flexible dose. Allowed dose range: 1-3 mg/day. Mean dose: 1.9 mg/day. N=87.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:11:27 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Adverse effects: open interviews, cardiac effects (ECG), death (natural causes, suicide) EPS (akinesia, dystonia, extrapyramidal symptoms, parkinsonism, tremor, use of antiparkinson medication, ESRS), sedation, seizures, weight change, laboratory (cholesterol, glucose, prolactin).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:12:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Keefe-2006">
<CHAR_METHODS MODIFIED="2010-02-14 18:07:24 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 52 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Countries: USA, Canada.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 13:11:54 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia or schizoaffective disorder.<BR/>N=414.<BR/>Age: 18-55 years (mean=39 years).<BR/>Sex: 282 M, 132 F.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 13:30:32 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: flexible dose. Allowed dose range: 2-19 mg/day. Mean dose: 8.2 mg/day. N=97.<BR/>2. Olanzapine: flexible dose. Allowed dose range: 5-20 mg/day. Mean dose: 12.3 mg/day. N=159.<BR/>3. Risperidone: flexible dose. Allowed dose range: 2-10 mg/day. Mean dose: 5.2 mg/day. N=158.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:12:23 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: relapse.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore, depression (MADRS), anxiety (Hamilton anxiety scale).<BR/>Cognitive Functioning: Neurocognitive Composite Score.<BR/>Adverse effects: open interviews, EPS (akathisia, tremor, use of antiparkinson medication, AIMS, BAS, SAS), sedation, weight change, laboratory (cholesterol, prolactin, urine analysis).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:13:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kinon-2006a">
<CHAR_METHODS MODIFIED="2010-02-14 18:08:57 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 24 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Country: USA.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-30 16:10:47 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia or schizoaffective disorder, dominant depressive symptoms, MADRS of 16 or more.<BR/>N=394.<BR/>Age: 18-60 years.<BR/>Sex: not reported.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 13:34:38 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: fixed dose: 10, 15 or 20 mg/day. N=202.<BR/>2. Ziprasidone: fixed dose: 80, 120 or 160 mg/day. N=192.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:13:06 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: PANSS total score, depression MADRS, Calgary depression scale for schizophrenia.<BR/>General Functioning: GAF.<BR/>Adverse effects: open interviews, EPS (use of antiparkinson medication, AIMS, BAS, SAS), cardiac effects (ECG), weight gain, laboratory (prolactin, glucose, lipids).</P>
<P>Unable to use -<BR/>PANSS (no data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-28 13:34:33 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:14:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kinon-2006b">
<CHAR_METHODS MODIFIED="2010-02-14 19:53:28 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, computer-generated randomisation.<BR/>Blindness: double, identical capsules.<BR/>Duration: 26 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Country: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-14 20:00:48 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia (n=230), schizoaffective disorder (n=116), prominent negative symptoms.<BR/>N=346.<BR/>Age: mean olanzapine=41.67 years, mean quetiapine=40.45 years.<BR/>Sex: 228 M, 118 F.<BR/>History: duration ill mean olanzapine=17.57 years, quetiapine=17.78 years, age at onset mean olanzapine=24.16 years, quetiapine=22.59 years.<BR/>Setting: outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 13:36:16 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine flexible dose. Allowed dose range: 10-20 mg/day. Mean dose: 15.6 mg/day. N=171.<BR/>2. Quetiapine flexible dose. Allowed dose range: 300-700 mg/day. Mean dose: 455.8 mg/day. N=175.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:14:52 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore, SANS total score, depression (Calgary Depression Scale).<BR/>General functioning: GAF, Case Manager Rating Scale, Patient Functioning Rating Scale.<BR/>Quality of life: QLS total score.<BR/>Adverse effects: Sedation, weight gain, laboratory (hematology, uric acid).<BR/>
</P>
<P>Unable to use -<BR/>Leukopenia (no useable data).<BR/>Use of antiparkinson medication (no data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-28 13:36:08 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:15:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Krakowski-2006">
<CHAR_METHODS MODIFIED="2010-02-17 13:15:08 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, block randomisation (block size of 3).<BR/>Blindness: double, no further details.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Country: not reported. (probably USA).<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-14 20:00:29 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia (n=71) or schizoaffective disorder (n=39), persistent aggression.<BR/>N=110.<BR/>Age: 18-60 years (mean clozapine=35.1 years, mean haloperidol=32.7 years, mean olanzapine=35.6 years).<BR/>Sex: 90 M, 20 F.<BR/>History: duration ill mean clozapine=15.7 years, mean haloperidol=13.9 years, mean olanzapine=16.8 years, age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 13:38:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 200-800 mg/day. Mean dose: 565.5 mg/day (at the end of the last 6 weeks). N=37.<BR/>2. Haloperidol: flexible dose. Allowed dose range: 10-30 mg/day. Mean dose: 23.3 mg/day (at the end of the last 6 weeks). N=36.<BR/>3. Olanzapine: flexible dose. Allowed dose range: 10-35 mg/day. Mean dose: 24.7 mg/day (at the end of the last 6 weeks). N=37.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:15:47 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore, modified overt aggression scale.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:19:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kumra-2007">
<CHAR_METHODS MODIFIED="2010-02-17 13:16:11 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, computer-generated randomisation.<BR/>Blindness: double, no further details.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>Location: single centre.<BR/>Country: not reported (probably USA).<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 13:16:27 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: Children and adolescents with (DSM-IV) schizophrenia (n=25) or schizoaffective disorder (n=14) (of intent-to-treat population), resistant to, or intolerant of, at least two antipsychotic treatments, BPRS of 35 or more.<BR/>N=40.<BR/>Age: 10-18 years (mean=15.6 years).<BR/>Sex: 21 M, 18 F (of intent-to-treat population).<BR/>History: duration ill not reported, age at onset mean clozapine=12.7 years, mean olanzapine=11.7 years (of intent-to-treat population).<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 13:40:46 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 50-700 mg/day. Mean dose: 403.1 mg/day. N=18 (of intent-to-treat population). <BR/>2. Olanzapine: flexible dose. Allowed dose range: 10-30 mg/day. Mean dose: 26.2 mg/day. N=21 (of intent-to-treat population).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:19:16 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: BPRS total score, SANS total score.<BR/>Adverse effects: open interviews, cholesterol (change from baseline in mg/dl).<BR/>EPS (AIMS, Simpson-Angus), sedation, weight change, laboratory (glucose, prolactin, hematology).</P>
<P>Unable to use -<BR/>Extrapyramidal symptoms (no data).<BR/>Diabetes mellitus (no data). <BR/>Hyperglycaemia (no data). <BR/>Neutropenia (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>One subject was excluded owing to withdrawal of parental consent after randomisation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:20:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lecrubier-2006">
<CHAR_METHODS MODIFIED="2010-02-14 18:25:12 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 26 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Countries: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-14 20:06:13 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia catatonic (n=11), disorganised (n=102) or residual (n=131) (of intent-to-treat population), SANS severity score of 10 or more (excluding the item attention).<BR/>N=245.<BR/>Age: mean amisulpride=37.8 years, mean olanzapine (5 mg/day)=38.1 years, mean olanzapine (20 mg/day)=36.4 years, mean placebo=38.2 years.<BR/>Sex: 167 M, 78 F.<BR/>History: duration ill mean amisulpride=12.33 years, mean olanzapine (5 mg/day)=10.08 years, mean olanzapine (20 mg/day)=11.08 years, mean placebo=15.42 years, age at onset not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 13:45:51 +0100" MODIFIED_BY="[Empty name]">
<P>1. Amisulpride: fixed dose: 150 mg/day. N=70.<BR/>2. Olanzapine: fixed dose: 5 mg/day. N=70.<BR/>3. Olanzapine: fixed dose: 20 mg/day. N=70.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:20:16 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI, relapse, Patient's global impression.<BR/>Mental State: PANSS total score, BPRS total score, PANSS positive subscore, PANSS negative subscore, SANS total score, Psychotic depression Scale.<BR/>Quality of life: Carpenters QLS total score.<BR/>Adverse effects: EPS (akathisia, akinesia, parkinsonism, tremor), prolactin associated side effects, sedation, seizures, weight, laboratory (leukopenia).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-28 13:46:41 +0100" MODIFIED_BY="[Empty name]">
<P>There is a placebo group (n=35), which is not relevant for this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:22:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lieberman-2005">
<CHAR_METHODS MODIFIED="2010-02-14 18:26:39 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, identical capsules.<BR/>Duration: 78 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Country: USA.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-30 16:10:48 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, previously more than one schizophrenic episode, responder.<BR/>N=1493.<BR/>Age: 18-65 years (mean=40.6 years).<BR/>Sex: 1080 M, 380 F.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 13:47:37 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose, allowed dose range: 7.5-30 mg/day, mean dose=20.1 mg/day. N=336.<BR/>2. Perphenazine: flexible dose, allowed dose range: 8-32 mg/day, mean dose=20.8 mg/day. N=261.<BR/>3. Quetiapine: flexible dose, allowed dose range: 200-800 mg/day, mean dose=543.4 mg/day. N=337.<BR/>4. Risperidone: flexible dose, allowed dose range: 1.5-6.0 mg/day, mean dose=3.9 mg/day. N=341.<BR/>5. Ziprasidone: flexible dose, allowed dose range: 40-160 mg/day, mean dose=112.8 mg/day. N=185.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:22:40 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI-S.<BR/>Mental State: PANSS total score.<BR/>Service use: number of participants re-hospitalised.<BR/>Death: suicide attempt.<BR/>Adverse effects: open interviews, EPS (use of antiparkinson medication, akathisia), cardiac effects (ECG), prolactin-associated side-effects, sedation, weight gain, laboratory (prolactin, lipids, glucose).</P>
<P>Unable to use -<BR/>Withdrawal due to "extrapyramidal effects" (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-02-17 13:22:50 +0000" MODIFIED_BY="[Empty name]">
<P>Note: 33 participants were excluded before analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 14:23:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McEvoy-2006">
<CHAR_METHODS MODIFIED="2010-02-14 18:27:54 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, identical capsules.<BR/>Duration: 52 weeks (26 weeks observed, because of small group sizes).<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Country: USA.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 14:23:01 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, inadequate efficacy in previous study, clozapine treatment (n=49) was open-label.<BR/>N=99, (observed N=50).<BR/>Age: 18-65 years (mean=39.7 years).<BR/>Sex: 80 M, 19 F.<BR/>History: duration ill, age at onset, not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 13:48:46 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 7.5-30 mg/day. Mean dose: 23.4 mg/day. N=19.<BR/>2. Quetiapine: flexible dose. Allowed dose range: 200-800 mg/day. Mean dose: 642.9 mg/day. N=15.<BR/>3. Risperidone: flexible dose. Allowed dose range: 1.5-6 mg/day. Mean dose: 4.8 mg/day. N=16.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:24:40 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global state: CGI.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Adverse effects: open interviews, amenorrhoea, galactorrhoea, sexual dysfunction, sedation, laboratory (lipids, glucose, prolactin, haemoglobin A1C level), weight gain.</P>
<P>Unable to use -<BR/>Global state CGI: no data.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-28 13:48:22 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-14 20:07:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McEvoy-2007">
<CHAR_METHODS MODIFIED="2010-02-14 18:31:26 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 52 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Country: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-14 20:07:01 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia (n=231), schizophreniform disorder (n=115) or schizoaffective disorder (n=54), first episode, psychotic symptoms for 1 month to 5 years, PANSS psychosis and CGI-S score of 4 or more.<BR/>N=400.<BR/>Age: 16-40 years (mean=24.5 years).<BR/>Sex: 292 M, 108 F.<BR/>History: duration ill mean=1.08 years, age at onset 23.5 years.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 13:49:37 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 2.5-20 mg/day. Mean dose: 11.7 mg/day. N=133.<BR/>2. Quetiapine: flexible dose. Allowed dose range: 100-800 mg/day. Mean dose: 506 mg/day. N=134.<BR/>3. Risperidone: flexible dose. Allowed dose range: 0.5-4 mg/day. Mean dose: 2.4 mg/day. N=133.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-28 13:49:37 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: PANSS total, PANSS positive subscore, PANSS negative subscore, depression Calgary depression scale.<BR/>Adverse effects: open interviews, death (suicide attempt, suicide, EPS (akathisia, akinesia, use of antiparkinson medication, laboratory (cholesterol, fasting glucose, prolactin), prolactin associated side effects (amenorrhoea, galactorrhoea, gynaecomastia, sexual dysfunction), sedation, insomnia, dry mouth, orthostatic faintness, constipation, sialorrhoea, skin rash, gynaecomastia, urinary hesitancy, incontinence, weight gain (BMI, waist circumference).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-28 13:49:16 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-14 18:32:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McQuade-2004">
<CHAR_METHODS MODIFIED="2010-02-14 18:32:31 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 26 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Country: USA, Canada, Argentina, Brazil, Mexico. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-30 16:10:49 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia disorganised (n=17), paranoid (n=271), residual (n=3) or undifferentiated (n=26), in acute relapse and hospitalised. PANSS total score of 60 or more.<BR/>N=317.<BR/>Age: &gt;17 years (mean=38.4 years).<BR/>Sex: 229 M, 88 F.<BR/>History: duration ill not reported, age at first hospitalisation mean=24.50 years.<BR/>Setting: originally inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 13:51:36 +0100" MODIFIED_BY="[Empty name]">
<P>1. Aripiprazole: flexible dose. Allowed dose range: 15-30 mg/day. Mean dose: 25.1 mg/day. N=156.<BR/>2. Olanzapine: flexible dose. Allowed dose range: 10-20 mg/day. Mean dose: 16.5 mg/day. N=161.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-28 13:51:36 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global state: CGI.<BR/>Mental state: PANSS total score.<BR/>Adverse effects: cardiac effects (ECG, QTc abnormalities in ms), extrapyramidal side-effects (akathisia, extrapyramidal symptoms, parkinsonism), laboratory (lipids, glucose (change from baseline in mg/dl, prolactin - increase of prolactin level above upper limit (males &gt;20 ng/ml, females &gt;27 ng/ml)), sedation, weight gain.</P>
<P>Unable to use -<BR/>Adverse effects: use of antiparkinson medication (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-28 13:51:32 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:28:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meltzer-2003">
<CHAR_METHODS MODIFIED="2010-02-17 13:26:29 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 104 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Countries: USA, Canada, France, Italy, UK, Czech Republic, Hungary, Croatia, South Africa, Argentina, Chile.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 13:26:46 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia (n=609) or schizoaffective disorder (n=371), high suicidal risk. N=980.<BR/>Age: 18-65 years (mean=37.1 years).<BR/>Sex: 602 M, 378 F.<BR/>History: duration ill not reported, age at onset mean=24.7 years.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 13:53:45 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 200-900 mg/day. Mean dose: 274.2 mg/day. N=490.<BR/>2. Olanzapine: flexible dose. Allowed dose range: 5-20 mg/day. Mean dose: 16.6 mg/day. N=490.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:28:41 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global state: CGI - of suicide severity.<BR/>Mental State: depression Calgary depression scale,<BR/>anxiety Covi anxiety scale.<BR/>General functioning: scale of functioning.<BR/>Service use: number of participants re-hospitalised.<BR/>Adverse effects: death (any reason, suicide attempt, suicide, scale of suicidal thinking), cardiomyopathy, EPS (akathisia, rigor), sedation, seizures, weight gain, suicide ideation, depression, insomnia, dysarthria, salivary hypersecretion, dry mouth, drug abuse, alcoholism, laboratory (glucose, hematology).<BR/>
<BR/>Unable to use -<BR/>ESRS (no data)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 14:26:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moresco-2004">
<CHAR_METHODS MODIFIED="2010-02-17 14:26:48 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: single centre.<BR/>Country: Italy.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 13:29:12 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, treatment resistance to two previous antipsychotic medications, BPRS score of 27 or more.<BR/>N=23.<BR/>Age: 18 years or more (mean clozapine=38.3 years, mean olanzapine=34.1 years) (of completer population).<BR/>Sex: 16 M, 7 F.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 13:58:39 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 300-400 mg/day. Mean dose: 325.4 mg/day. N=12.<BR/>2. Olanzapine: flexible dose. Allowed dose range: 15-20 mg/day. Mean dose: 18.3 mg/day. N=11.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:30:07 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental State: PANSS total score, BPRS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Receptor occupancy measures ([18F]FESP/ PET).<BR/>Adverse effects: open interviews, EPS (SAS, AIMS).</P>
<P>Unable to use -<BR/>AIMS (no useable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 14:22:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mori-2004">
<CHAR_METHODS MODIFIED="2010-02-17 13:30:30 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks (last 4 weeks observed).<BR/>Design: parallel.<BR/>Location: single centre.<BR/>Country: Japan.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 14:22:26 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia disorganised (n=23), paranoid (n=10), undifferentiated (n=34). <BR/>N=77.<BR/>Age: 28-84 years (mean=59.9 years).<BR/>Sex: 39 M, 38 F.<BR/>History: duration ill mean=34.51 years, age at onset, not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 14:01:20 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 2.5-20 mg/day. Mean dose: 16.5 mg/day. N=20.<BR/>2. Perospirone: flexible dose. Allowed dose range: 4-48 mg/day. Mean dose: 37.3 mg/day. N=18.<BR/>3. Quetiapine: flexible dose. Allowed dose range: 50-750 mg/day. Mean dose: 432.5 mg/day. N=20.<BR/>4. Risperidone: flexible dose. Allowed dose range: 1-12 mg/day. Mean dose: 7.37 mg/day. N=19.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-28 14:01:20 +0100" MODIFIED_BY="[Empty name]">
<P>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Cognitive functioning: digit span distractibility test.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-28 14:00:40 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 14:22:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mortimer-2004">
<CHAR_METHODS MODIFIED="2010-02-17 13:31:19 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, computer-generated randomisation.<BR/>Blindness: double, identical capsules.<BR/>Duration: 24 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Countries: Belgium, Czech Republic, Denmark, France, Hungary, Morocco, Portugal, UK, Switzerland, Tunisia.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 14:22:13 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia disorganised (n=33), paranoid (n=260) or undifferentiated (n=76) or schizophreniform disorder (n=8), dominant positive symptoms, BPRS of 36 or more, PANSS positive score higher than PANSS negative score.<BR/>N=377.<BR/>Age: 18-65 years (mean amisulpride=38.2 years, mean olanzapine=37.4 years).<BR/>Sex: 245 M, 132 F.<BR/>History: duration ill mean amisulpride=9.56 years, mean olanzapine=8.12 years, age at onset, not described.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 14:02:38 +0100" MODIFIED_BY="[Empty name]">
<P>1. Amisulpride: flexible dose. Allowed dose range: 200-800 mg/day. Mean dose: 504 mg/day. N=189.</P>
<P>2. Olanzapine: flexible dose. Allowed dose range: 5-20 mg/day. Mean dose: 13 mg/day. N=188.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:32:07 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: PANSS total score, BPRS total score, PANSS positive subscore, PANSS negative subscore, Depression MADRS.<BR/>General Functioning: SOFAS total score.<BR/>Quality of life: QLS total score.<BR/>Adverse effects: open interviews, cardiac effects (ECG), death (natural causes, suicide) EPS (akathisia, dystonia, parkinsonism, use of antiparkinson medication, AIMS, Simpson-Angus), glucose, sedation, weight.</P>
<P>Unable to use -<BR/>Amenorrhoea (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-28 14:02:06 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:33:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Naber-2005">
<CHAR_METHODS MODIFIED="2010-02-14 18:43:26 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, computer-generated randomisation.<BR/>Blindness: double, identical capsules.<BR/>Duration: 26 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Country: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 13:32:33 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, non-response to, or intolerance of, standard antipsychotic therapy, BPRS of 24 or more.<BR/>N=114.<BR/>Age: 18-65 years (mean=34.0 years).<BR/>Sex: 69 M, 45 F.<BR/>History: duration ill not reported, age at onset 26.9 years.<BR/>Setting: in- and outpatient, initially inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 14:09:07 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 100-400 mg/day. Mean dose: 209 mg/day. N=57.<BR/>2. Olanzapine: flexible dose. Allowed dose range: 5-25 mg/day. Mean dose: 16.2 mg/day. N=57.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:33:42 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: PANSS total score, BPRS total score, PANSS positive subscore, BPRS positive subscore, PANSS negative subscore, BPRS negative subscore.<BR/>Quality of life: Munich dimension list, subject well-being under neuroleptic treatment.<BR/>Cognitive functioning: Wisconsin card sorting test.<BR/>Adverse effects: open interviews, cardiac effects (ECG), EPS (use of antiparkinson medication, Simpson-Angus), dizziness, increased salivation, constipation, weight change.<BR/>
</P>
<P>Unable to use -<BR/>Glucose elevation (non fasting): no data.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 14:21:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ozguven-2004">
<CHAR_METHODS MODIFIED="2010-02-14 18:43:49 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: single, no further details.<BR/>Duration: 6 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>Country: not reported. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 14:21:38 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia.<BR/>N=30.<BR/>Age: mean=35.3 years.<BR/>Sex:: 8 M, 22 F.<BR/>History: duration ill, age at onset, not reported.<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 14:12:31 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range:<BR/>Mean dose: 23.0 mg/day. N=15.<BR/>2. Quetiapine: flexible dose. Allowed dose range:<BR/>Mean dose: 826.67 mg/day. N=15.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-28 14:12:31 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global state: CGI.<BR/>Mental state: SAPS total score, SANS total score.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-28 14:12:14 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:35:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Purdon-2000">
<CHAR_METHODS MODIFIED="2010-02-14 18:45:44 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, computer-generated randomisation.<BR/>Blindness: double, no further details.<BR/>Duration: 54 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Country: Canada.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-14 20:09:21 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, in early phase.<BR/>N=65.<BR/>Age: 18-65 years (mean haloperidol=28.83 years, mean olanzapine=26.01 years, mean risperidone=31.77 years).<BR/>Sex: 46 M, 19 F.<BR/>History: duration ill mean haloperidol=2.45 years, mean olanzapine=2.79 years, mean risperidone=2.67 years, age at onset mean haloperidol=24.25 years, mean olanzapine=23.37 years, mean risperidone=28.86 years.<BR/>Setting: outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 14:13:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: flexible dose. Allowed dose range: 5-20 mg/day. Mean dose: 9.70 mg/day. N=23.<BR/>2. Olanzapine: flexible dose. Allowed dose range: 5-20 mg/day. Mean dose: 11.00 mg/day. N=21.<BR/>3. Risperidone: flexible dose. Allowed dose range: 4-10 mg/day. Mean dose: 6.00 mg/day. N=21.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:35:58 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental state: PANSS positive subscore, PANSS negative subscore.<BR/>Cognitive functioning: Cognitive test battery (finger tapping, digit span, Peabody picture vocabulary test, trail making test).<BR/>Adverse effects: EPS (use of antiparkinson medication, ESRS).</P>
<P>Unable to use -<BR/>Cognitive Functioning (no overall score).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 14:21:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Riedel-2007">
<CHAR_METHODS MODIFIED="2010-02-17 14:21:05 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: single centre.<BR/>Country: Germany.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-14 20:10:04 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, acute episode, CGI of more than 4, PANSS total score of more than 60.<BR/>N=52.<BR/>Age: 18-65 years (mean olanzapine=34.47 years, mean quetiapine=36.69 years) (of completers).<BR/>Sex: 21 M, 12 F (of completers, here defined as participants who completed cognitive assessments at two or more time points out of three (baseline, week 4, weeks 8)).<BR/>History: duration ill mean olanzapine=4.71 years, mean quetiapine=8.44 years (of completers), age at onset mean olanzapine=29.76 years, mean quetiapine=28.25 years (of completers).<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-15 13:29:45 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 10-20 mg/day. Mean dose: 15.82 mg/day. N=26.<BR/>2. Quetiapine: flexible dose. Allowed dose range: 400-800 mg/day. Mean dose: 586.86 mg/day. N=26.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:37:23 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events.<BR/>Global state: CGI.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Adverse effects: open interviews, UKU, EPS (akathisia, use of antiparkinson medication, BAS, ESRS), sedation, headache, dizziness, obstipation, weight gain.</P>
<P>Unable to use -<BR/>Global state: no data.<BR/>BAS: no data.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:38:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Robinson-2006">
<CHAR_METHODS MODIFIED="2010-02-14 18:48:06 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 16 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Country: USA.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-14 20:10:22 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) first episode schizophrenia (n=84), schizophreniform disorder (n=19) or schizoaffective disorder (n=9) (of intent-to-treat population).<BR/>N=120.<BR/>Age: 16-40 years (mean=23.3 years) (of intent-to-treat population).<BR/>Sex: 78 M, 34 F (of intent-to-treat population).<BR/>History: duration ill mean=2.2 years (of intent-to-treat population), age at onset mean=20.7 years (of intent-to-treat population).<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-15 13:27:52 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 2.5-20 mg/day. Mean dose: 11.8 mg/day. N=60.<BR/>2. Risperidone: flexible dose. Allowed dose range: 1-6 mg/day. Mean dose: 3.9 mg/day. N=60.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:38:36 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: inefficacy.<BR/>Global State.<BR/>Adverse effects: EPS (parkinsonism, use of antiparkinson medication, Simpson-Angus), weight gain.</P>
<P>Unable to use -<BR/>Leaving the study early (incomplete data).<BR/>Weight gain (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 14:20:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sacchetti-2004">
<CHAR_METHODS MODIFIED="2010-02-14 19:40:17 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: single (rater-blinded).<BR/>Duration: 16 weeks (8 weeks observed).<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Country: not reported. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 14:20:45 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, PANSS total score of 70 or more, PANSS positive subscore of 4 or more on at least 2 items.<BR/>N=75.<BR/>Age: 18-65 years.<BR/>Sex: not reported.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-15 13:26:55 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 10-20 mg/day. Mean dose: 14.6 mg/day. N=25.<BR/>2. Quetiapine: flexible dose. Allowed dose range: 400-800 mg/day. Mean dose: 602.4 mg/day. N=25.<BR/>3. Risperidone: flexible dose. Allowed dose range: 4-8 mg/day. Mean dose: 4.3 mg/day. N=25.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:40:12 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason.<BR/>Mental State: BPRS hostility cluster score.<BR/>Adverse effects: EPS (BAS, SAS), weight gain.</P>
<P>Unable to use-<BR/>Mental State - PANSS total score, PANSS positive subscore, PANSS negative subscore (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-15 13:26:52 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:41:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shaw-2006">
<CHAR_METHODS MODIFIED="2010-02-14 19:39:56 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, random-numbers chart, blocks of 4.<BR/>Blindness: double, identical capsules.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>Country: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-14 20:10:53 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, treatment resistant to two previous antipsychotics, IQ of 70 or more.<BR/>N=25.<BR/>Age: 7-16 years (mean clozapine=11.7 years, mean olanzapine=12.8 years).<BR/>Sex: 15 M, 10 F.<BR/>History: duration ill mean clozapine=3.1 years, mean olanzapine=3.3 years, age at onset mean clozapine=8.6 years, mean olanzapine=9.5 years.<BR/>Setting: inpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-15 13:23:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 150-500 mg/day. Mean dose: 327 mg/day. N=12.<BR/>2. Olanzapine: flexible dose. Allowed dose range: 5-20 mg/day. Mean dose: 18.1 mg/day. N=13.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:41:12 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental state: SAPS total subscore, SANS total score.<BR/>Adverse effects: open interviews, cardiac effects (ECG), sedation, seizures, weight change, laboratory (cholesterol, white blood cell count).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:43:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sikich-2004">
<CHAR_METHODS MODIFIED="2010-02-14 18:55:40 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, computer-generated randomisation.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Country: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 13:42:05 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: Children and adolescents with (K-SADS-P or DSM-IV) schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, major depression with psychotic features or bipolar affective disorder with psychotic features, schizophrenia spectrum (n=26), affective disorders (n=24) subjects selected because of prominent positive psychotic symptoms (of intent-to-treat population).<BR/>N=51.<BR/>Age: 8-19 years (mean=14.8 years).<BR/>Sex: 30 M, 21 F.<BR/>History: duration ill not reported, age at onset mean=12.4 years.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-15 13:22:39 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol : flexible dose. Allowed dose range: 1-8 mg/day. Mean dose: 5.0 mg/day. N=15.<BR/>2. Olanzapine: flexible dose. Allowed dose range: 2.5-20 mg/day. Mean dose: 12.3 mg/day. N=16. <BR/>3. Risperidone: flexible dose. Allowed dose range: 0.5-6 mg/day. Mean dose: 4.0 mg/day. N=20.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:43:24 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: BPRS-C total score, CPRS.<BR/>Adverse effects: open interviews, cardiac effects (QTc, vital signs), EPS (akathisia, use of antiparkinson medication, Simpson-Angus), prolactin associated side effects (amenorrhoea, galactorrhoea, gynaecomastia), sedation, gastrointestinal malfunction, weight (BMI), laboratory (glucose, prolactin).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:44:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simpson-2004">
<CHAR_METHODS MODIFIED="2010-02-14 18:57:51 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 6 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Country: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-14 20:11:23 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) acute schizophrenia (n=170) or schizoaffective disorder (n=99), CGI-S score of 4 or more, CGI-I score of 3 or more.<BR/>N=269.<BR/>Age: 18-55 years (mean olanzapine=37.6 years, mean ziprasidone=37.7 years).<BR/>Sex: 176 M, 93 F.<BR/>History: duration ill mean olanzapine=14.0, mean risperidone=15.4, age at onset mean olanzapine=23.7 years, mean ziprasidone=22.2 years.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-15 13:16:52 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose, allowed dose range: 5-15 mg/day, mean dose=11.3 mg/day. N=133.<BR/>2. Ziprasidone: flexible dose, allowed dose range: 80-160 mg/day, mean dose=129.9 mg/day. N=136.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:44:55 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: BPRS total score, depression Calgary depression scale for schizophrenia.<BR/>Adverse effects: open interviews, EPS (use of antiparkinson medication, ESRS) cardiac effects (ECG), weight gain, laboratory.<BR/>
</P>
<P>Unable to use -<BR/>Laboratory (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-15 13:16:52 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:46:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sirota-2006">
<CHAR_METHODS MODIFIED="2010-02-17 13:45:08 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>Location: single centre.<BR/>Country: Israel.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-14 20:11:38 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, PANSS negative subscore of more than 15, SANS total score more than 60.<BR/>N=40.<BR/>Age: 21-64 years (mean olanzapine=36.2 years, mean quetiapine=38.3 years).<BR/>Sex: 32 M, 8 F.<BR/>History: duration ill mean olanzapine=13.3 years, mean quetiapine=15.9 years, age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-17 13:45:19 +0000" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 5-20 mg/day. Mean dose: 16.0 mg/day. N=21.<BR/>2. Quetiapine: flexible dose. Allowed dose range: 200-800 mg/day. Mean dose: 637.2 mg/day. N=19.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:46:09 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental State: PANSS total score, SANS.<BR/>Adverse effects: open interviews, cardiac effects (ECG), EPS (akathisia, parkinsonism, use of antiparkinson medication, SAS, AIMS, BAS), sedation, insomnia, abdominal pain, fever, rhinitis, conjunctivitis, seizures, weight gain.</P>
<P>Unable to use -<BR/>Mental State - PANSS total score (median change).<BR/>Negative Symptoms - SANS (median change).<BR/>EPS scales (no data).<BR/>Cardiac effects (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-15 13:15:35 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 14:19:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stroup-2006">
<CHAR_METHODS MODIFIED="2010-02-14 19:01:40 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, 2 steps of randomisation before and after availability of ziprasidone, subjects received other medication than in previous phase 1 treatment. Re-randomised.<BR/>Blindness: double, identical capsules.<BR/>Duration: 26 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Country: USA.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 14:19:38 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) chronic schizophrenia.<BR/>N=444.<BR/>Age: 18-65 years (mean olanzapine=40.0 years, mean quetiapine=40.1 years, mean risperidone=41.8 years, mean ziprasidone=41.3 years).<BR/>Sex: 308 M, 136 F.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-15 13:14:17 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose, allowed dose range: 7.5-30 mg/day, mean dose=20.5 mg/day. N=108.<BR/>2. Quetiapine: flexible dose, allowed dose range: 200-800 mg/day, mean dose=565.2 mg/day. N=95.<BR/>3. Risperidone: flexible dose, allowed dose range: 1.5-6.0 mg/day, mean dose=4.1 mg/day. N=104.<BR/>4. Ziprasidone: flexible dose, allowed dose range: 40-160 mg/day, mean dose=115.9 mg/day. N=137.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-15 13:14:44 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: PANSS total score.<BR/>Death: suicide.<BR/>Adverse effects: open interviews, EPS (akathisia), cardiac effects (ECG),<BR/>prolactin-associated side-effects, weight gain, laboratory (prolactin, glucose, cholesterol).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-02-14 20:11:43 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 14:19:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Svestka-2003a">
<CHAR_METHODS MODIFIED="2010-02-17 13:47:04 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 6 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>Country: Czech Republic.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 14:19:27 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or schizoaffective disorder, first episode.<BR/>N=42.<BR/>Age: not reported.<BR/>Sex: not reported.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 10:13:12 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: fixed/flexible dose: not reported. Allowed dose range: not reported. Mean dose: not reported. N=21.<BR/>2. Risperidone: fixed/flexible dose: not reported. Allowed dose range: not reported. Mean dose: not reported. N=21.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-15 13:12:54 +0100" MODIFIED_BY="[Empty name]">
<P>Mental State: PANSS total score.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:48:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Svestka-2003b">
<CHAR_METHODS MODIFIED="2010-02-17 13:47:29 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness:double, no further details.<BR/>Duration: 6 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>Country: Czech Republic.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 13:47:48 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (ICD-10) acute schizophrenia (n=32) or schizoaffective disorder (n=10), first episode. <BR/>N=42.<BR/>Age: mean=35.78 years.<BR/>Sex: 42 females.<BR/>History: duration ill mean=7.05 years, age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-15 13:11:58 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 10-20 mg/day. Mean dose: 19.5 mg/day. N=20.<BR/>2. Quetiapine: flexible dose. Allowed dose range: 50-700 mg/day. Mean dose: 677.3 mg/day. N=22.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:48:32 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: inefficacy.<BR/>Global State: CGI.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Adverse effects: cardiac effects (QTc), EPS (akathisia, dystonia, extrapyramidal symptoms, tremor), weight gain, laboratory (cholesterol, glucose, prolactin).<BR/>
</P>
<P>Unable to use -<BR/>Cholesterol (no data).<BR/>Glucose (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-15 13:11:58 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 14:19:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Svestka-2005">
<CHAR_METHODS MODIFIED="2010-02-17 13:48:51 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 6 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>Country: Czech Republic.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 14:19:11 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (ICD-10) acute schizophrenia or schizoaffective disorder, first episode.<BR/>N=48.<BR/>Age: not reported.<BR/>Sex: not reported.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-15 13:10:22 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: fixed/flexible dose: not reported, allowed dose range: not reported, mean dose: not reported. N=24.<BR/>2. Ziprasidone: fixed/flexible dose: not reported, allowed dose range: not reported, mean dose: not reported. N=24.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:49:27 +0000" MODIFIED_BY="[Empty name]">
<P>Mental State: PANSS total score.<BR/>Adverse effects: EPS (akathisia, parkinsonism, dystonia).</P>
<P>Unable to use -<BR/>EPS (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-15 13:10:17 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 14:19:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tollefson-2001">
<CHAR_METHODS MODIFIED="2010-02-14 19:09:23 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 18 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Countries: Belgium, Denmark, Finland, France, Germany, Italy, Norway, Portugal, South Africa, Spain, Sweden, Switzerland, Great Britain, Ireland.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 14:19:00 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia catatonic (n=3), disorganised (n=34), paranoid (n=101), residual (n=8) or undifferentiated (n=34), previous treatment resistance, BPRS of 45 or more.<BR/>N=180.<BR/>Age: 18-70 years (mean=38.6 years).<BR/>Sex: 115 M, 65 F.<BR/>History: duration ill not reported, age at onset mean=22.8 years.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-15 13:05:51 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 200-600 mg/day. Mean dose: 303.6 mg/day. N=90.<BR/>2. Olanzapine: flexible dose. Allowed dose range: 15-25 mg/day. Mean dose: 20.5 mg/day. N=90.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 14:18:51 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI-S.<BR/>Mental State: PANSS total score, BPRS total score, PANSS positive subscore, BPRS positive subscore, PANSS negative subscore, BPRS negative subscore.<BR/>Adverse effects: EPS (akathisia, akinesia, parkinsonism, use of antiparkinson medication, AIMS, BAS, SAS), death (natural cause), sedation, weight gain, laboratory (prolactin, white blood cell count).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 14:29:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tran-1997">
<CHAR_METHODS MODIFIED="2010-02-14 19:12:44 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 28 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Countries: Belgium, France, Germany, The Netherlands, South Africa, Spain, Switzerland, UK, USA. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 14:29:16 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia (n=277), schizophreniform disorder or schizoaffective disorder, BPRS score of 42 or more.<BR/>N=339.<BR/>Age: 18-65 years (mean=36.21 years).<BR/>Sex: 220 M, 119 F.<BR/>History: duration ill not reported, age at onset mean=23.7 years.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-15 13:00:33 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 10-20 mg/day. Mean dose: 17.2 mg/day. N=172. <BR/>2. Risperidone: flexible dose. Allowed dose range: 4-12 mg/day. Mean dose: 7.2 mg/day. N=167.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:50:33 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental State: PANSS total score, BPRS total score, PANSS positive subscore, PANSS negative subscore, SANS total score.<BR/>Quality of life: QLS total score.<BR/>Adverse effects: open interviews, cardiac effects (ECG), death (any reason, suicide attempt), EPS (akathisia, akinesia, dyskinesia, dystonia, extrapyramidal symptoms, parkinsonism, tremor, use of antiparkinson medication), Prolactin associated side effects (abnormal ejaculation, abnormally high prolactin value, amenorrhoea, decreased libido, galactorrhoea, gynaecomastia, impotence), sedation, backache, blurred vision, breathing difficulties, early wakening, nightmares, seizures, weight gain, laboratory (glucose, white blood cell count).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 14:18:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Nimwegen-2006">
<CHAR_METHODS MODIFIED="2010-02-14 19:34:06 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 6 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>Country: The Netherlands.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 14:18:14 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, schizophreniform disorder or schizoaffective disorder, cannabis positive last month olanzapine (n=20), risperidone (n=23).<BR/>N=131.<BR/>Age: mean olanzapine=24.4 years, mean risperidone=25.1 years.<BR/>Sex: 106 M, 25 F.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-15 12:59:53 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 5-20 mg/day. Mean dose: 10.95 mg/day. N=64.<BR/>2. Risperidone: flexible dose. Allowed dose range: 1-5 mg/day. Mean dose: 2.96 mg/day. N=67.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:51:02 +0000" MODIFIED_BY="[Empty name]">
<P>Quality of life: Subject well being.<BR/>Adverse effects: EPS (BAS).<BR/>Cannabis use.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:52:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vanelle-2006">
<CHAR_METHODS MODIFIED="2010-02-14 19:15:37 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Countries: France, Italy, Tunisia. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 13:51:50 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia and comorbid depression, disorganised (n=26), paranoid (n=32), residual (n=4) or undifferentiated (n=23) .<BR/>N=85.<BR/>Age: 18-65 years (mean=34 years).<BR/>Sex: 54 M, 31 F.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-15 12:54:49 +0100" MODIFIED_BY="[Empty name]">
<P>1. Amisulpride: flexible dose. Allowed dose range: 200-600 mg/day. Mean dose: 471 mg/day. N=45.<BR/>2. Olanzapine: flexible dose. Allowed dose range: 5-15 mg/day. Mean dose: 11.4 mg/day. N=40.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:52:44 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State.<BR/>Mental State: PANSS total score, BPRS total score, PANSS positive subscore, PANSS negative subscore, Calgary depression scale.<BR/>Adverse effects: open interviews, cardiac effects (QTc), EPS (tremor), weight, laboratory (cholesterol, glucose).<BR/>
</P>
<P>Unable to use -<BR/>Tremor: (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:53:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Volavka-2002">
<CHAR_METHODS MODIFIED="2010-02-14 19:16:55 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, identical capsules.<BR/>Duration: 14 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Country: USA.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 13:52:58 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) chronic schizophrenia (n=135) or schizoaffective disorder (n=22), sub optimal response to previous treatment, PANSS of 60 or more.<BR/>N=167.<BR/>Age: 18-60 years (mean=40.8 years) (of intent-to-treat population).<BR/>Sex: 133 M, 24 F (of intent-to-treat population).<BR/>History: duration ill mean=19.5 years (of intent-to-treat population), age at onset not reported.<BR/>Setting: inpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-15 12:49:48 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 200-800 mg/day. Mean dose: 526.6 mg/day (at the end of the last 6 weeks). N=40. <BR/>2. Haloperidol: flexible dose. Allowed dose range: 10-30 mg/day. Mean dose: 25.7 mg/day (at the end of the last 6 weeks). N=37. <BR/>3. Olanzapine: flexible dose. Allowed dose range: 10-40 mg/day. Mean dose: 30.4 mg/day (at the end of the last 6 weeks). N=39.<BR/>4. Risperidone: flexible dose. Allowed dose range: 4-16 mg/day. Mean dose: 11.6 mg/day (at the end of the last 6 weeks). N=41.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:53:30 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early. any reason, adverse events, inefficacy.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Quality of life: Quality of life scale, Nurses`observation scale for inpatient evaluation.<BR/>Cognitive Functioning: Global Neurocognitive Score.<BR/>Adverse effects: EPS (use of antiparkinson medication, ESRS), seizures, weight gain, laboratory (cholesterol, glucose, prolactin, white blood cell count).</P>
<P>Unable to use -<BR/>Quality of life scale (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-02-17 13:53:45 +0000" MODIFIED_BY="[Empty name]">
<P>The two participants with neutropenia (clozapine) are additional participants to the one with agranulocytosis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:56:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Voruganti-2007">
<CHAR_METHODS MODIFIED="2010-02-14 19:32:18 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 52 weeks.<BR/>Design: parallel.<BR/>Location: multi-centre.<BR/>Country: Canada.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 13:54:09 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N=86.<BR/>Age: not reported.<BR/>Sex: not reported.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 10:13:18 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: fixed/flexible dose: not reported. Allowed dose range: not reported. Mean dose: 17.2 mg/day. N=42.<BR/>2. Quetiapine: fixed/flexible dose: not reported. Allowed dose range: not reported. Mean dose: 612.8 mg/day. N=43.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:56:51 +0000" MODIFIED_BY="[Empty name]">
<P>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>General functioning: GAF.<BR/>Cognitive functioning: PANSS cognitive cluster, Wisconsin card sorting test.<BR/>Adverse effects: UKU, EPS (SAS, AIMS, BAS), weight gain, number of dysglycaemics.</P>
<P>Unable to use -<BR/>At the time the publication was available the update search was finished, therefore most of the data except for PANSS total, could not be considered.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-15 12:48:23 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:57:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wagner-2005">
<CHAR_METHODS MODIFIED="2010-02-17 13:57:06 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, medication containers according to a pseudo-random computer algorithm.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: single centre.<BR/>Country: Germany.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-14 20:15:01 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV and ICD-10) schizophrenia, CGI of 4 or more, PANSS of 61 or more.<BR/>N=52.<BR/>Age: 18-65 years (mean amisulpride=38.3 years, mean olanzapine=34.3 years).<BR/>Sex: 23 M, 13 F (of subjects with neuropsychological data, n=36).<BR/>History: duration ill mean=8.4 years (of subjects with neuropsychological data, n=36), age at onset 27.9 years (of subjects with neuropsychological data, n=36).<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-15 12:45:55 +0100" MODIFIED_BY="[Empty name]">
<P>1. Amisulpride: flexible dose. Allowed dose range: 400-800 mg/day. Mean dose: 511.1 mg/day. N=26.<BR/>2. Olanzapine: flexible dose. Allowed dose range: 10-20 mg/day. Mean dose: 15.0 mg/day. N=26.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-15 12:47:17 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore, SANS total score.<BR/>Cognitive Functioning: Global Cognitive Index total score, trail making test A &amp; B, continuos performance test, seld ordered pointing task, Rey auditory verbal learni g test.<BR/>Adverse effects: EPS (SAS).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 14:30:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2002">
<CHAR_METHODS MODIFIED="2010-02-17 13:57:28 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: single centre.<BR/>Country: China.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 14:30:19 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis:(CCMD-3) schizophrenia.<BR/>N=61.<BR/>Age: mean clozapine=30 years, mean olanzapine=25.8 years.<BR/>Sex: 29 M, 32 F.<BR/>History: duration ill mean=4.2 years, age at onset not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 10:13:18 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 25-400 mg/day. Mean dose: not reported. N=31.<BR/>2. Olanzapine: flexible dose. Allowed dose range: 5-20 mg/day. Mean dose: not reported. N=30.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:58:02 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: adverse events.<BR/>Mental State: BPRS total score.<BR/>Adverse effects: open interviews, cardiac effects (palpitation, blood pressure), EPS, sedation, dry mouth, congestion, weight gain, laboratory (leukopenia).<BR/>
</P>
<P>Unable to use -<BR/>Leaving the study early -adverse events (no usable data).<BR/>Leukopenia (no usable data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:58:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2006">
<CHAR_METHODS MODIFIED="2010-02-14 19:25:56 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, identical capsules.<BR/>Duration: 22 weeks (last 12 weeks observed).<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Country: USA.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 13:58:25 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia (n=24) or schizoaffective disorder (n=12).<BR/>N=36.<BR/>Age: mean=47.0 years.<BR/>Sex: 17 M, 19 F.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 14:30:17 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: not reported. Mean dose: 13.8 mg/day. N=17.<BR/>2. Risperidone: flexible dose. Allowed dose range: not reported. Mean dose: 5.3 mg/day. N=19.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:58:45 +0000" MODIFIED_BY="[Empty name]">
<P>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Adverse effects: EPS (SAS), weight gain.</P>
<P>Unable to use -<BR/>Leaving the study early (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-17 13:59:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wynn-2007">
<CHAR_METHODS MODIFIED="2010-02-14 19:26:48 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, 33 participants were assigned to a three-arm randomisation (1:1:1, blocks of 15) and 18 participants with a history of adverse experiences with haloperidol were assigned to a two-arm randomisation (1:1) for risperidone and olanzapine only.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Country: USA.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 13:59:01 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia or schizoaffective disorder.<BR/>N=51.<BR/>Age: 18-60 years (mean=48.8 years).<BR/>Sex: 43 M, 8 F.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-15 12:37:26 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: fixed dose: 8 mg/day. N=11.<BR/>2. Olanzapine: fixed dose: 15 mg/day. N=21.<BR/>3. Risperidone: fixed dose: 4 mg/day. N=19.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 13:59:10 +0000" MODIFIED_BY="[Empty name]">
<P>Neurological functioning: pre pulse inhibition, EMG.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Diagnostic tool<BR/>DSM III-R and DSM-IV - Diagnostic Statistical Manual version 3 Revised and version 4.<BR/>ICD 10 - The International Statistical Classification of Diseases and Related Health Problems.<BR/>BMI - Body Mass Index.</P>
<P>Rating Scales:</P>
<P>Global rating scales:<BR/>CGI - Clinical Global Impressions.<BR/>CGI-S - Clinical Global Impression-Severity.<BR/>CGI-I - Clinical Global Impression-Improvement.<BR/>
</P>
<P>Mental state:<BR/>BPRS - Brief Psychiatric Rating Scale.<BR/>MADRS - Montgomery-Asberg Depression Rating Scale.<BR/>MMSE - Wiing Mini Mental State Examination.<BR/>PANSS - Positive and Negative Syndrome Scale.<BR/>SANS - Scale for the Assessment of Negative Symptoms.</P>
<P>Side effects:<BR/>AIMS - Abnormal Involuntary Movement Scale.<BR/>BAS - Barnes Akathisia Scale.<BR/>BMI - Body mass index.<BR/>EPS- Extrapyramidal Symptoms<BR/>ESRS - Extrapyramidal Syndrome Rating Scale.<BR/>HAS - Hillside Akathisia Scale.<BR/>SAS - Simpson-Angus Index - for neurological side effects.<BR/>UKU - Udvalg for kliniske ndersogelser Side Effect Rating Scale -side effect rating scale.</P>
<P>Quality of Life:<BR/>QoL - Quality of Life Scale.<BR/>SWN -Subjective Well-being List.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-02-17 13:59:59 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Almond-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:40 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alvarez-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:44 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alvarez_x002d_Jimenez-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: pooled analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Antonova-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:44 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised,<BR/>Blindness: single-blind (rater-blinded).<BR/>Participants: people with schizophrenia.<BR/>Interventions: olanzapine, risperidone and quetiapine versus conventional antipsychotics.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-17 13:59:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Apiquian-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-17 13:59:59 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aquila-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:45 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-28 18:18:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ascher_x002d_Svanum-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-28 18:18:59 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-28 18:19:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baloescu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-28 18:19:17 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, controlled-trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Basson-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: pooled analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beasley-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: pooled analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beasley-2003a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:45 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beasley-2003b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: inappropriate intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bera-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:46 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beuzen-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:46 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-28 18:19:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bitter-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-28 18:19:46 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blonde-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:46 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boylan-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: inappropriate intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Briken-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:46 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cao-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:46 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Casey-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: pooled analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chaudhry-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:47 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:47 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:48 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chrzanowski-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:48 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Citrome-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: inappropriate intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ciudad-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:48 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Conley-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:48 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cornblatt-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:49 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Crespo_x002d_Facorro-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:49 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Czekalla-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:49 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dai-2004a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:49 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dai-2004b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:49 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dakhale-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: inappropriate intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-David-2000a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: pooled analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-David-2000b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: pooled analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Haan-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:49 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Deng-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:49 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-28 18:24:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dossenbach-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-28 18:24:33 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-28 18:25:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ertugrul-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-28 18:25:00 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, controlled-trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fleischhacker-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:50 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-28 18:25:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garc_x00ed_a-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-28 18:25:26 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-28 18:25:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goldberg-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-28 18:25:43 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, controlled-trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harrigan-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:50 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harrison-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, double-blind.<BR/>Participants: people with schizophrenia.<BR/>Intervention: olanzapine versus ziprasidone.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heresco_x002d_Levy-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:50 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomisation not mentioned.<BR/>Blindness: double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: inappropriate intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-28 18:26:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hrdlicka-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-28 18:26:03 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huber-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:50 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.<BR/>Intervention: other aims.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karow-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: pooled analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Keks-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:51 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-28 18:26:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kelemen-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-28 18:26:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, controlled-trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kern-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:51 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-28 18:26:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-28 18:26:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, controlled-trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kinon-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:51 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double-blind.<BR/>Participants: people with schizophrenia or schizoaffective or schiozophreniform disorder.<BR/>Interventions: inappropriate intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kolff-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:51 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kores-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: pooled analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-28 18:26:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kropp-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-28 18:26:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-28 18:28:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-28 18:28:12 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-28 18:28:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-28 18:28:22 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lipkovich-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: pooled analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Littrell-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:51 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:52 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loza-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:52 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-28 18:28:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malla-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-28 18:28:40 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, controlled-trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malyarov-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mazurek-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:52 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meltzer-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:52 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-28 18:28:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moritz-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-28 18:28:56 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mortimer-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:53 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Musil-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-28 18:29:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Naber-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-28 18:29:06 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Naber-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: pooled analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Newcomer-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: pooled analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oliemeulen-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:53 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Opjordsmoen-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ortega_x002d_Soto-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:53 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double-blind.<BR/>Participants: people with schizophrenia.<BR/>Intervention: olanzapine versus risperidone.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pan-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:53 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Perro-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:53 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-28 18:32:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peuskens-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-28 18:32:51 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, controlled-trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rabinowitz-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Intervention: inappropriate intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-28 18:33:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ray-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-28 18:33:12 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reznik-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:54 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roerig-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:54 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.<BR/>Intervention: inadequate diagnosis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ryu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sanchez-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:54 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-28 18:33:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharma-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-28 18:33:40 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, controlled-trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sowell-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:54 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-28 18:33:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Su-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-28 18:33:56 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, controlled-trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Swanson-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:54 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-28 18:37:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tudor-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-28 18:37:15 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, controlled-trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tunis-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:55 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Bruggen-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:55 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vaughan-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:55 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.<BR/>Intervention: other aims.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:55 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2004a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:56 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2004b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:56 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:56 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weickert-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: inappropriate intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wolf-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wolf-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-28 18:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wyszogrodzka_x002d_Kuchars-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-28 18:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, controlled-trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yagdiran-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yamashita-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-28 18:35:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zelaschi-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-28 18:35:04 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, cohort study. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zheng-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-03 08:32:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhong-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-03 08:32:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zoccali-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomisation not mentioned.<BR/>Participants: people with chronic schizophrenia.<BR/>Interventions: inappropriate intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-02-17 14:09:08 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2010-02-17 14:05:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eli-Lilly-2003a">
<CHAR_STUDY_NAME MODIFIED="2009-01-10 10:14:42 +0000" MODIFIED_BY="[Empty name]">
<P>Trial 8047<BR/>F1D-MC-HGLB</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-07-28 10:13:20 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 28 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>Setting: in- and outpatient.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 14:05:32 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia. N=not reported.<BR/>Sex: not reported M, not reported F.<BR/>Age: 18-65 years.<BR/>History: duration ill not reported, age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 10:13:22 +0100" MODIFIED_BY="[Empty name]">
<P>1. Aripiprazole:<BR/>Fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported.<BR/>Mean dose: not reported.<BR/>N=not reported.</P>
<P>2. Olanzapine:<BR/>Fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported.<BR/>Mean dose: not reported.<BR/>N=not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 14:05:13 +0000" MODIFIED_BY="[Empty name]">
<P>Long-time effectiveness and tolerability.<BR/>Global state (CGI, PG-I).<BR/>General Mental State (PANSS).<BR/>Depression (MADRS).<BR/>Quality of life (SWN-S, SF-36).<BR/>Cognitive functioning (MOS).<BR/>Sexual functioning (GISF).<BR/>Health resource utilisation and resource utilisation costs, hospitalisation time.<BR/>Treatment-emergent adverse events, EPS (SAS, BAS, AIMS).<BR/>Laboratory values.<BR/>Vital signs.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-01-12 22:15:09 +0000" MODIFIED_BY="[Empty name]">
<P>October 2003.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-01-10 09:56:31 +0000" MODIFIED_BY="[Empty name]">
<P>Eli Lilly and Company.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-02-17 14:05:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eli-Lilly-2003b">
<CHAR_STUDY_NAME MODIFIED="2009-01-10 10:40:33 +0000" MODIFIED_BY="[Empty name]">
<P>Trial 5296<BR/>F1D-MC-S014</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-07-28 10:13:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>Setting: not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 14:05:40 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or schizoaffective disorder. N=not reported.<BR/>Sex: not reported M, not reported F.<BR/>Age: 18-65 years.<BR/>History: duration ill not reported, age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 10:13:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine:<BR/>Fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported.<BR/>Mean dose: not reported.<BR/>N=not reported.</P>
<P>2. Risperidone:<BR/>Fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported.<BR/>Mean dose: not reported.<BR/>N=not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-01-12 22:35:32 +0000" MODIFIED_BY="[Empty name]">
<P>Global state (CGI-S).<BR/>General Mental State (BPRS).<BR/>EPS (AIMS, BAS, SAS).<BR/>Eating Behavior Assessment Scale.<BR/>Insuline sensitivity index, weight, BMI, waist circumference, visceral fat area, subcutaneous fat area, ratio of visceral fat area to subcutaneous fat area.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>October 2003</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-01-10 09:58:34 +0000" MODIFIED_BY="[Empty name]">
<P>Eli Lilly and Company.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-02-17 14:06:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eli-Lilly-2004a">
<CHAR_STUDY_NAME MODIFIED="2009-01-10 10:17:09 +0000" MODIFIED_BY="[Empty name]">
<P>Trial 8928<BR/>F1D-US-HGLS<BR/>
</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-07-28 10:13:26 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: not reported.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>Setting: initially inpatient.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 14:06:05 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia, schizoaffective disorder or schizophreniform disorder, acute phase. <BR/>N=not reported.<BR/>Sex: not reported.<BR/>Age: 18-55 years.<BR/>History: duration ill not reported, age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 10:13:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Aripiprazole:<BR/>Fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported.<BR/>Mean dose: not reported.<BR/>N=not reported.</P>
<P>2. Olanzapine:<BR/>Fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported.<BR/>Mean dose: not reported.<BR/>N=not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-01-12 22:36:46 +0000" MODIFIED_BY="[Empty name]">
<P>Efficacy, safety, side effects.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>July 2004</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-01-10 10:16:54 +0000" MODIFIED_BY="[Empty name]">
<P>Eli Lilly and Company.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-02-17 14:06:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eli-Lilly-2004b">
<CHAR_STUDY_NAME MODIFIED="2009-01-12 22:44:53 +0000" MODIFIED_BY="[Empty name]">
<P>Trial 8894<BR/>F1D-US-HGLR.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-07-28 10:15:01 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 26 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>Setting: not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 14:06:30 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or schizoaffective disorder. N=not reported.<BR/>Sex: not reported M, not reported F.<BR/>Age: 18-75 years.<BR/>History: duration ill not reported, age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 10:13:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine:<BR/>Flexible dose.<BR/>Allowed dose range: 7.5-20 mg/day.<BR/>Mean dose: not reported.<BR/>N=not reported.</P>
<P>2. Quetiapine:<BR/>Flexible dose.<BR/>Allowed dose range: 300-800 mg/day.<BR/>Mean dose: not reported.<BR/>N=not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 14:06:54 +0000" MODIFIED_BY="[Empty name]">
<P>Discontinuation for any reason, lack of efficacy or worsening of psychiatric syndromes.<BR/>Global state (CGI, PG-I).<BR/>General Mental State (PANSS).<BR/>Response.<BR/>Global functioning (DAI-10, GAF).<BR/>Depression (MADRS).<BR/>Quality of life (SF-36).<BR/>Treatment-emergent adverse events,<BR/>Extrapyramidal symptoms (Simpson-Angus, Barnes, AIMS).<BR/>Fasting laboratory analytes<BR/>Vital signs.<BR/>Fasting glucose, haemoglobin A1c, lipids, insulin. Weight, waist circumference, BMI, appetite, metabolic syndrome.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>July 2004</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-01-12 22:38:43 +0000" MODIFIED_BY="[Empty name]">
<P>Eli Lilly and company.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-02-17 14:07:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eli-Lilly-2006">
<CHAR_STUDY_NAME MODIFIED="2009-01-12 22:48:56 +0000" MODIFIED_BY="[Empty name]">
<P>Trial 10769<BR/>F1D-US-HGMN</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-07-28 10:14:45 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>Setting: not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 14:07:21 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or schizoaffective disorder or schizophreniform disorder. N=not reported.<BR/>Sex: not reportednM, not reported F.<BR/>Age: 18-65 years.<BR/>History: duration ill not reported, age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 10:13:33 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine:<BR/>Fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported.<BR/>Mean dose: not reported.<BR/>N=not reported.</P>
<P>2. Risperidone:<BR/>Fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported.<BR/>Mean dose: not reported.<BR/>N=not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-01-12 22:50:35 +0000" MODIFIED_BY="[Empty name]">
<P>Response.<BR/>Remission.<BR/>Psychiatric hospitalisations.<BR/>General Mental State (PANSS).<BR/>Safety.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>June 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-07-28 10:13:33 +0100" MODIFIED_BY="[Empty name]">
<P>not reported.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-02-17 14:07:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mortimer-2001">
<CHAR_STUDY_NAME MODIFIED="2009-01-12 23:01:56 +0000" MODIFIED_BY="[Empty name]">
<P>A1281014</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-07-28 10:13:55 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, double-dummy.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Setting: not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 14:07:44 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or schizoaffective disorder. <BR/>N=not reported.<BR/>Sex: not reported.<BR/>Age: not reported.<BR/>History: duration ill not reported, age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 10:14:04 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine:<BR/>Fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported.<BR/>Mean dose: not reported.<BR/>N=not reported.</P>
<P>2. Ziprasidone:<BR/>Fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported.<BR/>Mean dose: not reported.<BR/>N=not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-28 10:14:04 +0100" MODIFIED_BY="[Empty name]">
<P>not reported.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-01-12 23:03:46 +0000" MODIFIED_BY="[Empty name]">
<P>6 October 2000.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Prof Ann Mortimer<BR/>Coniston House<BR/>East Riding Campus<BR/>Willerby<BR/>HU10 6NS<BR/>UK<BR/>Telephone: 01482 466700<BR/>E-mail: A.M.Mortimer@medschool.hull.ac.uk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-02-17 14:08:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-N0081052094">
<CHAR_STUDY_NAME MODIFIED="2009-01-12 23:05:59 +0000" MODIFIED_BY="[Empty name]">
<P>RIS-INT-45</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-07-28 10:04:53 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, using a central randomisation procedure.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Setting: in- and outpatient.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 14:08:16 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-IV) schizophrenia, PANSS between 60 and 120. <BR/>N=not reported.<BR/>Sex: not reported.<BR/>Age: 18-65 years.<BR/>History: duration ill not reported, age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 10:14:06 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine:<BR/>Fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported.<BR/>Mean dose: not reported.<BR/>N=not reported.</P>
<P>2. Risperidone:<BR/>Fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported.<BR/>Mean dose: not reported.<BR/>N=not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-01-12 23:06:54 +0000" MODIFIED_BY="[Empty name]">
<P>Safety and efficacy.<BR/>Cognitive performance. <BR/>Sleepiness, weight gain.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>1 April 1997</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Professor Michael Reveley<BR/>Department of Psychiatry<BR/>Clinical Sciences Building<BR/>University of Leicester<BR/>Leicester Royal Infirmary<BR/>PO BOX 65<BR/>LE2 7LX<BR/>United Kingdom<BR/>Telephone: 0116 252 3242</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-02-17 14:08:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-N0081121981">
<CHAR_STUDY_NAME MODIFIED="2009-01-12 23:10:55 +0000" MODIFIED_BY="[Empty name]">
<P>MREC/00/147</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-07-28 10:14:22 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, double-dummy.<BR/>Duration: not reported.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Setting: not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 14:08:43 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or schizoaffective disorder. <BR/>N=not reported.<BR/>Sex: not reported M, not reported F.<BR/>Age: 18-70 years.<BR/>History: duration ill not reported, age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 10:14:11 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine:<BR/>Fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported.<BR/>Mean dose: not reported.<BR/>N=not reported.</P>
<P>2. Ziprasidone:<BR/>Fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported.<BR/>Mean dose: not reported.<BR/>N=not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-17 14:08:55 +0000" MODIFIED_BY="[Empty name]">
<P>Global state (CGI).<BR/>General Mental State (PANSS).<BR/>Quality of life (QLS).<BR/>Health of the nation outcome scale (HoNOS).<BR/>Drug attitude inventory (DAI).<BR/>Resource utilization questionnaire.<BR/>Treatment costs.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>1 May 2001</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]">
<P>Professor Michael Reveley<BR/>Department of Psychiatry<BR/>Section of Neuropsychiatry &amp; Psychopharmacology<BR/>Leicester General Hospital<BR/>Leicester<BR/>LE5 4PW<BR/>United Kingdom<BR/>Telephone: 0116 225 7924<BR/>E-mail: reveleym@leicspart.nhs.uk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-02-17 14:09:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00001656">
<CHAR_STUDY_NAME MODIFIED="2009-01-12 22:52:21 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment of childhood onset psychotic disorder with olanzapine or clozapine.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-07-28 10:13:33 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomisation not mentioned.<BR/>Blindness: double, no further details.<BR/>Duration: not reported.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>Setting: not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-17 14:09:08 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: (DSM-III-R or DSM-IV) schizophrenia or schizoaffective disorder or psychotic disorders not otherwise specified. <BR/>N=not reported.<BR/>Sex: not reported.<BR/>Age: 6-18 years.<BR/>History: duration ill not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 10:13:36 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine:<BR/>Fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported.<BR/>Mean dose: not reported.<BR/>N=not reported.</P>
<P>2. Olanzapine:<BR/>Fixed/flexible dose: not reported.<BR/>Allowed dose range: not reported.<BR/>Mean dose: not reported.<BR/>N=not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-28 10:13:36 +0100" MODIFIED_BY="[Empty name]">
<P>not reported.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-07-28 10:13:36 +0100" MODIFIED_BY="[Empty name]">
<P>not reported.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-07-28 10:13:36 +0100" MODIFIED_BY="[Empty name]">
<P>not reported.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-02-17 14:20:23 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-07-28 10:01:59 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:00:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:02:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bai-2005">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:33:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bitter-2004">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-29 20:32:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Breier-2005">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-29 20:32:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CN138003">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:33:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Canive-2000">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:18:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Conley-2001">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:34:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Conley-2003">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:21:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dollfus-2005">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:35:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dolnak-2001">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:24:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gureje-2003">
<DESCRIPTION>
<P>Random, computer-generated randomisation.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:25:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jeste-2003">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:26:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keefe-2006">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:38:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kinon-2006a">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:27:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinon-2006b">
<DESCRIPTION>
<P>Random, computer-generated randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:38:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Krakowski-2006">
<DESCRIPTION>
<P>Random, block randomisation (block size of 3).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:39:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumra-2007">
<DESCRIPTION>
<P>Random, computer-generated randomisation.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:29:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lecrubier-2006">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:31:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:33:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-2006">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:34:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-2007">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:35:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McQuade-2004">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:41:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meltzer-2003">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-28 10:01:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moresco-2004">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:36:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mori-2004">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:37:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mortimer-2004">
<DESCRIPTION>
<P>Random, computer-generated randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 16:16:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Naber-2005">
<DESCRIPTION>
<P>Random, computer-generated randomisation.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:38:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ozguven-2004">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:39:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Purdon-2000">
<DESCRIPTION>
<P>Random, computer-generated randomisation.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:40:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Riedel-2007">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:42:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-2006">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:43:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sacchetti-2004">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:44:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shaw-2006">
<DESCRIPTION>
<P>Random, random-numbers chart, blocks of 4.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:46:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sikich-2004">
<DESCRIPTION>
<P>Random, computer-generated randomisation.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:45:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-2004">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:48:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sirota-2006">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 16:32:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>Random, 2 steps of randomisation before and after the availability of ziprasidone, subjects were re-randomised to other medication than in phase 1.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:50:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-2003a">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:52:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-2003b">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:48:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-2005">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:48:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tollefson-2001">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:53:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tran-1997">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:54:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Nimwegen-2006">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:56:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vanelle-2006">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:57:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volavka-2002">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:59:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Voruganti-2007">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 13:12:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wagner-2005">
<DESCRIPTION>
<P>Random, medication containers according to a pseudo-random computer algorithm.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:51:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 16:01:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 16:02:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wynn-2007">
<DESCRIPTION>
<P>Random, 33 participants were assigned to a three-arm randomisation (1:1:1, blocks of 15) and 18 participants with a history of adverse experiences with haloperidol were assigned to a two-arm randomisation (1:1) for risperidone and olanzapine only.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-02-17 12:57:08 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:00:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>No further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:02:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bai-2005">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:33:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bitter-2004">
<DESCRIPTION>
<P>No further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-29 20:32:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Breier-2005">
<DESCRIPTION>
<P>No further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-29 20:32:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CN138003">
<DESCRIPTION>
<P>No further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-17 12:57:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Canive-2000">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:18:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Conley-2001">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:34:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Conley-2003">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:21:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dollfus-2005">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:35:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dolnak-2001">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:24:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gureje-2003">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:25:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jeste-2003">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:26:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keefe-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:38:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kinon-2006a">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:27:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kinon-2006b">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:39:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Krakowski-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:39:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kumra-2007">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:29:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lecrubier-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:31:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>No further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:33:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:34:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-2007">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:35:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McQuade-2004">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:41:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meltzer-2003">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:42:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moresco-2004">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:36:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mori-2004">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 12:47:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mortimer-2004">
<DESCRIPTION>
<P>Computer generated randomisation list was prepared and kept outside the study centre. Quote: Patient numbers were assigned in strict chronological order in each centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 16:16:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Naber-2005">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:38:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ozguven-2004">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:39:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Purdon-2000">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:40:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Riedel-2007">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:42:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:43:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sacchetti-2004">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-30 09:24:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shaw-2006">
<DESCRIPTION>
<P>Quote: Numbered containers were used to implement the random allocation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:46:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sikich-2004">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:45:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-2004">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:48:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sirota-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:49:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:50:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-2003a">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:52:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-2003b">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:48:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-2005">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:48:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tollefson-2001">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:53:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tran-1997">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:54:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Nimwegen-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:56:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vanelle-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:57:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volavka-2002">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:59:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Voruganti-2007">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 16:00:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wagner-2005">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 22:51:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 16:01:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 16:02:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wynn-2007">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-08-03 07:51:05 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-12 16:05:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>Single, rater-blind. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-12 16:05:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bai-2005">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bai-2005">
<DESCRIPTION>
<P>Single, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 12:56:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bitter-2004">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bitter-2004">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-12 16:04:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Breier-2005">
<DESCRIPTION>
<P>Double, no further details. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Breier-2005">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 12:58:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CN138003">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CN138003">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 13:08:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Canive-2000">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Canive-2000">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 13:08:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Conley-2001">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Conley-2001">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 13:12:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Conley-2003">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Conley-2003">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 13:17:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dollfus-2005">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dollfus-2005">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 13:19:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dolnak-2001">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dolnak-2001">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 13:24:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gureje-2003">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gureje-2003">
<DESCRIPTION>
<P>Double, double-dummy design. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 13:29:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jeste-2003">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jeste-2003">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 13:33:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Keefe-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keefe-2006">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 13:34:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinon-2006a">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kinon-2006a">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 13:36:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinon-2006b">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kinon-2006b">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 13:39:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krakowski-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Krakowski-2006">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 13:45:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumra-2007">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kumra-2007">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 13:46:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lecrubier-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lecrubier-2006">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 13:47:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 13:48:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McEvoy-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-2006">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 13:49:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McEvoy-2007">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-2007">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 13:52:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McQuade-2004">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-07-28 13:52:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McQuade-2004">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-12 16:10:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meltzer-2003">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meltzer-2003">
<DESCRIPTION>
<P>Single, rater-blind. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 14:00:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moresco-2004">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moresco-2004">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 14:01:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mori-2004">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mori-2004">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 14:02:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mortimer-2004">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mortimer-2004">
<DESCRIPTION>
<P>Double, identical capsules. Quote: "to permit dose adjustment whilst maintaining the double-blind, blister packs corresponding to a low and a high dosage were provided".<BR/>Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 14:11:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Naber-2005">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Naber-2005">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-12 16:11:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ozguven-2004">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ozguven-2004">
<DESCRIPTION>
<P>Single, rater blind. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 14:15:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Purdon-2000">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Purdon-2000">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-03 07:51:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Riedel-2007">
<DESCRIPTION>
<P>Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-12 16:04:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Riedel-2007">
<DESCRIPTION>
<P>Double, no further details. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-12 16:11:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Robinson-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-2006">
<DESCRIPTION>
<P>Single-blind, rater-blinded. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-12 16:11:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sacchetti-2004">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sacchetti-2004">
<DESCRIPTION>
<P>Single, rater-blind. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 14:18:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shaw-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shaw-2006">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 14:19:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sikich-2004">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sikich-2004">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 14:20:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Simpson-2004">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-2004">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-12 16:12:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sirota-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sirota-2006">
<DESCRIPTION>
<P>Single, rater-blind. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 14:21:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 14:22:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Svestka-2003a">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-2003a">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 14:22:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Svestka-2003b">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-2003b">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 14:23:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Svestka-2005">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-2005">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 14:24:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tollefson-2001">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tollefson-2001">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 14:25:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tran-1997">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tran-1997">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 14:25:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Nimwegen-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Nimwegen-2006">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 14:25:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vanelle-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vanelle-2006">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 14:26:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volavka-2002">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volavka-2002">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-12 16:14:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Voruganti-2007">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Voruganti-2007">
<DESCRIPTION>
<P>Single, rater-blind. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 14:27:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wagner-2005">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wagner-2005">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 14:29:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 14:30:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-28 14:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wynn-2007">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-15 16:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wynn-2007">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-02-17 13:50:42 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-10 13:37:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>Three subjects in the control groups left the study early (5.4%). Reason for drop-out were not assessed, only completer data were presented. But due to the very low rate we do not think that there was a risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-17 12:52:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bai-2005">
<DESCRIPTION>
<P>The rate of leaving the study early was low (5%), data on reasons for drop-out were provided. All data were analysed on an intent to treat basis with the last-observation- carried forward-method. This method is not perfect, but due to the very low attrition, the risk of bias was low.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-16 12:38:48 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bitter-2004">
<DESCRIPTION>
<P>The attrition was high (42.1%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption might be wrong, especially in case of high attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-16 12:39:32 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Breier-2005">
<DESCRIPTION>
<P>The attrition was high (48.9%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. Additionally mixed models analysis was performed but it is unclear whether any statistical method can account for such high numbers of leaving the study early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-08 17:51:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-CN138003">
<DESCRIPTION>
<P>The attrition rate within the first six weeks was 25% overall, but data on reason for leaving the study early were not available. The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-10 11:00:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Canive-2000">
<DESCRIPTION>
<P>Data on leaving the study early were not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-15 16:14:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Conley-2001">
<DESCRIPTION>
<P>The attrition rate was possibly acceptable (25.5%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. It is unclear whether this led to bias.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-15 16:19:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Conley-2003">
<DESCRIPTION>
<P>The attrition rate was possibly acceptable (23%).<BR/>The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. It is unclear whether this led to bias.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-15 16:16:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dollfus-2005">
<DESCRIPTION>
<P>Data on leaving the study early were not published separately for each group, the overall attrition was possibly acceptable (25%). (Data on both treatment attrition rates were provided from contact of the author).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-29 21:51:25 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dolnak-2001">
<DESCRIPTION>
<P>No data on leaving the study early available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-15 16:17:09 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gureje-2003">
<DESCRIPTION>
<P>The overall attrition was high (55.4%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-15 16:18:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jeste-2003">
<DESCRIPTION>
<P>Number of participants leaving the study early was possibly acceptable (23.9%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. It is unclear whether this led to bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-16 12:48:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Keefe-2006">
<DESCRIPTION>
<P>The attrition rate was high (62.8%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-16 12:48:16 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kinon-2006a">
<DESCRIPTION>
<P>The attrition rate was high (62.7%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-12 15:17:46 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kinon-2006b">
<DESCRIPTION>
<P>The drop-out rate was high (54.9%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong, especially in case of high attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-15 16:21:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Krakowski-2006">
<DESCRIPTION>
<P>Number of participants leaving the study early was considerable (33.3%).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-16 12:48:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kumra-2007">
<DESCRIPTION>
<P>Number of participants leaving the study early were moderate (28.2%). The statistical analysis was based on mixed effects model. It is unclear whether this led to bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-16 12:54:20 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lecrubier-2006">
<DESCRIPTION>
<P>The rate of leaving the study early was high (57.6%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong and poses problem given the high attrition.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-12 15:19:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>The attrition rate was high (75%), and it is unclear whether any statistical method can account for such a high drop-out rate. Efficacy outcomes were evaluated based on mixed effects model analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-15 16:23:36 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McEvoy-2006">
<DESCRIPTION>
<P>The overall attrition rate was high (74%). It is doubtful that the validity of the results was unaffected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-17 13:25:43 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McEvoy-2007">
<DESCRIPTION>
<P>The attrition rate was high (70.3.%). Analysis was based on mixed effects model and secondary on last-observation-carried forward and observed cases. It is unclear whether any statistical method can account for such a high drop-out rate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-12 14:20:42 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McQuade-2004">
<DESCRIPTION>
<P>Quote: " Because of the high number of participants who discontinued the study<BR/>(72%) results of analysis by time point are described on the observed case (OC) basis (except for primary outcome), as the last observation- carried-forward analysis would have included a large amount of data carried forward from patients who discontinued the study."<BR/>For the reason of the high number of participants leaving the study early, the validity is definitely limited.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-15 16:24:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meltzer-2003">
<DESCRIPTION>
<P>The number of participants leaving the study early was high (38.7%). It is unclear whether any statistical method can account for such a high attrition rate.<BR/>Quote: "every effort was made to follow patients for study end points for the two years of evaluation, even after they formally discontinued using the study drug. Such information from retrieved drop-outs was included in the intent-to- treat analysis". Numbers on "retrieved drop-outs" were not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-16 12:58:15 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moresco-2004">
<DESCRIPTION>
<P>Numbers of leaving the study early were high (34.8%). The statistical analysis was based on completer data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-12 15:20:30 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mori-2004">
<DESCRIPTION>
<P>There were no data on attrition available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-16 12:58:49 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mortimer-2004">
<DESCRIPTION>
<P>The rate of leaving the study early was high (35.8%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. It is unclear whether this led to bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-16 12:59:16 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Naber-2005">
<DESCRIPTION>
<P>The attrition rate was high (62.3%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong, given the high number of attrition. Completer data were also available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-16 13:00:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ozguven-2004">
<DESCRIPTION>
<P>The attrition rate was rather low (13%), there was no further explanation on the statistical method that was used, but due to the low attrition the risk of bias is rather low.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-16 13:00:32 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Purdon-2000">
<DESCRIPTION>
<P>The attrition rate was high (54.8%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-17 13:37:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Riedel-2007">
<DESCRIPTION>
<P>The attrition rate was high (61.5%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong, given the high number of attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-16 13:01:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-2006">
<DESCRIPTION>
<P>Data on leaving the study early is incomplete. The overall attrition is moderate (28%). Eight patients were excluded from the analysis for various reasons. Analysis was based on mixed effects model.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-16 13:01:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sacchetti-2004">
<DESCRIPTION>
<P>The attrition rate was moderate (18.6%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. It is unclear whether this led to bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-09 13:21:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shaw-2006">
<DESCRIPTION>
<P>Only one subject left the study early (4%). The attrition rate was very low, therefore a risk of bias is rather not expected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-16 13:03:10 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sikich-2004">
<DESCRIPTION>
<P>The attrition rate was rather high (33.3%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. It is unclear whether this led to bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-16 13:03:45 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Simpson-2004">
<DESCRIPTION>
<P>The overall attrition rate was high (42.8%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-15 16:31:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sirota-2006">
<DESCRIPTION>
<P>The attrition rate was quite low (12%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong. For the reason of low attrition the risk of bias can be considered as low.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-17 13:46:53 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>The attrition rate was high (72.5%). Efficacy data analysis was based on mixed effect models. It is unclear whether any statistical method can account for such high rates of leaving the study early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-06 15:50:52 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Svestka-2003a">
<DESCRIPTION>
<P>Data on subjects leaving the study early were not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-06 15:52:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Svestka-2003b">
<DESCRIPTION>
<P>Data on the overall attrition rate were not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-30 10:14:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Svestka-2005">
<DESCRIPTION>
<P>Data on subjects leaving the study early were not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-17 13:50:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tollefson-2001">
<DESCRIPTION>
<P>The attrition rate was high (40.1%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong, given the rather high number of attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-17 13:50:42 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tran-1997">
<DESCRIPTION>
<P>The attrition rate was high (47.5 %). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong, given the rather high number of attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-06 15:54:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Van-Nimwegen-2006">
<DESCRIPTION>
<P>Data on leaving the study early were not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-12 14:31:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vanelle-2006">
<DESCRIPTION>
<P>The rate of participants leaving the study early was 16.5% and reasons for leaving the study early were provided. The analysis was based on the last-observation carried forward method with two people being excluded due to no exploitable outcome data. In addition there was a per protocol population which excluded subjects with a major protocol deviation. As two different methods with similar results were applied and as the overall attrition was low we do not think that there was a bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-15 16:37:21 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Volavka-2002">
<DESCRIPTION>
<P>The attrition rate was high (41.7%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong, given the rather high number of attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-15 16:37:55 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Voruganti-2007">
<DESCRIPTION>
<P>There is a discrepancy between the abstract in the text. While according to the abstract there were fewer participants leaving the study early in the olanzapine group, this finding was no longer mentioned in the text according to which the overall attrition was only 1.2%.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-12 14:33:57 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wagner-2005">
<DESCRIPTION>
<P>The rate of participants leaving the study early was high (50%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change of his condition if he had remained in the study. This assumption can obviously be wrong and lead to bias in cases of high attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-30 10:47:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>Data on leaving the study early were not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-06 16:01:17 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>Data on leaving the study early were not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-06 16:02:23 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wynn-2007">
<DESCRIPTION>
<P>Data on leaving the study early were not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-02-17 13:59:21 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 12:17:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>Probably free of bias. The study focused on serum leptin and triglyceride levels which were adequately described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:02:54 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bai-2005">
<DESCRIPTION>
<P>The study is only available as an abstract. Data on BPRS and EPS scales were not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-16 12:39:01 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bitter-2004">
<DESCRIPTION>
<P>Only those adverse events that occurred in at least 5% of the participants were reported. This procedure can miss rare, but important adverse events.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-16 12:39:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Breier-2005">
<DESCRIPTION>
<P>Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 16:11:01 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-CN138003">
<DESCRIPTION>
<P>Data for the predefined primary outcome are available but secondary outcome measures like 30% PANSS total reduction are missing in the six weeks interim report. Treatment emergent adverse events were hardly addressed in the interim report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-29 21:19:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Canive-2000">
<DESCRIPTION>
<P>Data were only presented as a poster, data on primary outcomes were missing.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-15 06:26:11 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Conley-2001">
<DESCRIPTION>
<P>Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-16 12:45:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Conley-2003">
<DESCRIPTION>
<P>Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:23:09 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dollfus-2005">
<DESCRIPTION>
<P>Data on efficacy outcomes were incompletely reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-29 21:51:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dolnak-2001">
<DESCRIPTION>
<P>Insufficient data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-16 12:46:14 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gureje-2003">
<DESCRIPTION>
<P>Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-16 12:47:41 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jeste-2003">
<DESCRIPTION>
<P>Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-16 12:47:59 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Keefe-2006">
<DESCRIPTION>
<P>Only those adverse events that occurred in at least 10% of the participants were reported. This procedure can miss rare, but important adverse events.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-29 22:38:55 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kinon-2006a">
<DESCRIPTION>
<P>Secondary outcomes were not fully reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 12:22:25 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kinon-2006b">
<DESCRIPTION>
<P>Numbers of participants with antiparkinson medication or leukopenia were not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-07 12:33:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Krakowski-2006">
<DESCRIPTION>
<P>Data on adverse effects or use of antiparkinson medication were not presented. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 16:22:21 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kumra-2007">
<DESCRIPTION>
<P>Data on adverse effects were incompletely reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 16:22:42 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lecrubier-2006">
<DESCRIPTION>
<P>Only those adverse events were reported that occurred with an incidence of at least 10%, therefore rare but important side effects may have been missed by this procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 12:25:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>There was no evidence of selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 12:27:10 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McEvoy-2006">
<DESCRIPTION>
<P>Due to small numbers and the very high attrition only data on 26 weeks treatment (rather than 52 weeks) were presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 12:07:49 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McEvoy-2007">
<DESCRIPTION>
<P>Adverse events were presented only in case of moderate or worse severity.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 16:24:16 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McQuade-2004">
<DESCRIPTION>
<P>Although inclusion criteria required participants in acute relapse, no data on the PANSS positive subscore were available. Data on use of antiparkinson medication were missing.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 12:39:01 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Meltzer-2003">
<DESCRIPTION>
<P>Data on ESRS scales were not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-29 23:23:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moresco-2004">
<DESCRIPTION>
<P>Data on EPS scales were incompletely reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 13:26:42 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mori-2004">
<DESCRIPTION>
<P>Adverse events were not reported. Numbers on use of antiparkinson medication have not been presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-16 12:59:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mortimer-2004">
<DESCRIPTION>
<P>Only those adverse events that occurred in at least 5% of the participants were reported. This procedure can miss rare, but important adverse events.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-17 13:33:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Naber-2005">
<DESCRIPTION>
<P>Adverse effects data were not fully addressed (data on non fastening blood glucose level were not presented).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:38:51 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ozguven-2004">
<DESCRIPTION>
<P>The data were only published as an abstract. Data was only available in percent change.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 16:27:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Purdon-2000">
<DESCRIPTION>
<P>The study focused on neuropsychological changes, data for efficacy and EPS scales were also presented, probably ok.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 12:48:20 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Riedel-2007">
<DESCRIPTION>
<P>Data on global state have not been presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:42:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Robinson-2006">
<DESCRIPTION>
<P>The study included first episode schizophrenic patients but data on PANSS change were not presented.<BR/>Available data for adverse effects were incomplete. Data on weight gain were missing.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 12:50:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sacchetti-2004">
<DESCRIPTION>
<P>Efficacy data (PANSS) were only presented as per cent change, without indications of standard deviations, standard errors, p-values or ranges. Only interim data after half the patients had been recruited have been presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-30 09:33:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shaw-2006">
<DESCRIPTION>
<P>Review authors do not believe this will introduce bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 16:29:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sikich-2004">
<DESCRIPTION>
<P>No evidence for selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 16:30:43 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Simpson-2004">
<DESCRIPTION>
<P>The study focused on acutely ill schizophrenic or schizoaffective patients but data on positive symptoms were not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 16:31:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sirota-2006">
<DESCRIPTION>
<P>Efficacy data (PANSS, SANS) were only presented as median change. There were no data on EPS and cardiac effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:49:41 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>Use of antiparkinson medication was permitted but data on this was not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 11:16:02 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Svestka-2003a">
<DESCRIPTION>
<P>Allowed study medication dose ranges were not indicated. A publication was not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:52:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Svestka-2003b">
<DESCRIPTION>
<P>For some metabolic parameters there were no data available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 11:16:13 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Svestka-2005">
<DESCRIPTION>
<P>Allowed study medication dose ranges were not indicated. A publication was not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-16 13:10:33 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tollefson-2001">
<DESCRIPTION>
<P>Adverse events had to occur with an incidence of more than 5% or with a statistically significant difference of p&lt;0.05 for being reported. Important side effects may have been missed by this procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-17 13:50:45 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tran-1997">
<DESCRIPTION>
<P>Adverse effects were only reported in the case of a significant difference between groups, therefore important side effects may have been missed by this procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:54:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Van-Nimwegen-2006">
<DESCRIPTION>
<P>Outcome reporting was incomplete, standard deviation values were not published.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:56:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vanelle-2006">
<DESCRIPTION>
<P>Data on extrapyramidal symptoms were not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:57:42 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Volavka-2002">
<DESCRIPTION>
<P>Some outcomes were reported on subgroup from the entire sample. Quality of life scale data is not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 16:37:42 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Voruganti-2007">
<DESCRIPTION>
<P>Use of antiparkinson medication was permitted but data were not presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 16:38:14 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wagner-2005">
<DESCRIPTION>
<P>Additional treatment with biperiden up to 4mg/day was permitted, but data on use of antiparkinson medication was not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 16:38:24 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>Data were not available for all of the predefined adverse effect outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 16:40:25 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>Standard deviations for the primary outcome were not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-17 13:59:21 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wynn-2007">
<DESCRIPTION>
<P>Efficacy outcomes as change of PANSS score were not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-02-17 14:20:23 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-15 06:27:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>Data on the allowed dose range have not been presented. Furthermore, the pre-study treatment was quite heterogeneous as 19 participants had never taken any psychotropic drugs while most other participants had a long history of previous treatment. Sponsorship was neutral.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:02:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bai-2005">
<DESCRIPTION>
<P>Insufficient data to judge on baseline imbalance or industry sponsoring.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 10:41:46 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bitter-2004">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of olanzapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 10:42:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Breier-2005">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of olanzapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 14:13:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-CN138003">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of aripiprazole.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-29 21:20:53 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Canive-2000">
<DESCRIPTION>
<P>The study was sponsored by the manufacturers of olanzapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 16:14:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Conley-2001">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of risperidone. Total number of participants was very low (n=13), which may limit the validity of results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-14 17:54:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Conley-2003">
<DESCRIPTION>
<P>The fixed dose of olanzapine was rather high (50mg/day), and the total number of participants were rather low (N=13). The study had a neutral sponsor. <BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:23:09 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dollfus-2005">
<DESCRIPTION>
<P>The study was sponsored by the manufacturers of olanzapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-14 19:55:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dolnak-2001">
<DESCRIPTION>
<P>Insufficient data. Sponsorship unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 10:43:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gureje-2003">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of olanzapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-11 10:35:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jeste-2003">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of risperidone. The mean age of included subjects was about 71 years. Probably due to this reason the upper dose range limit of risperidone was rather low (3mg/day) compared with olanzapine (20mg/day).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:26:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Keefe-2006">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of olanzapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 10:43:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kinon-2006a">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of olanzapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:27:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kinon-2006b">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of olanzapine.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-17 13:16:00 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Krakowski-2006">
<DESCRIPTION>
<P>There was no wash-out period, pre study antipsychotic medication was gradually discontinued during the first six weeks leading to an overlap of medications. Sponsorship was neutral.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-14 19:52:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kumra-2007">
<DESCRIPTION>
<P>The age range of participants included was 10 to 18 years. Sponsorship was neutral.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 14:19:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lecrubier-2006">
<DESCRIPTION>
<P>The study was industry sponsored by the manufacturer of olanzapine and one of the authors is employee of that company. A fixed dose regimen was used where it might be difficult to decide which comparator doses are appropriate.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-17 13:23:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>Dose ranges were quite different, the upper dose range of olanzapine was 30 mg whereas risperidone could only be titrated up to <BR/>6mg /day. There was no wash-out period. An overlap in the administration of formerly given antipsychotics was permitted for the first four weeks after randomisation.<BR/>Allocation to ziprasidone treatment was not possible from the start of the study due to later availability of ziprasidone. Sponsorship was neutral.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-14 19:49:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-2006">
<DESCRIPTION>
<P>Dose ranges were quite different, the upper dose range of olanzapine was 30 mg whereas risperidone could only be titrated up to 6mg /day. Patients had a history of former inefficacy to one of the medications. It was excluded that the same medication could be given again but still this might implicate a risk of bias due to baseline imbalance in terms of former treatment. There was no wash out period. Sponsorship was neutral.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 10:45:51 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McEvoy-2007">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of quetiapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:35:23 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McQuade-2004">
<DESCRIPTION>
<P>The study was industry sponsored by the manufacturer of aripiprazole.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-14 19:47:51 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Meltzer-2003">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of clozapine.<BR/>Quote: "patients were allowed to reenter the study if they desired".<BR/>Comment: The study is not free of other bias.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 10:46:33 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moresco-2004">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of olanzapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-14 19:46:01 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mori-2004">
<DESCRIPTION>
<P>There was no wash-out period. The previous antipsychotic treatment was gradually tapered over four weeks. Thus, during a period of 4 weeks the participants were on two drugs.<BR/>Sponsorship is not reported.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 12:48:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mortimer-2004">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of amisulpride.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 10:46:57 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Naber-2005">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of olanzapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-14 19:42:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ozguven-2004">
<DESCRIPTION>
<P>Unclear due to insufficient information.<BR/>Sponsorship: unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 10:47:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Purdon-2000">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of olanzapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:40:52 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Riedel-2007">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of olanzapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-14 19:41:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-2006">
<DESCRIPTION>
<P>Quote:" .. the study was designed to detect differences in our primary analysis at alpha= 0.05 with 80% power based upon 130 subjects, the stability analysis included only 47 subjects and therefore might lack adequate power".<BR/>Comment: risk of other bias is unclear.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:43:26 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sacchetti-2004">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of quetiapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-14 19:39:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shaw-2006">
<DESCRIPTION>
<P>Upper dose limit of clozapine was 500mg/day. The low age of included participants and the small number of included subjects also has to be taken into account. Sponsorship was neutral.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-17 14:20:23 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sikich-2004">
<DESCRIPTION>
<P>Quote: "....this ..study has a number of limitations including limited sample size, differences in the diagnosis of participants, use of co-comitant medication, variations in age and perpetual status".<BR/>Comment: Probably not free of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 16:30:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Simpson-2004">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of ziprasidone. Upper dose limit of olanzapine was 15 mg/day, which is below the maximum dose for this medication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 12:51:41 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sirota-2006">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of quetiapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:49:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>Patients had a history of former intolerance to atypical antipsychotic treatment but baseline data on this was not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-14 19:37:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-2003a">
<DESCRIPTION>
<P>Insufficient information. Sponsorship was neutral.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-14 19:37:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-2003b">
<DESCRIPTION>
<P>There was a certain baseline imbalance in terms of mean age, which was not statistically significant. Sponsorship was neutral.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-14 19:36:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-2005">
<DESCRIPTION>
<P>Insufficient information. Sponsorship was neutral.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 10:49:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tollefson-2001">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of olanzapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 10:49:26 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tran-1997">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of olanzapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-16 13:12:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Nimwegen-2006">
<DESCRIPTION>
<P>Additional usage of cannabis. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-12 14:31:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vanelle-2006">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of amisulpride.<BR/>Additionally there was a relatively high number of subjects (18) with major protocol deviations.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-17 13:53:54 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Volavka-2002">
<DESCRIPTION>
<P>Quote: "The olanzapine arm was added in November 1997 and required a modified randomisation procedure"... It entails the potential for a bias that could be manifested as a cohort effect."<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 15:59:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Voruganti-2007">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of quetiapine. There was no wash-out period.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 16:00:30 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wagner-2005">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of olanzapine.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 16:39:23 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>The sponsor was unclear. The upper dose range limit of clozapine was 400mg/day which was reached rather quickly (10 days), which could mean a disadvantage for clozapine in terms of side effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 10:50:53 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>Dose ranges were not indicated. The study was sponsored by the manufacturer of risperidone.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-10 10:51:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wynn-2007">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of risperidone.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES MODIFIED="2009-07-28 10:04:55 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-07-28 10:04:55 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-12-29 15:07:15 +0000" MODIFIED_BY="[Empty name]">Suggested design of future study</TITLE>
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Methods</P>
</TH>
<TD>
<P>Allocation: randomised - clearly described generation of sequence and concealment of allocation.<BR/>Blindness: double - described and tested.<BR/>Duration: 6 months minimum.</P>
</TD>
</TR>
<TR>
<TH>
<P>Participants</P>
</TH>
<TD>
<P>Diagnosis: schizophrenia (operational criteria).<BR/>N=2700.*<BR/>Age: any.<BR/>Sex: both.<BR/>History: any.</P>
</TD>
</TR>
<TR>
<TH>
<P>Interventions</P>
</TH>
<TD>
<P>1. Olanzapine: dose ~ 10-20 mg/day. N=300.<BR/>2. Amisulpride: dose ~ 400-800 mg/day. N=300.<BR/>3. Aripiprazole: dose ~ 10-30 mg/day. N=300.<BR/>4. Clozapine: dose ~ 300-800 mg/day. N=300.<BR/>5. Quetiapine: dose ~300-800 mg/day. N=300.<BR/>6. Risperidone: dose ~ 4-8 mg/day. N=300.<BR/>7. Sertindole: dose ~ 12-24 mg/day. N=300.<BR/>8. Ziprasidone: dose ~ 120-160 mg/day. N=300.<BR/>9. Zotepine: dose ~ 100-300 mg/day. N=300.</P>
</TD>
</TR>
<TR>
<TH>
<P>Outcomes</P>
</TH>
<TD>
<P>Leaving study early (any reason, adverse events, inefficacy).<BR/>Service outcomes: hospitalised, time in hospital, attending out patient clinics.<BR/>Global impression: CGI**, relapse.<BR/>Mental state: PANSS.<BR/>Adverse events: UKU.<BR/>Employment, family satisfaction, patient satisfaction.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* power calculation suggested 300/group would allow good chance of showing a 10% difference between groups for primary outcome.<BR/>
<BR/>** Primary outcome<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-02-17 14:17:25 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-02-17 14:13:45 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>OLANZAPINE versus AMISULPRIDE</NAME>
<DICH_OUTCOME CHI2="2.971685276475692" CI_END="1.14373202788064" CI_START="0.8184273198463011" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9675027329164126" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="147" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.058324282809071176" LOG_CI_START="-0.08701988191018883" LOG_EFFECT_SIZE="-0.014347799550558791" METHOD="MH" MODIFIED="2009-09-16 07:58:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3960115615849784" P_Q="0.0" P_Z="0.6987860113900174" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="394" TOTAL_2="330" WEIGHT="100.0" Z="0.3869597438715586">
<NAME>Global state: 1a. No clinically significant response (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2457865316576078" CI_START="0.6263334511568066" EFFECT_SIZE="0.8833333333333333" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="30" LOG_CI_END="0.09544363135558923" LOG_CI_START="-0.2031943929212984" LOG_EFFECT_SIZE="-0.0538753807828546" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1540" O_E="0.0" SE="0.1754214537423054" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="140" TOTAL_2="70" VAR="0.030772686433063794" WEIGHT="23.686723655478207"/>
<DICH_DATA CI_END="1.1423153962179045" CI_START="0.7344539407783004" EFFECT_SIZE="0.9159574468085107" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="90" LOG_CI_END="0.05778603028965075" LOG_CI_START="-0.13403543458173856" LOG_EFFECT_SIZE="-0.03812470214604389" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1541" O_E="0.0" SE="0.11267687799701906" STUDY_ID="STD-Mortimer-2004" TOTAL_1="188" TOTAL_2="189" VAR="0.012696078835155118" WEIGHT="57.411751229706326"/>
<DICH_DATA CI_END="1.9433064450394382" CI_START="0.6512740197155653" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.28854129102471043" LOG_CI_START="-0.18623624612994782" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1542" O_E="0.0" SE="0.27888667551135854" STUDY_ID="STD-Vanelle-2006" TOTAL_1="40" TOTAL_2="45" VAR="0.07777777777777778" WEIGHT="9.37162439584284"/>
<DICH_DATA CI_END="2.501131290156371" CI_START="0.8458982092085894" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" LOG_CI_END="0.39813648944897323" LOG_CI_START="-0.07268189445357374" LOG_EFFECT_SIZE="0.16272729749769974" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1543" O_E="0.0" SE="0.2765610492929436" STUDY_ID="STD-Wagner-2005" TOTAL_1="26" TOTAL_2="26" VAR="0.07648601398601398" WEIGHT="9.52990071897263"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.023826100262689" CI_END="1.4299956305082802" CI_START="0.8417929132695887" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0971600556748078" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="111" I2="33.85863030197888" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.15533471043775982" LOG_CI_START="-0.07479473473062821" LOG_EFFECT_SIZE="0.04026998785356575" METHOD="MH" MODIFIED="2009-09-16 07:58:40 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.22048784430265078" P_Q="0.0" P_Z="0.492749688855045" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.019714070605730542" TOTALS="YES" TOTAL_1="254" TOTAL_2="260" WEIGHT="100.0" Z="0.685941999235275">
<NAME>Global State: 1b. No clinically important change (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.49791050443382817" CI_END="1.8211900323237815" CI_START="0.941734748358654" DF="1" EFFECT_SIZE="1.309609841442758" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="30" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.260355264676661" LOG_CI_START="-0.026071404580827014" LOG_EFFECT_SIZE="0.11714193004791701" MODIFIED="2009-09-15 13:30:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.48041972115293463" P_Z="0.10889921936471614" STUDIES="2" TAU2="0.0" TOTAL_1="66" TOTAL_2="71" WEIGHT="47.19810840341238" Z="1.6031605197142478">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.9433064450394382" CI_START="0.6512740197155653" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.28854129102471043" LOG_CI_START="-0.18623624612994782" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1544" O_E="0.0" SE="0.27888667551135854" STUDY_ID="STD-Vanelle-2006" TOTAL_1="40" TOTAL_2="45" VAR="0.07777777777777778" WEIGHT="18.743525458320935"/>
<DICH_DATA CI_END="2.1601017426983895" CI_START="0.9447778714262013" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="14" LOG_CI_END="0.3344742072860519" LOG_CI_START="-0.024670287314565588" LOG_EFFECT_SIZE="0.15490195998574316" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1545" O_E="0.0" SE="0.21096325392232293" STUDY_ID="STD-Wagner-2005" TOTAL_1="26" TOTAL_2="26" VAR="0.0445054945054945" WEIGHT="28.45458294509144"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.342947620344557E-31" CI_END="1.198152150772454" CI_START="0.7425968196839708" DF="0" EFFECT_SIZE="0.9432624113475178" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="81" I2="100.0" ID="CMP-001.02.02" LOG_CI_END="0.07851197168029542" LOG_CI_START="-0.1292469150568836" LOG_EFFECT_SIZE="-0.025367471688294094" MODIFIED="2009-09-15 13:31:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.632205210255514" STUDIES="1" TAU2="0.0" TOTAL_1="188" TOTAL_2="189" WEIGHT="52.80189159658763" Z="0.47862531099131567">
<NAME>medium term</NAME>
<DICH_DATA CI_END="1.198152150772454" CI_START="0.7425968196839708" EFFECT_SIZE="0.9432624113475178" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="81" LOG_CI_END="0.07851197168029542" LOG_CI_START="-0.1292469150568836" LOG_EFFECT_SIZE="-0.025367471688294094" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1546" O_E="0.0" SE="0.12203859849249449" STUDY_ID="STD-Mortimer-2004" TOTAL_1="188" TOTAL_2="189" VAR="0.014893419522012279" WEIGHT="52.80189159658763"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.506853122401755" CI_START="0.4579283777797231" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.3991288892038952" LOG_CI_START="-0.3392024424490088" LOG_EFFECT_SIZE="0.029963223377443202" METHOD="MH" MODIFIED="2009-09-16 07:58:48 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.8736059209284648" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="140" TOTAL_2="70" WEIGHT="100.0" Z="0.15907990400202948">
<NAME>Global State: 1c. Relapse - medium term (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.506853122401755" CI_START="0.4579283777797231" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.3991288892038952" LOG_CI_START="-0.3392024424490088" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2009-09-15 11:45:05 +0100" MODIFIED_BY="[Empty name]" ORDER="1338" O_E="0.0" SE="0.4336994790119514" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="140" TOTAL_2="70" VAR="0.18809523809523807" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.396228547194498" CI_END="1.0705068393941761" CI_START="0.7890139019905913" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9190455801852344" ESTIMABLE="YES" EVENTS_1="259" EVENTS_2="218" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.02958944631673614" LOG_CI_START="-0.1029153446934799" LOG_EFFECT_SIZE="-0.03666294918837188" METHOD="MH" MODIFIED="2009-09-15 13:30:46 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.581242765294889" P_Q="0.0" P_Z="0.27809411115492966" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1222" TOTAL_2="1030" WEIGHT="300.0" Z="1.0846107439343933">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.1673723247446377" CI_END="1.1119783048119134" CI_START="0.7922873805377316" DF="4" EFFECT_SIZE="0.9386194001480143" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="136" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.04609631405144879" LOG_CI_START="-0.10111726141087964" LOG_EFFECT_SIZE="-0.027510473679715427" MODIFIED="2009-09-15 13:30:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5302170598965461" P_Z="0.4638421819664681" STUDIES="5" TAU2="0.0" TOTAL_1="434" TOTAL_2="370" WEIGHT="100.0" Z="0.7325348554376653">
<NAME>due to any reason</NAME>
<DICH_DATA CI_END="21.18421544008581" CI_START="0.18881983197881402" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3260123844875458" LOG_CI_START="-0.7239523931595834" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1527" O_E="0.0" SE="1.2041594578792296" STUDY_ID="STD-Bai-2005" TOTAL_1="40" TOTAL_2="40" VAR="1.4500000000000002" WEIGHT="0.5157068776870748"/>
<DICH_DATA CI_END="1.24485500020694" CI_START="0.7645986046844944" EFFECT_SIZE="0.975609756097561" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="41" LOG_CI_END="0.09511876807644408" LOG_CI_START="-0.11656649885999035" LOG_EFFECT_SIZE="-0.010723865391773113" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1528" O_E="0.0" SE="0.12434497365743258" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="140" TOTAL_2="70" VAR="0.015461672473867602" WEIGHT="48.36313625903688"/>
<DICH_DATA CI_END="1.1537445476836277" CI_START="0.6706784534363586" EFFECT_SIZE="0.879654255319149" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="72" LOG_CI_END="0.06210966166863007" LOG_CI_START="-0.17348564580487502" LOG_EFFECT_SIZE="-0.05568799206812244" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1529" O_E="0.0" SE="0.13838984982551739" STUDY_ID="STD-Mortimer-2004" TOTAL_1="188" TOTAL_2="189" VAR="0.019151750534729256" WEIGHT="39.04473229693882"/>
<DICH_DATA CI_END="1.323086575951895" CI_START="0.1530512089538142" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.12158826310510455" LOG_CI_START="-0.8151632355544172" LOG_EFFECT_SIZE="-0.3467874862246563" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1530" O_E="0.0" SE="0.5502524673073059" STUDY_ID="STD-Vanelle-2006" TOTAL_1="40" TOTAL_2="45" VAR="0.30277777777777776" WEIGHT="2.4697155059876432"/>
<DICH_DATA CI_END="2.0157130460061565" CI_START="0.6752504349802944" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.3044287066394562" LOG_CI_START="-0.17053512737822976" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1531" O_E="0.0" SE="0.27899610721088536" STUDY_ID="STD-Wagner-2005" TOTAL_1="26" TOTAL_2="26" VAR="0.07783882783882784" WEIGHT="9.606709060349582"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9488359640064457" CI_END="1.355476555503061" CI_START="0.5204032874373398" DF="3" EFFECT_SIZE="0.8398776431885985" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="31" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.13209201036821658" LOG_CI_START="-0.28365996862200643" LOG_EFFECT_SIZE="-0.07578397912689491" MODIFIED="2009-09-15 13:30:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5830938925749884" P_Z="0.47489880707224175" STUDIES="4" TAU2="0.0" TOTAL_1="394" TOTAL_2="330" WEIGHT="99.99999999999999" Z="0.7145311493386409">
<NAME>due to adverse events</NAME>
<DICH_DATA CI_END="2.1936284501712042" CI_START="0.5515975141120933" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="10" LOG_CI_END="0.34116307004583823" LOG_CI_START="-0.25837769972938807" LOG_EFFECT_SIZE="0.04139268515822507" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1532" O_E="0.0" SE="0.35217321594064194" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="140" TOTAL_2="70" VAR="0.12402597402597401" WEIGHT="48.08739022719709"/>
<DICH_DATA CI_END="1.3487242211591652" CI_START="0.29271487158073495" EFFECT_SIZE="0.6283244680851063" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="16" LOG_CI_END="0.1299231568825761" LOG_CI_START="-0.5335552123752971" LOG_EFFECT_SIZE="-0.2018160277463605" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1533" O_E="0.0" SE="0.3897304783729706" STUDY_ID="STD-Mortimer-2004" TOTAL_1="188" TOTAL_2="189" VAR="0.1518898457728245" WEIGHT="39.265859945736366"/>
<DICH_DATA CI_END="4.538845420772668" CI_START="0.01109334575003539" EFFECT_SIZE="0.22439024390243903" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6569453922496556" LOG_CI_START="-1.9549374509980162" LOG_EFFECT_SIZE="-0.6489960293741802" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1534" O_E="0.0" SE="1.534232911152273" STUDY_ID="STD-Vanelle-2006" TOTAL_1="40" TOTAL_2="45" VAR="2.353870625662778" WEIGHT="2.533735434000719"/>
<DICH_DATA CI_END="4.504828095259613" CI_START="0.22198405329879073" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6536782229056234" LOG_CI_START="-0.6536782229056235" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1535" O_E="0.0" SE="0.7679476477883045" STUDY_ID="STD-Wagner-2005" TOTAL_1="26" TOTAL_2="26" VAR="0.5897435897435898" WEIGHT="10.113014393065814"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.651053419133051" CI_END="1.4039394400551246" CI_START="0.502755840041822" DF="3" EFFECT_SIZE="0.8401421025950071" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="51" I2="35.49848325416148" ID="CMP-001.04.03" LOG_CI_END="0.14734837459070335" LOG_CI_START="-0.298642875911317" LOG_EFFECT_SIZE="-0.07564725066030684" MODIFIED="2009-09-15 13:30:46 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.19920603258961733" P_Z="0.5061256595866923" STUDIES="4" TAU2="0.09087946465678483" TOTAL_1="394" TOTAL_2="330" WEIGHT="100.00000000000001" Z="0.6648824911106798">
<NAME>due to inefficacy</NAME>
<DICH_DATA CI_END="0.9975125237394143" CI_START="0.4285808776583243" EFFECT_SIZE="0.6538461538461539" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="26" LOG_CI_END="-0.001081643052966422" LOG_CI_START="-0.36796721013212164" LOG_EFFECT_SIZE="-0.18452442659254403" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1536" O_E="0.0" SE="0.21551039821514273" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="140" TOTAL_2="70" VAR="0.046444731738849394" WEIGHT="49.97822355081018"/>
<DICH_DATA CI_END="2.1829824742372015" CI_START="0.723398638062605" EFFECT_SIZE="1.2566489361702127" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="20" LOG_CI_END="0.33905024905195746" LOG_CI_START="-0.14062231321671612" LOG_EFFECT_SIZE="0.09921396791762066" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1537" O_E="0.0" SE="0.28176203749409623" STUDY_ID="STD-Mortimer-2004" TOTAL_1="188" TOTAL_2="189" VAR="0.0793898457728245" WEIGHT="40.30802361905187"/>
<DICH_DATA CI_END="3.011062075297681" CI_START="0.008531632913235922" EFFECT_SIZE="0.1602787456445993" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.47871970891075133" LOG_CI_START="-2.068967839015588" LOG_EFFECT_SIZE="-0.7951240650524183" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1538" O_E="0.0" SE="1.4965242769086855" STUDY_ID="STD-Vanelle-2006" TOTAL_1="40" TOTAL_2="45" VAR="2.239584911377064" WEIGHT="2.945000771939148"/>
<DICH_DATA CI_END="6.57367138033803" CI_START="0.15212199426199158" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8178079897862158" LOG_CI_START="-0.8178079897862158" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1539" O_E="0.0" SE="0.9607689228305228" STUDY_ID="STD-Wagner-2005" TOTAL_1="26" TOTAL_2="26" VAR="0.9230769230769231" WEIGHT="6.768752058198813"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.501131290156371" CI_START="0.8458982092085894" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.39813648944897323" LOG_CI_START="-0.07268189445357374" LOG_EFFECT_SIZE="0.16272729749769974" METHOD="MH" MODIFIED="2009-09-15 11:47:22 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.17547144605011544" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="1.3548308787493848">
<NAME>Mental State: 1a. General - no clinically important change - short term (less than 50% PANSS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.501131290156371" CI_START="0.8458982092085894" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" LOG_CI_END="0.39813648944897323" LOG_CI_START="-0.07268189445357374" LOG_EFFECT_SIZE="0.16272729749769974" MODIFIED="2009-09-15 11:47:22 +0100" MODIFIED_BY="[Empty name]" ORDER="1339" O_E="0.0" SE="0.2765610492929436" STUDY_ID="STD-Wagner-2005" TOTAL_1="26" TOTAL_2="26" VAR="0.07648601398601398" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="4.778519181484887" CI_END="2.9413460600931174" CI_START="-6.091254350686615" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.574954145296749" ESTIMABLE="YES" I2="37.21904451856205" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2009-09-15 13:31:17 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.18875234214658365" P_Q="0.692061331947785" P_Z="0.494296240116589" Q="0.15686311971933264" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="7.729543578864258" TOTALS="YES" TOTAL_1="383" TOTAL_2="318" UNITS="" WEIGHT="99.99999999999999" Z="0.6834916329077866">
<NAME>Mental State: 1b. General - average endpoint score (PANSS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.3062872844123175" CI_END="17.080960949869986" CI_START="-11.358259707713092" DF="1" EFFECT_SIZE="2.8613506210784463" ESTIMABLE="YES" I2="69.75459438402228" ID="CMP-001.06.01" MODIFIED="2009-09-15 13:31:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06901532012540612" P_Z="0.6932893863688379" STUDIES="2" TAU2="77.22335831390843" TOTAL_1="57" TOTAL_2="62" WEIGHT="39.90602136329389" Z="0.39439506672695734">
<NAME>short term</NAME>
<CONT_DATA CI_END="2.9341712761717513" CI_START="-8.79417127617175" EFFECT_SIZE="-2.9299999999999997" ESTIMABLE="YES" MEAN_1="-17.82" MEAN_2="-14.89" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1549" SD_1="12.47" SD_2="14.78" SE="2.9919790988138484" STUDY_ID="STD-Vanelle-2006" TOTAL_1="39" TOTAL_2="44" WEIGHT="31.82986366597944"/>
<CONT_DATA CI_END="26.87866682712316" CI_START="-2.9786668271231527" EFFECT_SIZE="11.950000000000003" ESTIMABLE="YES" MEAN_1="-33.33" MEAN_2="-45.28" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1550" SD_1="22.15" SD_2="23.53" SE="7.61680670914291" STUDY_ID="STD-Wagner-2005" TOTAL_1="18" TOTAL_2="18" WEIGHT="8.076157697314454"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.3153687773532365" CI_END="2.4808137498182106" CI_START="-7.541483346775273" DF="1" EFFECT_SIZE="-2.530334798478531" ESTIMABLE="YES" I2="23.975692808203675" ID="CMP-001.06.02" MODIFIED="2009-09-15 13:31:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.25142503713377884" P_Z="0.32233724253984175" STUDIES="2" TAU2="3.3041501651305696" TOTAL_1="326" TOTAL_2="256" WEIGHT="60.0939786367061" Z="0.9896663461577075">
<NAME>medium term</NAME>
<CONT_DATA CI_END="1.477748782685433" CI_START="-12.977748782685433" EFFECT_SIZE="-5.75" ESTIMABLE="YES" MEAN_1="-19.45" MEAN_2="-13.7" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1551" SD_1="24.77" SD_2="25.4" SE="3.6876946921968936" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="140" TOTAL_2="70" WEIGHT="24.894668410078065"/>
<CONT_DATA CI_END="4.815481416230663" CI_START="-5.815481416230663" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-27.3" MEAN_2="-26.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1552" SD_1="25.7" SD_2="26.6" SE="2.712030148593802" STUDY_ID="STD-Mortimer-2004" TOTAL_1="186" TOTAL_2="186" WEIGHT="35.199310226628036"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1423153962179045" CI_START="0.7344539407783004" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9159574468085107" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="90" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.05778603028965075" LOG_CI_START="-0.13403543458173856" LOG_EFFECT_SIZE="-0.03812470214604389" METHOD="MH" MODIFIED="2009-09-15 11:50:04 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.43592701050845417" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="188" TOTAL_2="189" WEIGHT="100.0" Z="0.7790894848776444">
<NAME>Mental State: 1c. General - no clinically important change - medium term (less than 50% BPRS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1423153962179045" CI_START="0.7344539407783004" EFFECT_SIZE="0.9159574468085107" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="90" LOG_CI_END="0.05778603028965075" LOG_CI_START="-0.13403543458173856" LOG_EFFECT_SIZE="-0.03812470214604389" MODIFIED="2009-09-15 11:49:46 +0100" MODIFIED_BY="[Empty name]" ORDER="1340" O_E="0.0" SE="0.11267687799701906" STUDY_ID="STD-Mortimer-2004" TOTAL_1="188" TOTAL_2="189" VAR="0.012696078835155118" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.7233247571016033" CI_END="0.8184842724255936" CI_START="-3.3395234535138636" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.260519590544135" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2009-09-15 13:31:29 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.4224595444398126" P_Q="0.9251170589522113" P_Z="0.23469769714583566" Q="0.008834130027671305" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="365" TOTAL_2="300" UNITS="" WEIGHT="100.00000000000001" Z="1.188344592945883">
<NAME>Mental State: 1d. General - average endpoint score (BPRS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.175196812404688" CI_START="-4.975196812404689" DF="0" EFFECT_SIZE="-1.4000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.01" MODIFIED="2009-09-15 13:31:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.44278662280198144" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="44" WEIGHT="33.815100592572534" Z="0.7674960910782664">
<NAME>short term</NAME>
<CONT_DATA CI_END="2.175196812404688" CI_START="-4.975196812404689" EFFECT_SIZE="-1.4000000000000004" ESTIMABLE="YES" MEAN_1="-11.49" MEAN_2="-10.09" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1554" SD_1="7.54" SD_2="9.07" SE="1.8241135248429994" STUDY_ID="STD-Vanelle-2006" TOTAL_1="39" TOTAL_2="44" WEIGHT="33.815100592572534"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.714490627073932" CI_END="2.0426503880759763" CI_START="-4.826017305710815" DF="1" EFFECT_SIZE="-1.3916834588174196" ESTIMABLE="YES" I2="41.67363856012039" ID="CMP-001.08.02" MODIFIED="2009-09-15 13:31:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.19040386399306497" P_Z="0.42706181036649804" STUDIES="2" TAU2="2.6259601497695866" TOTAL_1="326" TOTAL_2="256" WEIGHT="66.18489940742748" Z="0.7942295591413255">
<NAME>medium term</NAME>
<CONT_DATA CI_END="0.7905321537154091" CI_START="-7.690532153715408" EFFECT_SIZE="-3.4499999999999993" ESTIMABLE="YES" MEAN_1="-9.45" MEAN_2="-6.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1555" SD_1="14.33" SD_2="15.0" SE="2.163576569347286" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="140" TOTAL_2="70" WEIGHT="24.03642483536754"/>
<CONT_DATA CI_END="3.3023173298185515" CI_START="-3.1023173298185487" EFFECT_SIZE="0.10000000000000142" ESTIMABLE="YES" MEAN_1="-18.2" MEAN_2="-18.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1556" SD_1="15.3" SD_2="16.2" SE="1.6338653950164495" STUDY_ID="STD-Mortimer-2004" TOTAL_1="186" TOTAL_2="186" WEIGHT="42.14847457205993"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.7760973439810237" CI_START="0.7515657754617562" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4444444444444444" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.4434346906057972" LOG_CI_START="-0.12403300487077344" LOG_EFFECT_SIZE="0.15970084286751188" METHOD="MH" MODIFIED="2009-09-15 11:52:30 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.2699514796360025" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="1.1031743403759522">
<NAME>Mental State: 2a. Positive symptoms - no clinically important change - short term (less than 50% PANSS positive subscore reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.7760973439810237" CI_START="0.7515657754617562" EFFECT_SIZE="1.4444444444444444" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.4434346906057972" LOG_CI_START="-0.12403300487077344" LOG_EFFECT_SIZE="0.15970084286751188" MODIFIED="2009-09-15 11:52:30 +0100" MODIFIED_BY="[Empty name]" ORDER="1341" O_E="0.0" SE="0.3333333333333333" STUDY_ID="STD-Wagner-2005" TOTAL_1="26" TOTAL_2="26" VAR="0.1111111111111111" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="4.238030997960827" CI_END="0.5578421684565299" CI_START="-1.8845588186692632" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6633583251063667" ESTIMABLE="YES" I2="29.212410163033695" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2009-09-15 13:31:55 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.23688189061292508" P_Q="0.7949874461166035" P_Z="0.2870316465109407" Q="0.06751665930721984" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.45433934030696416" TOTALS="YES" TOTAL_1="383" TOTAL_2="318" UNITS="" WEIGHT="100.0" Z="1.064655994577952">
<NAME>Mental State: 2b. Positive symptoms - average endpoint score (PANSS positive, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.8142546029779028" CI_END="2.2716247051407157" CI_START="-2.5736115487065074" DF="1" EFFECT_SIZE="-0.15099342178289574" ESTIMABLE="YES" I2="44.88094458414998" ID="CMP-001.10.01" MODIFIED="2009-09-15 13:31:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.177998846242716" P_Z="0.9027740572971572" STUDIES="2" TAU2="1.587798057498058" TOTAL_1="57" TOTAL_2="62" WEIGHT="45.81044752585125" Z="0.12215778677952277">
<NAME>short term</NAME>
<CONT_DATA CI_END="0.5828139346745109" CI_START="-2.5628139346745114" EFFECT_SIZE="-0.9900000000000002" ESTIMABLE="YES" MEAN_1="-3.31" MEAN_2="-2.32" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1558" SD_1="3.15" SD_2="4.14" SE="0.802470834709549" STUDY_ID="STD-Vanelle-2006" TOTAL_1="39" TOTAL_2="44" WEIGHT="35.34738243847578"/>
<CONT_DATA CI_END="5.20665953290435" CI_START="-1.8666595329043503" EFFECT_SIZE="1.67" ESTIMABLE="YES" MEAN_1="-10.61" MEAN_2="-12.28" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1559" SD_1="5.98" SD_2="4.78" SE="1.8044512862486604" STUDY_ID="STD-Wagner-2005" TOTAL_1="18" TOTAL_2="18" WEIGHT="10.463065087375467"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.356259735675704" CI_END="1.1646004404405597" CI_START="-3.1207511177202694" DF="1" EFFECT_SIZE="-0.9780753386398549" ESTIMABLE="YES" I2="57.55985705399196" ID="CMP-001.10.02" MODIFIED="2009-09-15 13:31:55 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.12478120981811514" P_Z="0.3709623574283425" STUDIES="2" TAU2="1.3929485407066053" TOTAL_1="326" TOTAL_2="256" WEIGHT="54.189552474148755" Z="0.8946721928800914">
<NAME>medium term</NAME>
<CONT_DATA CI_END="0.03064715552728048" CI_START="-4.43064715552728" EFFECT_SIZE="-2.2" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="1.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1560" SD_1="6.6" SD_2="8.3" SE="1.13810619640072" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="140" TOTAL_2="70" WEIGHT="22.188746632937576"/>
<CONT_DATA CI_END="1.7073268705074673" CI_START="-1.7073268705074673" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-11.2" MEAN_2="-11.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1561" SD_1="8.3" SD_2="8.5" SE="0.8711011447019659" STUDY_ID="STD-Mortimer-2004" TOTAL_1="186" TOTAL_2="186" WEIGHT="32.00080584121118"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.8552737955948793" CI_END="0.68913822338847" CI_START="-1.1011430598802732" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.20600241824590163" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2009-09-15 13:32:12 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.6029814174207928" P_Q="0.6537204812989732" P_Z="0.6519501858053851" Q="0.20124166520387488" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="383" TOTAL_2="318" UNITS="" WEIGHT="100.0" Z="0.45105461835911426">
<NAME>Mental State: 3a. Negative symptoms - average endpoint score (PANSS negative, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.6047690247663782" CI_END="3.021821757020564" CI_START="-2.0498775984292474" DF="1" EFFECT_SIZE="0.4859720792956583" ESTIMABLE="YES" I2="37.68573641645534" ID="CMP-001.11.01" MODIFIED="2009-09-15 13:32:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2052287305131657" P_Z="0.7072076550242028" STUDIES="2" TAU2="1.6845712606837626" TOTAL_1="57" TOTAL_2="62" WEIGHT="42.36161804859517" Z="0.37560892559139364">
<NAME>short term</NAME>
<CONT_DATA CI_END="1.1881007331411906" CI_START="-1.708100733141191" EFFECT_SIZE="-0.26000000000000023" ESTIMABLE="YES" MEAN_1="-3.56" MEAN_2="-3.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1562" SD_1="3.1" SD_2="3.63" SE="0.7388404810310927" STUDY_ID="STD-Vanelle-2006" TOTAL_1="39" TOTAL_2="44" WEIGHT="38.21070093621269"/>
<CONT_DATA CI_END="7.1235871463623655" CI_START="-1.6635871463623646" EFFECT_SIZE="2.7300000000000004" ESTIMABLE="YES" MEAN_1="-6.83" MEAN_2="-9.56" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1563" SD_1="6.73" SD_2="6.72" SE="2.2416672862452676" STUDY_ID="STD-Wagner-2005" TOTAL_1="18" TOTAL_2="18" WEIGHT="4.150917112382482"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.04926310562462617" CI_END="0.7974124930089075" CI_START="-1.5607046796815034" DF="1" EFFECT_SIZE="-0.3816460933362979" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.02" MODIFIED="2009-09-15 13:32:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8243505225098879" P_Z="0.5258099465461684" STUDIES="2" TAU2="0.0" TOTAL_1="326" TOTAL_2="256" WEIGHT="57.63838195140483" Z="0.634415122744844">
<NAME>medium term</NAME>
<CONT_DATA CI_END="1.660103397402993" CI_START="-2.8601033974029924" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" MEAN_1="-7.6" MEAN_2="-7.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1564" SD_1="8.03" SD_2="7.8" SE="1.1531351673961359" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="140" TOTAL_2="70" WEIGHT="15.686495708525328"/>
<CONT_DATA CI_END="1.0820238232579964" CI_START="-1.682023823257996" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="-3.0" MEAN_2="-2.7" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1565" SD_1="6.8" SD_2="6.8" SE="0.7051271524166891" STUDY_ID="STD-Mortimer-2004" TOTAL_1="186" TOTAL_2="186" WEIGHT="41.9518862428795"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="5.069441234345766E-31" CI_END="1.2457865316576078" CI_START="0.6263334511568066" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8833333333333333" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="30" I2="100.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.09544363135558923" LOG_CI_START="-0.2031943929212984" LOG_EFFECT_SIZE="-0.0538753807828546" METHOD="MH" MODIFIED="2009-09-15 11:56:38 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.4794613430440192" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="140" TOTAL_2="70" WEIGHT="100.0" Z="0.7071691975156732">
<NAME>Mental State: 3b. Negative symptoms - no clinically important change - medium term (less than 20% SANS total plus 10% PANSS total reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2457865316576078" CI_START="0.6263334511568066" EFFECT_SIZE="0.8833333333333333" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="30" LOG_CI_END="0.09544363135558923" LOG_CI_START="-0.2031943929212984" LOG_EFFECT_SIZE="-0.0538753807828546" MODIFIED="2009-09-15 11:56:23 +0100" MODIFIED_BY="[Empty name]" ORDER="1342" O_E="0.0" SE="0.1754214537423054" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="140" TOTAL_2="70" VAR="0.030772686433063794" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.7893571246411785" CI_END="1.4309418577326751" CI_START="-1.4331805826424755" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.0011193624549001328" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2009-09-15 13:32:26 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.37429463486678793" P_Q="0.37429463486678793" P_Z="0.9987776456165687" Q="0.7893571246411785" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="156" TOTAL_2="87" UNITS="" WEIGHT="100.0" Z="0.0015319946286676462">
<NAME>Mental State: 3c. Negative symptoms - average endpoint score (SANS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="27.692283874226153" CI_START="-10.45228387422615" DF="0" EFFECT_SIZE="8.620000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.01" MODIFIED="2009-09-15 13:32:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.37570665501129685" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="17" WEIGHT="0.56379051378431" Z="0.8858346309309414">
<NAME>short term</NAME>
<CONT_DATA CI_END="27.692283874226153" CI_START="-10.45228387422615" EFFECT_SIZE="8.620000000000001" ESTIMABLE="YES" MEAN_1="-26.06" MEAN_2="-34.68" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1567" SD_1="24.46" SD_2="31.21" SE="9.730935886917257" STUDY_ID="STD-Wagner-2005" TOTAL_1="16" TOTAL_2="17" WEIGHT="0.56379051378431"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.386115283236928" CI_START="-1.4861152832369275" DF="0" EFFECT_SIZE="-0.04999999999999982" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.02" MODIFIED="2009-09-15 13:32:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9455958649136985" STUDIES="1" TAU2="0.0" TOTAL_1="140" TOTAL_2="70" WEIGHT="99.43620948621569" Z="0.06823839309482148">
<NAME>medium term</NAME>
<CONT_DATA CI_END="1.386115283236928" CI_START="-1.4861152832369275" EFFECT_SIZE="-0.04999999999999982" ESTIMABLE="YES" MEAN_1="-4.35" MEAN_2="-4.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1568" SD_1="5.21" SD_2="4.9" SE="0.7327253432026414" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="140" TOTAL_2="70" WEIGHT="99.43620948621569"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="10.54298344947703" CI_START="-10.942983449477028" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.14" MODIFIED="2010-02-17 14:12:46 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.9708930378838766" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="177" TOTAL_2="182" UNITS="" WEIGHT="100.0" Z="0.03648826219936993">
<NAME>General functioning: General - average endpoint score - medium term (SOFAS total - percent change, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.54298344947703" CI_START="-10.942983449477028" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" MEAN_1="-30.2" MEAN_2="-30.0" MODIFIED="2009-09-15 12:00:37 +0100" MODIFIED_BY="[Empty name]" ORDER="1343" SD_1="49.5" SD_2="54.3" SE="5.481214723442018" STUDY_ID="STD-Mortimer-2004" TOTAL_1="177" TOTAL_2="182" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.3558602874301315" CI_END="0.21948820318023998" CI_START="-0.22372431063147002" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.0021180537256150263" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.15" MODIFIED="2009-09-15 16:04:14 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.5508145884007354" P_Q="1.0" P_Z="0.9850542502359078" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="277" TOTAL_2="233" UNITS="" WEIGHT="99.99999999999999" Z="0.018732815027375036">
<NAME>Quality of Life: General - average endpoint score - medium term (QLS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.910456183599575" CI_START="-9.210456183599572" EFFECT_SIZE="-2.1499999999999986" ESTIMABLE="YES" MEAN_1="-52.85" MEAN_2="-50.7" MODIFIED="2009-09-15 12:01:34 +0100" MODIFIED_BY="[Empty name]" ORDER="1345" SD_1="24.61" SD_2="20.6" SE="3.602339756899387" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="107" TOTAL_2="58" WEIGHT="0.09851412677279199"/>
<CONT_DATA CI_END="0.22171549435765792" CI_START="-0.22171549435765792" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="-0.6" MODIFIED="2009-09-15 12:01:34 +0100" MODIFIED_BY="[Empty name]" ORDER="1344" SD_1="1.0" SD_2="1.1" SE="0.11312222882997924" STUDY_ID="STD-Mortimer-2004" TOTAL_1="170" TOTAL_2="175" WEIGHT="99.90148587322719"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3468114404098084" CI_START="0.7424944353722742" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.12930679682040805" LOG_CI_START="-0.12930679682040805" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2009-09-15 13:13:46 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="0.0">
<NAME>Cognitive Functioning: 1a. General - no clinically important change - short term (less than 50% Global Cognitive Index reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3468114404098084" CI_START="0.7424944353722742" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.12930679682040805" LOG_CI_START="-0.12930679682040805" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-15 13:13:46 +0100" MODIFIED_BY="[Empty name]" ORDER="1346" O_E="0.0" SE="0.15191090506255" STUDY_ID="STD-Wagner-2005" TOTAL_1="26" TOTAL_2="26" VAR="0.023076923076923078" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.34947124031163124" CI_START="-0.08947124031163123" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.13" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.17" MODIFIED="2009-09-15 13:15:22 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.24566191714618024" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="1.1609508272173545">
<NAME>Cognitive Functioning: 1b. General - average endpoint score - short term (global cognitive index, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.34947124031163124" CI_START="-0.08947124031163123" EFFECT_SIZE="0.13" ESTIMABLE="YES" MEAN_1="-0.12" MEAN_2="-0.25" MODIFIED="2009-09-15 13:15:22 +0100" MODIFIED_BY="[Empty name]" ORDER="1347" SD_1="0.41" SD_2="0.24" SE="0.11197718021493883" STUDY_ID="STD-Wagner-2005" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.18950163570055395" CI_END="1.14507009384313" CI_START="0.8243812624214734" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9715834135695578" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="131" I2="0.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.05883207221088941" LOG_CI_START="-0.08387188797414301" LOG_EFFECT_SIZE="-0.012519907881626817" METHOD="MH" MODIFIED="2009-09-15 13:16:24 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.6633317333382692" P_Q="0.0" P_Z="0.7309149302815576" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="228" TOTAL_2="234" WEIGHT="99.99999999999999" Z="0.34390872553124074">
<NAME>Adverse effects: 1. General - at least one adverse effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.178875553418487" CI_START="0.825564464280192" EFFECT_SIZE="0.9865281368065222" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="107" LOG_CI_END="0.07146796173951876" LOG_CI_START="-0.08324900915093333" LOG_EFFECT_SIZE="-0.0058905237057072755" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1574" O_E="0.0" SE="0.09088151456240914" STUDY_ID="STD-Mortimer-2004" TOTAL_1="188" TOTAL_2="189" VAR="0.008259449689157386" WEIGHT="85.0738608901533"/>
<DICH_DATA CI_END="1.3626369579802107" CI_START="0.582116084537111" EFFECT_SIZE="0.890625" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="24" LOG_CI_END="0.13438016387036825" LOG_CI_START="-0.23499040049315978" LOG_EFFECT_SIZE="-0.050305118311395766" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1575" O_E="0.0" SE="0.21697009792091826" STUDY_ID="STD-Vanelle-2006" TOTAL_1="40" TOTAL_2="45" VAR="0.047076023391812855" WEIGHT="14.926139109846687"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9701646013337413" CI_END="6.042609677359538" CI_START="0.25016228364615783" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2294848661413589" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="0.781224541883123" LOG_CI_START="-0.6017781672208389" LOG_EFFECT_SIZE="0.08972318733114207" METHOD="MH" MODIFIED="2009-09-15 13:33:13 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.6156465760200107" P_Q="0.0" P_Z="0.7992577437666916" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="516" TOTAL_2="448" WEIGHT="300.00000000000006" Z="0.25430783987561906">
<NAME>Adverse effects: 2. Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.856239391655999E-32" CI_END="8.173789011660682" CI_START="0.013737814914332598" DF="0" EFFECT_SIZE="0.3350970017636684" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="100.0" ID="CMP-001.19.01" LOG_CI_END="0.9124234231658697" LOG_CI_START="-1.8620823390460248" LOG_EFFECT_SIZE="-0.47482945794007764" MODIFIED="2009-09-15 13:32:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.5023114842884946" STUDIES="1" TAU2="0.0" TOTAL_1="188" TOTAL_2="189" WEIGHT="100.00000000000001" Z="0.6708572380972789">
<NAME>natural causes</NAME>
<DICH_DATA CI_END="8.173789011660682" CI_START="0.013737814914332598" EFFECT_SIZE="0.3350970017636684" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9124234231658697" LOG_CI_START="-1.8620823390460248" LOG_EFFECT_SIZE="-0.47482945794007764" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1580" O_E="0.0" SE="1.6297584187482894" STUDY_ID="STD-Mortimer-2004" TOTAL_1="188" TOTAL_2="189" VAR="2.6561125034809248" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.159371678319651" CI_START="0.15890535619211996" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-001.19.02" LOG_CI_END="1.1510439819771265" LOG_CI_START="-0.7988614638657641" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2009-09-15 13:33:08 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7233394513294846" STUDIES="1" TAU2="0.0" TOTAL_1="140" TOTAL_2="70" WEIGHT="100.00000000000001" Z="0.35399924286303697">
<NAME>suicide attempt</NAME>
<DICH_DATA CI_END="14.159371678319651" CI_START="0.15890535619211996" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1510439819771265" LOG_CI_START="-0.7988614638657641" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1581" O_E="0.0" SE="1.1453841110757395" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="140" TOTAL_2="70" VAR="1.311904761904762" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="73.56410110494616" CI_START="0.12364033422899336" DF="0" EFFECT_SIZE="3.015873015873016" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.19.03" LOG_CI_END="1.8666659326051946" LOG_CI_START="-0.9078398296067001" LOG_EFFECT_SIZE="0.4794130514992473" MODIFIED="2009-09-15 13:33:13 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.4981946294954601" STUDIES="1" TAU2="0.0" TOTAL_1="188" TOTAL_2="189" WEIGHT="100.00000000000001" Z="0.677333114570918">
<NAME>suicide</NAME>
<DICH_DATA CI_END="73.56410110494616" CI_START="0.12364033422899336" EFFECT_SIZE="3.015873015873016" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8666659326051946" LOG_CI_START="-0.9078398296067001" LOG_EFFECT_SIZE="0.4794130514992473" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1582" O_E="0.0" SE="1.6297584187482894" STUDY_ID="STD-Mortimer-2004" TOTAL_1="188" TOTAL_2="189" VAR="2.6561125034809248" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-09-15 13:17:12 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="188" TOTAL_2="189" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 3a. Cardiac effects - QTc interval of &gt;500 ms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1576" O_E="0.0" SE="0.0" STUDY_ID="STD-Mortimer-2004" TOTAL_1="188" TOTAL_2="189" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.019667570891277474" CI_END="0.5666557201541611" CI_START="-11.070466767074429" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.251905523460134" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.21" MODIFIED="2009-09-15 13:17:34 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.888469494287073" P_Q="1.0" P_Z="0.07687922449581426" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="146" TOTAL_2="157" UNITS="" WEIGHT="100.0" Z="1.7690877942525254">
<NAME>Adverse effects: 3b. Cardiac effects - QTc abnormalities - change from baseline in ms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.8007294962220044" CI_START="-11.800729496222004" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="3.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1577" SD_1="24.0" SD_2="27.2" SE="3.469823705876889" STUDY_ID="STD-Mortimer-2004" TOTAL_1="106" TOTAL_2="112" WEIGHT="73.20154005743264"/>
<CONT_DATA CI_END="5.299854557495155" CI_START="-17.179854557495155" EFFECT_SIZE="-5.94" ESTIMABLE="YES" MEAN_1="-7.65" MEAN_2="-1.71" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1578" SD_1="26.39" SD_2="26.39" SE="5.7347250491099295" STUDY_ID="STD-Vanelle-2006" TOTAL_1="40" TOTAL_2="45" WEIGHT="26.79845994256736"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.9127646721232853" CI_END="1.572965548946217" CI_START="0.4273698777836111" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8199012711363336" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="0.19671921082010815" LOG_CI_START="-0.3691960913749778" LOG_EFFECT_SIZE="-0.08623844027743478" METHOD="MH" MODIFIED="2009-09-15 13:21:47 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.3393820653360188" P_Q="0.0" P_Z="0.5502749486606957" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="328" TOTAL_2="259" WEIGHT="100.0" Z="0.5973481769129244">
<NAME>Adverse effects: 4a. Central nervous system - sedation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6699314304298207" CI_START="0.14970674570491374" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.22269863881384835" LOG_CI_START="-0.8247586301418107" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1602" O_E="0.0" SE="0.6152815847816581" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="140" TOTAL_2="70" VAR="0.3785714285714286" WEIGHT="29.189741214124776"/>
<DICH_DATA CI_END="2.180532261171802" CI_START="0.4634953626756344" EFFECT_SIZE="1.0053191489361701" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.3385625164830737" LOG_CI_START="-0.3339546066639452" LOG_EFFECT_SIZE="0.002303954909564255" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1603" O_E="0.0" SE="0.3950398871500081" STUDY_ID="STD-Mortimer-2004" TOTAL_1="188" TOTAL_2="189" VAR="0.15605651243949115" WEIGHT="70.81025878587522"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="36.61310703323739" CI_START="0.06232817293891549" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5106382978723405" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.23" LOG_CI_END="1.5636365852085996" LOG_CI_START="-1.2053156036418837" LOG_EFFECT_SIZE="0.17916049078335783" METHOD="MH" MODIFIED="2010-02-14 22:18:46 +0000" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="1.0" P_Q="0.0" P_Z="0.7997794995143178" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="140" TOTAL_2="70" WEIGHT="100.0" Z="0.2536324829311546">
<NAME>Adverse effects: 4b. Central nervous system - seizures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="36.61310703323739" CI_START="0.06232817293891549" EFFECT_SIZE="1.5106382978723405" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5636365852085996" LOG_CI_START="-1.2053156036418837" LOG_EFFECT_SIZE="0.17916049078335783" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1604" O_E="0.0" SE="1.6264962222651649" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="140" TOTAL_2="70" VAR="2.645489961042853" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.21869222272679" CI_END="1.2358632674607535" CI_START="0.6638952007167362" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9058055486743821" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="73" I2="28.690440550694262" I2_Q="0.0" ID="CMP-001.24" LOG_CI_END="0.09197042425432468" LOG_CI_START="-0.17790047084663618" LOG_EFFECT_SIZE="-0.042965023296155744" METHOD="MH" MODIFIED="2009-09-15 13:34:02 +0100" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.18961316371089532" P_Q="0.0" P_Z="0.5325780485805758" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.10551985061606133" TOTALS="SUB" TOTAL_1="1452" TOTAL_2="1106" WEIGHT="700.0" Z="0.6240754359515952">
<NAME>Adverse effects: 5a. Extrapyramidal effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.42838186376591303" CI_END="2.8104672941213433" CI_START="0.8236639041706558" DF="1" EFFECT_SIZE="1.5214731230028102" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="12" I2="0.0" ID="CMP-001.24.01" LOG_CI_END="0.44877853570073273" LOG_CI_START="-0.08424996590048756" LOG_EFFECT_SIZE="0.18226428490012256" MODIFIED="2009-09-15 13:33:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5127840328610186" P_Z="0.18012053900462097" STUDIES="2" TAU2="0.0" TOTAL_1="328" TOTAL_2="259" WEIGHT="100.0" Z="1.340383986969038">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="2.7157305513589867" CI_START="0.7217210849652187" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="10" LOG_CI_END="0.43388667803004394" LOG_CI_START="-0.141630606673568" LOG_EFFECT_SIZE="0.14612803567823798" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1583" O_E="0.0" SE="0.33806170189140666" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="140" TOTAL_2="70" VAR="0.1142857142857143" WEIGHT="85.77962053774662"/>
<DICH_DATA CI_END="12.793588538252463" CI_START="0.49373685703774645" EFFECT_SIZE="2.5132978723404253" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1069923790187173" LOG_CI_START="-0.30650445185551367" LOG_EFFECT_SIZE="0.40024396358160186" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1584" O_E="0.0" SE="0.830295035377681" STUDY_ID="STD-Mortimer-2004" TOTAL_1="188" TOTAL_2="189" VAR="0.6893898457728245" WEIGHT="14.220379462253382"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="36.61310703323739" CI_START="0.06232817293891549" DF="0" EFFECT_SIZE="1.5106382978723405" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.24.02" LOG_CI_END="1.5636365852085996" LOG_CI_START="-1.2053156036418837" LOG_EFFECT_SIZE="0.17916049078335783" MODIFIED="2009-09-15 13:33:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7997794995143178" STUDIES="1" TAU2="0.0" TOTAL_1="140" TOTAL_2="70" WEIGHT="100.0" Z="0.2536324829311546">
<NAME>dyskinesia</NAME>
<DICH_DATA CI_END="36.61310703323739" CI_START="0.06232817293891549" EFFECT_SIZE="1.5106382978723405" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5636365852085996" LOG_CI_START="-1.2053156036418837" LOG_EFFECT_SIZE="0.17916049078335783" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1585" O_E="0.0" SE="1.6264962222651649" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="140" TOTAL_2="70" VAR="2.645489961042853" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.1600147936018255" CI_START="0.009717369340833447" DF="0" EFFECT_SIZE="0.201058201058201" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.24.03" LOG_CI_END="0.6190948750421794" LOG_CI_START="-2.012451290155048" LOG_EFFECT_SIZE="-0.6966782075564342" MODIFIED="2009-09-15 13:33:35 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.29937915636241974" STUDIES="1" TAU2="0.0" TOTAL_1="188" TOTAL_2="189" WEIGHT="100.0" Z="1.0377657163557257">
<NAME>dystonia</NAME>
<DICH_DATA CI_END="4.160014793601826" CI_START="0.009717369340833455" EFFECT_SIZE="0.20105820105820105" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6190948750421795" LOG_CI_START="-2.0124512901550475" LOG_EFFECT_SIZE="-0.6966782075564341" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1586" O_E="0.0" SE="1.5457832438004555" STUDY_ID="STD-Mortimer-2004" TOTAL_1="188" TOTAL_2="189" VAR="2.389445836814258" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3864441734360406" CI_START="0.5008816494380692" DF="0" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="18" I2="0.0" ID="CMP-001.24.04" LOG_CI_END="0.14190238696343502" LOG_CI_START="-0.30026487905868454" LOG_EFFECT_SIZE="-0.07918124604762482" MODIFIED="2009-09-15 13:33:41 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.48270263742540387" STUDIES="1" TAU2="0.0" TOTAL_1="140" TOTAL_2="70" WEIGHT="100.0" Z="0.7019623677732199">
<NAME>extrapyramidal symptoms</NAME>
<DICH_DATA CI_END="1.3864441734360406" CI_START="0.5008816494380692" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="18" LOG_CI_END="0.14190238696343502" LOG_CI_START="-0.30026487905868454" LOG_EFFECT_SIZE="-0.07918124604762482" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1587" O_E="0.0" SE="0.2597312408246598" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="140" TOTAL_2="70" VAR="0.06746031746031744" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.5658618086147205" CI_END="2.396646333576057" CI_START="0.032129446774807044" DF="1" EFFECT_SIZE="0.2774940013994327" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" I2="61.026739762735374" ID="CMP-001.24.05" LOG_CI_END="0.3796039511347734" LOG_CI_START="-1.4930967523419472" LOG_EFFECT_SIZE="-0.5567464006035869" MODIFIED="2009-09-15 13:33:47 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.1091933956331258" P_Z="0.24386569583866757" STUDIES="2" TAU2="1.4814647528681986" TOTAL_1="328" TOTAL_2="259" WEIGHT="100.0" Z="1.1653788474362095">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="4.385739837778162" CI_START="0.12825658174128388" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.6420428657435847" LOG_CI_START="-0.8919203389601846" LOG_EFFECT_SIZE="-0.12493873660829993" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1588" O_E="0.0" SE="0.9010575796833197" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="140" TOTAL_2="70" VAR="0.8119047619047619" WEIGHT="52.76402483188486"/>
<DICH_DATA CI_END="0.7008551651958143" CI_START="0.011917749730803992" EFFECT_SIZE="0.0913926499032882" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.15437172162703244" LOG_CI_START="-1.9238057388702892" LOG_EFFECT_SIZE="-1.0390887302486607" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1589" O_E="0.0" SE="1.039374300568335" STUDY_ID="STD-Mortimer-2004" TOTAL_1="188" TOTAL_2="189" VAR="1.0802989366819153" WEIGHT="47.23597516811515"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9834864714608774E-32" CI_END="8.204394445819048" CI_START="0.3732755683828253" DF="0" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="100.0" ID="CMP-001.24.06" LOG_CI_END="0.914046531940672" LOG_CI_START="-0.42797043456808315" LOG_EFFECT_SIZE="0.24303804868629442" MODIFIED="2009-09-15 13:33:54 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.47776902065067883" STUDIES="1" TAU2="0.0" TOTAL_1="140" TOTAL_2="70" WEIGHT="100.0" Z="0.7098953801414876">
<NAME>tremor</NAME>
<DICH_DATA CI_END="8.204394445819048" CI_START="0.3732755683828253" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.914046531940672" LOG_CI_START="-0.42797043456808315" LOG_EFFECT_SIZE="0.24303804868629442" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1590" O_E="0.0" SE="0.7883074092183654" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="140" TOTAL_2="70" VAR="0.6214285714285714" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1705188175988241" CI_START="0.36913111685052113" DF="0" EFFECT_SIZE="0.6573240589198036" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="26" I2="0.0" ID="CMP-001.24.07" LOG_CI_END="0.06837839993237906" LOG_CI_START="-0.4328193432983386" LOG_EFFECT_SIZE="-0.18222047168297975" MODIFIED="2009-09-15 13:34:02 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.15410856433847514" STUDIES="1" TAU2="0.0" TOTAL_1="188" TOTAL_2="189" WEIGHT="100.0" Z="1.4251682756685335">
<NAME>use of antiparkinson medication</NAME>
<DICH_DATA CI_END="1.1705188175988241" CI_START="0.36913111685052113" EFFECT_SIZE="0.6573240589198036" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="26" LOG_CI_END="0.06837839993237906" LOG_CI_START="-0.4328193432983386" LOG_EFFECT_SIZE="-0.18222047168297975" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1591" O_E="0.0" SE="0.29440603534256504" STUDY_ID="STD-Mortimer-2004" TOTAL_1="188" TOTAL_2="189" VAR="0.08667491364612767" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.4057148810426274" CI_END="0.08526414584316602" CI_START="-0.07648242577249145" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.004390860035337286" ESTIMABLE="YES" I2="0.0" I2_Q="12.960892314904182" ID="CMP-001.25" MODIFIED="2009-09-15 15:50:53 +0100" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.49516842760172486" P_Q="0.28377772985576544" P_Z="0.9152550856021704" Q="1.1489088371838116" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="377" TOTAL_2="385" UNITS="" WEIGHT="200.0" Z="0.10641248768928188">
<NAME>Adverse effects: 5b. Extrapyramidal side effects- scale measured</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.1278952290562798" CI_START="-0.3278952290562799" DF="0" EFFECT_SIZE="0.4" ESTIMABLE="YES" I2="0.0" ID="CMP-001.25.01" MODIFIED="2009-09-15 15:50:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2814542399164566" STUDIES="1" TAU2="0.0" TOTAL_1="175" TOTAL_2="181" WEIGHT="100.0" Z="1.0770582942719151">
<NAME>abnormal involuntary movement: AIMS (high=poor)</NAME>
<CONT_DATA CI_END="1.1278952290562798" CI_START="-0.3278952290562799" EFFECT_SIZE="0.4" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="-0.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1592" SD_1="3.6" SD_2="3.4" SE="0.37138194109576733" STUDY_ID="STD-Mortimer-2004" TOTAL_1="175" TOTAL_2="181" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.2568060438588157" CI_END="0.0808233605688135" CI_START="-0.08193088794192156" DF="1" EFFECT_SIZE="-5.537636865540288E-4" ESTIMABLE="YES" I2="0.0" ID="CMP-001.25.02" MODIFIED="2009-09-15 15:50:53 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6123230248459987" P_Z="0.9893586332400979" STUDIES="2" TAU2="0.0" TOTAL_1="202" TOTAL_2="204" WEIGHT="99.99999999999999" Z="0.013337370809345541">
<NAME>extrapyramidal symptoms: SAS (high=poor)</NAME>
<CONT_DATA CI_END="0.08140530369587114" CI_START="-0.08140530369587114" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="-0.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1593" SD_1="0.4" SD_2="0.4" SE="0.04153408141067172" STUDY_ID="STD-Mortimer-2004" TOTAL_1="185" TOTAL_2="186" WEIGHT="99.93077953918073"/>
<CONT_DATA CI_END="2.293036858756264" CI_START="-3.893036858756264" EFFECT_SIZE="-0.8" ESTIMABLE="YES" MEAN_1="-0.24" MEAN_2="0.56" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1594" SD_1="1.71" SD_2="6.46" SE="1.5781090281014059" STUDY_ID="STD-Wagner-2005" TOTAL_1="17" TOTAL_2="18" WEIGHT="0.0692204608192536"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="51.743328089760745" CI_START="0.1225079075272778" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5177304964539005" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.26" LOG_CI_END="1.7138543587549895" LOG_CI_START="-0.9118358779555612" LOG_EFFECT_SIZE="0.40100924039971414" METHOD="MH" MODIFIED="2009-09-15 13:23:04 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="1.0" P_Q="0.0" P_Z="0.549391607196777" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="140" TOTAL_2="70" WEIGHT="100.0" Z="0.5986720426213376">
<NAME>Adverse effects: 6. Haematological - white blood cell count - leukopenia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="51.743328089760745" CI_START="0.1225079075272778" EFFECT_SIZE="2.517730496453901" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7138543587549895" LOG_CI_START="-0.9118358779555612" LOG_EFFECT_SIZE="0.4010092403997142" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1611" O_E="0.0" SE="1.5423434424200682" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="140" TOTAL_2="70" VAR="2.3788232943761862" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.225346343855358" CI_END="1.876967842449741" CI_START="0.15369661338125828" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5371066940655761" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.27" LOG_CI_END="0.2734568320426224" LOG_CI_START="-0.8133357018303508" LOG_EFFECT_SIZE="-0.2699394348938641" METHOD="MH" MODIFIED="2010-02-17 14:13:45 +0000" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.7469319254946829" P_Q="0.0" P_Z="0.33023603528897794" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="374" TOTAL_2="279" WEIGHT="300.0" Z="0.9736385812545667">
<NAME>Adverse effects: 7. Prolactin associated side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6074606521971875" CI_START="0.11790310522039571" DF="0" EFFECT_SIZE="0.6521739130434783" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-001.27.01" LOG_CI_END="0.5572016027934372" LOG_CI_START="-0.9284747567172604" LOG_EFFECT_SIZE="-0.18563657696191163" MODIFIED="2010-02-17 14:13:36 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6242765141433086" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="20" WEIGHT="100.00000000000001" Z="0.48979847155739153">
<NAME>amenorrhoea</NAME>
<DICH_DATA CI_END="3.6074606521971875" CI_START="0.11790310522039571" EFFECT_SIZE="0.6521739130434783" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.5572016027934372" LOG_CI_START="-0.9284747567172604" LOG_EFFECT_SIZE="-0.18563657696191163" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1598" O_E="0.0" SE="0.8726936477931707" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="46" TOTAL_2="20" VAR="0.7615942028985506" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.50697744708583" CI_START="0.006325099927881889" DF="0" EFFECT_SIZE="0.14893617021276595" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.27.02" LOG_CI_END="0.5449329729993615" LOG_CI_START="-2.198932608842283" LOG_EFFECT_SIZE="-0.8269998179214606" MODIFIED="2010-02-17 14:13:45 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.23741827782028113" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="20" WEIGHT="100.0" Z="1.1814644777601144">
<NAME>galactorrhoea</NAME>
<DICH_DATA CI_END="3.50697744708583" CI_START="0.006325099927881889" EFFECT_SIZE="0.14893617021276595" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.5449329729993615" LOG_CI_START="-2.198932608842283" LOG_EFFECT_SIZE="-0.8269998179214606" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1599" O_E="0.0" SE="1.6117602251274654" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="46" TOTAL_2="20" VAR="2.597771023302938" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.46598347223805237" CI_END="7.021826499255649" CI_START="0.07730553029414715" DF="1" EFFECT_SIZE="0.7367672774753592" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.27.03" LOG_CI_END="0.8464500943764446" LOG_CI_START="-1.1117894363492036" LOG_EFFECT_SIZE="-0.13266967098637944" MODIFIED="2009-09-15 13:35:03 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4948408193342725" P_Z="0.7905680794540322" STUDIES="2" TAU2="0.0" TOTAL_1="282" TOTAL_2="239" WEIGHT="100.0" Z="0.26557300360260416">
<NAME>sexual dysfunction</NAME>
<DICH_DATA CI_END="38.82380173726965" CI_START="0.06680940293800368" EFFECT_SIZE="1.6105263157894736" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5890980604875915" LOG_CI_START="-1.1751624094300894" LOG_EFFECT_SIZE="0.206967825528751" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1600" O_E="0.0" SE="1.6237402833396535" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="94" TOTAL_2="50" VAR="2.636532507739938" WEIGHT="50.18497363510565"/>
<DICH_DATA CI_END="8.173789011660682" CI_START="0.013737814914332598" EFFECT_SIZE="0.3350970017636684" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9124234231658697" LOG_CI_START="-1.8620823390460248" LOG_EFFECT_SIZE="-0.47482945794007764" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1601" O_E="0.0" SE="1.6297584187482894" STUDY_ID="STD-Mortimer-2004" TOTAL_1="188" TOTAL_2="189" VAR="2.6561125034809248" WEIGHT="49.815026364894344"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="9.566635634169851E-33" CI_END="12.318948543195413" CI_START="-5.478948543195413" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.4200000000000004" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-001.28" MODIFIED="2009-09-15 13:23:59 +0100" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.0" P_Q="1.0" P_Z="0.4513034964136825" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="45" UNITS="" WEIGHT="100.0" Z="0.7532436888010211">
<NAME>Adverse effects: 8a. Metabolic - cholesterol - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="12.318948543195413" CI_START="-5.478948543195413" EFFECT_SIZE="3.42" ESTIMABLE="YES" MEAN_1="2.88" MEAN_2="-0.54" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1579" SD_1="21.98" SD_2="19.6" SE="4.5403632992183445" STUDY_ID="STD-Vanelle-2006" TOTAL_1="40" TOTAL_2="45" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="73.56410110494616" CI_START="0.12364033422899336" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.015873015873016" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.29" LOG_CI_END="1.8666659326051946" LOG_CI_START="-0.9078398296067001" LOG_EFFECT_SIZE="0.4794130514992473" METHOD="MH" MODIFIED="2009-09-15 13:24:48 +0100" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="1.0" P_Q="0.0" P_Z="0.4981946294954601" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="188" TOTAL_2="189" WEIGHT="100.00000000000001" Z="0.677333114570918">
<NAME>Adverse effects: 8b. Metabolic - glucose - diabetes mellitus</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="73.56410110494616" CI_START="0.12364033422899336" EFFECT_SIZE="3.015873015873016" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8666659326051946" LOG_CI_START="-0.9078398296067001" LOG_EFFECT_SIZE="0.4794130514992473" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1595" O_E="0.0" SE="1.6297584187482894" STUDY_ID="STD-Mortimer-2004" TOTAL_1="188" TOTAL_2="189" VAR="2.6561125034809248" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.41534573143319004" CI_END="7.616226080017226" CI_START="6.988428474736233" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="7.30232727737673" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.30" MODIFIED="2009-09-15 13:25:25 +0100" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="0.5192686341207726" P_Q="1.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="198" TOTAL_2="208" UNITS="" WEIGHT="100.00000000000001" Z="45.59526301657949">
<NAME>Adverse effects: 8c. Metabolic - glucose - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.6139785851850315" CI_START="6.98602141481497" EFFECT_SIZE="7.300000000000001" ESTIMABLE="YES" MEAN_1="4.48" MEAN_2="-2.82" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1596" SD_1="1.71" SD_2="1.08" SE="0.16019609934756635" STUDY_ID="STD-Mortimer-2004" TOTAL_1="158" TOTAL_2="163" WEIGHT="99.94918608347757"/>
<CONT_DATA CI_END="25.805100049933998" CI_START="-2.0451000499339997" EFFECT_SIZE="11.879999999999999" ESTIMABLE="YES" MEAN_1="2.34" MEAN_2="-9.54" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1597" SD_1="36.7" SD_2="27.5" SE="7.1047734344984965" STUDY_ID="STD-Vanelle-2006" TOTAL_1="40" TOTAL_2="45" WEIGHT="0.050813916522445435"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.1677300192406332" CI_END="2.4994181865195246" CI_START="1.340033540507648" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8301104342883145" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-001.31" LOG_CI_END="0.3978389255556504" LOG_CI_START="0.12711566871935534" LOG_EFFECT_SIZE="0.2624772971375029" METHOD="MH" MODIFIED="2009-09-15 13:35:25 +0100" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="0.5577387302549248" P_Q="0.0" P_Z="1.443864211263856E-4" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="368" TOTAL_2="304" WEIGHT="100.0" Z="3.8005308827974598">
<NAME>Adverse effects: 8d. Metabolic - weight gain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.391460422723517" CI_START="1.2103288038278588" DF="0" EFFECT_SIZE="1.7013093289689034" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="39" I2="0.0" ID="CMP-001.31.01" LOG_CI_END="0.37866319794684483" LOG_CI_START="0.08290336890302258" LOG_EFFECT_SIZE="0.23078328342493373" MODIFIED="2009-09-15 13:35:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0022226638039664613" STUDIES="1" TAU2="0.0" TOTAL_1="188" TOTAL_2="189" WEIGHT="83.78625110107393" Z="3.0587448282555583">
<NAME>weight gain of 7% or more of total body weight</NAME>
<DICH_DATA CI_END="2.391460422723517" CI_START="1.2103288038278588" EFFECT_SIZE="1.7013093289689034" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="39" LOG_CI_END="0.37866319794684483" LOG_CI_START="0.08290336890302258" LOG_EFFECT_SIZE="0.23078328342493373" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1605" O_E="0.0" SE="0.17373078761510663" STUDY_ID="STD-Mortimer-2004" TOTAL_1="188" TOTAL_2="189" VAR="0.030182386565365288" WEIGHT="83.78625110107393"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.048825523207140904" CI_END="5.7866270324710065" CI_START="1.2305333684433897" DF="1" EFFECT_SIZE="2.6684522956560652" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="7" I2="0.0" ID="CMP-001.31.02" LOG_CI_END="0.7624254915289758" LOG_CI_START="0.0900933949866844" LOG_EFFECT_SIZE="0.42625944325783016" MODIFIED="2009-09-15 13:35:25 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8251197005030346" P_Z="0.012946428513808502" STUDIES="2" TAU2="0.0" TOTAL_1="180" TOTAL_2="115" WEIGHT="16.213748898926063" Z="2.4852395450166935">
<NAME>as "weight gain" reported adverse event</NAME>
<DICH_DATA CI_END="5.899214026770814" CI_START="1.1312712305107189" EFFECT_SIZE="2.5833333333333335" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="6" LOG_CI_END="0.7707941529006908" LOG_CI_START="0.053566742672604924" LOG_EFFECT_SIZE="0.41218044778664786" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1606" O_E="0.0" SE="0.42130293110091727" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="140" TOTAL_2="70" VAR="0.17749615975422425" WEIGHT="14.247457652588405"/>
<DICH_DATA CI_END="31.159791288670338" CI_START="0.3655552405494327" EFFECT_SIZE="3.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4935945400633526" LOG_CI_START="-0.43704698572926504" LOG_EFFECT_SIZE="0.5282737771670437" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1607" O_E="0.0" SE="1.1340683890802667" STUDY_ID="STD-Vanelle-2006" TOTAL_1="40" TOTAL_2="45" VAR="1.2861111111111112" WEIGHT="1.9662912463376576"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.0956040737675345" CI_END="2.936687664007056" CI_START="1.2891470935721192" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="2.1129173787895876" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.32" MODIFIED="2009-09-15 13:26:22 +0100" MODIFIED_BY="[Empty name]" NO="32" P_CHI2="0.5782194432211348" P_Q="1.0" P_Z="4.977436498819699E-7" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="367" TOTAL_2="304" UNITS="" WEIGHT="100.0" Z="5.027180561196273">
<NAME>Adverse effects: 8e. Metabolic - weight gain - change from baseline in kg</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.914133197173226" CI_START="0.5258668028267746" EFFECT_SIZE="2.22" ESTIMABLE="YES" MEAN_1="2.43" MEAN_2="0.21" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1608" SD_1="5.71" SD_2="5.99" SE="0.8643695550205678" STUDY_ID="STD-Lecrubier-2006" TOTAL_1="139" TOTAL_2="70" WEIGHT="23.64379248071511"/>
<CONT_DATA CI_END="3.3305235113809646" CI_START="1.269476488619035" EFFECT_SIZE="2.3" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="1.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1609" SD_1="5.3" SD_2="4.9" SE="0.5257869631838149" STUDY_ID="STD-Mortimer-2004" TOTAL_1="188" TOTAL_2="189" WEIGHT="63.89934920625971"/>
<CONT_DATA CI_END="3.284005417774667" CI_START="-1.3840054177746672" EFFECT_SIZE="0.95" ESTIMABLE="YES" MEAN_1="1.45" MEAN_2="0.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1610" SD_1="5.48" SD_2="5.48" SE="1.190840972683684" STUDY_ID="STD-Vanelle-2006" TOTAL_1="40" TOTAL_2="45" WEIGHT="12.45685831302518"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-09-15 15:50:00 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>OLANZAPINE versus ARIPIPRAZOLE</NAME>
<DICH_OUTCOME CHI2="0.5132372717696887" CI_END="1.0548151139508148" CI_START="0.8542967108019255" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9492760833141954" ESTIMABLE="YES" EVENTS_1="240" EVENTS_2="247" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.02317634396782529" LOG_CI_START="-0.06839126574674605" LOG_EFFECT_SIZE="-0.02260746088946038" METHOD="MH" MODIFIED="2009-09-15 13:29:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.47374087590794844" P_Q="0.0" P_Z="0.33314162720782325" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="509" TOTAL_2="511" WEIGHT="100.0" Z="0.9678053028436556">
<NAME>Global state: 1a. No clinically significant response (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2277301312110978" CI_START="0.8204867928412124" EFFECT_SIZE="1.003661475713756" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="124" LOG_CI_END="0.08910291452002977" LOG_CI_START="-0.0859284052779771" LOG_EFFECT_SIZE="0.0015872546210263581" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1616" O_E="0.0" SE="0.10281426366835568" STUDY_ID="STD-CN138003" TOTAL_1="348" TOTAL_2="355" VAR="0.010570772813666161" WEIGHT="27.368577163408354"/>
<DICH_DATA CI_END="1.0519553354951885" CI_START="0.8213985572250959" EFFECT_SIZE="0.9295561278594152" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="123" LOG_CI_END="0.021997300692466748" LOG_CI_START="-0.08544606431378805" LOG_EFFECT_SIZE="-0.031724381810660666" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1617" O_E="0.0" SE="0.06311276445790849" STUDY_ID="STD-McQuade-2004" TOTAL_1="161" TOTAL_2="156" VAR="0.0039832210375194375" WEIGHT="72.63142283659165"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5132372717696887" CI_END="1.0548151139508148" CI_START="0.8542967108019255" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9492760833141954" ESTIMABLE="YES" EVENTS_1="240" EVENTS_2="247" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.02317634396782529" LOG_CI_START="-0.06839126574674605" LOG_EFFECT_SIZE="-0.02260746088946038" METHOD="MH" MODIFIED="2009-09-15 13:36:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.47374087590794844" P_Q="0.0" P_Z="0.33314162720782325" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="509" TOTAL_2="511" WEIGHT="100.0" Z="0.9678053028436556">
<NAME>Global State: 1b. No clinically important change (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2277301312110978" CI_START="0.8204867928412124" DF="0" EFFECT_SIZE="1.003661475713756" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="124" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.08910291452002977" LOG_CI_START="-0.0859284052779771" LOG_EFFECT_SIZE="0.0015872546210263581" MODIFIED="2009-09-15 13:36:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9716431801368447" STUDIES="1" TAU2="0.0" TOTAL_1="348" TOTAL_2="355" WEIGHT="27.368577163408354" Z="0.03554748824492221">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.2277301312110978" CI_START="0.8204867928412124" EFFECT_SIZE="1.003661475713756" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="124" LOG_CI_END="0.08910291452002977" LOG_CI_START="-0.0859284052779771" LOG_EFFECT_SIZE="0.0015872546210263581" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1618" O_E="0.0" SE="0.10281426366835568" STUDY_ID="STD-CN138003" TOTAL_1="348" TOTAL_2="355" VAR="0.010570772813666161" WEIGHT="27.368577163408354"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0519553354951885" CI_START="0.8213985572250959" DF="0" EFFECT_SIZE="0.9295561278594152" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="123" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.021997300692466748" LOG_CI_START="-0.08544606431378805" LOG_EFFECT_SIZE="-0.031724381810660666" MODIFIED="2009-09-15 13:36:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.24710009670200905" STUDIES="1" TAU2="0.0" TOTAL_1="161" TOTAL_2="156" WEIGHT="72.63142283659165" Z="1.157421787321586">
<NAME>medium term</NAME>
<DICH_DATA CI_END="1.0519553354951885" CI_START="0.8213985572250959" EFFECT_SIZE="0.9295561278594152" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="123" LOG_CI_END="0.021997300692466748" LOG_CI_START="-0.08544606431378805" LOG_EFFECT_SIZE="-0.031724381810660666" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1619" O_E="0.0" SE="0.06311276445790849" STUDY_ID="STD-McQuade-2004" TOTAL_1="161" TOTAL_2="156" VAR="0.0039832210375194375" WEIGHT="72.63142283659165"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.145965831961868" CI_END="0.9942784534015278" CI_START="0.67599057089919" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8198309943809532" ESTIMABLE="YES" EVENTS_1="234" EVENTS_2="279" I2="41.701905959677376" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.0024919718999805327" LOG_CI_START="-0.17005936180246273" LOG_EFFECT_SIZE="-0.08627566685122161" METHOD="MH" MODIFIED="2009-09-15 13:36:33 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.1614158101543226" P_Q="0.0" P_Z="0.043564290139693776" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.015498950322262978" TOTALS="SUB" TOTAL_1="831" TOTAL_2="823" WEIGHT="300.0" Z="2.018259040365536">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.6419800289504987" CI_END="1.0922826481269452" CI_START="0.6892657880419166" DF="1" EFFECT_SIZE="0.867682580340144" ESTIMABLE="YES" EVENTS_1="190" EVENTS_2="219" I2="62.149600336031284" ID="CMP-002.03.01" LOG_CI_END="0.038335034557593524" LOG_CI_START="-0.1616132773354191" LOG_EFFECT_SIZE="-0.06163912138891278" MODIFIED="2009-09-15 13:36:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.10407381540120553" P_Z="0.22688697101042488" STUDIES="2" TAU2="0.017941995303235567" TOTAL_1="509" TOTAL_2="511" WEIGHT="99.99999999999999" Z="1.2084168835154188">
<NAME>due to any reason</NAME>
<DICH_DATA CI_END="0.9846977975209927" CI_START="0.5906119808876563" EFFECT_SIZE="0.7626101997544917" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="103" LOG_CI_END="-0.00669703346830764" LOG_CI_START="-0.22869774738004658" LOG_EFFECT_SIZE="-0.11769739042417712" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1612" O_E="0.0" SE="0.13040431827301252" STUDY_ID="STD-CN138003" TOTAL_1="348" TOTAL_2="355" VAR="0.01700528622424915" WEIGHT="39.47274137976547"/>
<DICH_DATA CI_END="1.0819102507919243" CI_START="0.8234687402324724" EFFECT_SIZE="0.9438852002570144" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="116" LOG_CI_END="0.034191235629646044" LOG_CI_START="-0.08435288247141974" LOG_EFFECT_SIZE="-0.02508082342088685" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1613" O_E="0.0" SE="0.06963340177541447" STUDY_ID="STD-McQuade-2004" TOTAL_1="161" TOTAL_2="156" VAR="0.004848810642816295" WEIGHT="60.52725862023451"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2055890957343882" CI_START="0.5119613725414196" DF="0" EFFECT_SIZE="0.7856303508477421" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="37" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.08119931123441149" LOG_CI_START="-0.2907628052838529" LOG_EFFECT_SIZE="-0.10478174702472068" MODIFIED="2009-09-15 13:36:25 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.2694873655048037" STUDIES="1" TAU2="0.0" TOTAL_1="161" TOTAL_2="156" WEIGHT="100.0" Z="1.1042439070300072">
<NAME>due to adverse events</NAME>
<DICH_DATA CI_END="1.2055890957343882" CI_START="0.5119613725414196" EFFECT_SIZE="0.7856303508477421" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="37" LOG_CI_END="0.08119931123441149" LOG_CI_START="-0.2907628052838529" LOG_EFFECT_SIZE="-0.10478174702472068" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1614" O_E="0.0" SE="0.21849238848500044" STUDY_ID="STD-McQuade-2004" TOTAL_1="161" TOTAL_2="156" VAR="0.04773892382588035" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1039030905741063" CI_START="0.3151134167383232" DF="0" EFFECT_SIZE="0.5897920604914934" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="23" I2="0.0" ID="CMP-002.03.03" LOG_CI_END="0.04293094922992605" LOG_CI_START="-0.5015331052634121" LOG_EFFECT_SIZE="-0.229301078016743" MODIFIED="2009-09-15 13:36:33 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.09876349650712041" STUDIES="1" TAU2="0.0" TOTAL_1="161" TOTAL_2="156" WEIGHT="100.0" Z="1.6508779627233385">
<NAME>due to inefficacy</NAME>
<DICH_DATA CI_END="1.1039030905741063" CI_START="0.3151134167383232" EFFECT_SIZE="0.5897920604914934" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="23" LOG_CI_END="0.04293094922992605" LOG_CI_START="-0.5015331052634121" LOG_EFFECT_SIZE="-0.229301078016743" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1615" O_E="0.0" SE="0.31982088074992326" STUDY_ID="STD-McQuade-2004" TOTAL_1="161" TOTAL_2="156" VAR="0.10228539576365663" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.1959363178473465" CI_END="-1.853397349571014" CI_START="-8.064376256488615" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.958886803029814" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2009-09-15 13:38:02 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6580211323636284" P_Q="0.6580211323636284" P_Z="0.001749869813069203" Q="0.1959363178473465" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="398" TOTAL_2="396" UNITS="" WEIGHT="100.0" Z="3.129696520632009">
<NAME>Mental State: General - average endpoint score (PANSS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.9114617441611719" CI_START="-8.508538255838829" DF="0" EFFECT_SIZE="-5.210000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.01" MODIFIED="2009-09-15 13:36:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0019632331877096117" STUDIES="1" TAU2="0.0" TOTAL_1="348" TOTAL_2="355" WEIGHT="88.6374119018015" Z="3.09573864768074">
<NAME>short term</NAME>
<CONT_DATA CI_END="-1.9114617441611719" CI_START="-8.508538255838829" EFFECT_SIZE="-5.210000000000001" ESTIMABLE="YES" MEAN_1="-27.36" MEAN_2="-22.15" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1620" SD_1="22.31" SD_2="22.31" SE="1.6829586063097475" STUDY_ID="STD-CN138003" TOTAL_1="348" TOTAL_2="355" WEIGHT="88.6374119018015"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.212795412393895" CI_START="-12.212795412393895" DF="0" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.02" MODIFIED="2009-09-15 13:36:46 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.52332330119073" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="41" WEIGHT="11.362588098198497" Z="0.6382310352523399">
<NAME>medium term</NAME>
<CONT_DATA CI_END="6.212795412393895" CI_START="-12.212795412393895" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="-42.0" MEAN_2="-39.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1621" SD_1="22.31" SD_2="22.31" SE="4.700492195297081" STUDY_ID="STD-McQuade-2004" TOTAL_1="50" TOTAL_2="41" WEIGHT="11.362588098198497"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.184457696884712" CI_START="0.5956994754438975" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.9068322981366457" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="1.151812736412968" LOG_CI_START="-0.22497278232841914" LOG_EFFECT_SIZE="0.4634199770422743" METHOD="MH" MODIFIED="2009-09-15 13:38:32 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.1870252006529062" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="161" TOTAL_2="156" WEIGHT="100.0" Z="1.3194305901031886">
<NAME>Adverse effects: 1a. Cardiac effects - QTc prolongation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.184457696884712" CI_START="0.5956994754438975" EFFECT_SIZE="2.906832298136646" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.151812736412968" LOG_CI_START="-0.22497278232841914" LOG_EFFECT_SIZE="0.46341997704227433" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1622" O_E="0.0" SE="0.8087306289069226" STUDY_ID="STD-McQuade-2004" TOTAL_1="161" TOTAL_2="156" VAR="0.6540452301321866" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.510879574565216" CI_START="-2.110879574565216" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.6999999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2009-09-15 13:38:42 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.21203807473638037" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="161" TOTAL_2="156" UNITS="" WEIGHT="100.0" Z="1.2479809037069578">
<NAME>Adverse effects: 1b. Cardiac effects - QTc abnormalities - change from baseline in ms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.510879574565216" CI_START="-2.110879574565216" EFFECT_SIZE="3.6999999999999997" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="-3.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1623" SD_1="26.39" SD_2="26.39" SE="2.964788955511781" STUDY_ID="STD-McQuade-2004" TOTAL_1="161" TOTAL_2="156" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.513561892579578" CI_START="1.6188482740269943" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.987577639751553" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.7414322541175424" LOG_CI_START="0.2092061465664216" LOG_EFFECT_SIZE="0.47531920034198205" METHOD="MH" MODIFIED="2009-09-15 13:39:33 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="4.6386424290394715E-4" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="161" TOTAL_2="156" WEIGHT="100.00000000000001" Z="3.5007997563936923">
<NAME>Adverse effects: 2. Central nervous system - sedation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.513561892579579" CI_START="1.618848274026994" EFFECT_SIZE="2.987577639751553" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="12" LOG_CI_END="0.7414322541175425" LOG_CI_START="0.20920614656642156" LOG_EFFECT_SIZE="0.47531920034198205" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1631" O_E="0.0" SE="0.3126322501372505" STUDY_ID="STD-McQuade-2004" TOTAL_1="161" TOTAL_2="156" VAR="0.09773892382588034" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2361142475898705" CI_END="1.328896677288015" CI_START="0.6389604429960343" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9214729565298746" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.12349121553410917" LOG_CI_START="-0.19452602747588152" LOG_EFFECT_SIZE="-0.035517405970886165" METHOD="MH" MODIFIED="2009-09-15 15:50:00 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.5389909184700067" P_Q="0.0" P_Z="0.6615364605887656" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="483" TOTAL_2="468" WEIGHT="300.0" Z="0.43779284335873475">
<NAME>Adverse effects: 3. Extrapyramidal effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5706283913022048" CI_START="0.18449261677295767" DF="0" EFFECT_SIZE="0.5383022774327122" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" I2="0.0" ID="CMP-002.08.01" LOG_CI_END="0.1960734436666911" LOG_CI_START="-0.7340210092280794" LOG_EFFECT_SIZE="-0.26897378278069417" MODIFIED="2009-09-15 13:57:27 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.25696113646855623" STUDIES="1" TAU2="0.0" TOTAL_1="161" TOTAL_2="156" WEIGHT="100.0" Z="1.1336029913841548">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="1.5706283913022048" CI_START="0.18449261677295767" EFFECT_SIZE="0.5383022774327122" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.1960734436666911" LOG_CI_START="-0.7340210092280794" LOG_EFFECT_SIZE="-0.26897378278069417" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1626" O_E="0.0" SE="0.5463420856721831" STUDY_ID="STD-McQuade-2004" TOTAL_1="161" TOTAL_2="156" VAR="0.2984896745766311" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.540557679830472" CI_START="0.5634466520886139" DF="0" EFFECT_SIZE="0.9316770186335404" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" I2="0.0" ID="CMP-002.08.02" LOG_CI_END="0.18767796332361034" LOG_CI_START="-0.24914719727594734" LOG_EFFECT_SIZE="-0.030734616976168472" MODIFIED="2009-09-15 13:57:33 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7826997402895891" STUDIES="1" TAU2="0.0" TOTAL_1="161" TOTAL_2="156" WEIGHT="100.0" Z="0.2758025305559039">
<NAME>extrapyramidal symptoms</NAME>
<DICH_DATA CI_END="1.540557679830472" CI_START="0.5634466520886139" EFFECT_SIZE="0.9316770186335404" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" LOG_CI_END="0.18767796332361034" LOG_CI_START="-0.24914719727594734" LOG_EFFECT_SIZE="-0.030734616976168472" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1627" O_E="0.0" SE="0.25659326165559854" STUDY_ID="STD-McQuade-2004" TOTAL_1="161" TOTAL_2="156" VAR="0.06584010192705846" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0054075094539807" CI_START="0.5847956950574075" DF="0" EFFECT_SIZE="1.0829375228352212" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" I2="0.0" ID="CMP-002.08.03" LOG_CI_END="0.302202636868631" LOG_CI_START="-0.23299583307429708" LOG_EFFECT_SIZE="0.034603401897166965" MODIFIED="2009-09-15 13:57:40 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.7999251276535083" STUDIES="1" TAU2="0.0" TOTAL_1="161" TOTAL_2="156" WEIGHT="100.0" Z="0.25344400356093877">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="2.0054075094539807" CI_START="0.5847956950574075" EFFECT_SIZE="1.0829375228352212" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.302202636868631" LOG_CI_START="-0.23299583307429708" LOG_EFFECT_SIZE="0.034603401897166965" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1628" O_E="0.0" SE="0.3143782305196292" STUDY_ID="STD-McQuade-2004" TOTAL_1="161" TOTAL_2="156" VAR="0.09883367182465311" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.331002902360138" CI_START="1.6766082821446067" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.7373558118899735" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.9206972857697368" LOG_CI_START="0.22443160716494803" LOG_EFFECT_SIZE="0.5725644464673424" METHOD="MH" MODIFIED="2009-09-15 13:58:39 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.0012663495082072328" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="161" TOTAL_2="156" WEIGHT="99.99999999999999" Z="3.223498524737953">
<NAME>Adverse effects: 4. Prolactin associated side effects - abnormally high prolactin value</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.331002902360138" CI_START="1.6766082821446067" EFFECT_SIZE="3.7373558118899735" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="7" LOG_CI_END="0.9206972857697368" LOG_CI_START="0.22443160716494803" LOG_EFFECT_SIZE="0.5725644464673424" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1630" O_E="0.0" SE="0.40898990618314757" STUDY_ID="STD-McQuade-2004" TOTAL_1="161" TOTAL_2="156" VAR="0.16727274335969985" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.595804400690134E-31" CI_END="5.387886466735765" CI_START="1.8449008844599823" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.152795031055901" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="14" I2="100.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="0.7314184357165638" LOG_CI_START="0.2659730390650713" LOG_EFFECT_SIZE="0.4986957373908175" METHOD="MH" MODIFIED="2009-09-15 15:27:45 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="2.6696385892567317E-5" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="115" TOTAL_2="108" WEIGHT="100.0" Z="4.199958541050975">
<NAME>Adverse effects: 5a. Metabolic - cholesterol - significant cholesterol increase</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.387886466735765" CI_START="1.8449008844599823" EFFECT_SIZE="3.1527950310559008" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="14" LOG_CI_END="0.7314184357165638" LOG_CI_START="0.2659730390650713" LOG_EFFECT_SIZE="0.4986957373908175" MODIFIED="2009-09-15 15:26:59 +0100" MODIFIED_BY="[Empty name]" ORDER="1373" O_E="0.0" SE="0.27340492998495836" STUDY_ID="STD-McQuade-2004" TOTAL_1="115" TOTAL_2="108" VAR="0.07475025574007997" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="27.21023740443414" CI_START="7.649762595565861" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="17.43" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.11" MODIFIED="2009-09-15 15:27:45 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="4.776625382934785E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="115" TOTAL_2="108" UNITS="" WEIGHT="100.0" Z="3.492979857017048">
<NAME>Adverse effects: 5b. Metabolic - cholesterol - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="27.21023740443414" CI_START="7.649762595565861" EFFECT_SIZE="17.43" ESTIMABLE="YES" MEAN_1="16.3" MEAN_2="-1.13" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1625" SD_1="37.24" SD_2="37.24" SE="4.990008735660147" STUDY_ID="STD-McQuade-2004" TOTAL_1="115" TOTAL_2="108" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="10.484016294353838" CI_START="-6.484016294353838" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.12" MODIFIED="2009-09-15 15:27:45 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.6440549127912474" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="161" TOTAL_2="156" UNITS="" WEIGHT="100.0" Z="0.4620368270259975">
<NAME>Adverse effects: 5c. Metabolic - glucose - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.484016294353838" CI_START="-6.484016294353838" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="5.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1629" SD_1="38.53" SD_2="38.53" SE="4.328659282147363" STUDY_ID="STD-McQuade-2004" TOTAL_1="161" TOTAL_2="156" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.188483159913209" CI_START="1.7098502201549435" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.676131322094055" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="0.6220567736708686" LOG_CI_START="0.23295806863239102" LOG_EFFECT_SIZE="0.4275074211516299" METHOD="MH" MODIFIED="2009-09-15 15:27:45 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="0.0" P_Z="1.6557939909242733E-5" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="161" TOTAL_2="156" WEIGHT="100.0" Z="4.306871946530546">
<NAME>Adverse effects: 5d. Metabolic - weight gain of 7% or more of total body weight</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.188483159913209" CI_START="1.7098502201549435" EFFECT_SIZE="2.676131322094055" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="21" LOG_CI_END="0.6220567736708686" LOG_CI_START="0.23295806863239102" LOG_EFFECT_SIZE="0.4275074211516299" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1632" O_E="0.0" SE="0.228558505409255" STUDY_ID="STD-McQuade-2004" TOTAL_1="161" TOTAL_2="156" VAR="0.05223899039491244" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.047310491923138" CI_START="2.152689508076862" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.6000000000000005" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.14" MODIFIED="2009-09-15 15:27:45 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.0014531882470008985" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="41" UNITS="" WEIGHT="100.0" Z="3.1838728594769763">
<NAME>Adverse effects: 5e. Metabolic - weight gain - change from baseline in kg</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.047310491923138" CI_START="2.152689508076862" EFFECT_SIZE="5.6000000000000005" ESTIMABLE="YES" MEAN_1="4.23" MEAN_2="-1.37" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1633" SD_1="8.31" SD_2="8.31" SE="1.7588642031767336" STUDY_ID="STD-McQuade-2004" TOTAL_1="49" TOTAL_2="41" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-02-17 14:12:16 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>OLANZAPINE versus CLOZAPINE</NAME>
<DICH_OUTCOME CHI2="4.4698403588170725" CI_END="1.0709593708748888" CI_START="0.9214850142794222" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9934148233056158" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="191" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.029772995258058675" LOG_CI_START="-0.03551172313473285" LOG_EFFECT_SIZE="-0.0028693639383370975" METHOD="MH" MODIFIED="2009-09-15 14:07:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4839290916576081" P_Q="0.0" P_Z="0.8632120043204705" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="264" TOTAL_2="254" WEIGHT="100.00000000000001" Z="0.17228687252175282">
<NAME>Global state: 1a. no clinically significant response (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2003719631812197" CI_START="0.7975752613475398" EFFECT_SIZE="0.9784615384615385" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="52" LOG_CI_END="0.07931584315244507" LOG_CI_START="-0.09822832514132847" LOG_EFFECT_SIZE="-0.009456240994441686" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1665" O_E="0.0" SE="0.10429032331356966" STUDY_ID="STD-Bitter-2004" TOTAL_1="75" TOTAL_2="72" VAR="0.01087647153684889" WEIGHT="13.521044639167416"/>
<DICH_DATA CI_END="1.3346075891202989" CI_START="0.7492839154759685" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.12535359009642288" LOG_CI_START="-0.1253535900964228" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1666" O_E="0.0" SE="0.14726663866583445" STUDY_ID="STD-Conley-2003" TOTAL_1="8" TOTAL_2="5" VAR="0.021687462863933443" WEIGHT="6.7809341318081335"/>
<DICH_DATA CI_END="4.108558431892023" CI_START="0.9735774886273112" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.6136894678869381" LOG_CI_START="-0.011629476558975801" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1667" O_E="0.0" SE="0.36731544334622646" STUDY_ID="STD-Kumra-2007" TOTAL_1="21" TOTAL_2="18" VAR="0.1349206349206349" WEIGHT="1.0899834354683722"/>
<DICH_DATA CI_END="1.3067975449954985" CI_START="0.7221267540650345" EFFECT_SIZE="0.9714285714285714" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="35" LOG_CI_END="0.11620830992039585" LOG_CI_START="-0.14138656453643683" LOG_EFFECT_SIZE="-0.012589127308020516" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1668" O_E="0.0" SE="0.15131250437113686" STUDY_ID="STD-Naber-2005" TOTAL_1="57" TOTAL_2="57" VAR="0.022895473979065314" WEIGHT="6.4231584504795345"/>
<DICH_DATA CI_END="1.147316914774389" CI_START="0.7515315836938896" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.05968339639049884" LOG_CI_START="-0.12405276313330127" LOG_EFFECT_SIZE="-0.03218468337140124" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1669" O_E="0.0" SE="0.1079275296129382" STUDY_ID="STD-Shaw-2006" TOTAL_1="13" TOTAL_2="12" VAR="0.011648351648351651" WEIGHT="12.625070190697599"/>
<DICH_DATA CI_END="1.1022917189034416" CI_START="0.907200864209339" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="81" LOG_CI_END="0.04229654473735869" LOG_CI_START="-0.042296544737358714" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1670" O_E="0.0" SE="0.049690399499995305" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.0024691358024691336" WEIGHT="59.55980915237895"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.153480690403754" CI_END="1.1595466962800318" CI_START="0.8135491804422964" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9712611721072723" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="135" I2="34.99613956312676" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.06428824286481215" LOG_CI_START="-0.08961618808777883" LOG_EFFECT_SIZE="-0.012663972611483323" METHOD="MH" MODIFIED="2009-09-15 14:35:40 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1879758671856634" P_Q="0.0" P_Z="0.7470361336893583" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.013822306422324676" TOTALS="YES" TOTAL_1="256" TOTAL_2="249" WEIGHT="100.0" Z="0.32254991056566645">
<NAME>Global State: no clinically important change (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.510177187876218" CI_END="4.442555113219893" CI_START="0.39314046097998273" DF="1" EFFECT_SIZE="1.3215703405949484" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="18" I2="90.4854125470546" ID="CMP-003.02.01" LOG_CI_END="0.6476328242587259" LOG_CI_START="-0.4054522574363928" LOG_EFFECT_SIZE="0.12109028341116651" MODIFIED="2009-09-15 14:35:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0011871932260496543" P_Z="0.6521785806697852" STUDIES="2" TAU2="0.6969485162592562" TOTAL_1="34" TOTAL_2="30" WEIGHT="37.582267010723335" Z="0.4507377390278997">
<NAME>short term</NAME>
<DICH_DATA CI_END="4.108558431892023" CI_START="0.9735774886273112" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.6136894678869381" LOG_CI_START="-0.011629476558975801" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1671" O_E="0.0" SE="0.36731544334622646" STUDY_ID="STD-Kumra-2007" TOTAL_1="21" TOTAL_2="18" VAR="0.1349206349206349" WEIGHT="5.494663308564119"/>
<DICH_DATA CI_END="1.147316914774389" CI_START="0.7515315836938896" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.05968339639049884" LOG_CI_START="-0.12405276313330127" LOG_EFFECT_SIZE="-0.03218468337140124" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1672" O_E="0.0" SE="0.1079275296129382" STUDY_ID="STD-Shaw-2006" TOTAL_1="13" TOTAL_2="12" VAR="0.011648351648351651" WEIGHT="32.087603702159214"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6725068948929633" CI_END="1.1002520928146136" CI_START="0.7720478537862389" DF="2" EFFECT_SIZE="0.9216546353604154" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="117" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.04149220331721303" LOG_CI_START="-0.11235577998653831" LOG_EFFECT_SIZE="-0.0354317883346626" MODIFIED="2009-09-15 14:35:40 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.43333124370560727" P_Z="0.36664552206129775" STUDIES="3" TAU2="0.0" TOTAL_1="222" TOTAL_2="219" WEIGHT="62.41773298927666" Z="0.9027746422476742">
<NAME>medium term</NAME>
<DICH_DATA CI_END="1.647649584293841" CI_START="0.7373496395965649" EFFECT_SIZE="1.1022222222222222" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="27" LOG_CI_END="0.21686485312000545" LOG_CI_START="-0.13232652769029796" LOG_EFFECT_SIZE="0.04226916271485377" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1673" O_E="0.0" SE="0.2051167456131845" STUDY_ID="STD-Bitter-2004" TOTAL_1="75" TOTAL_2="72" VAR="0.04207287933094384" WEIGHT="14.621874338386524"/>
<DICH_DATA CI_END="1.3067975449954985" CI_START="0.7221267540650345" EFFECT_SIZE="0.9714285714285714" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="35" LOG_CI_END="0.11620830992039585" LOG_CI_START="-0.14138656453643683" LOG_EFFECT_SIZE="-0.012589127308020516" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1674" O_E="0.0" SE="0.15131250437113686" STUDY_ID="STD-Naber-2005" TOTAL_1="57" TOTAL_2="57" VAR="0.022895473979065314" WEIGHT="22.258763282274156"/>
<DICH_DATA CI_END="1.0656775502589173" CI_START="0.6281651400469711" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="55" LOG_CI_END="0.02762581695389092" LOG_CI_START="-0.2019261683916912" LOG_EFFECT_SIZE="-0.08715017571890014" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1675" O_E="0.0" SE="0.1348399724926484" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.018181818181818174" WEIGHT="25.53709536861598"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="32.36994376682936" CI_END="1.0492306030055822" CI_START="0.8440133533497278" CI_STUDY="95" CI_TOTAL="95" DF="27" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9410444408633943" ESTIMABLE="YES" EVENTS_1="439" EVENTS_2="471" I2="16.589289760620876" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.02087094921018248" LOG_CI_START="-0.07365068223663702" LOG_EFFECT_SIZE="-0.026389866513227268" METHOD="MH" MODIFIED="2009-09-15 14:36:12 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.21866025964495162" P_Q="0.0" P_Z="0.2737707778896553" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.020393163283952666" TOTALS="SUB" TOTAL_1="2537" TOTAL_2="2513" WEIGHT="300.0" Z="1.0944201265050306">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.631693960695902" CI_END="1.0803424415351133" CI_START="0.8571352930729618" DF="10" EFFECT_SIZE="0.9622887483725238" ESTIMABLE="YES" EVENTS_1="327" EVENTS_2="338" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.03356143779829113" LOG_CI_START="-0.06695062218697623" LOG_EFFECT_SIZE="-0.016694592194342557" MODIFIED="2009-09-15 14:36:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8451997765811264" P_Z="0.5149935218052969" STUDIES="11" TAU2="0.0" TOTAL_1="855" TOTAL_2="847" WEIGHT="100.00000000000003" Z="0.6510820580593213">
<NAME>due to any reason</NAME>
<DICH_DATA CI_END="14.45413717356195" CI_START="0.06918434410800384" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1599921719703592" LOG_CI_START="-1.1599921719703592" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1634" O_E="0.0" SE="1.3627702877384937" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="14" VAR="1.8571428571428572" WEIGHT="0.1877008500974181"/>
<DICH_DATA CI_END="1.3145328614292537" CI_START="0.6161884755922422" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="32" LOG_CI_END="0.11877144731496193" LOG_CI_START="-0.21028642843631212" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1635" O_E="0.0" SE="0.19329022507905333" STUDY_ID="STD-Bitter-2004" TOTAL_1="75" TOTAL_2="72" VAR="0.0373611111111111" WEIGHT="9.33021750882546"/>
<DICH_DATA CI_END="75.01940870754389" CI_START="0.2902952469630413" EFFECT_SIZE="4.666666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.875173636780008" LOG_CI_START="-0.5371600748628567" LOG_EFFECT_SIZE="0.6690067809585756" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1636" O_E="0.0" SE="1.4170167634634772" STUDY_ID="STD-Conley-2003" TOTAL_1="8" TOTAL_2="5" VAR="2.007936507936508" WEIGHT="0.17360473882528"/>
<DICH_DATA CI_END="1.6389595055263744" CI_START="0.43684809108874295" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.2145682234035068" LOG_CI_START="-0.3596695577007303" LOG_EFFECT_SIZE="-0.07255066714861173" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1637" O_E="0.0" SE="0.33731011514348896" STUDY_ID="STD-Krakowski-2006" TOTAL_1="37" TOTAL_2="37" VAR="0.11377811377811378" WEIGHT="3.063746457582038"/>
<DICH_DATA CI_END="4.307510594585464" CI_START="0.522343462794554" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.6342263542951901" LOG_CI_START="-0.2820438361838277" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1638" O_E="0.0" SE="0.5382216454979674" STUDY_ID="STD-Kumra-2007" TOTAL_1="21" TOTAL_2="18" VAR="0.28968253968253965" WEIGHT="1.203342436240982"/>
<DICH_DATA CI_END="1.140330149867426" CI_START="0.8318598216312418" EFFECT_SIZE="0.9739583333333334" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="192" LOG_CI_END="0.057030607044815454" LOG_CI_START="-0.07994985137891679" LOG_EFFECT_SIZE="-0.011459622167050623" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1639" O_E="0.0" SE="0.0804629993423052" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.006474294263159808" WEIGHT="53.8417438054372"/>
<DICH_DATA CI_END="1.4387340099391903" CI_START="0.09190816651666323" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.15798050992454518" LOG_CI_START="-1.0366458975850703" LOG_EFFECT_SIZE="-0.43933269383026263" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1640" O_E="0.0" SE="0.701729465267237" STUDY_ID="STD-Moresco-2004" TOTAL_1="11" TOTAL_2="12" VAR="0.4924242424242424" WEIGHT="0.7079003489388341"/>
<DICH_DATA CI_END="1.3688342734902625" CI_START="0.7728906297589101" EFFECT_SIZE="1.0285714285714285" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="35" LOG_CI_END="0.1363508707304058" LOG_CI_START="-0.11188195789638263" LOG_EFFECT_SIZE="0.012234456417011586" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1641" O_E="0.0" SE="0.1458131923076946" STUDY_ID="STD-Naber-2005" TOTAL_1="57" TOTAL_2="57" VAR="0.02126148705096073" WEIGHT="16.395245177468"/>
<DICH_DATA CI_END="62.47773921986342" CI_START="0.1242075046013423" EFFECT_SIZE="2.7857142857142856" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7957253060468672" LOG_CI_START="-0.9058521633503449" LOG_EFFECT_SIZE="0.44493657134826115" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1642" O_E="0.0" SE="1.5869199785480734" STUDY_ID="STD-Shaw-2006" TOTAL_1="13" TOTAL_2="12" VAR="2.518315018315018" WEIGHT="0.13842084509002325"/>
<DICH_DATA CI_END="1.385951890323943" CI_START="0.683051419565939" EFFECT_SIZE="0.972972972972973" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="37" LOG_CI_END="0.1417481551463005" LOG_CI_START="-0.16554660174571587" LOG_EFFECT_SIZE="-0.011899223299707707" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1643" O_E="0.0" SE="0.1805064613319495" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.03258258258258258" WEIGHT="10.698577749463109"/>
<DICH_DATA CI_END="1.2976924584466687" CI_START="0.4228250240815366" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" LOG_CI_END="0.11317178073475927" LOG_CI_START="-0.37383931772477164" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1644" O_E="0.0" SE="0.28607272997894584" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="40" VAR="0.08183760683760685" WEIGHT="4.259500082031673"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.701875473665789" CI_END="0.9162987341798784" CI_START="0.4260473600725473" DF="7" EFFECT_SIZE="0.6248092962938003" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="95" I2="9.113046245237767" ID="CMP-003.03.02" LOG_CI_END="-0.03796291339032253" LOG_CI_START="-0.3705421213786655" LOG_EFFECT_SIZE="-0.204252517384494" MODIFIED="2009-09-15 14:36:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3596147947015552" P_Z="0.01606603635873716" STUDIES="10" TAU2="0.03243110220827916" TOTAL_1="841" TOTAL_2="833" WEIGHT="99.99999999999999" Z="2.407411938026392">
<NAME>due to adverse events</NAME>
<DICH_DATA CI_END="2.600399648229463" CI_START="0.35440706224810126" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.41504009861801444" LOG_CI_START="-0.45049763253887765" LOG_EFFECT_SIZE="-0.017728766960431602" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1645" O_E="0.0" SE="0.5084211477624269" STUDY_ID="STD-Bitter-2004" TOTAL_1="75" TOTAL_2="72" VAR="0.2584920634920635" WEIGHT="13.118587875333562"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1646" O_E="0.0" SE="0.0" STUDY_ID="STD-Conley-2003" TOTAL_1="8" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.0593713735736316" CI_START="0.03631828161525971" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4856321986925003" LOG_CI_START="-1.4398747081318253" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1647" O_E="0.0" SE="1.1310522884815182" STUDY_ID="STD-Krakowski-2006" TOTAL_1="37" TOTAL_2="37" VAR="1.2792792792792793" WEIGHT="2.9095608055507114"/>
<DICH_DATA CI_END="4.345461589910713" CI_START="0.04226788468553212" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6380359154920859" LOG_CI_START="-1.3739894860812747" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1648" O_E="0.0" SE="1.1818736805705576" STUDY_ID="STD-Kumra-2007" TOTAL_1="21" TOTAL_2="18" VAR="1.3968253968253967" WEIGHT="2.6702702536532237"/>
<DICH_DATA CI_END="1.1125752530972446" CI_START="0.4989964377668355" EFFECT_SIZE="0.7450980392156863" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="51" LOG_CI_END="0.04632939574247127" LOG_CI_START="-0.3019025547047236" LOG_EFFECT_SIZE="-0.12778657948112618" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1649" O_E="0.0" SE="0.2045531714686377" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.04184199995787789" WEIGHT="51.38470055649812"/>
<DICH_DATA CI_END="1.5882279960021655" CI_START="0.029972589517971864" EFFECT_SIZE="0.21818181818181817" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.20091284714532115" LOG_CI_START="-1.5232757340385592" LOG_EFFECT_SIZE="-0.661181443446619" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1650" O_E="0.0" SE="1.0127969074585368" STUDY_ID="STD-Moresco-2004" TOTAL_1="11" TOTAL_2="12" VAR="1.0257575757575759" WEIGHT="3.6066357481225295"/>
<DICH_DATA CI_END="2.9164669835623265" CI_START="0.3428806174169499" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.464857064277827" LOG_CI_START="-0.464857064277827" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1651" O_E="0.0" SE="0.5461186812727502" STUDY_ID="STD-Naber-2005" TOTAL_1="57" TOTAL_2="57" VAR="0.2982456140350877" WEIGHT="11.541487279683025"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1652" O_E="0.0" SE="0.0" STUDY_ID="STD-Shaw-2006" TOTAL_1="13" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9077734273824714" CI_START="0.1042931565930588" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.042022534206153726" LOG_CI_START="-0.9817441877515949" LOG_EFFECT_SIZE="-0.5118833609788743" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1653" O_E="0.0" SE="0.5519971509897987" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.3047008547008547" WEIGHT="11.320496428758373"/>
<DICH_DATA CI_END="0.9776575763015225" CI_START="0.01681217974116543" EFFECT_SIZE="0.1282051282051282" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.00981322983707264" LOG_CI_START="-1.7743759755438884" LOG_EFFECT_SIZE="-0.8920946026904805" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1654" O_E="0.0" SE="1.0365128915546467" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="40" VAR="1.0743589743589745" WEIGHT="3.4482610524004493"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.388680018907072" CI_END="2.4706112031008884" CI_START="0.7702626931976793" DF="8" EFFECT_SIZE="1.379499778595433" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="38" I2="35.424920267609274" ID="CMP-003.03.03" LOG_CI_END="0.39280440641656483" LOG_CI_START="-0.11336113619143269" LOG_EFFECT_SIZE="0.13972163511256605" MODIFIED="2009-09-15 14:36:12 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.13468622084872162" P_Z="0.27922829134844074" STUDIES="10" TAU2="0.253162201210507" TOTAL_1="841" TOTAL_2="833" WEIGHT="100.0" Z="1.0820545834498285">
<NAME>due to inefficacy</NAME>
<DICH_DATA CI_END="5.520460230065465" CI_START="0.2967868495957937" EFFECT_SIZE="1.28" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7419752855273863" LOG_CI_START="-0.5275553462316496" LOG_EFFECT_SIZE="0.10720996964786837" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1655" O_E="0.0" SE="0.7457285773732365" STUDY_ID="STD-Bitter-2004" TOTAL_1="75" TOTAL_2="72" VAR="0.5561111111111111" WEIGHT="10.92358366761245"/>
<DICH_DATA CI_END="75.01940870754389" CI_START="0.2902952469630413" EFFECT_SIZE="4.666666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.875173636780008" LOG_CI_START="-0.5371600748628567" LOG_EFFECT_SIZE="0.6690067809585756" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1656" O_E="0.0" SE="1.4170167634634772" STUDY_ID="STD-Conley-2003" TOTAL_1="8" TOTAL_2="5" VAR="2.007936507936508" WEIGHT="3.909676610467816"/>
<DICH_DATA CI_END="6.7278533183775675" CI_START="0.14863582077041354" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8278765143425244" LOG_CI_START="-0.8278765143425244" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1657" O_E="0.0" SE="0.9725975251592748" STUDY_ID="STD-Krakowski-2006" TOTAL_1="37" TOTAL_2="37" VAR="0.945945945945946" WEIGHT="7.372283107303114"/>
<DICH_DATA CI_END="38.816149287068065" CI_START="0.6813911239940653" EFFECT_SIZE="5.142857142857143" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.589012449488035" LOG_CI_START="-0.16660352798197403" LOG_EFFECT_SIZE="0.7112044607530305" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1658" O_E="0.0" SE="1.0312575156051293" STUDY_ID="STD-Kumra-2007" TOTAL_1="21" TOTAL_2="18" VAR="1.0634920634920635" WEIGHT="6.714112409082602"/>
<DICH_DATA CI_END="8.190358298130489" CI_START="1.0988530260091691" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.9133029009664358" LOG_CI_START="0.040939608472888835" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1659" O_E="0.0" SE="0.5124305162786515" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.2625850340136054" WEIGHT="17.1404985491966"/>
<DICH_DATA CI_END="8.039573882065785" CI_START="0.016219918677380755" EFFECT_SIZE="0.3611111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.905233030642515" LOG_CI_START="-1.7899513275634158" LOG_EFFECT_SIZE="-0.4423591484604505" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1660" O_E="0.0" SE="1.583164633387904" STUDY_ID="STD-Moresco-2004" TOTAL_1="11" TOTAL_2="12" VAR="2.506410256410256" WEIGHT="3.2034544745140825"/>
<DICH_DATA CI_END="1.058073311771534" CI_START="0.20582484725293004" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="0.02451576013279992" LOG_CI_START="-0.6865021982156487" LOG_EFFECT_SIZE="-0.3309932190414244" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1661" O_E="0.0" SE="0.4176554683295358" STUDY_ID="STD-Naber-2005" TOTAL_1="57" TOTAL_2="57" VAR="0.1744360902255639" WEIGHT="20.67399452748451"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1662" O_E="0.0" SE="0.0" STUDY_ID="STD-Shaw-2006" TOTAL_1="13" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.0073538321097786" CI_START="0.5911435358208568" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.4781845282975674" LOG_CI_START="-0.22830705508096752" LOG_EFFECT_SIZE="0.12493873660829992" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1663" O_E="0.0" SE="0.4149966532662911" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.17222222222222222" WEIGHT="20.78159013386876"/>
<DICH_DATA CI_END="10.564903329312394" CI_START="0.3982770047916526" EFFECT_SIZE="2.051282051282051" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0238655275371" LOG_CI_START="-0.39981476760621143" LOG_EFFECT_SIZE="0.3120253799654443" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1664" O_E="0.0" SE="0.8362768526983001" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="40" VAR="0.6993589743589743" WEIGHT="9.280806520470069"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.04573568286191844" CI_END="1.0875126224259901" CI_START="0.912150715704704" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9959796267413136" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="133" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.036434306378989915" LOG_CI_START="-0.03993339676918348" LOG_EFFECT_SIZE="-0.0017495451950967937" METHOD="MH" MODIFIED="2009-09-15 14:36:35 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8306571464751353" P_Q="0.0" P_Z="0.9284433240305753" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="162" WEIGHT="100.0" Z="0.08980355386783237">
<NAME>Mental State: 1a. General - no clinically important change - medium term (less than 50% PANSS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2003719631812197" CI_START="0.7975752613475398" EFFECT_SIZE="0.9784615384615385" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="52" LOG_CI_END="0.07931584315244507" LOG_CI_START="-0.09822832514132847" LOG_EFFECT_SIZE="-0.009456240994441686" MODIFIED="2009-09-15 14:36:35 +0100" MODIFIED_BY="[Empty name]" ORDER="1353" O_E="0.0" SE="0.10429032331356966" STUDY_ID="STD-Bitter-2004" TOTAL_1="75" TOTAL_2="72" VAR="0.01087647153684889" WEIGHT="18.50148696638717"/>
<DICH_DATA CI_END="1.1022917189034416" CI_START="0.907200864209339" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="81" LOG_CI_END="0.04229654473735869" LOG_CI_START="-0.042296544737358714" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-15 14:36:35 +0100" MODIFIED_BY="[Empty name]" ORDER="1354" O_E="0.0" SE="0.049690399499995305" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.0024691358024691336" WEIGHT="81.49851303361282"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.590283716572019" CI_START="0.49330178492262783" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8857142857142857" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.20147461208755674" LOG_CI_START="-0.3068873131195627" LOG_EFFECT_SIZE="-0.052706350516002975" METHOD="MH" MODIFIED="2009-09-15 14:37:01 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.6844388778608547" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="31" WEIGHT="100.0" Z="0.4064133981939025">
<NAME>Mental State: 1b. General - no clinically important change - short term (less than 50% BPRS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.590283716572019" CI_START="0.49330178492262783" EFFECT_SIZE="0.8857142857142857" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.20147461208755674" LOG_CI_START="-0.3068873131195627" LOG_EFFECT_SIZE="-0.052706350516002975" MODIFIED="2009-09-15 14:37:01 +0100" MODIFIED_BY="[Empty name]" ORDER="1355" O_E="0.0" SE="0.2986143112987762" STUDY_ID="STD-Wang-2002" TOTAL_1="30" TOTAL_2="31" VAR="0.08917050691244241" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.015329300648402" CI_START="0.7993466601432491" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2692307692307692" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.30434601909737646" LOG_CI_START="-0.09726483528323744" LOG_EFFECT_SIZE="0.10354059190706949" METHOD="MH" MODIFIED="2009-09-15 14:37:20 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.31220347938693727" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="12" WEIGHT="100.0" Z="1.0106092943568188">
<NAME>Mental State: 1c. General - no clinically important change - short term (less than 20% BPRS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.015329300648402" CI_START="0.7993466601432491" EFFECT_SIZE="1.2692307692307692" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.30434601909737646" LOG_CI_START="-0.09726483528323744" LOG_EFFECT_SIZE="0.10354059190706949" MODIFIED="2009-09-15 14:37:20 +0100" MODIFIED_BY="[Empty name]" ORDER="1356" O_E="0.0" SE="0.23590820386896394" STUDY_ID="STD-Shaw-2006" TOTAL_1="13" TOTAL_2="12" VAR="0.055652680652680656" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.684204124799995" CI_END="0.711404700190021" CI_START="-4.660559863177481" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.97457758149373" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.07" MODIFIED="2010-02-17 14:10:40 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.9463342345365607" P_Q="0.9940033152571863" P_Z="0.14962670933293853" Q="5.648725751683514E-5" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="309" TOTAL_2="309" UNITS="" WEIGHT="100.0" Z="1.4408512560931266">
<NAME>Mental State: 1d. General - average endpoint score (PANSS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.192129975281583" CI_END="1.4830752751990188" CI_START="-5.4156328726503915" DF="2" EFFECT_SIZE="-1.9662787987256862" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.01" MODIFIED="2009-09-15 14:37:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.550975704313222" P_Z="0.26388191510374104" STUDIES="3" TAU2="0.0" TOTAL_1="59" TOTAL_2="56" WEIGHT="60.6360264270746" Z="1.11726298503247">
<NAME>short term</NAME>
<CONT_DATA CI_END="2.3143529203010766" CI_START="-6.714352920301082" EFFECT_SIZE="-2.200000000000003" ESTIMABLE="YES" MEAN_1="74.86" MEAN_2="77.06" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1678" SD_1="6.41" SD_2="5.28" SE="2.3032836092447204" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="13" WEIGHT="35.40097886775607"/>
<CONT_DATA CI_END="3.101086382514089" CI_START="-7.981086382514089" EFFECT_SIZE="-2.44" ESTIMABLE="YES" MEAN_1="-4.83" MEAN_2="-2.39" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1679" SD_1="9.7" SD_2="14.2" SE="2.8271368383406386" STUDY_ID="STD-Krakowski-2006" TOTAL_1="37" TOTAL_2="37" WEIGHT="23.497217975875785"/>
<CONT_DATA CI_END="29.575090689580378" CI_START="-11.175090689580372" EFFECT_SIZE="9.200000000000003" ESTIMABLE="YES" MEAN_1="65.0" MEAN_2="55.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1680" SD_1="20.9" SD_2="18.9" SE="10.395645455884134" STUDY_ID="STD-Moresco-2004" TOTAL_1="9" TOTAL_2="6" WEIGHT="1.7378295834427375"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.49201766226089516" CI_END="2.293722317994718" CI_START="-6.268444270386883" DF="3" EFFECT_SIZE="-1.9873609761960824" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.02" MODIFIED="2009-09-15 14:37:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9206416115750281" P_Z="0.3629001162255946" STUDIES="4" TAU2="0.0" TOTAL_1="250" TOTAL_2="253" WEIGHT="39.363973572925396" Z="0.9098528736663926">
<NAME>medium term</NAME>
<CONT_DATA CI_END="7.902754640080635" CI_START="-7.502754640080644" EFFECT_SIZE="0.19999999999999574" ESTIMABLE="YES" MEAN_1="-37.7" MEAN_2="-37.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1681" SD_1="23.1" SD_2="23.4" SE="3.9300490727579613" STUDY_ID="STD-Bitter-2004" TOTAL_1="70" TOTAL_2="70" WEIGHT="12.159456360724386"/>
<CONT_DATA CI_END="8.77264486633714" CI_START="-13.572644866337145" EFFECT_SIZE="-2.400000000000002" ESTIMABLE="YES" MEAN_1="-32.6" MEAN_2="-30.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1682" SD_1="29.6" SD_2="29.6" SE="5.700433760245361" STUDY_ID="STD-Naber-2005" TOTAL_1="52" TOTAL_2="56" WEIGHT="5.7795536291635194"/>
<CONT_DATA CI_END="3.6852472277515522" CI_START="-10.685247227751553" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="-25.6" MEAN_2="-22.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1683" SD_1="25.5" SD_2="23.1" SE="3.6660098269294052" STUDY_ID="STD-Tollefson-2001" TOTAL_1="89" TOTAL_2="87" WEIGHT="13.974068099734723"/>
<CONT_DATA CI_END="7.440086310274894" CI_START="-12.240086310274894" EFFECT_SIZE="-2.3999999999999995" ESTIMABLE="YES" MEAN_1="-9.1" MEAN_2="-6.7" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1684" SD_1="22.31" SD_2="22.31" SE="5.020544452802316" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="40" WEIGHT="7.450895483302767"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.502288787479844" CI_END="-0.25121738977940167" CI_START="-2.6829901034252917" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.4671037466023467" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.08" MODIFIED="2009-09-15 14:37:47 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.4795773118983043" P_Q="0.9194705757023476" P_Z="0.018034104509859324" Q="0.010221338165080418" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="209" TOTAL_2="203" UNITS="" WEIGHT="100.0" Z="2.3649171559403372">
<NAME>Mental State: 1e. General - average endpoint score (BPRS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.340441213645777" CI_END="2.019645905280538" CI_START="-3.790512500842485" DF="3" EFFECT_SIZE="-0.8854332977809736" ESTIMABLE="YES" I2="30.88260265872524" ID="CMP-003.08.01" MODIFIED="2009-09-15 14:37:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.22697201633695763" P_Z="0.5502580355312432" STUDIES="4" TAU2="3.162178235779079" TOTAL_1="68" TOTAL_2="60" WEIGHT="88.5982591543847" Z="0.5973735148199648">
<NAME>short term</NAME>
<CONT_DATA CI_END="13.763876252308963" CI_START="-3.923876252308963" EFFECT_SIZE="4.92" ESTIMABLE="YES" MEAN_1="-0.88" MEAN_2="-5.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1687" SD_1="8.73" SD_2="7.36" SE="4.512264675304409" STUDY_ID="STD-Conley-2003" TOTAL_1="8" TOTAL_2="5" WEIGHT="1.8901690886785154"/>
<CONT_DATA CI_END="10.131342580269935" CI_START="-4.331342580269938" EFFECT_SIZE="2.8999999999999986" ESTIMABLE="YES" MEAN_1="34.3" MEAN_2="31.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1688" SD_1="13.6" SD_2="9.3" SE="3.689528296085971" STUDY_ID="STD-Kumra-2007" TOTAL_1="21" TOTAL_2="18" WEIGHT="2.827145094262047"/>
<CONT_DATA CI_END="1.6583004950186355" CI_START="-10.458300495018648" EFFECT_SIZE="-4.400000000000006" ESTIMABLE="YES" MEAN_1="44.3" MEAN_2="48.7" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1689" SD_1="6.5" SD_2="5.4" SE="3.0910264386518027" STUDY_ID="STD-Moresco-2004" TOTAL_1="9" TOTAL_2="6" WEIGHT="4.027952581053711"/>
<CONT_DATA CI_END="-0.23934698709390223" CI_START="-2.960653012906101" EFFECT_SIZE="-1.6000000000000014" ESTIMABLE="YES" MEAN_1="21.7" MEAN_2="23.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1690" SD_1="2.9" SD_2="2.5" SE="0.6942234773897666" STUDY_ID="STD-Wang-2002" TOTAL_1="30" TOTAL_2="31" WEIGHT="79.85299239039043"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.15162623566898653" CI_END="1.958931965959448" CI_START="-5.242807370973791" DF="1" EFFECT_SIZE="-1.6419377025071717" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.02" MODIFIED="2009-09-15 14:37:47 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6969862517324196" P_Z="0.37147626144104207" STUDIES="2" TAU2="0.0" TOTAL_1="141" TOTAL_2="143" WEIGHT="11.401740845615294" Z="0.8937115358420896">
<NAME>medium term</NAME>
<CONT_DATA CI_END="4.051519011407006" CI_START="-9.651519011407007" EFFECT_SIZE="-2.8000000000000007" ESTIMABLE="YES" MEAN_1="-20.3" MEAN_2="-17.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1691" SD_1="18.2" SD_2="18.1" SE="3.495737199994956" STUDY_ID="STD-Naber-2005" TOTAL_1="52" TOTAL_2="56" WEIGHT="3.149286971183377"/>
<CONT_DATA CI_END="3.032543522440447" CI_START="-5.4325435224404455" EFFECT_SIZE="-1.1999999999999993" ESTIMABLE="YES" MEAN_1="-15.2" MEAN_2="-14.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1692" SD_1="15.3" SD_2="13.3" SE="2.1595006621683916" STUDY_ID="STD-Tollefson-2001" TOTAL_1="89" TOTAL_2="87" WEIGHT="8.252453874431916"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.60324923026021" CI_END="0.9553409615314157" CI_START="-1.1082770823949366" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.07646806043176047" ESTIMABLE="YES" I2="0.0" I2_Q="16.611708658993027" ID="CMP-003.09" MODIFIED="2009-09-15 14:37:57 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.7608715712060875" P_Q="0.27347986930212764" P_Z="0.8845101357298245" Q="1.1992091262676354" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="296" TOTAL_2="296" UNITS="" WEIGHT="100.0" Z="0.14525424882283278">
<NAME>Mental State: 2a. Positive symptoms - average endpoint score (PANSS positive, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.770053615907459" CI_END="2.2696486336896196" CI_START="-1.0032366777644288" DF="1" EFFECT_SIZE="0.6332059779625954" ESTIMABLE="YES" I2="0.0" ID="CMP-003.09.01" MODIFIED="2009-09-15 14:37:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3802005058455832" P_Z="0.4482178538598849" STUDIES="2" TAU2="0.0" TOTAL_1="46" TOTAL_2="43" WEIGHT="39.755485289988464" Z="0.7583894903123157">
<NAME>short term</NAME>
<CONT_DATA CI_END="2.1152277208444965" CI_START="-1.8552277208444963" EFFECT_SIZE="0.13000000000000012" ESTIMABLE="YES" MEAN_1="-1.41" MEAN_2="-1.54" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1693" SD_1="3.6" SD_2="5.0" SE="1.0128898982347223" STUDY_ID="STD-Krakowski-2006" TOTAL_1="37" TOTAL_2="37" WEIGHT="27.01332105130934"/>
<CONT_DATA CI_END="4.590531600763036" CI_START="-1.190531600763037" EFFECT_SIZE="1.6999999999999993" ESTIMABLE="YES" MEAN_1="11.2" MEAN_2="9.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1694" SD_1="1.8" SD_2="3.3" SE="1.4747881203752624" STUDY_ID="STD-Moresco-2004" TOTAL_1="9" TOTAL_2="6" WEIGHT="12.742164238679125"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.6339864880851155" CI_END="0.7845702622082072" CI_START="-1.8741372424911993" DF="3" EFFECT_SIZE="-0.544783490141496" ESTIMABLE="YES" I2="0.0" ID="CMP-003.09.02" MODIFIED="2009-09-15 14:37:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8886097540629018" P_Z="0.4218508556935363" STUDIES="4" TAU2="0.0" TOTAL_1="250" TOTAL_2="253" WEIGHT="60.24451471001153" Z="0.8032143574741097">
<NAME>medium term</NAME>
<CONT_DATA CI_END="2.6197981369101515" CI_START="-2.4197981369101487" EFFECT_SIZE="0.10000000000000142" ESTIMABLE="YES" MEAN_1="-11.7" MEAN_2="-11.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1695" SD_1="7.3" SD_2="7.9" SE="1.28563491818523" STUDY_ID="STD-Bitter-2004" TOTAL_1="70" TOTAL_2="70" WEIGHT="16.76745467017197"/>
<CONT_DATA CI_END="1.7189181115803573" CI_START="-4.5189181115803585" EFFECT_SIZE="-1.4000000000000004" ESTIMABLE="YES" MEAN_1="-9.0" MEAN_2="-7.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1696" SD_1="8.5" SD_2="8.0" SE="1.5913139915743277" STUDY_ID="STD-Naber-2005" TOTAL_1="52" TOTAL_2="56" WEIGHT="10.944368242758081"/>
<CONT_DATA CI_END="1.7867883329020366" CI_START="-2.5867883329020356" EFFECT_SIZE="-0.39999999999999947" ESTIMABLE="YES" MEAN_1="-6.8" MEAN_2="-6.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1697" SD_1="7.6" SD_2="7.2" SE="1.1157288348924488" STUDY_ID="STD-Tollefson-2001" TOTAL_1="89" TOTAL_2="87" WEIGHT="22.263074807208003"/>
<CONT_DATA CI_END="2.219750339085913" CI_START="-4.219750339085913" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-3.3" MEAN_2="-2.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1698" SD_1="7.3" SD_2="7.3" SE="1.6427599509393502" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="40" WEIGHT="10.26961698987348"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.666604810334966" CI_END="1.0039420552396947" CI_START="-1.254591233638146" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1253245891992257" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.10" MODIFIED="2009-09-15 14:38:10 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.7165535396922185" P_Q="0.41984456332308917" P_Z="0.8278075382305514" Q="0.6507510422810427" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="149" TOTAL_2="148" UNITS="" WEIGHT="100.0" Z="0.21751433323331953">
<NAME>Mental State: 2b. Positive symptoms - average endpoint score (BPRS positive, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.316798473876558" CI_START="-2.0967984738765573" DF="0" EFFECT_SIZE="1.11" ESTIMABLE="YES" I2="0.0" ID="CMP-003.10.01" MODIFIED="2009-09-15 14:38:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4975046846602792" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="5" WEIGHT="12.40079888886351" Z="0.6784211856660645">
<NAME>short term</NAME>
<CONT_DATA CI_END="4.316798473876558" CI_START="-2.0967984738765573" EFFECT_SIZE="1.11" ESTIMABLE="YES" MEAN_1="0.31" MEAN_2="-0.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1699" SD_1="2.87" SD_2="2.87" SE="1.636151735017263" STUDY_ID="STD-Conley-2003" TOTAL_1="8" TOTAL_2="5" WEIGHT="12.40079888886351"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.01585376805392319" CI_END="0.906352318358919" CI_START="-1.5067538141031054" DF="1" EFFECT_SIZE="-0.30020074787209317" ESTIMABLE="YES" I2="0.0" ID="CMP-003.10.02" MODIFIED="2009-09-15 14:38:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8998017876447708" P_Z="0.6257936347954762" STUDIES="2" TAU2="0.0" TOTAL_1="141" TOTAL_2="143" WEIGHT="87.5992011111365" Z="0.4876558440974841">
<NAME>medium term</NAME>
<CONT_DATA CI_END="1.5670050537394364" CI_START="-2.367005053739437" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="-5.9" MEAN_2="-5.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1700" SD_1="5.4" SD_2="5.0" SE="1.0035924482566627" STUDY_ID="STD-Naber-2005" TOTAL_1="52" TOTAL_2="56" WEIGHT="32.9596088743018"/>
<CONT_DATA CI_END="1.2877165224202352" CI_START="-1.7677165224202356" EFFECT_SIZE="-0.2400000000000002" ESTIMABLE="YES" MEAN_1="8.16" MEAN_2="8.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1701" SD_1="5.29" SD_2="5.05" SE="0.7794615281049388" STUDY_ID="STD-Tollefson-2001" TOTAL_1="89" TOTAL_2="87" WEIGHT="54.6395922368347"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="22.063815373103846" CI_START="-4.063815373103846" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="9.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.11" MODIFIED="2009-09-18 14:26:02 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.1769294437764986" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="1.3502698374915458">
<NAME>Mental State: 2c. Positive symptoms - average endpoint score (SAPS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="22.063815373103846" CI_START="-4.063815373103846" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="-13.0" MEAN_2="-22.0" MODIFIED="2009-09-18 14:26:02 +0100" MODIFIED_BY="[Empty name]" ORDER="925" SD_1="16.65" SD_2="16.65" SE="6.665334402136751" STUDY_ID="STD-Shaw-2006" TOTAL_1="13" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.8848673903709494" CI_END="0.21016250788587165" CI_START="-1.7672440198602581" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7785407559871932" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.12" MODIFIED="2009-09-15 14:38:29 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.8648354821124211" P_Q="0.4582981195992948" P_Z="0.12274669741245474" Q="0.5500481420354704" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="296" TOTAL_2="296" UNITS="" WEIGHT="100.0" Z="1.543346621770018">
<NAME>Mental State: 3a. Negative symptoms - average endpoint score (PANSS negative, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.01383171959485478" CI_END="0.4175807140557266" CI_START="-3.054706569431767" DF="1" EFFECT_SIZE="-1.3185629276880202" ESTIMABLE="YES" I2="0.0" ID="CMP-003.12.01" MODIFIED="2009-09-15 14:38:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9063780056817814" P_Z="0.13660602300381136" STUDIES="2" TAU2="0.0" TOTAL_1="46" TOTAL_2="43" WEIGHT="32.43102144246948" Z="1.4885495574678131">
<NAME>short term</NAME>
<CONT_DATA CI_END="0.571270970800164" CI_START="-3.131270970800164" EFFECT_SIZE="-1.28" ESTIMABLE="YES" MEAN_1="-0.72" MEAN_2="0.56" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1703" SD_1="3.0" SD_2="4.9" SE="0.9445433617162117" STUDY_ID="STD-Krakowski-2006" TOTAL_1="37" TOTAL_2="37" WEIGHT="28.522786646423878"/>
<CONT_DATA CI_END="3.401216373073388" CI_START="-6.601216373073384" EFFECT_SIZE="-1.5999999999999979" ESTIMABLE="YES" MEAN_1="17.3" MEAN_2="18.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1704" SD_1="3.4" SD_2="5.6" SE="2.5516878945339516" STUDY_ID="STD-Moresco-2004" TOTAL_1="9" TOTAL_2="6" WEIGHT="3.9082347960456003"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.3209875287406243" CI_END="0.6834500713631845" CI_START="-1.7221436780082966" DF="3" EFFECT_SIZE="-0.519346803322556" ESTIMABLE="YES" I2="0.0" ID="CMP-003.12.02" MODIFIED="2009-09-15 14:38:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7241556528400533" P_Z="0.3973974559915958" STUDIES="4" TAU2="0.0" TOTAL_1="250" TOTAL_2="253" WEIGHT="67.56897855753051" Z="0.8462784127737012">
<NAME>medium term</NAME>
<CONT_DATA CI_END="2.104399447868246" CI_START="-1.9043994478682449" EFFECT_SIZE="0.10000000000000053" ESTIMABLE="YES" MEAN_1="-7.6" MEAN_2="-7.7" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1705" SD_1="6.0" SD_2="6.1" SE="1.0226715713547252" STUDY_ID="STD-Bitter-2004" TOTAL_1="70" TOTAL_2="70" WEIGHT="24.331192055394755"/>
<CONT_DATA CI_END="2.727987652368163" CI_START="-3.727987652368163" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-8.5" MEAN_2="-8.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1706" SD_1="8.6" SD_2="8.5" SE="1.6469627390248585" STUDY_ID="STD-Naber-2005" TOTAL_1="52" TOTAL_2="56" WEIGHT="9.381411933976818"/>
<CONT_DATA CI_END="0.6132395651685871" CI_START="-3.613239565168587" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-5.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1707" SD_1="7.4" SD_2="6.9" SE="1.0782032638546173" STUDY_ID="STD-Tollefson-2001" TOTAL_1="89" TOTAL_2="87" WEIGHT="21.889430837449925"/>
<CONT_DATA CI_END="2.858079753051605" CI_START="-2.858079753051605" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-1.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1708" SD_1="6.48" SD_2="6.48" SE="1.4582307509708206" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="40" WEIGHT="11.966943730709023"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.1168292609683212" CI_END="0.80214441516483" CI_START="-0.4376978675398193" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.1822232738125054" ESTIMABLE="YES" I2="5.519068690257944" I2_Q="52.61714474756668" ID="CMP-003.13" MODIFIED="2009-09-15 14:38:39 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.3470056929280302" P_Q="0.14629462719823272" P_Z="0.564531802586878" Q="2.1104680050884976" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.01774533615175393" TOTALS="YES" TOTAL_1="149" TOTAL_2="148" UNITS="" WEIGHT="100.0" Z="0.5761233647208507">
<NAME>Mental State: 3b. Negative symptoms - average endpoint score (BPRS negative, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.7856162461633804" CI_START="-0.22561624616338039" DF="0" EFFECT_SIZE="0.78" ESTIMABLE="YES" I2="0.0" ID="CMP-003.13.01" MODIFIED="2009-09-15 14:38:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.12845220013253508" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="5" WEIGHT="35.602262763893926" Z="1.520233900132184">
<NAME>short term</NAME>
<CONT_DATA CI_END="1.7856162461633804" CI_START="-0.22561624616338039" EFFECT_SIZE="0.78" ESTIMABLE="YES" MEAN_1="1.08" MEAN_2="0.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1709" SD_1="0.9" SD_2="0.9" SE="0.5130789412946121" STUDY_ID="STD-Conley-2003" TOTAL_1="8" TOTAL_2="5" WEIGHT="35.602262763893926"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.006361255879823715" CI_END="0.5971755796427719" CI_START="-0.8921474502831558" DF="1" EFFECT_SIZE="-0.14748593532019194" ESTIMABLE="YES" I2="0.0" ID="CMP-003.13.02" MODIFIED="2009-09-15 14:38:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9364301414251006" P_Z="0.6978784467719754" STUDIES="2" TAU2="0.0" TOTAL_1="141" TOTAL_2="143" WEIGHT="64.39773723610607" Z="0.3881859282981168">
<NAME>medium term</NAME>
<CONT_DATA CI_END="1.2899218723883374" CI_START="-1.6899218723883378" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="-3.5" MEAN_2="-3.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1710" SD_1="3.8" SD_2="4.1" SE="0.7601781890589068" STUDY_ID="STD-Naber-2005" TOTAL_1="52" TOTAL_2="56" WEIGHT="16.79616762704195"/>
<CONT_DATA CI_END="0.7297458975617305" CI_START="-0.9897458975617303" EFFECT_SIZE="-0.1299999999999999" ESTIMABLE="YES" MEAN_1="5.15" MEAN_2="5.28" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1711" SD_1="3.22" SD_2="2.57" SE="0.4386539264717598" STUDY_ID="STD-Tollefson-2001" TOTAL_1="89" TOTAL_2="87" WEIGHT="47.60156960906412"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.6648406974518517" CI_END="14.331185781683494" CI_START="-4.707182423930136" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="4.812001678876679" ESTIMABLE="YES" I2="72.71368437118439" I2_Q="0.0" ID="CMP-003.14" MODIFIED="2009-09-18 14:26:13 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.055572165187241285" P_Q="1.0" P_Z="0.3217964803149891" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="36.356842185592164" TOTALS="YES" TOTAL_1="34" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.9907729362397403">
<NAME>Mental State: 3c. Negative symptoms - average endpoint score (SANS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.6025300443585557" CI_START="-1.6025300443585557" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="7.6" MEAN_2="6.6" MODIFIED="2009-09-18 14:26:13 +0100" MODIFIED_BY="[Empty name]" ORDER="926" SD_1="3.8" SD_2="4.4" SE="1.3278458506824515" STUDY_ID="STD-Kumra-2007" TOTAL_1="21" TOTAL_2="18" WEIGHT="61.87998321123322"/>
<CONT_DATA CI_END="20.901822823337568" CI_START="1.0981771766624302" EFFECT_SIZE="11.0" ESTIMABLE="YES" MEAN_1="-14.0" MEAN_2="-25.0" MODIFIED="2009-09-18 14:26:13 +0100" MODIFIED_BY="[Empty name]" ORDER="927" SD_1="12.62" SD_2="12.62" SE="5.052043252550498" STUDY_ID="STD-Shaw-2006" TOTAL_1="13" TOTAL_2="12" WEIGHT="38.12001678876679"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.274358431556536" CI_START="-21.674358431556534" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.2" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.15" MODIFIED="2009-09-15 14:24:37 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.23296256071310084" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="50" UNITS="" WEIGHT="100.0" Z="1.1927621455867614">
<NAME>Quality of Life: General - average endpoint score - medium term (SWN total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.274358431556536" CI_START="-21.674358431556534" EFFECT_SIZE="-8.2" ESTIMABLE="YES" MEAN_1="-21.9" MEAN_2="-13.7" MODIFIED="2009-09-15 14:24:37 +0100" MODIFIED_BY="[Empty name]" ORDER="1351" SD_1="38.4" SD_2="29.3" SE="6.8747989952063175" STUDY_ID="STD-Naber-2005" TOTAL_1="49" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8705425523038219" CI_START="0.42599844075031923" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6089743589743589" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-003.16" LOG_CI_END="-0.06020999562180682" LOG_CI_START="-0.37059199050942093" LOG_EFFECT_SIZE="-0.2154009930656139" METHOD="MH" MODIFIED="2009-09-15 14:22:02 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.006520731171794632" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="40" WEIGHT="100.0" Z="2.7203780863360403">
<NAME>Cognitive functioning: 1a. General - no clinically important change - medium term (less than ½ SD in global neurocognitive score improved)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8705425523038219" CI_START="0.42599844075031923" EFFECT_SIZE="0.6089743589743589" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="32" LOG_CI_END="-0.06020999562180682" LOG_CI_START="-0.37059199050942093" LOG_EFFECT_SIZE="-0.2154009930656139" MODIFIED="2009-09-15 14:22:02 +0100" MODIFIED_BY="[Empty name]" ORDER="1349" O_E="0.0" SE="0.18231992021263824" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="40" VAR="0.03324055330634278" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.6566152399988853" CI_START="-0.07661523999888531" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.29" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.17" MODIFIED="2010-02-17 14:11:01 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.12105254774736093" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="1.5503707797808512">
<NAME>Cognitive functioning: 1b. General - average endpoint score - medium term (global neurocognitive score, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6566152399988853" CI_START="-0.07661523999888531" EFFECT_SIZE="0.29" ESTIMABLE="YES" MEAN_1="0.25" MEAN_2="-0.04" MODIFIED="2009-09-15 14:24:27 +0100" MODIFIED_BY="[Empty name]" ORDER="1350" SD_1="0.59" SD_2="0.72" SE="0.1870520289610929" STUDY_ID="STD-Volavka-2002" TOTAL_1="26" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6104703411858263" CI_START="1.0173425477637847" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.28" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="100" I2="0.0" I2_Q="0.0" ID="CMP-003.18" LOG_CI_END="0.20695273115636753" LOG_CI_START="0.007467208139369269" LOG_EFFECT_SIZE="0.10720996964786837" METHOD="MH" MODIFIED="2010-02-17 14:12:16 +0000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="1.0" P_Q="0.0" P_Z="0.03514393690541478" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="490" TOTAL_2="490" WEIGHT="100.0" Z="2.1066960260123664">
<NAME>Service use: Number of patients re-hospitalised - long term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6104703411858263" CI_START="1.0173425477637847" EFFECT_SIZE="1.28" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="100" LOG_CI_END="0.20695273115636753" LOG_CI_START="0.007467208139369269" LOG_EFFECT_SIZE="0.10720996964786837" MODIFIED="2009-09-15 14:28:15 +0100" MODIFIED_BY="[Empty name]" ORDER="1352" O_E="0.0" SE="0.11717878368944942" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.013730867346938777" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="29.688749325030283" CI_END="0.9748954386892784" CI_START="0.5284091432598247" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7177350928620618" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="128" I2="79.79032415844658" I2_Q="0.0" ID="CMP-003.19" LOG_CI_END="-0.011041961568540652" LOG_CI_START="-0.2770296762336391" LOG_EFFECT_SIZE="-0.1440358189010899" METHOD="MH" MODIFIED="2009-09-15 14:28:38 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="4.5042132841954796E-5" P_Q="0.0" P_Z="0.033779656892934655" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.10142672156806215" TOTALS="YES" TOTAL_1="215" TOTAL_2="207" WEIGHT="99.99999999999999" Z="2.1226921542998047">
<NAME>Adverse effects: 1. General - at least one adverse effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4887546069395912" CI_START="0.2506859865391608" EFFECT_SIZE="0.610909090909091" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.17282311841382114" LOG_CI_START="-0.6008699426226207" LOG_EFFECT_SIZE="-0.21402341210439976" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1718" O_E="0.0" SE="0.454471133895225" STUDY_ID="STD-Bitter-2004" TOTAL_1="75" TOTAL_2="72" VAR="0.20654401154401153" WEIGHT="7.926635962825942"/>
<DICH_DATA CI_END="1.3346075891202989" CI_START="0.7492839154759685" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.12535359009642288" LOG_CI_START="-0.1253535900964228" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1719" O_E="0.0" SE="0.14726663866583445" STUDY_ID="STD-Conley-2003" TOTAL_1="8" TOTAL_2="5" VAR="0.021687462863933443" WEIGHT="19.828518540302394"/>
<DICH_DATA CI_END="1.0756498167359423" CI_START="0.7704007530247264" EFFECT_SIZE="0.9103194103194103" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.031670907564394155" LOG_CI_START="-0.11328330138414028" LOG_EFFECT_SIZE="-0.040806196909873055" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1720" O_E="0.0" SE="0.08514681987127566" STUDY_ID="STD-Kumra-2007" TOTAL_1="21" TOTAL_2="18" VAR="0.007249980934191463" WEIGHT="22.462697453793382"/>
<DICH_DATA CI_END="1.9089738099007443" CI_START="0.2770732720854939" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.28079997014662067" LOG_CI_START="-0.5574053664791835" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1721" O_E="0.0" SE="0.4923659639173309" STUDY_ID="STD-Moresco-2004" TOTAL_1="11" TOTAL_2="12" VAR="0.24242424242424238" WEIGHT="7.099505728413975"/>
<DICH_DATA CI_END="0.9954128062610806" CI_START="0.7192757887556831" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="52" LOG_CI_END="-0.0019967762374199726" LOG_CI_START="-0.1431045580598035" LOG_EFFECT_SIZE="-0.07255066714861173" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1722" O_E="0.0" SE="0.08288740953725329" STUDY_ID="STD-Naber-2005" TOTAL_1="57" TOTAL_2="57" VAR="0.006870322659796348" WEIGHT="22.5414452073851"/>
<DICH_DATA CI_END="1.1446122623134711" CI_START="0.18610472602201733" EFFECT_SIZE="0.46153846153846156" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.05865839422530557" LOG_CI_START="-0.7302425980716918" LOG_EFFECT_SIZE="-0.3357921019231931" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1723" O_E="0.0" SE="0.46340434799814917" STUDY_ID="STD-Shaw-2006" TOTAL_1="13" TOTAL_2="12" VAR="0.21474358974358976" WEIGHT="7.721066150887736"/>
<DICH_DATA CI_END="0.5403808659720912" CI_START="0.16130388466478457" EFFECT_SIZE="0.29523809523809524" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="28" LOG_CI_END="-0.2673000370553624" LOG_CI_START="-0.7923551734159682" LOG_EFFECT_SIZE="-0.5298276052356654" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1724" O_E="0.0" SE="0.308419986163062" STUDY_ID="STD-Wang-2002" TOTAL_1="30" TOTAL_2="31" VAR="0.09512288786482334" WEIGHT="12.420130956391466"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.561940972639736" CI_END="2.037166989414686" CI_START="1.0299825418681299" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4485325104971527" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="54" I2="64.04132999903474" I2_Q="0.0" ID="CMP-003.20" LOG_CI_END="0.30902663018271925" LOG_CI_START="0.012829863506539094" LOG_EFFECT_SIZE="0.1609282468446291" METHOD="MH" MODIFIED="2009-09-15 14:39:20 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.06197837429376285" P_Q="0.0" P_Z="0.03319168079844224" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.31401195868543313" TOTALS="SUB" TOTAL_1="1576" TOTAL_2="1570" WEIGHT="300.0" Z="2.1297569953251627">
<NAME>Adverse effects: 2. Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6166000599467671" CI_START="0.2749254162832825" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" I2="0.0" ID="CMP-003.20.01" LOG_CI_END="0.20860259056704142" LOG_CI_START="-0.5607851086784039" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2009-09-15 14:39:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3696327354849107" STUDIES="1" TAU2="0.0" TOTAL_1="490" TOTAL_2="490" WEIGHT="100.0" Z="0.8971615378824658">
<NAME>any reason</NAME>
<DICH_DATA CI_END="1.6166000599467671" CI_START="0.2749254162832825" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.20860259056704142" LOG_CI_START="-0.5607851086784039" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1732" O_E="0.0" SE="0.4519421430673091" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.2042517006802721" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.20.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-15 14:39:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="98" TOTAL_2="95" WEIGHT="0.0" Z="0.0">
<NAME>natural causes</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1733" O_E="0.0" SE="0.0" STUDY_ID="STD-Conley-2003" TOTAL_1="8" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1734" O_E="0.0" SE="0.0" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6150704045350928" CI_START="1.2167491099941028" DF="0" EFFECT_SIZE="1.7837837837837838" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="37" I2="0.0" ID="CMP-003.20.03" LOG_CI_END="0.4174833857040544" LOG_CI_START="0.08520103724569288" LOG_EFFECT_SIZE="0.2513422114748737" MODIFIED="2009-09-15 14:39:16 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.003026053555682757" STUDIES="1" TAU2="0.0" TOTAL_1="490" TOTAL_2="490" WEIGHT="100.0" Z="2.965078852794571">
<NAME>suicide attempt</NAME>
<DICH_DATA CI_END="2.6150704045350928" CI_START="1.2167491099941028" EFFECT_SIZE="1.7837837837837838" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="37" LOG_CI_END="0.4174833857040544" LOG_CI_START="0.08520103724569288" LOG_EFFECT_SIZE="0.2513422114748737" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1735" O_E="0.0" SE="0.19518429630859385" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.03809690952548096" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.49688023550441" CI_START="0.1441799229618533" DF="0" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-003.20.04" LOG_CI_END="0.397397711631699" LOG_CI_START="-0.8410952108644117" LOG_EFFECT_SIZE="-0.22184874961635637" MODIFIED="2009-09-15 14:39:20 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.4825738906578896" STUDIES="2" TAU2="0.0" TOTAL_1="498" TOTAL_2="495" WEIGHT="100.0" Z="0.7021688236812158">
<NAME>suicide</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1736" O_E="0.0" SE="0.0" STUDY_ID="STD-Conley-2003" TOTAL_1="8" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.49688023550441" CI_START="0.1441799229618533" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.397397711631699" LOG_CI_START="-0.8410952108644117" LOG_EFFECT_SIZE="-0.22184874961635637" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1737" O_E="0.0" SE="0.7274968733130556" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.529251700680272" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.026881881883944067" CI_END="2.6217167485821906" CI_START="0.06523617597010117" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.413558671961149" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.21" LOG_CI_END="0.41858576852386786" LOG_CI_START="-1.1855115044643494" LOG_EFFECT_SIZE="-0.3834628679702408" METHOD="MH" MODIFIED="2009-09-15 14:29:03 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.8697650569456338" P_Q="0.0" P_Z="0.34872404140772084" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="78" TOTAL_2="74" WEIGHT="200.0" Z="0.9370671258982066">
<NAME>Adverse effects: 3. Cardiac effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.461189224607842" CI_START="0.04774909575776068" DF="0" EFFECT_SIZE="0.46153846153846156" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.21.01" LOG_CI_END="0.6494506445507751" LOG_CI_START="-1.3210348483971615" LOG_EFFECT_SIZE="-0.3357921019231931" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.504134716733027" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="12" WEIGHT="100.00000000000001" Z="0.6679982455266427">
<NAME>ECG abnormalities</NAME>
<DICH_DATA CI_END="4.461189224607842" CI_START="0.04774909575776068" EFFECT_SIZE="0.46153846153846156" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6494506445507751" LOG_CI_START="-1.3210348483971615" LOG_EFFECT_SIZE="-0.3357921019231931" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1725" O_E="0.0" SE="1.1574729326181195" STUDY_ID="STD-Shaw-2006" TOTAL_1="13" TOTAL_2="12" VAR="1.3397435897435899" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.01435715286672" CI_START="0.013864007928741599" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-003.21.02" LOG_CI_END="0.9038686924843776" LOG_CI_START="-1.8581112019237023" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.49830935313259794" STUDIES="2" TAU2="0.0" TOTAL_1="65" TOTAL_2="62" WEIGHT="99.99999999999999" Z="0.6771522684885509">
<NAME>QTc prolongation</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1726" O_E="0.0" SE="0.0" STUDY_ID="STD-Conley-2003" TOTAL_1="8" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.01435715286672" CI_START="0.013864007928741599" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9038686924843776" LOG_CI_START="-1.8581112019237023" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1727" O_E="0.0" SE="1.622400661996283" STUDY_ID="STD-Naber-2005" TOTAL_1="57" TOTAL_2="57" VAR="2.632183908045977" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="56.64892716377765" CI_END="0.9482783596508516" CI_START="0.3877301633912796" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6063630293214117" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="297" I2="89.40844902030818" I2_Q="0.0" ID="CMP-003.22" LOG_CI_END="-0.023064160219475934" LOG_CI_START="-0.41147041182532273" LOG_EFFECT_SIZE="-0.2172672860223994" METHOD="MH" MODIFIED="2009-09-15 14:29:36 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="2.1516954884504003E-10" P_Q="0.0" P_Z="0.02832645352409447" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.24422624381461278" TOTALS="YES" TOTAL_1="727" TOTAL_2="718" WEIGHT="100.0" Z="2.192735332462168">
<NAME>Adverse effects: 4a. Central nervous system - sedation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7602962627242212" CI_START="0.04007137374753896" EFFECT_SIZE="0.17454545454545456" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.11901714430508824" LOG_CI_START="-1.3971657686042627" LOG_EFFECT_SIZE="-0.7580914564546755" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1775" O_E="0.0" SE="0.7507908288510647" STUDY_ID="STD-Bitter-2004" TOTAL_1="75" TOTAL_2="72" VAR="0.5636868686868688" WEIGHT="6.442923431855855"/>
<DICH_DATA CI_END="1.3346075891202989" CI_START="0.7492839154759685" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.12535359009642288" LOG_CI_START="-0.1253535900964228" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1776" O_E="0.0" SE="0.14726663866583445" STUDY_ID="STD-Conley-2003" TOTAL_1="8" TOTAL_2="5" VAR="0.021687462863933443" WEIGHT="19.575231335223812"/>
<DICH_DATA CI_END="1.0756498167359423" CI_START="0.7704007530247264" EFFECT_SIZE="0.9103194103194103" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.031670907564394155" LOG_CI_START="-0.11328330138414028" LOG_EFFECT_SIZE="-0.040806196909873055" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1777" O_E="0.0" SE="0.08514681987127566" STUDY_ID="STD-Kumra-2007" TOTAL_1="21" TOTAL_2="18" VAR="0.007249980934191463" WEIGHT="20.699063414996417"/>
<DICH_DATA CI_END="0.6455569498153823" CI_START="0.445639924557386" EFFECT_SIZE="0.5363636363636364" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="220" LOG_CI_END="-0.1900654390682271" LOG_CI_START="-0.35101590796393456" LOG_EFFECT_SIZE="-0.27054067351608085" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1778" O_E="0.0" SE="0.09454310214700891" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.008938398163579761" WEIGHT="20.56101627291134"/>
<DICH_DATA CI_END="5.56234492778025" CI_START="0.15318557496526802" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7452579164926992" LOG_CI_START="-0.814782129011123" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1779" O_E="0.0" SE="0.9163752450517145" STUDY_ID="STD-Shaw-2006" TOTAL_1="13" TOTAL_2="12" VAR="0.8397435897435898" WEIGHT="4.802091499495495"/>
<DICH_DATA CI_END="1.0342562750946585" CI_START="0.2876662857373476" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" LOG_CI_END="0.014628164550113218" LOG_CI_START="-0.541111034099276" LOG_EFFECT_SIZE="-0.26324143477458145" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1780" O_E="0.0" SE="0.32644395624005135" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.10656565656565656" WEIGHT="14.838775689508966"/>
<DICH_DATA CI_END="0.7036482481535002" CI_START="0.15132844391961717" EFFECT_SIZE="0.3263157894736842" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="19" LOG_CI_END="-0.15264438924240317" LOG_CI_START="-0.8200794336667468" LOG_EFFECT_SIZE="-0.4863619114545751" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1781" O_E="0.0" SE="0.3920546489516133" STUDY_ID="STD-Wang-2002" TOTAL_1="30" TOTAL_2="31" VAR="0.15370684776457272" WEIGHT="13.080898356008106"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.05287311254483192" CI_END="0.5790007454209949" CI_START="0.04087014177133309" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.1538305644241859" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-003.23" LOG_CI_END="-0.2373208771499103" LOG_CI_START="-1.3885938557946247" LOG_EFFECT_SIZE="-0.8129573664722674" METHOD="MH" MODIFIED="2009-09-15 14:30:06 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.8181371970395255" P_Q="0.0" P_Z="0.005639984521415206" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="550" TOTAL_2="547" WEIGHT="99.99999999999999" Z="2.7680093058865953">
<NAME>Adverse effects: 4b. Central nervous system - seizures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1782" O_E="0.0" SE="0.0" STUDY_ID="STD-Conley-2003" TOTAL_1="8" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.7407748278150497" CI_START="0.037498274421270024" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.13031378378665284" LOG_CI_START="-1.4259887169806345" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1783" O_E="0.0" SE="0.7610858694525028" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.5792517006802721" WEIGHT="78.95224970445891"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1784" O_E="0.0" SE="0.0" STUDY_ID="STD-Shaw-2006" TOTAL_1="13" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.0473753342126653" CI_START="0.006335271699135546" EFFECT_SIZE="0.11388888888888889" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.31119746681250704" LOG_CI_START="-2.1982347549076104" LOG_EFFECT_SIZE="-0.9435186440475518" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1785" O_E="0.0" SE="1.4740529089282322" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="40" VAR="2.1728319783197834" WEIGHT="21.047750295541082"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.418823600395276" CI_END="1.9251699797458686" CI_START="0.903946824991375" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3191858439052428" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="68" I2="16.77545732877242" I2_Q="0.0" ID="CMP-003.24" LOG_CI_END="0.28446908086093814" LOG_CI_START="-0.043857116307881" LOG_EFFECT_SIZE="0.12030598227652857" METHOD="MH" MODIFIED="2009-09-15 14:40:01 +0100" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.2747662560776566" P_Q="0.0" P_Z="0.15090324825726054" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.07125337432086101" TOTALS="SUB" TOTAL_1="1807" TOTAL_2="1792" WEIGHT="500.0" Z="1.4363483293139019">
<NAME>Adverse effects: 5a. Extrapyramidal effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.65744407783331" CI_END="2.6269122740484665" CI_START="0.7101032576265337" DF="3" EFFECT_SIZE="1.3657887696495903" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="33" I2="35.58698827371364" ID="CMP-003.24.01" LOG_CI_END="0.4194455697282775" LOG_CI_START="-0.14867849500372274" LOG_EFFECT_SIZE="0.13538353736227737" MODIFIED="2009-09-15 14:39:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.19866934404031167" P_Z="0.3502441288314534" STUDIES="4" TAU2="0.15565919249984111" TOTAL_1="663" TOTAL_2="657" WEIGHT="99.99999999999999" Z="0.93411588701094">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="157.74559078529512" CI_START="0.4737468394344402" EFFECT_SIZE="8.644736842105264" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.19795722893438" LOG_CI_START="-0.324453674376401" LOG_EFFECT_SIZE="0.9367517772789895" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1738" O_E="0.0" SE="1.4816766507400978" STUDY_ID="STD-Bitter-2004" TOTAL_1="75" TOTAL_2="72" VAR="2.195365697348394" WEIGHT="4.737010510215855"/>
<DICH_DATA CI_END="3.127616147313433" CI_START="0.1248954416402857" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.4952134466470529" LOG_CI_START="-0.9034534119589024" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1739" O_E="0.0" SE="0.8215838362577492" STUDY_ID="STD-Conley-2003" TOTAL_1="8" TOTAL_2="5" VAR="0.675" WEIGHT="13.407218885370115"/>
<DICH_DATA CI_END="3.109758008589811" CI_START="1.1090829518920515" EFFECT_SIZE="1.8571428571428572" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="21" LOG_CI_END="0.4927265949358066" LOG_CI_START="0.04496402964935331" LOG_EFFECT_SIZE="0.26884531229257996" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1740" O_E="0.0" SE="0.2630179473097074" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.06917844060701203" WEIGHT="49.53276486279959"/>
<DICH_DATA CI_END="2.1095323316433627" CI_START="0.3839713607844995" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.32418618596189125" LOG_CI_START="-0.41570116708324145" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1741" O_E="0.0" SE="0.4346134936801766" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.1888888888888889" WEIGHT="32.32300574161444"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4387820195812616" CI_END="6.4534317439874815" CI_START="0.8131130178828598" DF="1" EFFECT_SIZE="2.2907137230685786" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" I2="0.0" ID="CMP-003.24.02" LOG_CI_END="0.8097907210127614" LOG_CI_START="-0.0898490858553801" LOG_EFFECT_SIZE="0.35997081757869065" MODIFIED="2009-09-15 14:39:41 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5077109322640112" P_Z="0.11677106391210541" STUDIES="2" TAU2="0.0" TOTAL_1="165" TOTAL_2="162" WEIGHT="100.0" Z="1.5684718096140888">
<NAME>dyskinesia</NAME>
<DICH_DATA CI_END="15.63912644025415" CI_START="0.7218817523555063" EFFECT_SIZE="3.36" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.194212490873914" LOG_CI_START="-0.14153393609422593" LOG_EFFECT_SIZE="0.5263392773898441" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1742" O_E="0.0" SE="0.7846240632525366" STUDY_ID="STD-Bitter-2004" TOTAL_1="75" TOTAL_2="72" VAR="0.6156349206349206" WEIGHT="45.36169613298584"/>
<DICH_DATA CI_END="6.766904654857571" CI_START="0.41049459382936204" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8303900573522516" LOG_CI_START="-0.3866925581195388" LOG_EFFECT_SIZE="0.22184874961635637" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1743" O_E="0.0" SE="0.7149203529842406" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.5111111111111112" WEIGHT="54.63830386701415"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.24.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-15 14:39:45 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="41" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>extrapyramidal symptoms</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1744" O_E="0.0" SE="0.0" STUDY_ID="STD-Moresco-2004" TOTAL_1="11" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1745" O_E="0.0" SE="0.0" STUDY_ID="STD-Wang-2002" TOTAL_1="30" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9981312723190336" CI_START="0.3027520163391698" DF="0" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" ID="CMP-003.24.04" LOG_CI_END="0.3006240169084849" LOG_CI_START="-0.518912955758621" LOG_EFFECT_SIZE="-0.10914446942506803" MODIFIED="2009-09-15 14:39:50 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.6016362153104362" STUDIES="2" TAU2="0.0" TOTAL_1="165" TOTAL_2="162" WEIGHT="100.0" Z="0.5220490016177952">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1746" O_E="0.0" SE="0.0" STUDY_ID="STD-Bitter-2004" TOTAL_1="75" TOTAL_2="72" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.9981312723190336" CI_START="0.3027520163391698" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.3006240169084849" LOG_CI_START="-0.518912955758621" LOG_EFFECT_SIZE="-0.10914446942506803" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1747" O_E="0.0" SE="0.4814000745180995" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.23174603174603176" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="49.652863998071" CI_START="0.7250337060395668" DF="0" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-003.24.05" LOG_CI_END="1.6959443038421902" LOG_CI_START="-0.139641803074903" LOG_EFFECT_SIZE="0.7781512503836436" MODIFIED="2009-09-15 14:39:56 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.09656163958053487" STUDIES="1" TAU2="0.0" TOTAL_1="490" TOTAL_2="490" WEIGHT="100.0" Z="1.6617563398736674">
<NAME>rigor</NAME>
<DICH_DATA CI_END="49.652863998071" CI_START="0.7250337060395668" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6959443038421902" LOG_CI_START="-0.139641803074903" LOG_EFFECT_SIZE="0.7781512503836436" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1748" O_E="0.0" SE="1.0782323655008716" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="1.1625850340136055" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.5191101427675395" CI_END="2.185152626872546" CI_START="0.5979743128255618" DF="4" EFFECT_SIZE="1.1430945457279909" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" I2="11.48699912964795" ID="CMP-003.24.06" LOG_CI_END="0.3394817766353059" LOG_CI_START="-0.22331747159306153" LOG_EFFECT_SIZE="0.05808215252112215" MODIFIED="2009-09-15 14:40:01 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.3402876490224821" P_Z="0.6858116913659126" STUDIES="6" TAU2="0.0640917207690411" TOTAL_1="283" TOTAL_2="278" WEIGHT="100.0" Z="0.40454541275353395">
<NAME>use of antiparkinson medication</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1749" O_E="0.0" SE="0.0" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.388861351229945" CI_START="0.4989131375954651" EFFECT_SIZE="1.92" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8685775172881333" LOG_CI_START="-0.3019750598810341" LOG_EFFECT_SIZE="0.28330122870354957" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1750" O_E="0.0" SE="0.6875883781578757" STUDY_ID="STD-Bitter-2004" TOTAL_1="75" TOTAL_2="72" VAR="0.4727777777777778" WEIGHT="20.356986585717298"/>
<DICH_DATA CI_END="41.366590273818105" CI_START="0.09669639130329037" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6166497247559435" LOG_CI_START="-1.014589733427981" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1751" O_E="0.0" SE="1.5456030825826172" STUDY_ID="STD-Conley-2003" TOTAL_1="8" TOTAL_2="5" VAR="2.388888888888889" WEIGHT="4.455414419978815"/>
<DICH_DATA CI_END="8.576441277979425" CI_START="0.6348139359880434" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9333071183912652" LOG_CI_START="-0.19735354780207648" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1752" O_E="0.0" SE="0.6641556721825317" STUDY_ID="STD-Naber-2005" TOTAL_1="57" TOTAL_2="57" VAR="0.44110275689223055" WEIGHT="21.633342531361144"/>
<DICH_DATA CI_END="1.3910327152018094" CI_START="0.14200303273879028" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.14333734412902846" LOG_CI_START="-0.8477023803517534" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1753" O_E="0.0" SE="0.582141639885766" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.33888888888888885" WEIGHT="27.12052371322651"/>
<DICH_DATA CI_END="3.2667179989190243" CI_START="0.3220172398799246" EFFECT_SIZE="1.0256410256410255" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5141116454030732" LOG_CI_START="-0.49212087680014693" LOG_EFFECT_SIZE="0.010995384301463145" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1754" O_E="0.0" SE="0.5910659644734878" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="40" VAR="0.34935897435897434" WEIGHT="26.433732749716235"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="14.462866383002218" CI_END="0.1843055193169726" CI_START="-0.24886788112874259" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.032281180905885005" ESTIMABLE="YES" I2="23.94315408370241" I2_Q="30.913514986859994" ID="CMP-003.25" MODIFIED="2009-09-15 15:48:54 +0100" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.20843059746681447" P_Q="0.21540223356961619" P_Z="0.7701925987080621" Q="5.789844423607908" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.06383587803032942" TOTALS="SUB" TOTAL_1="620" TOTAL_2="604" UNITS="" WEIGHT="500.0" Z="0.29212297841397866">
<NAME>Adverse effects: 5b. Extrapyramidal effects - scale measured</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.315220956864533" CI_END="0.25203618494507596" CI_START="-0.5095780588143263" DF="2" EFFECT_SIZE="-0.12877093693462519" ESTIMABLE="YES" I2="0.0" ID="CMP-003.25.01" MODIFIED="2009-09-15 15:47:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5180878737736643" P_Z="0.5074797876747562" STUDIES="3" TAU2="0.0" TOTAL_1="179" TOTAL_2="173" WEIGHT="100.0" Z="0.6627670128687198">
<NAME>abnormal involuntary movements: AIMS (high=poor)</NAME>
<CONT_DATA CI_END="1.1821573637565417" CI_START="-0.5821573637565416" EFFECT_SIZE="0.30000000000000004" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="-0.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1755" SD_1="2.5" SD_2="2.8" SE="0.45008855811376447" STUDY_ID="STD-Bitter-2004" TOTAL_1="69" TOTAL_2="70" WEIGHT="18.634510824105465"/>
<CONT_DATA CI_END="0.22984766224587827" CI_START="-0.8298476622458784" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1756" SD_1="0.2" SD_2="1.1" SE="0.270335407397916" STUDY_ID="STD-Kumra-2007" TOTAL_1="21" TOTAL_2="17" WEIGHT="51.65449011552351"/>
<CONT_DATA CI_END="0.5986287184904151" CI_START="-0.7986287184904153" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-0.7" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1757" SD_1="2.2" SD_2="2.5" SE="0.3564497735678356" STUDY_ID="STD-Tollefson-2001" TOTAL_1="89" TOTAL_2="86" WEIGHT="29.710999060371034"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.38218737983157086" CI_START="-0.1821873798315708" DF="0" EFFECT_SIZE="0.10000000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-003.25.02" MODIFIED="2009-09-15 15:48:04 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.48733035462310526" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="86" WEIGHT="100.0" Z="0.6945611762332882">
<NAME>akathisia: BAS (high=poor)</NAME>
<CONT_DATA CI_END="0.38218737983157086" CI_START="-0.1821873798315708" EFFECT_SIZE="0.10000000000000003" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="-0.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1758" SD_1="0.9" SD_2="1.0" SE="0.14397579856437612" STUDY_ID="STD-Tollefson-2001" TOTAL_1="89" TOTAL_2="86" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.0983747844675396" CI_START="-2.298374784467539" DF="0" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" I2="0.0" ID="CMP-003.25.03" MODIFIED="2009-09-15 15:48:19 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.7714032158524604" STUDIES="1" TAU2="0.0" TOTAL_1="68" TOTAL_2="69" WEIGHT="100.0" Z="0.2905399199284037">
<NAME>akathisia: HAS (high=poor)</NAME>
<CONT_DATA CI_END="3.0983747844675396" CI_START="-2.298374784467539" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-2.7" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1759" SD_1="8.9" SD_2="7.1" SE="1.376747126861501" STUDY_ID="STD-Bitter-2004" TOTAL_1="68" TOTAL_2="69" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.22752790065100315" CI_START="-2.8275279006510026" DF="0" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-003.25.04" MODIFIED="2009-09-15 15:48:34 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.09531096505265486" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="40" WEIGHT="100.0" Z="1.6680239875266316">
<NAME>extrapyramidal symptoms: ESRS (high=poor)</NAME>
<CONT_DATA CI_END="0.22752790065100315" CI_START="-2.8275279006510026" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="5.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1760" SD_1="3.1" SD_2="3.8" SE="0.7793652907400075" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.357801002529777" CI_END="0.45110211586480503" CI_START="-1.3046422530258184" DF="5" EFFECT_SIZE="-0.42677006858050665" ESTIMABLE="YES" I2="32.0449139861096" ID="CMP-003.25.05" MODIFIED="2009-09-15 15:48:54 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.19536102783734388" P_Z="0.34068141244077743" STUDIES="6" TAU2="0.3722853202867586" TOTAL_1="245" TOTAL_2="236" WEIGHT="100.0" Z="0.9528197600041287">
<NAME>extrapyramidal symptoms: SAS (high=poor)</NAME>
<CONT_DATA CI_END="1.355131378937334" CI_START="-1.5551313789373342" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="-3.0" MEAN_2="-2.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1761" SD_1="4.8" SD_2="3.9" SE="0.7424276111271557" STUDY_ID="STD-Bitter-2004" TOTAL_1="69" TOTAL_2="70" WEIGHT="21.723859381258883"/>
<CONT_DATA CI_END="5.4101179569610025" CI_START="-2.590117956961002" EFFECT_SIZE="1.41" ESTIMABLE="YES" MEAN_1="0.25" MEAN_2="-1.16" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1762" SD_1="3.58" SD_2="3.58" SE="2.040914010927457" STUDY_ID="STD-Conley-2003" TOTAL_1="8" TOTAL_2="5" WEIGHT="4.421185322324288"/>
<CONT_DATA CI_END="1.9957966620851664" CI_START="-0.9957966620851664" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="1.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1763" SD_1="2.7" SD_2="2.0" SE="0.7631755858188312" STUDY_ID="STD-Kumra-2007" TOTAL_1="21" TOTAL_2="17" WEIGHT="21.013061448192605"/>
<CONT_DATA CI_END="2.510169880833475" CI_START="-2.510169880833475" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1764" SD_1="2.43" SD_2="2.43" SE="1.2807224523681937" STUDY_ID="STD-Moresco-2004" TOTAL_1="9" TOTAL_2="6" WEIGHT="9.968340952916607"/>
<CONT_DATA CI_END="1.1918401944191759" CI_START="-2.391840194419176" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="-2.7" MEAN_2="-2.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1765" SD_1="4.8" SD_2="4.5" SE="0.9142209798511517" STUDY_ID="STD-Naber-2005" TOTAL_1="50" TOTAL_2="54" WEIGHT="16.60614355254618"/>
<CONT_DATA CI_END="-0.5737123253188225" CI_START="-3.026287674681178" EFFECT_SIZE="-1.8000000000000003" ESTIMABLE="YES" MEAN_1="-3.2" MEAN_2="-1.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1766" SD_1="4.8" SD_2="3.3" SE="0.625668473683179" STUDY_ID="STD-Tollefson-2001" TOTAL_1="88" TOTAL_2="84" WEIGHT="26.26740934276145"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.8813710443908875" CI_END="0.4149448110778203" CI_START="0.07884306567374899" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.18087432374660023" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-003.26" LOG_CI_END="-0.38200966193421787" LOG_CI_START="-1.1032364972882376" LOG_EFFECT_SIZE="-0.7426230796112276" METHOD="MH" MODIFIED="2009-09-15 14:31:35 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.8299210214129877" P_Q="0.0" P_Z="5.4319667513931065E-5" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="632" TOTAL_2="632" WEIGHT="100.0" Z="4.036218340133662">
<NAME>Adverse effects: 6. Haematological - significant low white blood cell count (as def. by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.40422831385276814" CI_START="0.05048672387837574" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="28" LOG_CI_END="-0.39337326994155225" LOG_CI_START="-1.2968228100869617" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1800" O_E="0.0" SE="0.530690732028763" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.2816326530612244" WEIGHT="63.72883109010574"/>
<DICH_DATA CI_END="4.461189224607842" CI_START="0.04774909575776068" EFFECT_SIZE="0.46153846153846156" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6494506445507751" LOG_CI_START="-1.3210348483971615" LOG_EFFECT_SIZE="-0.3357921019231931" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1801" O_E="0.0" SE="1.1574729326181195" STUDY_ID="STD-Shaw-2006" TOTAL_1="13" TOTAL_2="12" VAR="1.3397435897435899" WEIGHT="13.396682703913642"/>
<DICH_DATA CI_END="1.6780329195458952" CI_START="0.023837434614110364" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.22480047653850477" LOG_CI_START="-1.6227404852105425" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1802" O_E="0.0" SE="1.0852547064066471" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="1.1777777777777778" WEIGHT="15.238969621469256"/>
<DICH_DATA CI_END="4.137999122815991" CI_START="0.010155874554995345" EFFECT_SIZE="0.205" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6167903942668315" LOG_CI_START="-1.9932826721553232" LOG_EFFECT_SIZE="-0.6882461389442457" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1803" O_E="0.0" SE="1.5331698392864246" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="40" VAR="2.350609756097561" WEIGHT="7.6355165845113575"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="19.70307548069967" CI_END="1.0700097445486072" CI_START="0.11902061544569703" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5945151799971521" ESTIMABLE="YES" I2="84.773950630506" I2_Q="88.21226961020481" ID="CMP-003.27" MODIFIED="2009-09-15 14:42:10 +0100" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="1.9557201808628744E-4" P_Q="2.06876777043008E-4" P_Z="0.014263387126396833" Q="16.966794572527963" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="102.33279140363943" TOTALS="SUB" TOTAL_1="95" TOTAL_2="90" UNITS="" WEIGHT="300.0" Z="2.4505608011648934">
<NAME>Adverse effects: 7. Prolactin - change from baseline in ng/ml</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.045925642228764" CI_START="0.09407435777123624" DF="0" EFFECT_SIZE="0.5700000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-003.27.01" MODIFIED="2009-09-15 14:42:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.018905840777939786" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="60" WEIGHT="100.0" Z="2.347382389307855">
<NAME>change from baseline in ng/ml</NAME>
<CONT_DATA CI_END="1.045925642228764" CI_START="0.09407435777123624" EFFECT_SIZE="0.5700000000000001" ESTIMABLE="YES" MEAN_1="0.32" MEAN_2="-0.25" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1771" SD_1="1.33" SD_2="1.33" SE="0.24282366716062365" STUDY_ID="STD-Tollefson-2001" TOTAL_1="60" TOTAL_2="60" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.7362809081717065" CI_END="20.55387861355755" CI_START="-3.2616654988034526" DF="1" EFFECT_SIZE="8.646106557377049" ESTIMABLE="YES" I2="63.45404461166353" ID="CMP-003.27.02" MODIFIED="2009-09-15 14:42:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.09809289854431591" P_Z="0.15470456278007916" STUDIES="2" TAU2="47.22249999999997" TOTAL_1="27" TOTAL_2="20" WEIGHT="100.0" Z="1.4231089895745095">
<NAME>change from baseline in ng/ml - of men only</NAME>
<CONT_DATA CI_END="23.081686601257324" CI_START="5.318313398742674" EFFECT_SIZE="14.2" ESTIMABLE="YES" MEAN_1="24.0" MEAN_2="9.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1772" SD_1="14.3" SD_2="6.2" SE="4.5315560241488795" STUDY_ID="STD-Kumra-2007" TOTAL_1="13" TOTAL_2="8" WEIGHT="54.47628325718893"/>
<CONT_DATA CI_END="13.404902264758919" CI_START="-9.404902264758919" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="12.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1773" SD_1="9.8" SD_2="18.0" SE="5.818934610390462" STUDY_ID="STD-Volavka-2002" TOTAL_1="14" TOTAL_2="12" WEIGHT="45.523716742811075"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="86.73887120486103" CI_START="22.06112879513897" DF="0" EFFECT_SIZE="54.4" ESTIMABLE="YES" I2="0.0" ID="CMP-003.27.03" MODIFIED="2009-09-15 14:42:10 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="9.771508362332669E-4" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="10" WEIGHT="100.0" Z="3.2970241936877507">
<NAME>change from baseline in ng/ml - of women only</NAME>
<CONT_DATA CI_END="86.73887120486103" CI_START="22.06112879513897" EFFECT_SIZE="54.4" ESTIMABLE="YES" MEAN_1="74.0" MEAN_2="19.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1774" SD_1="45.6" SD_2="11.1" SE="16.499727270473294" STUDY_ID="STD-Kumra-2007" TOTAL_1="8" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.9419710244292725" CI_START="0.013800833844593588" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.30952380952380953" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.28" LOG_CI_END="0.8414827966075425" LOG_CI_START="-1.86009467278967" LOG_EFFECT_SIZE="-0.5093059380910636" METHOD="MH" MODIFIED="2009-09-15 14:32:29 +0100" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="1.0" P_Q="0.0" P_Z="0.4599122083836974" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="12" WEIGHT="100.0" Z="0.7389914278442652">
<NAME>Adverse effects: 8a. Metabolic - cholesterol - significant cholesterol increase</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.9419710244292725" CI_START="0.013800833844593588" EFFECT_SIZE="0.30952380952380953" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8414827966075425" LOG_CI_START="-1.86009467278967" LOG_EFFECT_SIZE="-0.5093059380910636" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1728" O_E="0.0" SE="1.5869199785480734" STUDY_ID="STD-Shaw-2006" TOTAL_1="13" TOTAL_2="12" VAR="2.518315018315018" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.0048832629345696" CI_END="19.84903185503153" CI_START="-17.521688204433662" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="1.1636718252989326" ESTIMABLE="YES" I2="33.44167393555251" I2_Q="0.0" ID="CMP-003.29" MODIFIED="2009-09-15 14:32:56 +0100" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="0.22258609252142503" P_Q="1.0" P_Z="0.9028506601946598" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="92.5817913071367" TOTALS="YES" TOTAL_1="50" TOTAL_2="39" UNITS="" WEIGHT="100.0" Z="0.12206106084018194">
<NAME>Adverse effects: 8b. Metabolic - cholesterol - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="11.417231347711969" CI_START="-78.01723134771197" EFFECT_SIZE="-33.300000000000004" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="37.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1729" SD_1="35.6" SD_2="41.2" SE="22.815333190015625" STUDY_ID="STD-Conley-2003" TOTAL_1="7" TOTAL_2="5" WEIGHT="14.823829504693"/>
<CONT_DATA CI_END="31.592748876129846" CI_START="-10.792748876129892" EFFECT_SIZE="10.399999999999977" ESTIMABLE="YES" MEAN_1="178.2" MEAN_2="167.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1730" SD_1="33.8" SD_2="32.6" SE="10.812825665826294" STUDY_ID="STD-Kumra-2007" TOTAL_1="21" TOTAL_2="17" WEIGHT="43.38352381121282"/>
<CONT_DATA CI_END="25.70359314961563" CI_START="-18.10359314961563" EFFECT_SIZE="3.8000000000000007" ESTIMABLE="YES" MEAN_1="20.1" MEAN_2="16.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1731" SD_1="26.8" SD_2="39.6" SE="11.175507979936558" STUDY_ID="STD-Volavka-2002" TOTAL_1="22" TOTAL_2="17" WEIGHT="41.79264668409418"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.4847309046863724" CI_START="0.6932969066191242" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-003.30" LOG_CI_END="0.3952793617060155" LOG_CI_START="-0.15908073755002655" LOG_EFFECT_SIZE="0.11809931207799448" METHOD="MH" MODIFIED="2009-09-15 14:33:23 +0100" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="1.0" P_Q="0.0" P_Z="0.40366682008580923" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="490" TOTAL_2="490" WEIGHT="100.0" Z="0.8350903991194947">
<NAME>Adverse effects: 8c. Metabolic - glucose - diabetes mellitus</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4847309046863724" CI_START="0.6932969066191242" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.3952793617060155" LOG_CI_START="-0.15908073755002655" LOG_EFFECT_SIZE="0.11809931207799448" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1767" O_E="0.0" SE="0.3256338664297471" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.1060374149659864" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.123726649563487" CI_END="11.089879831685561" CI_START="-16.33536564875796" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.6227429085361997" ESTIMABLE="YES" I2="67.34014899011594" I2_Q="0.0" ID="CMP-003.31" MODIFIED="2009-09-15 14:33:50 +0100" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="0.04680057194403897" P_Q="1.0" P_Z="0.7077554840555873" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="96.30474234647289" TOTALS="YES" TOTAL_1="50" TOTAL_2="39" UNITS="" WEIGHT="100.0" Z="0.3748722428103239">
<NAME>Adverse effects: 8d. Metabolic - glucose - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.35042984456708" CI_START="-28.15042984456708" EFFECT_SIZE="-7.4" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="10.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1768" SD_1="27.8" SD_2="2.9" SE="10.587148543669079" STUDY_ID="STD-Conley-2003" TOTAL_1="7" TOTAL_2="5" WEIGHT="23.488910842508144"/>
<CONT_DATA CI_END="-1.4615410004299605" CI_START="-18.738458999570028" EFFECT_SIZE="-10.099999999999994" ESTIMABLE="YES" MEAN_1="84.0" MEAN_2="94.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1769" SD_1="7.7" SD_2="16.8" SE="4.407458028672514" STUDY_ID="STD-Kumra-2007" TOTAL_1="21" TOTAL_2="17" WEIGHT="42.29580666391146"/>
<CONT_DATA CI_END="23.302113688287985" CI_START="-3.5021136882879844" EFFECT_SIZE="9.9" ESTIMABLE="YES" MEAN_1="14.3" MEAN_2="4.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1770" SD_1="25.5" SD_2="17.1" SE="6.837938754998636" STUDY_ID="STD-Volavka-2002" TOTAL_1="22" TOTAL_2="17" WEIGHT="34.21528249358039"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="21.922112899657176" CI_END="1.8058632774268488" CI_START="0.7037156454033652" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.127303970446601" ESTIMABLE="YES" EVENTS_1="320" EVENTS_2="210" I2="72.63037542291906" I2_Q="0.0" ID="CMP-003.32" LOG_CI_END="0.25668486662711365" LOG_CI_START="-0.15260279338525753" LOG_EFFECT_SIZE="0.05204103662092806" METHOD="MH" MODIFIED="2009-09-15 14:42:27 +0100" MODIFIED_BY="[Empty name]" NO="32" P_CHI2="0.0012508591828237492" P_Q="0.0" P_Z="0.6181881145855996" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.23490472605996734" TOTALS="YES" TOTAL_1="802" TOTAL_2="798" WEIGHT="100.00000000000001" Z="0.49841990101566236">
<NAME>Adverse effects: 8e. Metabolic - weight gain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.757050459903031" CI_END="2.1301215985889193" CI_START="0.4015167941819265" DF="2" EFFECT_SIZE="0.9248132760093267" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="40" I2="65.25998835810643" ID="CMP-003.32.01" LOG_CI_END="0.3284043959687006" LOG_CI_START="-0.39629628483610463" LOG_EFFECT_SIZE="-0.03394594443370207" MODIFIED="2009-09-15 14:42:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.05621768148695183" P_Z="0.8543157748146678" STUDIES="3" TAU2="0.33461679541399625" TOTAL_1="117" TOTAL_2="115" WEIGHT="40.52026680334198" Z="0.1836146433238256">
<NAME>significant weight gain (as defined by the original studies)</NAME>
<DICH_DATA CI_END="3.0500568362749836" CI_START="0.10705722213481368" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.48430793228141267" LOG_CI_START="-0.9703840296540016" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1786" O_E="0.0" SE="0.8544932592822075" STUDY_ID="STD-Kumra-2007" TOTAL_1="21" TOTAL_2="18" VAR="0.73015873015873" WEIGHT="5.989307834027449"/>
<DICH_DATA CI_END="0.9854376219959771" CI_START="0.40703856049119724" EFFECT_SIZE="0.6333333333333333" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="30" LOG_CI_END="-0.00637086126818119" LOG_CI_START="-0.39036444626548583" LOG_EFFECT_SIZE="-0.1983676537668335" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1787" O_E="0.0" SE="0.22555973262631815" STUDY_ID="STD-Naber-2005" TOTAL_1="57" TOTAL_2="57" VAR="0.05087719298245613" WEIGHT="20.22542971938759"/>
<DICH_DATA CI_END="4.264915229281454" CI_START="0.850689338189603" EFFECT_SIZE="1.9047619047619047" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.6299104034235496" LOG_CI_START="-0.07022901023546349" LOG_EFFECT_SIZE="0.2798406965940431" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1788" O_E="0.0" SE="0.41126535732929675" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="40" VAR="0.16913919413919415" WEIGHT="14.30552924992694"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.083445330688247" CI_END="2.0136890137426966" CI_START="1.3899835276596402" DF="3" EFFECT_SIZE="1.6730195931104737" ESTIMABLE="YES" EVENTS_1="286" EVENTS_2="170" I2="2.706236749448761" ID="CMP-003.32.02" LOG_CI_END="0.30399240065454197" LOG_CI_START="0.14300965357142503" LOG_EFFECT_SIZE="0.22350102711298347" MODIFIED="2009-09-15 14:42:27 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3789378895568829" P_Z="5.261255333118029E-8" STUDIES="4" TAU2="0.0036430233960249156" TOTAL_1="685" TOTAL_2="683" WEIGHT="59.47973319665803" Z="5.442247341238207">
<NAME>as "weight gain" reported adverse event</NAME>
<DICH_DATA CI_END="2.600399648229463" CI_START="0.35440706224810126" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.41504009861801444" LOG_CI_START="-0.45049763253887765" LOG_EFFECT_SIZE="-0.017728766960431602" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1789" O_E="0.0" SE="0.5084211477624269" STUDY_ID="STD-Bitter-2004" TOTAL_1="75" TOTAL_2="72" VAR="0.2584920634920635" WEIGHT="11.714835282799742"/>
<DICH_DATA CI_END="2.065523943047772" CI_START="1.5110505601333157" EFFECT_SIZE="1.7666666666666666" ESTIMABLE="YES" EVENTS_1="265" EVENTS_2="150" LOG_CI_END="0.3150302335770734" LOG_CI_START="0.17927899618517978" LOG_EFFECT_SIZE="0.24715461488112658" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1790" O_E="0.0" SE="0.07974094882346096" STUDY_ID="STD-Meltzer-2003" TOTAL_1="490" TOTAL_2="490" VAR="0.00635861891926582" WEIGHT="23.957481478016362"/>
<DICH_DATA CI_END="2.9838537792251403" CI_START="0.3351370656841249" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.47477753715465826" LOG_CI_START="-0.4747775371546582" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1791" O_E="0.0" SE="0.557773351022717" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" VAR="0.31111111111111106" WEIGHT="10.58588730431501"/>
<DICH_DATA CI_END="2.851356126384488" CI_START="0.4891176213213002" EFFECT_SIZE="1.180952380952381" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4550514628600417" LOG_CI_START="-0.31058669067544775" LOG_EFFECT_SIZE="0.07223238609229701" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1792" O_E="0.0" SE="0.4497396413567304" STUDY_ID="STD-Wang-2002" TOTAL_1="30" TOTAL_2="31" VAR="0.2022657450076805" WEIGHT="13.221529131526914"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="8.07983980664061" CI_END="1.0583112585274181" CI_START="-0.9690950483237158" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="0.044608105101851106" ESTIMABLE="YES" I2="25.74110200713687" I2_Q="0.0" ID="CMP-003.33" MODIFIED="2009-09-15 14:34:48 +0100" MODIFIED_BY="[Empty name]" NO="33" P_CHI2="0.23231227674491728" P_Q="1.0" P_Z="0.9312689529677198" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.4665060685211194" TOTALS="YES" TOTAL_1="294" TOTAL_2="287" UNITS="" WEIGHT="100.0" Z="0.08624840430135383">
<NAME>Adverse effects: 8f. Metabolic - weight gain - change from baseline in kg</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.916151750856113" CI_START="-0.11615175085611185" EFFECT_SIZE="2.4000000000000004" ESTIMABLE="YES" MEAN_1="8.92" MEAN_2="6.52" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1793" SD_1="3.13" SD_2="3.41" SE="1.2837744829513176" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="13" WEIGHT="12.65029572996175"/>
<CONT_DATA CI_END="0.9640643717757371" CI_START="-2.5640643717757365" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="4.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1794" SD_1="5.3" SD_2="5.6" SE="0.9000493813613166" STUDY_ID="STD-Bitter-2004" TOTAL_1="75" TOTAL_2="72" WEIGHT="20.95425807065211"/>
<CONT_DATA CI_END="7.225640885178976" CI_START="-3.4256408851789764" EFFECT_SIZE="1.9" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="1.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1795" SD_1="5.3" SD_2="4.4" SE="2.717213646366439" STUDY_ID="STD-Conley-2003" TOTAL_1="8" TOTAL_2="5" WEIGHT="3.4077619681119753"/>
<CONT_DATA CI_END="0.8371531543673929" CI_START="-3.837153154367393" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="5.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1796" SD_1="5.9" SD_2="6.8" SE="1.1924469902521468" STUDY_ID="STD-Naber-2005" TOTAL_1="57" TOTAL_2="57" WEIGHT="14.165214867631994"/>
<CONT_DATA CI_END="3.8314173413155532" CI_START="-4.231417341315552" EFFECT_SIZE="-0.19999999999999973" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="3.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1797" SD_1="4.0" SD_2="6.0" SE="2.0568833780186058" STUDY_ID="STD-Shaw-2006" TOTAL_1="13" TOTAL_2="12" WEIGHT="5.694812095280806"/>
<CONT_DATA CI_END="0.946335971428105" CI_START="-1.9463359714281045" EFFECT_SIZE="-0.4999999999999998" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="2.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1798" SD_1="5.0" SD_2="4.9" SE="0.7379400758568108" STUDY_ID="STD-Tollefson-2001" TOTAL_1="90" TOTAL_2="90" WEIGHT="26.45743795655509"/>
<CONT_DATA CI_END="3.2909774470518567" CI_START="-0.8909774470518563" EFFECT_SIZE="1.2000000000000002" ESTIMABLE="YES" MEAN_1="5.4" MEAN_2="4.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1799" SD_1="4.6" SD_2="4.7" SE="1.066844831611815" STUDY_ID="STD-Volavka-2002" TOTAL_1="38" TOTAL_2="38" WEIGHT="16.67021931180627"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2010-02-17 14:15:29 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>OLANZAPINE versus QUETIAPINE</NAME>
<DICH_OUTCOME CHI2="0.9742566738466444" CI_END="1.1600691856146252" CI_START="0.6986270348085665" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9002531284692845" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="74" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.06448389098092999" LOG_CI_START="-0.15575461245588074" LOG_EFFECT_SIZE="-0.04563536073747541" METHOD="MH" MODIFIED="2009-09-15 14:43:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6143882302580352" P_Q="0.0" P_Z="0.41665184225506446" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="168" TOTAL_2="171" WEIGHT="100.0" Z="0.8122436546850907">
<NAME>Global state: 1a. No clinically significant response (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.167809592149544" CI_START="0.638617326607896" EFFECT_SIZE="0.8635875402792696" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="56" LOG_CI_END="0.06737203813611786" LOG_CI_START="-0.19475930260190055" LOG_EFFECT_SIZE="-0.06369363223289133" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1830" O_E="0.0" SE="0.15397724712057562" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.02370899263083081" WEIGHT="70.5908801605452"/>
<DICH_DATA CI_END="1.892323407364669" CI_START="0.23486706485515438" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.2769953614690809" LOG_CI_START="-0.6291778795804434" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1831" O_E="0.0" SE="0.5322906474223771" STUDY_ID="STD-Ozguven-2004" TOTAL_1="15" TOTAL_2="15" VAR="0.2833333333333333" WEIGHT="5.906959967753742"/>
<DICH_DATA CI_END="1.8558416557264168" CI_START="0.6519952800210101" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.2685409185542382" LOG_CI_START="-0.18575554823778798" LOG_EFFECT_SIZE="0.04139268515822507" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1832" O_E="0.0" SE="0.266855993397415" STUDY_ID="STD-Svestka-2003b" TOTAL_1="20" TOTAL_2="22" VAR="0.0712121212121212" WEIGHT="23.502159871701064"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.12984385883719027" CI_END="1.1257181185525602" CI_START="0.6380304504573663" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8474918514464365" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="65" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.05142965616105382" LOG_CI_START="-0.19515859377095826" LOG_EFFECT_SIZE="-0.07186446880495226" METHOD="MH" MODIFIED="2009-09-16 12:35:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7185940683547349" P_Q="0.0" P_Z="0.25328591573609704" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="153" TOTAL_2="156" WEIGHT="100.0" Z="1.1424045603522754">
<NAME>Global state: 1b. No clinically important change (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6933968057702549" CI_START="0.3175733980041171" DF="0" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="0.2287587362330488" LOG_CI_START="-0.4981558840279613" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2009-09-16 12:35:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4676122065193855" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="22" WEIGHT="11.507419597161054" Z="0.7263696347533259">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.6933968057702549" CI_START="0.3175733980041171" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.2287587362330488" LOG_CI_START="-0.4981558840279613" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1833" O_E="0.0" SE="0.42699324622672" STUDY_ID="STD-Svestka-2003b" TOTAL_1="20" TOTAL_2="22" VAR="0.18232323232323233" WEIGHT="11.507419597161054"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.123204449786643E-31" CI_END="1.167809592149544" CI_START="0.638617326607896" DF="0" EFFECT_SIZE="0.8635875402792696" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="56" I2="100.0" ID="CMP-004.02.02" LOG_CI_END="0.06737203813611786" LOG_CI_START="-0.19475930260190055" LOG_EFFECT_SIZE="-0.06369363223289133" MODIFIED="2009-09-16 12:35:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.3408544068979209" STUDIES="1" TAU2="0.0" TOTAL_1="133" TOTAL_2="134" WEIGHT="88.49258040283894" Z="0.9524784397739945">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.167809592149544" CI_START="0.638617326607896" EFFECT_SIZE="0.8635875402792696" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="56" LOG_CI_END="0.06737203813611786" LOG_CI_START="-0.19475930260190055" LOG_EFFECT_SIZE="-0.06369363223289133" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1834" O_E="0.0" SE="0.15397724712057562" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.02370899263083081" WEIGHT="88.49258040283894"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="41.08514242114177" CI_END="0.8642259028994499" CI_START="0.7532703158975809" CI_STUDY="95" CI_TOTAL="95" DF="24" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8068430571579213" ESTIMABLE="YES" EVENTS_1="675" EVENTS_2="860" I2="41.584722394317474" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-0.06337272099434688" LOG_CI_START="-0.12304914646080134" LOG_EFFECT_SIZE="-0.09321093372757414" METHOD="MH" MODIFIED="2009-09-15 14:45:36 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.016302212489650025" P_Q="0.0" P_Z="9.200963690598224E-10" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0232809963671803" TOTALS="SUB" TOTAL_1="2400" TOTAL_2="2387" WEIGHT="300.0" Z="6.122688202030107">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.461411153775884" CI_END="0.8812514391211832" CI_START="0.7591099858199735" DF="9" EFFECT_SIZE="0.8179038864408902" ESTIMABLE="YES" EVENTS_1="470" EVENTS_2="574" I2="4.876768869638894" ID="CMP-004.03.01" LOG_CI_END="-0.054900160778555286" LOG_CI_START="-0.11969529554831249" LOG_EFFECT_SIZE="-0.08729772816343388" MODIFIED="2009-09-15 14:45:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.39581641766368447" P_Z="1.282892493393461E-7" STUDIES="10" TAU2="8.247690490768625E-4" TOTAL_1="828" TOTAL_2="823" WEIGHT="99.99999999999999" Z="5.281273161649744">
<NAME>due to any reason</NAME>
<DICH_DATA CI_END="67.90969947701805" CI_START="0.13252893282270775" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8319318085736291" LOG_CI_START="-0.8776892991343044" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1804" O_E="0.0" SE="1.5916448515084427" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="14" VAR="2.5333333333333328" WEIGHT="0.05716448465946289"/>
<DICH_DATA CI_END="0.9247846562659697" CI_START="0.6254034936794408" EFFECT_SIZE="0.7605021728633511" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="109" LOG_CI_END="-0.03395938454022201" LOG_CI_START="-0.20383969699544457" LOG_EFFECT_SIZE="-0.11889954076783327" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1805" O_E="0.0" SE="0.09978853645730656" STUDY_ID="STD-Kinon-2006b" TOTAL_1="171" TOTAL_2="175" VAR="0.009957752008291201" WEIGHT="13.435062282517173"/>
<DICH_DATA CI_END="0.8591182760836187" CI_START="0.7119938678434753" EFFECT_SIZE="0.7821041774110367" ESTIMABLE="YES" EVENTS_1="216" EVENTS_2="277" LOG_CI_END="-0.06594704208909172" LOG_CI_START="-0.14752374677495436" LOG_EFFECT_SIZE="-0.10673539443202305" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1806" O_E="0.0" SE="0.04791856014367654" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="337" VAR="0.002296188406243146" WEIGHT="46.416474444839615"/>
<DICH_DATA CI_END="1.0835345704519914" CI_START="0.49012666600192756" EFFECT_SIZE="0.728744939271255" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.03484277215516795" LOG_CI_START="-0.30969166846788726" LOG_EFFECT_SIZE="-0.13742444815635965" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1807" O_E="0.0" SE="0.20238123589496917" STUDY_ID="STD-McEvoy-2006" TOTAL_1="19" TOTAL_2="15" VAR="0.04095816464237516" WEIGHT="3.4670576996351308"/>
<DICH_DATA CI_END="1.1307730017687654" CI_START="0.8236950537875564" EFFECT_SIZE="0.9650969529085872" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="95" LOG_CI_END="0.05337543076652696" LOG_CI_START="-0.08423354190659169" LOG_EFFECT_SIZE="-0.01542905557003235" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1808" O_E="0.0" SE="0.0808321917235905" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.006533843218839292" WEIGHT="19.686299086568948"/>
<DICH_DATA CI_END="1.8986706334266805" CI_START="0.006502275220881497" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.27844963325122957" LOG_CI_START="-2.1869346521298794" LOG_EFFECT_SIZE="-0.9542425094393249" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1809" O_E="0.0" SE="1.4481789330818973" STUDY_ID="STD-Ozguven-2004" TOTAL_1="15" TOTAL_2="15" VAR="2.0972222222222223" WEIGHT="0.0690469958828298"/>
<DICH_DATA CI_END="1.3590320499124013" CI_START="0.5728685448242009" EFFECT_SIZE="0.8823529411764706" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.13322969877515342" LOG_CI_START="-0.2419450234203388" LOG_EFFECT_SIZE="-0.0543576623225927" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1810" O_E="0.0" SE="0.22037948896245868" STUDY_ID="STD-Riedel-2007" TOTAL_1="26" TOTAL_2="26" VAR="0.04856711915535444" WEIGHT="2.9329480454099355"/>
<DICH_DATA CI_END="4.1178990744020965" CI_START="0.37944106248569703" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6146756982879912" LOG_CI_START="-0.42085567227187837" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1811" O_E="0.0" SE="0.608276253029822" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" VAR="0.37000000000000005" WEIGHT="0.39065309024468325"/>
<DICH_DATA CI_END="7.268192940288198" CI_START="0.25341054507296074" EFFECT_SIZE="1.3571428571428572" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8614264475009272" LOG_CI_START="-0.5961753169517454" LOG_EFFECT_SIZE="0.13262556527459096" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1812" O_E="0.0" SE="0.8562024916845998" STUDY_ID="STD-Sirota-2006" TOTAL_1="21" TOTAL_2="19" VAR="0.7330827067669172" WEIGHT="0.19738706409445708"/>
<DICH_DATA CI_END="0.9784834945526267" CI_START="0.6608055675807827" EFFECT_SIZE="0.8041065482796892" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="53" LOG_CI_END="-0.009446495795630967" LOG_CI_START="-0.1799263065481082" LOG_EFFECT_SIZE="-0.0946864011718696" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1813" O_E="0.0" SE="0.10014068472467842" STUDY_ID="STD-Stroup-2006" TOTAL_1="68" TOTAL_2="63" VAR="0.010028156737127442" WEIGHT="13.347906806147751"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.347830947755257" CI_END="1.4565924512297508" CI_START="0.8492079495544602" DF="6" EFFECT_SIZE="1.112182489003186" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="88" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="0.163338054898933" LOG_CI_START="-0.0709859489955864" LOG_EFFECT_SIZE="0.04617605295167332" MODIFIED="2009-09-15 14:45:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5000358787034049" P_Z="0.4398398086011943" STUDIES="8" TAU2="0.0" TOTAL_1="789" TOTAL_2="784" WEIGHT="100.0" Z="0.7724637615379271">
<NAME>due to adverse events</NAME>
<DICH_DATA CI_END="1.3107115822950517" CI_START="0.16509403336743736" EFFECT_SIZE="0.46517809675704413" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.1175071371530456" LOG_CI_START="-0.7822686222091769" LOG_EFFECT_SIZE="-0.3323807425280656" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1814" O_E="0.0" SE="0.5285327350112109" STUDY_ID="STD-Kinon-2006b" TOTAL_1="171" TOTAL_2="175" VAR="0.2793468519784309" WEIGHT="6.782112375868416"/>
<DICH_DATA CI_END="1.788011181672371" CI_START="0.9007457786789391" EFFECT_SIZE="1.2690719144800777" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="49" LOG_CI_END="0.25237023041259726" LOG_CI_START="-0.04539776451012765" LOG_EFFECT_SIZE="0.10348623295123478" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1815" O_E="0.0" SE="0.17491039419295543" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="337" VAR="0.03059364599673505" WEIGHT="61.926641308622905"/>
<DICH_DATA CI_END="2.2808567833027062" CI_START="0.030362308615470835" EFFECT_SIZE="0.2631578947368421" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.3580980164585659" LOG_CI_START="-1.5176652096921863" LOG_EFFECT_SIZE="-0.5797835966168101" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1816" O_E="0.0" SE="1.1018326042186708" STUDY_ID="STD-McEvoy-2006" TOTAL_1="19" TOTAL_2="15" VAR="1.2140350877192982" WEIGHT="1.560549411732363"/>
<DICH_DATA CI_END="2.2197068608194095" CI_START="0.5303713514228137" EFFECT_SIZE="1.0850202429149798" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.346295624390044" LOG_CI_START="-0.2754199428517979" LOG_EFFECT_SIZE="0.035437840769123104" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1817" O_E="0.0" SE="0.36519880173954977" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.13337016479200298" WEIGHT="14.20528905334605"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1818" O_E="0.0" SE="0.0" STUDY_ID="STD-Ozguven-2004" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.149704352020958" CI_START="0.06600788878540728" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.180404157621246" LOG_CI_START="-1.180404157621246" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1819" O_E="0.0" SE="1.3867504905630728" STUDY_ID="STD-Riedel-2007" TOTAL_1="26" TOTAL_2="26" VAR="1.923076923076923" WEIGHT="0.9851721058206554"/>
<DICH_DATA CI_END="63.1873598871894" CI_START="0.1177136778970504" EFFECT_SIZE="2.727272727272727" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8006302099235953" LOG_CI_START="-0.9291730708007208" LOG_EFFECT_SIZE="0.43572856956143735" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1820" O_E="0.0" SE="1.6034999598416337" STUDY_ID="STD-Sirota-2006" TOTAL_1="21" TOTAL_2="19" VAR="2.5712121212121213" WEIGHT="0.7368360339984956"/>
<DICH_DATA CI_END="2.2632522945102966" CI_START="0.5297020314054158" EFFECT_SIZE="1.0949197860962567" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.3547329693353218" LOG_CI_START="-0.27596836154340754" LOG_EFFECT_SIZE="0.039382303895957135" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1821" O_E="0.0" SE="0.3704770837801048" STUDY_ID="STD-Stroup-2006" TOTAL_1="68" TOTAL_2="63" VAR="0.1372532696062108" WEIGHT="13.80339971061111"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.535543633365886" CI_END="0.7018601092367819" CI_START="0.44036046113312766" DF="7" EFFECT_SIZE="0.5559419406327036" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="198" I2="7.106901099936641" ID="CMP-004.03.03" LOG_CI_END="-0.15374944034979893" LOG_CI_START="-0.356191682167529" LOG_EFFECT_SIZE="-0.25497056125866396" MODIFIED="2009-09-15 14:45:36 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3753225399376332" P_Z="7.931562331535523E-7" STUDIES="8" TAU2="0.008844129630675112" TOTAL_1="783" TOTAL_2="780" WEIGHT="100.00000000000001" Z="4.937043896548849">
<NAME>due to inefficacy</NAME>
<DICH_DATA CI_END="0.627931428431584" CI_START="0.2574192163426758" EFFECT_SIZE="0.402046783625731" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="56" LOG_CI_END="-0.20208777963821106" LOG_CI_START="-0.5893590361414961" LOG_EFFECT_SIZE="-0.3957234078898536" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1822" O_E="0.0" SE="0.22748505309366665" STUDY_ID="STD-Kinon-2006b" TOTAL_1="171" TOTAL_2="175" VAR="0.05174944938102834" WEIGHT="23.33731427668001"/>
<DICH_DATA CI_END="0.7167364512253365" CI_START="0.3820573640277341" EFFECT_SIZE="0.5232919254658385" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="92" LOG_CI_END="-0.1446405079576034" LOG_CI_START="-0.4178714250193436" LOG_EFFECT_SIZE="-0.28125596648847345" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1823" O_E="0.0" SE="0.16049719319691874" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="337" VAR="0.025759349024089058" WEIGHT="40.865584950381134"/>
<DICH_DATA CI_END="1.954955664853877" CI_START="0.31881474821452177" EFFECT_SIZE="0.7894736842105263" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.29113691276633874" LOG_CI_START="-0.4964615965606342" LOG_EFFECT_SIZE="-0.10266234189714772" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1824" O_E="0.0" SE="0.46263926305416214" STUDY_ID="STD-McEvoy-2006" TOTAL_1="19" TOTAL_2="15" VAR="0.21403508771929824" WEIGHT="6.344653455618097"/>
<DICH_DATA CI_END="1.7055291775981758" CI_START="0.4633741864937743" EFFECT_SIZE="0.8889871738168952" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.23185915356545708" LOG_CI_START="-0.3340681634151988" LOG_EFFECT_SIZE="-0.05110450492487085" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1825" O_E="0.0" SE="0.3324285073798365" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.110508712518786" WEIGHT="11.847990974309194"/>
<DICH_DATA CI_END="1.8986706334266805" CI_START="0.006502275220881497" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.27844963325122957" LOG_CI_START="-2.1869346521298794" LOG_EFFECT_SIZE="-0.9542425094393249" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1826" O_E="0.0" SE="1.4481789330818973" STUDY_ID="STD-Ozguven-2004" TOTAL_1="15" TOTAL_2="15" VAR="2.0972222222222223" WEIGHT="0.6714372485467331"/>
<DICH_DATA CI_END="13.482091688489398" CI_START="0.060717144136267914" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1297572763459856" LOG_CI_START="-1.2166886639081658" LOG_EFFECT_SIZE="-0.0434656937810903" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1827" O_E="0.0" SE="1.3783139604000185" STUDY_ID="STD-Sirota-2006" TOTAL_1="21" TOTAL_2="19" VAR="1.899749373433584" WEIGHT="0.7409075815644518"/>
<DICH_DATA CI_END="1.1055185881363596" CI_START="0.360939473735069" EFFECT_SIZE="0.6316844919786097" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="22" LOG_CI_END="0.04356604918264973" LOG_CI_START="-0.4425656192210089" LOG_EFFECT_SIZE="-0.19949978501917956" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1828" O_E="0.0" SE="0.28555614841087745" STUDY_ID="STD-Stroup-2006" TOTAL_1="68" TOTAL_2="63" VAR="0.08154231389525507" WEIGHT="15.644950076382734"/>
<DICH_DATA CI_END="76.32862590851101" CI_START="0.14143996749380944" EFFECT_SIZE="3.2857142857142856" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8826874441486245" LOG_CI_START="-0.8494278521419525" LOG_EFFECT_SIZE="0.516629796003336" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1829" O_E="0.0" SE="1.6048580492299167" STUDY_ID="STD-Svestka-2003b" TOTAL_1="20" TOTAL_2="22" VAR="2.5755693581780537" WEIGHT="0.5471614365176312"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8558416557264168" CI_START="0.6519952800210101" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.2685409185542382" LOG_CI_START="-0.18575554823778798" LOG_EFFECT_SIZE="0.04139268515822507" METHOD="MH" MODIFIED="2009-09-15 14:47:06 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.7209723292906791" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.0" Z="0.35715959979352746">
<NAME>Mental state: 1a. General - no clinically important change - short term (less than 50% PANSS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8558416557264168" CI_START="0.6519952800210101" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.2685409185542382" LOG_CI_START="-0.18575554823778798" LOG_EFFECT_SIZE="0.04139268515822507" MODIFIED="2009-09-15 14:47:06 +0100" MODIFIED_BY="[Empty name]" ORDER="1357" O_E="0.0" SE="0.266855993397415" STUDY_ID="STD-Svestka-2003b" TOTAL_1="20" TOTAL_2="22" VAR="0.0712121212121212" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.516571965707022" CI_END="-1.9265561353890932" CI_START="-5.38892379445046" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.657739964919777" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.05" MODIFIED="2009-09-15 14:47:59 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6873092792937692" P_Q="0.41806058811414115" P_Z="3.456152822467378E-5" Q="1.7442595797173341" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="721" TOTAL_2="728" UNITS="" WEIGHT="100.0" Z="4.141119200494762">
<NAME>Mental state: 1b. General - average endpoint score (PANSS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.6812394080555267" CI_END="1.5065179499668262" CI_START="-5.846980394009616" DF="3" EFFECT_SIZE="-2.170231222021395" ESTIMABLE="YES" I2="0.0" ID="CMP-004.05.01" MODIFIED="2009-09-15 14:47:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8776075218739622" P_Z="0.24731947136506938" STUDIES="4" TAU2="0.0" TOTAL_1="70" TOTAL_2="72" WEIGHT="22.169626021730267" Z="1.156884746365807">
<NAME>short term</NAME>
<CONT_DATA CI_END="2.3406578757445438" CI_START="-7.100657875744535" EFFECT_SIZE="-2.3799999999999955" ESTIMABLE="YES" MEAN_1="74.86" MEAN_2="77.24" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1836" SD_1="6.41" SD_2="6.08" SE="2.4085431737422147" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="14" WEIGHT="13.448731419358124"/>
<CONT_DATA CI_END="4.636211595553027" CI_START="-11.636211595553027" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="69.4" MEAN_2="72.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1837" SD_1="10.8" SD_2="15.1" SE="4.151204644437564" STUDY_ID="STD-Mori-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="4.527327423065439"/>
<CONT_DATA CI_END="18.728628616249424" CI_START="-11.48862861624942" EFFECT_SIZE="3.620000000000001" ESTIMABLE="YES" MEAN_1="-17.88" MEAN_2="-21.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1838" SD_1="20.71" SD_2="23.39" SE="7.708625635687367" STUDY_ID="STD-Riedel-2007" TOTAL_1="17" TOTAL_2="16" WEIGHT="1.312914007070521"/>
<CONT_DATA CI_END="8.459941957500934" CI_START="-11.939941957500938" EFFECT_SIZE="-1.740000000000002" ESTIMABLE="YES" MEAN_1="-45.65" MEAN_2="-43.91" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1839" SD_1="11.96" SD_2="20.94" SE="5.204147646567374" STUDY_ID="STD-Svestka-2003b" TOTAL_1="20" TOTAL_2="22" WEIGHT="2.8806531722361814"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.8626019212952212" CI_END="-1.971786894776419" CI_START="-9.170788884691813" DF="2" EFFECT_SIZE="-5.571287889734116" ESTIMABLE="YES" I2="0.0" ID="CMP-004.05.02" MODIFIED="2009-09-15 14:47:53 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.39404080345024217" P_Z="0.002416373862140372" STUDIES="3" TAU2="0.0" TOTAL_1="242" TOTAL_2="240" WEIGHT="23.131392493033996" Z="3.0336215010579153">
<NAME>medium term</NAME>
<CONT_DATA CI_END="0.13860867047987746" CI_START="-8.338608670479879" EFFECT_SIZE="-4.1000000000000005" ESTIMABLE="YES" MEAN_1="-11.3" MEAN_2="-7.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1840" SD_1="18.3" SD_2="21.2" SE="2.1625951823163496" STUDY_ID="STD-Kinon-2006b" TOTAL_1="166" TOTAL_2="169" WEIGHT="16.681677822294123"/>
<CONT_DATA CI_END="8.244500510629546" CI_START="-21.044500510629547" EFFECT_SIZE="-6.4" ESTIMABLE="YES" MEAN_1="-7.7" MEAN_2="-1.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1841" SD_1="9.8" SD_2="19.23" SE="7.47182123046316" STUDY_ID="STD-McEvoy-2006" TOTAL_1="10" TOTAL_2="8" WEIGHT="1.3974531167962232"/>
<CONT_DATA CI_END="-2.4980574654665384" CI_START="-17.90194253453346" EFFECT_SIZE="-10.2" ESTIMABLE="YES" MEAN_1="-8.2" MEAN_2="2.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1842" SD_1="22.31" SD_2="22.31" SE="3.929634725579348" STUDY_ID="STD-Stroup-2006" TOTAL_1="66" TOTAL_2="63" WEIGHT="5.052261553943649"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.228471056638939" CI_END="-0.9085561358636469" CI_START="-5.882219388780285" DF="2" EFFECT_SIZE="-3.395387762321966" ESTIMABLE="YES" I2="10.252368140851132" ID="CMP-004.05.03" MODIFIED="2009-09-15 14:47:59 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.328166353198023" P_Z="0.007449982507964473" STUDIES="3" TAU2="0.5112091552200568" TOTAL_1="409" TOTAL_2="416" WEIGHT="54.69898148523574" Z="2.6760306797194575">
<NAME>long term</NAME>
<CONT_DATA CI_END="-1.783287769494819" CI_START="-8.59671223050518" EFFECT_SIZE="-5.1899999999999995" ESTIMABLE="YES" MEAN_1="-11.27" MEAN_2="-6.08" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1843" SD_1="22.31" SD_2="22.31" SE="1.7381504238735466" STUDY_ID="STD-Lieberman-2005" TOTAL_1="330" TOTAL_2="329" WEIGHT="25.82352200435032"/>
<CONT_DATA CI_END="1.6483213660509701" CI_START="-7.248321366050968" EFFECT_SIZE="-2.799999999999999" ESTIMABLE="YES" MEAN_1="-18.4" MEAN_2="-15.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1844" SD_1="9.73" SD_2="10.68" SE="2.2695934216846636" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="44" WEIGHT="15.145864376094138"/>
<CONT_DATA CI_END="3.7721235840620313" CI_START="-5.5721235840620285" EFFECT_SIZE="-0.8999999999999986" ESTIMABLE="YES" MEAN_1="48.5" MEAN_2="49.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1845" SD_1="9.9" SD_2="12.0" SE="2.383780325003492" STUDY_ID="STD-Voruganti-2007" TOTAL_1="42" TOTAL_2="43" WEIGHT="13.729595104791281"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0719999801768236" CI_START="0.0041459370584235895" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.06666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="0.030194777325877904" LOG_CI_START="-2.38237729543724" LOG_EFFECT_SIZE="-1.1760912590556813" METHOD="MH" MODIFIED="2009-09-15 14:48:48 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.05601695110440141" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.9109037498237105">
<NAME>Mental state: 2a. Positive symptoms - no clinically important change-short term (less than 20% SAPS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0719999801768236" CI_START="0.0041459370584235895" EFFECT_SIZE="0.06666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.030194777325877904" LOG_CI_START="-2.38237729543724" LOG_EFFECT_SIZE="-1.1760912590556813" MODIFIED="2009-09-15 14:48:48 +0100" MODIFIED_BY="[Empty name]" ORDER="1358" O_E="0.0" SE="1.4171567779654208" STUDY_ID="STD-Ozguven-2004" TOTAL_1="15" TOTAL_2="15" VAR="2.0083333333333333" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="4.181541095171354" CI_END="-1.0154544962805399" CI_START="-2.5904158581441297" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.8029351772123348" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.07" MODIFIED="2009-09-15 14:49:48 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.6521240374145092" P_Q="0.6288714188450271" P_Z="7.212031757281754E-6" Q="0.9276570414585512" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="337" TOTAL_2="342" UNITS="" WEIGHT="100.0" Z="4.487332958587939">
<NAME>Mental state: 2b. Positive symptoms - average endpoint score (PANSS positive subscore, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.9935441978441191" CI_END="0.745149244938065" CI_START="-2.8518977056374784" DF="2" EFFECT_SIZE="-1.0533742303497067" ESTIMABLE="YES" I2="0.0" ID="CMP-004.07.01" MODIFIED="2009-09-15 14:49:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6084917031367767" P_Z="0.25099828507978905" STUDIES="3" TAU2="0.0" TOTAL_1="57" TOTAL_2="58" WEIGHT="19.171124812035124" Z="1.1479280543712018">
<NAME>short term</NAME>
<CONT_DATA CI_END="0.6231981497658015" CI_START="-4.023198149765804" EFFECT_SIZE="-1.700000000000001" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="13.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1846" SD_1="3.1" SD_2="4.3" SE="1.1853269591129698" STUDY_ID="STD-Mori-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="11.48966351105205"/>
<CONT_DATA CI_END="5.943603349657839" CI_START="-4.023603349657839" EFFECT_SIZE="0.96" ESTIMABLE="YES" MEAN_1="-6.82" MEAN_2="-7.78" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1847" SD_1="7.3" SD_2="7.3" SE="2.542701492970211" STUDY_ID="STD-Riedel-2007" TOTAL_1="17" TOTAL_2="16" WEIGHT="2.4968524468082878"/>
<CONT_DATA CI_END="2.8684532509568945" CI_START="-4.048453250956895" EFFECT_SIZE="-0.5899999999999999" ESTIMABLE="YES" MEAN_1="-13.55" MEAN_2="-12.96" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1848" SD_1="5.14" SD_2="6.28" SE="1.7645493887830246" STUDY_ID="STD-Svestka-2003b" TOTAL_1="20" TOTAL_2="22" WEIGHT="5.184608854174788"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.260339855868683" CI_END="-0.9030691428647901" CI_START="-3.5210687931832028" DF="2" EFFECT_SIZE="-2.2120689680239964" ESTIMABLE="YES" I2="11.517730627663978" ID="CMP-004.07.02" MODIFIED="2009-09-15 14:49:43 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.32297870559034303" P_Z="9.258903688393746E-4" STUDIES="3" TAU2="0.21368085879104873" TOTAL_1="243" TOTAL_2="240" WEIGHT="49.74734160342038" Z="3.3121284092749255">
<NAME>medium term</NAME>
<CONT_DATA CI_END="-0.3112402051957588" CI_START="-2.888759794804241" EFFECT_SIZE="-1.5999999999999999" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-0.7" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1849" SD_1="5.4" SD_2="6.6" SE="0.6575425900525794" STUDY_ID="STD-Kinon-2006b" TOTAL_1="167" TOTAL_2="169" WEIGHT="37.33669381242566"/>
<CONT_DATA CI_END="1.3406190420477353" CI_START="-8.340619042047734" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="-2.9" MEAN_2="0.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1850" SD_1="4.11" SD_2="5.94" SE="2.4697489750984816" STUDY_ID="STD-McEvoy-2006" TOTAL_1="10" TOTAL_2="8" WEIGHT="2.6465372222432273"/>
<CONT_DATA CI_END="-1.0798664051055908" CI_START="-6.120133594894409" EFFECT_SIZE="-3.6" ESTIMABLE="YES" MEAN_1="-3.4" MEAN_2="0.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1851" SD_1="7.3" SD_2="7.3" SE="1.2858060733630319" STUDY_ID="STD-Stroup-2006" TOTAL_1="66" TOTAL_2="63" WEIGHT="9.764110568751493"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.38749924499717747" CI_START="-3.2125007550028224" DF="0" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-004.07.03" MODIFIED="2009-09-15 14:49:48 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.01250188961929898" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="44" WEIGHT="31.0815335845445" Z="2.4976518842038056">
<NAME>long term</NAME>
<CONT_DATA CI_END="-0.38749924499717747" CI_START="-3.2125007550028224" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-5.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1852" SD_1="3.1" SD_2="3.38" SE="0.7206768931186737" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="44" WEIGHT="31.0815335845445"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-23.974429244555072" CI_START="-57.705570755444924" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-40.839999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.08" MODIFIED="2009-09-15 14:50:20 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="2.0742216785789077E-6" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="4.7460551610904655">
<NAME>Mental state: 2c. Positive symptoms - SAPS total score - percent change-short term (high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-23.974429244555072" CI_START="-57.705570755444924" EFFECT_SIZE="-40.839999999999996" ESTIMABLE="YES" MEAN_1="-58.87" MEAN_2="-18.03" MODIFIED="2009-09-15 14:50:20 +0100" MODIFIED_BY="[Empty name]" ORDER="1359" SD_1="19.13" SD_2="27.29" SE="8.605041158142901" STUDY_ID="STD-Ozguven-2004" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.892323407364669" CI_START="0.23486706485515438" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-004.09" LOG_CI_END="0.2769953614690809" LOG_CI_START="-0.6291778795804434" LOG_EFFECT_SIZE="-0.17609125905568127" METHOD="MH" MODIFIED="2009-09-15 14:51:09 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.44621741204055665" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.7617362996543963">
<NAME>Mental state: 3a. Negative symptoms - no clinically important change-short term (less than 20% SANS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.892323407364669" CI_START="0.23486706485515438" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.2769953614690809" LOG_CI_START="-0.6291778795804434" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2009-09-15 14:51:09 +0100" MODIFIED_BY="[Empty name]" ORDER="1360" O_E="0.0" SE="0.5322906474223771" STUDY_ID="STD-Ozguven-2004" TOTAL_1="15" TOTAL_2="15" VAR="0.2833333333333333" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.7301878993544135" CI_END="0.356499047836819" CI_START="-1.1756379878749164" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4095694700190487" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.10" MODIFIED="2009-09-15 14:52:12 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.9427670242507222" P_Q="0.8320631061682435" P_Z="0.29469780370508647" Q="0.36769409469784353" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="337" TOTAL_2="342" UNITS="" WEIGHT="100.00000000000001" Z="1.047871556778326">
<NAME>Mental state: 3b. Negative symptoms - average endpoint score (PANSS negative subscore, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.21159231069863" CI_END="1.7166648784527287" CI_START="-1.7324996507566912" DF="2" EFFECT_SIZE="-0.007917386151981282" ESTIMABLE="YES" I2="0.0" ID="CMP-004.10.01" MODIFIED="2009-09-15 14:51:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5456401026374467" P_Z="0.9928207313704008" STUDIES="3" TAU2="0.0" TOTAL_1="57" TOTAL_2="58" WEIGHT="19.731831538944657" Z="0.008998000285672832">
<NAME>short term</NAME>
<CONT_DATA CI_END="1.4811162326989713" CI_START="-3.4811162326989713" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="22.8" MEAN_2="23.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1855" SD_1="3.3" SD_2="4.6" SE="1.2658988901172161" STUDY_ID="STD-Mori-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="9.533250609642456"/>
<CONT_DATA CI_END="5.053801329559288" CI_START="-3.7938013295592885" EFFECT_SIZE="0.6299999999999999" ESTIMABLE="YES" MEAN_1="-3.35" MEAN_2="-3.98" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1856" SD_1="6.48" SD_2="6.48" SE="2.2570829691023246" STUDY_ID="STD-Riedel-2007" TOTAL_1="17" TOTAL_2="16" WEIGHT="2.9987758210036413"/>
<CONT_DATA CI_END="3.8950074425959054" CI_START="-1.815007442595907" EFFECT_SIZE="1.0399999999999991" ESTIMABLE="YES" MEAN_1="-8.55" MEAN_2="-9.59" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1857" SD_1="4.53" SD_2="4.91" SE="1.4566632168324727" STUDY_ID="STD-Svestka-2003b" TOTAL_1="20" TOTAL_2="22" WEIGHT="7.19980510829856"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.15090149395794006" CI_END="0.66696781739775" CI_START="-1.4689115547914637" DF="2" EFFECT_SIZE="-0.4009718686968568" ESTIMABLE="YES" I2="0.0" ID="CMP-004.10.02" MODIFIED="2009-09-15 14:52:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9273254221229614" P_Z="0.46179520663723483" STUDIES="3" TAU2="0.0" TOTAL_1="243" TOTAL_2="240" WEIGHT="51.45668196352669" Z="0.7358940132036091">
<NAME>medium term</NAME>
<CONT_DATA CI_END="0.8617889458647219" CI_START="-1.6617889458647217" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="-4.0" MEAN_2="-3.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1858" SD_1="5.8" SD_2="6.0" SE="0.6437816999789547" STUDY_ID="STD-Kinon-2006b" TOTAL_1="167" TOTAL_2="169" WEIGHT="36.860548497190116"/>
<CONT_DATA CI_END="4.922576017319448" CI_START="-4.122576017319448" EFFECT_SIZE="0.40000000000000013" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-1.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1859" SD_1="2.21" SD_2="6.22" SE="2.307479144001089" STUDY_ID="STD-McEvoy-2006" TOTAL_1="10" TOTAL_2="8" WEIGHT="2.8692175548228436"/>
<CONT_DATA CI_END="1.637050095193941" CI_START="-2.8370500951939412" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="0.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1860" SD_1="6.48" SD_2="6.48" SE="1.141373062382527" STUDY_ID="STD-Stroup-2006" TOTAL_1="66" TOTAL_2="63" WEIGHT="11.726915911513728"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7271998196488385" CI_START="-2.1271998196488386" DF="0" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-004.10.03" MODIFIED="2009-09-15 14:52:12 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.3363986823427271" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="44" WEIGHT="28.81148649752866" Z="0.9613053268992225">
<NAME>long term</NAME>
<CONT_DATA CI_END="0.7271998196488385" CI_START="-2.1271998196488386" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="-3.5" MEAN_2="-2.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1861" SD_1="3.1" SD_2="3.45" SE="0.7281765537052766" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="44" WEIGHT="28.81148649752866"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.47728020452890085" CI_START="-7.877280204528899" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.6999999999999993" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.11" MODIFIED="2009-09-15 14:52:46 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.08255925018496671" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="166" TOTAL_2="169" UNITS="" WEIGHT="100.0" Z="1.7360259278120511">
<NAME>Mental state: 3c. Negative symptoms - average endpoint score-medium term (SANS total score, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.47728020452890085" CI_START="-7.877280204528899" EFFECT_SIZE="-3.6999999999999993" ESTIMABLE="YES" MEAN_1="-12.0" MEAN_2="-8.3" MODIFIED="2009-09-15 14:52:46 +0100" MODIFIED_BY="[Empty name]" ORDER="1361" SD_1="18.9" SD_2="20.1" SE="2.1313045736956155" STUDY_ID="STD-Kinon-2006b" TOTAL_1="166" TOTAL_2="169" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="31.90138665554241" CI_START="-36.82138665554241" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.460000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.12" MODIFIED="2009-09-15 14:53:11 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.8884089650119402" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="0.140317719139278">
<NAME>Mental state: 3d. Negative symptoms - average endpoint score-short term (SANS total score- percent change, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="31.90138665554241" CI_START="-36.82138665554241" EFFECT_SIZE="-2.460000000000001" ESTIMABLE="YES" MEAN_1="-28.14" MEAN_2="-25.68" MODIFIED="2009-09-15 14:53:11 +0100" MODIFIED_BY="[Empty name]" ORDER="1362" SD_1="42.33" SD_2="53.09" SE="17.531641870248965" STUDY_ID="STD-Ozguven-2004" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.7687292303141868" CI_START="-6.831270769685814" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.8000000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.13" MODIFIED="2009-09-15 14:54:22 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.014009871636778904" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="138" TOTAL_2="140" UNITS="" WEIGHT="100.0" Z="2.457010180593061">
<NAME>General functioning: average endpoint score-medium term (GAF total score, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.7687292303141868" CI_START="-6.831270769685814" EFFECT_SIZE="-3.8000000000000003" ESTIMABLE="YES" MEAN_1="-6.2" MEAN_2="-2.4" MODIFIED="2009-09-15 14:54:22 +0100" MODIFIED_BY="[Empty name]" ORDER="1363" SD_1="11.7" SD_2="14.0" SE="1.5465951382760552" STUDY_ID="STD-Kinon-2006b" TOTAL_1="138" TOTAL_2="140" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.419154707805794" CI_START="-6.019154707805795" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.8000000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.14" MODIFIED="2009-09-15 14:54:58 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.4030586704722481" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="143" TOTAL_2="143" UNITS="" WEIGHT="100.0" Z="0.8361710855601288">
<NAME>Quality of life: General - average endpoint score-medium term (QLS total score, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.419154707805794" CI_START="-6.019154707805795" EFFECT_SIZE="-1.8000000000000003" ESTIMABLE="YES" MEAN_1="-4.2" MEAN_2="-2.4" MODIFIED="2009-09-15 14:54:58 +0100" MODIFIED_BY="[Empty name]" ORDER="1364" SD_1="17.9" SD_2="18.5" SE="2.152669508769522" STUDY_ID="STD-Kinon-2006b" TOTAL_1="143" TOTAL_2="143" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="5.1630689504322E-4" CI_END="0.7716043188643689" CI_START="0.4054673703927591" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5593392299433606" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="87" I2="0.0" I2_Q="0.0" ID="CMP-004.15" LOG_CI_END="-0.11260535016538195" LOG_CI_START="-0.3920440894887053" LOG_EFFECT_SIZE="-0.25232471982704363" METHOD="MH" MODIFIED="2010-02-17 14:14:39 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.9818717181006644" P_Q="0.0" P_Z="4.0076996790744233E-4" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="444" TOTAL_2="432" WEIGHT="100.0" Z="3.539576255373464">
<NAME>Service use - number of patients re-hospitalised</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0835783232545788" CI_START="0.28483587082253664" DF="0" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" I2="0.0" ID="CMP-004.15.01" LOG_CI_END="0.03486030848268394" LOG_CI_START="-0.545405318689296" LOG_EFFECT_SIZE="-0.255272505103306" MODIFIED="2009-09-15 14:55:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.08462328934709792" STUDIES="1" TAU2="0.0" TOTAL_1="108" TOTAL_2="95" WEIGHT="23.191003213020572" Z="1.7244685634205594">
<NAME>medium term</NAME>
<DICH_DATA CI_END="1.0835783232545788" CI_START="0.28483587082253664" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.03486030848268394" LOG_CI_START="-0.545405318689296" LOG_EFFECT_SIZE="-0.255272505103306" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1867" O_E="0.0" SE="0.34085090176200034" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="95" VAR="0.1161793372319688" WEIGHT="23.191003213020572"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8090738382969189" CI_START="0.38827770722656607" DF="0" EFFECT_SIZE="0.5604866946778712" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="68" I2="0.0" ID="CMP-004.15.02" LOG_CI_END="-0.09201184167379252" LOG_CI_START="-0.41085754354207066" LOG_EFFECT_SIZE="-0.25143469260793155" MODIFIED="2009-09-15 14:55:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0019937026347869556" STUDIES="1" TAU2="0.0" TOTAL_1="336" TOTAL_2="337" WEIGHT="76.80899678697944" Z="3.0911687947359106">
<NAME>long term</NAME>
<DICH_DATA CI_END="0.8090738382969189" CI_START="0.38827770722656607" EFFECT_SIZE="0.5604866946778712" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="68" LOG_CI_END="-0.09201184167379252" LOG_CI_START="-0.41085754354207066" LOG_EFFECT_SIZE="-0.25143469260793155" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1868" O_E="0.0" SE="0.1872915435891055" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="337" VAR="0.03507812229998981" WEIGHT="76.80899678697944"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.694598825763687" CI_END="1.1315675959971194" CI_START="0.9477601378448253" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0355938686391337" ESTIMABLE="YES" EVENTS_1="369" EVENTS_2="356" I2="0.0" I2_Q="0.0" ID="CMP-004.16" LOG_CI_END="0.05368050233997364" LOG_CI_START="-0.023301561386868546" LOG_EFFECT_SIZE="0.015189470476552523" METHOD="MH" MODIFIED="2009-09-15 14:55:54 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.5941681710960167" P_Q="0.0" P_Z="0.43925724530662613" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="643" TOTAL_2="626" WEIGHT="100.0" Z="0.7734480900359888">
<NAME>Adverse effects: 1. General - at least one adverse effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1896934996439963" CI_START="0.9647982814488196" EFFECT_SIZE="1.0713609307359306" ESTIMABLE="YES" EVENTS_1="235" EVENTS_2="220" LOG_CI_END="0.07543508865423924" LOG_CI_START="-0.01556347879219011" LOG_EFFECT_SIZE="0.02993580493102457" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1869" O_E="0.0" SE="0.053453008968206234" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="337" VAR="0.0028572241677551364" WEIGHT="71.56653454707246"/>
<DICH_DATA CI_END="1.7290700796965344" CI_START="0.7065107785647693" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" LOG_CI_END="0.23781259570811336" LOG_CI_START="-0.15088120814593267" LOG_EFFECT_SIZE="0.043465693781090345" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1870" O_E="0.0" SE="0.22832066444922663" STUDY_ID="STD-McEvoy-2006" TOTAL_1="19" TOTAL_2="15" VAR="0.052130325814536346" WEIGHT="3.922508231348122"/>
<DICH_DATA CI_END="1.1524295690512205" CI_START="0.7489057568099944" EFFECT_SIZE="0.9290108387852749" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="77" LOG_CI_END="0.061614392884176146" LOG_CI_START="-0.12557283099554564" LOG_EFFECT_SIZE="-0.03197921905568473" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1871" O_E="0.0" SE="0.10995470189865063" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.012090036469621125" WEIGHT="16.913235342522196"/>
<DICH_DATA CI_END="2.4161111789039773" CI_START="0.6994711231652163" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.3831169147477556" LOG_CI_START="-0.1552302101340821" LOG_EFFECT_SIZE="0.11394335230683678" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1872" O_E="0.0" SE="0.31622776601683794" STUDY_ID="STD-Riedel-2007" TOTAL_1="26" TOTAL_2="26" VAR="0.1" WEIGHT="2.044816321103783"/>
<DICH_DATA CI_END="2.1043037918109073" CI_START="0.38900947073042624" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.3231084377550546" LOG_CI_START="-0.41003982531723515" LOG_EFFECT_SIZE="-0.0434656937810903" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1873" O_E="0.0" SE="0.4306549188710953" STUDY_ID="STD-Sirota-2006" TOTAL_1="21" TOTAL_2="19" VAR="0.18546365914786966" WEIGHT="1.1025428542167697"/>
<DICH_DATA CI_END="1.2134040050158148" CI_START="0.5237093344315282" EFFECT_SIZE="0.7971643518518519" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="32" LOG_CI_END="0.08400542406228839" LOG_CI_START="-0.280909685300392" LOG_EFFECT_SIZE="-0.09845213061905181" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1874" O_E="0.0" SE="0.2143529415985624" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="95" VAR="0.045947183571956714" WEIGHT="4.450362703736668"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.359209958964361" CI_END="6.748155250949248" CI_START="0.2772046987950136" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3677062344529163" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="15.225858029272054" I2_Q="0.0" ID="CMP-004.17" LOG_CI_END="0.829185065596839" LOG_CI_START="-0.5571994124316211" LOG_EFFECT_SIZE="0.13599282658260903" METHOD="MH" MODIFIED="2009-09-15 14:56:23 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.3074001964902694" P_Q="0.0" P_Z="0.7005986750914202" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.3674457270630753" TOTALS="SUB" TOTAL_1="710" TOTAL_2="700" WEIGHT="200.0" Z="0.3845124443931395">
<NAME>Adverse effects: 2. Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.22158517354916407" CI_END="18.713979145244508" CI_START="0.43701755628489247" DF="1" EFFECT_SIZE="2.8597792632336496" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-004.17.01" LOG_CI_END="1.2721661411656737" LOG_CI_START="-0.35950111578816357" LOG_EFFECT_SIZE="0.4563325126887551" MODIFIED="2009-09-15 14:56:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6378347586231359" P_Z="0.27294919805736817" STUDIES="2" TAU2="0.0" TOTAL_1="469" TOTAL_2="471" WEIGHT="100.0" Z="1.0962961793011348">
<NAME>suicide attempt</NAME>
<DICH_DATA CI_END="22.01698775459328" CI_START="0.18276092077169157" EFFECT_SIZE="2.005952380952381" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3427579008734836" LOG_CI_START="-0.738116662582532" LOG_EFFECT_SIZE="0.30232061914547576" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1884" O_E="0.0" SE="1.2223160190692768" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="337" VAR="1.4940564504733644" WEIGHT="61.48531384757077"/>
<DICH_DATA CI_END="103.94012002875226" CI_START="0.244126393288838" EFFECT_SIZE="5.037313432835821" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.016783214004973" LOG_CI_START="-0.6123852650725384" LOG_EFFECT_SIZE="0.7021989744662173" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1885" O_E="0.0" SE="1.5443865792039984" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="2.385129906025428" WEIGHT="38.514686152429235"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.15760480115009" CI_START="0.00976505573155352" DF="0" EFFECT_SIZE="0.20149253731343286" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-004.17.02" LOG_CI_END="0.6188432053329355" LOG_CI_START="-2.0103252737445763" LOG_EFFECT_SIZE="-0.6957410342058202" MODIFIED="2009-09-15 14:56:23 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.2995928420490723" STUDIES="2" TAU2="0.0" TOTAL_1="241" TOTAL_2="229" WEIGHT="100.0" Z="1.0373069511988897">
<NAME>suicide</NAME>
<DICH_DATA CI_END="4.15760480115009" CI_START="0.00976505573155352" EFFECT_SIZE="0.20149253731343283" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6188432053329355" LOG_CI_START="-2.0103252737445763" LOG_EFFECT_SIZE="-0.6957410342058203" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1886" O_E="0.0" SE="1.5443865792039984" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="2.385129906025428" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1887" O_E="0.0" SE="0.0" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="95" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3640996320389618" CI_START="0.004363558497161674" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.07715133531157269" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-004.18" LOG_CI_END="0.1348460917753901" LOG_CI_START="-2.3601591975764316" LOG_EFFECT_SIZE="-1.1126565529005208" METHOD="MH" MODIFIED="2009-09-15 14:56:40 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="1.0" P_Q="0.0" P_Z="0.08044568635342961" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="336" TOTAL_2="337" WEIGHT="100.0" Z="1.748105929999089">
<NAME>Adverse effects: 3a. Cardiac effects - QTc prolongation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3640996320389618" CI_START="0.004363558497161674" EFFECT_SIZE="0.0771513353115727" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.1348460917753901" LOG_CI_START="-2.3601591975764316" LOG_EFFECT_SIZE="-1.1126565529005206" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1875" O_E="0.0" SE="1.4655784574406283" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="337" VAR="2.1479202149140515" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.7688481542032892" CI_END="-0.3430771860969948" CI_START="-9.284771679799716" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.8139244329483555" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.19" MODIFIED="2009-09-15 14:56:46 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.6808428121952017" P_Q="1.0" P_Z="0.03482694873282708" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="334" TOTAL_2="309" UNITS="" WEIGHT="100.0" Z="2.1103647680025204">
<NAME>Adverse effects: 3b. Cardiac effects - QTc abnormalities - change from baseline in ms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4340002950453927" CI_START="-9.834000295045392" EFFECT_SIZE="-4.7" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="5.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1876" SD_1="27.4" SD_2="27.8" SE="2.619436038387303" STUDY_ID="STD-Lieberman-2005" TOTAL_1="231" TOTAL_2="214" WEIGHT="75.83468462898553"/>
<CONT_DATA CI_END="2.979653738255715" CI_START="-16.979653738255713" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="-5.1" MEAN_2="1.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1877" SD_1="33.0" SD_2="33.3" SE="5.091753632706493" STUDY_ID="STD-Stroup-2006" TOTAL_1="89" TOTAL_2="81" WEIGHT="20.070062168187988"/>
<CONT_DATA CI_END="25.882733433654376" CI_START="-18.302733433654378" EFFECT_SIZE="3.7899999999999996" ESTIMABLE="YES" MEAN_1="4.43" MEAN_2="0.64" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1878" SD_1="32.25" SD_2="27.18" SE="11.272009898099679" STUDY_ID="STD-Svestka-2003b" TOTAL_1="14" TOTAL_2="14" WEIGHT="4.095253202826478"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.8027161576622848" CI_END="1.1516319833179067" CI_START="0.8814077666941834" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0075005580493885" ESTIMABLE="YES" EVENTS_1="265" EVENTS_2="257" I2="0.0" I2_Q="0.0" ID="CMP-004.20" LOG_CI_END="0.061313717673218644" LOG_CI_START="-0.05482312693982192" LOG_EFFECT_SIZE="0.0032452953666983753" METHOD="MH" MODIFIED="2009-09-15 14:59:55 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.8757136125397711" P_Q="0.0" P_Z="0.9127762861454156" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="814" TOTAL_2="801" WEIGHT="100.0" Z="0.10953736618412126">
<NAME>Adverse effects: 4a. Central nervous system - sedation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5357467016303903" CI_START="0.7164931061584713" EFFECT_SIZE="1.0489766081871346" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="40" LOG_CI_END="0.18631959124521705" LOG_CI_START="-0.1447879838733895" LOG_EFFECT_SIZE="0.020765803685913735" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1932" O_E="0.0" SE="0.19449422863359994" STUDY_ID="STD-Kinon-2006b" TOTAL_1="171" TOTAL_2="175" VAR="0.037828004971779045" WEIGHT="12.302739013665269"/>
<DICH_DATA CI_END="1.2704248743190927" CI_START="0.8072805474954453" EFFECT_SIZE="1.012713823393435" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="103" LOG_CI_END="0.10394898844713131" LOG_CI_START="-0.09297551229692591" LOG_EFFECT_SIZE="0.005486738075102693" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1933" O_E="0.0" SE="0.11567442652905915" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="337" VAR="0.013380572952826705" WEIGHT="34.78087778573896"/>
<DICH_DATA CI_END="2.5111563040584715" CI_START="0.357407829913744" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.3998737457186695" LOG_CI_START="-0.4468359374177153" LOG_EFFECT_SIZE="-0.023481095849522914" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1934" O_E="0.0" SE="0.49736145915484004" STUDY_ID="STD-McEvoy-2006" TOTAL_1="19" TOTAL_2="15" VAR="0.24736842105263163" WEIGHT="1.8813560380708865"/>
<DICH_DATA CI_END="1.1524295690512205" CI_START="0.7489057568099944" EFFECT_SIZE="0.9290108387852749" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="77" LOG_CI_END="0.061614392884176146" LOG_CI_START="-0.12557283099554564" LOG_EFFECT_SIZE="-0.03197921905568473" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1935" O_E="0.0" SE="0.10995470189865063" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.012090036469621125" WEIGHT="38.493520986873754"/>
<DICH_DATA CI_END="2.4161111789039773" CI_START="0.6994711231652163" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.3831169147477556" LOG_CI_START="-0.1552302101340821" LOG_EFFECT_SIZE="0.11394335230683678" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1936" O_E="0.0" SE="0.31622776601683794" STUDY_ID="STD-Riedel-2007" TOTAL_1="26" TOTAL_2="26" VAR="0.1" WEIGHT="4.6538807257542985"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1937" O_E="0.0" SE="0.0" STUDY_ID="STD-Sirota-2006" TOTAL_1="21" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.9308947274974582" CI_START="0.7451406404370045" EFFECT_SIZE="1.1994949494949494" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="22" LOG_CI_END="0.28575859666223463" LOG_CI_START="-0.1277617492635262" LOG_EFFECT_SIZE="0.07899842369935423" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1938" O_E="0.0" SE="0.24290389815551716" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="95" VAR="0.059002303739145855" WEIGHT="7.887625449896833"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.02081776524327" CI_START="0.013079297544116708" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.30303030303030304" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.21" LOG_CI_END="0.8463877004842706" LOG_CI_START="-1.8834155802400456" LOG_EFFECT_SIZE="-0.5185139398778874" METHOD="MH" MODIFIED="2009-09-15 15:00:22 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="1.0" P_Q="0.0" P_Z="0.4565300169923171" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="19" WEIGHT="99.99999999999999" Z="0.7445728084647721">
<NAME>Adverse effects: 4b. Central nervous system - seizures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.02081776524327" CI_START="0.013079297544116708" EFFECT_SIZE="0.30303030303030304" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8463877004842706" LOG_CI_START="-1.8834155802400456" LOG_EFFECT_SIZE="-0.5185139398778874" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1939" O_E="0.0" SE="1.6034999598416337" STUDY_ID="STD-Sirota-2006" TOTAL_1="21" TOTAL_2="19" VAR="2.5712121212121213" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.964192926188586" CI_END="1.452811440138632" CI_START="0.9338358799004833" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1647692687959053" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="126" I2="6.443333970261556" I2_Q="0.0" ID="CMP-004.22" LOG_CI_END="0.16220925103488318" LOG_CI_START="-0.029729443594940442" LOG_EFFECT_SIZE="0.06623990371997136" METHOD="MH" MODIFIED="2009-09-15 15:01:02 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.38060690993130397" P_Q="0.0" P_Z="0.1761178926003309" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.014406945492456693" TOTALS="SUB" TOTAL_1="1511" TOTAL_2="1492" WEIGHT="700.0" Z="1.3528051327110762">
<NAME>Adverse effects: 5a. Extrapyramidal effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7468914733514254" CI_END="1.4701256530403488" CI_START="0.7149962981586961" DF="4" EFFECT_SIZE="1.025248457571132" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="50" I2="0.0" ID="CMP-004.22.01" LOG_CI_END="0.16735445589776685" LOG_CI_START="-0.1456962067211753" LOG_EFFECT_SIZE="0.010829124588295819" MODIFIED="2009-09-15 15:00:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9454228312231445" P_Z="0.8921382163799529" STUDIES="6" TAU2="0.0" TOTAL_1="644" TOTAL_2="633" WEIGHT="99.99999999999999" Z="0.13559910079470103">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="1.8709425764980347" CI_START="0.4725669462142457" EFFECT_SIZE="0.9402901785714286" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.2720604582147378" LOG_CI_START="-0.32553665845223567" LOG_EFFECT_SIZE="-0.026738100118748945" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1888" O_E="0.0" SE="0.3510315044836162" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="337" VAR="0.12322311714003108" WEIGHT="27.441779347252876"/>
<DICH_DATA CI_END="1.7730432178197704" CI_START="0.6677816857528596" EFFECT_SIZE="1.0881203007518796" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="25" LOG_CI_END="0.24871932163131516" LOG_CI_START="-0.17536549586197217" LOG_EFFECT_SIZE="0.0366769128846715" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1889" O_E="0.0" SE="0.2491095210492599" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.06205555347739166" WEIGHT="54.49087795614255"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1890" O_E="0.0" SE="0.0" STUDY_ID="STD-Riedel-2007" TOTAL_1="26" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.9550669145102075" CI_START="0.20697351574638634" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5971538355850753" LOG_CI_START="-0.6840852231472558" LOG_EFFECT_SIZE="-0.0434656937810903" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1891" O_E="0.0" SE="0.7526061653349982" STUDY_ID="STD-Sirota-2006" TOTAL_1="21" TOTAL_2="19" VAR="0.5664160401002507" WEIGHT="5.969925552318287"/>
<DICH_DATA CI_END="2.635924753946469" CI_START="0.2935395952270316" EFFECT_SIZE="0.8796296296296297" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.42093300857285937" LOG_CI_START="-0.5323333089690633" LOG_EFFECT_SIZE="-0.05570015019810193" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1892" O_E="0.0" SE="0.5599533536685002" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="95" VAR="0.3135477582846004" WEIGHT="10.784518471881874"/>
<DICH_DATA CI_END="76.32862590851101" CI_START="0.14143996749380944" EFFECT_SIZE="3.2857142857142856" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8826874441486245" LOG_CI_START="-0.8494278521419525" LOG_EFFECT_SIZE="0.516629796003336" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1893" O_E="0.0" SE="1.6048580492299167" STUDY_ID="STD-Svestka-2003b" TOTAL_1="20" TOTAL_2="22" VAR="2.5755693581780537" WEIGHT="1.3128986724044027"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4913591712971606" CI_START="0.6400238270623342" DF="0" EFFECT_SIZE="0.9769879243563454" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="33" I2="0.0" ID="CMP-004.22.02" LOG_CI_END="0.17358224930642108" LOG_CI_START="-0.1938038576269405" LOG_EFFECT_SIZE="-0.010110804160259666" MODIFIED="2009-09-15 15:00:36 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9140908588972604" STUDIES="1" TAU2="0.0" TOTAL_1="133" TOTAL_2="134" WEIGHT="100.0" Z="0.10788002940155365">
<NAME>akinesia</NAME>
<DICH_DATA CI_END="1.4913591712971606" CI_START="0.6400238270623342" EFFECT_SIZE="0.9769879243563454" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="33" LOG_CI_END="0.17358224930642108" LOG_CI_START="-0.1938038576269405" LOG_EFFECT_SIZE="-0.010110804160259666" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1894" O_E="0.0" SE="0.2158044178032158" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.04657154674338492" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.304726536702083" CI_START="0.011146319981382718" DF="0" EFFECT_SIZE="0.21904761904761905" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-004.22.03" LOG_CI_END="0.6339455675496006" LOG_CI_START="-1.9528684936542908" LOG_EFFECT_SIZE="-0.6594614630523452" MODIFIED="2009-09-15 15:00:40 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.3176422582292885" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.0" Z="0.9993147448511664">
<NAME>dystonia</NAME>
<DICH_DATA CI_END="4.304726536702083" CI_START="0.011146319981382718" EFFECT_SIZE="0.21904761904761905" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6339455675496006" LOG_CI_START="-1.9528684936542908" LOG_EFFECT_SIZE="-0.6594614630523452" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1895" O_E="0.0" SE="1.5195073844872842" STUDY_ID="STD-Svestka-2003b" TOTAL_1="20" TOTAL_2="22" VAR="2.308902691511387" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.20811252378151124" CI_END="1.3900923707965274" CI_START="0.2727548550604254" DF="1" EFFECT_SIZE="0.6157551811533621" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" I2="0.0" ID="CMP-004.22.04" LOG_CI_END="0.14304365981837217" LOG_CI_START="-0.5642275101908176" LOG_EFFECT_SIZE="-0.21059192518622283" MODIFIED="2009-09-15 15:00:45 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6482508403498206" P_Z="0.2431420371679126" STUDIES="2" TAU2="0.0" TOTAL_1="128" TOTAL_2="117" WEIGHT="100.0" Z="1.1671692734049577">
<NAME>extrapyramidal symptoms</NAME>
<DICH_DATA CI_END="1.6640722157173886" CI_START="0.15182784673850855" EFFECT_SIZE="0.5026455026455027" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2211721694348922" LOG_CI_START="-0.818648567203685" LOG_EFFECT_SIZE="-0.29873819888439634" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1896" O_E="0.0" SE="0.6107958478971595" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="95" VAR="0.37307156780840994" WEIGHT="46.26525529719342"/>
<DICH_DATA CI_END="2.2270236340266645" CI_START="0.2414782535582821" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3477248259576583" LOG_CI_START="-0.6171219737525707" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1897" O_E="0.0" SE="0.5667557862184746" STUDY_ID="STD-Svestka-2003b" TOTAL_1="20" TOTAL_2="22" VAR="0.32121212121212117" WEIGHT="53.73474470280658"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.477097180270866" CI_START="0.4151601545721154" DF="0" EFFECT_SIZE="1.507936507936508" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-004.22.05" LOG_CI_END="0.7385504466948914" LOG_CI_START="-0.38178433502435927" LOG_EFFECT_SIZE="0.17838305583526606" MODIFIED="2009-09-15 15:00:49 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.5325339039773274" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="19" WEIGHT="100.0" Z="0.6241426591304969">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="5.477097180270866" CI_START="0.4151601545721154" EFFECT_SIZE="1.507936507936508" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7385504466948914" LOG_CI_START="-0.38178433502435927" LOG_EFFECT_SIZE="0.17838305583526606" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1898" O_E="0.0" SE="0.6580901965284981" STUDY_ID="STD-Sirota-2006" TOTAL_1="21" TOTAL_2="19" VAR="0.4330827067669173" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.601876322621589" CI_START="0.7658535801605233" DF="0" EFFECT_SIZE="2.5666666666666673" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-004.22.06" LOG_CI_END="0.9345931939970645" LOG_CI_START="-0.11585425309142545" LOG_EFFECT_SIZE="0.4093694704528196" MODIFIED="2009-09-15 15:00:54 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.12660352942341171" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.00000000000001" Z="1.527633620666356">
<NAME>tremor</NAME>
<DICH_DATA CI_END="8.601876322621589" CI_START="0.7658535801605232" EFFECT_SIZE="2.566666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9345931939970645" LOG_CI_START="-0.11585425309142552" LOG_EFFECT_SIZE="0.40936947045281946" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1899" O_E="0.0" SE="0.6170380302185033" STUDY_ID="STD-Svestka-2003b" TOTAL_1="20" TOTAL_2="22" VAR="0.3807359307359307" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.245424818295132" CI_END="3.320764807942748" CI_START="1.2636736094983059" DF="3" EFFECT_SIZE="2.048502587537531" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="22" I2="0.0" ID="CMP-004.22.07" LOG_CI_END="0.5212381179260953" LOG_CI_START="0.10163491579897994" LOG_EFFECT_SIZE="0.3114365168625376" MODIFIED="2009-09-15 15:01:02 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.5230567061581244" P_Z="0.00362081371446456" STUDIES="6" TAU2="0.0" TOTAL_1="545" TOTAL_2="545" WEIGHT="100.0" Z="2.909436121682685">
<NAME>use of antiparkinson medication</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1900" O_E="0.0" SE="0.0" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.5576571809504856" CI_START="1.1400771431277028" EFFECT_SIZE="2.279491341991342" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="11" LOG_CI_END="0.6587416551969745" LOG_CI_START="0.05693423879363986" LOG_EFFECT_SIZE="0.35783794699530713" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1901" O_E="0.0" SE="0.35350465539007453" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="337" VAR="0.12496554138245534" WEIGHT="48.614129839666184"/>
<DICH_DATA CI_END="8.079922683043186" CI_START="1.1306849700197512" EFFECT_SIZE="3.0225563909774436" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.9074072050210766" LOG_CI_START="0.05334161921369212" LOG_EFFECT_SIZE="0.4803744121173843" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1902" O_E="0.0" SE="0.5016823527960907" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.25168518310702126" WEIGHT="24.137658718144007"/>
<DICH_DATA CI_END="19.775299481351468" CI_START="0.20227253720086952" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.296123069267743" LOG_CI_START="-0.6940630779397805" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1903" O_E="0.0" SE="1.1690451944500122" STUDY_ID="STD-Ozguven-2004" TOTAL_1="15" TOTAL_2="15" VAR="1.3666666666666667" WEIGHT="4.445188576281119"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1904" O_E="0.0" SE="0.0" STUDY_ID="STD-Riedel-2007" TOTAL_1="26" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.9858468699796568" CI_START="0.39478766377999575" EFFECT_SIZE="1.0857142857142856" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.4750675310420053" LOG_CI_START="-0.4036364265089364" LOG_EFFECT_SIZE="0.03571555226653449" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1905" O_E="0.0" SE="0.5161550543201633" STUDY_ID="STD-Sirota-2006" TOTAL_1="21" TOTAL_2="19" VAR="0.26641604010025066" WEIGHT="22.803022865908687"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.4538189471758149" CI_END="0.5167691470192418" CI_START="-0.3967527407234305" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.06000820314790564" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.23" MODIFIED="2009-09-15 15:45:54 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.796993084065681" P_Q="0.796993084065681" P_Z="0.7967962394064786" Q="0.4538189471758149" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="67" TOTAL_2="66" UNITS="" WEIGHT="300.0" Z="0.2574955642004027">
<NAME>Adverse effects: 5b. Extrapyramidal effects - scale measured</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5767509155762891" CI_START="-0.3767509155762892" DF="0" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-004.23.01" MODIFIED="2009-09-15 15:45:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6809929098600277" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.411108593713109">
<NAME>akathisia: BAS (high=poor)</NAME>
<CONT_DATA CI_END="0.5767509155762891" CI_START="-0.3767509155762892" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-0.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1906" SD_1="0.86" SD_2="0.86" SE="0.24324473272817232" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.6761267302272236" CI_START="-2.6761267302272236" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.23.02" MODIFIED="2009-09-15 15:45:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="16" WEIGHT="100.0" Z="0.0">
<NAME>extrapyramidal symptoms: ESRS (high=poor)</NAME>
<CONT_DATA CI_END="2.6761267302272236" CI_START="-2.6761267302272236" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1907" SD_1="3.92" SD_2="3.92" SE="1.3653958701977025" STUDY_ID="STD-Riedel-2007" TOTAL_1="17" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.384614276468739" CI_START="-2.5846142764687388" DF="0" EFFECT_SIZE="-0.6" ESTIMABLE="YES" I2="0.0" ID="CMP-004.23.03" MODIFIED="2009-09-15 15:45:54 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5534839711341664" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.5925475819999002">
<NAME>extrapyramidal symptoms: SAS (high=poor)</NAME>
<CONT_DATA CI_END="1.384614276468739" CI_START="-2.5846142764687388" EFFECT_SIZE="-0.6" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-0.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1908" SD_1="3.58" SD_2="3.58" SE="1.012576910659136" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.3212874248329465" CI_END="1.610280367238699" CI_START="1.0919987977362808" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3260558906181128" ESTIMABLE="YES" EVENTS_1="193" EVENTS_2="140" I2="0.0" I2_Q="0.0" ID="CMP-004.24" LOG_CI_END="0.2069014979846584" LOG_CI_START="0.038222160221478084" LOG_EFFECT_SIZE="0.12256182910306829" METHOD="MH" MODIFIED="2010-02-17 14:15:29 +0000" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.6948051150109709" P_Q="0.0" P_Z="0.004396642259516472" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1392" TOTAL_2="1371" WEIGHT="500.0" Z="2.848206236837643">
<NAME>Adverse effects: 6a. Prolactin associated side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="172.3323478821665" CI_START="0.5638132741773969" DF="0" EFFECT_SIZE="9.857142857142858" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-004.24.01" LOG_CI_END="2.2363668049474272" LOG_CI_START="-0.24886470350143036" LOG_EFFECT_SIZE="0.9937510507229985" MODIFIED="2009-09-15 15:02:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.1170136415398662" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.0" Z="1.5674324604322831">
<NAME>abnormally high prolactin value</NAME>
<DICH_DATA CI_END="172.3323478821665" CI_START="0.5638132741773969" EFFECT_SIZE="9.857142857142858" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2363668049474272" LOG_CI_START="-0.24886470350143036" LOG_EFFECT_SIZE="0.9937510507229985" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1914" O_E="0.0" SE="1.4598372901572316" STUDY_ID="STD-Svestka-2003b" TOTAL_1="20" TOTAL_2="22" VAR="2.1311249137336095" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.40053706739649175" CI_END="2.756500505297632" CI_START="0.8284734204090962" DF="1" EFFECT_SIZE="1.5111874145794528" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" I2="0.0" ID="CMP-004.24.02" LOG_CI_END="0.4403580764263719" LOG_CI_START="-0.0817214203222902" LOG_EFFECT_SIZE="0.17931832805204084" MODIFIED="2010-02-17 14:15:12 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.526812446080214" P_Z="0.17818151847141334" STUDIES="3" TAU2="0.0" TOTAL_1="125" TOTAL_2="127" WEIGHT="100.0" Z="1.34637528169062">
<NAME>amenorrhoea</NAME>
<DICH_DATA CI_END="5.407255382816769" CI_START="0.7110833832658525" EFFECT_SIZE="1.9608695652173913" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.7329768816394127" LOG_CI_START="-0.14807946991867746" LOG_EFFECT_SIZE="0.29244870586036764" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1915" O_E="0.0" SE="0.5175368622045005" STUDY_ID="STD-Lieberman-2005" TOTAL_1="92" TOTAL_2="82" VAR="0.2678444037404801" WEIGHT="35.11283558029534"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1916" O_E="0.0" SE="0.0" STUDY_ID="STD-McEvoy-2006" TOTAL_1="1" TOTAL_2="3" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.767965466858908" CI_START="0.6223546755281137" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.44216066755994665" LOG_CI_START="-0.20596204340395768" LOG_EFFECT_SIZE="0.11809931207799448" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1917" O_E="0.0" SE="0.3807104886793588" STUDY_ID="STD-McEvoy-2007" TOTAL_1="32" TOTAL_2="42" VAR="0.1449404761904762" WEIGHT="64.88716441970466"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3884683885805278" CI_END="3.9825244568414413" CI_START="0.5781558546622644" DF="2" EFFECT_SIZE="1.5174056250912389" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" I2="0.0" ID="CMP-004.24.03" LOG_CI_END="0.6001584515010836" LOG_CI_START="-0.23795507214046951" LOG_EFFECT_SIZE="0.181101689680307" MODIFIED="2010-02-17 14:15:29 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4994568438036693" P_Z="0.3969795519229341" STUDIES="4" TAU2="0.0" TOTAL_1="518" TOTAL_2="507" WEIGHT="99.99999999999999" Z="0.8470279486017656">
<NAME>galactorrhoea</NAME>
<DICH_DATA CI_END="3.4453507651391493" CI_START="0.3974123718096446" EFFECT_SIZE="1.1701388888888888" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5372334432565953" LOG_CI_START="-0.40075861703237975" LOG_EFFECT_SIZE="0.06823741311210775" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1918" O_E="0.0" SE="0.5509811793493259" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="337" VAR="0.303580259997174" WEIGHT="79.83758145611738"/>
<DICH_DATA CI_END="55.02767409037393" CI_START="0.10467460410084109" EFFECT_SIZE="2.4" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7405811564407443" LOG_CI_START="-0.980158673017532" LOG_EFFECT_SIZE="0.38021124171160603" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1919" O_E="0.0" SE="1.5981760437031542" STUDY_ID="STD-McEvoy-2006" TOTAL_1="19" TOTAL_2="15" VAR="2.5541666666666667" WEIGHT="9.48924518211824"/>
<DICH_DATA CI_END="135.2165632245977" CI_START="0.36781050331697795" EFFECT_SIZE="7.052238805970149" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.131029893354567" LOG_CI_START="-0.4343758730656567" LOG_EFFECT_SIZE="0.8483270101444553" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1920" O_E="0.0" SE="1.5069320461585896" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="2.2708441917397137" WEIGHT="10.673173361764377"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1921" O_E="0.0" SE="0.0" STUDY_ID="STD-Stroup-2006" TOTAL_1="30" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.919328336842488" CI_START="0.836667499576295" DF="0" EFFECT_SIZE="3.022556390977444" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="0.0" ID="CMP-004.24.04" LOG_CI_END="1.0381959251293187" LOG_CI_START="-0.07744710089455002" LOG_EFFECT_SIZE="0.4803744121173843" MODIFIED="2010-02-17 14:15:28 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.09144088516044684" STUDIES="1" TAU2="0.0" TOTAL_1="133" TOTAL_2="134" WEIGHT="100.00000000000001" Z="1.6878455292285066">
<NAME>gynaecomastia</NAME>
<DICH_DATA CI_END="10.919328336842488" CI_START="0.836667499576295" EFFECT_SIZE="3.0225563909774436" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.0381959251293187" LOG_CI_START="-0.07744710089455002" LOG_EFFECT_SIZE="0.4803744121173843" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1922" O_E="0.0" SE="0.6553342360084654" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.429462960884799" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4481816689842557" CI_END="1.5506468889388096" CI_START="1.0118111296741983" DF="3" EFFECT_SIZE="1.2525820453858336" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="116" I2="0.0" ID="CMP-004.24.05" LOG_CI_END="0.19051291216251204" LOG_CI_START="0.005099452231577647" LOG_EFFECT_SIZE="0.09780618219704491" MODIFIED="2009-09-15 15:02:51 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6942805707237406" P_Z="0.038661250505670285" STUDIES="4" TAU2="0.0" TOTAL_1="596" TOTAL_2="581" WEIGHT="100.00000000000001" Z="2.067774309836801">
<NAME>sexual dysfunction</NAME>
<DICH_DATA CI_END="1.7396551472031212" CI_START="1.0057792782595834" EFFECT_SIZE="1.3227657004830917" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="69" LOG_CI_END="0.2404631663802801" LOG_CI_START="0.0025026837503855886" LOG_EFFECT_SIZE="0.12148292506533283" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1923" O_E="0.0" SE="0.13977916542018634" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="337" VAR="0.019538215085563818" WEIGHT="60.71176156456611"/>
<DICH_DATA CI_END="4.967682164133248" CI_START="0.12546468905779695" EFFECT_SIZE="0.7894736842105263" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.6961538015850384" LOG_CI_START="-0.9014784853793337" LOG_EFFECT_SIZE="-0.10266234189714772" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1924" O_E="0.0" SE="0.9384571137702378" STUDY_ID="STD-McEvoy-2006" TOTAL_1="19" TOTAL_2="15" VAR="0.880701754385965" WEIGHT="1.3468798600259295"/>
<DICH_DATA CI_END="1.58101154247948" CI_START="0.717527637318939" EFFECT_SIZE="1.065091299677766" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="35" LOG_CI_END="0.19893504059435135" LOG_CI_START="-0.1441613663654689" LOG_EFFECT_SIZE="0.02738683711444124" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1925" O_E="0.0" SE="0.20153652780280357" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.04061697203881021" WEIGHT="29.204526977996416"/>
<DICH_DATA CI_END="3.259975996062351" CI_START="0.7690070256567912" EFFECT_SIZE="1.5833333333333333" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.5132144022716063" LOG_CI_START="-0.11406969246119805" LOG_EFFECT_SIZE="0.1995723549052041" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1926" O_E="0.0" SE="0.36846978235239675" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="95" VAR="0.13576998050682262" WEIGHT="8.736831597411557"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="9.842237474749158" CI_END="11.61783921964609" CI_START="0.15675957730341938" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="5.887299398474755" ESTIMABLE="YES" I2="59.35883471352692" I2_Q="0.0" ID="CMP-004.25" MODIFIED="2009-09-15 15:03:03 +0100" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.0431707592803936" P_Q="1.0" P_Z="0.04405375040809965" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="22.395969826513973" TOTALS="YES" TOTAL_1="512" TOTAL_2="509" UNITS="" WEIGHT="100.0" Z="2.0135790252402903">
<NAME>Adverse effects: 6b. Prolactin - change from baseline in ng/ml</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.814200781201451" CI_START="-0.41420078120144854" EFFECT_SIZE="3.200000000000001" ESTIMABLE="YES" MEAN_1="-6.1" MEAN_2="-9.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1927" SD_1="22.0" SD_2="25.7" SE="1.8440138745965762" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="337" WEIGHT="33.13877947251473"/>
<CONT_DATA CI_END="19.883096344023684" CI_START="-1.6830963440236832" EFFECT_SIZE="9.1" ESTIMABLE="YES" MEAN_1="-4.1" MEAN_2="-13.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1928" SD_1="9.2" SD_2="18.02" SE="5.50168086203592" STUDY_ID="STD-McEvoy-2006" TOTAL_1="16" TOTAL_2="13" WEIGHT="16.23219436882294"/>
<CONT_DATA CI_END="10.034380975829144" CI_START="-4.434380975829147" EFFECT_SIZE="2.799999999999999" ESTIMABLE="YES" MEAN_1="-15.9" MEAN_2="-18.7" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1929" SD_1="15.57" SD_2="17.64" SE="3.6910785263877397" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="44" WEIGHT="23.732900097028693"/>
<CONT_DATA CI_END="11.174455695202793" CI_START="-4.774455695202791" EFFECT_SIZE="3.200000000000001" ESTIMABLE="YES" MEAN_1="-5.1" MEAN_2="-8.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1930" SD_1="37.4" SD_2="18.5" SE="4.068674607341911" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="95" WEIGHT="21.947572953138067"/>
<CONT_DATA CI_END="64.10282484344903" CI_START="16.03717515655097" EFFECT_SIZE="40.07" ESTIMABLE="YES" MEAN_1="25.33" MEAN_2="-14.74" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1931" SD_1="41.78" SD_2="26.07" SE="12.261870643040835" STUDY_ID="STD-Svestka-2003b" TOTAL_1="15" TOTAL_2="20" WEIGHT="4.948553108495567"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7045702448866589" CI_START="0.5955132264793657" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0075187969924813" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-004.26" LOG_CI_END="0.23161490309383762" LOG_CI_START="-0.22510858829839392" LOG_EFFECT_SIZE="0.0032531573977218607" METHOD="MH" MODIFIED="2009-09-15 15:03:28 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="1.0" P_Q="0.0" P_Z="0.9777252186470543" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="134" WEIGHT="100.0" Z="0.027920925705567257">
<NAME>Adverse effects: 7a. Metabolic - cholesterol - significant cholesterol increase</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7045702448866589" CI_START="0.5955132264793657" EFFECT_SIZE="1.0075187969924813" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" LOG_CI_END="0.23161490309383762" LOG_CI_START="-0.22510858829839392" LOG_EFFECT_SIZE="0.0032531573977218607" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1879" O_E="0.0" SE="0.2682816396615412" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.07197503817948506" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="8.717415390063037" CI_END="13.835476449886327" CI_START="-4.450609955403364" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="4.692433247241482" ESTIMABLE="YES" I2="65.58612999651602" I2_Q="0.0" ID="CMP-004.27" MODIFIED="2009-09-15 15:03:43 +0100" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.03329387560516239" P_Q="1.0" P_Z="0.3144630054866582" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="53.21034233258447" TOTALS="YES" TOTAL_1="497" TOTAL_2="489" UNITS="" WEIGHT="99.99999999999999" Z="1.005901422601961">
<NAME>Adverse effects: 7b. Metabolic - cholesterol - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.22498678873758" CI_START="-1.4249867887375807" EFFECT_SIZE="4.3999999999999995" ESTIMABLE="YES" MEAN_1="9.7" MEAN_2="5.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1880" SD_1="38.5" SD_2="38.6" SE="2.9719866460222395" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="337" WEIGHT="35.074560976512224"/>
<CONT_DATA CI_END="33.62345266168927" CI_START="-7.223452661689272" EFFECT_SIZE="13.2" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="-13.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1881" SD_1="31.6" SD_2="24.5" SE="10.420320384857508" STUDY_ID="STD-McEvoy-2006" TOTAL_1="16" TOTAL_2="13" WEIGHT="13.450068882056248"/>
<CONT_DATA CI_END="2.6425509866182466" CI_START="-21.642550986618247" EFFECT_SIZE="-9.5" ESTIMABLE="YES" MEAN_1="15.7" MEAN_2="25.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1882" SD_1="26.16" SD_2="29.58" SE="6.1952929147663625" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="44" WEIGHT="23.758982374708005"/>
<CONT_DATA CI_END="22.959213484723843" CI_START="3.2407865152761524" EFFECT_SIZE="13.099999999999998" ESTIMABLE="YES" MEAN_1="17.9" MEAN_2="4.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1883" SD_1="34.3" SD_2="37.0" SE="5.030303394599117" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="95" WEIGHT="27.716387766723518"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.062388481721139" CI_START="0.6496838985027887" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4105263157894736" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-004.28" LOG_CI_END="0.4860602826281113" LOG_CI_START="-0.18729789647619163" LOG_EFFECT_SIZE="0.14938119307595982" METHOD="MH" MODIFIED="2009-09-15 15:04:00 +0100" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="1.0" P_Q="0.0" P_Z="0.3845099181107501" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="134" WEIGHT="100.0" Z="0.8696166987559637">
<NAME>Adverse effects: 7c. Metabolic - glucose - abnormally high fasting glucose value</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.062388481721139" CI_START="0.6496838985027887" EFFECT_SIZE="1.4105263157894736" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" LOG_CI_END="0.4860602826281113" LOG_CI_START="-0.18729789647619163" LOG_EFFECT_SIZE="0.14938119307595982" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1909" O_E="0.0" SE="0.39553392758261086" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.15644708786892605" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="9.4512200753642" CI_END="17.823246924242824" CI_START="0.8199288994073992" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="9.321587911825112" ESTIMABLE="YES" I2="68.25806640753314" I2_Q="0.0" ID="CMP-004.29" MODIFIED="2009-09-15 15:04:18 +0100" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="0.023856067949953874" P_Q="1.0" P_Z="0.031635226366858955" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="43.369618685533986" TOTALS="YES" TOTAL_1="497" TOTAL_2="489" UNITS="" WEIGHT="99.99999999999999" Z="2.148989574766009">
<NAME>Adverse effects: 7d. Metabolic - glucose - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="15.555500274494282" CI_START="0.8444997255057158" EFFECT_SIZE="8.2" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="6.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1910" SD_1="51.3" SD_2="45.9" SE="3.752875222459969" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="337" WEIGHT="32.74863833205592"/>
<CONT_DATA CI_END="85.10487551850203" CI_START="8.695124481497984" EFFECT_SIZE="46.900000000000006" ESTIMABLE="YES" MEAN_1="23.6" MEAN_2="-23.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1911" SD_1="60.8" SD_2="44.0" SE="19.492641609670994" STUDY_ID="STD-McEvoy-2006" TOTAL_1="16" TOTAL_2="13" WEIGHT="4.444566108116455"/>
<CONT_DATA CI_END="6.919582188330009" CI_START="-2.1195821883300097" EFFECT_SIZE="2.3999999999999995" ESTIMABLE="YES" MEAN_1="8.6" MEAN_2="6.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1912" SD_1="9.67" SD_2="11.08" SE="2.305951652162946" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="44" WEIGHT="38.64540690543042"/>
<CONT_DATA CI_END="26.51281726178678" CI_START="3.4871827382132228" EFFECT_SIZE="15.0" ESTIMABLE="YES" MEAN_1="14.8" MEAN_2="-0.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1913" SD_1="41.6" SD_2="41.9" SE="5.873994294078059" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="95" WEIGHT="24.161388654397197"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="12.060329526736252" CI_END="1.9785025345238991" CI_START="1.091772343902905" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4697191396777125" ESTIMABLE="YES" EVENTS_1="243" EVENTS_2="151" I2="41.95846817881825" I2_Q="0.0" ID="CMP-004.30" LOG_CI_END="0.2963366109472771" LOG_CI_START="0.038132088831927924" LOG_EFFECT_SIZE="0.16723434988960248" METHOD="MH" MODIFIED="2009-09-15 15:04:54 +0100" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="0.09859232780487104" P_Q="0.0" P_Z="0.01112125044527964" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.056226609464071944" TOTALS="YES" TOTAL_1="838" TOTAL_2="829" WEIGHT="99.99999999999999" Z="2.538865702864514">
<NAME>Adverse effects: 7e. Metabolic - weight gain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.020877656148642" CI_END="1.9794354286277136" CI_START="1.050605959487504" DF="6" EFFECT_SIZE="1.442084136843956" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="150" I2="50.086839150791796" ID="CMP-004.30.01" LOG_CI_END="0.29654133915310615" LOG_CI_START="0.021439859978604415" LOG_EFFECT_SIZE="0.15899059956585532" MODIFIED="2009-09-15 15:04:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06150477056659609" P_Z="0.023484398900683746" STUDIES="7" TAU2="0.06763761223588413" TOTAL_1="667" TOTAL_2="654" WEIGHT="98.51074604176473" Z="2.2654610943174354">
<NAME>significant weight gain (as defined by the original studies)</NAME>
<DICH_DATA CI_END="2.5725610348402137" CI_START="1.3784755081922109" EFFECT_SIZE="1.8831389698736638" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="49" LOG_CI_END="0.41036568733334766" LOG_CI_START="0.13939905426372468" LOG_EFFECT_SIZE="0.27488237079853617" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1940" O_E="0.0" SE="0.1591671415715626" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="337" VAR="0.025334178956061847" WEIGHT="28.20469949495941"/>
<DICH_DATA CI_END="4.967682164133248" CI_START="0.12546468905779695" EFFECT_SIZE="0.7894736842105263" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.6961538015850384" LOG_CI_START="-0.9014784853793337" LOG_EFFECT_SIZE="-0.10266234189714772" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1941" O_E="0.0" SE="0.9384571137702378" STUDY_ID="STD-McEvoy-2006" TOTAL_1="19" TOTAL_2="15" VAR="0.880701754385965" WEIGHT="2.455254442835969"/>
<DICH_DATA CI_END="1.9271432116110292" CI_START="1.3184220275214982" EFFECT_SIZE="1.593984962406015" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="67" LOG_CI_END="0.28491398953940417" LOG_CI_START="0.12005445038392702" LOG_EFFECT_SIZE="0.2024842199616656" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1942" O_E="0.0" SE="0.09683930936780745" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="134" VAR="0.009377851838833919" WEIGHT="35.064650822152934"/>
<DICH_DATA CI_END="2.2600666525183493" CI_START="0.4424648268163769" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.35412124728637384" LOG_CI_START="-0.3541212472863738" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1943" O_E="0.0" SE="0.41602514716892186" STUDY_ID="STD-Riedel-2007" TOTAL_1="26" TOTAL_2="26" VAR="0.17307692307692307" WEIGHT="10.032106799534684"/>
<DICH_DATA CI_END="1.2563880426648426" CI_START="0.157221222655511" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.09912379446525373" LOG_CI_START="-0.8034888306879787" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1944" O_E="0.0" SE="0.5301991240195623" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" VAR="0.28111111111111114" WEIGHT="6.819271571644904"/>
<DICH_DATA CI_END="3.92668731060674" CI_START="1.1508186313067001" EFFECT_SIZE="2.1257716049382718" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="12" LOG_CI_END="0.5940263189722585" LOG_CI_START="0.061006884334200186" LOG_EFFECT_SIZE="0.3275166016532294" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1945" O_E="0.0" SE="0.31309825439514993" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="95" VAR="0.09803051690529004" WEIGHT="14.912747191035029"/>
<DICH_DATA CI_END="2.8536510799567147" CI_START="0.008578673366015468" EFFECT_SIZE="0.1564625850340136" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.45540087021058673" LOG_CI_START="-2.066579867671753" LOG_EFFECT_SIZE="-0.8055894987305832" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1946" O_E="0.0" SE="1.4814239694380784" STUDY_ID="STD-Svestka-2003b" TOTAL_1="20" TOTAL_2="22" VAR="2.1946169772256727" WEIGHT="1.0220157196018103"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="22.36407755552935" CI_START="0.1873237650942029" DF="0" EFFECT_SIZE="2.046783625730994" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-004.30.02" LOG_CI_END="1.349550989662473" LOG_CI_START="-0.7274071217462293" LOG_EFFECT_SIZE="0.3110719339581218" MODIFIED="2009-09-15 15:04:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5571373695445696" STUDIES="1" TAU2="0.0" TOTAL_1="171" TOTAL_2="175" WEIGHT="1.489253958235246" Z="0.5870987804810538">
<NAME>as "weight gain" reported adverse event</NAME>
<DICH_DATA CI_END="22.36407755552935" CI_START="0.1873237650942029" EFFECT_SIZE="2.046783625730994" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.349550989662473" LOG_CI_START="-0.7274071217462293" LOG_EFFECT_SIZE="0.3110719339581218" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1947" O_E="0.0" SE="1.2200154757499349" STUDY_ID="STD-Kinon-2006b" TOTAL_1="171" TOTAL_2="175" VAR="1.48843776106934" WEIGHT="1.489253958235246"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="24.877009225663556" CI_END="4.261201709832784" CI_START="1.095886516764201" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="2.678544113298493" ESTIMABLE="YES" I2="75.88134511840637" I2_Q="0.0" ID="CMP-004.31" MODIFIED="2009-09-15 15:05:13 +0100" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="3.598303942842218E-4" P_Q="1.0" P_Z="9.095366483917082E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="2.862297678454247" TOTALS="YES" TOTAL_1="585" TOTAL_2="588" UNITS="" WEIGHT="99.99999999999999" Z="3.317110412614173">
<NAME>Adverse effects: 7f. Metabolic - weight gain - change from baseline in kg</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.5679360302353" CI_START="2.4520639697646995" EFFECT_SIZE="4.51" ESTIMABLE="YES" MEAN_1="8.92" MEAN_2="4.41" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1948" SD_1="3.13" SD_2="2.21" SE="1.0499866561161517" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="14" WEIGHT="16.44598123278794"/>
<CONT_DATA CI_END="1.7552126971657027" CI_START="-0.4752126971657028" EFFECT_SIZE="0.64" ESTIMABLE="YES" MEAN_1="1.03" MEAN_2="0.39" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1949" SD_1="5.78" SD_2="4.74" SE="0.5689965254271804" STUDY_ID="STD-Kinon-2006b" TOTAL_1="171" TOTAL_2="175" WEIGHT="20.465601818865267"/>
<CONT_DATA CI_END="4.909181799612205" CI_START="2.6908182003877945" EFFECT_SIZE="3.8" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="0.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1950" SD_1="7.0" SD_2="7.0" SE="0.5659194803380518" STUDY_ID="STD-Lieberman-2005" TOTAL_1="307" TOTAL_2="305" WEIGHT="20.488058478419884"/>
<CONT_DATA CI_END="10.182840031334539" CI_START="-5.5828400313345385" EFFECT_SIZE="2.3" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="0.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1951" SD_1="14.38" SD_2="8.91" SE="4.021931062771242" STUDY_ID="STD-McEvoy-2006" TOTAL_1="19" TOTAL_2="15" WEIGHT="3.4249264304744362"/>
<CONT_DATA CI_END="10.000770133401431" CI_START="0.3592298665985654" EFFECT_SIZE="5.179999999999999" ESTIMABLE="YES" MEAN_1="10.87" MEAN_2="5.69" MODIFIED="2008-12-12 12:29:04 +0000" MODIFIED_BY="[Empty name]" ORDER="1952" SD_1="10.64" SD_2="11.47" SE="2.4596217948018704" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="44" WEIGHT="7.316456045107844"/>
<CONT_DATA CI_END="2.516291570911831" CI_START="-1.556291570911831" EFFECT_SIZE="0.48" ESTIMABLE="YES" MEAN_1="3.76" MEAN_2="3.28" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1953" SD_1="2.77" SD_2="3.17" SE="1.0389433617014594" STUDY_ID="STD-Riedel-2007" TOTAL_1="17" TOTAL_2="16" WEIGHT="16.542230771230248"/>
<CONT_DATA CI_END="5.514730694511526" CI_START="0.8852693054884733" EFFECT_SIZE="3.1999999999999997" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="-0.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1954" SD_1="3.73" SD_2="3.73" SE="1.181006749496331" STUDY_ID="STD-Sirota-2006" TOTAL_1="21" TOTAL_2="19" WEIGHT="15.316745223114369"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2010-02-17 14:16:37 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>OLANZAPINE versus RISPERIDONE</NAME>
<DICH_OUTCOME CHI2="5.241998684630929" CI_END="1.0098268279562548" CI_START="0.88206529939453" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9437866301966046" ESTIMABLE="YES" EVENTS_1="397" EVENTS_2="406" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.0042469043655996965" LOG_CI_START="-0.054499262808119106" LOG_EFFECT_SIZE="-0.025126179221259703" METHOD="MH" MODIFIED="2009-09-15 15:09:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5131707947171105" P_Q="0.0" P_Z="0.09362409503224138" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="691" TOTAL_2="685" WEIGHT="100.0" Z="1.676582786997515">
<NAME>Global state: 1a. No clinically significant response (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1721471844751343" CI_START="0.8287135818122878" EFFECT_SIZE="0.9855832241153342" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="109" LOG_CI_END="0.06898214870592427" LOG_CI_START="-0.08159554343240073" LOG_EFFECT_SIZE="-0.006306697363238239" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1998" O_E="0.0" SE="0.0884500817336494" STUDY_ID="STD-Conley-2001" TOTAL_1="189" TOTAL_2="188" VAR="0.00782341695868926" WEIGHT="15.220811255371538"/>
<DICH_DATA CI_END="1.1245719974563644" CI_START="0.8383690185065557" EFFECT_SIZE="0.9709821428571429" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="28" LOG_CI_END="0.05098726510474496" LOG_CI_START="-0.07656477919175829" LOG_EFFECT_SIZE="-0.012788757043506651" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1999" O_E="0.0" SE="0.07492470221256828" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="30" VAR="0.005613711001642034" WEIGHT="21.212127390499976"/>
<DICH_DATA CI_END="1.3315818682339993" CI_START="0.6812846410418787" EFFECT_SIZE="0.9524632670700086" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="39" LOG_CI_END="0.12436787286227048" LOG_CI_START="-0.16667140173423722" LOG_EFFECT_SIZE="-0.021151764435983322" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2000" O_E="0.0" SE="0.17095791056563267" STUDY_ID="STD-Jeste-2003" TOTAL_1="89" TOTAL_2="87" VAR="0.029226607184966856" WEIGHT="4.0743269359548515"/>
<DICH_DATA CI_END="1.4099291735369022" CI_START="0.7397576449882186" EFFECT_SIZE="1.0212765957446808" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="47" LOG_CI_END="0.14919729682937174" LOG_CI_START="-0.1309105379496323" LOG_EFFECT_SIZE="0.009143379439869719" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2001" O_E="0.0" SE="0.16453672870533126" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.027072335093051778" WEIGHT="4.398540151449444"/>
<DICH_DATA CI_END="1.6635971585692082" CI_START="0.8655941689864901" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="30" LOG_CI_END="0.22104816991676746" LOG_CI_START="-0.06268567782151782" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2002" O_E="0.0" SE="0.16666666666666666" STUDY_ID="STD-Robinson-2006" TOTAL_1="60" TOTAL_2="60" VAR="0.027777777777777773" WEIGHT="4.286835104410155"/>
<DICH_DATA CI_END="1.792434823653244" CI_START="0.09685769815455067" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.2534433728517676" LOG_CI_START="-1.0138658562749796" LOG_EFFECT_SIZE="-0.38021124171160603" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2003" O_E="0.0" SE="0.7444237144709097" STUDY_ID="STD-Sikich-2004" TOTAL_1="16" TOTAL_2="20" VAR="0.5541666666666666" WEIGHT="0.21487895260201276"/>
<DICH_DATA CI_END="0.9878828858860804" CI_START="0.8167962476831225" EFFECT_SIZE="0.8982755893054897" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="147" LOG_CI_END="-0.005294538234406663" LOG_CI_START="-0.08788626604144172" LOG_EFFECT_SIZE="-0.0465904021379242" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2004" O_E="0.0" SE="0.04851478974949865" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="0.0023536848244380595" WEIGHT="50.59248020971203"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.339223756729819" CI_END="1.142065774475754" CI_START="0.9199407938532815" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0250038513117343" ESTIMABLE="YES" EVENTS_1="267" EVENTS_2="260" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.05769111675507844" LOG_CI_START="-0.036240122361206335" LOG_EFFECT_SIZE="0.010725497196936044" METHOD="MH" MODIFIED="2009-09-15 15:22:41 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5027419009099161" P_Q="0.0" P_Z="0.654445333287243" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="487" TOTAL_2="488" WEIGHT="100.0" Z="0.4475952498881811">
<NAME>Global state: 1b. No clinically important change (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.3429362103234173" CI_END="1.15080314390703" CI_START="0.8614488321865577" DF="2" EFFECT_SIZE="0.9956696361722246" ESTIMABLE="YES" EVENTS_1="183" EVENTS_2="183" I2="14.637027197427564" ID="CMP-005.02.01" LOG_CI_END="0.06100103967954123" LOG_CI_START="-0.06477051340919404" LOG_EFFECT_SIZE="-0.001884736864826416" MODIFIED="2009-09-15 15:09:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3099116732827851" P_Z="0.9531578580968074" STUDIES="3" TAU2="0.002926549451741433" TOTAL_1="294" TOTAL_2="295" WEIGHT="77.79505936650959" Z="0.05874168338826953">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.2270808712122354" CI_START="0.9057128949875404" EFFECT_SIZE="1.054221498665943" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="117" LOG_CI_END="0.0888731860064107" LOG_CI_START="-0.043009448993392485" LOG_EFFECT_SIZE="0.022931868506509117" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2005" O_E="0.0" SE="0.07746851262845636" STUDY_ID="STD-Conley-2001" TOTAL_1="189" TOTAL_2="188" VAR="0.006001370448865302" WEIGHT="50.72766492632706"/>
<DICH_DATA CI_END="1.1456604019643837" CI_START="0.7527483286539822" EFFECT_SIZE="0.9286516853932584" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="60" LOG_CI_END="0.05905590261418405" LOG_CI_START="-0.12335020008907713" LOG_EFFECT_SIZE="-0.03214714873744652" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2006" O_E="0.0" SE="0.1071462476526662" STUDY_ID="STD-Jeste-2003" TOTAL_1="89" TOTAL_2="87" VAR="0.011480318386046476" WEIGHT="26.51803713029598"/>
<DICH_DATA CI_END="1.792434823653244" CI_START="0.09685769815455067" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.2534433728517676" LOG_CI_START="-1.0138658562749796" LOG_EFFECT_SIZE="-0.38021124171160603" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2007" O_E="0.0" SE="0.7444237144709097" STUDY_ID="STD-Sikich-2004" TOTAL_1="16" TOTAL_2="20" VAR="0.5541666666666666" WEIGHT="0.5493573098865566"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6635971585692082" CI_START="0.8655941689864901" DF="0" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="30" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="0.22104816991676746" LOG_CI_START="-0.06268567782151782" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2009-09-15 15:09:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.27398598632828397" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="60" WEIGHT="10.959678332236805" Z="1.0939293407637276">
<NAME>medium term</NAME>
<DICH_DATA CI_END="1.6635971585692082" CI_START="0.8655941689864901" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="30" LOG_CI_END="0.22104816991676746" LOG_CI_START="-0.06268567782151782" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2008" O_E="0.0" SE="0.16666666666666666" STUDY_ID="STD-Robinson-2006" TOTAL_1="60" TOTAL_2="60" VAR="0.027777777777777773" WEIGHT="10.959678332236805"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4099291735369022" CI_START="0.7397576449882186" DF="0" EFFECT_SIZE="1.0212765957446808" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="47" I2="0.0" ID="CMP-005.02.03" LOG_CI_END="0.14919729682937174" LOG_CI_START="-0.1309105379496323" LOG_EFFECT_SIZE="0.009143379439869719" MODIFIED="2009-09-15 15:09:26 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.8981840459845767" STUDIES="1" TAU2="0.0" TOTAL_1="133" TOTAL_2="133" WEIGHT="11.245262301253602" Z="0.12795568116305997">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.4099291735369022" CI_START="0.7397576449882186" EFFECT_SIZE="1.0212765957446808" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="47" LOG_CI_END="0.14919729682937174" LOG_CI_START="-0.1309105379496323" LOG_EFFECT_SIZE="0.009143379439869719" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2009" O_E="0.0" SE="0.16453672870533126" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.027072335093051778" WEIGHT="11.245262301253602"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4319590315614137" CI_END="1.7497923701736395" CI_START="0.3686104219834352" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8031137553006427" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="22" I2="30.16559985591235" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.2429865184933943" LOG_CI_START="-0.4334323898279884" LOG_EFFECT_SIZE="-0.09522293566729699" METHOD="MH" MODIFIED="2009-09-15 15:22:35 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.23144524816894085" P_Q="0.0" P_Z="0.581066046602353" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.10101630162919858" TOTALS="YES" TOTAL_1="96" TOTAL_2="115" WEIGHT="100.0" Z="0.5518282298560543">
<NAME>Global state: 1c. Relapse (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.997892445683197" CI_START="0.44467874059427687" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-005.03.01" LOG_CI_END="0.6018311062216669" LOG_CI_START="-0.3519536330050671" LOG_EFFECT_SIZE="0.12493873660829992" MODIFIED="2009-09-15 15:10:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6076145288601198" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="40" WEIGHT="38.05027627495314" Z="0.5134815309054593">
<NAME>short term</NAME>
<DICH_DATA CI_END="3.997892445683197" CI_START="0.44467874059427687" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6018311062216669" LOG_CI_START="-0.3519536330050671" LOG_EFFECT_SIZE="0.12493873660829992" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2010" O_E="0.0" SE="0.5602578771323871" STUDY_ID="STD-Dollfus-2005" TOTAL_1="36" TOTAL_2="40" VAR="0.3138888888888889" WEIGHT="38.05027627495314"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.268806054377761" CI_START="0.27271367444362316" DF="0" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" I2="0.0" ID="CMP-005.03.02" LOG_CI_END="0.10339524230689841" LOG_CI_START="-0.5642930850634462" LOG_EFFECT_SIZE="-0.2304489213782739" MODIFIED="2009-09-15 15:10:40 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.17607435584406747" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="75" WEIGHT="61.94972372504686" Z="1.3529413879568757">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.268806054377761" CI_START="0.27271367444362316" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="0.10339524230689841" LOG_CI_START="-0.5642930850634462" LOG_EFFECT_SIZE="-0.2304489213782739" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2011" O_E="0.0" SE="0.39220342860786506" STUDY_ID="STD-Keefe-2006" TOTAL_1="60" TOTAL_2="75" VAR="0.15382352941176472" WEIGHT="61.94972372504686"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="50.36430777084803" CI_END="0.9321990555388814" CI_START="0.8257158705024029" CI_STUDY="95" CI_TOTAL="95" DF="42" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8773434644572246" ESTIMABLE="YES" EVENTS_1="959" EVENTS_2="1105" I2="16.607609914752913" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="-0.030491341410363002" LOG_CI_START="-0.08316936805592215" LOG_EFFECT_SIZE="-0.05683035473314258" METHOD="MH" MODIFIED="2009-09-15 15:11:08 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.17620722924702525" P_Q="0.0" P_Z="2.3482103794871437E-5" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.00900313114066722" TOTALS="SUB" TOTAL_1="4028" TOTAL_2="4049" WEIGHT="300.0" Z="4.228914999228997">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.067383732253992" CI_END="0.9372087117776139" CI_START="0.8240374137830228" DF="15" EFFECT_SIZE="0.8788031878800527" ESTIMABLE="YES" EVENTS_1="653" EVENTS_2="762" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="-0.028163683093255953" LOG_CI_START="-0.0840530695763786" LOG_EFFECT_SIZE="-0.0561083763348173" MODIFIED="2009-09-15 15:10:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7478032315116585" P_Z="8.309722507065437E-5" STUDIES="16" TAU2="0.0" TOTAL_1="1365" TOTAL_2="1373" WEIGHT="99.99999999999999" Z="3.935287315435819">
<NAME>due to any reason</NAME>
<DICH_DATA CI_END="14.45413717356195" CI_START="0.06918434410800384" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1599921719703592" LOG_CI_START="-1.1599921719703592" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1955" O_E="0.0" SE="1.3627702877384937" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="14" VAR="1.8571428571428572" WEIGHT="0.05803481124020251"/>
<DICH_DATA CI_END="1.1428638340677766" CI_START="0.5698791560310907" EFFECT_SIZE="0.8070280523110712" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="53" LOG_CI_END="0.05799448968161679" LOG_CI_START="-0.24421722754315042" LOG_EFFECT_SIZE="-0.09311136893076678" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1956" O_E="0.0" SE="0.17752065866995523" STUDY_ID="STD-Conley-2001" TOTAL_1="189" TOTAL_2="188" VAR="0.03151358425461475" WEIGHT="3.4200786013286724"/>
<DICH_DATA CI_END="2.1812359076767756" CI_START="0.458455683991144" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.3387026384634917" LOG_CI_START="-0.3387026384634917" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1957" O_E="0.0" SE="0.39791121287711073" STUDY_ID="STD-Dollfus-2005" TOTAL_1="36" TOTAL_2="40" VAR="0.15833333333333335" WEIGHT="0.6807090641707962"/>
<DICH_DATA CI_END="1.1553203620664947" CI_START="0.4696446983221564" EFFECT_SIZE="0.7366071428571429" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" LOG_CI_END="0.06270242767909394" LOG_CI_START="-0.32823057591960686" LOG_EFFECT_SIZE="-0.13276407412025648" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1958" O_E="0.0" SE="0.2296359814634544" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="33" VAR="0.05273268398268398" WEIGHT="2.043873495909441"/>
<DICH_DATA CI_END="1.2517305839804325" CI_START="0.4294080236163288" EFFECT_SIZE="0.7331460674157303" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="24" LOG_CI_END="0.09751086363351413" LOG_CI_START="-0.3671298449027026" LOG_EFFECT_SIZE="-0.13480949063459424" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1959" O_E="0.0" SE="0.27293225220277506" STUDY_ID="STD-Jeste-2003" TOTAL_1="89" TOTAL_2="87" VAR="0.07449201429247922" WEIGHT="1.4468522053545483"/>
<DICH_DATA CI_END="1.0759219191649694" CI_START="0.7658076528277328" EFFECT_SIZE="0.9077164973391388" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="104" LOG_CI_END="0.03178075524653008" LOG_CI_START="-0.11588029799845298" LOG_EFFECT_SIZE="-0.04204977137596145" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1960" O_E="0.0" SE="0.08673683361010498" STUDY_ID="STD-Keefe-2006" TOTAL_1="159" TOTAL_2="158" VAR="0.007523278304707036" WEIGHT="14.32605983656657"/>
<DICH_DATA CI_END="0.9588708558084346" CI_START="0.7829545357893642" EFFECT_SIZE="0.8664596273291926" ESTIMABLE="YES" EVENTS_1="216" EVENTS_2="253" LOG_CI_END="-0.018239881240776235" LOG_CI_START="-0.10626345560369041" LOG_EFFECT_SIZE="-0.06225166842223333" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1961" O_E="0.0" SE="0.05170548330449618" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="341" VAR="0.0026734570037515335" WEIGHT="40.31444493370759"/>
<DICH_DATA CI_END="1.3140156735198405" CI_START="0.5396748977420167" EFFECT_SIZE="0.8421052631578947" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.11860054549969974" LOG_CI_START="-0.2678677820935081" LOG_EFFECT_SIZE="-0.07463361829690421" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1962" O_E="0.0" SE="0.22701340867732514" STUDY_ID="STD-McEvoy-2006" TOTAL_1="19" TOTAL_2="16" VAR="0.05153508771929824" WEIGHT="2.091369975877936"/>
<DICH_DATA CI_END="1.1215695284570746" CI_START="0.818105613240119" EFFECT_SIZE="0.9578947368421052" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="95" LOG_CI_END="0.04982620158307214" LOG_CI_START="-0.08719062751858048" LOG_EFFECT_SIZE="-0.018682212967754176" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1963" O_E="0.0" SE="0.08048436365855338" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.006477732793522269" WEIGHT="16.638373115383057"/>
<DICH_DATA CI_END="1.1471432366936334" CI_START="0.3602560629774427" EFFECT_SIZE="0.6428571428571429" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.059617648957757015" LOG_CI_START="-0.4433887014355832" LOG_EFFECT_SIZE="-0.1918855262389131" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1964" O_E="0.0" SE="0.2954684201426394" STUDY_ID="STD-Purdon-2000" TOTAL_1="21" TOTAL_2="21" VAR="0.0873015873015873" WEIGHT="1.2345587118370354"/>
<DICH_DATA CI_END="3.030486172073819" CI_START="0.32998005706644784" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.481512306690943" LOG_CI_START="-0.48151230669094314" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1965" O_E="0.0" SE="0.5656854249492381" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" VAR="0.32000000000000006" WEIGHT="0.33680917237617525"/>
<DICH_DATA CI_END="0.982333924359881" CI_START="0.06362398615188511" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.0077408575740219076" LOG_CI_START="-1.1963791250819027" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1966" O_E="0.0" SE="0.698212002188447" STUDY_ID="STD-Sikich-2004" TOTAL_1="16" TOTAL_2="20" VAR="0.4875" WEIGHT="0.2210849952007715"/>
<DICH_DATA CI_END="1.3374568097567305" CI_START="0.8279214300759863" EFFECT_SIZE="1.0522875816993464" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="45" LOG_CI_END="0.12627976632901675" LOG_CI_START="-0.0820108759005149" LOG_EFFECT_SIZE="0.02213444521425092" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1967" O_E="0.0" SE="0.12235095430093454" STUDY_ID="STD-Stroup-2006" TOTAL_1="68" TOTAL_2="70" VAR="0.014969756018349373" WEIGHT="7.1997790096421515"/>
<DICH_DATA CI_END="1.0093618896831391" CI_START="0.642701807504096" EFFECT_SIZE="0.8054307610993657" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="88" LOG_CI_END="0.004046903119312622" LOG_CI_START="-0.19199047869866942" LOG_EFFECT_SIZE="-0.09397178778967838" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1968" O_E="0.0" SE="0.11515332848057308" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="0.013260289060154763" WEIGHT="8.127947639108116"/>
<DICH_DATA CI_END="1.250106202771815" CI_START="0.4138768090232965" EFFECT_SIZE="0.7192982456140351" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" LOG_CI_END="0.0969469100628605" LOG_CI_START="-0.38312890796837223" LOG_EFFECT_SIZE="-0.1430909989527559" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1969" O_E="0.0" SE="0.2819989119251716" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="41" VAR="0.0795233863269807" WEIGHT="1.3553111875444477"/>
<DICH_DATA CI_END="1.7279562470677028" CI_START="0.28238176743674687" EFFECT_SIZE="0.6985294117647058" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.23753274167433938" LOG_CI_START="-0.549163347837079" LOG_EFFECT_SIZE="-0.1558153030813698" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1970" O_E="0.0" SE="0.4621091771874552" STUDY_ID="STD-Wang-2006" TOTAL_1="17" TOTAL_2="19" VAR="0.21354489164086687" WEIGHT="0.5047132447524679"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="17.276063764585743" CI_END="1.4175718049041197" CI_START="0.7685408333989557" DF="12" EFFECT_SIZE="1.0437728758421891" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="138" I2="30.539733104025476" ID="CMP-005.04.02" LOG_CI_END="0.15154506663642134" LOG_CI_START="-0.11433305301949993" LOG_EFFECT_SIZE="0.018606006808460678" MODIFIED="2009-09-15 15:11:02 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1395046177642688" P_Z="0.7838429917301711" STUDIES="13" TAU2="0.08239183444893522" TOTAL_1="1294" TOTAL_2="1301" WEIGHT="100.00000000000003" Z="0.27431443616257617">
<NAME>due to adverse events</NAME>
<DICH_DATA CI_END="1.4003427619870004" CI_START="0.4219006751005774" EFFECT_SIZE="0.7686387686387687" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="22" LOG_CI_END="0.14623435097815382" LOG_CI_START="-0.37478977968514693" LOG_EFFECT_SIZE="-0.11427771435349658" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1971" O_E="0.0" SE="0.306052153462665" STUDY_ID="STD-Conley-2001" TOTAL_1="189" TOTAL_2="188" VAR="0.09366792063913466" WEIGHT="13.854163480009685"/>
<DICH_DATA CI_END="6.175967491975178" CI_START="0.35537547482631504" EFFECT_SIZE="1.4814814814814814" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.790705001367033" LOG_CI_START="-0.44931254702908296" LOG_EFFECT_SIZE="0.17069622716897506" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1972" O_E="0.0" SE="0.7283924461137385" STUDY_ID="STD-Dollfus-2005" TOTAL_1="36" TOTAL_2="40" VAR="0.5305555555555554" WEIGHT="3.9793963870581406"/>
<DICH_DATA CI_END="3.258042468384944" CI_START="0.2932930358618264" EFFECT_SIZE="0.9775280898876404" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5129567410114805" LOG_CI_START="-0.532698249064069" LOG_EFFECT_SIZE="-0.009870754026294283" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1973" O_E="0.0" SE="0.6142229172460574" STUDY_ID="STD-Jeste-2003" TOTAL_1="89" TOTAL_2="87" VAR="0.377269792070257" WEIGHT="5.306426485306676"/>
<DICH_DATA CI_END="1.138893822010556" CI_START="0.33868559286199185" EFFECT_SIZE="0.6210691823899371" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="24" LOG_CI_END="0.056483237104244084" LOG_CI_START="-0.47020327714815136" LOG_EFFECT_SIZE="-0.2068600200219536" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1974" O_E="0.0" SE="0.30937826561215004" STUDY_ID="STD-Keefe-2006" TOTAL_1="159" TOTAL_2="158" VAR="0.09571491123318207" WEIGHT="13.694936819484482"/>
<DICH_DATA CI_END="2.7339047889836614" CI_START="1.2527729352440515" EFFECT_SIZE="1.8506652661064427" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="34" LOG_CI_END="0.4367833857478879" LOG_CI_START="0.09787236236941706" LOG_EFFECT_SIZE="0.26732787405865244" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1975" O_E="0.0" SE="0.19907801276913606" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="341" VAR="0.039632055168108304" WEIGHT="19.98920569484863"/>
<DICH_DATA CI_END="58.59881074398402" CI_START="0.11096641582726273" EFFECT_SIZE="2.55" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7678888021517716" LOG_CI_START="-0.9548084412838611" LOG_EFFECT_SIZE="0.4065401804339551" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1976" O_E="0.0" SE="1.599325838362809" STUDY_ID="STD-McEvoy-2006" TOTAL_1="19" TOTAL_2="16" VAR="2.557843137254902" WEIGHT="0.9238422547166362"/>
<DICH_DATA CI_END="2.202810151941312" CI_START="0.5264926315086123" EFFECT_SIZE="1.0769230769230769" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.34297706931729505" LOG_CI_START="-0.2786077025744926" LOG_EFFECT_SIZE="0.032184683371401235" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1977" O_E="0.0" SE="0.36512197190348045" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.13331405436668595" WEIGHT="11.307807323357348"/>
<DICH_DATA CI_END="3.590847863778261" CI_START="0.12377144933586896" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5551970054264799" LOG_CI_START="-0.9073795235378426" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1978" O_E="0.0" SE="0.8591246929842244" STUDY_ID="STD-Purdon-2000" TOTAL_1="21" TOTAL_2="21" VAR="0.7380952380952379" WEIGHT="2.9728203049893493"/>
<DICH_DATA CI_END="2.3749899601687643" CI_START="0.007932205368533788" EFFECT_SIZE="0.13725490196078433" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.37566177806508705" LOG_CI_START="-2.100606050232446" LOG_EFFECT_SIZE="-0.8624721360836795" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1979" O_E="0.0" SE="1.4545719800654109" STUDY_ID="STD-Sikich-2004" TOTAL_1="16" TOTAL_2="20" VAR="2.1157796451914104" WEIGHT="1.1096316424047459"/>
<DICH_DATA CI_END="4.500220573639792" CI_START="0.8121478116130185" EFFECT_SIZE="1.911764705882353" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.653233800790223" LOG_CI_START="-0.09036492158902205" LOG_EFFECT_SIZE="0.2814344396006005" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1980" O_E="0.0" SE="0.43679357039860867" STUDY_ID="STD-Stroup-2006" TOTAL_1="68" TOTAL_2="70" VAR="0.1907886231415643" WEIGHT="8.92875226417885"/>
<DICH_DATA CI_END="1.8370314071772467" CI_START="0.5131678820581239" EFFECT_SIZE="0.9709302325581395" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.26411658137231375" LOG_CI_START="-0.28974053289224516" LOG_EFFECT_SIZE="-0.01281197575996566" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1981" O_E="0.0" SE="0.32533841055593404" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="0.1058450813830615" WEIGHT="12.957929205648277"/>
<DICH_DATA CI_END="5.567504680592264" CI_START="0.049626987975438436" EFFECT_SIZE="0.5256410256410257" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7456605908169043" LOG_CI_START="-1.3042820827583939" LOG_EFFECT_SIZE="-0.27931074597074484" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1982" O_E="0.0" SE="1.2041464738380192" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="41" VAR="1.4499687304565354" WEIGHT="1.5917667715437822"/>
<DICH_DATA CI_END="2.6758475007516775" CI_START="0.11670460926360615" EFFECT_SIZE="0.5588235294117647" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.42746135892043036" LOG_CI_START="-0.9329119910992825" LOG_EFFECT_SIZE="-0.2527253160894261" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1983" O_E="0.0" SE="0.7990900397582659" STUDY_ID="STD-Wang-2006" TOTAL_1="17" TOTAL_2="19" VAR="0.6385448916408669" WEIGHT="3.383321366453396"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="14.604479551184511" CI_END="0.9801604342727955" CI_START="0.6244093137454891" DF="13" EFFECT_SIZE="0.782317904770661" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="205" I2="10.986215192135196" ID="CMP-005.04.03" LOG_CI_END="-0.008702832453674621" LOG_CI_START="-0.20453062758574994" LOG_EFFECT_SIZE="-0.10661673001971224" MODIFIED="2009-09-15 15:11:08 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.33269049866029465" P_Z="0.032828827186685505" STUDIES="14" TAU2="0.019748484766757442" TOTAL_1="1369" TOTAL_2="1375" WEIGHT="100.0" Z="2.134170492468966">
<NAME>due to inefficacy</NAME>
<DICH_DATA CI_END="12.658564802105067" CI_START="0.48852595042529934" EFFECT_SIZE="2.486772486772487" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1023844691995888" LOG_CI_START="-0.31111236167464207" LOG_EFFECT_SIZE="0.39563605376247335" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1984" O_E="0.0" SE="0.8302950353776809" STUDY_ID="STD-Conley-2001" TOTAL_1="189" TOTAL_2="188" VAR="0.6893898457728244" WEIGHT="1.8659195356745364"/>
<DICH_DATA CI_END="4.184993162974907" CI_START="0.13111057142160282" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6216947528227803" LOG_CI_START="-0.8823622898127927" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1985" O_E="0.0" SE="0.8834905520465713" STUDY_ID="STD-Dollfus-2005" TOTAL_1="36" TOTAL_2="40" VAR="0.7805555555555554" WEIGHT="1.653365468349418"/>
<DICH_DATA CI_END="1.33963770352564" CI_START="0.23618792541243538" EFFECT_SIZE="0.5625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.12698736207080466" LOG_CI_START="-0.6267423085040044" LOG_EFFECT_SIZE="-0.24987747321659987" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1986" O_E="0.0" SE="0.4427445395176854" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="33" VAR="0.19602272727272727" WEIGHT="6.13239853427387"/>
<DICH_DATA CI_END="3.0723941764326166" CI_START="0.0345572400055375" EFFECT_SIZE="0.3258426966292135" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.487476933256508" LOG_CI_START="-1.4614609507484215" LOG_EFFECT_SIZE="-0.48699200874595666" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1987" O_E="0.0" SE="1.1448157604626126" STUDY_ID="STD-Jeste-2003" TOTAL_1="89" TOTAL_2="87" VAR="1.3106031254035901" WEIGHT="0.9946205607102631"/>
<DICH_DATA CI_END="2.006833235533348" CI_START="0.607468302538887" EFFECT_SIZE="1.1041229909154437" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" LOG_CI_END="0.30251128484585404" LOG_CI_START="-0.2164763784565615" LOG_EFFECT_SIZE="0.04301745319464627" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1988" O_E="0.0" SE="0.30485592245420506" STUDY_ID="STD-Keefe-2006" TOTAL_1="159" TOTAL_2="158" VAR="0.09293713345540429" WEIGHT="11.742359720126213"/>
<DICH_DATA CI_END="0.7339032968097234" CI_START="0.39047304096211377" EFFECT_SIZE="0.5353218210361067" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="91" LOG_CI_END="-0.13436116137646498" LOG_CI_START="-0.40840894530924043" LOG_EFFECT_SIZE="-0.27138505334285273" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1989" O_E="0.0" SE="0.1609770248405211" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="341" VAR="0.02591360252650575" WEIGHT="28.97798026514332"/>
<DICH_DATA CI_END="2.1036827601919534" CI_START="0.33709515886013175" EFFECT_SIZE="0.8421052631578947" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.3229802478933123" LOG_CI_START="-0.4722474844871208" LOG_EFFECT_SIZE="-0.07463361829690421" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1990" O_E="0.0" SE="0.4671207064410278" STUDY_ID="STD-McEvoy-2006" TOTAL_1="19" TOTAL_2="16" VAR="0.2182017543859649" WEIGHT="5.560805776707681"/>
<DICH_DATA CI_END="2.5681351838247255" CI_START="0.6084181276131141" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.40961788078462313" LOG_CI_START="-0.21579785476851024" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1991" O_E="0.0" SE="0.3673722989217309" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.1349624060150376" WEIGHT="8.552695015606062"/>
<DICH_DATA CI_END="2.0541866278162013" CI_START="0.030425667830601914" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3126398977562814" LOG_CI_START="-1.516759880412206" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1992" O_E="0.0" SE="1.0745984853711197" STUDY_ID="STD-Purdon-2000" TOTAL_1="21" TOTAL_2="21" VAR="1.1547619047619047" WEIGHT="1.126592898833733"/>
<DICH_DATA CI_END="5.704356984776904" CI_START="0.31165261615324824" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7562066963086507" LOG_CI_START="-0.5063292230920509" LOG_EFFECT_SIZE="0.12493873660829992" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1993" O_E="0.0" SE="0.7416198487095662" STUDY_ID="STD-Robinson-2006" TOTAL_1="60" TOTAL_2="60" VAR="0.5499999999999998" WEIGHT="2.3224196287088326"/>
<DICH_DATA CI_END="2.9888901109434096" CI_START="0.13069232574653053" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.47550994813121833" LOG_CI_START="-0.8837499134430681" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1994" O_E="0.0" SE="0.7984359711335656" STUDY_ID="STD-Sikich-2004" TOTAL_1="16" TOTAL_2="20" VAR="0.6375" WEIGHT="2.013234104174473"/>
<DICH_DATA CI_END="1.5606701574470536" CI_START="0.47152490526192303" EFFECT_SIZE="0.8578431372549019" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" LOG_CI_END="0.19331112603669115" LOG_CI_START="-0.32649536351589986" LOG_EFFECT_SIZE="-0.06659211873960434" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1995" O_E="0.0" SE="0.30533690504681343" STUDY_ID="STD-Stroup-2006" TOTAL_1="68" TOTAL_2="70" VAR="0.09323062558356675" WEIGHT="11.71185593820385"/>
<DICH_DATA CI_END="1.3747390334886371" CI_START="0.5038046890580776" EFFECT_SIZE="0.8322259136212624" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="28" LOG_CI_END="0.13822026393175488" LOG_CI_START="-0.29773779471291256" LOG_EFFECT_SIZE="-0.07975876539057886" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1996" O_E="0.0" SE="0.25608392167507216" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="0.06557897494048448" WEIGHT="15.507259550317187"/>
<DICH_DATA CI_END="10.83676472045748" CI_START="0.40794239973169455" EFFECT_SIZE="2.1025641025641026" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0348996444006682" LOG_CI_START="-0.3894011536862331" LOG_EFFECT_SIZE="0.3227492453572175" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="1997" O_E="0.0" SE="0.8366413391989038" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="41" VAR="0.6999687304565353" WEIGHT="1.838493003170572"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.34986138303139" CI_END="0.9965442164267564" CI_START="0.8495896442634375" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9201378409384074" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="176" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="-0.0015034269944736785" LOG_CI_START="-0.07079078989096643" LOG_EFFECT_SIZE="-0.036147108442720066" METHOD="MH" MODIFIED="2009-09-15 15:22:30 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5091917544019036" P_Q="0.0" P_Z="0.04085286003881075" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="237" TOTAL_2="235" WEIGHT="99.99999999999999" Z="2.045020267226284">
<NAME>Mental state: 1a. General - no clinically important change (less than 50% PANSS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="24.262748430717867" CI_START="0.2186046066389075" DF="0" EFFECT_SIZE="2.303030303030303" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-005.05.01" LOG_CI_END="1.3849399952398005" LOG_CI_START="-0.6603406904339928" LOG_EFFECT_SIZE="0.3622996524029039" MODIFIED="2009-09-15 15:11:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.48744806426416787" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="38" WEIGHT="0.11476308920712967" Z="0.6943734180789372">
<NAME>short term</NAME>
<DICH_DATA CI_END="24.262748430717867" CI_START="0.2186046066389075" EFFECT_SIZE="2.303030303030303" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3849399952398005" LOG_CI_START="-0.6603406904339928" LOG_EFFECT_SIZE="0.3622996524029039" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2012" O_E="0.0" SE="1.201407999067463" STUDY_ID="STD-Dollfus-2005" TOTAL_1="33" TOTAL_2="38" VAR="1.4433811802232854" WEIGHT="0.11476308920712967"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8198934526967105" CI_END="0.9955399076238397" CI_START="0.8486556730395143" DF="1" EFFECT_SIZE="0.9191684232730177" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="175" I2="0.0" ID="CMP-005.05.02" LOG_CI_END="-0.0019413259796828887" LOG_CI_START="-0.07126848128874962" LOG_EFFECT_SIZE="-0.036604903634216264" MODIFIED="2009-09-15 15:11:36 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.36521138148085064" P_Z="0.03847751086027538" STUDIES="2" TAU2="0.0" TOTAL_1="204" TOTAL_2="197" WEIGHT="99.88523691079286" Z="2.0697313328602807">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.1245719974563644" CI_START="0.8383690185065557" EFFECT_SIZE="0.9709821428571429" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="28" LOG_CI_END="0.05098726510474496" LOG_CI_START="-0.07656477919175829" LOG_EFFECT_SIZE="-0.012788757043506651" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2013" O_E="0.0" SE="0.07492470221256828" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="30" VAR="0.005613711001642034" WEIGHT="29.507554467517938"/>
<DICH_DATA CI_END="0.9878828858860804" CI_START="0.8167962476831225" EFFECT_SIZE="0.8982755893054897" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="147" LOG_CI_END="-0.005294538234406663" LOG_CI_START="-0.08788626604144172" LOG_EFFECT_SIZE="-0.0465904021379242" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2014" O_E="0.0" SE="0.04851478974949865" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="0.0023536848244380595" WEIGHT="70.37768244327492"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.032023182966227616" CI_END="1.1413734413213483" CI_START="0.838860078697333" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9784950765383912" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="148" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="0.057427762709364776" LOG_CI_START="-0.07631047316095281" LOG_EFFECT_SIZE="-0.009441355225794028" METHOD="MH" MODIFIED="2009-09-15 15:22:25 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.8579768296292946" P_Q="0.0" P_Z="0.7819871453494917" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="278" TOTAL_2="275" WEIGHT="100.00000000000001" Z="0.276730376879636">
<NAME>Mental state: 1b. General - no clinically important change - short term (less than 20% PANSS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1721471844751343" CI_START="0.8287135818122878" EFFECT_SIZE="0.9855832241153342" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="109" LOG_CI_END="0.06898214870592427" LOG_CI_START="-0.08159554343240073" LOG_EFFECT_SIZE="-0.006306697363238239" MODIFIED="2009-09-15 15:12:13 +0100" MODIFIED_BY="[Empty name]" ORDER="1366" O_E="0.0" SE="0.0884500817336494" STUDY_ID="STD-Conley-2001" TOTAL_1="189" TOTAL_2="188" VAR="0.00782341695868926" WEIGHT="78.88417851401368"/>
<DICH_DATA CI_END="1.3315818682339993" CI_START="0.6812846410418787" EFFECT_SIZE="0.9524632670700086" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="39" LOG_CI_END="0.12436787286227048" LOG_CI_START="-0.16667140173423722" LOG_EFFECT_SIZE="-0.021151764435983322" MODIFIED="2009-09-15 15:12:13 +0100" MODIFIED_BY="[Empty name]" ORDER="1365" O_E="0.0" SE="0.17095791056563267" STUDY_ID="STD-Jeste-2003" TOTAL_1="89" TOTAL_2="87" VAR="0.029226607184966856" WEIGHT="21.115821485986327"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="11.446175010973946" CI_END="-0.5755430634914969" CI_START="-3.3080845656443616" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.9418138145679293" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.07" MODIFIED="2009-09-15 15:22:09 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.6506845835346778" P_Q="0.39259864571917713" P_Z="0.005342859587442829" Q="1.8699352005882623" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1201" TOTAL_2="1189" UNITS="" WEIGHT="99.99999999999999" Z="2.7856009786032305">
<NAME>Mental state: 1c. General - average endpoint score (PANSS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.326154731640508" CI_END="1.0978889966709158" CI_START="-3.0466669223860556" DF="6" EFFECT_SIZE="-0.9743889628575698" ESTIMABLE="YES" I2="0.0" ID="CMP-005.07.01" MODIFIED="2009-09-15 15:12:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8873939186314329" P_Z="0.35674837210847343" STUDIES="7" TAU2="0.0" TOTAL_1="368" TOTAL_2="360" WEIGHT="43.46878750650933" Z="0.9215787222717511">
<NAME>short term</NAME>
<CONT_DATA CI_END="0.8951840456939086" CI_START="-7.69518404569392" EFFECT_SIZE="-3.4000000000000057" ESTIMABLE="YES" MEAN_1="74.86" MEAN_2="78.26" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2017" SD_1="6.41" SD_2="4.62" SE="2.191460700081113" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="13" WEIGHT="10.118356729092273"/>
<CONT_DATA CI_END="3.22427920354235" CI_START="-3.4242792035423495" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="-12.9" MEAN_2="-12.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2018" SD_1="16.1" SD_2="15.9" SE="1.6960919842220774" STUDY_ID="STD-Conley-2001" TOTAL_1="181" TOTAL_2="175" WEIGHT="16.89190214420437"/>
<CONT_DATA CI_END="7.897000872241492" CI_START="-9.097000872241495" EFFECT_SIZE="-0.6000000000000014" ESTIMABLE="YES" MEAN_1="-17.5" MEAN_2="-16.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2019" SD_1="17.7" SD_2="18.8" SE="4.3352841885181315" STUDY_ID="STD-Dollfus-2005" TOTAL_1="33" TOTAL_2="38" WEIGHT="2.5854861553621022"/>
<CONT_DATA CI_END="5.077521730134338" CI_START="-5.077521730134338" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-12.3" MEAN_2="-12.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2020" SD_1="15.67" SD_2="18.04" SE="2.59061991454189" STUDY_ID="STD-Jeste-2003" TOTAL_1="88" TOTAL_2="83" WEIGHT="7.240523389520455"/>
<CONT_DATA CI_END="5.077576336221427" CI_START="-9.277576336221415" EFFECT_SIZE="-2.0999999999999943" ESTIMABLE="YES" MEAN_1="69.4" MEAN_2="71.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2021" SD_1="10.8" SD_2="12.0" SE="3.6620960348441236" STUDY_ID="STD-Mori-2004" TOTAL_1="20" TOTAL_2="19" WEIGHT="3.6234135334755866"/>
<CONT_DATA CI_END="8.54092067952405" CI_START="-8.920920679524045" EFFECT_SIZE="-0.18999999999999773" ESTIMABLE="YES" MEAN_1="49.29" MEAN_2="49.48" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2022" SD_1="10.17" SD_2="17.7" SE="4.4546332220349125" STUDY_ID="STD-Svestka-2003a" TOTAL_1="21" TOTAL_2="21" WEIGHT="2.4488007911826855"/>
<CONT_DATA CI_END="24.252594840357954" CI_START="-12.252594840357954" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="-9.0" MEAN_2="-15.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2023" SD_1="22.31" SD_2="22.31" SE="9.312719511344133" STUDY_ID="STD-Wang-2006" TOTAL_1="12" TOTAL_2="11" WEIGHT="0.5603047636718635"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7999604544536205" CI_END="0.7147127623588334" CI_START="-8.928299336757078" DF="2" EFFECT_SIZE="-4.106793287199123" ESTIMABLE="YES" I2="0.0" ID="CMP-005.07.02" MODIFIED="2009-09-15 15:12:55 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.40657774134073776" P_Z="0.09503218860734909" STUDIES="3" TAU2="0.0" TOTAL_1="115" TOTAL_2="116" WEIGHT="8.029862528877242" Z="1.6694300187799413">
<NAME>medium term</NAME>
<CONT_DATA CI_END="0.7867549391483113" CI_START="-15.586754939148312" EFFECT_SIZE="-7.4" ESTIMABLE="YES" MEAN_1="-7.7" MEAN_2="-0.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2024" SD_1="9.8" SD_2="6.86" SE="4.176992538497845" STUDY_ID="STD-McEvoy-2006" TOTAL_1="10" TOTAL_2="6" WEIGHT="2.785158794202662"/>
<CONT_DATA CI_END="7.328666030926337" CI_START="-7.728666030926336" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" MEAN_1="-8.2" MEAN_2="-8.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2025" SD_1="22.31" SD_2="22.31" SE="3.8412267216701395" STUDY_ID="STD-Stroup-2006" TOTAL_1="66" TOTAL_2="69" WEIGHT="3.2933468886935087"/>
<CONT_DATA CI_END="3.7806658759388743" CI_START="-15.780665875938874" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="-9.1" MEAN_2="-3.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2026" SD_1="22.31" SD_2="22.31" SE="4.990227347587771" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="41" WEIGHT="1.9513568459810722"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.450124624291555" CI_END="-0.20196365546916306" CI_START="-4.980614052622716" DF="4" EFFECT_SIZE="-2.59128885404594" ESTIMABLE="YES" I2="26.607182849145442" ID="CMP-005.07.03" MODIFIED="2009-09-15 15:12:59 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.24414868007685187" P_Z="0.03353367836301015" STUDIES="5" TAU2="1.9590283502343937" TOTAL_1="718" TOTAL_2="713" WEIGHT="48.50134996461341" Z="2.125634815426282">
<NAME>long term</NAME>
<CONT_DATA CI_END="-2.628659047466469" CI_START="-21.171340952533527" EFFECT_SIZE="-11.899999999999999" ESTIMABLE="YES" MEAN_1="-28.2" MEAN_2="-16.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2027" SD_1="20.8" SD_2="16.3" SE="4.730362917719246" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="30" WEIGHT="2.1716430242428295"/>
<CONT_DATA CI_END="0.6585700182422052" CI_START="-6.458570018242206" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="-12.4" MEAN_2="-9.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2028" SD_1="16.0" SD_2="15.5" SE="1.8156303107157843" STUDY_ID="STD-Keefe-2006" TOTAL_1="153" TOTAL_2="148" WEIGHT="14.740849474522134"/>
<CONT_DATA CI_END="1.436450885289283" CI_START="-5.356450885289281" EFFECT_SIZE="-1.959999999999999" ESTIMABLE="YES" MEAN_1="-11.27" MEAN_2="-9.31" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2029" SD_1="22.31" SD_2="22.31" SE="1.7329149474582457" STUDY_ID="STD-Lieberman-2005" TOTAL_1="330" TOTAL_2="333" WEIGHT="16.18165228115687"/>
<CONT_DATA CI_END="4.574988808061814" CI_START="-4.374988808061811" EFFECT_SIZE="0.10000000000000142" ESTIMABLE="YES" MEAN_1="-18.4" MEAN_2="-18.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2030" SD_1="9.73" SD_2="9.91" SE="2.283199509460354" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="37" WEIGHT="9.321582235078772"/>
<CONT_DATA CI_END="2.338399132890399" CI_START="-8.738399132890404" EFFECT_SIZE="-3.200000000000003" ESTIMABLE="YES" MEAN_1="-28.1" MEAN_2="-24.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2031" SD_1="28.0" SD_2="23.2" SE="2.8257657674205174" STUDY_ID="STD-Tran-1997" TOTAL_1="166" TOTAL_2="165" WEIGHT="6.085622949612798"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.365060367587292" CI_END="-0.03244567972542889" CI_START="-8.294738027049467" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.163591853387448" ESTIMABLE="YES" I2="40.56570220064206" I2_Q="0.0" ID="CMP-005.08" MODIFIED="2009-09-15 15:22:05 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.18590324079798015" P_Q="0.7683986827244538" P_Z="0.04822760591623386" Q="0.08671266959851032" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="5.567598399288111" TOTALS="YES" TOTAL_1="214" TOTAL_2="214" UNITS="" WEIGHT="100.0" Z="1.9753573792645482">
<NAME>Mental state: 1d. General - average endpoint score (BPRS total score, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.744577547024276" CI_START="-15.744577547024276" DF="0" EFFECT_SIZE="-5.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.08.01" MODIFIED="2009-09-15 15:13:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3617312392529196" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="19" WEIGHT="12.472348085872063" Z="0.9120712173010788">
<NAME>short term</NAME>
<CONT_DATA CI_END="5.744577547024276" CI_START="-15.744577547024276" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="27.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2032" SD_1="12.0" SD_2="20.0" SE="5.482028053462274" STUDY_ID="STD-Sikich-2004" TOTAL_1="16" TOTAL_2="19" WEIGHT="12.472348085872063"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.2783476979887816" CI_END="1.3418164287482535" CI_START="-9.907846603522582" DF="1" EFFECT_SIZE="-4.283015087387165" ESTIMABLE="YES" I2="69.4968291309221" ID="CMP-005.08.02" MODIFIED="2009-09-15 15:13:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.07019963163782827" P_Z="0.1355916711670666" STUDIES="2" TAU2="11.689366659821088" TOTAL_1="198" TOTAL_2="195" WEIGHT="87.52765191412794" Z="1.4924100912960423">
<NAME>long term</NAME>
<CONT_DATA CI_END="-2.2148599971621286" CI_START="-12.985140002837866" EFFECT_SIZE="-7.599999999999998" ESTIMABLE="YES" MEAN_1="-16.4" MEAN_2="-8.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2033" SD_1="12.3" SD_2="9.2" SE="2.74757089687115" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="30" WEIGHT="33.87028818344039"/>
<CONT_DATA CI_END="1.4277702134121224" CI_START="-5.027770213412124" EFFECT_SIZE="-1.8000000000000007" ESTIMABLE="YES" MEAN_1="-17.0" MEAN_2="-15.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2034" SD_1="16.5" SD_2="13.3" SE="1.6468517987434272" STUDY_ID="STD-Tran-1997" TOTAL_1="166" TOTAL_2="165" WEIGHT="53.65736373068755"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.073877417020152" CI_START="0.9642261128049938" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0175758681505809" ESTIMABLE="YES" EVENTS_1="178" EVENTS_2="174" I2="0.0" I2_Q="0.0" ID="CMP-005.09" LOG_CI_END="0.030954709529167474" LOG_CI_START="-0.015821111295707437" LOG_EFFECT_SIZE="0.0075667991167300075" METHOD="MH" MODIFIED="2009-09-15 15:22:01 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.5260049705800991" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="189" TOTAL_2="188" WEIGHT="100.0" Z="0.6341162372143138">
<NAME>Mental state: 2a. Positive symptoms - no clinically important change - short term (less than 50% PANSS positive subscore reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.073877417020152" CI_START="0.9642261128049938" EFFECT_SIZE="1.0175758681505809" ESTIMABLE="YES" EVENTS_1="178" EVENTS_2="174" LOG_CI_END="0.030954709529167474" LOG_CI_START="-0.015821111295707437" LOG_EFFECT_SIZE="0.0075667991167300075" MODIFIED="2009-09-15 15:14:20 +0100" MODIFIED_BY="[Empty name]" ORDER="1367" O_E="0.0" SE="0.027476348696578903" STUDY_ID="STD-Conley-2001" TOTAL_1="189" TOTAL_2="188" VAR="7.549497376959933E-4" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="8.453158868349169" CI_END="0.09456044751508602" CI_START="-1.0189225853228443" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.46218106890387917" ESTIMABLE="YES" I2="0.0" I2_Q="62.37032571825011" ID="CMP-005.10" MODIFIED="2009-09-15 15:21:56 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.7487913022891727" P_Q="0.0701250619893915" P_Z="0.10372191500930168" Q="5.314954323083218" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="858" TOTAL_2="844" UNITS="" WEIGHT="100.0" Z="1.627071491298921">
<NAME>Mental state: 2b. Positive symptoms - average endpoint score (PANSS positive, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.3345674388777733" CI_END="1.5309078913271117" CI_START="-0.5680793541087903" DF="4" EFFECT_SIZE="0.48141426860916064" ESTIMABLE="YES" I2="0.0" ID="CMP-005.10.01" MODIFIED="2009-09-15 15:15:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8554840019175778" P_Z="0.3686222900369712" STUDIES="5" TAU2="0.0" TOTAL_1="334" TOTAL_2="327" WEIGHT="28.141523695100265" Z="0.8990570382638948">
<NAME>short term</NAME>
<CONT_DATA CI_END="10.059970711802848" CI_START="-9.059970711802848" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="-4.1" MEAN_2="-4.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2036" SD_1="65.4" SD_2="5.3" SE="4.877625704967375" STUDY_ID="STD-Conley-2001" TOTAL_1="181" TOTAL_2="175" WEIGHT="0.3391517735582294"/>
<CONT_DATA CI_END="2.81923524152352" CI_START="-1.2192352415235201" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-1.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2037" SD_1="4.7" SD_2="3.91" SE="1.0302409929218035" STUDY_ID="STD-Dollfus-2005" TOTAL_1="33" TOTAL_2="39" WEIGHT="7.6020965557670985"/>
<CONT_DATA CI_END="1.5258975113126552" CI_START="-2.3258975113126548" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="-4.0" MEAN_2="-3.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2038" SD_1="5.72" SD_2="7.02" SE="0.9826188269294175" STUDY_ID="STD-Jeste-2003" TOTAL_1="88" TOTAL_2="83" WEIGHT="8.356816617876799"/>
<CONT_DATA CI_END="2.4805897930204606" CI_START="-0.8805897930204627" EFFECT_SIZE="0.7999999999999989" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="10.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2039" SD_1="3.1" SD_2="2.2" SE="0.8574595279692583" STUDY_ID="STD-Mori-2004" TOTAL_1="20" TOTAL_2="19" WEIGHT="10.97447549068658"/>
<CONT_DATA CI_END="8.112386478467641" CI_START="-3.8323864784676407" EFFECT_SIZE="2.14" ESTIMABLE="YES" MEAN_1="-2.36" MEAN_2="-4.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2040" SD_1="7.3" SD_2="7.3" SE="3.047191951269035" STUDY_ID="STD-Wang-2006" TOTAL_1="12" TOTAL_2="11" WEIGHT="0.8689832572115573"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.46690689369471294" CI_END="0.034246268075140085" CI_START="-3.201580707579363" DF="2" EFFECT_SIZE="-1.5836672197521116" ESTIMABLE="YES" I2="0.0" ID="CMP-005.10.02" MODIFIED="2009-09-15 15:15:15 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7917946395508001" P_Z="0.05505048530675875" STUDIES="3" TAU2="0.0" TOTAL_1="115" TOTAL_2="116" WEIGHT="11.841224769264828" Z="1.9184775561635172">
<NAME>medium term</NAME>
<CONT_DATA CI_END="0.4915680193919023" CI_START="-5.291568019391902" EFFECT_SIZE="-2.4" ESTIMABLE="YES" MEAN_1="-2.9" MEAN_2="-0.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2041" SD_1="4.11" SD_2="1.71" SE="1.4753169151067171" STUDY_ID="STD-McEvoy-2006" TOTAL_1="10" TOTAL_2="6" WEIGHT="3.7071519753804214"/>
<CONT_DATA CI_END="1.3634362180978155" CI_START="-3.5634362180978156" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="-3.4" MEAN_2="-2.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2042" SD_1="7.3" SD_2="7.3" SE="1.256878308749082" STUDY_ID="STD-Stroup-2006" TOTAL_1="66" TOTAL_2="69" WEIGHT="5.107690478499043"/>
<CONT_DATA CI_END="1.800307525520116" CI_START="-4.600307525520115" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="-3.3" MEAN_2="-1.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2043" SD_1="7.3" SD_2="7.3" SE="1.6328399658176034" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="41" WEIGHT="3.0263823153853635"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.3367302126934646" CI_END="0.03528874229455581" CI_START="-1.40200505733471" DF="4" EFFECT_SIZE="-0.6833581575200771" ESTIMABLE="YES" I2="0.0" ID="CMP-005.10.03" MODIFIED="2009-09-15 15:15:20 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8551136536984457" P_Z="0.06236088332451102" STUDIES="5" TAU2="0.0" TOTAL_1="409" TOTAL_2="401" WEIGHT="60.01725153563491" Z="1.8637210814190848">
<NAME>long term</NAME>
<CONT_DATA CI_END="0.6878722278772726" CI_START="-4.887872227877274" EFFECT_SIZE="-2.1000000000000005" ESTIMABLE="YES" MEAN_1="-6.2" MEAN_2="-4.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2044" SD_1="5.8" SD_2="5.4" SE="1.4224099268495" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="30" WEIGHT="3.9880581754770845"/>
<CONT_DATA CI_END="0.4781323726651181" CI_START="-1.8781323726651176" EFFECT_SIZE="-0.6999999999999997" ESTIMABLE="YES" MEAN_1="-4.3" MEAN_2="-3.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2045" SD_1="4.9" SD_2="5.5" SE="0.6010989905723144" STUDY_ID="STD-Keefe-2006" TOTAL_1="153" TOTAL_2="148" WEIGHT="22.331558680477617"/>
<CONT_DATA CI_END="0.9263513314482366" CI_START="-1.9263513314482366" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-6.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2046" SD_1="3.1" SD_2="3.16" SE="0.7277436436072876" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="37" WEIGHT="15.23541162458707"/>
<CONT_DATA CI_END="1.3376310753164962" CI_START="-3.2376310753164965" EFFECT_SIZE="-0.9500000000000002" ESTIMABLE="YES" MEAN_1="-2.14" MEAN_2="-1.19" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2047" SD_1="4.33" SD_2="3.14" SE="1.1671801591054929" STUDY_ID="STD-Purdon-2000" TOTAL_1="21" TOTAL_2="21" WEIGHT="5.922911469465866"/>
<CONT_DATA CI_END="1.2722324691910585" CI_START="-1.8722324691910581" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="-7.2" MEAN_2="-6.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2048" SD_1="8.1" SD_2="6.4" SE="0.8021741631951542" STUDY_ID="STD-Tran-1997" TOTAL_1="166" TOTAL_2="165" WEIGHT="12.539311585627273"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="11.982542033609239" CI_END="0.08055646543853617" CI_START="-0.9620788570154244" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.44076119578844414" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.11" MODIFIED="2009-09-15 15:21:52 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.4470828340075008" P_Q="0.3776868790620481" P_Z="0.09749903692444394" Q="1.947380040629124" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="858" TOTAL_2="844" UNITS="" WEIGHT="100.0" Z="1.6571010993468505">
<NAME>Mental state: 3a. Negative symptoms - average endpoint score (PANSS negative, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.929494190338148" CI_END="0.8452628053190034" CI_START="-1.2190729801955502" DF="4" EFFECT_SIZE="-0.18690508743827342" ESTIMABLE="YES" I2="18.855772102540758" ID="CMP-005.11.01" MODIFIED="2009-09-15 15:16:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.29460869594128325" P_Z="0.7226566303800492" STUDIES="5" TAU2="0.2776833639276352" TOTAL_1="334" TOTAL_2="327" WEIGHT="38.60202095292706" Z="0.3549105164739615">
<NAME>short term</NAME>
<CONT_DATA CI_END="1.3115246897369577" CI_START="-0.9115246897369582" EFFECT_SIZE="0.19999999999999973" ESTIMABLE="YES" MEAN_1="-2.6" MEAN_2="-2.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2049" SD_1="5.4" SD_2="5.3" SE="0.5671148544077966" STUDY_ID="STD-Conley-2001" TOTAL_1="181" TOTAL_2="175" WEIGHT="21.9971617681255"/>
<CONT_DATA CI_END="2.3517447230565023" CI_START="-2.951744723056502" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="-5.2" MEAN_2="-4.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2050" SD_1="5.9" SD_2="5.5" SE="1.3529558420323669" STUDY_ID="STD-Dollfus-2005" TOTAL_1="33" TOTAL_2="39" WEIGHT="3.864928374300159"/>
<CONT_DATA CI_END="2.373027731991619" CI_START="-1.3730277319916189" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="-3.8" MEAN_2="-4.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2051" SD_1="6.1" SD_2="6.38" SE="0.955643954055188" STUDY_ID="STD-Jeste-2003" TOTAL_1="88" TOTAL_2="83" WEIGHT="7.746695069301624"/>
<CONT_DATA CI_END="-0.20193368000977285" CI_START="-5.398066319990228" EFFECT_SIZE="-2.8000000000000007" ESTIMABLE="YES" MEAN_1="22.8" MEAN_2="25.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2052" SD_1="3.3" SD_2="4.8" SE="1.3255683984417281" STUDY_ID="STD-Mori-2004" TOTAL_1="20" TOTAL_2="19" WEIGHT="4.026284048794975"/>
<CONT_DATA CI_END="5.991515668557577" CI_START="-4.611515668557576" EFFECT_SIZE="0.69" ESTIMABLE="YES" MEAN_1="-3.48" MEAN_2="-4.17" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2053" SD_1="6.48" SD_2="6.48" SE="2.704904636194979" STUDY_ID="STD-Wang-2006" TOTAL_1="12" TOTAL_2="11" WEIGHT="0.966951692404809"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.0502516849226375" CI_END="1.5815318340180444" CI_START="-1.5899637311215082" DF="2" EFFECT_SIZE="-0.004215948551731926" ESTIMABLE="YES" I2="2.4510007864977656" ID="CMP-005.11.02" MODIFIED="2009-09-15 15:16:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.35875145602683955" P_Z="0.9958423552641051" STUDIES="3" TAU2="0.051980081687575036" TOTAL_1="115" TOTAL_2="116" WEIGHT="11.148755896620404" Z="0.0052108585065637845">
<NAME>medium term</NAME>
<CONT_DATA CI_END="2.8994441974443683" CI_START="-4.299444197444368" EFFECT_SIZE="-0.7" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2054" SD_1="2.21" SD_2="4.16" SE="1.8364848669854774" STUDY_ID="STD-McEvoy-2006" TOTAL_1="10" TOTAL_2="6" WEIGHT="2.097654636707852"/>
<CONT_DATA CI_END="3.2867214648320338" CI_START="-1.0867214648320336" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-1.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2055" SD_1="6.48" SD_2="6.48" SE="1.1156947179032948" STUDY_ID="STD-Stroup-2006" TOTAL_1="66" TOTAL_2="69" WEIGHT="5.6835271698016"/>
<CONT_DATA CI_END="1.440820926763062" CI_START="-4.240820926763062" EFFECT_SIZE="-1.4000000000000001" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-0.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2056" SD_1="6.48" SD_2="6.48" SE="1.449425065547681" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="41" WEIGHT="3.3675740901109523"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.0554161177193278" CI_END="-0.07358240346478295" CI_START="-1.5444302802010939" DF="4" EFFECT_SIZE="-0.8090063418329384" ESTIMABLE="YES" I2="0.0" ID="CMP-005.11.03" MODIFIED="2009-09-15 15:16:34 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5485949415257554" P_Z="0.031078432922932497" STUDIES="5" TAU2="0.0" TOTAL_1="409" TOTAL_2="401" WEIGHT="50.249223150452536" Z="2.1560670118726692">
<NAME>long term</NAME>
<CONT_DATA CI_END="0.7708705394401059" CI_START="-5.170870539440106" EFFECT_SIZE="-2.2" ESTIMABLE="YES" MEAN_1="-6.3" MEAN_2="-4.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2057" SD_1="6.6" SD_2="5.3" SE="1.5157781280033478" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="30" WEIGHT="3.0791966259982084"/>
<CONT_DATA CI_END="0.252592980921428" CI_START="-2.052592980921428" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-1.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2058" SD_1="5.3" SD_2="4.9" SE="0.5880684492230134" STUDY_ID="STD-Keefe-2006" TOTAL_1="153" TOTAL_2="148" WEIGHT="20.457517694882853"/>
<CONT_DATA CI_END="1.5263513314482366" CI_START="-1.3263513314482365" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="-3.5" MEAN_2="-3.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2059" SD_1="3.1" SD_2="3.16" SE="0.7277436436072876" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="37" WEIGHT="13.358320305279731"/>
<CONT_DATA CI_END="1.4790774767079276" CI_START="-5.659077476707927" EFFECT_SIZE="-2.09" ESTIMABLE="YES" MEAN_1="-2.76" MEAN_2="-0.67" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2060" SD_1="5.81" SD_2="5.99" SE="1.8209913574230725" STUDY_ID="STD-Purdon-2000" TOTAL_1="21" TOTAL_2="21" WEIGHT="2.1335013657687245"/>
<CONT_DATA CI_END="0.45629782746293257" CI_START="-2.656297827462932" EFFECT_SIZE="-1.0999999999999996" ESTIMABLE="YES" MEAN_1="-7.3" MEAN_2="-6.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2061" SD_1="7.8" SD_2="6.6" SE="0.7940440945541912" STUDY_ID="STD-Tran-1997" TOTAL_1="166" TOTAL_2="165" WEIGHT="11.220687158523019"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.3730343500712814" CI_START="-2.4269656499287184" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.4" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.12" MODIFIED="2009-09-15 15:21:49 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.007542310847489012" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="157" TOTAL_2="151" UNITS="" WEIGHT="100.0" Z="2.6719000567804123">
<NAME>Mental state: 3b. Negative symptoms - average endpoint score - long term (SANS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.3730343500712814" CI_START="-2.4269656499287184" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="-4.3" MEAN_2="-2.9" MODIFIED="2009-09-15 15:17:26 +0100" MODIFIED_BY="[Empty name]" ORDER="1368" SD_1="5.3" SD_2="3.8" SE="0.5239716943930054" STUDY_ID="STD-Tran-1997" TOTAL_1="157" TOTAL_2="151" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.22644424679024605" CI_END="-1.090415333034679" CI_START="-9.104605215151475" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.097510274093077" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.13" MODIFIED="2009-09-15 15:21:45 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.6341730123113762" P_Q="1.0" P_Z="0.012655770513836056" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="148" TOTAL_2="148" UNITS="" WEIGHT="100.0" Z="2.4933116621904685">
<NAME>Quality of life: General - average endpoint score - long term (QLS total score, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.8010446919058083" CI_START="-15.801044691905808" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="-11.9" MEAN_2="-4.9" MODIFIED="2009-09-15 15:18:26 +0100" MODIFIED_BY="[Empty name]" ORDER="1369" SD_1="13.4" SD_2="19.2" SE="4.490411436805638" STUDY_ID="STD-Gureje-2003" TOTAL_1="30" TOTAL_2="26" WEIGHT="20.729594753878224"/>
<CONT_DATA CI_END="-0.099361891388412" CI_START="-9.100638108611587" EFFECT_SIZE="-4.6" ESTIMABLE="YES" MEAN_1="-13.4" MEAN_2="-8.8" MODIFIED="2009-09-15 15:18:26 +0100" MODIFIED_BY="[Empty name]" ORDER="1370" SD_1="18.6" SD_2="16.9" SE="2.296286127761554" STUDY_ID="STD-Tran-1997" TOTAL_1="118" TOTAL_2="122" WEIGHT="79.27040524612177"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1428378814127778" CI_START="0.5164334662470556" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7682445759368837" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-005.14" LOG_CI_END="0.05798462741937943" LOG_CI_START="-0.2869856220688848" LOG_EFFECT_SIZE="-0.11450049732475269" METHOD="MH" MODIFIED="2009-09-15 15:21:36 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="0.0" P_Z="0.19323126158382814" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="41" WEIGHT="100.00000000000001" Z="1.3010794484529873">
<NAME>Cognitive functioning: 1a.General - no clinically important change - medium term (less than ½ SD in Global Neurocognitive Score improved)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1428378814127778" CI_START="0.5164334662470556" EFFECT_SIZE="0.7682445759368837" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="26" LOG_CI_END="0.05798462741937943" LOG_CI_START="-0.2869856220688848" LOG_EFFECT_SIZE="-0.11450049732475269" MODIFIED="2009-09-15 15:19:18 +0100" MODIFIED_BY="[Empty name]" ORDER="1371" O_E="0.0" SE="0.2026372321796817" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="41" VAR="0.04106184786544222" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.30604926139833094" CI_START="-0.3860492613983309" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.03999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.15" MODIFIED="2009-09-15 15:21:31 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.8207712054789031" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="26" UNITS="" WEIGHT="100.0" Z="0.22655317646050108">
<NAME>Cognitive functioning: 1b. General - average endpoint score - medium term (global neurocognitive score, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.30604926139833094" CI_START="-0.3860492613983309" EFFECT_SIZE="-0.03999999999999998" ESTIMABLE="YES" MEAN_1="0.25" MEAN_2="0.29" MODIFIED="2009-09-15 15:20:23 +0100" MODIFIED_BY="[Empty name]" ORDER="1372" SD_1="0.59" SD_2="0.68" SE="0.1765589899242656" STUDY_ID="STD-Volavka-2002" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.10736439977179599" CI_START="-0.12736439977179595" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.009999999999999981" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.16" MODIFIED="2009-09-18 14:28:28 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.8673714898344678" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="131" UNITS="" WEIGHT="100.0" Z="0.1669981688102198">
<NAME>Cognitive functioning: 1c. General - average endpoint score - long term (neurocognitive composite score, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.10736439977179597" CI_START="-0.12736439977179592" EFFECT_SIZE="-0.009999999999999981" ESTIMABLE="YES" MEAN_1="0.17" MEAN_2="0.18" MODIFIED="2009-09-18 14:28:28 +0100" MODIFIED_BY="[Empty name]" ORDER="928" SD_1="0.51" SD_2="0.46" SE="0.05988089612745508" STUDY_ID="STD-Keefe-2006" TOTAL_1="132" TOTAL_2="131" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.012882338444629939" CI_END="1.0378967192165907" CI_START="0.538136303531737" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7473485826084996" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="73" I2="0.0" I2_Q="0.0" ID="CMP-005.17" LOG_CI_END="0.01615413915216465" LOG_CI_START="-0.269107708768074" LOG_EFFECT_SIZE="-0.12647678480795466" METHOD="MH" MODIFIED="2010-02-17 14:15:55 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.9935795307118942" P_Q="0.0" P_Z="0.08221402920707209" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="480" TOTAL_2="485" WEIGHT="100.0" Z="1.737981751932882">
<NAME>Service use - number of patients re-hospitalised</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.416229994239551" CI_START="0.22708800333630075" DF="0" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-005.17.01" LOG_CI_END="0.3831382712053263" LOG_CI_START="-0.6438058081953386" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2009-09-15 15:23:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6188404144835117" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="40" WEIGHT="7.716027940595987" Z="0.49749445435953277">
<NAME>short term</NAME>
<DICH_DATA CI_END="2.416229994239551" CI_START="0.22708800333630075" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3831382712053263" LOG_CI_START="-0.6438058081953386" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2068" O_E="0.0" SE="0.6032320356951285" STUDY_ID="STD-Dollfus-2005" TOTAL_1="36" TOTAL_2="40" VAR="0.3638888888888888" WEIGHT="7.716027940595987"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.451993615413875" CI_START="0.35923363073668" DF="0" EFFECT_SIZE="0.7222222222222222" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" I2="0.0" ID="CMP-005.17.02" LOG_CI_END="0.16196470672452987" LOG_CI_START="-0.4446230123174684" LOG_EFFECT_SIZE="-0.1413291527964693" MODIFIED="2009-09-15 15:23:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.36108172859328647" STUDIES="1" TAU2="0.0" TOTAL_1="108" TOTAL_2="104" WEIGHT="22.115672790185073" Z="0.9133058278334827">
<NAME>medium term</NAME>
<DICH_DATA CI_END="1.451993615413875" CI_START="0.35923363073668" EFFECT_SIZE="0.7222222222222222" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.16196470672452987" LOG_CI_START="-0.4446230123174684" LOG_EFFECT_SIZE="-0.1413291527964693" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2069" O_E="0.0" SE="0.35631262882290526" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="104" VAR="0.12695868945868946" WEIGHT="22.115672790185073"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1191814815624552" CI_START="0.5109242648499325" DF="0" EFFECT_SIZE="0.7561858076563959" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="51" I2="0.0" ID="CMP-005.17.03" LOG_CI_END="0.04890051552793161" LOG_CI_START="-0.2916434712848767" LOG_EFFECT_SIZE="-0.12137147787847256" MODIFIED="2009-09-15 15:23:11 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.1623892878299282" STUDIES="1" TAU2="0.0" TOTAL_1="336" TOTAL_2="341" WEIGHT="70.16829926921893" Z="1.3970807566951233">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.1191814815624552" CI_START="0.5109242648499325" EFFECT_SIZE="0.7561858076563959" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="51" LOG_CI_END="0.04890051552793161" LOG_CI_START="-0.2916434712848767" LOG_EFFECT_SIZE="-0.12137147787847256" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2070" O_E="0.0" SE="0.20003722357376524" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="341" VAR="0.04001489081510054" WEIGHT="70.16829926921893"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.116420958269057" CI_END="1.1312679240745545" CI_START="0.9666197850439625" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0457083520734045" ESTIMABLE="YES" EVENTS_1="621" EVENTS_2="604" I2="10.042989218023417" I2_Q="0.0" ID="CMP-005.18" LOG_CI_END="0.0535654733314949" LOG_CI_START="-0.014744319845307864" LOG_EFFECT_SIZE="0.019410576743093485" METHOD="MH" MODIFIED="2009-09-15 15:29:41 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.34852010976343173" P_Q="0.0" P_Z="0.26533602590485506" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.001823675641069335" TOTALS="YES" TOTAL_1="1289" TOTAL_2="1287" WEIGHT="100.0" Z="1.1138675603114958">
<NAME>Adverse effects: 1. General - at least one adverse effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3646906835353296" CI_START="0.8115315380841859" EFFECT_SIZE="1.0523732842573423" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="69" LOG_CI_END="0.1350342267199788" LOG_CI_START="-0.09069459777270615" LOG_EFFECT_SIZE="0.02216981447363634" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2071" O_E="0.0" SE="0.13259422888270517" STUDY_ID="STD-Conley-2001" TOTAL_1="189" TOTAL_2="188" VAR="0.017581229532999204" WEIGHT="8.29716296245432"/>
<DICH_DATA CI_END="1.8600741030081043" CI_START="0.9836602583516416" EFFECT_SIZE="1.3526570048309179" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="23" LOG_CI_END="0.26953024630740446" LOG_CI_START="-0.00715487453680149" LOG_EFFECT_SIZE="0.13118768588530147" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2072" O_E="0.0" SE="0.16252620959732356" STUDY_ID="STD-Dollfus-2005" TOTAL_1="36" TOTAL_2="40" VAR="0.02641476880607315" WEIGHT="5.701647652780401"/>
<DICH_DATA CI_END="0.8613003315763612" CI_START="0.25003357831304535" EFFECT_SIZE="0.4640625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" LOG_CI_END="-0.06484538559265975" LOG_CI_START="-0.6020016637406898" LOG_EFFECT_SIZE="-0.33342352466667485" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2073" O_E="0.0" SE="0.315528256750613" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="33" VAR="0.09955808080808079" WEIGHT="1.5881127545957936"/>
<DICH_DATA CI_END="1.1676126527476025" CI_START="0.7922021020369984" EFFECT_SIZE="0.9617615077926785" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="62" LOG_CI_END="0.06729879254130339" LOG_CI_START="-0.10116400956886552" LOG_EFFECT_SIZE="-0.01693260851378108" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2074" O_E="0.0" SE="0.09895588386383271" STUDY_ID="STD-Jeste-2003" TOTAL_1="89" TOTAL_2="87" VAR="0.009792266951272346" WEIGHT="13.860748640955723"/>
<DICH_DATA CI_END="1.4832353508344698" CI_START="0.6994514717442661" EFFECT_SIZE="1.018553459119497" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="40" LOG_CI_END="0.17121006772368555" LOG_CI_START="-0.15524241167219696" LOG_EFFECT_SIZE="0.007983828025744266" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2075" O_E="0.0" SE="0.1917598023629764" STUDY_ID="STD-Keefe-2006" TOTAL_1="159" TOTAL_2="158" VAR="0.03677182180228777" WEIGHT="4.171617705835044"/>
<DICH_DATA CI_END="1.1372879896709465" CI_START="0.9292220463840875" EFFECT_SIZE="1.0280044129720853" ESTIMABLE="YES" EVENTS_1="235" EVENTS_2="232" LOG_CI_END="0.05587045280372864" LOG_CI_START="-0.031880494836748145" LOG_EFFECT_SIZE="0.011994978983490246" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2076" O_E="0.0" SE="0.051545341018212384" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="341" VAR="0.002656922180683808" WEIGHT="35.93396839112471"/>
<DICH_DATA CI_END="2.1789635517063504" CI_START="0.7875059615851883" EFFECT_SIZE="1.3099415204678362" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.3382499657096805" LOG_CI_START="-0.1037461498256626" LOG_EFFECT_SIZE="0.11725190794200895" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2077" O_E="0.0" SE="0.25963070618151873" STUDY_ID="STD-McEvoy-2006" TOTAL_1="19" TOTAL_2="16" VAR="0.06740810359231411" WEIGHT="2.325603390279229"/>
<DICH_DATA CI_END="1.3587550450074437" CI_START="0.8517019797291545" EFFECT_SIZE="1.0757575757575757" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="66" LOG_CI_END="0.13314116961676228" LOG_CI_START="-0.06971234326234907" LOG_EFFECT_SIZE="0.03171441317720659" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2078" O_E="0.0" SE="0.11915715760627336" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.01419842820880627" WEIGHT="10.048971221808035"/>
<DICH_DATA CI_END="1.3790107642000922" CI_START="0.8821390451291766" EFFECT_SIZE="1.1029411764705883" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.13956765617908168" LOG_CI_START="-0.054462954808154156" LOG_EFFECT_SIZE="0.04255235068546376" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2079" O_E="0.0" SE="0.11397454136091695" STUDY_ID="STD-Sikich-2004" TOTAL_1="16" TOTAL_2="20" VAR="0.012990196078431368" WEIGHT="10.868573965594345"/>
<DICH_DATA CI_END="1.6941939484526962" CI_START="0.6809345043710564" EFFECT_SIZE="1.0740740740740742" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="26" LOG_CI_END="0.22896312613713163" LOG_CI_START="-0.16689465865719397" LOG_EFFECT_SIZE="0.031034233739968817" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2080" O_E="0.0" SE="0.23252882231582442" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="104" VAR="0.054069653207584244" WEIGHT="2.8805881456119096"/>
<DICH_DATA CI_END="1.5795702638558433" CI_START="0.7553394088351754" EFFECT_SIZE="1.092296511627907" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="40" LOG_CI_END="0.19853894934604754" LOG_CI_START="-0.12185785597121611" LOG_EFFECT_SIZE="0.0383405466874157" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2081" O_E="0.0" SE="0.18820266943312552" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="0.035420244781754325" WEIGHT="4.323005168960486"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.803872686661313" CI_END="2.1147276390287315" CI_START="0.310538933883424" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8103735351538774" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-005.19" LOG_CI_END="0.3252544414587301" LOG_CI_START="-0.5078839423127939" LOG_EFFECT_SIZE="-0.09131475042703191" METHOD="MH" MODIFIED="2009-09-15 15:30:17 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.4495824940079478" P_Q="0.0" P_Z="0.6674595720101648" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1525" TOTAL_2="1520" WEIGHT="400.0" Z="0.42963720212734074">
<NAME>Adverse effects: 2. Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.890181552097111" CI_START="0.013279962582461915" DF="0" EFFECT_SIZE="0.3236994219653179" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-005.19.01" LOG_CI_END="0.8970869963864565" LOG_CI_START="-1.8768031486316468" LOG_EFFECT_SIZE="-0.48985807612259497" MODIFIED="2009-09-15 15:29:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4887842146762401" STUDIES="1" TAU2="0.0" TOTAL_1="172" TOTAL_2="167" WEIGHT="100.0" Z="0.6922438427929168">
<NAME>any reason</NAME>
<DICH_DATA CI_END="7.890181552097111" CI_START="0.013279962582461915" EFFECT_SIZE="0.3236994219653179" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8970869963864565" LOG_CI_START="-1.8768031486316468" LOG_EFFECT_SIZE="-0.48985807612259497" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2100" O_E="0.0" SE="1.629396802161302" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="2.6549339388934765" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="71.03915961661964" CI_START="0.12112255396714221" DF="0" EFFECT_SIZE="2.9333333333333327" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-005.19.02" LOG_CI_END="1.8514978151576003" LOG_CI_START="-0.9167749802965881" LOG_EFFECT_SIZE="0.4673614174305061" MODIFIED="2009-09-15 15:30:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5081040050566963" STUDIES="2" TAU2="0.0" TOTAL_1="125" TOTAL_2="127" WEIGHT="100.0" Z="0.661792831567449">
<NAME>natural causes</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2101" O_E="0.0" SE="0.0" STUDY_ID="STD-Dollfus-2005" TOTAL_1="36" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="71.03915961661964" CI_START="0.12112255396714221" EFFECT_SIZE="2.933333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8514978151576003" LOG_CI_START="-0.9167749802965881" LOG_EFFECT_SIZE="0.4673614174305062" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2102" O_E="0.0" SE="1.6260971432211297" STUDY_ID="STD-Jeste-2003" TOTAL_1="89" TOTAL_2="87" VAR="2.644191919191919" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.524847612512348" CI_END="2.6696250397051506" CI_START="0.282169470727767" DF="4" EFFECT_SIZE="0.8679208976025385" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" I2="27.599813052924087" ID="CMP-005.19.03" LOG_CI_END="0.42645026712395245" LOG_CI_START="-0.549489976448795" LOG_EFFECT_SIZE="-0.06151985466242132" MODIFIED="2009-09-15 15:30:11 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.23755421517859288" P_Z="0.804831972067529" STUDIES="5" TAU2="0.4518420210702839" TOTAL_1="862" TOTAL_2="862" WEIGHT="99.99999999999997" Z="0.24709852937526983">
<NAME>suicide attempt</NAME>
<DICH_DATA CI_END="12.658564802105067" CI_START="0.48852595042529934" EFFECT_SIZE="2.486772486772487" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1023844691995888" LOG_CI_START="-0.31111236167464207" LOG_EFFECT_SIZE="0.39563605376247335" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2103" O_E="0.0" SE="0.8302950353776809" STUDY_ID="STD-Conley-2001" TOTAL_1="189" TOTAL_2="188" VAR="0.6893898457728244" WEIGHT="28.797034559584745"/>
<DICH_DATA CI_END="8.132024275521538" CI_START="0.014504032975555047" EFFECT_SIZE="0.3434343434343434" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.910198666413285" LOG_CI_START="-1.8385112215238746" LOG_EFFECT_SIZE="-0.4641562775552948" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2104" O_E="0.0" SE="1.614605794507673" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="33" VAR="2.606951871657754" WEIGHT="10.744134669587039"/>
<DICH_DATA CI_END="7.163052825334987" CI_START="0.14379111429455368" EFFECT_SIZE="1.0148809523809523" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.855098153960087" LOG_CI_START="-0.8422679507547797" LOG_EFFECT_SIZE="0.006415101602653649" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2105" O_E="0.0" SE="0.9970412520072384" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="341" VAR="0.9940912582041614" WEIGHT="22.7286376080031"/>
<DICH_DATA CI_END="21.791943782711062" CI_START="0.183554071168881" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3382959698724735" LOG_CI_START="-0.736235978544511" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2106" O_E="0.0" SE="1.2185903355988992" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="1.4849624060150375" WEIGHT="16.96820445595391"/>
<DICH_DATA CI_END="1.1151980359283469" CI_START="0.017251544095240007" EFFECT_SIZE="0.13870431893687707" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.04735199588105746" LOG_CI_START="-1.7631720274295022" LOG_EFFECT_SIZE="-0.8579100157742225" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2107" O_E="0.0" SE="1.0635107735310794" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="1.131055165416675" WEIGHT="20.761988706871183"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.794101429990147" CI_START="0.013228696098106067" DF="0" EFFECT_SIZE="0.3211009174311927" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-005.19.04" LOG_CI_END="0.8917660532655488" LOG_CI_START="-1.878482960446245" LOG_EFFECT_SIZE="-0.49335845359034797" MODIFIED="2009-09-15 15:30:17 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.4851104272141801" STUDIES="4" TAU2="0.0" TOTAL_1="366" TOTAL_2="364" WEIGHT="100.0" Z="0.698106773592778">
<NAME>suicide</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2108" O_E="0.0" SE="0.0" STUDY_ID="STD-Dollfus-2005" TOTAL_1="36" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2109" O_E="0.0" SE="0.0" STUDY_ID="STD-Jeste-2003" TOTAL_1="89" TOTAL_2="87" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2110" O_E="0.0" SE="0.0" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.794101429990147" CI_START="0.013228696098106067" EFFECT_SIZE="0.3211009174311927" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8917660532655488" LOG_CI_START="-1.878482960446245" LOG_EFFECT_SIZE="-0.49335845359034797" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2111" O_E="0.0" SE="1.6272579836080852" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="104" VAR="2.6479685452162514" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.49326354928762" CI_END="6.91993181486453" CI_START="0.3482001913557639" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5522633739493656" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" I2="45.38765575176076" I2_Q="0.0" ID="CMP-005.20" LOG_CI_END="0.8401018151830622" LOG_CI_START="-0.45817099454916" LOG_EFFECT_SIZE="0.19096541031695108" METHOD="MH" MODIFIED="2009-09-15 15:30:29 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.13904218101282872" P_Q="0.0" P_Z="0.5642167016186033" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.0533642948437019" TOTALS="SUB" TOTAL_1="633" TOTAL_2="635" WEIGHT="200.0" Z="0.5765896408033637">
<NAME>Adverse effects: 3a. Cardiac effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4970173084698263" CI_END="13.138162280456712" CI_START="0.43395358947444596" DF="1" EFFECT_SIZE="2.3877505482570753" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-005.20.01" LOG_CI_END="1.1185346219001064" LOG_CI_START="-0.3625567149873197" LOG_EFFECT_SIZE="0.37798895345639344" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.48081368152939286" P_Z="0.3171151226082306" STUDIES="2" TAU2="0.0" TOTAL_1="208" TOTAL_2="207" WEIGHT="100.0" Z="1.0004038466465321">
<NAME>ECG abnormalities</NAME>
<DICH_DATA CI_END="17.12177745550138" CI_START="0.07210512485886156" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2335488479022445" LOG_CI_START="-1.1420338667808942" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2082" O_E="0.0" SE="1.3954290459289653" STUDY_ID="STD-Dollfus-2005" TOTAL_1="36" TOTAL_2="40" VAR="1.9472222222222224" WEIGHT="38.87079026975814"/>
<DICH_DATA CI_END="34.388796059296716" CI_START="0.43861053576630826" EFFECT_SIZE="3.883720930232558" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5364169715778573" LOG_CI_START="-0.35792094044186384" LOG_EFFECT_SIZE="0.5892480155679967" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2083" O_E="0.0" SE="1.112743466644281" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="1.2381980225595322" WEIGHT="61.129209730241854"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.8250133865453533" CI_END="8.304998334249605" CI_START="0.016665474225984907" DF="1" EFFECT_SIZE="0.3720305574630723" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" I2="73.85630064674957" ID="CMP-005.20.02" LOG_CI_END="0.9193395496800951" LOG_CI_START="-1.7781823237197354" LOG_EFFECT_SIZE="-0.42942138701982013" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.05049299117557415" P_Z="0.5326160837260345" STUDIES="2" TAU2="3.796881728167061" TOTAL_1="425" TOTAL_2="428" WEIGHT="100.0" Z="0.6240175184858142">
<NAME>QTc prolongation</NAME>
<DICH_DATA CI_END="5.6544688500886515" CI_START="0.3004305890055312" EFFECT_SIZE="1.303370786516854" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7523918159264751" LOG_CI_START="-0.5222558507624636" LOG_EFFECT_SIZE="0.1150679825820057" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2084" O_E="0.0" SE="0.7487343490207927" STUDY_ID="STD-Jeste-2003" TOTAL_1="89" TOTAL_2="87" VAR="0.5606031254035903" WEIGHT="57.61947112791246"/>
<DICH_DATA CI_END="1.1799035809695098" CI_START="0.0038793893844239497" EFFECT_SIZE="0.06765578635014836" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.07184651920122707" LOG_CI_START="-2.411236626942997" LOG_EFFECT_SIZE="-1.1696950538708848" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2085" O_E="0.0" SE="1.4585753315049246" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="341" VAR="2.1274419976747008" WEIGHT="42.380528872087545"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="7.052493389018494" CI_END="2.7410645131374465" CI_START="-4.66597472560903" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9624551062357919" ESTIMABLE="YES" I2="29.103088451163263" I2_Q="0.0" ID="CMP-005.21" MODIFIED="2009-09-15 15:30:42 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.21676558413467928" P_Q="1.0" P_Z="0.6105088815735213" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="5.980126993950941" TOTALS="YES" TOTAL_1="770" TOTAL_2="748" UNITS="" WEIGHT="100.0" Z="0.5093471991051752">
<NAME>Adverse effects: 3b. Cardiac effects - QTc abnormalities - change from baseline in ms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.167919320791895" CI_START="-2.1679193207918948" EFFECT_SIZE="2.5" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="-1.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2086" SD_1="20.2" SD_2="25.7" SE="2.381635253306615" STUDY_ID="STD-Conley-2001" TOTAL_1="189" TOTAL_2="188" WEIGHT="30.64227160089205"/>
<CONT_DATA CI_END="4.412771943565636" CI_START="-17.612771943565633" EFFECT_SIZE="-6.6" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="4.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2087" SD_1="32.15" SD_2="36.57" SE="5.618864443649462" STUDY_ID="STD-Jeste-2003" TOTAL_1="78" TOTAL_2="73" WEIGHT="9.50829761953132"/>
<CONT_DATA CI_END="5.995306251165945" CI_START="-3.995306251165945" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="0.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2088" SD_1="27.4" SD_2="26.6" SE="2.54867247080471" STUDY_ID="STD-Lieberman-2005" TOTAL_1="231" TOTAL_2="218" WEIGHT="28.619542159977282"/>
<CONT_DATA CI_END="15.91766343580982" CI_START="-15.91766343580982" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="402.0" MEAN_2="402.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2089" SD_1="23.0" SD_2="25.0" SE="8.121406087747692" STUDY_ID="STD-Sikich-2004" TOTAL_1="16" TOTAL_2="19" WEIGHT="4.963392251277222"/>
<CONT_DATA CI_END="8.721786747963076" CI_START="-10.121786747963075" EFFECT_SIZE="-0.6999999999999993" ESTIMABLE="YES" MEAN_1="-5.1" MEAN_2="-4.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2090" SD_1="33.0" SD_2="30.4" SE="4.807122387085133" STUDY_ID="STD-Stroup-2006" TOTAL_1="89" TOTAL_2="85" WEIGHT="12.274703340525104"/>
<CONT_DATA CI_END="-0.6364617973664455" CI_START="-17.963538202633558" EFFECT_SIZE="-9.3" ESTIMABLE="YES" MEAN_1="-4.9" MEAN_2="4.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2091" SD_1="44.9" SD_2="35.1" SE="4.420253775564469" STUDY_ID="STD-Tran-1997" TOTAL_1="167" TOTAL_2="165" WEIGHT="13.991793027797023"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="10.463901520165651" CI_END="1.1904972249398618" CI_START="0.9622679167044124" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0703164412851298" ESTIMABLE="YES" EVENTS_1="411" EVENTS_2="388" I2="4.433351358206465" I2_Q="0.0" ID="CMP-005.22" LOG_CI_END="0.07572838739758944" LOG_CI_START="-0.016703993921684902" LOG_EFFECT_SIZE="0.029512196737952218" METHOD="MH" MODIFIED="2009-09-15 15:31:05 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.40077832734383434" P_Q="0.0" P_Z="0.21072626146036666" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0014928694951649494" TOTALS="YES" TOTAL_1="1289" TOTAL_2="1287" WEIGHT="99.99999999999999" Z="1.251570972974279">
<NAME>Adverse effects: 4a. Central nervous system - sedation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3646906835353296" CI_START="0.8115315380841859" EFFECT_SIZE="1.0523732842573423" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="69" LOG_CI_END="0.1350342267199788" LOG_CI_START="-0.09069459777270615" LOG_EFFECT_SIZE="0.02216981447363634" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2236" O_E="0.0" SE="0.13259422888270517" STUDY_ID="STD-Conley-2001" TOTAL_1="189" TOTAL_2="188" VAR="0.017581229532999204" WEIGHT="15.455371713542359"/>
<DICH_DATA CI_END="1.4721674567005305" CI_START="0.20965140473922747" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.16795721311604206" LOG_CI_START="-0.6785022233226541" LOG_EFFECT_SIZE="-0.255272505103306" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2237" O_E="0.0" SE="0.49721446300587663" STUDY_ID="STD-Dollfus-2005" TOTAL_1="36" TOTAL_2="40" VAR="0.24722222222222226" WEIGHT="1.1852810721923124"/>
<DICH_DATA CI_END="0.8613003315763612" CI_START="0.25003357831304535" EFFECT_SIZE="0.4640625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" LOG_CI_END="-0.06484538559265975" LOG_CI_START="-0.6020016637406898" LOG_EFFECT_SIZE="-0.33342352466667485" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2238" O_E="0.0" SE="0.315528256750613" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="33" VAR="0.09955808080808079" WEIGHT="2.9173133918734178"/>
<DICH_DATA CI_END="2.056204228494916" CI_START="0.46472094224746485" EFFECT_SIZE="0.9775280898876404" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.3130662479222162" LOG_CI_START="-0.3328077559748047" LOG_EFFECT_SIZE="-0.009870754026294283" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2239" O_E="0.0" SE="0.37938958701699194" STUDY_ID="STD-Jeste-2003" TOTAL_1="89" TOTAL_2="87" VAR="0.14393645873692368" WEIGHT="2.0270828048571548"/>
<DICH_DATA CI_END="1.9828611134045697" CI_START="0.871107905921946" EFFECT_SIZE="1.314262527896125" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="31" LOG_CI_END="0.29729229575124916" LOG_CI_START="-0.059928044712381175" LOG_EFFECT_SIZE="0.118682125519434" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2240" O_E="0.0" SE="0.20983299625754" STUDY_ID="STD-Keefe-2006" TOTAL_1="159" TOTAL_2="158" VAR="0.0440298863184168" WEIGHT="6.475822592735939"/>
<DICH_DATA CI_END="1.3878269042950984" CI_START="0.8710019218902811" EFFECT_SIZE="1.0994543650793651" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="96" LOG_CI_END="0.14233530243200027" LOG_CI_START="-0.059980886708268975" LOG_EFFECT_SIZE="0.04117720786186563" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2241" O_E="0.0" SE="0.11884153098228208" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="341" VAR="0.01412330948621271" WEIGHT="18.87768390287667"/>
<DICH_DATA CI_END="3.7057082564308588" CI_START="0.43057028687217186" EFFECT_SIZE="1.263157894736842" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.5688712251259954" LOG_CI_START="-0.3659559436084414" LOG_EFFECT_SIZE="0.10145764075877703" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2242" O_E="0.0" SE="0.5491221063837243" STUDY_ID="STD-McEvoy-2006" TOTAL_1="19" TOTAL_2="16" VAR="0.3015350877192982" WEIGHT="0.9728385898485135"/>
<DICH_DATA CI_END="1.3587550450074437" CI_START="0.8517019797291545" EFFECT_SIZE="1.0757575757575757" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="66" LOG_CI_END="0.13314116961676228" LOG_CI_START="-0.06971234326234907" LOG_EFFECT_SIZE="0.03171441317720659" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2243" O_E="0.0" SE="0.11915715760627336" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.01419842820880627" WEIGHT="18.787311039709962"/>
<DICH_DATA CI_END="1.3790107642000922" CI_START="0.8821390451291766" EFFECT_SIZE="1.1029411764705883" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.13956765617908168" LOG_CI_START="-0.054462954808154156" LOG_EFFECT_SIZE="0.04255235068546376" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2244" O_E="0.0" SE="0.11397454136091695" STUDY_ID="STD-Sikich-2004" TOTAL_1="16" TOTAL_2="20" VAR="0.012990196078431368" WEIGHT="20.354619613034888"/>
<DICH_DATA CI_END="2.0132051277839373" CI_START="0.7836424921864876" EFFECT_SIZE="1.2560386473429952" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="23" LOG_CI_END="0.3038880279070173" LOG_CI_START="-0.1058820228792169" LOG_EFFECT_SIZE="0.09900300251390022" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2245" O_E="0.0" SE="0.24070095622629892" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="104" VAR="0.05793695032825467" WEIGHT="4.960427129967887"/>
<DICH_DATA CI_END="1.5795702638558433" CI_START="0.7553394088351754" EFFECT_SIZE="1.092296511627907" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="40" LOG_CI_END="0.19853894934604754" LOG_CI_START="-0.12185785597121611" LOG_EFFECT_SIZE="0.0383405466874157" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2246" O_E="0.0" SE="0.18820266943312552" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="0.035420244781754325" WEIGHT="7.9862481493609"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.05075799103364659" CI_END="34.34658401703868" CI_START="0.4254433379875473" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.8226333008383997" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.23" LOG_CI_END="1.5358835502362758" LOG_CI_START="-0.371158272566369" LOG_EFFECT_SIZE="0.5823626388349534" METHOD="MH" MODIFIED="2009-09-15 15:31:28 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.8217495244763945" P_Q="0.0" P_Z="0.2312880731102125" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="336" TOTAL_2="335" WEIGHT="100.0" Z="1.1970474736424672">
<NAME>Adverse effects: 4b. Central nervous system - seizures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2247" O_E="0.0" SE="0.0" STUDY_ID="STD-Dollfus-2005" TOTAL_1="36" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="71.03915961661964" CI_START="0.12112255396714221" EFFECT_SIZE="2.933333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8514978151576003" LOG_CI_START="-0.9167749802965881" LOG_EFFECT_SIZE="0.4673614174305062" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2248" O_E="0.0" SE="1.6260971432211297" STUDY_ID="STD-Jeste-2003" TOTAL_1="89" TOTAL_2="87" VAR="2.644191919191919" WEIGHT="47.457260583438924"/>
<DICH_DATA CI_END="100.38798361465146" CI_START="0.23484679342849524" EFFECT_SIZE="4.855491329479769" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0016817311140644" LOG_CI_START="-0.6292153652478921" LOG_EFFECT_SIZE="0.6862331829330862" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2249" O_E="0.0" SE="1.5454019775536751" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="2.38826727222681" WEIGHT="52.54273941656107"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2250" O_E="0.0" SE="0.0" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="41" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="49.564861904124875" CI_END="0.8850721681326796" CI_START="0.690518073368011" CI_STUDY="95" CI_TOTAL="95" DF="45" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7817661596223171" ESTIMABLE="YES" EVENTS_1="537" EVENTS_2="690" I2="9.209875159048874" I2_Q="0.0" ID="CMP-005.24" LOG_CI_END="-0.053021315806189864" LOG_CI_START="-0.1608249498713382" LOG_EFFECT_SIZE="-0.10692313283876403" METHOD="MH" MODIFIED="2009-09-15 15:32:27 +0100" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.29612415498802025" P_Q="0.0" P_Z="1.0111051446396142E-4" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.012752932177284551" TOTALS="SUB" TOTAL_1="4722" TOTAL_2="4711" WEIGHT="900.0" Z="3.8879114103245183">
<NAME>Adverse effects: 5a. Extrapyramidal effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.638203630982409" CI_END="0.9847609467443114" CI_START="0.6029397450286369" DF="7" EFFECT_SIZE="0.7705527328769746" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="125" I2="0.0" ID="CMP-005.24.01" LOG_CI_END="-0.006669182812067177" LOG_CI_START="-0.21972608704575308" LOG_EFFECT_SIZE="-0.11319763492891015" MODIFIED="2009-09-15 15:31:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4674959969148731" P_Z="0.03728159101872457" STUDIES="8" TAU2="0.0" TOTAL_1="992" TOTAL_2="996" WEIGHT="100.00000000000003" Z="2.082666960676685">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="5.8712101997418" CI_START="0.05256871493414002" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.768727629168976" LOG_CI_START="-1.2792726393755882" LOG_EFFECT_SIZE="-0.255272505103306" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2112" O_E="0.0" SE="1.203005495507906" STUDY_ID="STD-Dollfus-2005" TOTAL_1="36" TOTAL_2="40" VAR="1.4472222222222224" WEIGHT="1.0822590002355814"/>
<DICH_DATA CI_END="3.6536268444959368" CI_START="0.4191468683527468" EFFECT_SIZE="1.2375" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5627241895266937" LOG_CI_START="-0.37763377431548095" LOG_EFFECT_SIZE="0.09254520760560635" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2113" O_E="0.0" SE="0.5523709228078868" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="33" VAR="0.3051136363636364" WEIGHT="5.133396507635107"/>
<DICH_DATA CI_END="1.3278181711191017" CI_START="0.36439918556342343" EFFECT_SIZE="0.6955974842767295" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="20" LOG_CI_END="0.12313860764781788" LOG_CI_START="-0.4384226023513619" LOG_EFFECT_SIZE="-0.15764199735177206" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2114" O_E="0.0" SE="0.32986383452633933" STUDY_ID="STD-Keefe-2006" TOTAL_1="159" TOTAL_2="158" VAR="0.10881014932842016" WEIGHT="14.39451452835976"/>
<DICH_DATA CI_END="1.4613656834427113" CI_START="0.39645493221591116" EFFECT_SIZE="0.7611607142857143" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="20" LOG_CI_END="0.1647589047975842" LOG_CI_START="-0.40180617480887676" LOG_EFFECT_SIZE="-0.11852363500564626" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2115" O_E="0.0" SE="0.3328031323032103" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="341" VAR="0.1107579248708281" WEIGHT="14.141374327549089"/>
<DICH_DATA CI_END="1.4271511349319765" CI_START="0.5675642755513821" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="30" LOG_CI_END="0.15446996722213358" LOG_CI_START="-0.2459849483434838" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2116" O_E="0.0" SE="0.23522919968704556" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.055332776385407956" WEIGHT="28.306356153745917"/>
<DICH_DATA CI_END="120.18275827137116" CI_START="0.3174231435194403" EFFECT_SIZE="6.176470588235294" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.079842167128457" LOG_CI_START="-0.4983614117451286" LOG_EFFECT_SIZE="0.7907403776916642" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2117" O_E="0.0" SE="1.5144495445438875" STUDY_ID="STD-Sikich-2004" TOTAL_1="16" TOTAL_2="20" VAR="2.293557422969188" WEIGHT="0.6828995252768871"/>
<DICH_DATA CI_END="7.499981829033435" CI_START="0.49455995450480433" EFFECT_SIZE="1.9259259259259258" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8750602111836907" LOG_CI_START="-0.3057810522320671" LOG_EFFECT_SIZE="0.2846395794758118" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2118" O_E="0.0" SE="0.6936320033889412" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="104" VAR="0.4811253561253561" WEIGHT="3.255428664069102"/>
<DICH_DATA CI_END="0.8928343933070191" CI_START="0.38010854922525866" EFFECT_SIZE="0.5825581395348837" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="45" LOG_CI_END="-0.0492290884157317" LOG_CI_START="-0.42009236233691233" LOG_EFFECT_SIZE="-0.23466072537632202" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2119" O_E="0.0" SE="0.21784692290411486" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="0.047457281818791365" WEIGHT="33.00377129312857"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5252798595692951" CI_END="1.2253806307188575" CI_START="0.5571753016496864" DF="2" EFFECT_SIZE="0.8262879779813224" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="43" I2="0.0" ID="CMP-005.24.02" LOG_CI_END="0.0882710112673557" LOG_CI_START="-0.2540081431364224" LOG_EFFECT_SIZE="-0.08286856593453339" MODIFIED="2009-09-15 15:31:46 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.46643357004900954" P_Z="0.34259701015193056" STUDIES="3" TAU2="0.0" TOTAL_1="341" TOTAL_2="340" WEIGHT="100.0" Z="0.9490464294566191">
<NAME>akinesia</NAME>
<DICH_DATA CI_END="1.7201316356256418" CI_START="0.07974634522572027" EFFECT_SIZE="0.37037037037037035" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.23556168320890084" LOG_CI_START="-1.0982892115268756" LOG_EFFECT_SIZE="-0.43136376415898736" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2120" O_E="0.0" SE="0.7835106182362105" STUDY_ID="STD-Dollfus-2005" TOTAL_1="36" TOTAL_2="40" VAR="0.6138888888888888" WEIGHT="6.584856755358597"/>
<DICH_DATA CI_END="1.3408404454473868" CI_START="0.589274778720215" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="36" LOG_CI_END="0.12737710165142685" LOG_CI_START="-0.2296821465461895" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2121" O_E="0.0" SE="0.20973836986306385" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.04399018379281537" WEIGHT="91.89255530457221"/>
<DICH_DATA CI_END="7.890181552097111" CI_START="0.013279962582461915" EFFECT_SIZE="0.3236994219653179" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8970869963864565" LOG_CI_START="-1.8768031486316468" LOG_EFFECT_SIZE="-0.48985807612259497" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2122" O_E="0.0" SE="1.629396802161302" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="2.6549339388934765" WEIGHT="1.5225879400691837"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.34226152600465964" CI_END="2.802287725803832" CI_START="0.34469698042184727" DF="2" EFFECT_SIZE="0.9828225258701523" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" ID="CMP-005.24.03" LOG_CI_END="0.4475127245663325" LOG_CI_START="-0.4625625210361294" LOG_EFFECT_SIZE="-0.007524898234898433" MODIFIED="2009-09-15 15:31:50 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8427114009297877" P_Z="0.974143755606568" STUDIES="3" TAU2="0.0" TOTAL_1="293" TOTAL_2="287" WEIGHT="100.0" Z="0.03241167057118791">
<NAME>dyskinesia</NAME>
<DICH_DATA CI_END="15.793408793243062" CI_START="0.06733673372369049" EFFECT_SIZE="1.03125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1984758767036463" LOG_CI_START="-1.1717479535876834" LOG_EFFECT_SIZE="0.013363961557981502" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2123" O_E="0.0" SE="1.392281210710311" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="33" VAR="1.9384469696969697" WEIGHT="14.742661115320397"/>
<DICH_DATA CI_END="3.8054369831704435" CI_START="0.11160186166913297" EFFECT_SIZE="0.651685393258427" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5804045345580732" LOG_CI_START="-0.9523285607220243" LOG_EFFECT_SIZE="-0.18596201308197546" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2124" O_E="0.0" SE="0.9003350073187149" STUDY_ID="STD-Jeste-2003" TOTAL_1="89" TOTAL_2="87" VAR="0.8106031254035903" WEIGHT="35.25506609665929"/>
<DICH_DATA CI_END="5.696820204540848" CI_START="0.2941853276110415" EFFECT_SIZE="1.2945736434108528" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7556325130484015" LOG_CI_START="-0.5313789913517328" LOG_EFFECT_SIZE="0.11212676084833434" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2125" O_E="0.0" SE="0.7559969284943328" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="0.5715313558928653" WEIGHT="50.00227278802031"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.9025819083710838" CI_END="2.727525703755603" CI_START="0.11401904751478538" DF="2" EFFECT_SIZE="0.5576646687878913" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" I2="31.09582905371338" ID="CMP-005.24.04" LOG_CI_END="0.4357688519997464" LOG_CI_START="-0.9430225912989154" LOG_EFFECT_SIZE="-0.2536268696495845" MODIFIED="2009-09-15 15:31:54 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.23426771199133434" P_Z="0.4708691686753126" STUDIES="3" TAU2="0.693687893235615" TOTAL_1="297" TOTAL_2="294" WEIGHT="100.0" Z="0.721065586011391">
<NAME>dystonia</NAME>
<DICH_DATA CI_END="8.790250747464718" CI_START="0.015521028346964482" EFFECT_SIZE="0.36936936936936937" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9440012637753723" LOG_CI_START="-1.8090795079092161" LOG_EFFECT_SIZE="-0.4325391220669219" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2126" O_E="0.0" SE="1.6171732732571362" STUDY_ID="STD-Dollfus-2005" TOTAL_1="36" TOTAL_2="40" VAR="2.6152493957372003" WEIGHT="19.823659370467535"/>
<DICH_DATA CI_END="100.39152452040268" CI_START="0.23808020330484944" EFFECT_SIZE="4.888888888888889" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.001697049368832" LOG_CI_START="-0.6232767152751068" LOG_EFFECT_SIZE="0.6892101670468626" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2127" O_E="0.0" SE="1.5419225831815464" STUDY_ID="STD-Jeste-2003" TOTAL_1="89" TOTAL_2="87" VAR="2.3775252525252526" WEIGHT="21.35808964785631"/>
<DICH_DATA CI_END="1.0398140434524312" CI_START="0.08159487460169854" EFFECT_SIZE="0.29127906976744183" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.016955678603150042" LOG_CI_START="-1.0883371206837567" LOG_EFFECT_SIZE="-0.5356907210403032" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2128" O_E="0.0" SE="0.6492544615887252" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="0.42153135589286544" WEIGHT="58.81825098167616"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.962758323810483" CI_END="1.207541746992785" CI_START="0.4696479667189096" DF="3" EFFECT_SIZE="0.7530733869971514" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="116" I2="62.32461318046903" ID="CMP-005.24.05" LOG_CI_END="0.08190215406139355" LOG_CI_START="-0.3282275535460114" LOG_EFFECT_SIZE="-0.12316269974230896" MODIFIED="2009-09-15 15:31:58 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.046787788179204925" P_Z="0.239131063441975" STUDIES="4" TAU2="0.13173656786791524" TOTAL_1="558" TOTAL_2="546" WEIGHT="100.0" Z="1.177161523567174">
<NAME>extrapyramidal symptoms</NAME>
<DICH_DATA CI_END="1.2303800285874333" CI_START="0.573449241686878" EFFECT_SIZE="0.8399764844209289" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="45" LOG_CI_END="0.09003927308750322" LOG_CI_START="-0.24150501722369883" LOG_EFFECT_SIZE="-0.0757328720680978" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2129" O_E="0.0" SE="0.19475075729950558" STUDY_ID="STD-Conley-2001" TOTAL_1="189" TOTAL_2="188" VAR="0.03792785746873093" WEIGHT="34.20793595013552"/>
<DICH_DATA CI_END="3.8718962927196356" CI_START="0.7558069357302126" EFFECT_SIZE="1.7106741573033708" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.5879237163784085" LOG_CI_START="-0.12158912705840805" LOG_EFFECT_SIZE="0.2331672946600002" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2130" O_E="0.0" SE="0.4167713563800042" STUDY_ID="STD-Jeste-2003" TOTAL_1="89" TOTAL_2="87" VAR="0.17369836349882845" WEIGHT="19.00198437998463"/>
<DICH_DATA CI_END="0.9634148857786278" CI_START="0.10694569468191156" EFFECT_SIZE="0.32098765432098764" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.0161866476608078" LOG_CI_START="-0.970836694154856" LOG_EFFECT_SIZE="-0.4935116709078318" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2131" O_E="0.0" SE="0.5607661629045474" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="104" VAR="0.31445868945868943" WEIGHT="13.007466349388476"/>
<DICH_DATA CI_END="0.8736869323179398" CI_START="0.3986605337745601" EFFECT_SIZE="0.5901732786137711" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="51" LOG_CI_END="-0.05864415995568968" LOG_CI_START="-0.399396756091569" LOG_EFFECT_SIZE="-0.2290204580236293" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2132" O_E="0.0" SE="0.20015976172276995" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="0.04006393021291604" WEIGHT="33.782613320491365"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.1421861187144695" CI_END="0.9233410125694158" CI_START="0.39772016639479196" DF="4" EFFECT_SIZE="0.6059961560589668" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="49" I2="0.0" ID="CMP-005.24.06" LOG_CI_END="-0.03463787370288101" LOG_CI_START="-0.4004223875608307" LOG_EFFECT_SIZE="-0.2175301306318559" MODIFIED="2009-09-15 15:32:09 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.5343192739838079" P_Z="0.019744893359020424" STUDIES="5" TAU2="0.0" TOTAL_1="389" TOTAL_2="387" WEIGHT="99.99999999999997" Z="2.3311605901189236">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="8.790250747464718" CI_START="0.015521028346964482" EFFECT_SIZE="0.36936936936936937" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9440012637753723" LOG_CI_START="-1.8090795079092161" LOG_EFFECT_SIZE="-0.4325391220669219" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2133" O_E="0.0" SE="1.6171732732571362" STUDY_ID="STD-Dollfus-2005" TOTAL_1="36" TOTAL_2="40" VAR="2.6152493957372003" WEIGHT="1.7652764334855164"/>
<DICH_DATA CI_END="8.132024275521538" CI_START="0.014504032975555047" EFFECT_SIZE="0.3434343434343434" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.910198666413285" LOG_CI_START="-1.8385112215238746" LOG_EFFECT_SIZE="-0.4641562775552948" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2134" O_E="0.0" SE="1.614605794507673" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="33" VAR="2.606951871657754" WEIGHT="1.7708950349921146"/>
<DICH_DATA CI_END="34.29012855988418" CI_START="0.44587113861674305" EFFECT_SIZE="3.9101123595505616" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5351691133664354" LOG_CI_START="-0.3507906387630991" LOG_EFFECT_SIZE="0.5921892373016682" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2135" O_E="0.0" SE="1.107822094052225" STUDY_ID="STD-Jeste-2003" TOTAL_1="89" TOTAL_2="87" VAR="1.2272697920702569" WEIGHT="3.76171413637942"/>
<DICH_DATA CI_END="1.5608102159044583" CI_START="0.19774471755990533" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.19335009896489205" LOG_CI_START="-0.7038951091715042" LOG_EFFECT_SIZE="-0.255272505103306" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2136" O_E="0.0" SE="0.5270462766947299" STUDY_ID="STD-Robinson-2006" TOTAL_1="60" TOTAL_2="60" VAR="0.2777777777777778" WEIGHT="16.61989725353562"/>
<DICH_DATA CI_END="0.9355939457905768" CI_START="0.3562300559964172" EFFECT_SIZE="0.5773098680075425" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="37" LOG_CI_END="-0.028912597164564652" LOG_CI_START="-0.44826944084494413" LOG_EFFECT_SIZE="-0.23859101900475438" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2137" O_E="0.0" SE="0.24633228582770994" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="0.06067959504110459" WEIGHT="76.0822171416073"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.05636654943359422" CI_END="16.14174905784913" CI_START="0.3697976020504107" DF="1" EFFECT_SIZE="2.4431905563201743" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-005.24.07" LOG_CI_END="1.2079505914156003" LOG_CI_START="-0.4320359093468053" LOG_EFFECT_SIZE="0.38795734103439755" MODIFIED="2009-09-15 15:32:14 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.8123337660217069" P_Z="0.35376911202092753" STUDIES="2" TAU2="0.0" TOTAL_1="68" TOTAL_2="73" WEIGHT="100.0" Z="0.9273032620839889">
<NAME>rigor</NAME>
<DICH_DATA CI_END="79.11225672718244" CI_START="0.13968925512268032" EFFECT_SIZE="3.324324324324324" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.898243773214697" LOG_CI_START="-0.8548369984698914" LOG_EFFECT_SIZE="0.5217033873724028" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2138" O_E="0.0" SE="1.6171732732571362" STUDY_ID="STD-Dollfus-2005" TOTAL_1="36" TOTAL_2="40" VAR="2.6152493957372003" WEIGHT="35.48482274011919"/>
<DICH_DATA CI_END="21.641375044468823" CI_START="0.1965635843960492" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.335284851409265" LOG_CI_START="-0.7064969369653394" LOG_EFFECT_SIZE="0.31439395722196267" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2139" O_E="0.0" SE="1.1993527294740984" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="33" VAR="1.4384469696969697" WEIGHT="64.5151772598808"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.511279016247649" CI_END="2.078055658579944" CI_START="0.6385870433828904" DF="4" EFFECT_SIZE="1.1519632889105673" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="26" I2="11.333349464891127" ID="CMP-005.24.08" LOG_CI_END="0.3176571755072141" LOG_CI_START="-0.19477989732867357" LOG_EFFECT_SIZE="0.06143863908927022" MODIFIED="2009-09-15 15:32:19 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.3412122992559916" P_Z="0.6383694974600649" STUDIES="5" TAU2="0.05605208834283682" TOTAL_1="488" TOTAL_2="485" WEIGHT="100.00000000000001" Z="0.4699797351027691">
<NAME>tremor</NAME>
<DICH_DATA CI_END="23.484840798967205" CI_START="0.2102748597365601" EFFECT_SIZE="2.2222222222222223" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3707876204969385" LOG_CI_START="-0.6772126480476257" LOG_EFFECT_SIZE="0.3467874862246563" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2140" O_E="0.0" SE="1.203005495507906" STUDY_ID="STD-Dollfus-2005" TOTAL_1="36" TOTAL_2="40" VAR="1.4472222222222224" WEIGHT="6.027233984356978"/>
<DICH_DATA CI_END="8.654550617374264" CI_START="0.27648139937171773" EFFECT_SIZE="1.546875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9372445223025239" LOG_CI_START="-0.5583340810751983" LOG_EFFECT_SIZE="0.18945522061366274" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2141" O_E="0.0" SE="0.8785102748575585" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="33" VAR="0.771780303030303" WEIGHT="10.944952271581911"/>
<DICH_DATA CI_END="47.71806351911828" CI_START="0.7209052391850552" EFFECT_SIZE="5.865168539325842" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6786828109407668" LOG_CI_START="-0.14212181822606837" LOG_EFFECT_SIZE="0.7682804963573493" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2142" O_E="0.0" SE="1.0695496523008754" STUDY_ID="STD-Jeste-2003" TOTAL_1="89" TOTAL_2="87" VAR="1.1439364587369236" WEIGHT="7.550560407012198"/>
<DICH_DATA CI_END="2.541908993934503" CI_START="0.5425768523858999" EFFECT_SIZE="1.1743853630646084" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.40515999777598677" LOG_CI_START="-0.26553873821082097" LOG_EFFECT_SIZE="0.06981062978258287" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2143" O_E="0.0" SE="0.3939717575309385" STUDY_ID="STD-Keefe-2006" TOTAL_1="159" TOTAL_2="158" VAR="0.15521374573201657" WEIGHT="42.887133417125476"/>
<DICH_DATA CI_END="1.5556814251183821" CI_START="0.24539521604057132" EFFECT_SIZE="0.6178646934460887" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.19192066625360477" LOG_CI_START="-0.6101339080614725" LOG_EFFECT_SIZE="-0.2091066209039339" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2144" O_E="0.0" SE="0.47113082718685034" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="0.22196425632576586" WEIGHT="32.59011991992345"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="16.567512097433443" CI_END="0.9460411597209716" CI_START="0.645039698870011" DF="12" EFFECT_SIZE="0.7811748234454637" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="312" I2="27.569088651162172" ID="CMP-005.24.09" LOG_CI_END="-0.024089968195635667" LOG_CI_START="-0.1904135559544604" LOG_EFFECT_SIZE="-0.10725176207504805" MODIFIED="2009-09-15 15:32:27 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.1666029058073708" P_Z="0.011480641609376844" STUDIES="13" TAU2="0.02924097999226309" TOTAL_1="1296" TOTAL_2="1303" WEIGHT="100.00000000000001" Z="2.5277183324155397">
<NAME>use of antiparkinson medication</NAME>
<DICH_DATA CI_END="2.5333740706490695" CI_START="0.00805572438028364" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4036993211858072" LOG_CI_START="-2.093895401214321" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2145" O_E="0.0" SE="1.4670995032311038" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="14" VAR="2.152380952380952" WEIGHT="0.4375255326070887"/>
<DICH_DATA CI_END="1.1756734770047075" CI_START="0.6353271848736677" EFFECT_SIZE="0.8642553560586348" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="61" LOG_CI_END="0.07028672069803799" LOG_CI_START="-0.19700256133712257" LOG_EFFECT_SIZE="-0.06335792031954225" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2146" O_E="0.0" SE="0.15700704737073812" STUDY_ID="STD-Conley-2001" TOTAL_1="189" TOTAL_2="188" VAR="0.024651212924077202" WEIGHT="17.711569083682335"/>
<DICH_DATA CI_END="7.205716119224991" CI_START="0.47592150793417276" EFFECT_SIZE="1.8518518518518519" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8576771483940109" LOG_CI_START="-0.3224646680399479" LOG_EFFECT_SIZE="0.2676062401770315" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2147" O_E="0.0" SE="0.693221144769514" STUDY_ID="STD-Dollfus-2005" TOTAL_1="36" TOTAL_2="40" VAR="0.4805555555555555" WEIGHT="1.8723455954505286"/>
<DICH_DATA CI_END="1.3398624481447117" CI_START="0.15678433613489548" EFFECT_SIZE="0.4583333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.1270602154707706" LOG_CI_START="-0.8046973285775325" LOG_EFFECT_SIZE="-0.338818556553381" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2148" O_E="0.0" SE="0.5473189936482021" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="33" VAR="0.2995580808080808" WEIGHT="2.903035354132309"/>
<DICH_DATA CI_END="2.437371579999033" CI_START="0.5475680295075648" EFFECT_SIZE="1.1552604698672115" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.38692174290718256" LOG_CI_START="-0.2615619166625476" LOG_EFFECT_SIZE="0.06267991312231751" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2149" O_E="0.0" SE="0.38092251167714525" STUDY_ID="STD-Jeste-2003" TOTAL_1="89" TOTAL_2="87" VAR="0.14510195990242486" WEIGHT="5.474929460782713"/>
<DICH_DATA CI_END="1.08836214917813" CI_START="0.663660583306028" EFFECT_SIZE="0.8498841443230718" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="76" LOG_CI_END="0.0367734295714136" LOG_CI_START="-0.1780539755793429" LOG_EFFECT_SIZE="-0.07064027300396465" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2150" O_E="0.0" SE="0.1261906811983604" STUDY_ID="STD-Keefe-2006" TOTAL_1="159" TOTAL_2="158" VAR="0.01592408802130623" WEIGHT="21.133928053028146"/>
<DICH_DATA CI_END="1.3085451958150651" CI_START="0.4804205063069996" EFFECT_SIZE="0.7928757440476191" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="32" LOG_CI_END="0.11678872732294861" LOG_CI_START="-0.318378463413378" LOG_EFFECT_SIZE="-0.10079486804521469" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2151" O_E="0.0" SE="0.2556193619508535" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="341" VAR="0.06534125820416144" WEIGHT="10.091908545519916"/>
<DICH_DATA CI_END="2.8580059884508184" CI_START="0.6506298936201139" EFFECT_SIZE="1.3636363636363635" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.456063134443902" LOG_CI_START="-0.18666598664898973" LOG_EFFECT_SIZE="0.13469857389745615" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2152" O_E="0.0" SE="0.3775422672904256" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.14253816359079519" WEIGHT="5.556642546930452"/>
<DICH_DATA CI_END="1.061414694141651" CI_START="0.10468209242285352" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.025885095673677673" LOG_CI_START="-0.9801276051130026" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2153" O_E="0.0" SE="0.5909368402852788" STUDY_ID="STD-Purdon-2000" TOTAL_1="21" TOTAL_2="21" VAR="0.3492063492063492" WEIGHT="2.522187961876088"/>
<DICH_DATA CI_END="1.0357330172109798" CI_START="0.2674514625354273" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" LOG_CI_END="0.015247820954616792" LOG_CI_START="-0.5727550228602748" LOG_EFFECT_SIZE="-0.278753600952829" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2154" O_E="0.0" SE="0.3453957811178867" STUDY_ID="STD-Robinson-2006" TOTAL_1="60" TOTAL_2="60" VAR="0.1192982456140351" WEIGHT="6.426015040894523"/>
<DICH_DATA CI_END="2.081854090229646" CI_START="0.6079316537790558" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.31845028808101056" LOG_CI_START="-0.2161452431862479" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2155" O_E="0.0" SE="0.3140240613569462" STUDY_ID="STD-Sikich-2004" TOTAL_1="16" TOTAL_2="20" VAR="0.09861111111111111" WEIGHT="7.465777756713639"/>
<DICH_DATA CI_END="0.8696415036122969" CI_START="0.414255463876899" EFFECT_SIZE="0.6002114164904863" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="55" LOG_CI_END="-0.060659741737221294" LOG_CI_START="-0.3827317546866874" LOG_EFFECT_SIZE="-0.22169574821195434" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2156" O_E="0.0" SE="0.18918669468869273" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="0.03579160544723264" WEIGHT="14.677492697825276"/>
<DICH_DATA CI_END="1.028490080568924" CI_START="0.15896140621879618" EFFECT_SIZE="0.40433925049309666" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="0.012200107430884595" LOG_CI_START="-0.798708303986048" LOG_EFFECT_SIZE="-0.3932540982775817" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2157" O_E="0.0" SE="0.47633161492768067" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="41" VAR="0.22689180737961226" WEIGHT="3.7266423705569975"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="44.530722823521444" CI_END="0.10086682308474569" CI_START="-0.2979681219056194" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09855064941043686" ESTIMABLE="YES" I2="57.332828224463356" I2_Q="13.306720138598205" ID="CMP-005.25" MODIFIED="2009-09-15 15:34:57 +0100" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="7.970146379169263E-4" P_Q="0.3260754936204464" P_Z="0.3327449166751578" Q="8.074443614535099" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.10854215585193829" TOTALS="SUB" TOTAL_1="1711" TOTAL_2="1693" UNITS="" WEIGHT="800.0" Z="0.9685997976037729">
<NAME>Adverse effects: 5b. Extrapyramidal effects - scale measured</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7176276154591641" CI_START="-0.7776276154591641" DF="0" EFFECT_SIZE="-0.03" ESTIMABLE="YES" I2="0.0" ID="CMP-005.25.01" MODIFIED="2009-09-15 15:33:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9373131362220316" STUDIES="1" TAU2="0.0" TOTAL_1="152" TOTAL_2="150" WEIGHT="100.0" Z="0.07864733501061166">
<NAME>abnormal involuntary movement: AIMS (high=poor)</NAME>
<CONT_DATA CI_END="0.7176276154591641" CI_START="-0.7776276154591641" EFFECT_SIZE="-0.03" ESTIMABLE="YES" MEAN_1="0.09" MEAN_2="0.12" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2158" SD_1="2.91" SD_2="3.67" SE="0.38144967017575593" STUDY_ID="STD-Keefe-2006" TOTAL_1="152" TOTAL_2="150" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="16.829049071993843" CI_END="0.36237608789899756" CI_START="-1.8117244598003106" DF="1" EFFECT_SIZE="-0.7246741859506566" ESTIMABLE="YES" I2="94.0578936116827" ID="CMP-005.25.02" MODIFIED="2009-09-15 15:34:24 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="4.090326396466448E-5" P_Z="0.19135002919303315" STUDIES="2" TAU2="0.5794436535947715" TOTAL_1="178" TOTAL_2="175" WEIGHT="100.0" Z="1.3065957841666578">
<NAME>akathisia: BAS (high=poor)</NAME>
<CONT_DATA CI_END="0.042275933063826904" CI_START="-0.42227593306382694" EFFECT_SIZE="-0.19" ESTIMABLE="YES" MEAN_1="-0.18" MEAN_2="0.01" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2159" SD_1="0.92" SD_2="1.13" SE="0.11851030676889464" STUDY_ID="STD-Keefe-2006" TOTAL_1="153" TOTAL_2="150" WEIGHT="51.831154418859775"/>
<CONT_DATA CI_END="-0.8232490844237108" CI_START="-1.7767509155762893" EFFECT_SIZE="-1.3" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="1.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2160" SD_1="0.86" SD_2="0.86" SE="0.24324473272817232" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" WEIGHT="48.16884558114023"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2689526944750777" CI_START="-0.2689526944750777" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.25.03" MODIFIED="2009-09-15 15:34:30 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="180" TOTAL_2="179" WEIGHT="100.0" Z="0.0">
<NAME>akathisia: ESRS subscore for akathisia (high=poor)</NAME>
<CONT_DATA CI_END="0.2689526944750777" CI_START="-0.2689526944750777" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="-0.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2161" SD_1="1.3" SD_2="1.3" SE="0.13722328399732966" STUDY_ID="STD-Conley-2001" TOTAL_1="180" TOTAL_2="179" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.0618028104684942" CI_END="0.7555598211089617" CI_START="-0.5992586954998166" DF="2" EFFECT_SIZE="0.07815056280457253" ESTIMABLE="YES" I2="34.67900698366741" ID="CMP-005.25.04" MODIFIED="2009-09-15 15:34:38 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.21634065360899613" P_Z="0.8211121002225804" STUDIES="3" TAU2="0.13460958435097692" TOTAL_1="289" TOTAL_2="283" WEIGHT="100.0" Z="0.22611484356133618">
<NAME>dyskinesia: ESRS subscore for dyskinesia (high=poor)</NAME>
<CONT_DATA CI_END="0.5585940577559307" CI_START="-0.5585940577559307" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2162" SD_1="2.7" SD_2="2.7" SE="0.2850022052252232" STUDY_ID="STD-Conley-2001" TOTAL_1="180" TOTAL_2="179" WEIGHT="55.34552472700382"/>
<CONT_DATA CI_END="1.8942722384899533" CI_START="-0.29427223848995276" EFFECT_SIZE="0.8000000000000003" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="2.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2163" SD_1="3.7" SD_2="3.6" SE="0.5583124216166383" STUDY_ID="STD-Jeste-2003" TOTAL_1="88" TOTAL_2="83" WEIGHT="26.764395825598935"/>
<CONT_DATA CI_END="0.6710549544424003" CI_START="-2.1910549544424" EFFECT_SIZE="-0.76" ESTIMABLE="YES" MEAN_1="-0.57" MEAN_2="0.19" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2164" SD_1="2.87" SD_2="1.72" SE="0.7301434953552102" STUDY_ID="STD-Purdon-2000" TOTAL_1="21" TOTAL_2="21" WEIGHT="17.89007944739724"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.1040161825662489E-33" CI_END="0.9086167265207599" CI_START="-0.7286167265207599" DF="0" EFFECT_SIZE="0.09000000000000002" ESTIMABLE="YES" I2="99.99999999999999" ID="CMP-005.25.05" MODIFIED="2009-09-15 15:34:44 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.829391935776428" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.0" Z="0.21548149811000905">
<NAME>dystonia: ESRS subscore for dystonia (high=poor)</NAME>
<CONT_DATA CI_END="0.9086167265207599" CI_START="-0.7286167265207599" EFFECT_SIZE="0.09000000000000001" ESTIMABLE="YES" MEAN_1="-0.05" MEAN_2="-0.14" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2165" SD_1="0.97" SD_2="1.65" SE="0.41766926993450093" STUDY_ID="STD-Purdon-2000" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7403247853050652" CI_END="0.3472544495891562" CI_START="-0.9386455796744663" DF="3" EFFECT_SIZE="-0.29569556504265504" ESTIMABLE="YES" I2="0.0" ID="CMP-005.25.06" MODIFIED="2009-09-15 15:34:48 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.6280063045527713" P_Z="0.36737774599997197" STUDIES="4" TAU2="0.0" TOTAL_1="340" TOTAL_2="342" WEIGHT="100.00000000000003" Z="0.9013961345093193">
<NAME>extrapyramidal symptoms: ESRS total score (high=poor)</NAME>
<CONT_DATA CI_END="0.5275467522310086" CI_START="-1.1275467522310083" EFFECT_SIZE="-0.29999999999999993" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="-0.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2166" SD_1="4.0" SD_2="4.0" SE="0.4222254892225529" STUDY_ID="STD-Conley-2001" TOTAL_1="180" TOTAL_2="179" WEIGHT="60.36279542063544"/>
<CONT_DATA CI_END="3.0857286452147603" CI_START="-2.48572864521476" EFFECT_SIZE="0.30000000000000004" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="1.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2167" SD_1="6.1" SD_2="5.9" SE="1.4213162421290555" STUDY_ID="STD-Dollfus-2005" TOTAL_1="33" TOTAL_2="39" WEIGHT="5.326927684597708"/>
<CONT_DATA CI_END="2.05023818008037" CI_START="-1.2502381800803697" EFFECT_SIZE="0.40000000000000013" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="-2.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2168" SD_1="5.63" SD_2="5.38" SE="0.841973726607855" STUDY_ID="STD-Jeste-2003" TOTAL_1="88" TOTAL_2="83" WEIGHT="15.179629079509052"/>
<CONT_DATA CI_END="0.46998320289938555" CI_START="-2.4699832028993853" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="4.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2169" SD_1="3.1" SD_2="3.6" SE="0.7500052115724705" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="41" WEIGHT="19.130647815257813"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="10.118034825257736" CI_END="0.07816406263663289" CI_START="-1.3258913592079338" DF="4" EFFECT_SIZE="-0.6238636482856504" ESTIMABLE="YES" I2="60.46663142515811" ID="CMP-005.25.07" MODIFIED="2009-09-15 15:34:53 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.038485750662415" P_Z="0.0815538160014937" STUDIES="5" TAU2="0.3010426727347331" TOTAL_1="262" TOTAL_2="260" WEIGHT="100.0" Z="1.7417407644738978">
<NAME>extrapyramidal symptoms: Simpson-Angus Scale (high=poor)</NAME>
<CONT_DATA CI_END="0.01667458962355206" CI_START="-1.356674589623552" EFFECT_SIZE="-0.6699999999999999" ESTIMABLE="YES" MEAN_1="-0.73" MEAN_2="-0.06" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2170" SD_1="2.92" SD_2="3.16" SE="0.35035061615415053" STUDY_ID="STD-Keefe-2006" TOTAL_1="153" TOTAL_2="149" WEIGHT="30.27355625310474"/>
<CONT_DATA CI_END="0.014831058814786607" CI_START="-0.41483105881478655" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2171" SD_1="0.58" SD_2="0.58" SE="0.1096096971726759" STUDY_ID="STD-Robinson-2006" TOTAL_1="56" TOTAL_2="56" WEIGHT="40.98160536751037"/>
<CONT_DATA CI_END="-1.2153857235312613" CI_START="-5.184614276468739" EFFECT_SIZE="-3.2" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="2.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2172" SD_1="3.58" SD_2="3.58" SE="1.012576910659136" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" WEIGHT="9.672809989999301"/>
<CONT_DATA CI_END="1.3367128113316797" CI_START="-1.73671281133168" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="2.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2173" SD_1="2.4" SD_2="2.2" SE="0.7840515557699399" STUDY_ID="STD-Sikich-2004" TOTAL_1="16" TOTAL_2="19" WEIGHT="14.009460269432152"/>
<CONT_DATA CI_END="2.8989237798512537" CI_START="-2.9589237798512533" EFFECT_SIZE="-0.03" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-0.17" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2174" SD_1="3.58" SD_2="3.58" SE="1.494376326786732" STUDY_ID="STD-Wang-2006" TOTAL_1="12" TOTAL_2="11" WEIGHT="5.062568119953447"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.707067715961208" CI_END="1.090500408470457" CI_START="-1.565713586648704" DF="2" EFFECT_SIZE="-0.23760658908912352" ESTIMABLE="YES" I2="57.51070261389708" ID="CMP-005.25.08" MODIFIED="2009-09-15 15:34:57 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.09503294236343007" P_Z="0.7258511456533683" STUDIES="3" TAU2="0.7826299031838861" TOTAL_1="289" TOTAL_2="283" WEIGHT="100.00000000000001" Z="0.35064972774017633">
<NAME>parkinsonism: ESRS subscore for parkinsonism (high=poor)</NAME>
<CONT_DATA CI_END="0.3585940577559308" CI_START="-0.7585940577559307" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-0.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2175" SD_1="2.7" SD_2="2.7" SE="0.2850022052252232" STUDY_ID="STD-Conley-2001" TOTAL_1="180" TOTAL_2="179" WEIGHT="53.15308955941102"/>
<CONT_DATA CI_END="2.4971369594646804" CI_START="-0.6971369594646799" EFFECT_SIZE="0.9000000000000004" ESTIMABLE="YES" MEAN_1="6.4" MEAN_2="5.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2176" SD_1="6.0" SD_2="4.6" SE="0.8148807692706054" STUDY_ID="STD-Jeste-2003" TOTAL_1="88" TOTAL_2="83" WEIGHT="31.739735469670887"/>
<CONT_DATA CI_END="0.18436035927229844" CI_START="-5.7043603592722985" EFFECT_SIZE="-2.76" ESTIMABLE="YES" MEAN_1="-1.43" MEAN_2="1.33" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2177" SD_1="4.32" SD_2="5.36" SE="1.5022522773362352" STUDY_ID="STD-Purdon-2000" TOTAL_1="21" TOTAL_2="21" WEIGHT="15.107174970918102"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.512931305805299" CI_END="10.587586334595063" CI_START="0.09442010329415218" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9998404849515846" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="55.68290619830042" I2_Q="0.0" ID="CMP-005.26" LOG_CI_END="1.024796964730533" LOG_CI_START="-1.024935528792968" LOG_EFFECT_SIZE="-6.928203121753113E-5" METHOD="MH" MODIFIED="2009-09-15 15:35:25 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.10472007331063815" P_Q="0.0" P_Z="0.9998942837929212" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="2.421929310819417" TOTALS="YES" TOTAL_1="243" TOTAL_2="241" WEIGHT="100.00000000000001" Z="1.3249561724874837E-4">
<NAME>Adverse effects: 6. Haematological: white blood cells - significant low white blood cell count (as def. by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.132024275521538" CI_START="0.014504032975555047" EFFECT_SIZE="0.3434343434343434" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.910198666413285" LOG_CI_START="-1.8385112215238746" LOG_EFFECT_SIZE="-0.4641562775552948" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2275" O_E="0.0" SE="1.614605794507673" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="33" VAR="2.606951871657754" WEIGHT="28.826917227028904"/>
<DICH_DATA CI_END="54.644703760488994" CI_START="0.8453256606667598" EFFECT_SIZE="6.796511627906977" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.737548075909571" LOG_CI_START="-0.07297594740098878" LOG_EFFECT_SIZE="0.8322860642542912" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2276" O_E="0.0" SE="1.0635107735310794" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="1.131055165416675" WEIGHT="40.80151280182507"/>
<DICH_DATA CI_END="4.24049956671144" CI_START="0.010399718077132148" EFFECT_SIZE="0.21" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6274170231695753" LOG_CI_START="-1.9829784337017367" LOG_EFFECT_SIZE="-0.6777807052660807" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2277" O_E="0.0" SE="1.533359213032118" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="41" VAR="2.3511904761904763" WEIGHT="30.37156997114604"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="43.607086961887056" CI_END="0.9255887567272799" CI_START="0.6933889999437888" CI_STUDY="95" CI_TOTAL="95" DF="37" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8011198801592327" ESTIMABLE="YES" EVENTS_1="344" EVENTS_2="504" I2="15.151406393327083" I2_Q="0.0" ID="CMP-005.27" LOG_CI_END="-0.0335819294678857" LOG_CI_START="-0.15902305235600903" LOG_EFFECT_SIZE="-0.09630249091194734" METHOD="MH" MODIFIED="2010-02-17 14:16:37 +0000" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.2109611820945022" P_Q="0.0" P_Z="0.0026178956645704545" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.02591936296731742" TOTALS="SUB" TOTAL_1="3674" TOTAL_2="3658" WEIGHT="900.0" Z="3.0093706029282274">
<NAME>Adverse effects: 7a. Prolactin associated side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.14461830389700134" CI_END="0.673094488324852" CI_START="0.07879378771419071" DF="2" EFFECT_SIZE="0.23029473338454834" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="16" I2="0.0" ID="CMP-005.27.01" LOG_CI_END="-0.17192396567546808" LOG_CI_START="-1.1035080219495432" LOG_EFFECT_SIZE="-0.6377159938125057" MODIFIED="2009-09-15 15:38:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9302432803456964" P_Z="0.007288054966236963" STUDIES="3" TAU2="0.0" TOTAL_1="270" TOTAL_2="261" WEIGHT="100.0" Z="2.683387230212438">
<NAME>abnormal ejaculation</NAME>
<DICH_DATA CI_END="2.6805267562921715" CI_START="0.0072883964784222" EFFECT_SIZE="0.1397738951695786" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4282201465928688" LOG_CI_START="-2.1373680103891375" LOG_EFFECT_SIZE="-0.8545739318981345" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2188" O_E="0.0" SE="1.5070391832774284" STUDY_ID="STD-Conley-2001" TOTAL_1="138" TOTAL_2="135" VAR="2.2711670999334985" WEIGHT="13.184698708282253"/>
<DICH_DATA CI_END="6.966924792831061" CI_START="0.013055243623743749" EFFECT_SIZE="0.30158730158730157" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8430411223998254" LOG_CI_START="-1.8842150194013312" LOG_EFFECT_SIZE="-0.5205869485007527" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2189" O_E="0.0" SE="1.6020037578296284" STUDY_ID="STD-Gureje-2003" TOTAL_1="20" TOTAL_2="18" VAR="2.5664160401002505" WEIGHT="11.667887614829837"/>
<DICH_DATA CI_END="0.8307459801328501" CI_START="0.0699557205972586" EFFECT_SIZE="0.24107142857142858" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.08053175153627519" LOG_CI_START="-1.1551767654861131" LOG_EFFECT_SIZE="-0.6178542585111942" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2190" O_E="0.0" SE="0.631251800772747" STUDY_ID="STD-Tran-1997" TOTAL_1="112" TOTAL_2="108" VAR="0.39847883597883593" WEIGHT="75.14741367688791"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.932330542392219" CI_END="1.0122756609357157" CI_START="0.10830871841583706" DF="2" EFFECT_SIZE="0.3311167158563454" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="174" I2="49.139575667936924" ID="CMP-005.27.02" LOG_CI_END="0.005298794836871573" LOG_CI_START="-0.9653365830100303" LOG_EFFECT_SIZE="-0.4800188940865794" MODIFIED="2009-09-15 15:38:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.139992833460999" P_Z="0.05255436432078479" STUDIES="3" TAU2="0.534106291426612" TOTAL_1="236" TOTAL_2="241" WEIGHT="100.0" Z="1.938564708810434">
<NAME>abnormally high prolactin value</NAME>
<DICH_DATA CI_END="2.371713513517146" CI_START="0.03253364851504974" EFFECT_SIZE="0.2777777777777778" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.375062228110081" LOG_CI_START="-1.4876672296446556" LOG_EFFECT_SIZE="-0.5563025007672873" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2191" O_E="0.0" SE="1.094176504144657" STUDY_ID="STD-Dollfus-2005" TOTAL_1="36" TOTAL_2="40" VAR="1.1972222222222224" WEIGHT="18.776210929638083"/>
<DICH_DATA CI_END="0.6707878369968101" CI_START="0.013006782786769805" EFFECT_SIZE="0.09340659340659341" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="13" LOG_CI_END="-0.17341482080217593" LOG_CI_START="-1.8858301124114258" LOG_EFFECT_SIZE="-1.0296224666068008" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2192" O_E="0.0" SE="1.0058812188836757" STUDY_ID="STD-Jeste-2003" TOTAL_1="28" TOTAL_2="34" VAR="1.0117970265029088" WEIGHT="21.02834568225525"/>
<DICH_DATA CI_END="0.6328854187047354" CI_START="0.46796890657867685" EFFECT_SIZE="0.544215671752333" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="157" LOG_CI_END="-0.19867491009101074" LOG_CI_START="-0.3297830019470507" LOG_EFFECT_SIZE="-0.26422895601903074" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2193" O_E="0.0" SE="0.0770135421517594" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="0.005931085674760821" WEIGHT="60.19544338810667"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6175688698379698" CI_END="0.9834506446567627" CI_START="0.4502800096785412" DF="5" EFFECT_SIZE="0.6654533535826646" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="49" I2="0.0" ID="CMP-005.27.03" LOG_CI_END="-0.007247430651683073" LOG_CI_START="-0.34651733324806266" LOG_EFFECT_SIZE="-0.17688238194987282" MODIFIED="2010-02-17 14:16:23 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8991166797789039" P_Z="0.04098310689207867" STUDIES="7" TAU2="0.0" TOTAL_1="279" TOTAL_2="286" WEIGHT="100.0" Z="2.043700873365406">
<NAME>amenorrhoea</NAME>
<DICH_DATA CI_END="1.8783943021519942" CI_START="0.38487905128235367" EFFECT_SIZE="0.8502673796791443" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.2737867621975776" LOG_CI_START="-0.4146757266296725" LOG_EFFECT_SIZE="-0.0704444822160475" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2194" O_E="0.0" SE="0.40440627388140904" STUDY_ID="STD-Conley-2001" TOTAL_1="51" TOTAL_2="53" VAR="0.16354443435464522" WEIGHT="24.28455239869125"/>
<DICH_DATA CI_END="8.790250747464718" CI_START="0.015521028346964482" EFFECT_SIZE="0.36936936936936937" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9440012637753723" LOG_CI_START="-1.8090795079092161" LOG_EFFECT_SIZE="-0.4325391220669219" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2195" O_E="0.0" SE="1.6171732732571362" STUDY_ID="STD-Dollfus-2005" TOTAL_1="36" TOTAL_2="40" VAR="2.6152493957372003" WEIGHT="1.5186327514589355"/>
<DICH_DATA CI_END="1.3373883270348523" CI_START="0.3233535001431816" EFFECT_SIZE="0.657608695652174" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.12625752828030518" LOG_CI_START="-0.49032243366647793" LOG_EFFECT_SIZE="-0.18203245269308635" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2196" O_E="0.0" SE="0.362182121767576" STUDY_ID="STD-Lieberman-2005" TOTAL_1="92" TOTAL_2="88" VAR="0.13117588932806326" WEIGHT="30.27693127101242"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2197" O_E="0.0" SE="0.0" STUDY_ID="STD-McEvoy-2006" TOTAL_1="1" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.241210023045732" CI_START="0.3552815363383529" EFFECT_SIZE="0.6640625" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="16" LOG_CI_END="0.09384527395037953" LOG_CI_START="-0.44942736181753073" LOG_EFFECT_SIZE="-0.17779104393357564" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2198" O_E="0.0" SE="0.31912103549298915" STUDY_ID="STD-McEvoy-2007" TOTAL_1="32" TOTAL_2="34" VAR="0.10183823529411765" WEIGHT="38.99913793801874"/>
<DICH_DATA CI_END="6.070653789293791" CI_START="0.014013226152753591" EFFECT_SIZE="0.2916666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7832354656704027" LOG_CI_START="-1.853461869065101" LOG_EFFECT_SIZE="-0.5351132016973491" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2199" O_E="0.0" SE="1.5488090662859395" STUDY_ID="STD-Sikich-2004" TOTAL_1="7" TOTAL_2="6" VAR="2.3988095238095237" WEIGHT="1.655656001937345"/>
<DICH_DATA CI_END="2.135154567990404" CI_START="0.028304287044969276" EFFECT_SIZE="0.24583333333333332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3294293199209905" LOG_CI_START="-1.5481477800599142" LOG_EFFECT_SIZE="-0.6093592300694619" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2200" O_E="0.0" SE="1.1028980826853225" STUDY_ID="STD-Tran-1997" TOTAL_1="60" TOTAL_2="59" VAR="1.2163841807909606" WEIGHT="3.2650896388813164"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5588272135635632" CI_END="1.3015379236859406" CI_START="0.12499171113062263" DF="2" EFFECT_SIZE="0.40333788835528883" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" I2="0.0" ID="CMP-005.27.04" LOG_CI_END="0.11445682692668849" LOG_CI_START="-0.9031187864286677" LOG_EFFECT_SIZE="-0.39433097975098963" MODIFIED="2009-09-15 15:39:00 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7562270785519188" P_Z="0.12874971272098915" STUDIES="3" TAU2="0.0" TOTAL_1="393" TOTAL_2="388" WEIGHT="100.0" Z="1.519050787296002">
<NAME>decreased libido</NAME>
<DICH_DATA CI_END="3.158923854479415" CI_START="0.03480249849264068" EFFECT_SIZE="0.3315696649029982" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.49953915740942945" LOG_CI_START="-1.458389576667883" LOG_EFFECT_SIZE="-0.47942520962922675" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2201" O_E="0.0" SE="1.150097030300556" STUDY_ID="STD-Conley-2001" TOTAL_1="189" TOTAL_2="188" VAR="1.3227231791061578" WEIGHT="27.010935178239233"/>
<DICH_DATA CI_END="15.793408793243062" CI_START="0.06733673372369049" EFFECT_SIZE="1.03125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1984758767036463" LOG_CI_START="-1.1717479535876834" LOG_EFFECT_SIZE="0.013363961557981502" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2202" O_E="0.0" SE="1.392281210710311" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="33" VAR="1.9384469696969697" WEIGHT="18.431244500424057"/>
<DICH_DATA CI_END="1.5808499164235295" CI_START="0.0662586981219257" EFFECT_SIZE="0.3236434108527132" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.19889064060706246" LOG_CI_START="-1.1787571015663185" LOG_EFFECT_SIZE="-0.489933230479628" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2203" O_E="0.0" SE="0.8092371032189507" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="0.6548646892261987" WEIGHT="54.557820321336706"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.338914955246684" CI_END="1.1078425156264813" CI_START="0.2976372569938333" DF="6" EFFECT_SIZE="0.574225746141893" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="24" I2="0.0" ID="CMP-005.27.05" LOG_CI_END="0.04447802803188622" LOG_CI_START="-0.5263127065465636" LOG_EFFECT_SIZE="-0.24091733925733866" MODIFIED="2010-02-17 14:16:30 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.886042189882837" P_Z="0.09802406189459112" STUDIES="7" TAU2="0.0" TOTAL_1="636" TOTAL_2="636" WEIGHT="100.0" Z="1.6545093660090016">
<NAME>galactorrhoea</NAME>
<DICH_DATA CI_END="3.222419432482004" CI_START="0.03723803962371684" EFFECT_SIZE="0.3464052287581699" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5081820678513844" LOG_CI_START="-1.429013190285004" LOG_EFFECT_SIZE="-0.46041556121680977" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2204" O_E="0.0" SE="1.137918083900496" STUDY_ID="STD-Conley-2001" TOTAL_1="51" TOTAL_2="53" VAR="1.2948575656677765" WEIGHT="8.681745186160832"/>
<DICH_DATA CI_END="1.2414932617209857" CI_START="0.20740816306926282" EFFECT_SIZE="0.5074404761904762" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="0.09394436673767532" LOG_CI_START="-0.6831741548603305" LOG_EFFECT_SIZE="-0.29461489406132757" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2205" O_E="0.0" SE="0.4564832663853909" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="341" VAR="0.20837697248987572" WEIGHT="53.94849201989602"/>
<DICH_DATA CI_END="58.59881074398402" CI_START="0.11096641582726273" EFFECT_SIZE="2.55" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7678888021517716" LOG_CI_START="-0.9548084412838611" LOG_EFFECT_SIZE="0.4065401804339551" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2206" O_E="0.0" SE="1.599325838362809" STUDY_ID="STD-McEvoy-2006" TOTAL_1="19" TOTAL_2="16" VAR="2.557843137254902" WEIGHT="4.394962018493736"/>
<DICH_DATA CI_END="4.86541692186525" CI_START="0.20553223209011884" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6871200612759742" LOG_CI_START="-0.6871200612759742" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2207" O_E="0.0" SE="0.8072354505853322" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.6516290726817042" WEIGHT="17.251568275240622"/>
<DICH_DATA CI_END="10.95900445015833" CI_START="0.0670402025012779" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0397711032869779" LOG_CI_START="-1.1736646825482042" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2208" O_E="0.0" SE="1.300183137283433" STUDY_ID="STD-Sikich-2004" TOTAL_1="7" TOTAL_2="6" VAR="1.6904761904761905" WEIGHT="6.649974427816993"/>
<DICH_DATA CI_END="7.352190024768055" CI_START="0.013225538843870599" EFFECT_SIZE="0.3118279569892473" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8664167233021149" LOG_CI_START="-1.878586624612073" LOG_EFFECT_SIZE="-0.506084950654979" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2209" O_E="0.0" SE="1.6124285545505104" STUDY_ID="STD-Stroup-2006" TOTAL_1="30" TOTAL_2="28" VAR="2.599925843529848" WEIGHT="4.323824645028226"/>
<DICH_DATA CI_END="4.012483571075416" CI_START="0.009644718465036143" EFFECT_SIZE="0.19672131147540983" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6034132672183123" LOG_CI_START="-2.0157104451445966" LOG_EFFECT_SIZE="-0.7061485889631423" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2210" O_E="0.0" SE="1.5384862335134437" STUDY_ID="STD-Tran-1997" TOTAL_1="60" TOTAL_2="59" VAR="2.3669398907103827" WEIGHT="4.749433427363565"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8581221890536698" CI_END="1.424468758218246" CI_START="0.36146179013519786" DF="4" EFFECT_SIZE="0.7175590758517584" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" I2="0.0" ID="CMP-005.27.06" LOG_CI_END="0.15365292863185986" LOG_CI_START="-0.4419376048991722" LOG_EFFECT_SIZE="-0.14414233813365618" MODIFIED="2010-02-17 14:16:37 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.9304904909673695" P_Z="0.3427810469561573" STUDIES="5" TAU2="0.0" TOTAL_1="542" TOTAL_2="541" WEIGHT="99.99999999999999" Z="0.9486846263806198">
<NAME>gynaecomastia</NAME>
<DICH_DATA CI_END="15.786268702215601" CI_START="0.06267763477357445" EFFECT_SIZE="0.9947089947089947" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1982794907724221" LOG_CI_START="-1.2028874005915506" LOG_EFFECT_SIZE="-0.002303954909564312" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2211" O_E="0.0" SE="1.4104573179550044" STUDY_ID="STD-Conley-2001" TOTAL_1="189" TOTAL_2="188" VAR="1.9893898457728245" WEIGHT="6.1524894807098365"/>
<DICH_DATA CI_END="8.132024275521538" CI_START="0.014504032975555047" EFFECT_SIZE="0.3434343434343434" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.910198666413285" LOG_CI_START="-1.8385112215238746" LOG_EFFECT_SIZE="-0.4641562775552948" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2212" O_E="0.0" SE="1.614605794507673" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="33" VAR="2.606951871657754" WEIGHT="4.695023422647642"/>
<DICH_DATA CI_END="1.564365454350718" CI_START="0.3063797781365155" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.19433821692563766" LOG_CI_START="-0.5137399026606615" LOG_EFFECT_SIZE="-0.1597008428675119" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2213" O_E="0.0" SE="0.4159285924882126" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.17299659404922563" WEIGHT="70.7511044735684"/>
<DICH_DATA CI_END="7.921424913226403" CI_START="0.19724986566382696" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8988033099089441" LOG_CI_START="-0.7049832838928313" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2214" O_E="0.0" SE="0.9420721840708386" STUDY_ID="STD-Sikich-2004" TOTAL_1="16" TOTAL_2="20" VAR="0.8875" WEIGHT="13.79121137932199"/>
<DICH_DATA CI_END="7.890181552097111" CI_START="0.013279962582461915" EFFECT_SIZE="0.3236994219653179" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8970869963864565" LOG_CI_START="-1.8768031486316468" LOG_EFFECT_SIZE="-0.48985807612259497" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2215" O_E="0.0" SE="1.629396802161302" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="2.6549339388934765" WEIGHT="4.6101712437521245"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6698078541189592" CI_END="1.4711022568119674" CI_START="0.16980218416393522" DF="2" EFFECT_SIZE="0.49979633485567543" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" I2="0.0" ID="CMP-005.27.07" LOG_CI_END="0.16764286173206897" LOG_CI_START="-0.7700567277302057" LOG_EFFECT_SIZE="-0.30120693299906837" MODIFIED="2009-09-15 15:39:14 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.715406884279004" P_Z="0.20797423998602538" STUDIES="3" TAU2="0.0" TOTAL_1="270" TOTAL_2="261" WEIGHT="99.99999999999999" Z="1.2591553781323146">
<NAME>impotence</NAME>
<DICH_DATA CI_END="2.1600920692039596" CI_START="0.027689627868361197" EFFECT_SIZE="0.24456521739130435" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3344722623986536" LOG_CI_START="-1.557682880867039" LOG_EFFECT_SIZE="-0.6116053092341928" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2216" O_E="0.0" SE="1.1114612974732851" STUDY_ID="STD-Conley-2001" TOTAL_1="138" TOTAL_2="135" VAR="1.2353462157809985" WEIGHT="24.559185903751953"/>
<DICH_DATA CI_END="4.5537318334993575" CI_START="0.04446902176151794" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6583674516940081" LOG_CI_START="-1.3519424241433209" LOG_EFFECT_SIZE="-0.3467874862246563" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2217" O_E="0.0" SE="1.1808659722612234" STUDY_ID="STD-Gureje-2003" TOTAL_1="20" TOTAL_2="18" VAR="1.3944444444444444" WEIGHT="21.757121619104236"/>
<DICH_DATA CI_END="3.1562226339418116" CI_START="0.1657167328554388" EFFECT_SIZE="0.7232142857142857" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4991676299246497" LOG_CI_START="-0.7806336375077133" LOG_EFFECT_SIZE="-0.14073300379153186" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2218" O_E="0.0" SE="0.7517615996082153" STUDY_ID="STD-Tran-1997" TOTAL_1="112" TOTAL_2="108" VAR="0.5651455026455026" WEIGHT="53.6836924771438"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.1163404000623505" CI_START="0.009615350421715005" DF="0" EFFECT_SIZE="0.19894736842105265" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-005.27.08" LOG_CI_END="0.6145112814830099" LOG_CI_START="-2.017034883714217" LOG_EFFECT_SIZE="-0.7012618011156035" MODIFIED="2009-09-15 15:39:19 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.2962109477801017" STUDIES="1" TAU2="0.0" TOTAL_1="189" TOTAL_2="188" WEIGHT="100.0" Z="1.0445933969144428">
<NAME>orgastic dysfunction</NAME>
<DICH_DATA CI_END="4.1163404000623505" CI_START="0.009615350421715005" EFFECT_SIZE="0.19894736842105262" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6145112814830099" LOG_CI_START="-2.017034883714217" LOG_EFFECT_SIZE="-0.7012618011156037" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2219" O_E="0.0" SE="1.5457832438004555" STUDY_ID="STD-Conley-2001" TOTAL_1="189" TOTAL_2="188" VAR="2.389445836814258" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.786752332408986" CI_END="1.107124305882713" CI_START="0.7839935405283118" DF="6" EFFECT_SIZE="0.931653532368089" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="201" I2="0.0" ID="CMP-005.27.09" LOG_CI_END="0.04419638540277741" LOG_CI_START="-0.10568751553554485" LOG_EFFECT_SIZE="-0.0307455650663837" MODIFIED="2009-09-15 15:39:26 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.4474974229102169" P_Z="0.4213440260921838" STUDIES="7" TAU2="0.0" TOTAL_1="859" TOTAL_2="856" WEIGHT="99.99999999999999" Z="0.8040916981369755">
<NAME>sexual dysfunction</NAME>
<DICH_DATA CI_END="1.384154593013831" CI_START="0.6167051832343506" EFFECT_SIZE="0.9239130434782609" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="36" LOG_CI_END="0.14118459817233905" LOG_CI_START="-0.20992240143486415" LOG_EFFECT_SIZE="-0.034368901631262536" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2220" O_E="0.0" SE="0.20624198957694945" STUDY_ID="STD-Conley-2001" TOTAL_1="138" TOTAL_2="135" VAR="0.042535758264658524" WEIGHT="18.223466813976156"/>
<DICH_DATA CI_END="6.175967491975178" CI_START="0.35537547482631504" EFFECT_SIZE="1.4814814814814814" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.790705001367033" LOG_CI_START="-0.44931254702908296" LOG_EFFECT_SIZE="0.17069622716897506" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2221" O_E="0.0" SE="0.7283924461137385" STUDY_ID="STD-Dollfus-2005" TOTAL_1="36" TOTAL_2="40" VAR="0.5305555555555554" WEIGHT="1.461013782678503"/>
<DICH_DATA CI_END="7.8932399574021845" CI_START="0.013458061551904692" EFFECT_SIZE="0.32592592592592595" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8972553057182756" LOG_CI_START="-1.8710174897359129" LOG_EFFECT_SIZE="-0.48688109200881863" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2222" O_E="0.0" SE="1.6260971432211297" STUDY_ID="STD-Jeste-2003" TOTAL_1="89" TOTAL_2="87" VAR="2.644191919191919" WEIGHT="0.2931515573877886"/>
<DICH_DATA CI_END="1.3011200811397974" CI_START="0.7916128283896676" EFFECT_SIZE="1.0148809523809523" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="91" LOG_CI_END="0.11431737970518109" LOG_CI_START="-0.1014871764998738" LOG_EFFECT_SIZE="0.006415101602653649" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2223" O_E="0.0" SE="0.12676466456463098" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="341" VAR="0.01606928018218341" WEIGHT="48.23794036541552"/>
<DICH_DATA CI_END="2.007068159460427" CI_START="0.08833049227746081" EFFECT_SIZE="0.42105263157894735" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.30256212125426274" LOG_CI_START="-1.0538893491760337" LOG_EFFECT_SIZE="-0.37566361396088543" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2224" O_E="0.0" SE="0.7967863082738255" STUDY_ID="STD-McEvoy-2006" TOTAL_1="19" TOTAL_2="16" VAR="0.6348684210526316" WEIGHT="1.2209600500495765"/>
<DICH_DATA CI_END="1.519299632627568" CI_START="0.6952724385689156" EFFECT_SIZE="1.0277777777777777" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="36" LOG_CI_END="0.18164343282530301" LOG_CI_START="-0.15784498622588766" LOG_EFFECT_SIZE="0.01189922329970769" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2225" O_E="0.0" SE="0.1994171778454464" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.0397672108198424" WEIGHT="19.49216359817082"/>
<DICH_DATA CI_END="0.9704887552847891" CI_START="0.34397839096638044" EFFECT_SIZE="0.5777777777777777" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="30" LOG_CI_END="-0.013009492265374565" LOG_CI_START="-0.463468839343677" LOG_EFFECT_SIZE="-0.23823916580452575" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2226" O_E="0.0" SE="0.2646020502835248" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="104" VAR="0.070014245014245" WEIGHT="11.071303832321638"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="25.163046103219394" CI_END="-19.917674638098223" CI_START="-27.4518316739581" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-23.68475315602816" ESTIMABLE="YES" I2="68.2073467290732" I2_Q="80.50576369191249" ID="CMP-005.28" MODIFIED="2009-09-15 15:39:40 +0100" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.0014586672289426117" P_Q="0.0059182377033065725" P_Z="6.821240459034183E-35" Q="10.259442680348894" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="32.88530077939391" TOTALS="SUB" TOTAL_1="720" TOTAL_2="712" UNITS="" WEIGHT="300.0" Z="12.32288176303947">
<NAME>Adverse effects: 7b. Prolactin - change from baseline in ng/ml</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="14.288768970726155" CI_END="-17.690310112510772" CI_START="-27.981435694895694" DF="5" EFFECT_SIZE="-22.835872903703233" ESTIMABLE="YES" I2="65.00748237833746" ID="CMP-005.28.01" MODIFIED="2009-09-15 15:39:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.013875537257302173" P_Z="3.3698545363053386E-18" STUDIES="6" TAU2="24.865975102106482" TOTAL_1="649" TOTAL_2="642" WEIGHT="99.99999999999997" Z="8.69826883142944">
<NAME>change from baseline in ng/ml</NAME>
<CONT_DATA CI_END="-21.849927202410484" CI_START="-35.11007279758952" EFFECT_SIZE="-28.48" ESTIMABLE="YES" MEAN_1="-9.73" MEAN_2="18.75" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2227" SD_1="23.15" SD_2="31.23" SE="3.3827523617202577" STUDY_ID="STD-Keefe-2006" TOTAL_1="136" TOTAL_2="130" WEIGHT="18.982588368804805"/>
<CONT_DATA CI_END="-17.73472936889368" CI_START="-25.26527063110632" EFFECT_SIZE="-21.5" ESTIMABLE="YES" MEAN_1="-6.1" MEAN_2="15.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2228" SD_1="22.0" SD_2="27.7" SE="1.9210917449536282" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="341" WEIGHT="24.135903556141454"/>
<CONT_DATA CI_END="-7.996040460628402" CI_START="-31.0039595393716" EFFECT_SIZE="-19.5" ESTIMABLE="YES" MEAN_1="-4.1" MEAN_2="15.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2229" SD_1="9.2" SD_2="17.91" SE="5.869474964904132" STUDY_ID="STD-McEvoy-2006" TOTAL_1="16" TOTAL_2="11" WEIGHT="11.619635823751203"/>
<CONT_DATA CI_END="-20.83404663234478" CI_START="-35.16595336765522" EFFECT_SIZE="-28.0" ESTIMABLE="YES" MEAN_1="-15.9" MEAN_2="12.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2230" SD_1="15.57" SD_2="15.88" SE="3.6561658398722354" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="37" WEIGHT="18.02707461618278"/>
<CONT_DATA CI_END="3.71865471845892" CI_START="-18.118654718458927" EFFECT_SIZE="-7.200000000000003" ESTIMABLE="YES" MEAN_1="30.0" MEAN_2="37.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2231" SD_1="12.9" SD_2="19.8" SE="5.57084456887161" STUDY_ID="STD-Sikich-2004" TOTAL_1="16" TOTAL_2="19" WEIGHT="12.329786761723135"/>
<CONT_DATA CI_END="-18.03824543158005" CI_START="-36.16175456841995" EFFECT_SIZE="-27.1" ESTIMABLE="YES" MEAN_1="-5.1" MEAN_2="22.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2232" SD_1="37.4" SD_2="29.6" SE="4.623429124156319" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="104" WEIGHT="14.905010873396607"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.6148344521443445" CI_END="-13.644413832306093" CI_START="-26.17760994953352" DF="1" EFFECT_SIZE="-19.911011890919806" ESTIMABLE="YES" I2="0.0" ID="CMP-005.28.02" MODIFIED="2009-09-15 15:39:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4329735300855909" P_Z="4.741168715997045E-10" STUDIES="2" TAU2="0.0" TOTAL_1="32" TOTAL_2="38" WEIGHT="100.0" Z="6.227440444869478">
<NAME>change from baseline in ng/ml - of men only</NAME>
<CONT_DATA CI_END="-12.862826229177038" CI_START="-33.53717377082296" EFFECT_SIZE="-23.2" ESTIMABLE="YES" MEAN_1="9.7" MEAN_2="32.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2233" SD_1="5.01" SD_2="24.11" SE="5.274165164442443" STUDY_ID="STD-Jeste-2003" TOTAL_1="18" TOTAL_2="22" WEIGHT="36.750228671534664"/>
<CONT_DATA CI_END="-10.120432867887423" CI_START="-25.879567132112577" EFFECT_SIZE="-18.0" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="32.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2234" SD_1="9.8" SD_2="12.2" SE="4.0202611855450385" STUDY_ID="STD-Volavka-2002" TOTAL_1="14" TOTAL_2="16" WEIGHT="63.24977132846534"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-29.642883718374257" CI_START="-53.15711628162574" DF="0" EFFECT_SIZE="-41.4" ESTIMABLE="YES" I2="0.0" ID="CMP-005.28.03" MODIFIED="2009-09-15 15:39:40 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="5.1432520371392045E-12" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="32" WEIGHT="100.0" Z="6.901565572398853">
<NAME>change from baseline in ng/ml - of women only</NAME>
<CONT_DATA CI_END="-29.642883718374257" CI_START="-53.15711628162574" EFFECT_SIZE="-41.4" ESTIMABLE="YES" MEAN_1="18.9" MEAN_2="60.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2235" SD_1="12.05" SD_2="32.13" SE="5.998638941513403" STUDY_ID="STD-Jeste-2003" TOTAL_1="39" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.2550253513142517" CI_START="0.7240344541719463" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2777777777777777" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-005.29" LOG_CI_END="0.3531514286414741" LOG_CI_START="-0.14024076681290054" LOG_EFFECT_SIZE="0.10645533091428679" METHOD="MH" MODIFIED="2009-09-15 15:36:15 +0100" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="1.0" P_Q="0.0" P_Z="0.39768004140471447" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="133" WEIGHT="100.00000000000001" Z="0.8457718483452982">
<NAME>Adverse effects: 8a. Metabolic - cholesterol - significant cholesterol increase</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2550253513142517" CI_START="0.7240344541719463" EFFECT_SIZE="1.2777777777777777" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="18" LOG_CI_END="0.3531514286414741" LOG_CI_START="-0.14024076681290054" LOG_EFFECT_SIZE="0.10645533091428679" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2092" O_E="0.0" SE="0.28982101794065657" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.08399622244015836" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="7.853495030980796" CI_END="14.434490169576566" CI_START="6.276492678498869" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="10.355491424037718" ESTIMABLE="YES" I2="23.600893916263413" I2_Q="0.0" ID="CMP-005.30" MODIFIED="2009-09-15 15:36:08 +0100" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="0.2490345625469642" P_Q="1.0" P_Z="6.496980696348506E-7" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="6.892596987537467" TOTALS="YES" TOTAL_1="703" TOTAL_2="688" UNITS="" WEIGHT="99.99999999999999" Z="4.975826544571812">
<NAME>Adverse effects: 8b. Metabolic - cholesterol - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="11.844734976302203" CI_START="-2.1247349763022036" EFFECT_SIZE="4.859999999999999" ESTIMABLE="YES" MEAN_1="100.36" MEAN_2="95.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2093" SD_1="21.53" SD_2="20.78" SE="3.5637057779616876" STUDY_ID="STD-Jeste-2003" TOTAL_1="73" TOTAL_2="68" WEIGHT="22.106448721381003"/>
<CONT_DATA CI_END="18.836080835735196" CI_START="3.863919164264808" EFFECT_SIZE="11.350000000000001" ESTIMABLE="YES" MEAN_1="8.97" MEAN_2="-2.38" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2094" SD_1="31.41" SD_2="25.38" SE="3.819499182017855" STUDY_ID="STD-Keefe-2006" TOTAL_1="111" TOTAL_2="113" WEIGHT="20.162900612226633"/>
<CONT_DATA CI_END="17.352059720909686" CI_START="6.247940279090313" EFFECT_SIZE="11.799999999999999" ESTIMABLE="YES" MEAN_1="9.7" MEAN_2="-2.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2095" SD_1="38.5" SD_2="35.1" SE="2.8327355832574597" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="341" WEIGHT="29.0355344789389"/>
<CONT_DATA CI_END="26.51848966235897" CI_START="-18.11848966235897" EFFECT_SIZE="4.2" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="-4.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2096" SD_1="31.6" SD_2="27.2" SE="11.387193763969321" STUDY_ID="STD-McEvoy-2006" TOTAL_1="16" TOTAL_2="11" WEIGHT="3.171647961242878"/>
<CONT_DATA CI_END="16.71307549671829" CI_START="-8.11307549671829" EFFECT_SIZE="4.299999999999999" ESTIMABLE="YES" MEAN_1="15.7" MEAN_2="11.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2097" SD_1="26.16" SD_2="28.28" SE="6.333318160247353" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="37" WEIGHT="9.21468761074968"/>
<CONT_DATA CI_END="30.517809012073606" CI_START="10.482190987926394" EFFECT_SIZE="20.5" ESTIMABLE="YES" MEAN_1="17.9" MEAN_2="-2.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2098" SD_1="34.3" SD_2="39.8" SE="5.111220966861026" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="104" WEIGHT="13.118102702670944"/>
<CONT_DATA CI_END="33.14828504476205" CI_START="-11.34828504476204" EFFECT_SIZE="10.900000000000002" ESTIMABLE="YES" MEAN_1="20.1" MEAN_2="9.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2099" SD_1="26.8" SD_2="36.7" SE="11.35137442333312" STUDY_ID="STD-Volavka-2002" TOTAL_1="22" TOTAL_2="14" WEIGHT="3.190677912789956"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.595530312134525" CI_END="4.600504533031332" CI_START="0.8650270718477965" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9948836971689872" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-005.31" LOG_CI_END="0.6628054629632888" LOG_CI_START="-0.06297030066219694" LOG_EFFECT_SIZE="0.2999175811505459" METHOD="MH" MODIFIED="2009-09-15 15:36:36 +0100" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="0.7424757169368577" P_Q="0.0" P_Z="0.10526229886222252" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="337" TOTAL_2="333" WEIGHT="100.00000000000001" Z="1.619860256697052">
<NAME>Adverse effects: 8c. Metabolic - glucose - abnormally high fasting glucose value</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.793408793243062" CI_START="0.06733673372369049" EFFECT_SIZE="1.03125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1984758767036463" LOG_CI_START="-1.1717479535876834" LOG_EFFECT_SIZE="0.013363961557981502" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2178" O_E="0.0" SE="1.392281210710311" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="33" VAR="1.9384469696969697" WEIGHT="9.376185746634853"/>
<DICH_DATA CI_END="5.888308858716434" CI_START="0.9246193729096023" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7699905819201819" LOG_CI_START="-0.03403701133099303" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2179" O_E="0.0" SE="0.47228978827651535" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.22305764411027568" WEIGHT="81.48225056521596"/>
<DICH_DATA CI_END="15.396137724710425" CI_START="0.06123000023456423" EFFECT_SIZE="0.9709302325581395" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1874117873806094" LOG_CI_START="-1.2130357389005408" LOG_EFFECT_SIZE="-0.01281197575996566" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2180" O_E="0.0" SE="1.4100347593444398" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="1.9881980225595322" WEIGHT="9.141563688149194"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.750642548567492" CI_END="11.232323974825103" CI_START="3.9258789604303934" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="7.579101467627749" ESTIMABLE="YES" I2="11.11957185063488" I2_Q="0.0" ID="CMP-005.32" MODIFIED="2009-09-15 15:36:55 +0100" MODIFIED_BY="[Empty name]" NO="32" P_CHI2="0.34452465089357975" P_Q="1.0" P_Z="4.778410427072843E-5" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="2.894721916071794" TOTALS="YES" TOTAL_1="608" TOTAL_2="593" UNITS="" WEIGHT="100.0" Z="4.066208910751838">
<NAME>Adverse effects: 8d. Metabolic - glucose - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="19.054580264352587" CI_START="-6.814580264352577" EFFECT_SIZE="6.1200000000000045" ESTIMABLE="YES" MEAN_1="120.9" MEAN_2="114.78" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2181" SD_1="46.22" SD_2="30.94" SE="6.599396910544734" STUDY_ID="STD-Jeste-2003" TOTAL_1="73" TOTAL_2="67" WEIGHT="7.479983313534603"/>
<CONT_DATA CI_END="15.039940244608871" CI_START="1.5600597553911308" EFFECT_SIZE="8.3" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="6.7" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2182" SD_1="51.3" SD_2="36.9" SE="3.4388082116674887" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="341" WEIGHT="23.601771624245718"/>
<CONT_DATA CI_END="63.497642147453455" CI_START="-80.69764214745345" EFFECT_SIZE="-8.600000000000001" ESTIMABLE="YES" MEAN_1="23.6" MEAN_2="32.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2183" SD_1="60.8" SD_2="111.1" SE="36.78518723616885" STUDY_ID="STD-McEvoy-2006" TOTAL_1="16" TOTAL_2="11" WEIGHT="0.25620172798518387"/>
<CONT_DATA CI_END="8.361657070325311" CI_START="-0.7616570703253123" EFFECT_SIZE="3.8" ESTIMABLE="YES" MEAN_1="8.6" MEAN_2="4.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2184" SD_1="9.67" SD_2="10.34" SE="2.3274188231554667" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="37" WEIGHT="41.799531819650404"/>
<CONT_DATA CI_END="29.559962787357158" CI_START="6.840037212642848" EFFECT_SIZE="18.200000000000003" ESTIMABLE="YES" MEAN_1="97.2" MEAN_2="79.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2185" SD_1="14.4" SD_2="19.8" SE="5.796005884272921" STUDY_ID="STD-Sikich-2004" TOTAL_1="16" TOTAL_2="19" WEIGHT="9.521407972019754"/>
<CONT_DATA CI_END="21.52128266381864" CI_START="-1.5212826638186385" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="14.8" MEAN_2="4.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2186" SD_1="41.6" SD_2="43.9" SE="5.878313456112993" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="104" WEIGHT="9.27710489737579"/>
<CONT_DATA CI_END="24.02503500914552" CI_START="-0.8250350091455179" EFFECT_SIZE="11.600000000000001" ESTIMABLE="YES" MEAN_1="14.3" MEAN_2="2.7" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2187" SD_1="25.5" SD_2="12.2" SE="6.339420064425984" STUDY_ID="STD-Volavka-2002" TOTAL_1="22" TOTAL_2="14" WEIGHT="8.063998645188555"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="20.975642140669187" CI_END="2.346489169607492" CI_START="1.3912618214843935" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8068150974024766" ESTIMABLE="YES" EVENTS_1="357" EVENTS_2="200" I2="52.32565500051495" I2_Q="0.0" ID="CMP-005.33" LOG_CI_END="0.37041855403517115" LOG_CI_START="0.14340886753764576" LOG_EFFECT_SIZE="0.2569137107864084" METHOD="MH" MODIFIED="2009-09-15 15:37:25 +0100" MODIFIED_BY="[Empty name]" NO="33" P_CHI2="0.02126407856192447" P_Q="0.0" P_Z="9.151796836465913E-6" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.07708643472671758" TOTALS="YES" TOTAL_1="1301" TOTAL_2="1293" WEIGHT="99.99999999999999" Z="4.436300741566722">
<NAME>Adverse effects: 8e. Metabolic - weight gain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="19.764642897923665" CI_END="2.578581293801099" CI_START="1.3152681388372598" DF="7" EFFECT_SIZE="1.841609572938397" ESTIMABLE="YES" EVENTS_1="302" EVENTS_2="168" I2="64.58322047025007" ID="CMP-005.33.01" LOG_CI_END="0.4113808277701506" LOG_CI_START="0.11901429985722933" LOG_EFFECT_SIZE="0.26519756381369" MODIFIED="2009-09-15 15:37:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.006101136324390799" P_Z="3.7703445404404346E-4" STUDIES="8" TAU2="0.1143841478688335" TOTAL_1="938" TOTAL_2="935" WEIGHT="76.98373892881472" Z="3.555657876249133">
<NAME>significant weight gain (as defined by the original studies)</NAME>
<DICH_DATA CI_END="4.048624956052571" CI_START="1.460309414694089" EFFECT_SIZE="2.4315108759553206" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="18" LOG_CI_END="0.607307547807986" LOG_CI_START="0.1644448851386482" LOG_EFFECT_SIZE="0.3858762164733171" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2251" O_E="0.0" SE="0.2601397202575047" STUDY_ID="STD-Conley-2001" TOTAL_1="189" TOTAL_2="188" VAR="0.06767267405565279" WEIGHT="12.283385480018676"/>
<DICH_DATA CI_END="8.742593153143885" CI_START="0.9836956093034919" EFFECT_SIZE="2.932584269662921" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.9416402684540681" LOG_CI_START="-0.007139267067331775" LOG_EFFECT_SIZE="0.46725050069336815" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2252" O_E="0.0" SE="0.557317795699716" STUDY_ID="STD-Jeste-2003" TOTAL_1="89" TOTAL_2="87" VAR="0.31060312540359036" WEIGHT="4.586483923684086"/>
<DICH_DATA CI_END="3.099794803787602" CI_START="1.5943157306643523" EFFECT_SIZE="2.2230725623582765" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="42" LOG_CI_END="0.4913329459206385" LOG_CI_START="0.2025743311799784" LOG_EFFECT_SIZE="0.3469536385503085" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2253" O_E="0.0" SE="0.16961823967685946" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="341" VAR="0.028770347231076545" WEIGHT="16.797524939184022"/>
<DICH_DATA CI_END="5.3219394033706635" CI_START="0.13324865626788057" EFFECT_SIZE="0.8421052631578947" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7260699252827195" LOG_CI_START="-0.875337161876528" LOG_EFFECT_SIZE="-0.07463361829690421" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2254" O_E="0.0" SE="0.9406744500902698" STUDY_ID="STD-McEvoy-2006" TOTAL_1="19" TOTAL_2="16" VAR="0.8848684210526316" WEIGHT="1.8484567381046366"/>
<DICH_DATA CI_END="1.6291309633308275" CI_START="1.1632532704377252" EFFECT_SIZE="1.3766233766233766" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="77" LOG_CI_END="0.21195599797685533" LOG_CI_START="0.06567428220772137" LOG_EFFECT_SIZE="0.13881514009228837" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2255" O_E="0.0" SE="0.08592660394896058" STUDY_ID="STD-McEvoy-2007" TOTAL_1="133" TOTAL_2="133" VAR="0.0073833812662015275" WEIGHT="21.05050086846251"/>
<DICH_DATA CI_END="1.7102905981831071" CI_START="0.190921129188093" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.23306990832484717" LOG_CI_START="-0.7191460056974361" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2256" O_E="0.0" SE="0.5593363414414827" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" VAR="0.3128571428571429" WEIGHT="4.5599723578866"/>
<DICH_DATA CI_END="3.5563202323167333" CI_START="1.1188148742670938" EFFECT_SIZE="1.9947089947089947" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="14" LOG_CI_END="0.5510008605282994" LOG_CI_START="0.0487582315367979" LOG_EFFECT_SIZE="0.2998795460325487" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2257" O_E="0.0" SE="0.29501980641071746" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="104" VAR="0.08703668617461721" WEIGHT="10.834134308150064"/>
<DICH_DATA CI_END="9.583170255462647" CI_START="1.2181366708430184" EFFECT_SIZE="3.4166666666666665" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.981509203931521" LOG_CI_START="0.08569601741270018" LOG_EFFECT_SIZE="0.5336026106721107" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2258" O_E="0.0" SE="0.5262051001079449" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="41" VAR="0.2768918073796122" WEIGHT="5.023280313324139"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5450891650418495" CI_END="2.5337058730217223" CI_START="1.1066358415227715" DF="2" EFFECT_SIZE="1.674481929123925" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="32" I2="0.0" ID="CMP-005.33.02" LOG_CI_END="0.4037561981016378" LOG_CI_START="0.04400473195755635" LOG_EFFECT_SIZE="0.22388046502959702" MODIFIED="2009-09-15 15:37:25 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4618365261713121" P_Z="0.014709685356256958" STUDIES="3" TAU2="0.0" TOTAL_1="363" TOTAL_2="358" WEIGHT="23.016261071185273" Z="2.439448839518278">
<NAME>as "weight gain" reported adverse event</NAME>
<DICH_DATA CI_END="12.343504774018015" CI_START="0.538479843230245" EFFECT_SIZE="2.578125" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0914384893491913" LOG_CI_START="-0.268830548889153" LOG_EFFECT_SIZE="0.41130397023001913" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2259" O_E="0.0" SE="0.7990287665015382" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="33" VAR="0.6384469696969697" WEIGHT="2.4850439181801365"/>
<DICH_DATA CI_END="2.327758535079745" CI_START="0.7104434529995487" EFFECT_SIZE="1.2859785423603403" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" LOG_CI_END="0.36693792772986134" LOG_CI_START="-0.1484704835740545" LOG_EFFECT_SIZE="0.10923372207790343" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2260" O_E="0.0" SE="0.3027534521127032" STUDY_ID="STD-Keefe-2006" TOTAL_1="159" TOTAL_2="158" VAR="0.0916596527661589" WEIGHT="10.53732244306331"/>
<DICH_DATA CI_END="3.896711430096299" CI_START="1.1222953438372663" EFFECT_SIZE="2.0912343470483004" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="13" LOG_CI_END="0.5906982454239105" LOG_CI_START="0.05010716112692316" LOG_EFFECT_SIZE="0.32040270327541676" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2261" O_E="0.0" SE="0.317545878885075" STUDY_ID="STD-Tran-1997" TOTAL_1="172" TOTAL_2="167" VAR="0.10083538519689474" WEIGHT="9.993894709941829"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="69.45866646299368" CI_END="3.7361048643105814" CI_START="1.4834109839849559" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="2.6097579241477686" ESTIMABLE="YES" I2="82.72353816871308" I2_Q="0.0" ID="CMP-005.34" MODIFIED="2009-09-15 15:38:02 +0100" MODIFIED_BY="[Empty name]" NO="34" P_CHI2="4.0436853865344347E-10" P_Q="1.0" P_Z="5.591966973425173E-6" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="3.0439167458611536" TOTALS="YES" TOTAL_1="1066" TOTAL_2="1050" UNITS="" WEIGHT="100.0" Z="4.541257544463402">
<NAME>Adverse effects: 8f. Metabolic - weight gain - change from baseline in kg</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.12589188521349" CI_START="6.634108114786509" EFFECT_SIZE="8.379999999999999" ESTIMABLE="YES" MEAN_1="8.92" MEAN_2="0.54" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2262" SD_1="3.13" SD_2="0.72" SE="0.8907775341714761" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="13" WEIGHT="8.60619059477224"/>
<CONT_DATA CI_END="2.76135195133788" CI_START="0.8386480486621198" EFFECT_SIZE="1.7999999999999998" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="1.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2263" SD_1="5.1" SD_2="3.5" SE="0.4904947024133614" STUDY_ID="STD-Conley-2001" TOTAL_1="161" TOTAL_2="155" WEIGHT="10.054921423398085"/>
<CONT_DATA CI_END="2.783922545532006" CI_START="0.016077454467994468" EFFECT_SIZE="1.4000000000000001" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="0.7" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2264" SD_1="3.2" SD_2="2.5" SE="0.7060959060718514" STUDY_ID="STD-Dollfus-2005" TOTAL_1="32" TOTAL_2="35" WEIGHT="9.322658503668645"/>
<CONT_DATA CI_END="3.41799402452152" CI_START="-2.59799402452152" EFFECT_SIZE="0.41000000000000014" ESTIMABLE="YES" MEAN_1="4.88" MEAN_2="4.47" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2265" SD_1="7.4" SD_2="4.54" SE="1.5347190296598268" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="32" WEIGHT="6.116632609590498"/>
<CONT_DATA CI_END="1.8176387932902105" CI_START="-0.21763879329021074" EFFECT_SIZE="0.7999999999999999" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="0.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2266" SD_1="4.1" SD_2="2.2" SE="0.5192130066252317" STUDY_ID="STD-Jeste-2003" TOTAL_1="81" TOTAL_2="78" WEIGHT="9.966928790034887"/>
<CONT_DATA CI_END="3.7927787750559983" CI_START="0.5872212249440019" EFFECT_SIZE="2.19" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="0.81" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2267" SD_1="7.87" SD_2="6.26" SE="0.817759299506783" STUDY_ID="STD-Keefe-2006" TOTAL_1="152" TOTAL_2="150" WEIGHT="8.895380397129598"/>
<CONT_DATA CI_END="5.00578993427027" CI_START="2.7942100657297297" EFFECT_SIZE="3.9" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="0.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2268" SD_1="7.0" SD_2="6.9" SE="0.5641889049965203" STUDY_ID="STD-Lieberman-2005" TOTAL_1="307" TOTAL_2="300" WEIGHT="9.8224833238387"/>
<CONT_DATA CI_END="7.949831501533465" CI_START="-5.949831501533465" EFFECT_SIZE="0.9999999999999998" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="1.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2269" SD_1="14.38" SD_2="5.2" SE="3.5458975554412473" STUDY_ID="STD-McEvoy-2006" TOTAL_1="19" TOTAL_2="16" WEIGHT="2.1146673465483805"/>
<CONT_DATA CI_END="9.224809277224399" CI_START="-0.4448092772244019" EFFECT_SIZE="4.389999999999999" ESTIMABLE="YES" MEAN_1="10.87" MEAN_2="6.48" MODIFIED="2008-12-12 12:31:14 +0000" MODIFIED_BY="[Empty name]" ORDER="2270" SD_1="10.64" SD_2="10.58" SE="2.4667847549040487" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="37" WEIGHT="3.6176592084618644"/>
<CONT_DATA CI_END="4.779963556582059" CI_START="-0.37996355658206005" EFFECT_SIZE="2.1999999999999993" ESTIMABLE="YES" MEAN_1="7.1" MEAN_2="4.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2271" SD_1="4.1" SD_2="3.6" SE="1.3163321249433575" STUDY_ID="STD-Sikich-2004" TOTAL_1="16" TOTAL_2="19" WEIGHT="6.913930931291855"/>
<CONT_DATA CI_END="2.9689782473458184" CI_START="0.6510217526541819" EFFECT_SIZE="1.81" ESTIMABLE="YES" MEAN_1="4.13" MEAN_2="2.32" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2272" SD_1="5.88" SD_2="4.83" SE="0.5913262980787864" STUDY_ID="STD-Tran-1997" TOTAL_1="166" TOTAL_2="165" WEIGHT="9.731720803907633"/>
<CONT_DATA CI_END="4.806258403320167" CI_START="1.393741596679834" EFFECT_SIZE="3.1000000000000005" ESTIMABLE="YES" MEAN_1="5.4" MEAN_2="2.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2273" SD_1="4.6" SD_2="2.8" SE="0.8705559983647225" STUDY_ID="STD-Volavka-2002" TOTAL_1="38" TOTAL_2="39" WEIGHT="8.686817354248104"/>
<CONT_DATA CI_END="4.8892249886250845" CI_START="-1.089224988625085" EFFECT_SIZE="1.9" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="1.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2274" SD_1="4.4" SD_2="2.8" SE="1.525142814971964" STUDY_ID="STD-Wang-2006" TOTAL_1="12" TOTAL_2="11" WEIGHT="6.1500087131095045"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2010-02-17 14:17:25 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>OLANZAPINE versus ZIPRASIDONE</NAME>
<DICH_OUTCOME CHI2="6.31506345242091" CI_END="1.0852638656800098" CI_START="0.6417029413009301" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8345160362116955" ESTIMABLE="YES" EVENTS_1="221" EVENTS_2="270" I2="84.164846362444" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.03553534323208998" LOG_CI_START="-0.19266597007792902" LOG_EFFECT_SIZE="-0.07856531342291952" METHOD="MH" MODIFIED="2009-09-15 15:40:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.011971664817092331" P_Q="0.0" P_Z="0.17715856143419084" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.030304762152993606" TOTALS="YES" TOTAL_1="410" TOTAL_2="407" WEIGHT="100.0" Z="1.3495556402327065">
<NAME>Global state: 1a. General - no clinically significant response (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8673486043986435" CI_START="0.6207373622121259" EFFECT_SIZE="0.733754512635379" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="160" LOG_CI_END="-0.06180631597486528" LOG_CI_START="-0.20709211362182026" LOG_EFFECT_SIZE="-0.13444921479834276" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2293" O_E="0.0" SE="0.08534159671411845" STUDY_ID="STD-Breier-2005" TOTAL_1="277" TOTAL_2="271" VAR="0.007283188129715233" WEIGHT="47.803846064654515"/>
<DICH_DATA CI_END="1.0647638297263795" CI_START="0.8279014103447981" EFFECT_SIZE="0.9388926862611073" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="110" LOG_CI_END="0.027253289633175026" LOG_CI_START="-0.08202137757807651" LOG_EFFECT_SIZE="-0.027384043972450735" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2294" O_E="0.0" SE="0.06418848043821569" STUDY_ID="STD-Simpson-2004" TOTAL_1="133" TOTAL_2="136" VAR="0.004120161020967199" WEIGHT="52.196153935345485"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0920261128249826" CI_START="0.6534209296768886" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.84472049689441" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="69" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.038233023460481574" LOG_CI_START="-0.1848069587837459" LOG_EFFECT_SIZE="-0.07328696766163217" METHOD="MH" MODIFIED="2009-09-18 14:29:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.19773950632435136" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="136" WEIGHT="100.0" Z="1.2880185490300657">
<NAME>Global state: 1b. General - no clinically important change (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0920261128249826" CI_START="0.6534209296768886" EFFECT_SIZE="0.84472049689441" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="69" LOG_CI_END="0.038233023460481574" LOG_CI_START="-0.1848069587837459" LOG_EFFECT_SIZE="-0.07328696766163217" MODIFIED="2009-09-18 14:29:48 +0100" MODIFIED_BY="[Empty name]" ORDER="929" O_E="0.0" SE="0.13101478963597743" STUDY_ID="STD-Simpson-2004" TOTAL_1="133" TOTAL_2="136" VAR="0.01716487510335942" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.162700890773046" CI_END="0.8319102510216423" CI_START="0.7292062682661713" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7788672349507749" ESTIMABLE="YES" EVENTS_1="781" EVENTS_2="905" I2="22.918953055532434" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="-0.07992352417620607" LOG_CI_START="-0.13714960680023613" LOG_EFFECT_SIZE="-0.10853656548822109" METHOD="MH" MODIFIED="2009-09-15 15:41:57 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.19947087357411786" P_Q="0.0" P_Z="1.0485041150345495E-13" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.005626884188275427" TOTALS="SUB" TOTAL_1="3048" TOTAL_2="2763" WEIGHT="300.0" Z="7.434643421608548">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.2934514944439246" CI_END="0.8499875757461942" CI_START="0.7381104479464993" DF="4" EFFECT_SIZE="0.7920762023208262" ESTIMABLE="YES" EVENTS_1="535" EVENTS_2="610" I2="0.0" ID="CMP-006.03.01" LOG_CI_END="-0.07058742231430076" LOG_CI_START="-0.1318786471949375" LOG_EFFECT_SIZE="-0.10123303475461913" MODIFIED="2009-09-15 15:41:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5099706623833966" P_Z="9.516579652846288E-11" STUDIES="5" TAU2="0.0" TOTAL_1="1016" TOTAL_2="921" WEIGHT="100.00000000000001" Z="6.474437492517078">
<NAME>due to any reason</NAME>
<DICH_DATA CI_END="0.8373375562965142" CI_START="0.5892035049235584" EFFECT_SIZE="0.7023974821808757" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="156" LOG_CI_END="-0.07709942936192991" LOG_CI_START="-0.22973467838671568" LOG_EFFECT_SIZE="-0.15341705387432278" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2278" O_E="0.0" SE="0.08965870083382725" STUDY_ID="STD-Breier-2005" TOTAL_1="277" TOTAL_2="271" VAR="0.008038682635209736" WEIGHT="16.124524709633437"/>
<DICH_DATA CI_END="0.9198863427463435" CI_START="0.6759803252857459" EFFECT_SIZE="0.7885588558855886" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="135" LOG_CI_END="-0.03626582892332099" LOG_CI_START="-0.1700659442124763" LOG_EFFECT_SIZE="-0.10316588656789863" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2279" O_E="0.0" SE="0.07859485004210232" STUDY_ID="STD-Kinon-2006a" TOTAL_1="202" TOTAL_2="192" VAR="0.006177150453140551" WEIGHT="20.983775248414098"/>
<DICH_DATA CI_END="0.9015375616105545" CI_START="0.7260289009837011" EFFECT_SIZE="0.8090379008746356" ESTIMABLE="YES" EVENTS_1="216" EVENTS_2="147" LOG_CI_END="-0.04501617414361726" LOG_CI_START="-0.13904609102453364" LOG_EFFECT_SIZE="-0.09203113258407546" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2280" O_E="0.0" SE="0.055233638631445627" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="185" VAR="0.0030507548364691224" WEIGHT="42.48782472942333"/>
<DICH_DATA CI_END="1.006399258660428" CI_START="0.5726753838446533" EFFECT_SIZE="0.759170653907496" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="66" LOG_CI_END="0.002770308188828927" LOG_CI_START="-0.24209148440927547" LOG_EFFECT_SIZE="-0.11966058811022326" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2281" O_E="0.0" SE="0.1438330290575481" STUDY_ID="STD-Simpson-2004" TOTAL_1="133" TOTAL_2="136" VAR="0.020687940247869477" WEIGHT="6.265482944716518"/>
<DICH_DATA CI_END="1.0547890808500637" CI_START="0.7247055985821704" EFFECT_SIZE="0.8743063263041065" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="106" LOG_CI_END="0.023165625339154117" LOG_CI_START="-0.13983838360520556" LOG_EFFECT_SIZE="-0.058336379133025716" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2282" O_E="0.0" SE="0.09574936173677437" STUDY_ID="STD-Stroup-2006" TOTAL_1="68" TOTAL_2="137" VAR="0.009167940272999673" WEIGHT="14.13839236781263"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.505168150904376" CI_END="1.291268003564186" CI_START="0.6222866798174063" DF="4" EFFECT_SIZE="0.8964033013618412" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="117" I2="46.70339265459365" ID="CMP-006.03.02" LOG_CI_END="0.11101638974089903" LOG_CI_START="-0.20600949508448543" LOG_EFFECT_SIZE="-0.047496552671793216" MODIFIED="2009-09-15 15:41:47 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.11148171414005126" P_Z="0.5570154545772605" STUDIES="5" TAU2="0.07549328984675623" TOTAL_1="1016" TOTAL_2="921" WEIGHT="100.0" Z="0.5872803268275618">
<NAME>due to adverse events</NAME>
<DICH_DATA CI_END="1.1749085521513223" CI_START="0.49625765816192074" EFFECT_SIZE="0.7635819318481993" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="41" LOG_CI_END="0.07000406504041634" LOG_CI_START="-0.30429277822016104" LOG_EFFECT_SIZE="-0.11714435658987234" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2283" O_E="0.0" SE="0.21986381853051884" STUDY_ID="STD-Breier-2005" TOTAL_1="277" TOTAL_2="271" VAR="0.04834009869882092" WEIGHT="28.00444007311947"/>
<DICH_DATA CI_END="0.9931502688175817" CI_START="0.28527309114012744" EFFECT_SIZE="0.5322772277227723" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="25" LOG_CI_END="-0.0029850355117989613" LOG_CI_START="-0.5447391919619484" LOG_EFFECT_SIZE="-0.2738621137368737" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2284" O_E="0.0" SE="0.31822907322514254" STUDY_ID="STD-Kinon-2006a" TOTAL_1="202" TOTAL_2="192" VAR="0.10126974304573315" WEIGHT="19.618834616201497"/>
<DICH_DATA CI_END="1.8345102368381538" CI_START="0.8102370133797933" EFFECT_SIZE="1.2191751700680271" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="28" LOG_CI_END="0.26352013952610037" LOG_CI_START="-0.0913879211876916" LOG_EFFECT_SIZE="0.08606610916920437" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2285" O_E="0.0" SE="0.2084747516865156" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="185" VAR="0.04346172209075434" WEIGHT="29.15290959239013"/>
<DICH_DATA CI_END="2.7445696043290493" CI_START="0.09524458507807022" EFFECT_SIZE="0.5112781954887218" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4384742492887787" LOG_CI_START="-1.0211597058104775" LOG_EFFECT_SIZE="-0.29134272826084945" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2286" O_E="0.0" SE="0.8573962105299091" STUDY_ID="STD-Simpson-2004" TOTAL_1="133" TOTAL_2="136" VAR="0.7351282618310482" WEIGHT="4.2780563894436225"/>
<DICH_DATA CI_END="2.621505341310577" CI_START="0.7248565450259713" EFFECT_SIZE="1.3784829721362228" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" LOG_CI_END="0.4185507469245644" LOG_CI_START="-0.13974793531620788" LOG_EFFECT_SIZE="0.13940140580417823" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2287" O_E="0.0" SE="0.3279474095712778" STUDY_ID="STD-Stroup-2006" TOTAL_1="68" TOTAL_2="137" VAR="0.10754950344451146" WEIGHT="18.945759328845284"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7487595923140575" CI_END="0.7881891051505869" CI_START="0.5147701309515671" DF="4" EFFECT_SIZE="0.6369742607617408" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="178" I2="0.0" ID="CMP-006.03.03" LOG_CI_END="-0.10336957252253769" LOG_CI_START="-0.28838666056184237" LOG_EFFECT_SIZE="-0.19587811654219" MODIFIED="2009-09-15 15:41:57 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7818425314544183" P_Z="3.3241881514015695E-5" STUDIES="5" TAU2="0.0" TOTAL_1="1016" TOTAL_2="921" WEIGHT="100.00000000000001" Z="4.15003887317342">
<NAME>due to inefficacy</NAME>
<DICH_DATA CI_END="0.8873292147723358" CI_START="0.31517430670362606" EFFECT_SIZE="0.5288320811786515" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="37" LOG_CI_END="-0.05191521936515224" LOG_CI_START="-0.5014491938209611" LOG_EFFECT_SIZE="-0.27668220659305665" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2288" O_E="0.0" SE="0.26405848182440367" STUDY_ID="STD-Breier-2005" TOTAL_1="277" TOTAL_2="271" VAR="0.06972688182340893" WEIGHT="16.939424156435607"/>
<DICH_DATA CI_END="0.9829923439275423" CI_START="0.41803117210703805" EFFECT_SIZE="0.6410315450149666" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="43" LOG_CI_END="-0.007449864673428768" LOG_CI_START="-0.3787913321739804" LOG_EFFECT_SIZE="-0.1931205984237046" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2289" O_E="0.0" SE="0.2181278161797338" STUDY_ID="STD-Kinon-2006a" TOTAL_1="202" TOTAL_2="192" VAR="0.04757974419133974" WEIGHT="24.82428702353908"/>
<DICH_DATA CI_END="0.8675069355194023" CI_START="0.4158809891467635" EFFECT_SIZE="0.6006493506493507" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="44" LOG_CI_END="-0.06172704443822393" LOG_CI_START="-0.38103093175663694" LOG_EFFECT_SIZE="-0.22137898809743045" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2290" O_E="0.0" SE="0.18756068399056924" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="185" VAR="0.03517901017901018" WEIGHT="33.574941998144006"/>
<DICH_DATA CI_END="2.0497885971999503" CI_START="0.42863570064214157" EFFECT_SIZE="0.9373433583959899" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.3117090728587899" LOG_CI_START="-0.3679116598313261" LOG_EFFECT_SIZE="-0.028101293486268084" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2291" O_E="0.0" SE="0.3992125825590577" STUDY_ID="STD-Simpson-2004" TOTAL_1="133" TOTAL_2="136" VAR="0.15937068607347246" WEIGHT="7.411232613806171"/>
<DICH_DATA CI_END="1.2016757180001714" CI_START="0.43084391208135947" EFFECT_SIZE="0.7195378151260504" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="42" LOG_CI_END="0.07978728556690091" LOG_CI_START="-0.36568003935099846" LOG_EFFECT_SIZE="-0.14294637689204875" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2292" O_E="0.0" SE="0.2616697117555958" STUDY_ID="STD-Stroup-2006" TOTAL_1="68" TOTAL_2="137" VAR="0.06847103805025659" WEIGHT="17.250114208075132"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8673486043986435" CI_START="0.6207373622121259" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.733754512635379" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="160" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="-0.06180631597486528" LOG_CI_START="-0.20709211362182026" LOG_EFFECT_SIZE="-0.13444921479834276" METHOD="MH" MODIFIED="2009-09-18 14:29:55 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="2.8612534388345673E-4" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="277" TOTAL_2="271" WEIGHT="100.0" Z="3.627548225942709">
<NAME>Mental state: 1a. General - no clinically important change - long term (less than 30% PANSS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8673486043986435" CI_START="0.6207373622121259" EFFECT_SIZE="0.733754512635379" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="160" LOG_CI_END="-0.06180631597486528" LOG_CI_START="-0.20709211362182026" LOG_EFFECT_SIZE="-0.13444921479834276" MODIFIED="2009-09-18 14:29:55 +0100" MODIFIED_BY="[Empty name]" ORDER="930" O_E="0.0" SE="0.08534159671411845" STUDY_ID="STD-Breier-2005" TOTAL_1="277" TOTAL_2="271" VAR="0.007283188129715233" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0647638297263795" CI_START="0.8279014103447981" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9388926862611073" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="110" I2="0.0" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="0.027253289633175026" LOG_CI_START="-0.08202137757807651" LOG_EFFECT_SIZE="-0.027384043972450735" METHOD="MH" MODIFIED="2009-09-18 14:30:02 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.32593868229575984" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="136" WEIGHT="100.0" Z="0.9823272183168587">
<NAME>Mental state: 1b. General - no clinically important change - short term (less than 40% BPRS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0647638297263795" CI_START="0.8279014103447981" EFFECT_SIZE="0.9388926862611073" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="110" LOG_CI_END="0.027253289633175026" LOG_CI_START="-0.08202137757807651" LOG_EFFECT_SIZE="-0.027384043972450735" MODIFIED="2009-09-18 14:30:02 +0100" MODIFIED_BY="[Empty name]" ORDER="931" O_E="0.0" SE="0.06418848043821569" STUDY_ID="STD-Simpson-2004" TOTAL_1="133" TOTAL_2="136" VAR="0.004120161020967199" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.6588217876124229" CI_END="-5.644615541437438" CI_START="-10.99351071962763" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.319063130532534" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.06" MODIFIED="2009-09-16 12:42:17 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.8828440293894123" P_Q="0.8365123330703385" P_Z="1.0834135464808386E-9" Q="0.35702812224983776" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="688" TOTAL_2="603" UNITS="" WEIGHT="100.00000000000001" Z="6.096610076578711">
<NAME>Mental state: 1c. General - average endpoint score (PANSS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.0009832528081173" CI_START="-18.740983252808114" DF="0" EFFECT_SIZE="-8.369999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-006.06.01" MODIFIED="2009-09-15 15:53:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.1136935342622551" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="6.650102159896471" Z="1.5818074478288595">
<NAME>short term</NAME>
<CONT_DATA CI_END="2.0009832528081155" CI_START="-18.74098325280811" EFFECT_SIZE="-8.369999999999997" ESTIMABLE="YES" MEAN_1="51.92" MEAN_2="60.29" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2297" SD_1="18.33" SD_2="18.33" SE="5.291415217122919" STUDY_ID="STD-Svestka-2005" TOTAL_1="24" TOTAL_2="24" WEIGHT="6.650102159896471"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.06760217469525998" CI_START="-13.067602174695258" DF="0" EFFECT_SIZE="-6.499999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-006.06.02" MODIFIED="2009-09-15 15:53:27 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.05240527426518377" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="135" WEIGHT="16.582671861170372" Z="1.939789524492854">
<NAME>medium term</NAME>
<CONT_DATA CI_END="0.06760217469525998" CI_START="-13.067602174695258" EFFECT_SIZE="-6.499999999999999" ESTIMABLE="YES" MEAN_1="-8.2" MEAN_2="-1.7" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2298" SD_1="22.31" SD_2="22.31" SE="3.350879009257143" STUDY_ID="STD-Stroup-2006" TOTAL_1="66" TOTAL_2="135" WEIGHT="16.582671861170372"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.3017936653625852" CI_END="-5.655157608114122" CI_START="-11.760023997138989" DF="1" EFFECT_SIZE="-8.707590802626555" ESTIMABLE="YES" I2="0.0" ID="CMP-006.06.03" MODIFIED="2009-09-15 15:53:31 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5827602256060537" P_Z="2.2559082005320522E-8" STUDIES="2" TAU2="0.0" TOTAL_1="598" TOTAL_2="444" WEIGHT="76.76722597893317" Z="5.591134441842001">
<NAME>long term</NAME>
<CONT_DATA CI_END="-5.025216817504835" CI_START="-14.374783182495172" EFFECT_SIZE="-9.700000000000003" ESTIMABLE="YES" MEAN_1="-35.7" MEAN_2="-26.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2299" SD_1="26.5" SD_2="28.3" SE="2.385137287914095" STUDY_ID="STD-Breier-2005" TOTAL_1="268" TOTAL_2="261" WEIGHT="32.729942095500206"/>
<CONT_DATA CI_END="-3.939825701716341" CI_START="-12.000174298283659" EFFECT_SIZE="-7.97" ESTIMABLE="YES" MEAN_1="-11.27" MEAN_2="-3.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2300" SD_1="22.31" SD_2="22.31" SE="2.056249160736197" STUDY_ID="STD-Lieberman-2005" TOTAL_1="330" TOTAL_2="183" WEIGHT="44.037283883432956"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.8476686810170233" CI_START="-3.8476686810170233" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.07" MODIFIED="2009-09-15 15:54:25 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.7697242128767854" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="126" TOTAL_2="125" UNITS="" WEIGHT="100.0" Z="0.2927356574523104">
<NAME>Mental state: 1d. General - average endpoint score - short term (BPRS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.8476686810170233" CI_START="-3.8476686810170233" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-11.95" MEAN_2="-11.45" MODIFIED="2009-09-15 15:54:25 +0100" MODIFIED_BY="[Empty name]" ORDER="1374" SD_1="13.53" SD_2="13.53" SE="1.708025610380092" STUDY_ID="STD-Simpson-2004" TOTAL_1="126" TOTAL_2="125" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.28307811812891015" CI_END="-1.9260748119775293" CI_START="-4.30162061340871" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.11384771269312" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.08" MODIFIED="2009-09-15 15:56:14 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.5946908359090073" P_Q="0.5946908359090073" P_Z="2.7736437609926155E-7" Q="0.28307811812891015" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="334" TOTAL_2="396" UNITS="" WEIGHT="100.0" Z="5.138212335492825">
<NAME>Mental state: 2. Positive symptoms - average endpoint score (PANSS positive, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.4510311127173736" CI_START="-5.748968887282627" DF="0" EFFECT_SIZE="-3.6" ESTIMABLE="YES" I2="0.0" ID="CMP-006.08.01" MODIFIED="2009-09-15 15:56:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.001025721856229936" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="135" WEIGHT="30.549673241874178" Z="3.283374825061498">
<NAME>medium term</NAME>
<CONT_DATA CI_END="-1.4510311127173736" CI_START="-5.748968887282627" EFFECT_SIZE="-3.6" ESTIMABLE="YES" MEAN_1="-3.4" MEAN_2="0.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2303" SD_1="7.3" SD_2="7.3" SE="1.0964328448039957" STUDY_ID="STD-Stroup-2006" TOTAL_1="66" TOTAL_2="135" WEIGHT="30.549673241874178"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.4747328817146013" CI_START="-4.3252671182853994" DF="0" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-006.08.02" MODIFIED="2009-09-15 15:56:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="6.664639957515337E-5" STUDIES="1" TAU2="0.0" TOTAL_1="268" TOTAL_2="261" WEIGHT="69.45032675812583" Z="3.987951088076671">
<NAME>long term</NAME>
<CONT_DATA CI_END="-1.4747328817146013" CI_START="-4.3252671182853994" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="-10.5" MEAN_2="-7.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2304" SD_1="8.0" SD_2="8.7" SE="0.727190463461433" STUDY_ID="STD-Breier-2005" TOTAL_1="268" TOTAL_2="261" WEIGHT="69.45032675812583"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.458722696458569" CI_END="2.4503667647031397" CI_START="-3.813375246458418" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6815042408776392" ESTIMABLE="YES" I2="86.59287869121607" I2_Q="86.59287869121607" ID="CMP-006.09" MODIFIED="2009-09-15 15:57:24 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.006313018721630481" P_Q="0.006313018721630481" P_Z="0.6697480192134999" Q="7.458722696458569" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="4.433555388990264" TOTALS="YES" TOTAL_1="334" TOTAL_2="396" UNITS="" WEIGHT="99.99999999999999" Z="0.42649386422726693">
<NAME>Mental state: 3. Negative symptoms - average endpoint score (PANSS negative, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.3012240887082851E-32" CI_END="2.907577861587866" CI_START="-0.9075778615878662" DF="0" EFFECT_SIZE="0.9999999999999998" ESTIMABLE="YES" I2="100.0" ID="CMP-006.09.01" MODIFIED="2009-09-15 15:57:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.30420293018215727" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="135" WEIGHT="47.452992472573776" Z="1.027462115181281">
<NAME>medium term</NAME>
<CONT_DATA CI_END="2.907577861587866" CI_START="-0.9075778615878661" EFFECT_SIZE="0.9999999999999999" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-1.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2305" SD_1="6.48" SD_2="6.48" SE="0.9732718951136841" STUDY_ID="STD-Stroup-2006" TOTAL_1="66" TOTAL_2="135" WEIGHT="47.452992472573776"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.9213115650235706" CI_START="-3.47868843497643" DF="0" EFFECT_SIZE="-2.2" ESTIMABLE="YES" I2="0.0" ID="CMP-006.09.02" MODIFIED="2009-09-15 15:57:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="7.458560339923234E-4" STUDIES="1" TAU2="0.0" TOTAL_1="268" TOTAL_2="261" WEIGHT="52.54700752742621" Z="3.372143399472916">
<NAME>long term</NAME>
<CONT_DATA CI_END="-0.9213115650235706" CI_START="-3.47868843497643" EFFECT_SIZE="-2.2" ESTIMABLE="YES" MEAN_1="-8.5" MEAN_2="-6.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2306" SD_1="7.4" SD_2="7.6" SE="0.6524040467388996" STUDY_ID="STD-Breier-2005" TOTAL_1="268" TOTAL_2="261" WEIGHT="52.54700752742621"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9755929715140556" CI_START="0.7074073556597388" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8307476416933032" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="127" I2="0.0" I2_Q="0.0" ID="CMP-006.10" LOG_CI_END="-0.01073133714434343" LOG_CI_START="-0.15033042868040372" LOG_EFFECT_SIZE="-0.08053088291237359" METHOD="MH" MODIFIED="2009-09-18 14:30:25 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.023740759556657845" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="202" TOTAL_2="192" WEIGHT="100.0" Z="2.261298815267616">
<NAME>General functioning: 1a. General - no clinically important change - medium term (less than 5 points improvement on GAF total score)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9755929715140556" CI_START="0.7074073556597388" EFFECT_SIZE="0.8307476416933032" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="127" LOG_CI_END="-0.01073133714434343" LOG_CI_START="-0.15033042868040372" LOG_EFFECT_SIZE="-0.08053088291237359" MODIFIED="2009-09-18 14:30:25 +0100" MODIFIED_BY="[Empty name]" ORDER="932" O_E="0.0" SE="0.08200119739492966" STUDY_ID="STD-Kinon-2006a" TOTAL_1="202" TOTAL_2="192" VAR="0.006724196374202219" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.6380728161352747" CI_START="-6.341927183864724" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.4899999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.11" MODIFIED="2009-09-15 15:59:33 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.016463527812802886" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="168" TOTAL_2="158" UNITS="" WEIGHT="100.0" Z="2.398474387685924">
<NAME>General functioning: 1b. General - average endpoint score - medium term (GAF total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.6380728161352747" CI_START="-6.341927183864724" EFFECT_SIZE="-3.4899999999999998" ESTIMABLE="YES" MEAN_1="-6.64" MEAN_2="-3.15" MODIFIED="2009-09-15 15:59:33 +0100" MODIFIED_BY="[Empty name]" ORDER="1375" SD_1="13.13" SD_2="13.13" SE="1.4550916273770145" STUDY_ID="STD-Kinon-2006a" TOTAL_1="168" TOTAL_2="158" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.1391621265264625E-32" CI_END="1.2126003986618774" CI_START="-8.612600398661876" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.699999999999999" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-006.12" MODIFIED="2009-09-15 16:00:49 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="1.0" P_Z="0.1398964355656598" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="200" TOTAL_2="193" UNITS="" WEIGHT="100.0" Z="1.4761768013481222">
<NAME>Quality of life: General - average endpoint score - long term (QLS total, Heinrichs-Carpenter, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.212600398661877" CI_START="-8.612600398661876" EFFECT_SIZE="-3.6999999999999993" ESTIMABLE="YES" MEAN_1="-14.6" MEAN_2="-10.9" MODIFIED="2009-09-15 16:00:49 +0100" MODIFIED_BY="[Empty name]" ORDER="1376" SD_1="24.16" SD_2="25.48" SE="2.5064748318907086" STUDY_ID="STD-Breier-2005" TOTAL_1="200" TOTAL_2="193" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.1710439793693936" CI_START="-3.6289560206306053" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.3999999999999995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.13" MODIFIED="2009-09-15 16:02:32 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="1.2941528442744733E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="268" TOTAL_2="261" UNITS="" WEIGHT="100.0" Z="3.827568671238896">
<NAME>Cognitive functioning: General - average endpoint score - long term(PANSS cognitive subscore, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.1710439793693936" CI_START="-3.6289560206306053" EFFECT_SIZE="-2.3999999999999995" ESTIMABLE="YES" MEAN_1="-8.2" MEAN_2="-5.8" MODIFIED="2009-09-15 16:02:32 +0100" MODIFIED_BY="[Empty name]" ORDER="1377" SD_1="6.9" SD_2="7.5" SE="0.6270298996943077" STUDY_ID="STD-Breier-2005" TOTAL_1="268" TOTAL_2="261" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.08392428011489866" CI_END="-0.007928198821700184" CI_START="-0.11109973902832943" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.0595139689250148" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-006.14" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-17 14:17:03 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.7720481580106893" P_Q="0.0" P_Z="0.023747484277625453" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="444" TOTAL_2="322" WEIGHT="99.99999999999999" Z="2.2611901583799368">
<NAME>Service use - number of patients re-hospitalised</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.035924321818464944" CI_START="-0.13486998280792156" DF="0" EFFECT_SIZE="-0.04947283049472831" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" I2="0.0" ID="CMP-006.14.01" LOG_CI_END="-1.4446114217540282" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-09-15 16:02:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.25618306608884955" STUDIES="1" TAU2="0.0" TOTAL_1="108" TOTAL_2="137" WEIGHT="36.48993242595375" Z="1.135459009538214">
<NAME>medium term</NAME>
<DICH_DATA CI_END="0.035924321818464944" CI_START="-0.13486998280792156" EFFECT_SIZE="-0.04947283049472831" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2311" O_E="0.0" SE="0.04357077629323553" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="137" VAR="0.0018984125467951755" WEIGHT="36.48993242595375"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="-5.526895796784531E-4" CI_START="-0.13001359098660215" DF="0" EFFECT_SIZE="-0.06528314028314029" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="33" I2="0.0" ID="CMP-006.14.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-09-15 16:02:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.04807568737527422" STUDIES="1" TAU2="0.0" TOTAL_1="336" TOTAL_2="185" WEIGHT="63.51006757404624" Z="1.9766987926408486">
<NAME>long term</NAME>
<DICH_DATA CI_END="-5.526895796784531E-4" CI_START="-0.13001359098660215" EFFECT_SIZE="-0.06528314028314029" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="33" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2312" O_E="0.0" SE="0.03302634702170416" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="185" VAR="0.0010907395975980271" WEIGHT="63.51006757404624"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.813199326459232" CI_END="1.06737285084724" CI_START="0.8461256851307799" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9503323548701869" ESTIMABLE="YES" EVENTS_1="567" EVENTS_2="490" I2="61.60343702175158" I2_Q="0.0" ID="CMP-006.15" LOG_CI_END="0.02831615211457802" LOG_CI_START="-0.07256512123459156" LOG_EFFECT_SIZE="-0.02212448456000675" METHOD="MH" MODIFIED="2009-09-15 16:05:14 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.05003434541524654" P_Q="0.0" P_Z="0.3899612476370924" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.00782518221475946" TOTALS="YES" TOTAL_1="854" TOTAL_2="729" WEIGHT="100.00000000000001" Z="0.8596876600484085">
<NAME>Adverse effects: 1. General - at least one adverse effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0210666524366847" CI_START="0.8533724807352638" EFFECT_SIZE="0.933461398337363" ESTIMABLE="YES" EVENTS_1="208" EVENTS_2="218" LOG_CI_END="0.009054092567472" LOG_CI_START="-0.0688613662312442" LOG_EFFECT_SIZE="-0.029903636831886102" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2313" O_E="0.0" SE="0.04576792618610722" STUDY_ID="STD-Breier-2005" TOTAL_1="277" TOTAL_2="271" VAR="0.0020947030673769593" WEIGHT="35.39889170063151"/>
<DICH_DATA CI_END="1.2360084568000684" CI_START="0.9565006325470355" EFFECT_SIZE="1.0873099239695878" ESTIMABLE="YES" EVENTS_1="235" EVENTS_2="119" LOG_CI_END="0.09202144221642143" LOG_CI_START="-0.019314738431670968" LOG_EFFECT_SIZE="0.03635335189237525" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2314" O_E="0.0" SE="0.06539942363567208" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="185" VAR="0.004277084611878104" WEIGHT="29.015468739470705"/>
<DICH_DATA CI_END="0.9612915233074494" CI_START="0.7422854571924938" EFFECT_SIZE="0.84472049689441" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="115" LOG_CI_END="-0.01714488729057819" LOG_CI_START="-0.12942904803268615" LOG_EFFECT_SIZE="-0.07328696766163217" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2315" O_E="0.0" SE="0.06595627183547396" STUDY_ID="STD-Simpson-2004" TOTAL_1="133" TOTAL_2="136" VAR="0.004350229794434937" WEIGHT="28.84115498677651"/>
<DICH_DATA CI_END="1.461999028423417" CI_START="0.6410255528302196" EFFECT_SIZE="0.9680799220272904" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="38" LOG_CI_END="0.16494708401001612" LOG_CI_START="-0.1931246581068101" LOG_EFFECT_SIZE="-0.014088787048397012" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2316" O_E="0.0" SE="0.2103331138031335" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="137" VAR="0.044240018762121906" WEIGHT="6.744484573121285"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5683968698817953" CI_END="4.087548978032057" CI_START="0.09567953358382598" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6253757108484082" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-006.16" LOG_CI_END="0.6114629695243963" LOG_CI_START="-1.019180950438277" LOG_EFFECT_SIZE="-0.2038589904569403" METHOD="MH" MODIFIED="2009-09-15 16:05:41 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.4508967791064453" P_Q="0.0" P_Z="0.6240917913101673" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="444" TOTAL_2="322" WEIGHT="200.0" Z="0.4900595087975353">
<NAME>Adverse effects: 2. Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.062865162329269" CI_START="0.10052507829064204" DF="0" EFFECT_SIZE="1.1011904761904763" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-006.16.01" LOG_CI_END="1.0814504733432868" LOG_CI_START="-0.9977255799889848" LOG_EFFECT_SIZE="0.04186244667715098" MODIFIED="2009-09-15 16:05:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9370927350770851" STUDIES="1" TAU2="0.0" TOTAL_1="336" TOTAL_2="185" WEIGHT="100.0" Z="0.07892442552947412">
<NAME>suicide attempt</NAME>
<DICH_DATA CI_END="12.062865162329269" CI_START="0.10052507829064204" EFFECT_SIZE="1.1011904761904763" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0814504733432868" LOG_CI_START="-0.9977255799889848" LOG_EFFECT_SIZE="0.04186244667715098" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2329" O_E="0.0" SE="1.221318305814829" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="185" VAR="1.4916184041184042" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.21962668270154" CI_START="0.012283601695033263" DF="0" EFFECT_SIZE="0.25321100917431194" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-006.16.02" LOG_CI_END="0.71763944257305" LOG_CI_START="-1.9106742743238618" LOG_EFFECT_SIZE="-0.5965174158754059" MODIFIED="2009-09-15 16:05:41 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3736485450269994" STUDIES="1" TAU2="0.0" TOTAL_1="108" TOTAL_2="137" WEIGHT="100.0" Z="0.8896598939087406">
<NAME>suicide</NAME>
<DICH_DATA CI_END="5.21962668270154" CI_START="0.012283601695033263" EFFECT_SIZE="0.25321100917431194" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.71763944257305" LOG_CI_START="-1.9106742743238618" LOG_EFFECT_SIZE="-0.5965174158754059" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2330" O_E="0.0" SE="1.5438844876679731" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="137" VAR="2.3835793112618" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.8854229070886053" CI_END="9.930739557986412" CI_START="0.040518020909066615" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6343294988040431" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="65.34303524300356" I2_Q="0.0" ID="CMP-006.17" LOG_CI_END="0.9969815923012859" LOG_CI_START="-1.392351775781215" LOG_EFFECT_SIZE="-0.1976850917399644" METHOD="MH" MODIFIED="2009-09-15 16:05:49 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.08938466641347809" P_Q="0.0" P_Z="0.7456949175368597" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="2.716420666895665" TOTALS="YES" TOTAL_1="671" TOTAL_2="513" WEIGHT="100.00000000000001" Z="0.32432113933249057">
<NAME>Adverse effects: 3a. Cardiac effects - QTc prolongation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.49418413225153" CI_START="0.48220904274044885" EFFECT_SIZE="1.900990099009901" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8747243595128323" LOG_CI_START="-0.3167646496710185" LOG_EFFECT_SIZE="0.278979854920907" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2317" O_E="0.0" SE="0.6998865419603106" STUDY_ID="STD-Kinon-2006a" TOTAL_1="202" TOTAL_2="192" VAR="0.48984117161716173" WEIGHT="61.43695951340516"/>
<DICH_DATA CI_END="2.2871496790017916" CI_START="0.005327598534073333" EFFECT_SIZE="0.11038575667655787" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.35929458727287" LOG_CI_START="-2.273468509251752" LOG_EFFECT_SIZE="-0.9570869609894411" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2318" O_E="0.0" SE="1.5464980752860746" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="185" VAR="2.391656296863533" WEIGHT="38.56304048659486"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2319" O_E="0.0" SE="0.0" STUDY_ID="STD-Simpson-2004" TOTAL_1="133" TOTAL_2="136" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.6830447596230464" CI_END="0.5786091730136826" CI_START="-4.962046211832247" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.191718519409282" ESTIMABLE="YES" I2="18.54565459293943" I2_Q="0.0" ID="CMP-006.18" MODIFIED="2009-09-15 16:05:55 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.29778642374946707" P_Q="1.0" P_Z="0.12099590656930999" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="1.600810830105687" TOTALS="YES" TOTAL_1="723" TOTAL_2="649" UNITS="" WEIGHT="100.0" Z="1.5506069459005332">
<NAME>Adverse effects: 3b. Cardiac effects - QTc abnormalities - change from baseline in ms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.33535490664879" CI_START="-3.875354906648791" EFFECT_SIZE="-0.7700000000000005" ESTIMABLE="YES" MEAN_1="4.81" MEAN_2="5.58" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2320" SD_1="18.46" SD_2="17.98" SE="1.5843938618992153" STUDY_ID="STD-Breier-2005" TOTAL_1="270" TOTAL_2="259" WEIGHT="48.59666950223645"/>
<CONT_DATA CI_END="5.479193785646073" CI_START="-5.679193785646074" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2321" SD_1="27.4" SD_2="26.8" SE="2.84657974822703" STUDY_ID="STD-Lieberman-2005" TOTAL_1="231" TOTAL_2="148" WEIGHT="20.588421699518978"/>
<CONT_DATA CI_END="-0.02436417350242248" CI_START="-11.095635826497578" EFFECT_SIZE="-5.5600000000000005" ESTIMABLE="YES" MEAN_1="0.52" MEAN_2="6.08" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2322" SD_1="23.16" SD_2="23.16" SE="2.824355891313293" STUDY_ID="STD-Simpson-2004" TOTAL_1="133" TOTAL_2="136" WEIGHT="20.859335779179826"/>
<CONT_DATA CI_END="2.022600094545271" CI_START="-14.822600094545269" EFFECT_SIZE="-6.3999999999999995" ESTIMABLE="YES" MEAN_1="-5.1" MEAN_2="1.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2323" SD_1="33.0" SD_2="25.7" SE="4.297323910531859" STUDY_ID="STD-Stroup-2006" TOTAL_1="89" TOTAL_2="106" WEIGHT="9.95557301906474"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.6950603271153852" CI_END="2.5489270904325707" CI_START="0.9587307240634081" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5632449312232726" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="63" I2="62.89507919585852" I2_Q="0.0" ID="CMP-006.19" LOG_CI_END="0.40635741307787077" LOG_CI_START="-0.018303354742625216" LOG_EFFECT_SIZE="0.19402702916762274" METHOD="MH" MODIFIED="2009-09-15 16:08:29 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.1006597447515688" P_Q="0.0" P_Z="0.07329157820468381" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.08118183826718221" TOTALS="YES" TOTAL_1="444" TOTAL_2="322" WEIGHT="100.00000000000001" Z="1.7910106984810523">
<NAME>Adverse effects: 4. Central nervous system - sedation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.717978868607921" CI_START="0.9425160086316197" EFFECT_SIZE="1.2724867724867726" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="45" LOG_CI_END="0.23501781764224597" LOG_CI_START="-0.025711264569033037" LOG_EFFECT_SIZE="0.10465327653660646" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2361" O_E="0.0" SE="0.15315355352067725" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="185" VAR="0.023456010956010954" WEIGHT="59.46626761445552"/>
<DICH_DATA CI_END="3.5815440189715515" CI_START="1.2480179430534522" EFFECT_SIZE="2.1141975308641974" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="18" LOG_CI_END="0.5540702932243526" LOG_CI_START="0.09622082934727431" LOG_EFFECT_SIZE="0.3251455612858134" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2362" O_E="0.0" SE="0.26894304147279385" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="137" VAR="0.07233035955663691" WEIGHT="40.533732385544496"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.094071733303661" CI_END="0.8806139483284541" CI_START="0.5101246663375518" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6702409242677194" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="194" I2="33.85188895506335" I2_Q="0.0" ID="CMP-006.20" LOG_CI_END="-0.05521443989159146" LOG_CI_START="-0.29232367628200506" LOG_EFFECT_SIZE="-0.17376905808679827" METHOD="MH" MODIFIED="2009-09-15 16:08:54 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.14705584549812123" P_Q="0.0" P_Z="0.004068799593162712" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.056150519749284464" TOTALS="SUB" TOTAL_1="2054" TOTAL_2="1785" WEIGHT="400.0" Z="2.872777970713781">
<NAME>Adverse effects: 5a. Extrapyramidal effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8850891915666201" CI_END="1.2809082647353653" CI_START="0.39542342012915593" DF="1" EFFECT_SIZE="0.7116889256644088" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="21" I2="0.0" ID="CMP-006.20.01" LOG_CI_END="0.10751802783538518" LOG_CI_START="-0.40293761187707294" LOG_EFFECT_SIZE="-0.14770979202084392" MODIFIED="2009-09-15 16:08:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.34681167591787543" P_Z="0.25666717658163807" STUDIES="2" TAU2="0.0" TOTAL_1="444" TOTAL_2="322" WEIGHT="100.0" Z="1.1343037474826834">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="1.1949852675833679" CI_START="0.2912250963882338" EFFECT_SIZE="0.5899234693877551" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.07736255110282718" LOG_CI_START="-0.5357712023216012" LOG_EFFECT_SIZE="-0.22920432560938703" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2331" O_E="0.0" SE="0.36015780182253754" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="185" VAR="0.12971364221364223" WEIGHT="69.3115423225924"/>
<DICH_DATA CI_END="3.141041278604648" CI_START="0.37637988071068385" EFFECT_SIZE="1.0873015873015872" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.49707364380137736" LOG_CI_START="-0.4243735997236896" LOG_EFFECT_SIZE="0.036350022038843834" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2332" O_E="0.0" SE="0.5412626720840424" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="137" VAR="0.2929652801915576" WEIGHT="30.68845767740759"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.329511148201813" CI_START="0.004260587886752473" DF="0" EFFECT_SIZE="0.07526286662977312" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" I2="0.0" ID="CMP-006.20.02" LOG_CI_END="0.12369198332402177" LOG_CI_START="-2.3705304717054503" LOG_EFFECT_SIZE="-1.1234192441907143" MODIFIED="2009-09-15 16:08:44 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.07746813953711003" STUDIES="1" TAU2="0.0" TOTAL_1="277" TOTAL_2="271" WEIGHT="100.0" Z="1.76556926886218">
<NAME>dystonia</NAME>
<DICH_DATA CI_END="1.329511148201813" CI_START="0.004260587886752473" EFFECT_SIZE="0.0752628666297731" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.12369198332402177" LOG_CI_START="-2.3705304717054503" LOG_EFFECT_SIZE="-1.1234192441907143" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2333" O_E="0.0" SE="1.4651186166845878" STUDY_ID="STD-Breier-2005" TOTAL_1="277" TOTAL_2="271" VAR="2.14657256095576" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7943524818796286" CI_END="1.3067566303245717" CI_START="0.2115001977421924" DF="1" EFFECT_SIZE="0.5257178765408002" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="36" I2="44.269589721163634" ID="CMP-006.20.03" LOG_CI_END="0.11619471233287947" LOG_CI_START="-0.6746892222449538" LOG_EFFECT_SIZE="-0.2792472549560371" MODIFIED="2009-09-15 16:08:48 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.18039689477313503" P_Z="0.16634073915731257" STUDIES="2" TAU2="0.21516336663978108" TOTAL_1="385" TOTAL_2="408" WEIGHT="100.0" Z="1.3840578587240076">
<NAME>extrapyramidal symptoms</NAME>
<DICH_DATA CI_END="0.7218041621234229" CI_START="0.19870041128829874" EFFECT_SIZE="0.37871200652148596" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="31" LOG_CI_END="-0.14158061800659746" LOG_CI_START="-0.701801233946784" LOG_EFFECT_SIZE="-0.42169092597669067" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2334" O_E="0.0" SE="0.329076362940039" STUDY_ID="STD-Breier-2005" TOTAL_1="277" TOTAL_2="271" VAR="0.10829125264584426" WEIGHT="66.724811214814"/>
<DICH_DATA CI_END="3.68795965732475" CI_START="0.2792463052903026" EFFECT_SIZE="1.0148148148148148" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.5667861616502807" LOG_CI_START="-0.5540125643274794" LOG_EFFECT_SIZE="0.006386798661400661" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2335" O_E="0.0" SE="0.6583627196825076" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="137" VAR="0.4334414706677481" WEIGHT="33.275188785186"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.280271148666415" CI_END="0.9718358204977939" CI_START="0.5025429165903346" DF="3" EFFECT_SIZE="0.6988484869268319" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="131" I2="43.18473586801163" ID="CMP-006.20.04" LOG_CI_END="-0.012407097495867648" LOG_CI_START="-0.29882684407167037" LOG_EFFECT_SIZE="-0.15561697078376896" MODIFIED="2009-09-15 16:08:54 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.1523877573167879" P_Z="0.033190856758251994" STUDIES="4" TAU2="0.048629962704337684" TOTAL_1="948" TOTAL_2="784" WEIGHT="100.0" Z="2.129766971486989">
<NAME>use of antiparkinson medication</NAME>
<DICH_DATA CI_END="0.7723072333962333" CI_START="0.28102849118582957" EFFECT_SIZE="0.46587588103833594" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="42" LOG_CI_END="-0.1122098975591964" LOG_CI_START="-0.5512496482887277" LOG_EFFECT_SIZE="-0.33172977292396205" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2336" O_E="0.0" SE="0.257894122860343" STUDY_ID="STD-Breier-2005" TOTAL_1="277" TOTAL_2="271" VAR="0.06650937860590571" WEIGHT="24.584273324442012"/>
<DICH_DATA CI_END="1.307225185863868" CI_START="0.5936750419899594" EFFECT_SIZE="0.8809466312484907" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="41" LOG_CI_END="0.11635040667329205" LOG_CI_START="-0.2264512083652911" LOG_EFFECT_SIZE="-0.05505040084599949" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2337" O_E="0.0" SE="0.20136336556902537" STUDY_ID="STD-Kinon-2006a" TOTAL_1="202" TOTAL_2="192" VAR="0.04054720499328495" WEIGHT="31.74149964893651"/>
<DICH_DATA CI_END="1.8445398487392293" CI_START="0.5240838852217374" EFFECT_SIZE="0.9832057823129252" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="14" LOG_CI_END="0.2658880419974222" LOG_CI_START="-0.2805991939834836" LOG_EFFECT_SIZE="-0.007355575993030644" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2338" O_E="0.0" SE="0.32100930757063034" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="185" VAR="0.10304697554697555" WEIGHT="18.662145147452787"/>
<DICH_DATA CI_END="0.9896549311612468" CI_START="0.36558881401822063" EFFECT_SIZE="0.6015037593984962" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="34" LOG_CI_END="-0.004516207034831663" LOG_CI_START="-0.4370071009154528" LOG_EFFECT_SIZE="-0.22076165397514222" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2339" O_E="0.0" SE="0.254047291929929" STUDY_ID="STD-Simpson-2004" TOTAL_1="133" TOTAL_2="136" VAR="0.06454002653693056" WEIGHT="25.01208187916869"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.2706985123210663" CI_END="0.00985055149675608" CI_START="-0.1890351390882199" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.08959229379573191" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.21" MODIFIED="2009-09-15 16:09:24 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.7741842846929644" P_Q="0.6273834609368674" P_Z="0.0774268889918198" Q="1.7431509157918028" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1547" TOTAL_2="1493" UNITS="" WEIGHT="400.0" Z="1.7658150127893688">
<NAME>Adverse effects: 5b. Extrapyramidal symptoms scales</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.5719841399556892" CI_END="0.1504429362780875" CI_START="-0.46227322950249405" DF="1" EFFECT_SIZE="-0.15591514661220326" ESTIMABLE="YES" I2="0.0" ID="CMP-006.21.01" MODIFIED="2009-09-15 16:09:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4494716696604615" P_Z="0.31852840477599864" STUDIES="2" TAU2="0.0" TOTAL_1="472" TOTAL_2="453" WEIGHT="100.0" Z="0.9974865657898575">
<NAME>abnormal involuntary movement: AIMS (high=poor)</NAME>
<CONT_DATA CI_END="0.28408852306943294" CI_START="-0.44408852306943297" EFFECT_SIZE="-0.08000000000000002" ESTIMABLE="YES" MEAN_1="-0.53" MEAN_2="-0.45" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2340" SD_1="2.14" SD_2="2.14" SE="0.185762863981847" STUDY_ID="STD-Breier-2005" TOTAL_1="270" TOTAL_2="261" WEIGHT="70.80186668761414"/>
<CONT_DATA CI_END="0.22695919039591333" CI_START="-0.9069591903959133" EFFECT_SIZE="-0.34" ESTIMABLE="YES" MEAN_1="-0.68" MEAN_2="-0.34" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2341" SD_1="2.87" SD_2="2.87" SE="0.289270208467102" STUDY_ID="STD-Kinon-2006a" TOTAL_1="202" TOTAL_2="192" WEIGHT="29.19813331238587"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.9555634565735744" CI_END="0.043067739884729006" CI_START="-0.1736058646024361" DF="1" EFFECT_SIZE="-0.06526906235885355" ESTIMABLE="YES" I2="0.0" ID="CMP-006.21.02" MODIFIED="2009-09-15 16:09:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.328307382546943" P_Z="0.23767884743744283" STUDIES="2" TAU2="0.0" TOTAL_1="472" TOTAL_2="452" WEIGHT="100.00000000000001" Z="1.180808449934008">
<NAME>akathisia: Barnes Akathisia Scale (high=poor)</NAME>
<CONT_DATA CI_END="0.030643176999865573" CI_START="-0.25064317699986555" EFFECT_SIZE="-0.10999999999999999" ESTIMABLE="YES" MEAN_1="-0.21" MEAN_2="-0.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2342" SD_1="0.8" SD_2="0.85" SE="0.07175804152996738" STUDY_ID="STD-Breier-2005" TOTAL_1="270" TOTAL_2="260" WEIGHT="59.33551123532141"/>
<CONT_DATA CI_END="0.1698902103625385" CI_START="-0.1698902103625385" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.12" MEAN_2="-0.12" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2343" SD_1="0.86" SD_2="0.86" SE="0.08668027152672743" STUDY_ID="STD-Kinon-2006a" TOTAL_1="202" TOTAL_2="192" WEIGHT="40.6644887646786"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7329410111225614" CI_START="-1.5329410111225616" DF="0" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" I2="0.0" ID="CMP-006.21.03" MODIFIED="2009-09-15 16:09:20 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.4889426472797386" STUDIES="1" TAU2="0.0" TOTAL_1="133" TOTAL_2="136" WEIGHT="99.99999999999999" Z="0.6919915389409541">
<NAME>extrapyramidal symptoms: ESRS total score (high=poor)</NAME>
<CONT_DATA CI_END="0.7329410111225614" CI_START="-1.5329410111225616" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="1.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2344" SD_1="4.74" SD_2="4.74" SE="0.5780417497765549" STUDY_ID="STD-Simpson-2004" TOTAL_1="133" TOTAL_2="136" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.1320206742456766" CI_START="-0.8120206742456766" DF="1" EFFECT_SIZE="-0.33999999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-006.21.04" MODIFIED="2009-09-15 16:09:24 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.15801574298595344" STUDIES="2" TAU2="0.0" TOTAL_1="470" TOTAL_2="452" WEIGHT="100.00000000000001" Z="1.4117766256924118">
<NAME>extrapyramidal symptoms: Simpson-Angus Scale (high=poor)</NAME>
<CONT_DATA CI_END="0.29386618248435714" CI_START="-0.9738661824843571" EFFECT_SIZE="-0.33999999999999997" ESTIMABLE="YES" MEAN_1="-1.16" MEAN_2="-0.82" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2345" SD_1="3.31" SD_2="4.07" SE="0.3234070561929773" STUDY_ID="STD-Breier-2005" TOTAL_1="268" TOTAL_2="260" WEIGHT="55.45323377944655"/>
<CONT_DATA CI_END="0.3672173873231255" CI_START="-1.0472173873231254" EFFECT_SIZE="-0.33999999999999997" ESTIMABLE="YES" MEAN_1="-0.37" MEAN_2="-0.03" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2346" SD_1="3.58" SD_2="3.58" SE="0.3608318279833537" STUDY_ID="STD-Kinon-2006a" TOTAL_1="202" TOTAL_2="192" WEIGHT="44.546766220553465"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.1856550740302727" CI_END="1.4881472044118913" CI_START="0.9438631575078675" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1851613051364416" ESTIMABLE="YES" EVENTS_1="166" EVENTS_2="103" I2="0.0" I2_Q="0.0" ID="CMP-006.22" LOG_CI_END="0.1726458928373987" LOG_CI_START="-0.025090965709483225" LOG_EFFECT_SIZE="0.07377746356395773" METHOD="MH" MODIFIED="2010-02-17 14:17:25 +0000" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.5272511390539685" P_Q="0.0" P_Z="0.1435873678516853" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1109" TOTAL_2="796" WEIGHT="400.0" Z="1.4625616338674607">
<NAME>Adverse effects: 6a Prolactin associated side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7085835915764322" CI_START="0.738524354161777" DF="0" EFFECT_SIZE="1.1233123312331232" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="33" I2="0.0" ID="CMP-006.22.01" LOG_CI_END="0.23263623128947986" LOG_CI_START="-0.1316351784784048" LOG_EFFECT_SIZE="0.05050052640553754" MODIFIED="2009-09-15 16:09:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5868292161325303" STUDIES="1" TAU2="0.0" TOTAL_1="202" TOTAL_2="192" WEIGHT="100.00000000000001" Z="0.543436626103803">
<NAME>abnormally high prolactin value</NAME>
<DICH_DATA CI_END="1.7085835915764322" CI_START="0.738524354161777" EFFECT_SIZE="1.1233123312331232" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="33" LOG_CI_END="0.23263623128947986" LOG_CI_START="-0.1316351784784048" LOG_EFFECT_SIZE="0.05050052640553754" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2352" O_E="0.0" SE="0.213974829270215" STUDY_ID="STD-Kinon-2006a" TOTAL_1="202" TOTAL_2="192" VAR="0.04578522756121766" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9542119520317809" CI_START="0.3584545773314724" DF="0" EFFECT_SIZE="0.8369565217391305" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" ID="CMP-006.22.02" LOG_CI_END="0.29097166511757655" LOG_CI_START="-0.4455658694637233" LOG_EFFECT_SIZE="-0.07729710217307337" MODIFIED="2010-02-17 14:17:19 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6807916665124558" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="56" WEIGHT="100.0" Z="0.4113830708021137">
<NAME>amenorrhoea</NAME>
<DICH_DATA CI_END="1.9542119520317809" CI_START="0.3584545773314724" EFFECT_SIZE="0.8369565217391305" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.29097166511757655" LOG_CI_START="-0.4455658694637233" LOG_EFFECT_SIZE="-0.07729710217307337" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2353" O_E="0.0" SE="0.43264579373265233" STUDY_ID="STD-Lieberman-2005" TOTAL_1="92" TOTAL_2="56" VAR="0.18718238283455677" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.883164359031306" CI_START="0.21911406462692176" DF="0" EFFECT_SIZE="0.6423611111111112" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" ID="CMP-006.22.03" LOG_CI_END="0.2748882260736436" LOG_CI_START="-0.6593297447860776" LOG_EFFECT_SIZE="-0.19222075935621702" MODIFIED="2010-02-17 14:17:25 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.41992701522555054" STUDIES="2" TAU2="0.0" TOTAL_1="371" TOTAL_2="226" WEIGHT="100.0" Z="0.8065478874751741">
<NAME>galactorrhoea</NAME>
<DICH_DATA CI_END="1.883164359031306" CI_START="0.21911406462692176" EFFECT_SIZE="0.6423611111111112" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.2748882260736436" LOG_CI_START="-0.6593297447860776" LOG_EFFECT_SIZE="-0.19222075935621702" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2354" O_E="0.0" SE="0.5487642605365383" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="185" VAR="0.30114221364221366" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2355" O_E="0.0" SE="0.0" STUDY_ID="STD-Stroup-2006" TOTAL_1="35" TOTAL_2="41" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6422761415759818" CI_END="1.790899269662496" CI_START="0.989244248089214" DF="1" EFFECT_SIZE="1.3310284750600936" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="56" I2="0.0" ID="CMP-006.22.04" LOG_CI_END="0.25307115934987207" LOG_CI_START="-0.00469646623795394" LOG_EFFECT_SIZE="0.12418734655595906" MODIFIED="2009-09-15 16:09:46 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.4228880248963385" P_Z="0.05895298257480032" STUDIES="2" TAU2="0.0" TOTAL_1="444" TOTAL_2="322" WEIGHT="100.00000000000001" Z="1.8885438078595518">
<NAME>sexual dysfunction</NAME>
<DICH_DATA CI_END="2.0235175900002935" CI_START="1.0127555083920028" EFFECT_SIZE="1.431547619047619" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="35" LOG_CI_END="0.3061069839718953" LOG_CI_START="0.005504613996080226" LOG_EFFECT_SIZE="0.15580579898398772" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2356" O_E="0.0" SE="0.1765753201295234" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="185" VAR="0.031178843678843673" WEIGHT="73.5312487712098"/>
<DICH_DATA CI_END="1.935814858125098" CI_START="0.6107116787467866" EFFECT_SIZE="1.0873015873015872" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" LOG_CI_END="0.28686381891269136" LOG_CI_START="-0.2141637748350037" LOG_EFFECT_SIZE="0.036350022038843834" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2357" O_E="0.0" SE="0.29430608869398406" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="137" VAR="0.0866160738423512" WEIGHT="26.468751228790207"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.2607983981283497" CI_END="3.326449081582278" CI_START="-3.724844970247748" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.19919794433273513" ESTIMABLE="YES" I2="11.535676880532877" I2_Q="0.0" ID="CMP-006.23" MODIFIED="2009-09-15 16:10:04 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.32290466507723536" P_Q="1.0" P_Z="0.911824629805991" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="1.3319265655906523" TOTALS="YES" TOTAL_1="612" TOTAL_2="467" UNITS="" WEIGHT="99.99999999999997" Z="0.11073734659675677">
<NAME>Adverse effects: 6b. Prolactin - change from baseline in ng/ml</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="11.46500357406256" CI_START="-2.565003574062559" EFFECT_SIZE="4.45" ESTIMABLE="YES" MEAN_1="-2.74" MEAN_2="-7.19" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2358" SD_1="27.79" SD_2="34.51" SE="3.5791492238612608" STUDY_ID="STD-Kinon-2006a" TOTAL_1="168" TOTAL_2="145" WEIGHT="22.880389136069837"/>
<CONT_DATA CI_END="2.324502333062244" CI_START="-5.524502333062243" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="-6.1" MEAN_2="-4.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2359" SD_1="22.0" SD_2="21.8" SE="2.0023339020605566" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="185" WEIGHT="60.581097928891104"/>
<CONT_DATA CI_END="6.869139460703845" CI_START="-9.869139460703845" EFFECT_SIZE="-1.4999999999999996" ESTIMABLE="YES" MEAN_1="-5.1" MEAN_2="-3.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2360" SD_1="37.4" SD_2="26.9" SE="4.270047575730243" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="137" WEIGHT="16.53851293503904"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.4397088866494" CI_START="0.24085450284496704" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4257425742574257" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-006.24" LOG_CI_END="0.92632746663724" LOG_CI_START="-0.6182452300120257" LOG_EFFECT_SIZE="0.15404111831260706" METHOD="MH" MODIFIED="2009-09-15 16:12:33 +0100" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="1.0" P_Q="0.0" P_Z="0.695844057642372" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="202" TOTAL_2="192" WEIGHT="100.0" Z="0.3909366579973163">
<NAME>Adverse effects: 7a. Metabolic - cholesterol - significant cholesterol increase</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.4397088866494" CI_START="0.24085450284496704" EFFECT_SIZE="1.4257425742574257" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.92632746663724" LOG_CI_START="-0.6182452300120257" LOG_EFFECT_SIZE="0.15404111831260706" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2324" O_E="0.0" SE="0.9072896477699363" STUDY_ID="STD-Kinon-2006a" TOTAL_1="202" TOTAL_2="192" VAR="0.8231745049504949" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="23.33054994344727" CI_END="25.716799891632498" CI_START="5.94577070946074" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="15.83128530054662" ESTIMABLE="YES" I2="87.14132325525145" I2_Q="0.0" ID="CMP-006.25" MODIFIED="2009-09-15 16:12:25 +0100" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="3.4457431228540614E-5" P_Q="1.0" P_Z="0.0016963557723927436" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="85.10809882466997" TOTALS="YES" TOTAL_1="831" TOTAL_2="671" UNITS="" WEIGHT="99.99999999999997" Z="3.1388096929247844">
<NAME>Adverse effects: 7b. Metabolic - cholesterol - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.43384432224611" CI_START="4.346155677753892" EFFECT_SIZE="7.390000000000001" ESTIMABLE="YES" MEAN_1="1.44" MEAN_2="-5.95" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2325" SD_1="17.12" SD_2="14.59" SE="1.5530103339936672" STUDY_ID="STD-Breier-2005" TOTAL_1="215" TOTAL_2="203" WEIGHT="29.066676023755267"/>
<CONT_DATA CI_END="16.823465142375664" CI_START="2.0365348576243347" EFFECT_SIZE="9.43" ESTIMABLE="YES" MEAN_1="-2.27" MEAN_2="-11.7" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2326" SD_1="33.92" SD_2="33.18" SE="3.7722454089434163" STUDY_ID="STD-Kinon-2006a" TOTAL_1="172" TOTAL_2="146" WEIGHT="25.608683717286844"/>
<CONT_DATA CI_END="29.88809775561656" CI_START="7.9119022443834375" EFFECT_SIZE="18.9" ESTIMABLE="YES" MEAN_1="9.7" MEAN_2="-9.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2327" SD_1="38.5" SD_2="70.7" SE="5.606275340919156" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="185" WEIGHT="21.828970181497674"/>
<CONT_DATA CI_END="39.8330073274167" CI_START="20.966992672583295" EFFECT_SIZE="30.4" ESTIMABLE="YES" MEAN_1="17.9" MEAN_2="-12.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2328" SD_1="34.3" SD_2="41.0" SE="4.812847277716866" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="137" WEIGHT="23.495670077460193"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.680619862727067" CI_START="0.1352330858059971" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9504950495049505" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-006.26" LOG_CI_END="0.8248167604504693" LOG_CI_START="-0.8689170419366177" LOG_EFFECT_SIZE="-0.02205014074307418" METHOD="MH" MODIFIED="2009-09-15 16:12:20 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="1.0" P_Q="0.0" P_Z="0.9592998614786125" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="202" TOTAL_2="192" WEIGHT="100.0" Z="0.051032200750266085">
<NAME>Adverse effects: 7c Metabolic - glucose - abnormally high fasting glucose value</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.680619862727067" CI_START="0.1352330858059971" EFFECT_SIZE="0.9504950495049505" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8248167604504693" LOG_CI_START="-0.8689170419366177" LOG_EFFECT_SIZE="-0.02205014074307418" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2347" O_E="0.0" SE="0.994907619639714" STUDY_ID="STD-Kinon-2006a" TOTAL_1="202" TOTAL_2="192" VAR="0.9898411716171617" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="5.122723469234302" CI_END="13.722864858068824" CI_START="2.7674564542944644" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="8.245160656181644" ESTIMABLE="YES" I2="41.43740106181424" I2_Q="0.0" ID="CMP-006.27" MODIFIED="2009-09-15 16:12:16 +0100" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.16302839274774894" P_Q="1.0" P_Z="0.0031758798955907382" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="12.950914302972766" TOTALS="YES" TOTAL_1="789" TOTAL_2="631" UNITS="" WEIGHT="100.00000000000001" Z="2.950180830738385">
<NAME>Adverse effects: 7d. Metabolic - glucose - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.077774697294192" CI_START="0.382225302705808" EFFECT_SIZE="5.2299999999999995" ESTIMABLE="YES" MEAN_1="5.05" MEAN_2="-0.18" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2348" SD_1="30.27" SD_2="21.44" SE="2.473399886698337" STUDY_ID="STD-Breier-2005" TOTAL_1="228" TOTAL_2="219" WEIGHT="40.962049406506345"/>
<CONT_DATA CI_END="12.86383587793108" CI_START="-7.443835877931082" EFFECT_SIZE="2.71" ESTIMABLE="YES" MEAN_1="2.85" MEAN_2="0.14" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2349" SD_1="37.84" SD_2="36.25" SE="5.180623704324796" STUDY_ID="STD-Kinon-2006a" TOTAL_1="117" TOTAL_2="90" WEIGHT="19.630414673113147"/>
<CONT_DATA CI_END="22.102965669054665" CI_START="3.2970343309453334" EFFECT_SIZE="12.7" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="2.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2350" SD_1="51.3" SD_2="53.0" SE="4.797519619352222" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="185" WEIGHT="21.716780523765834"/>
<CONT_DATA CI_END="26.84802862972584" CI_START="4.951971370274162" EFFECT_SIZE="15.9" ESTIMABLE="YES" MEAN_1="14.8" MEAN_2="-1.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2351" SD_1="41.6" SD_2="45.6" SE="5.5858315336825015" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="137" WEIGHT="17.690755396614687"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.898710047652552" CI_END="7.116209097383512" CI_START="3.376672243297418" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="4.90194917727994" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-006.28" LOG_CI_END="0.8522487005846927" LOG_CI_START="0.5284889078858193" LOG_EFFECT_SIZE="0.690368804235256" METHOD="MH" MODIFIED="2009-09-15 16:13:06 +0100" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.8257392120615636" P_Q="0.0" P_Z="6.343803484936629E-17" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="923" TOTAL_2="785" WEIGHT="100.0" Z="8.358653686250603">
<NAME>Adverse effects: 7e. Metabolic - weight gain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2929593339612439" CI_END="6.902143396718027" CI_START="3.0549530144695547" DF="2" EFFECT_SIZE="4.5919194000009265" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="25" I2="0.0" ID="CMP-006.28.01" LOG_CI_END="0.8389839778120951" LOG_CI_START="0.48500453513061204" LOG_EFFECT_SIZE="0.6619942564713536" MODIFIED="2009-09-15 16:13:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8637433067678882" P_Z="2.286994360782562E-13" STUDIES="3" TAU2="0.0" TOTAL_1="646" TOTAL_2="514" WEIGHT="83.65458408305213" Z="7.330848881095755">
<NAME>weight gain of 7% or more of total body weight</NAME>
<DICH_DATA CI_END="14.395282789543746" CI_START="2.2593422223304507" EFFECT_SIZE="5.702970297029703" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="5" LOG_CI_END="1.1582202008384193" LOG_CI_START="0.35398201844271954" LOG_EFFECT_SIZE="0.7561011096405694" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2363" O_E="0.0" SE="0.47241348938244243" STUDY_ID="STD-Kinon-2006a" TOTAL_1="202" TOTAL_2="192" VAR="0.22317450495049504" WEIGHT="16.206022986030465"/>
<DICH_DATA CI_END="7.495504153022558" CI_START="2.3772629151019316" EFFECT_SIZE="4.221230158730159" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="12" LOG_CI_END="0.8748008491272161" LOG_CI_START="0.3760772154949842" LOG_EFFECT_SIZE="0.6254390323111002" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2364" O_E="0.0" SE="0.2929527311173746" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="185" VAR="0.08582130266912875" WEIGHT="42.143046593776546"/>
<DICH_DATA CI_END="9.647266992878107" CI_START="2.191822329972069" EFFECT_SIZE="4.59837962962963" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="8" LOG_CI_END="0.9844042980048417" LOG_CI_START="0.3408053471480973" LOG_EFFECT_SIZE="0.6626048225764696" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2365" O_E="0.0" SE="0.3780532095994395" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="137" VAR="0.14292422928843773" WEIGHT="25.305514503245128"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.218224082017652" CI_START="2.72387245618732" DF="0" EFFECT_SIZE="6.848375451263539" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="5" I2="0.0" ID="CMP-006.28.02" LOG_CI_END="1.2359883555291444" LOG_CI_START="0.4351867681192837" LOG_EFFECT_SIZE="0.8355875618242141" MODIFIED="2009-09-15 16:13:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="4.309911561660156E-5" STUDIES="1" TAU2="0.0" TOTAL_1="277" TOTAL_2="271" WEIGHT="16.34541591694787" Z="4.090205496225842">
<NAME>as "weight gain" reported adverse event</NAME>
<DICH_DATA CI_END="17.218224082017652" CI_START="2.723872456187319" EFFECT_SIZE="6.8483754512635375" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="5" LOG_CI_END="1.2359883555291444" LOG_CI_START="0.4351867681192836" LOG_EFFECT_SIZE="0.835587561824214" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2366" O_E="0.0" SE="0.47039481647634096" STUDY_ID="STD-Breier-2005" TOTAL_1="277" TOTAL_2="271" VAR="0.2212712833678105" WEIGHT="16.34541591694787"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="9.759378564406" CI_END="4.688071974009748" CI_START="2.9589660854731017" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="3.823519029741425" ESTIMABLE="YES" I2="59.013783781391226" I2_Q="0.0" ID="CMP-006.29" MODIFIED="2009-09-15 16:13:30 +0100" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="0.04468201774516134" P_Q="1.0" P_Z="4.3971120329985476E-18" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.5483409230311257" TOTALS="YES" TOTAL_1="916" TOTAL_2="743" UNITS="" WEIGHT="100.00000000000001" Z="8.668016970133518">
<NAME>Adverse effects: 7f. Metabolic - weight gain - change from baseline in kg</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.180186152609731" CI_START="3.1798138473902684" EFFECT_SIZE="4.18" ESTIMABLE="YES" MEAN_1="3.06" MEAN_2="-1.12" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2367" SD_1="6.87" SD_2="4.7" SE="0.5103084344911806" STUDY_ID="STD-Breier-2005" TOTAL_1="269" TOTAL_2="260" WEIGHT="24.058563567615014"/>
<CONT_DATA CI_END="5.097954464632621" CI_START="3.2620455353673785" EFFECT_SIZE="4.18" ESTIMABLE="YES" MEAN_1="2.53" MEAN_2="-1.65" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2368" SD_1="4.91" SD_2="4.16" SE="0.4683527206996296" STUDY_ID="STD-Kinon-2006a" TOTAL_1="194" TOTAL_2="182" WEIGHT="25.34534367075486"/>
<CONT_DATA CI_END="6.249053631020204" CI_START="3.750946368979796" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="-0.7" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2369" SD_1="7.0" SD_2="6.3" SE="0.6372839709671093" STUDY_ID="STD-Lieberman-2005" TOTAL_1="307" TOTAL_2="161" WEIGHT="20.385619438723054"/>
<CONT_DATA CI_END="3.916277060698346" CI_START="1.3237229393016543" EFFECT_SIZE="2.62" ESTIMABLE="YES" MEAN_1="3.57" MEAN_2="0.95" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2370" SD_1="5.1" SD_2="5.1" SE="0.6613780002710324" STUDY_ID="STD-Simpson-2004" TOTAL_1="122" TOTAL_2="116" WEIGHT="19.738540159156425"/>
<CONT_DATA CI_END="4.363042275093182" CI_START="-0.12304227509318144" EFFECT_SIZE="2.12" ESTIMABLE="YES" MEAN_1="1.58" MEAN_2="-0.54" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2371" SD_1="2.93" SD_2="4.78" SE="1.1444303532034326" STUDY_ID="STD-Svestka-2005" TOTAL_1="24" TOTAL_2="24" WEIGHT="10.471933163750654"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2009-09-15 16:20:33 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>OLANZAPINE versus CLOZAPINE - sensitivity analysis (skewed data excluded)</NAME>
<CONT_OUTCOME CHI2="0.5082971711174739" CI_END="0.5374226832304356" CI_START="-4.881837006915685" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.1722071618426244" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.01" MODIFIED="2009-09-15 16:15:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9918163346988833" P_Q="0.9129591740848179" P_Z="0.11612956801515555" Q="0.01194797118462565" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="300" TOTAL_2="303" UNITS="" WEIGHT="99.99999999999997" Z="1.5712285616844905">
<NAME>Mental state: 1a. General - average endpoint score (PANSS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.004331537671953175" CI_END="1.2041247467968157" CI_START="-5.79561897298449" DF="1" EFFECT_SIZE="-2.295747113093837" ESTIMABLE="YES" I2="0.0" ID="CMP-007.01.01" MODIFIED="2009-09-15 16:15:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9475255769269068" P_Z="0.19856809138759227" STUDIES="2" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="59.93984927663215" Z="1.2856418290172213">
<NAME>short term</NAME>
<CONT_DATA CI_END="2.3143529203010766" CI_START="-6.714352920301082" EFFECT_SIZE="-2.200000000000003" ESTIMABLE="YES" MEAN_1="74.86" MEAN_2="77.06" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2372" SD_1="6.41" SD_2="5.28" SE="2.3032836092447204" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="13" WEIGHT="36.02706791197742"/>
<CONT_DATA CI_END="3.101086382514089" CI_START="-7.981086382514089" EFFECT_SIZE="-2.44" ESTIMABLE="YES" MEAN_1="-4.83" MEAN_2="-2.39" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2373" SD_1="9.7" SD_2="14.2" SE="2.8271368383406386" STUDY_ID="STD-Krakowski-2006" TOTAL_1="37" TOTAL_2="37" WEIGHT="23.912781364654734"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.49201766226089505" CI_END="2.2937223179947175" CI_START="-6.2684442703868815" DF="3" EFFECT_SIZE="-1.9873609761960822" ESTIMABLE="YES" I2="0.0" ID="CMP-007.01.02" MODIFIED="2009-09-15 16:15:15 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9206416115750281" P_Z="0.3629001162255947" STUDIES="4" TAU2="0.0" TOTAL_1="250" TOTAL_2="253" WEIGHT="40.060150723367826" Z="0.9098528736663927">
<NAME>medium term</NAME>
<CONT_DATA CI_END="7.902754640080635" CI_START="-7.502754640080644" EFFECT_SIZE="0.19999999999999574" ESTIMABLE="YES" MEAN_1="-37.7" MEAN_2="-37.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2374" SD_1="23.1" SD_2="23.4" SE="3.9300490727579613" STUDY_ID="STD-Bitter-2004" TOTAL_1="70" TOTAL_2="70" WEIGHT="12.374504154729626"/>
<CONT_DATA CI_END="8.77264486633714" CI_START="-13.572644866337145" EFFECT_SIZE="-2.400000000000002" ESTIMABLE="YES" MEAN_1="-32.6" MEAN_2="-30.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2375" SD_1="29.6" SD_2="29.6" SE="5.700433760245361" STUDY_ID="STD-Naber-2005" TOTAL_1="52" TOTAL_2="56" WEIGHT="5.881768746469353"/>
<CONT_DATA CI_END="3.6852472277515522" CI_START="-10.685247227751553" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="-25.6" MEAN_2="-22.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2376" SD_1="25.5" SD_2="23.1" SE="3.6660098269294052" STUDY_ID="STD-Tollefson-2001" TOTAL_1="89" TOTAL_2="87" WEIGHT="14.221208467607875"/>
<CONT_DATA CI_END="7.440086310274894" CI_START="-12.240086310274894" EFFECT_SIZE="-2.3999999999999995" ESTIMABLE="YES" MEAN_1="-9.1" MEAN_2="-6.7" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2377" SD_1="22.31" SD_2="22.31" SE="5.020544452802316" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="40" WEIGHT="7.582669354560974"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.0601072338436217" CI_END="1.3993972714666558" CI_START="-4.527680978972594" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.564141853752969" ESTIMABLE="YES" I2="1.964219854090686" I2_Q="0.0" ID="CMP-007.02" MODIFIED="2009-09-15 16:16:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.38245058733418336" P_Q="0.9445447190866212" P_Z="0.3009213370085698" Q="0.004838446107369165" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.19818319760408457" TOTALS="YES" TOTAL_1="158" TOTAL_2="154" UNITS="" WEIGHT="100.0" Z="1.0344596681646114">
<NAME>Mental state: 1b. General - average endpoint score(BPRS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.903642552067266" CI_END="8.74275393947953" CI_START="-9.382205447586353" DF="1" EFFECT_SIZE="-0.31972575405341186" ESTIMABLE="YES" I2="65.56049919822108" ID="CMP-007.02.01" MODIFIED="2009-09-15 16:16:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.08837977242140882" P_Z="0.9448719354290896" STUDIES="2" TAU2="28.47371152777783" TOTAL_1="17" TOTAL_2="11" WEIGHT="34.5631016405331" Z="0.06914784739565064">
<NAME>short term</NAME>
<CONT_DATA CI_END="13.763876252308963" CI_START="-3.923876252308963" EFFECT_SIZE="4.92" ESTIMABLE="YES" MEAN_1="-0.88" MEAN_2="-5.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2378" SD_1="8.73" SD_2="7.36" SE="4.512264675304409" STUDY_ID="STD-Conley-2003" TOTAL_1="8" TOTAL_2="5" WEIGHT="11.120624271819526"/>
<CONT_DATA CI_END="1.6583004950186355" CI_START="-10.458300495018648" EFFECT_SIZE="-4.400000000000006" ESTIMABLE="YES" MEAN_1="44.3" MEAN_2="48.7" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2379" SD_1="6.5" SD_2="5.4" SE="3.0910264386518027" STUDY_ID="STD-Moresco-2004" TOTAL_1="9" TOTAL_2="6" WEIGHT="23.442477368713572"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.15162623566898653" CI_END="1.958931965959448" CI_START="-5.242807370973791" DF="1" EFFECT_SIZE="-1.6419377025071717" ESTIMABLE="YES" I2="0.0" ID="CMP-007.02.02" MODIFIED="2009-09-15 16:15:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6969862517324196" P_Z="0.37147626144104207" STUDIES="2" TAU2="0.0" TOTAL_1="141" TOTAL_2="143" WEIGHT="65.43689835946691" Z="0.8937115358420896">
<NAME>medium term</NAME>
<CONT_DATA CI_END="4.051519011407006" CI_START="-9.651519011407007" EFFECT_SIZE="-2.8000000000000007" ESTIMABLE="YES" MEAN_1="-20.3" MEAN_2="-17.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2380" SD_1="18.2" SD_2="18.1" SE="3.495737199994956" STUDY_ID="STD-Naber-2005" TOTAL_1="52" TOTAL_2="56" WEIGHT="18.41029896184303"/>
<CONT_DATA CI_END="3.032543522440447" CI_START="-5.4325435224404455" EFFECT_SIZE="-1.1999999999999993" ESTIMABLE="YES" MEAN_1="-15.2" MEAN_2="-14.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2381" SD_1="15.3" SD_2="13.3" SE="2.1595006621683916" STUDY_ID="STD-Tollefson-2001" TOTAL_1="89" TOTAL_2="87" WEIGHT="47.02659939762388"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.940406757442491" CI_END="0.7686961083348066" CI_START="-1.4404635202403453" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3358837059527694" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.03" MODIFIED="2009-09-15 16:17:04 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9186936238700567" P_Q="0.5798853047079968" P_Z="0.5511810374820301" Q="0.30642026935737565" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="287" TOTAL_2="290" UNITS="" WEIGHT="99.99999999999999" Z="0.5959913065094969">
<NAME>Mental state: 2a. Positive symptoms - average endpoint score - (PANSS positive, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.1152277208444965" CI_START="-1.8552277208444963" DF="0" EFFECT_SIZE="0.13000000000000012" ESTIMABLE="YES" I2="0.0" ID="CMP-007.03.01" MODIFIED="2009-09-15 16:16:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8978754500196496" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="37" WEIGHT="30.958046134904986" Z="0.1283456377900163">
<NAME>short term</NAME>
<CONT_DATA CI_END="2.1152277208444965" CI_START="-1.8552277208444963" EFFECT_SIZE="0.13000000000000012" ESTIMABLE="YES" MEAN_1="-1.41" MEAN_2="-1.54" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2382" SD_1="3.6" SD_2="5.0" SE="1.0128898982347223" STUDY_ID="STD-Krakowski-2006" TOTAL_1="37" TOTAL_2="37" WEIGHT="30.958046134904986"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.6339864880851154" CI_END="0.7845702622082074" CI_START="-1.874137242491199" DF="3" EFFECT_SIZE="-0.5447834901414959" ESTIMABLE="YES" I2="0.0" ID="CMP-007.03.02" MODIFIED="2009-09-15 16:17:04 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8886097540629018" P_Z="0.4218508556935364" STUDIES="4" TAU2="0.0" TOTAL_1="250" TOTAL_2="253" WEIGHT="69.041953865095" Z="0.8032143574741096">
<NAME>medium term</NAME>
<CONT_DATA CI_END="2.6197981369101515" CI_START="-2.4197981369101487" EFFECT_SIZE="0.10000000000000142" ESTIMABLE="YES" MEAN_1="-11.7" MEAN_2="-11.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2383" SD_1="7.3" SD_2="7.9" SE="1.28563491818523" STUDY_ID="STD-Bitter-2004" TOTAL_1="70" TOTAL_2="70" WEIGHT="19.21598733669778"/>
<CONT_DATA CI_END="1.7189181115803573" CI_START="-4.5189181115803585" EFFECT_SIZE="-1.4000000000000004" ESTIMABLE="YES" MEAN_1="-9.0" MEAN_2="-7.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2384" SD_1="8.5" SD_2="8.0" SE="1.5913139915743277" STUDY_ID="STD-Naber-2005" TOTAL_1="52" TOTAL_2="56" WEIGHT="12.542562106049202"/>
<CONT_DATA CI_END="1.7867883329020366" CI_START="-2.5867883329020356" EFFECT_SIZE="-0.39999999999999947" ESTIMABLE="YES" MEAN_1="-6.8" MEAN_2="-6.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2385" SD_1="7.6" SD_2="7.2" SE="1.1157288348924488" STUDY_ID="STD-Tollefson-2001" TOTAL_1="89" TOTAL_2="87" WEIGHT="25.51412674055416"/>
<CONT_DATA CI_END="2.219750339085913" CI_START="-4.219750339085913" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-3.3" MEAN_2="-2.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2386" SD_1="7.3" SD_2="7.3" SE="1.6427599509393502" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="40" WEIGHT="11.769277681793861"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6188876830384709" CI_END="1.689519753451264" CI_START="-1.6639007942941288" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.012809479578567654" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.04" MODIFIED="2009-09-15 16:18:01 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.4314611301511746" P_Q="0.4314611301511746" P_Z="0.9880533707905738" Q="0.6188876830384709" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="61" UNITS="" WEIGHT="100.0" Z="0.014973438778248988">
<NAME>Mental state: 2b. Positive symptoms - average endpoint score - (BPRS positive, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.316798473876558" CI_START="-2.0967984738765573" DF="0" EFFECT_SIZE="1.11" ESTIMABLE="YES" I2="0.0" ID="CMP-007.04.01" MODIFIED="2009-09-15 16:17:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4975046846602792" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="5" WEIGHT="27.338376131030987" Z="0.6784211856660645">
<NAME>short term</NAME>
<CONT_DATA CI_END="4.316798473876558" CI_START="-2.0967984738765573" EFFECT_SIZE="1.11" ESTIMABLE="YES" MEAN_1="0.31" MEAN_2="-0.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2387" SD_1="2.87" SD_2="2.87" SE="1.636151735017263" STUDY_ID="STD-Conley-2003" TOTAL_1="8" TOTAL_2="5" WEIGHT="27.338376131030987"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5670050537394364" CI_START="-2.367005053739437" DF="0" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" I2="0.0" ID="CMP-007.04.02" MODIFIED="2009-09-15 16:18:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6902114239678874" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="56" WEIGHT="72.66162386896902" Z="0.3985681644923087">
<NAME>medium term</NAME>
<CONT_DATA CI_END="1.5670050537394364" CI_START="-2.367005053739437" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="-5.9" MEAN_2="-5.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2388" SD_1="5.4" SD_2="5.0" SE="1.0035924482566627" STUDY_ID="STD-Naber-2005" TOTAL_1="52" TOTAL_2="56" WEIGHT="72.66162386896902"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.141809725379531" CI_END="1.3579080965370163" CI_START="-0.4568663831483647" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.45052085669432584" ESTIMABLE="YES" I2="12.419733535935178" I2_Q="12.419733535935178" ID="CMP-007.05" MODIFIED="2009-09-15 16:19:55 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.2852702909507939" P_Q="0.2852702909507939" P_Z="0.33048930568212886" Q="1.141809725379531" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.05963956043956076" TOTALS="YES" TOTAL_1="60" TOTAL_2="61" UNITS="" WEIGHT="100.0" Z="0.973128797312702">
<NAME>Mental state: 3a. Negative symptoms - average endpoint score (BPRS negative, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.7856162461633804" CI_START="-0.22561624616338039" DF="0" EFFECT_SIZE="0.78" ESTIMABLE="YES" I2="0.0" ID="CMP-007.05.01" MODIFIED="2009-09-15 16:18:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.12845220013253508" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="5" WEIGHT="66.37967925452305" Z="1.520233900132184">
<NAME>short term</NAME>
<CONT_DATA CI_END="1.7856162461633804" CI_START="-0.22561624616338039" EFFECT_SIZE="0.78" ESTIMABLE="YES" MEAN_1="1.08" MEAN_2="0.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2389" SD_1="0.9" SD_2="0.9" SE="0.5130789412946121" STUDY_ID="STD-Conley-2003" TOTAL_1="8" TOTAL_2="5" WEIGHT="66.37967925452305"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.2899218723883374" CI_START="-1.6899218723883378" DF="0" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-007.05.02" MODIFIED="2009-09-15 16:19:00 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7924764258051689" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="56" WEIGHT="33.62032074547694" Z="0.2630962093869047">
<NAME>medium term</NAME>
<CONT_DATA CI_END="1.2899218723883374" CI_START="-1.6899218723883378" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="-3.5" MEAN_2="-3.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2390" SD_1="3.8" SD_2="4.1" SE="0.7601781890589068" STUDY_ID="STD-Naber-2005" TOTAL_1="52" TOTAL_2="56" WEIGHT="33.62032074547694"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="20.901822823337568" CI_START="1.0981771766624302" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="11.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.06" MODIFIED="2009-09-15 16:20:00 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.029455442788192808" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="2.1773368615652107">
<NAME>Mental state: 6. Negative symptoms - average endpoint score - short term (SANS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="20.901822823337568" CI_START="1.0981771766624302" EFFECT_SIZE="11.0" ESTIMABLE="YES" MEAN_1="-14.0" MEAN_2="-25.0" MODIFIED="2009-09-15 16:20:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1378" SD_1="12.62" SD_2="12.62" SE="5.052043252550498" STUDY_ID="STD-Shaw-2006" TOTAL_1="13" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.654635553431483" CI_END="0.3768383340680553" CI_START="-0.6005540957432205" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.11185788083758262" ESTIMABLE="YES" I2="42.227492201938574" I2_Q="71.83863934758645" ID="CMP-007.07" MODIFIED="2009-09-15 16:20:33 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.12365827272506835" P_Q="0.05951098758215834" P_Z="0.6537079873055623" Q="3.5509647859088647" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.2734021130154215" TOTALS="SUB" TOTAL_1="373" TOTAL_2="369" UNITS="" WEIGHT="200.0" Z="0.44861697541685985">
<NAME>Adverse effects: 1. Extrapyramidal symptoms - scale measured</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.4853836553033076" CI_END="0.6018579353430902" CI_START="-0.4935023363452373" DF="1" EFFECT_SIZE="0.05417779949892644" ESTIMABLE="YES" I2="0.0" ID="CMP-007.07.01" MODIFIED="2009-09-15 16:20:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4859938524294065" P_Z="0.846266540206045" STUDIES="2" TAU2="0.0" TOTAL_1="158" TOTAL_2="156" WEIGHT="99.99999999999999" Z="0.19388421969304764">
<NAME>abnormal involuntary movement: AIMS (high=poor)</NAME>
<CONT_DATA CI_END="1.1821573637565417" CI_START="-0.5821573637565416" EFFECT_SIZE="0.30000000000000004" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="-0.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2392" SD_1="2.5" SD_2="2.8" SE="0.45008855811376447" STUDY_ID="STD-Bitter-2004" TOTAL_1="69" TOTAL_2="70" WEIGHT="38.54444987473161"/>
<CONT_DATA CI_END="0.5986287184904151" CI_START="-0.7986287184904153" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-0.7" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2393" SD_1="2.2" SD_2="2.5" SE="0.3564497735678356" STUDY_ID="STD-Tollefson-2001" TOTAL_1="89" TOTAL_2="86" WEIGHT="61.455550125268374"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.618287112219311" CI_END="0.3219966419107937" CI_START="-1.84306563936439" DF="3" EFFECT_SIZE="-0.7605344987267982" ESTIMABLE="YES" I2="35.04085114018919" ID="CMP-007.07.02" MODIFIED="2009-09-15 16:20:33 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.20197898699745032" P_Z="0.16851943202427228" STUDIES="4" TAU2="0.4194923163873284" TOTAL_1="215" TOTAL_2="213" WEIGHT="100.0" Z="1.37697676357541">
<NAME>extrapyramidal symptoms: Simpson-Angus Scale (high=poor)</NAME>
<CONT_DATA CI_END="1.355131378937334" CI_START="-1.5551313789373342" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="-3.0" MEAN_2="-2.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2394" SD_1="4.8" SD_2="3.9" SE="0.7424276111271557" STUDY_ID="STD-Bitter-2004" TOTAL_1="69" TOTAL_2="70" WEIGHT="31.42704724947193"/>
<CONT_DATA CI_END="5.4101179569610025" CI_START="-2.590117956961002" EFFECT_SIZE="1.41" ESTIMABLE="YES" MEAN_1="0.25" MEAN_2="-1.16" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2395" SD_1="3.58" SD_2="3.58" SE="2.040914010927457" STUDY_ID="STD-Conley-2003" TOTAL_1="8" TOTAL_2="5" WEIGHT="6.653682988533183"/>
<CONT_DATA CI_END="1.1918401944191759" CI_START="-2.391840194419176" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="-2.7" MEAN_2="-2.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2396" SD_1="4.8" SD_2="4.5" SE="0.9142209798511517" STUDY_ID="STD-Naber-2005" TOTAL_1="50" TOTAL_2="54" WEIGHT="24.301872841688667"/>
<CONT_DATA CI_END="-0.5737123253188225" CI_START="-3.026287674681178" EFFECT_SIZE="-1.8000000000000003" ESTIMABLE="YES" MEAN_1="-3.2" MEAN_2="-1.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2397" SD_1="4.8" SD_2="3.3" SE="0.625668473683179" STUDY_ID="STD-Tollefson-2001" TOTAL_1="88" TOTAL_2="84" WEIGHT="37.61739692030622"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2009-09-15 16:21:44 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>OLANZAPINE versus QUETIAPINE - sensitivity analysis (skewed data excluded)</NAME>
<CONT_OUTCOME CHI2="4.181541095171354" CI_END="-1.0154544962805399" CI_START="-2.5904158581441297" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.8029351772123348" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.01" MODIFIED="2009-09-15 16:21:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6521240374145092" P_Q="0.6288714188450271" P_Z="7.212031757281754E-6" Q="0.9276570414585512" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="337" TOTAL_2="342" UNITS="" WEIGHT="100.0" Z="4.487332958587939">
<NAME>Mental state: 1. Positive symptoms - average endpoint score (PANSS positive, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.9935441978441191" CI_END="0.745149244938065" CI_START="-2.8518977056374784" DF="2" EFFECT_SIZE="-1.0533742303497067" ESTIMABLE="YES" I2="0.0" ID="CMP-008.01.01" MODIFIED="2009-09-15 16:20:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6084917031367767" P_Z="0.25099828507978905" STUDIES="3" TAU2="0.0" TOTAL_1="57" TOTAL_2="58" WEIGHT="19.171124812035124" Z="1.1479280543712018">
<NAME>short term</NAME>
<CONT_DATA CI_END="0.6231981497658015" CI_START="-4.023198149765804" EFFECT_SIZE="-1.700000000000001" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="13.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2398" SD_1="3.1" SD_2="4.3" SE="1.1853269591129698" STUDY_ID="STD-Mori-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="11.48966351105205"/>
<CONT_DATA CI_END="5.943603349657839" CI_START="-4.023603349657839" EFFECT_SIZE="0.96" ESTIMABLE="YES" MEAN_1="-6.82" MEAN_2="-7.78" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2399" SD_1="7.3" SD_2="7.3" SE="2.542701492970211" STUDY_ID="STD-Riedel-2007" TOTAL_1="17" TOTAL_2="16" WEIGHT="2.4968524468082878"/>
<CONT_DATA CI_END="2.8684532509568945" CI_START="-4.048453250956895" EFFECT_SIZE="-0.5899999999999999" ESTIMABLE="YES" MEAN_1="-13.55" MEAN_2="-12.96" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2400" SD_1="5.14" SD_2="6.28" SE="1.7645493887830246" STUDY_ID="STD-Svestka-2003b" TOTAL_1="20" TOTAL_2="22" WEIGHT="5.184608854174788"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.260339855868683" CI_END="-0.9030691428647901" CI_START="-3.5210687931832028" DF="2" EFFECT_SIZE="-2.2120689680239964" ESTIMABLE="YES" I2="11.517730627663978" ID="CMP-008.01.02" MODIFIED="2009-09-15 16:20:55 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.32297870559034303" P_Z="9.258903688393746E-4" STUDIES="3" TAU2="0.21368085879104873" TOTAL_1="243" TOTAL_2="240" WEIGHT="49.74734160342038" Z="3.3121284092749255">
<NAME>medium term</NAME>
<CONT_DATA CI_END="-0.3112402051957588" CI_START="-2.888759794804241" EFFECT_SIZE="-1.5999999999999999" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-0.7" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2401" SD_1="5.4" SD_2="6.6" SE="0.6575425900525794" STUDY_ID="STD-Kinon-2006b" TOTAL_1="167" TOTAL_2="169" WEIGHT="37.33669381242566"/>
<CONT_DATA CI_END="1.3406190420477353" CI_START="-8.340619042047734" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="-2.9" MEAN_2="0.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2402" SD_1="4.11" SD_2="5.94" SE="2.4697489750984816" STUDY_ID="STD-McEvoy-2006" TOTAL_1="10" TOTAL_2="8" WEIGHT="2.6465372222432273"/>
<CONT_DATA CI_END="-1.0798664051055908" CI_START="-6.120133594894409" EFFECT_SIZE="-3.6" ESTIMABLE="YES" MEAN_1="-3.4" MEAN_2="0.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2403" SD_1="7.3" SD_2="7.3" SE="1.2858060733630319" STUDY_ID="STD-Stroup-2006" TOTAL_1="66" TOTAL_2="63" WEIGHT="9.764110568751493"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.38749924499717747" CI_START="-3.2125007550028224" DF="0" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-008.01.03" MODIFIED="2009-09-15 16:21:02 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.01250188961929898" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="44" WEIGHT="31.0815335845445" Z="2.4976518842038056">
<NAME>long term</NAME>
<CONT_DATA CI_END="-0.38749924499717747" CI_START="-3.2125007550028224" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-5.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2404" SD_1="3.1" SD_2="3.38" SE="0.7206768931186737" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="44" WEIGHT="31.0815335845445"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2009-09-18 14:31:27 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>OLANZAPINE versus RISPERIDONE - sensitivity analysis (skewed data excluded)</NAME>
<CONT_OUTCOME CHI2="11.287642120614855" CI_END="-0.6024760919148098" CI_START="-3.369102133213947" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.9857891125643783" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.01" MODIFIED="2009-09-15 16:26:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5867347492995343" P_Q="0.41806075280153765" P_Z="0.004899172936149818" Q="1.7442587918464802" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1180" TOTAL_2="1168" UNITS="" WEIGHT="100.0" Z="2.813589609451025">
<NAME>Mental state: 1. General - average endpoint score (PANSS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.293298250023199" CI_END="1.1120213201429938" CI_START="-3.1544517536549193" DF="5" EFFECT_SIZE="-1.0212152167559627" ESTIMABLE="YES" I2="0.0" ID="CMP-009.01.01" MODIFIED="2009-09-15 16:25:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.807250796708822" P_Z="0.3481073218759504" STUDIES="6" TAU2="0.0" TOTAL_1="347" TOTAL_2="339" WEIGHT="42.049700104167464" Z="0.9382668122755661">
<NAME>short term</NAME>
<CONT_DATA CI_END="0.8951840456939086" CI_START="-7.69518404569392" EFFECT_SIZE="-3.4000000000000057" ESTIMABLE="YES" MEAN_1="74.86" MEAN_2="78.26" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2405" SD_1="6.41" SD_2="4.62" SE="2.191460700081113" STUDY_ID="STD-Atmaca-2003" TOTAL_1="13" TOTAL_2="13" WEIGHT="10.372355041410616"/>
<CONT_DATA CI_END="3.22427920354235" CI_START="-3.4242792035423495" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="-12.9" MEAN_2="-12.8" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2406" SD_1="16.1" SD_2="15.9" SE="1.6960919842220774" STUDY_ID="STD-Conley-2001" TOTAL_1="181" TOTAL_2="175" WEIGHT="17.31593489491165"/>
<CONT_DATA CI_END="7.897000872241492" CI_START="-9.097000872241495" EFFECT_SIZE="-0.6000000000000014" ESTIMABLE="YES" MEAN_1="-17.5" MEAN_2="-16.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2407" SD_1="17.7" SD_2="18.8" SE="4.3352841885181315" STUDY_ID="STD-Dollfus-2005" TOTAL_1="33" TOTAL_2="38" WEIGHT="2.6503888997075595"/>
<CONT_DATA CI_END="5.077521730134338" CI_START="-5.077521730134338" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-12.3" MEAN_2="-12.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2408" SD_1="15.67" SD_2="18.04" SE="2.59061991454189" STUDY_ID="STD-Jeste-2003" TOTAL_1="88" TOTAL_2="83" WEIGHT="7.422280246931101"/>
<CONT_DATA CI_END="5.077576336221427" CI_START="-9.277576336221415" EFFECT_SIZE="-2.0999999999999943" ESTIMABLE="YES" MEAN_1="69.4" MEAN_2="71.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2409" SD_1="10.8" SD_2="12.0" SE="3.6620960348441236" STUDY_ID="STD-Mori-2004" TOTAL_1="20" TOTAL_2="19" WEIGHT="3.7143710819170326"/>
<CONT_DATA CI_END="24.252594840357954" CI_START="-12.252594840357954" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="-9.0" MEAN_2="-15.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2410" SD_1="22.31" SD_2="22.31" SE="9.312719511344133" STUDY_ID="STD-Wang-2006" TOTAL_1="12" TOTAL_2="11" WEIGHT="0.5743699392895004"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7999604544536205" CI_END="0.7147127623588334" CI_START="-8.928299336757078" DF="2" EFFECT_SIZE="-4.106793287199123" ESTIMABLE="YES" I2="0.0" ID="CMP-009.01.02" MODIFIED="2009-09-15 16:25:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.40657774134073776" P_Z="0.09503218860734909" STUDIES="3" TAU2="0.0" TOTAL_1="115" TOTAL_2="116" WEIGHT="8.23143394853464" Z="1.6694300187799413">
<NAME>medium term</NAME>
<CONT_DATA CI_END="0.7867549391483113" CI_START="-15.586754939148312" EFFECT_SIZE="-7.4" ESTIMABLE="YES" MEAN_1="-7.7" MEAN_2="-0.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2411" SD_1="9.8" SD_2="6.86" SE="4.176992538497845" STUDY_ID="STD-McEvoy-2006" TOTAL_1="10" TOTAL_2="6" WEIGHT="2.855073865612635"/>
<CONT_DATA CI_END="7.328666030926337" CI_START="-7.728666030926336" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" MEAN_1="-8.2" MEAN_2="-8.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2412" SD_1="22.31" SD_2="22.31" SE="3.8412267216701395" STUDY_ID="STD-Stroup-2006" TOTAL_1="66" TOTAL_2="69" WEIGHT="3.3760188653793968"/>
<CONT_DATA CI_END="3.7806658759388743" CI_START="-15.780665875938874" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="-9.1" MEAN_2="-3.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2413" SD_1="22.31" SD_2="22.31" SE="4.990227347587771" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="41" WEIGHT="2.0003412175426094"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.450124624291555" CI_END="-0.20196365546916306" CI_START="-4.980614052622716" DF="4" EFFECT_SIZE="-2.59128885404594" ESTIMABLE="YES" I2="26.607182849145442" ID="CMP-009.01.03" MODIFIED="2009-09-15 16:26:00 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.24414868007685187" P_Z="0.03353367836301015" STUDIES="5" TAU2="1.9590283502343937" TOTAL_1="718" TOTAL_2="713" WEIGHT="49.71886594729791" Z="2.125634815426282">
<NAME>long term</NAME>
<CONT_DATA CI_END="-2.628659047466469" CI_START="-21.171340952533527" EFFECT_SIZE="-11.899999999999999" ESTIMABLE="YES" MEAN_1="-28.2" MEAN_2="-16.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2414" SD_1="20.8" SD_2="16.3" SE="4.730362917719246" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="30" WEIGHT="2.2261571788515164"/>
<CONT_DATA CI_END="0.6585700182422052" CI_START="-6.458570018242206" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="-12.4" MEAN_2="-9.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2415" SD_1="16.0" SD_2="15.5" SE="1.8156303107157843" STUDY_ID="STD-Keefe-2006" TOTAL_1="153" TOTAL_2="148" WEIGHT="15.110884944600214"/>
<CONT_DATA CI_END="1.436450885289283" CI_START="-5.356450885289281" EFFECT_SIZE="-1.959999999999999" ESTIMABLE="YES" MEAN_1="-11.27" MEAN_2="-9.31" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2416" SD_1="22.31" SD_2="22.31" SE="1.7329149474582457" STUDY_ID="STD-Lieberman-2005" TOTAL_1="330" TOTAL_2="333" WEIGHT="16.5878558258608"/>
<CONT_DATA CI_END="4.574988808061814" CI_START="-4.374988808061811" EFFECT_SIZE="0.10000000000000142" ESTIMABLE="YES" MEAN_1="-18.4" MEAN_2="-18.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2417" SD_1="9.73" SD_2="9.91" SE="2.283199509460354" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="37" WEIGHT="9.555579337497502"/>
<CONT_DATA CI_END="2.338399132890399" CI_START="-8.738399132890404" EFFECT_SIZE="-3.200000000000003" ESTIMABLE="YES" MEAN_1="-28.1" MEAN_2="-24.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2418" SD_1="28.0" SD_2="23.2" SE="2.8257657674205174" STUDY_ID="STD-Tran-1997" TOTAL_1="166" TOTAL_2="165" WEIGHT="6.238388660487878"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.2783476979887816" CI_END="1.3418164287482535" CI_START="-9.907846603522582" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.283015087387165" ESTIMABLE="YES" I2="69.4968291309221" I2_Q="0.0" ID="CMP-009.02" MODIFIED="2009-09-18 14:31:27 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.07019963163782827" P_Q="1.0" P_Z="0.1355916711670666" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="11.689366659821088" TOTALS="YES" TOTAL_1="198" TOTAL_2="195" UNITS="" WEIGHT="100.0" Z="1.4924100912960423">
<NAME>Mental state: 2. General - average endpoint score - long term (BPRS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.2148599971621286" CI_START="-12.985140002837866" EFFECT_SIZE="-7.599999999999998" ESTIMABLE="YES" MEAN_1="-16.4" MEAN_2="-8.8" MODIFIED="2009-09-18 14:31:27 +0100" MODIFIED_BY="[Empty name]" ORDER="933" SD_1="12.3" SD_2="9.2" SE="2.74757089687115" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="30" WEIGHT="42.81060495495113"/>
<CONT_DATA CI_END="1.4277702134121224" CI_START="-5.027770213412124" EFFECT_SIZE="-1.8000000000000007" ESTIMABLE="YES" MEAN_1="-17.0" MEAN_2="-15.2" MODIFIED="2009-09-18 14:31:27 +0100" MODIFIED_BY="[Empty name]" ORDER="934" SD_1="16.5" SD_2="13.3" SE="1.6468517987434272" STUDY_ID="STD-Tran-1997" TOTAL_1="166" TOTAL_2="165" WEIGHT="57.18939504504887"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.019265642630455" CI_END="-0.027714148774739544" CI_START="-1.2078345904451808" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6177743696099601" ESTIMABLE="YES" I2="0.0" I2_Q="35.63662705455148" ID="CMP-009.03" MODIFIED="2009-09-15 16:24:19 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8720757560020795" P_Q="0.21146871595562822" P_Z="0.04016769560061568" Q="3.1073573501113896" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="838" TOTAL_2="825" UNITS="" WEIGHT="99.99999999999999" Z="2.0520202383640913">
<NAME>Mental state: 3. Positive symptoms - average endpoint score (PANSS positive, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.108271186130888" CI_END="1.621460935161191" CI_START="-1.0659605838021373" DF="3" EFFECT_SIZE="0.27775017567952687" ESTIMABLE="YES" I2="0.0" ID="CMP-009.03.01" MODIFIED="2009-09-15 16:24:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7750778047865592" P_Z="0.6853804245436173" STUDIES="4" TAU2="0.0" TOTAL_1="314" TOTAL_2="308" WEIGHT="19.283287909882237" Z="0.40513208455779576">
<NAME>short term</NAME>
<CONT_DATA CI_END="10.059970711802848" CI_START="-9.059970711802848" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="-4.1" MEAN_2="-4.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2421" SD_1="65.4" SD_2="5.3" SE="4.877625704967375" STUDY_ID="STD-Conley-2001" TOTAL_1="181" TOTAL_2="175" WEIGHT="0.38096015207722694"/>
<CONT_DATA CI_END="2.81923524152352" CI_START="-1.2192352415235201" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-1.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2422" SD_1="4.7" SD_2="3.91" SE="1.0302409929218035" STUDY_ID="STD-Dollfus-2005" TOTAL_1="33" TOTAL_2="39" WEIGHT="8.539232537710916"/>
<CONT_DATA CI_END="1.5258975113126552" CI_START="-2.3258975113126548" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="-4.0" MEAN_2="-3.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2423" SD_1="5.72" SD_2="7.02" SE="0.9826188269294175" STUDY_ID="STD-Jeste-2003" TOTAL_1="88" TOTAL_2="83" WEIGHT="9.386989477385834"/>
<CONT_DATA CI_END="8.112386478467641" CI_START="-3.8323864784676407" EFFECT_SIZE="2.14" ESTIMABLE="YES" MEAN_1="-2.36" MEAN_2="-4.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2424" SD_1="7.3" SD_2="7.3" SE="3.047191951269035" STUDY_ID="STD-Wang-2006" TOTAL_1="12" TOTAL_2="11" WEIGHT="0.9761057427082592"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.46690689369471294" CI_END="0.034246268075140085" CI_START="-3.201580707579363" DF="2" EFFECT_SIZE="-1.5836672197521116" ESTIMABLE="YES" I2="0.0" ID="CMP-009.03.02" MODIFIED="2009-09-15 16:24:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7917946395508001" P_Z="0.05505048530675875" STUDIES="3" TAU2="0.0" TOTAL_1="115" TOTAL_2="116" WEIGHT="13.300932327588875" Z="1.9184775561635172">
<NAME>medium term</NAME>
<CONT_DATA CI_END="0.4915680193919023" CI_START="-5.291568019391902" EFFECT_SIZE="-2.4" ESTIMABLE="YES" MEAN_1="-2.9" MEAN_2="-0.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2425" SD_1="4.11" SD_2="1.71" SE="1.4753169151067171" STUDY_ID="STD-McEvoy-2006" TOTAL_1="10" TOTAL_2="6" WEIGHT="4.164145053694794"/>
<CONT_DATA CI_END="1.3634362180978155" CI_START="-3.5634362180978156" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="-3.4" MEAN_2="-2.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2426" SD_1="7.3" SD_2="7.3" SE="1.256878308749082" STUDY_ID="STD-Stroup-2006" TOTAL_1="66" TOTAL_2="69" WEIGHT="5.73733264325188"/>
<CONT_DATA CI_END="1.800307525520116" CI_START="-4.600307525520115" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="-3.3" MEAN_2="-1.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2427" SD_1="7.3" SD_2="7.3" SE="1.6328399658176034" STUDY_ID="STD-Volavka-2002" TOTAL_1="39" TOTAL_2="41" WEIGHT="3.399454630642201"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.3367302126934648" CI_END="0.03528874229455581" CI_START="-1.40200505733471" DF="4" EFFECT_SIZE="-0.6833581575200771" ESTIMABLE="YES" I2="0.0" ID="CMP-009.03.03" MODIFIED="2009-09-15 16:24:19 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8551136536984457" P_Z="0.06236088332451102" STUDIES="5" TAU2="0.0" TOTAL_1="409" TOTAL_2="401" WEIGHT="67.41577976252887" Z="1.8637210814190848">
<NAME>long term</NAME>
<CONT_DATA CI_END="0.6878722278772726" CI_START="-4.887872227877274" EFFECT_SIZE="-2.1000000000000005" ESTIMABLE="YES" MEAN_1="-6.2" MEAN_2="-4.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2428" SD_1="5.8" SD_2="5.4" SE="1.4224099268495" STUDY_ID="STD-Gureje-2003" TOTAL_1="32" TOTAL_2="30" WEIGHT="4.479679504791766"/>
<CONT_DATA CI_END="0.4781323726651181" CI_START="-1.8781323726651176" EFFECT_SIZE="-0.6999999999999997" ESTIMABLE="YES" MEAN_1="-4.3" MEAN_2="-3.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2429" SD_1="4.9" SD_2="5.5" SE="0.6010989905723144" STUDY_ID="STD-Keefe-2006" TOTAL_1="153" TOTAL_2="148" WEIGHT="25.084444942687636"/>
<CONT_DATA CI_END="0.9263513314482366" CI_START="-1.9263513314482366" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-6.6" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2430" SD_1="3.1" SD_2="3.16" SE="0.7277436436072876" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="37" WEIGHT="17.113531999458438"/>
<CONT_DATA CI_END="1.3376310753164962" CI_START="-3.2376310753164965" EFFECT_SIZE="-0.9500000000000002" ESTIMABLE="YES" MEAN_1="-2.14" MEAN_2="-1.19" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2431" SD_1="4.33" SD_2="3.14" SE="1.1671801591054929" STUDY_ID="STD-Purdon-2000" TOTAL_1="21" TOTAL_2="21" WEIGHT="6.653048664539167"/>
<CONT_DATA CI_END="1.2722324691910585" CI_START="-1.8722324691910581" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="-7.2" MEAN_2="-6.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2432" SD_1="8.1" SD_2="6.4" SE="0.8021741631951542" STUDY_ID="STD-Tran-1997" TOTAL_1="166" TOTAL_2="165" WEIGHT="14.085074651051865"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="14.843930058107507" CI_END="0.10934737608849665" CI_START="-0.6417923188007796" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.26622247135614147" ESTIMABLE="YES" I2="39.36915651873238" I2_Q="0.0" ID="CMP-009.04" MODIFIED="2009-09-15 16:23:26 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.09531317499779768" P_Q="0.9321632201454514" P_Z="0.1647356629013059" Q="0.43857609363779204" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.08482128746587621" TOTALS="SUB" TOTAL_1="916" TOTAL_2="903" UNITS="" WEIGHT="400.0" Z="1.3893193484074857">
<NAME>Adverse effects: 1. Extrapyramidal symptoms - scale measured</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.9402024398687009" CI_END="0.41987157932455216" CI_START="-0.620842960895722" DF="1" EFFECT_SIZE="-0.10048569078558495" ESTIMABLE="YES" I2="0.0" ID="CMP-009.04.01" MODIFIED="2009-09-15 16:23:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.33222594866367106" P_Z="0.7050690316557731" STUDIES="2" TAU2="0.0" TOTAL_1="201" TOTAL_2="200" WEIGHT="100.0" Z="0.37848675557024397">
<NAME>dyskinesia: ESRS subscore for dyskinesia (high=poor)</NAME>
<CONT_DATA CI_END="0.5585940577559307" CI_START="-0.5585940577559307" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2433" SD_1="2.7" SD_2="2.7" SE="0.2850022052252232" STUDY_ID="STD-Conley-2001" TOTAL_1="180" TOTAL_2="179" WEIGHT="86.77819858084409"/>
<CONT_DATA CI_END="0.6710549544424003" CI_START="-2.1910549544424" EFFECT_SIZE="-0.76" ESTIMABLE="YES" MEAN_1="-0.57" MEAN_2="0.19" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2434" SD_1="2.87" SD_2="1.72" SE="0.7301434953552102" STUDY_ID="STD-Purdon-2000" TOTAL_1="21" TOTAL_2="21" WEIGHT="13.221801419155913"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.5523030292107468" CI_END="0.5804037548154243" CI_START="-0.8990852658745242" DF="1" EFFECT_SIZE="-0.15934075552954993" ESTIMABLE="YES" I2="0.0" ID="CMP-009.04.02" MODIFIED="2009-09-15 16:23:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4573782997000886" P_Z="0.6728967922431175" STUDIES="2" TAU2="0.0" TOTAL_1="268" TOTAL_2="262" WEIGHT="100.0" Z="0.4221756805760946">
<NAME>extrapyramidal symptoms: ESRS total score (high=poor)</NAME>
<CONT_DATA CI_END="0.5275467522310086" CI_START="-1.1275467522310083" EFFECT_SIZE="-0.29999999999999993" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="-0.9" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2435" SD_1="4.0" SD_2="4.0" SE="0.4222254892225529" STUDY_ID="STD-Conley-2001" TOTAL_1="180" TOTAL_2="179" WEIGHT="79.90582221850714"/>
<CONT_DATA CI_END="2.05023818008037" CI_START="-1.2502381800803697" EFFECT_SIZE="0.40000000000000013" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="-2.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2436" SD_1="5.63" SD_2="5.38" SE="0.841973726607855" STUDY_ID="STD-Jeste-2003" TOTAL_1="88" TOTAL_2="83" WEIGHT="20.094177781492856"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="10.109754746999261" CI_END="0.1024545310958015" CI_START="-1.5936638434144528" DF="3" EFFECT_SIZE="-0.7456046561593257" ESTIMABLE="YES" I2="70.32568964256578" ID="CMP-009.04.03" MODIFIED="2009-09-15 16:23:13 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.01765589975018056" P_Z="0.08485605552674162" STUDIES="4" TAU2="0.40800588619012823" TOTAL_1="246" TOTAL_2="241" WEIGHT="100.0" Z="1.7231795784296116">
<NAME>extrapyramidal symptoms: Simpson-Angus Scale (high=poor)</NAME>
<CONT_DATA CI_END="0.01667458962355206" CI_START="-1.356674589623552" EFFECT_SIZE="-0.6699999999999999" ESTIMABLE="YES" MEAN_1="-0.73" MEAN_2="-0.06" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2437" SD_1="2.92" SD_2="3.16" SE="0.35035061615415053" STUDY_ID="STD-Keefe-2006" TOTAL_1="153" TOTAL_2="149" WEIGHT="35.27483273881471"/>
<CONT_DATA CI_END="0.014831058814786607" CI_START="-0.41483105881478655" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2438" SD_1="0.58" SD_2="0.58" SE="0.1096096971726759" STUDY_ID="STD-Robinson-2006" TOTAL_1="56" TOTAL_2="56" WEIGHT="44.57445032260043"/>
<CONT_DATA CI_END="-1.2153857235312613" CI_START="-5.184614276468739" EFFECT_SIZE="-3.2" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="2.2" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2439" SD_1="3.58" SD_2="3.58" SE="1.012576910659136" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" WEIGHT="13.06211864613536"/>
<CONT_DATA CI_END="2.8989237798512537" CI_START="-2.9589237798512533" EFFECT_SIZE="-0.03" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-0.17" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2440" SD_1="3.58" SD_2="3.58" SE="1.494376326786732" STUDY_ID="STD-Wang-2006" TOTAL_1="12" TOTAL_2="11" WEIGHT="7.088598292449501"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.8030937483910066" CI_END="1.311400112810753" CI_START="-3.421581500397212" DF="1" EFFECT_SIZE="-1.0550906937932294" ESTIMABLE="YES" I2="64.32513180930869" ID="CMP-009.04.04" MODIFIED="2009-09-15 16:23:26 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.09408270795585383" P_Z="0.3822041522032069" STUDIES="2" TAU2="2.107805919127427" TOTAL_1="201" TOTAL_2="200" WEIGHT="100.0" Z="0.8738422961489092">
<NAME>parkinsonism: ESRS subscore for parkinsonism (high=poor)</NAME>
<CONT_DATA CI_END="0.3585940577559308" CI_START="-0.7585940577559307" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-0.5" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2441" SD_1="2.7" SD_2="2.7" SE="0.2850022052252232" STUDY_ID="STD-Conley-2001" TOTAL_1="180" TOTAL_2="179" WEIGHT="66.59801977370198"/>
<CONT_DATA CI_END="0.18436035927229844" CI_START="-5.7043603592722985" EFFECT_SIZE="-2.76" ESTIMABLE="YES" MEAN_1="-1.43" MEAN_2="1.33" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2442" SD_1="4.32" SD_2="5.36" SE="1.5022522773362352" STUDY_ID="STD-Purdon-2000" TOTAL_1="21" TOTAL_2="21" WEIGHT="33.40198022629802"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.680218144911848" CI_END="-21.080933066530186" CI_START="-28.328788046662694" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-24.70486055659644" ESTIMABLE="YES" I2="29.58016931826697" I2_Q="0.0" ID="CMP-009.05" MODIFIED="2009-07-22 11:09:30 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.2243365196171827" P_Q="1.0" P_Z="1.0167509215531829E-40" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="5.0493679076191365" TOTALS="SUB" TOTAL_1="633" TOTAL_2="623" UNITS="" WEIGHT="100.0" Z="13.36137024450451">
<NAME>Adverse effects: 2. Prolactin - change from baseline in ng/ml</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.680218144911848" CI_END="-21.080933066530186" CI_START="-28.328788046662694" DF="4" EFFECT_SIZE="-24.70486055659644" ESTIMABLE="YES" I2="29.58016931826697" ID="CMP-009.05.01" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2243365196171827" P_Z="1.0167509215531829E-40" STUDIES="5" TAU2="5.0493679076191365" TOTAL_1="633" TOTAL_2="623" WEIGHT="100.0" Z="13.36137024450451">
<NAME>Change from baseline in ng/ml</NAME>
<CONT_DATA CI_END="-21.849927202410484" CI_START="-35.11007279758952" EFFECT_SIZE="-28.48" ESTIMABLE="YES" MEAN_1="-9.73" MEAN_2="18.75" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2443" SD_1="23.15" SD_2="31.23" SE="3.3827523617202577" STUDY_ID="STD-Keefe-2006" TOTAL_1="136" TOTAL_2="130" WEIGHT="20.729052234274313"/>
<CONT_DATA CI_END="-17.73472936889368" CI_START="-25.26527063110632" EFFECT_SIZE="-21.5" ESTIMABLE="YES" MEAN_1="-6.1" MEAN_2="15.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2444" SD_1="22.0" SD_2="27.7" SE="1.9210917449536282" STUDY_ID="STD-Lieberman-2005" TOTAL_1="336" TOTAL_2="341" WEIGHT="39.11589775493603"/>
<CONT_DATA CI_END="-7.996040460628402" CI_START="-31.0039595393716" EFFECT_SIZE="-19.5" ESTIMABLE="YES" MEAN_1="-4.1" MEAN_2="15.4" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2445" SD_1="9.2" SD_2="17.91" SE="5.869474964904132" STUDY_ID="STD-McEvoy-2006" TOTAL_1="16" TOTAL_2="11" WEIGHT="8.654950229057075"/>
<CONT_DATA CI_END="-20.83404663234478" CI_START="-35.16595336765522" EFFECT_SIZE="-28.0" ESTIMABLE="YES" MEAN_1="-15.9" MEAN_2="12.1" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2446" SD_1="15.57" SD_2="15.88" SE="3.6561658398722354" STUDY_ID="STD-McEvoy-2007" TOTAL_1="37" TOTAL_2="37" WEIGHT="18.562903049801395"/>
<CONT_DATA CI_END="-18.03824543158005" CI_START="-36.16175456841995" EFFECT_SIZE="-27.1" ESTIMABLE="YES" MEAN_1="-5.1" MEAN_2="22.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2447" SD_1="37.4" SD_2="29.6" SE="4.623429124156319" STUDY_ID="STD-Stroup-2006" TOTAL_1="108" TOTAL_2="104" WEIGHT="12.937196731931179"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2009-09-15 16:22:40 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>OLANZAPINE versus ZIPRASIDONE - sensitivity analysis (skewed data excluded)</NAME>
<CONT_OUTCOME CHI2="0.6587225201387525" CI_END="-5.547363832923879" CI_START="-11.083505100741771" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.315434466832825" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.01" MODIFIED="2009-09-15 16:22:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7193831479912258" P_Q="0.5502170664829134" P_Z="3.912798524344886E-9" Q="0.35692885477616737" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="664" TOTAL_2="579" UNITS="" WEIGHT="100.0" Z="5.887838218846361">
<NAME>Mental State: 1. General - average endpoint score (PANSS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.06760217469525998" CI_START="-13.067602174695258" DF="0" EFFECT_SIZE="-6.499999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-010.01.01" MODIFIED="2009-09-15 16:22:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.05240527426518377" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="135" WEIGHT="17.76399572453135" Z="1.939789524492854">
<NAME>medium term</NAME>
<CONT_DATA CI_END="0.06760217469525998" CI_START="-13.067602174695258" EFFECT_SIZE="-6.499999999999999" ESTIMABLE="YES" MEAN_1="-8.2" MEAN_2="-1.7" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2448" SD_1="22.31" SD_2="22.31" SE="3.350879009257143" STUDY_ID="STD-Stroup-2006" TOTAL_1="66" TOTAL_2="135" WEIGHT="17.76399572453135"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.3017936653625852" CI_END="-5.655157608114122" CI_START="-11.760023997138989" DF="1" EFFECT_SIZE="-8.707590802626555" ESTIMABLE="YES" I2="0.0" ID="CMP-010.01.02" MODIFIED="2009-09-15 16:22:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5827602256060537" P_Z="2.2559082005320522E-8" STUDIES="2" TAU2="0.0" TOTAL_1="598" TOTAL_2="444" WEIGHT="82.23600427546864" Z="5.591134441842001">
<NAME>long term</NAME>
<CONT_DATA CI_END="-5.025216817504835" CI_START="-14.374783182495172" EFFECT_SIZE="-9.700000000000003" ESTIMABLE="YES" MEAN_1="-35.7" MEAN_2="-26.0" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2449" SD_1="26.5" SD_2="28.3" SE="2.385137287914095" STUDY_ID="STD-Breier-2005" TOTAL_1="268" TOTAL_2="261" WEIGHT="35.0615724845917"/>
<CONT_DATA CI_END="-3.939825701716341" CI_START="-12.000174298283659" EFFECT_SIZE="-7.97" ESTIMABLE="YES" MEAN_1="-11.27" MEAN_2="-3.3" MODIFIED="2008-10-16 09:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="2450" SD_1="22.31" SD_2="22.31" SE="2.056249160736197" STUDY_ID="STD-Lieberman-2005" TOTAL_1="330" TOTAL_2="183" WEIGHT="47.17443179087695"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-02-17 14:20:24 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-02-17 14:20:24 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAAEACAMAAACQ12/OAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-02-17 14:20:24 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAV4AAAbGCAIAAAB220rtAABVOklEQVR42u3dvY7t2HWu4Q04cdCB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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2008-10-16 09:34:42 +0100" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2008-10-16 09:34:42 +0100" MODIFIED_BY="[Empty name]"/>
<EXTENSIONS MODIFIED="2008-10-16 09:34:42 +0100" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>